{"meta":{"query_hash":"0fcb7d059508","filters":{"venue":"The Oncologist"},"cohort_total":406,"direct_labels_cover":2,"predictions_cover":406,"exported":406,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/0fcb7d059508","api":"https://metacan.xera.ac/api/v1/cohort?venue=The+Oncologist"},"results":[{"id":"W1973742157","doi":"10.1634/theoncologist.2013-0359","title":"Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Hospital; Royal Victoria Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; Conjoint analysis; Breast cancer; Oncology; Chemotherapy; Internal medicine; Cancer; Preference; Statistics","score_opus":0.0910081580114505,"score_gpt":0.3948186789986069,"score_spread":0.3038105209871564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973742157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784466,0.0011627569,0.015151404,0.0002632106,0.000040783514,0.0013205203,0.00070974743,0.000039506576,0.0028655436],"genre_scores_gemma":[0.9859104,0.00028211172,0.012536918,0.000061544655,0.000014553372,0.0007060135,0.00021720423,0.000003698156,0.0002675365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9742649,0.02139592,0.0011027427,0.0004932399,0.00239859,0.000344606],"domain_scores_gemma":[0.9631729,0.028170524,0.0048602982,0.0012136953,0.0019578252,0.00062475406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018910613,0.0007994484,0.0010378027,0.0034647223,0.0006070935,0.0013362118,0.00054313877,0.0004373842,0.002599296],"category_scores_gemma":[0.03262193,0.00023624637,0.0020787062,0.0034295274,0.0004906756,0.00071113347,0.0011085058,0.0009948262,0.0003060916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0113947475,0.0028963606,0.66515523,0.0014081509,0.004468529,0.00035779143,0.004786252,0.019181645,0.0034814563,0.0018098395,0.0017466197,0.2833133],"study_design_scores_gemma":[0.00086009386,0.015128853,0.8217601,0.00046736997,0.0014002009,0.0014265055,0.008171234,0.13450997,0.004705655,0.0076725236,0.0034846014,0.00041286557],"about_ca_topic_score_codex":0.0008930044,"about_ca_topic_score_gemma":0.0012768541,"teacher_disagreement_score":0.018910613,"about_ca_system_score_codex":0.0009597761,"about_ca_system_score_gemma":0.0006750848,"threshold_uncertainty_score":0.1000101},"labels":[],"label_agreement":null},{"id":"W1988674152","doi":"10.1634/theoncologist.2014-0078","title":"Pre-Exercise Participation Cardiovascular Screening in a Heterogeneous Cohort of Adult Cancer Patients","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Physical therapy; Cohort; Internal medicine; Sports medicine; Risk stratification; Adverse effect; Metabolic equivalent; Disease; Risk assessment; Physical activity","score_opus":0.018076689303366512,"score_gpt":0.2949200106106782,"score_spread":0.27684332130731165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988674152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995566,0.00009344252,0.000048660906,0.000028587914,0.0000026673881,0.000008515754,0.00010717796,0.0000013981773,0.00015297742],"genre_scores_gemma":[0.99964464,0.00005465749,0.00003950412,0.000029335391,0.000007683022,0.00000770211,0.00018877408,7.0597326e-7,0.000027024436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996493,0.000084192376,0.00003527842,0.00010215414,0.000068492445,0.000060625534],"domain_scores_gemma":[0.99914324,0.00013984511,0.00037336725,0.000057101275,0.000060234055,0.00022614317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003627486,0.00019682455,0.00032318188,0.00057040865,0.00047018664,0.0005774353,0.00023436744,0.0004059629,0.00076700945],"category_scores_gemma":[0.0015598536,0.00015402902,0.00030149895,0.00070023385,0.0002462061,0.0003031358,0.0003893525,0.00047155138,0.00015264413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059739887,0.000021496517,0.9991345,0.00000267461,0.00001608948,0.000064051026,0.000031672593,0.000015694375,0.00013867041,0.000005209639,0.000026488817,0.00048376276],"study_design_scores_gemma":[0.000004726421,0.00010059112,0.9993129,0.0000026493988,0.000015798098,0.0002775252,0.00011229672,0.00007966965,0.00002254172,0.000010792967,0.000058794598,0.0000015461236],"about_ca_topic_score_codex":0.0033330906,"about_ca_topic_score_gemma":0.0036672803,"teacher_disagreement_score":0.0033330906,"about_ca_system_score_codex":0.00017342174,"about_ca_system_score_gemma":0.00024936016,"threshold_uncertainty_score":0.006627381},"labels":[],"label_agreement":null},{"id":"W1991358323","doi":"10.1634/theoncologist.2013-0290","title":"Barriers and Challenges to Global Clinical Cancer Research","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Global Health and Surgery","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Test (biology); Cancer; Clinical research; Family medicine; Medical education; Political science; Internal medicine","score_opus":0.30175418580204844,"score_gpt":0.536503614276339,"score_spread":0.23474942847429053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991358323","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38923463,0.044916842,0.0035859903,0.5002619,0.001401546,0.0011335277,0.0007975626,0.00015258732,0.058515336],"genre_scores_gemma":[0.9342277,0.021662043,0.0054932744,0.034380548,0.0009771717,0.00092882756,0.00046282538,0.000047022033,0.0018206714],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9346629,0.048807237,0.004001754,0.0019052722,0.005688035,0.0049347575],"domain_scores_gemma":[0.75570536,0.15721744,0.027068209,0.0059145135,0.016558556,0.037535988],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.07618636,0.0002483591,0.00060343754,0.0019456835,0.0038511958,0.0058963685,0.0017042235,0.001993165,0.007879219],"category_scores_gemma":[0.098571666,0.00035176726,0.0006729881,0.003508001,0.0063567813,0.0031766726,0.008506641,0.0026093347,0.00077015185],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005765972,0.0007630211,0.43572477,0.017396387,0.0006006046,0.0025005725,0.09967162,0.0018369878,0.0017590169,0.04174237,0.107661396,0.2897666],"study_design_scores_gemma":[0.00023053106,0.0012290904,0.28386727,0.020621607,0.00023715524,0.0043093073,0.3245771,0.00063882634,0.0007021871,0.027123535,0.33624244,0.00022094329],"about_ca_topic_score_codex":0.005749072,"about_ca_topic_score_gemma":0.005701675,"teacher_disagreement_score":0.92381364,"about_ca_system_score_codex":0.0046170694,"about_ca_system_score_gemma":0.028507305,"threshold_uncertainty_score":0.4029168},"labels":[],"label_agreement":null},{"id":"W1993411111","doi":"10.1634/theoncologist.2014-0097","title":"Radiation Therapy for Liver Tumors: Ready for Inclusion in Guidelines?","year":2014,"lang":"en","type":"review","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Context (archaeology); Liver transplantation; Hepatocellular carcinoma; Radiofrequency ablation; Selective internal radiation therapy; Radiology; Transplantation; Surgery; Ablation; Internal medicine","score_opus":0.3872888074408159,"score_gpt":0.4455272626865611,"score_spread":0.058238455245745224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993411111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014246623,0.9793235,0.0006231908,0.011634345,0.003563491,0.00003992637,0.00015666147,0.00005205454,0.0044644624],"genre_scores_gemma":[0.0007542092,0.9888221,0.0019740625,0.0042009824,0.002004603,0.00004041787,0.00029058993,0.000018109222,0.0018949538],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99908555,0.00018920835,0.00027146278,0.000062924926,0.00034629743,0.000044515302],"domain_scores_gemma":[0.9970831,0.0009893589,0.0004932103,0.00009702567,0.0011534657,0.00018383603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015359846,0.00064417225,0.0017978676,0.0026349425,0.00036764648,0.0016708155,0.0015193187,0.002288659,0.006394886],"category_scores_gemma":[0.0048197736,0.000384284,0.00077979325,0.0034780076,0.00067276624,0.0031694106,0.0009880795,0.0033893632,0.0054872986],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030609117,0.000041023322,0.00018533076,0.015163642,0.00005566841,0.00022900467,0.000101392034,0.00017187436,0.00051557954,0.0026548088,0.2305666,0.7502845],"study_design_scores_gemma":[0.000011540854,0.000022755943,0.00035476385,0.011042601,0.00006046825,0.00082389696,0.00007532863,0.000038086328,0.00008319255,0.0014448772,0.98603016,0.000012443249],"about_ca_topic_score_codex":0.0022459156,"about_ca_topic_score_gemma":0.0061022653,"teacher_disagreement_score":0.006394886,"about_ca_system_score_codex":0.0009370333,"about_ca_system_score_gemma":0.003890668,"threshold_uncertainty_score":0.02139306},"labels":[],"label_agreement":null},{"id":"W2025163366","doi":"10.1634/theoncologist.6-suppl_4-17","title":"Optimizing the Use of Irinotecan in Colorectal Cancer","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Irinotecan; Medicine; Colorectal cancer; Tolerability; Capecitabine; Oncology; Internal medicine; Clinical trial; Combination therapy; Cancer; Adverse effect","score_opus":0.225416423760074,"score_gpt":0.4210969218419179,"score_spread":0.19568049808184387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025163366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033696845,0.9471734,0.008832816,0.00165547,0.00013518757,0.00010338456,0.00011666195,0.000078728575,0.0082074385],"genre_scores_gemma":[0.21748026,0.7617229,0.015600365,0.0009804323,0.00068538217,0.00008991145,0.0002610816,0.000045373676,0.0031341969],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962246,0.00011726994,0.000052725343,0.000048912992,0.00011412093,0.000044523087],"domain_scores_gemma":[0.99985373,0.000032858978,0.000060845025,0.0000045061574,0.000029186804,0.000018877243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005443757,0.0003574885,0.00034864398,0.0007514997,0.000114993556,0.0005896866,0.0002787537,0.00033319744,0.0009661839],"category_scores_gemma":[0.00050825364,0.00010313958,0.00030866338,0.00065702904,0.0001263397,0.0006170683,0.00031452402,0.0005060464,0.00046944525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005036039,0.00013819791,0.0031929102,0.003854117,0.00010558043,0.0004542996,0.00008448215,0.0020431427,0.033180803,0.0014096845,0.0027855232,0.95224756],"study_design_scores_gemma":[0.0002198736,0.005284289,0.03623159,0.0024831493,0.0006483971,0.009648737,0.00026642843,0.00315772,0.07467734,0.0035248788,0.8637541,0.00010345769],"about_ca_topic_score_codex":0.00075301225,"about_ca_topic_score_gemma":0.0020843223,"teacher_disagreement_score":0.0009661839,"about_ca_system_score_codex":0.0006123745,"about_ca_system_score_gemma":0.00062404014,"threshold_uncertainty_score":0.004443109},"labels":[],"label_agreement":null},{"id":"W2027587146","doi":"10.1634/theoncologist.2012-0226","title":"The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada","keywords":"Cardiotoxicity; Medicine; Cancer; Discontinuation; Adverse effect; Cancer therapy; Disease; Toxicity; Bioinformatics; Pharmacology; Internal medicine; Biology","score_opus":0.03731525061052608,"score_gpt":0.34261238579630016,"score_spread":0.30529713518577406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027587146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076612784,0.9971335,0.00020112452,0.00019234512,0.0001331961,0.000008739242,0.000020811265,0.000007046947,0.0015371476],"genre_scores_gemma":[0.004176334,0.99424946,0.00027300935,0.00018063377,0.000103039776,0.00001457184,0.000034511075,0.0000016984173,0.00096680765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999145,0.00001692319,0.000011928637,0.000015900929,0.000030071185,0.000010735338],"domain_scores_gemma":[0.99991596,0.00003999306,0.000015169438,0.0000027048159,0.000019605359,0.000006705806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023489897,0.00049804285,0.00080763747,0.001253239,0.00020574457,0.00052832905,0.0004434885,0.0006747279,0.0023799706],"category_scores_gemma":[0.00026239164,0.00015819453,0.00047064782,0.00075020536,0.0002539677,0.0005745969,0.0003769191,0.0010149195,0.0007369259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013777798,0.00020699007,0.00030605242,0.019676879,0.00013560895,0.00032458486,0.000103153354,0.00058470736,0.0122666275,0.0042476244,0.011359484,0.9506506],"study_design_scores_gemma":[0.00006736494,0.0005322072,0.003454075,0.004198953,0.0002472572,0.002559528,0.00012120266,0.00034865728,0.0059606466,0.0029368398,0.97953564,0.00003756546],"about_ca_topic_score_codex":0.0005489411,"about_ca_topic_score_gemma":0.001357607,"teacher_disagreement_score":0.0023799706,"about_ca_system_score_codex":0.00027818102,"about_ca_system_score_gemma":0.00042350692,"threshold_uncertainty_score":0.00796181},"labels":[],"label_agreement":null},{"id":"W2036207363","doi":"10.1634/theoncologist.2009-0275","title":"Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Tamoxifen; Oncology; Cost effectiveness; Internal medicine; Cost-effectiveness analysis; Quality-adjusted life year; Cancer","score_opus":0.07588753672040834,"score_gpt":0.38078216170724855,"score_spread":0.3048946249868402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036207363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631498,0.008252929,0.01890826,0.0022342156,0.00008581884,0.00090698886,0.0015344693,0.00009134375,0.004836259],"genre_scores_gemma":[0.9963749,0.0006412752,0.0022130609,0.00012416355,0.0000105383815,0.00013024706,0.00020456861,0.0000042661463,0.00029693055],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.997649,0.0018364302,0.000051618234,0.00013263595,0.00013544362,0.0001947959],"domain_scores_gemma":[0.9919682,0.0066029616,0.0007302875,0.00013163655,0.00019199675,0.00037476883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048571476,0.0009557283,0.0016780627,0.0008642153,0.00026014875,0.0009835811,0.0010898525,0.0010137889,0.0025232765],"category_scores_gemma":[0.012658988,0.0005337302,0.0028872779,0.00056436454,0.0005851279,0.0007067985,0.0008206223,0.0011495239,0.00010770743],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010413782,0.00057060394,0.010274025,0.0004724904,0.0013446676,0.00012108524,0.000029769415,0.9551669,0.0004280217,0.0022884815,0.00062315137,0.018267067],"study_design_scores_gemma":[0.0033067828,0.006736219,0.010628779,0.00029155202,0.0026963076,0.0002396122,0.00007239041,0.9708699,0.0005632813,0.0037299925,0.000793068,0.00007203773],"about_ca_topic_score_codex":0.033104952,"about_ca_topic_score_gemma":0.019609634,"teacher_disagreement_score":0.033104952,"about_ca_system_score_codex":0.007772813,"about_ca_system_score_gemma":0.004611855,"threshold_uncertainty_score":0.06582451},"labels":[],"label_agreement":null},{"id":"W2047262695","doi":"10.1634/theoncologist.2009-s106","title":"Imaging in Radiation Oncology: A Perspective","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Radiation oncology; Medical physics; Perspective (graphical); Medicine; Radiology; Oncology; Nuclear medicine; Radiation therapy; Computer science; Artificial intelligence","score_opus":0.028152886793410395,"score_gpt":0.4226798123966626,"score_spread":0.3945269256032522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047262695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000060258357,0.9960341,0.00022330695,0.0008917744,0.0005448195,0.0000032852556,0.000004128914,0.0000063052516,0.0022319134],"genre_scores_gemma":[0.0005848508,0.9963319,0.0003834671,0.00057568995,0.0009069194,0.0000052420314,0.0000066200296,0.0000024604287,0.0012028867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999549,0.00011732116,0.00004608238,0.000056300112,0.00019584777,0.00003533188],"domain_scores_gemma":[0.9986187,0.00073713437,0.000105877654,0.000053124055,0.0003849542,0.00010017958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013956538,0.0012562583,0.0017632088,0.0035269575,0.00054909644,0.0021445437,0.0014885113,0.0034569832,0.0050535044],"category_scores_gemma":[0.001424102,0.0005381192,0.00073639554,0.003682921,0.0020040378,0.004960009,0.001078264,0.0047509456,0.0043657674],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006816861,0.00012443341,0.00029411103,0.011858113,0.00006613129,0.0005332829,0.00023875304,0.00068338955,0.0021881,0.03008252,0.070319004,0.8835441],"study_design_scores_gemma":[0.000007757506,0.00007636367,0.00050232693,0.002796548,0.000023186374,0.0028877412,0.00014428754,0.000112544454,0.00028317294,0.0074213427,0.9857233,0.000021336795],"about_ca_topic_score_codex":0.0017768093,"about_ca_topic_score_gemma":0.0026221916,"teacher_disagreement_score":0.0050535044,"about_ca_system_score_codex":0.0014781936,"about_ca_system_score_gemma":0.0015515471,"threshold_uncertainty_score":0.016905606},"labels":[],"label_agreement":null},{"id":"W2086678943","doi":"10.1634/theoncologist.2009-0042","title":"Studying Genetic Variations in Cancer Prognosis (and Risk): A Primer for Clinicians","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Candidate gene; Single-nucleotide polymorphism; Computational biology; Genome-wide association study; Genetic association; Primer (cosmetics); Bioinformatics; Gene; Genetic variation; Genetics; Genotype; Biology","score_opus":0.09955752394625256,"score_gpt":0.4293655560473131,"score_spread":0.3298080321010605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086678943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005228241,0.90343684,0.0065155127,0.08374315,0.0026386706,0.000036643713,0.000121824625,0.00011144853,0.0028731208],"genre_scores_gemma":[0.00513062,0.95693105,0.014586236,0.015137403,0.0062106806,0.00010313551,0.0001219885,0.000029097033,0.0017497583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983583,0.00074975897,0.00023752092,0.00013340563,0.00047231046,0.000048625563],"domain_scores_gemma":[0.9914643,0.0059540006,0.00030370467,0.00024118015,0.0015981357,0.0004385635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072854725,0.0012956402,0.003172957,0.003291435,0.00060204935,0.0024286509,0.0020743476,0.004710992,0.0023150821],"category_scores_gemma":[0.014362841,0.0005190832,0.00073688064,0.0022102061,0.002612363,0.0069979713,0.0015485436,0.008836231,0.0025826418],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012247864,0.00016644514,0.0047558853,0.0034823564,0.00011440917,0.0012892876,0.0004295374,0.00035956988,0.001027014,0.008923066,0.15819594,0.821134],"study_design_scores_gemma":[0.000117084746,0.00033206752,0.01476642,0.020438762,0.00027058373,0.015386544,0.0023545185,0.0010136861,0.00082111824,0.1045342,0.8397505,0.00021448992],"about_ca_topic_score_codex":0.0023880794,"about_ca_topic_score_gemma":0.002794188,"teacher_disagreement_score":0.0072854725,"about_ca_system_score_codex":0.0013079066,"about_ca_system_score_gemma":0.002486046,"threshold_uncertainty_score":0.038529754},"labels":[],"label_agreement":null},{"id":"W2094948739","doi":"10.1634/theoncologist.2014-0229","title":"Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety","year":2015,"lang":"en","type":"review","venue":"The Oncologist","topic":"Nausea and vomiting management","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aprepitant; Medicine; Chemotherapy-induced nausea and vomiting; Antiemetic; Adverse effect; Vomiting; Nausea; Oncology; Pharmacology; Internal medicine; Intensive care medicine","score_opus":0.1153224472111678,"score_gpt":0.4187728673947717,"score_spread":0.3034504201836039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094948739","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011215512,0.9994081,0.000026650914,0.00012584902,0.00006303295,0.0000033797764,0.000021768983,0.0000023217438,0.00023672063],"genre_scores_gemma":[0.00061919214,0.9989912,0.00006932728,0.00013396653,0.000063359264,0.0000041881735,0.000025128658,7.6918025e-7,0.00009297156],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9995629,0.00007626656,0.00013746138,0.00006673583,0.00013121584,0.000025421057],"domain_scores_gemma":[0.99861944,0.0008197014,0.00026404473,0.000021900632,0.00022972414,0.000045201945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090134074,0.00081077043,0.0017538973,0.003264042,0.00029158292,0.0010538232,0.0008221913,0.0009118931,0.0035749513],"category_scores_gemma":[0.0023554526,0.00034405815,0.0012363619,0.003896312,0.00038047478,0.00132034,0.00064189674,0.0011085443,0.00064909353],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001804726,0.000065365275,0.00041215363,0.14211042,0.0005018031,0.00021137713,0.00014144817,0.00032235298,0.0010095328,0.0013199416,0.021502305,0.8322229],"study_design_scores_gemma":[0.00006280579,0.0003694668,0.00344859,0.060033303,0.002394459,0.002571914,0.00019809052,0.00016357648,0.00067172904,0.0013810964,0.92865586,0.000049203925],"about_ca_topic_score_codex":0.0014125737,"about_ca_topic_score_gemma":0.0027406213,"teacher_disagreement_score":0.0035749513,"about_ca_system_score_codex":0.00065280474,"about_ca_system_score_gemma":0.0019207753,"threshold_uncertainty_score":0.011959374},"labels":[],"label_agreement":null},{"id":"W2095839943","doi":"10.1634/theoncologist.2009-0298","title":"Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chemoradiotherapy; Stage (stratigraphy); Oncology; Current (fluid); Lung cancer; Internal medicine; Cancer; Intensive care medicine","score_opus":0.14461746522540633,"score_gpt":0.4771418083636698,"score_spread":0.3325243431382635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095839943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024097478,0.94576794,0.0014302563,0.045888543,0.0008895641,0.000060293838,0.000086050575,0.000035371508,0.0034322059],"genre_scores_gemma":[0.045403037,0.9139589,0.0040320195,0.02948232,0.0049304166,0.00032999853,0.00035424647,0.000054236418,0.001454867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980317,0.0008015757,0.00026530493,0.0004417772,0.00034859413,0.000110996865],"domain_scores_gemma":[0.99524766,0.00255742,0.0005892371,0.00022658867,0.0010209369,0.0003582626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008202293,0.00061074307,0.0019557246,0.0009271879,0.0005171571,0.0026605988,0.002242102,0.0015404739,0.0035811258],"category_scores_gemma":[0.006109517,0.00035937192,0.001692969,0.0013271365,0.0018074517,0.0038429382,0.0014720423,0.005106442,0.0013668766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010331463,0.0003172761,0.0024569407,0.009614144,0.000389399,0.00004851363,0.00022441952,0.001518408,0.00080459594,0.014675759,0.02653298,0.9423845],"study_design_scores_gemma":[0.0014075225,0.003884449,0.011157017,0.02950032,0.002003711,0.0007522083,0.0010901756,0.0036489733,0.001228791,0.07279866,0.87234986,0.00017833053],"about_ca_topic_score_codex":0.0040156394,"about_ca_topic_score_gemma":0.011238693,"teacher_disagreement_score":0.008202293,"about_ca_system_score_codex":0.004102354,"about_ca_system_score_gemma":0.003435099,"threshold_uncertainty_score":0.043378413},"labels":[],"label_agreement":null},{"id":"W2097068862","doi":"10.1634/theoncologist.2008-0184","title":"Commentary: Hormone Receptor Testing in Breast Cancer: A Distress Signal from Canada","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genomic Health; Pfizer","keywords":"Medicine; Breast cancer; Estrogen receptor; Hormone receptor; Distress; Cancer; Oncology; Receptor; Estrogen; Hormone; Internal medicine; Gynecology; Clinical psychology","score_opus":0.018827514875361384,"score_gpt":0.24858736979699678,"score_spread":0.2297598549216354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097068862","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001096634,0.0021725474,0.000034884524,0.95618945,0.040550947,0.000010497043,0.00006781645,0.000014704837,0.00084941887],"genre_scores_gemma":[0.0015783494,0.0020715573,0.00010924454,0.96212804,0.031266544,0.000016993325,0.0000343724,0.000022513568,0.002772406],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9920649,0.001700844,0.0007209812,0.0008648826,0.0037039616,0.00094446656],"domain_scores_gemma":[0.94495887,0.021385422,0.0019719882,0.0006388431,0.022253947,0.0087909065],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0075722197,0.0013385084,0.0019079136,0.0015180323,0.008579062,0.0040695732,0.0044910233,0.04770796,0.007082861],"category_scores_gemma":[0.042975157,0.0008902098,0.0015866108,0.0020609638,0.00625057,0.0042760824,0.0019121334,0.044368736,0.003174422],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023509214,0.00000466807,0.00011839504,0.00004192166,0.000005320386,0.00011654626,0.00005261705,0.00001565566,0.00004370839,0.00032812604,0.9974343,0.0018151394],"study_design_scores_gemma":[0.000110516106,0.000040821837,0.0013520909,0.0007830674,0.000047417478,0.00054795045,0.00066936866,0.00015199243,0.00017221042,0.0019371096,0.99410135,0.00008615807],"about_ca_topic_score_codex":0.42878914,"about_ca_topic_score_gemma":0.55959356,"teacher_disagreement_score":0.99242777,"about_ca_system_score_codex":0.02643808,"about_ca_system_score_gemma":0.052194167,"threshold_uncertainty_score":0.8525866},"labels":[],"label_agreement":null},{"id":"W2098169322","doi":"10.1634/theoncologist.8-3-232","title":"Population-Based Pharmacoeconomic Model for Adopting Capecitabine/Docetaxel Combination Treatment for Anthracycline-Pretreated Metastatic Breast Cancer","year":2003,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Ottawa Regional Cancer Foundation","funders":"","keywords":"Docetaxel; Medicine; Capecitabine; Taxane; Oncology; Population; Metastatic breast cancer; Internal medicine; Quality-adjusted life year; Anthracycline; Breast cancer; Cost effectiveness; Cancer; Colorectal cancer; Environmental health","score_opus":0.0934897234531395,"score_gpt":0.41733139480526843,"score_spread":0.32384167135212893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098169322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90500575,0.0012354568,0.04766698,0.007532961,0.00017049458,0.0009992181,0.009841724,0.00025912025,0.027288357],"genre_scores_gemma":[0.98482424,0.0003400771,0.004731416,0.0003092275,0.00005004524,0.0005331413,0.0016393038,0.000022399552,0.0075501483],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99878806,0.000687611,0.000032384174,0.00017790297,0.00008701137,0.00022698847],"domain_scores_gemma":[0.99488586,0.0037466309,0.00045687117,0.00007367945,0.00045850535,0.0003785042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030887637,0.0010951776,0.0018755641,0.0016550914,0.0006758477,0.002329085,0.0025745658,0.0026735414,0.010535497],"category_scores_gemma":[0.008416805,0.0010237854,0.0022281108,0.0014405567,0.0010340426,0.00096849026,0.0010551673,0.0022545464,0.0007006804],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036320955,0.0001401639,0.0074679833,0.00003329549,0.00011571018,0.00020525508,0.0000371734,0.9856705,0.00006546004,0.0030036874,0.00094893645,0.001948581],"study_design_scores_gemma":[0.00021886505,0.00013603113,0.0027958225,0.000018062947,0.00012662965,0.000064120955,0.0000755629,0.9944159,0.000021951819,0.0017660243,0.0003444784,0.000016515183],"about_ca_topic_score_codex":0.16752605,"about_ca_topic_score_gemma":0.093782306,"teacher_disagreement_score":0.16752605,"about_ca_system_score_codex":0.009257139,"about_ca_system_score_gemma":0.0050281966,"threshold_uncertainty_score":0.33310193},"labels":[],"label_agreement":null},{"id":"W2100458353","doi":"10.1634/theoncologist.2011-0448","title":"Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Waterloo","funders":"","keywords":"Medicine; Zoledronic acid; Prostate cancer; Internal medicine; Hazard ratio; Parathyroid hormone; Placebo; Urology; Bone remodeling; Gastroenterology; Oncology; Cancer; Endocrinology; Confidence interval; Pathology; Calcium","score_opus":0.025674338114922663,"score_gpt":0.33319968739375033,"score_spread":0.3075253492788277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100458353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986162,0.0011161211,0.00003843844,0.000021933922,0.000004564867,0.000006797942,0.0000931761,0.0000022654483,0.000100474506],"genre_scores_gemma":[0.9997105,0.00012983524,0.00003018655,0.000008801684,0.000008059874,0.000002985745,0.0000911807,2.8851986e-7,0.000018164212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996933,0.00009663085,0.00003036258,0.00004974296,0.00008775629,0.00004227476],"domain_scores_gemma":[0.9982461,0.00050268945,0.0007965145,0.000049809703,0.0001136199,0.00029128385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061913754,0.00019090324,0.00057339005,0.00042403772,0.0002195959,0.0004566882,0.00020095835,0.00034905635,0.0007179525],"category_scores_gemma":[0.0020020695,0.00014861129,0.00054293533,0.00071144354,0.00024015558,0.0002017484,0.00020607655,0.00045417305,0.00008261667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046736645,0.00006879145,0.9910686,0.00003063235,0.00014492808,0.00009288037,0.000031177347,0.00019302113,0.00072321686,0.000010588922,0.000056559868,0.0029058852],"study_design_scores_gemma":[0.00014294442,0.0010687794,0.99771714,0.0000064069845,0.00013317763,0.0002861361,0.000023091257,0.00029234146,0.00018947736,0.000024005292,0.00011000811,0.000006474457],"about_ca_topic_score_codex":0.0011823733,"about_ca_topic_score_gemma":0.0014125744,"teacher_disagreement_score":0.0011823733,"about_ca_system_score_codex":0.00028637698,"about_ca_system_score_gemma":0.00036485918,"threshold_uncertainty_score":0.0032743812},"labels":[],"label_agreement":null},{"id":"W2101024529","doi":"10.1634/theoncologist.2014-0059","title":"Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Genentech","keywords":"Medicine; Capecitabine; Metastatic breast cancer; Taxane; Adverse effect; Internal medicine; Cohort; Breast cancer; Cancer; Pharmacy; Leukopenia; Anemia; Chemotherapy; Oncology","score_opus":0.024192563102551974,"score_gpt":0.34294199914562395,"score_spread":0.318749436043072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101024529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924056,0.001727234,0.0003639783,0.0007412164,0.000019093637,0.00014379936,0.0027341496,0.000009254219,0.0018557635],"genre_scores_gemma":[0.9977186,0.00041984505,0.0005145774,0.00010638468,0.0000299059,0.00006412443,0.0010726473,0.0000023798252,0.00007159248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99615437,0.0020703475,0.0005579066,0.00026725465,0.000726478,0.00022360138],"domain_scores_gemma":[0.9823727,0.0039899945,0.010900816,0.00024301135,0.0014760222,0.0010174967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033606405,0.0004085608,0.00046024338,0.001835991,0.00045973234,0.0013052244,0.00067236915,0.00050313363,0.0019381673],"category_scores_gemma":[0.014971453,0.00020908852,0.0009961431,0.0025267068,0.0003068776,0.0009860876,0.0007747134,0.0008675246,0.0002013621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003201811,0.00017087467,0.9915809,0.00015354503,0.00024305932,0.00013714292,0.00004512395,0.0010011832,0.000039616858,0.00011728275,0.00055614865,0.0056348443],"study_design_scores_gemma":[0.000073054165,0.0008599409,0.98868793,0.00010073575,0.0001832498,0.0010670024,0.0004534218,0.0067757093,0.00010423361,0.00022638304,0.0014461582,0.000022170489],"about_ca_topic_score_codex":0.004233732,"about_ca_topic_score_gemma":0.006316513,"teacher_disagreement_score":0.004233732,"about_ca_system_score_codex":0.0027046981,"about_ca_system_score_gemma":0.0014533098,"threshold_uncertainty_score":0.019624054},"labels":[],"label_agreement":null},{"id":"W2101719282","doi":"10.1634/theoncologist.2010-0278","title":"In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; University of Alberta; Bibliographical Society of Canada; Jewish General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"University of Toronto; Eli Lilly and Company","keywords":"Medicine; Clinical trial; Metastatic breast cancer; Clinical research; Clinical endpoint; Breast cancer; Phases of clinical research; Oncology; Drug; Food and drug administration; Cancer; Internal medicine; Intensive care medicine; Pharmacology","score_opus":0.19286006184339724,"score_gpt":0.5378821186998671,"score_spread":0.3450220568564699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101719282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006553793,0.99819416,0.00009054383,0.0011035384,0.0003062582,0.000022391943,0.000030420384,0.000003917618,0.00018329226],"genre_scores_gemma":[0.0011417978,0.99584645,0.00060002884,0.0016216091,0.00056138745,0.00008023199,0.000055326265,0.0000058874484,0.00008730522],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.981406,0.009830732,0.00548361,0.0006447588,0.0024611917,0.00017380138],"domain_scores_gemma":[0.93312913,0.051137637,0.00710721,0.0009413445,0.0069580553,0.00072662457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020812126,0.0014053595,0.0063606706,0.012135468,0.00079982786,0.004808452,0.0021443316,0.0021609426,0.0023574838],"category_scores_gemma":[0.054837804,0.00080773945,0.0027530682,0.01741087,0.001967591,0.0058743875,0.0015067281,0.003428701,0.00081418856],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003744215,0.00006269761,0.0010681173,0.30281106,0.0012531531,0.00012976264,0.00043583196,0.0003151932,0.00042631853,0.004244255,0.04457965,0.6442995],"study_design_scores_gemma":[0.00024500696,0.0005735006,0.0088470485,0.47091585,0.0036449172,0.0010722105,0.0007521478,0.00021181109,0.00023384947,0.0072209635,0.5061838,0.00009880641],"about_ca_topic_score_codex":0.0023424325,"about_ca_topic_score_gemma":0.005213323,"teacher_disagreement_score":0.020812126,"about_ca_system_score_codex":0.003284127,"about_ca_system_score_gemma":0.007722387,"threshold_uncertainty_score":0.110066354},"labels":[],"label_agreement":null},{"id":"W2102718441","doi":"10.1634/theoncologist.2010-0307","title":"Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Texas MD Anderson Cancer Center; Merck KGaA","keywords":"Medicine; Keyhole limpet hemocyanin; Cyclophosphamide; Adjuvant; Metastatic breast cancer; Internal medicine; Breast cancer; Population; Seroconversion; Immunology; Cancer; Gastroenterology; Oncology; Chemotherapy; Antibody","score_opus":0.11081854182778034,"score_gpt":0.4328358542687114,"score_spread":0.32201731244093107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102718441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925712,0.0020394672,0.00056210614,0.0004248359,0.00014350754,0.0029159156,0.00045300397,0.000083008366,0.000806926],"genre_scores_gemma":[0.98817074,0.0015228095,0.0020821795,0.0005954449,0.00024533586,0.0043740775,0.0012547494,0.000021696298,0.0017329459],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995797,0.00024494427,0.000018849514,0.000060053608,0.00003393495,0.00006250146],"domain_scores_gemma":[0.9993284,0.00014186937,0.00019295685,0.000043738593,0.00004003071,0.000252977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016602862,0.0013720152,0.0015450757,0.00026279446,0.00030557462,0.00054750196,0.00073719665,0.0011798858,0.0024530326],"category_scores_gemma":[0.00096509175,0.00034590074,0.0006146544,0.00026623486,0.00085277547,0.00049316784,0.000251372,0.0019351699,0.0005521094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8649816,0.041981097,0.0035203488,0.0007102439,0.0004853353,0.00010394913,0.00010997115,0.0017884977,0.0362898,0.0001620863,0.0018738173,0.047993258],"study_design_scores_gemma":[0.63387424,0.35642236,0.0035521968,0.000023976823,0.00013650468,0.0000979462,0.000020008145,0.000775772,0.0040951855,0.00009076061,0.0009026351,0.000008573303],"about_ca_topic_score_codex":0.0007217217,"about_ca_topic_score_gemma":0.0015104429,"teacher_disagreement_score":0.0024530326,"about_ca_system_score_codex":0.00084572035,"about_ca_system_score_gemma":0.0016629788,"threshold_uncertainty_score":0.008780539},"labels":[],"label_agreement":null},{"id":"W2102727846","doi":"10.1634/theoncologist.2011-0450","title":"The Utility of Hedgehog Signaling Pathway Inhibition for Cancer","year":2012,"lang":"en","type":"review","venue":"The Oncologist","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hedgehog signaling pathway; Hedgehog; Signal transduction; Cancer research; Smoothened; Metastasis; Biology; Downregulation and upregulation; Cancer; Bioinformatics; Medicine; Cell biology; Genetics","score_opus":0.1417067204821225,"score_gpt":0.3886677874465042,"score_spread":0.24696106696438172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102727846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027483812,0.9977397,0.00014957445,0.00018124834,0.000121299134,0.000005287059,0.000025575557,0.000009422937,0.0014930987],"genre_scores_gemma":[0.0016939844,0.9965372,0.00020958361,0.00024725287,0.00008317672,0.000008114745,0.00005431524,0.0000024120095,0.0011639881],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985254,0.000025229598,0.00001716075,0.000029612005,0.000062544284,0.000012881656],"domain_scores_gemma":[0.9998604,0.000060944563,0.0000189589,0.000007409282,0.000038417027,0.000013882365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004523905,0.0007642523,0.0009913817,0.0018237334,0.00022390536,0.00066694635,0.0006760651,0.00075727847,0.0029721598],"category_scores_gemma":[0.00039614347,0.0002567456,0.0004283009,0.0012438513,0.0004142482,0.000937931,0.0005389127,0.0015666351,0.0023838333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010825077,0.000072116476,0.00016308119,0.009588914,0.00010460812,0.00027950516,0.000042588912,0.0003792822,0.004528457,0.0053614606,0.023383768,0.955988],"study_design_scores_gemma":[0.000027348928,0.00012642205,0.00069332164,0.0010027774,0.00007521418,0.0013802819,0.000027367505,0.00009136919,0.0016919463,0.0017221911,0.9931456,0.000016318458],"about_ca_topic_score_codex":0.0009245948,"about_ca_topic_score_gemma":0.0017817206,"teacher_disagreement_score":0.0029721598,"about_ca_system_score_codex":0.00064655876,"about_ca_system_score_gemma":0.00053417304,"threshold_uncertainty_score":0.00994283},"labels":[],"label_agreement":null},{"id":"W2103017000","doi":"10.1634/theoncologist.2013-0175","title":"Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Medical Research Council; National Health and Medical Research Council; Ovarian Cancer Research Foundation","keywords":"Medicine; Quality of life (healthcare); Depression (economics); Chemotherapy; Anxiety; Internal medicine; Odds ratio; Ovarian cancer; Confidence interval; Cancer; Oncology; Psychiatry","score_opus":0.05196534679095932,"score_gpt":0.359249558680084,"score_spread":0.3072842118891247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103017000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991929,0.0003252545,0.000041963023,0.000074773656,0.0000059771387,0.000024521556,0.00018537516,0.0000015403045,0.00014775633],"genre_scores_gemma":[0.99935323,0.0001058183,0.00007897696,0.00004053798,0.000010920039,0.000024287381,0.0003085348,5.8520055e-7,0.000077077224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995951,0.00024943764,0.000032118336,0.00002744603,0.00006008461,0.00003582294],"domain_scores_gemma":[0.99845624,0.00032547594,0.0007474857,0.00007898572,0.000053227835,0.0003386193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014244282,0.00028950762,0.00032885533,0.000342191,0.0002624379,0.0004778295,0.00021940649,0.00046256985,0.0006324632],"category_scores_gemma":[0.002976661,0.00018171934,0.00047542993,0.0003618409,0.00022076207,0.00027592026,0.00048144796,0.0005096819,0.00007375792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026630114,0.00025762367,0.9930935,0.000033067565,0.0003260982,0.000034585802,0.00011478739,0.000076255295,0.00023237965,0.000018340865,0.00016509218,0.0029850905],"study_design_scores_gemma":[0.00019450727,0.0007966827,0.9982907,0.000009276484,0.00008100293,0.00008625768,0.00006987439,0.00021475833,0.000037112415,0.000024409954,0.00019040583,0.0000049670207],"about_ca_topic_score_codex":0.00089067814,"about_ca_topic_score_gemma":0.001978451,"teacher_disagreement_score":0.0014244282,"about_ca_system_score_codex":0.0001808485,"about_ca_system_score_gemma":0.0001711198,"threshold_uncertainty_score":0.0075331926},"labels":[],"label_agreement":null},{"id":"W2105446438","doi":"10.1634/theoncologist.2013-0249","title":"Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Stage (stratigraphy); Lymphoma; Internal medicine; Radiation therapy; Confidence interval; Diffuse large B-cell lymphoma; Chemotherapy; Gastroenterology; International Prognostic Index; Surgery","score_opus":0.016547005499426972,"score_gpt":0.288071779150658,"score_spread":0.27152477365123107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105446438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992372,0.00027992588,0.00004721759,0.000014267514,0.0000022033153,0.000009073811,0.0002240772,0.0000020952366,0.0001839358],"genre_scores_gemma":[0.9988757,0.00015029343,0.00006918698,0.000027792315,0.000009817302,0.000014418738,0.0007744304,0.0000018765692,0.0000765665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995659,0.00012557153,0.00006445845,0.0001218727,0.00006857746,0.000053570748],"domain_scores_gemma":[0.9992442,0.00016288465,0.00034411327,0.00006729079,0.000050987743,0.00013048865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007082151,0.0003640545,0.00038814155,0.0008241078,0.00035655723,0.0005729219,0.00034439683,0.00039873578,0.0007897324],"category_scores_gemma":[0.0011364488,0.00031713155,0.00026820038,0.0007506938,0.00040209232,0.0005077135,0.00044213817,0.00029263063,0.00027323567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013099858,0.00003343101,0.997511,0.000011374588,0.00003307933,0.0003199218,0.00009389864,0.000044420485,0.0003017239,0.0000052135842,0.000093889954,0.001420891],"study_design_scores_gemma":[0.00005372673,0.00037617204,0.99506867,0.000013310771,0.000043215703,0.0034285595,0.0002171372,0.00013596148,0.0001709705,0.000011270027,0.00047484422,0.00000604447],"about_ca_topic_score_codex":0.0011876939,"about_ca_topic_score_gemma":0.0016670069,"teacher_disagreement_score":0.0011876939,"about_ca_system_score_codex":0.0003810924,"about_ca_system_score_gemma":0.00021713536,"threshold_uncertainty_score":0.0037454963},"labels":[],"label_agreement":null},{"id":"W2106800598","doi":"10.1634/theoncologist.2011-0446","title":"Shared Decision-Making in Pediatric Allogeneic Blood and Marrow Transplantation: What If There Is No Decision to Make?","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Grandparent; Transplantation; Context (archaeology); Sibling; Interview; Family medicine; Legal guardian; Pediatrics; Developmental psychology; Surgery; Psychology","score_opus":0.13220681816854635,"score_gpt":0.42895530111885155,"score_spread":0.2967484829503052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106800598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9564607,0.0020361075,0.0059466306,0.026356967,0.00022889547,0.00025046756,0.00008076842,0.000020935044,0.008618429],"genre_scores_gemma":[0.99607134,0.00063736114,0.0016014475,0.0011010042,0.000023869803,0.00011435684,0.000020005364,0.0000074311324,0.0004232291],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.95188314,0.042053163,0.00093824056,0.00095857354,0.002108494,0.002058497],"domain_scores_gemma":[0.94015896,0.04861607,0.004566673,0.0007678509,0.002072756,0.003817757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035930794,0.0003628932,0.0006057685,0.000787431,0.008032834,0.0046281735,0.0019518464,0.0016560506,0.0020068532],"category_scores_gemma":[0.04848207,0.00048732196,0.00064853113,0.0008551763,0.01690349,0.005983324,0.00509984,0.004130291,0.00017975099],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004245515,0.000058266374,0.0066893166,0.00021376587,0.000010696267,0.0012016455,0.97449964,0.00012342723,0.00017008316,0.007636689,0.001422123,0.007931897],"study_design_scores_gemma":[0.000010395509,0.000039854276,0.001288372,0.00028461512,0.000005964312,0.00045406606,0.98745817,0.0001983859,0.00013473864,0.0027828848,0.0073250653,0.00001748711],"about_ca_topic_score_codex":0.0047718105,"about_ca_topic_score_gemma":0.006339189,"teacher_disagreement_score":0.035930794,"about_ca_system_score_codex":0.009004327,"about_ca_system_score_gemma":0.011139406,"threshold_uncertainty_score":0.19002247},"labels":[],"label_agreement":null},{"id":"W2107249625","doi":"10.1634/theoncologist.2012-0384","title":"Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Research Manitoba; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Otsuka Canada Pharmaceutical; Otsuka Pharmaceutical","keywords":"Medicine; Melphalan; Multiple myeloma; Busulfan; Lenalidomide; Thalidomide; Bortezomib; Regimen; Oncology; Conditioning regimen; Transplantation; Internal medicine; Surgery; Hematopoietic stem cell transplantation","score_opus":0.11800804324453118,"score_gpt":0.4107763555520448,"score_spread":0.2927683123075136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107249625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001733327,0.9993753,0.000023679018,0.000060340164,0.000026100855,0.0000029415426,0.000013674638,0.0000019653496,0.00032272868],"genre_scores_gemma":[0.0013825187,0.9982698,0.0000705737,0.00007585394,0.00004240886,0.000004933079,0.000025101126,6.4954736e-7,0.00012812877],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997371,0.000056623638,0.00006202442,0.000039820523,0.00009118451,0.000013337924],"domain_scores_gemma":[0.9995715,0.00023242635,0.00008693193,0.000007734301,0.000085833475,0.000015536112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006209047,0.0004815485,0.00133546,0.0017083968,0.00018759894,0.0005917848,0.0006752898,0.00062127615,0.0028786492],"category_scores_gemma":[0.0011072229,0.00016222963,0.0007187572,0.0016713723,0.0002442696,0.0005925987,0.00032426888,0.0008253818,0.0006191963],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020832305,0.000084594365,0.00030346366,0.04515772,0.00031115708,0.00016551894,0.00005266985,0.00022866699,0.0014479514,0.0009840606,0.010262193,0.94079363],"study_design_scores_gemma":[0.00015387595,0.00067672465,0.005835871,0.028440326,0.0017829313,0.0037693395,0.00014530247,0.00020862486,0.0026293497,0.0014906441,0.95482016,0.000046861354],"about_ca_topic_score_codex":0.0009849966,"about_ca_topic_score_gemma":0.001630177,"teacher_disagreement_score":0.0028786492,"about_ca_system_score_codex":0.00046603216,"about_ca_system_score_gemma":0.0008082515,"threshold_uncertainty_score":0.009630024},"labels":[],"label_agreement":null},{"id":"W2107480310","doi":"10.1634/theoncologist.2014-0009","title":"Adolescents and Young Adults With a “Rare” Cancer: Getting Past Semantics to Optimal Care for Patients With Germ Cell Tumors","year":2014,"lang":"en","type":"editorial","venue":"The Oncologist","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Teenage Cancer Trust","keywords":"Germ cell tumors; Young adult; Germ cell; Medicine; Semantics (computer science); Cancer; Oncology; Internal medicine; Biology; Chemotherapy; Computer science","score_opus":0.004093347523698311,"score_gpt":0.2515041690484088,"score_spread":0.24741082152471047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107480310","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010702859,0.027617712,0.00019580773,0.16364461,0.80701953,0.000020686892,0.000019802752,0.000039467526,0.001335396],"genre_scores_gemma":[0.0008541444,0.023475017,0.0001802706,0.05130862,0.92166096,0.000021600652,0.000016794136,0.000019842186,0.0024627727],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962453,0.0011788487,0.00069687515,0.0002862297,0.0013589729,0.00023369344],"domain_scores_gemma":[0.97298694,0.016390953,0.0013685446,0.0004009632,0.006061131,0.002791482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006767687,0.002008204,0.0026267276,0.0019625505,0.0024198028,0.005055811,0.0026483915,0.015260885,0.0038375717],"category_scores_gemma":[0.03393683,0.0009824417,0.0018424594,0.0011204515,0.0021420717,0.0058786077,0.0015605764,0.031925563,0.0023566196],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032536656,0.000020444568,0.00008849342,0.0004928851,0.000029016328,0.0002584476,0.000071222166,0.00004943362,0.00003383903,0.00047585255,0.9805433,0.017904516],"study_design_scores_gemma":[0.00010672192,0.00006339584,0.00068937027,0.0023289379,0.000119658944,0.0010970035,0.0002205344,0.0001685112,0.00007389274,0.0015448658,0.9935528,0.000034320547],"about_ca_topic_score_codex":0.001965359,"about_ca_topic_score_gemma":0.006150368,"teacher_disagreement_score":0.015260885,"about_ca_system_score_codex":0.0033828637,"about_ca_system_score_gemma":0.0037344089,"threshold_uncertainty_score":0.035791397},"labels":[],"label_agreement":null},{"id":"W2107651401","doi":"10.1634/theoncologist.12-10-1156","title":"Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor–Positive Operable Breast Cancer","year":2007,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Cardiorespiratory fitness; Cardiology; Cardiac function curve; Oncology; Brain natriuretic peptide; Tamoxifen; Cancer; Endocrinology; Heart failure","score_opus":0.013212033564643616,"score_gpt":0.2841265179975229,"score_spread":0.2709144844328793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107651401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992737,0.0004286183,0.00002340575,0.000026232976,0.000004310684,0.0000031361942,0.0000623763,0.0000014793677,0.00017675971],"genre_scores_gemma":[0.9996087,0.00013233256,0.000030061528,0.00003207479,0.000013993408,0.0000050462672,0.000087967135,6.6425525e-7,0.00008927508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998933,0.000024446388,0.000008915103,0.000022228442,0.00002803423,0.000023089555],"domain_scores_gemma":[0.9996803,0.00006130944,0.00012531565,0.000012358978,0.000023936509,0.00009668905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018562443,0.0002156811,0.00037518475,0.00037378262,0.00025261508,0.00031614443,0.00012764714,0.0003836142,0.00070505275],"category_scores_gemma":[0.0008928776,0.00014067811,0.0002081183,0.00028332826,0.00017936781,0.00015129505,0.0001653851,0.00030587454,0.00013775837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036863342,0.00004999799,0.996655,0.000008026111,0.00004387458,0.00018808409,0.000056735604,0.000023006478,0.000701999,0.000009336575,0.000052048228,0.0018431126],"study_design_scores_gemma":[0.000013298875,0.00023495143,0.99886656,0.000002759321,0.000030217956,0.0005386152,0.0000707567,0.000066721084,0.000055440312,0.000013736397,0.00010501426,0.0000019867196],"about_ca_topic_score_codex":0.0012163619,"about_ca_topic_score_gemma":0.001387894,"teacher_disagreement_score":0.0012163619,"about_ca_system_score_codex":0.00011919395,"about_ca_system_score_gemma":0.00009944588,"threshold_uncertainty_score":0.002418518},"labels":[],"label_agreement":null},{"id":"W2107752418","doi":"10.1634/theoncologist.2006-0214","title":"A Case of Small Bowel Obstruction Due to Intraluminal Metastases from Metastatic Renal Cell Cancer","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Bowel obstruction; Nausea; Vomiting; Perforation; Renal cell carcinoma; Cancer; Colorectal cancer; Metastasis; Surgery; Diarrhea; Disease; Internal medicine","score_opus":0.07083448650561572,"score_gpt":0.32438910693756134,"score_spread":0.25355462043194565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107752418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94664097,0.013096893,0.0075888764,0.01098155,0.0017852843,0.00041814143,0.0004323296,0.00037067576,0.01868528],"genre_scores_gemma":[0.9896774,0.0017044188,0.0018039751,0.0022649984,0.0024919368,0.0000561858,0.00012835154,0.000029193292,0.0018434373],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9988587,0.00016628069,0.00010203131,0.00021263529,0.0001662577,0.0004941538],"domain_scores_gemma":[0.99589765,0.0012451224,0.00069378404,0.0003408154,0.00016625786,0.001656471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057557534,0.002713843,0.002263707,0.0035501164,0.0051387823,0.0021655827,0.0019186822,0.010237623,0.0024946553],"category_scores_gemma":[0.005987239,0.0016976884,0.0019017552,0.002972639,0.0021976419,0.0030214938,0.0030190398,0.006139887,0.0011276492],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023971257,0.00002128994,0.0012582808,0.000021263359,0.000006140045,0.9978173,0.00007363148,0.000039017657,0.00017651958,0.000109532026,0.00011641502,0.0003366183],"study_design_scores_gemma":[0.000027901488,0.000065394735,0.00239381,0.0000124939625,0.0000140430275,0.9964598,0.00007209444,0.00019990266,0.00017681198,0.00016595761,0.00040179692,0.000009931982],"about_ca_topic_score_codex":0.0026329297,"about_ca_topic_score_gemma":0.004082339,"teacher_disagreement_score":0.010237623,"about_ca_system_score_codex":0.0023429317,"about_ca_system_score_gemma":0.0011044098,"threshold_uncertainty_score":0.016999185},"labels":[],"label_agreement":null},{"id":"W2108248587","doi":"10.1634/theoncologist.2013-0427","title":"Discordance in Hormone Receptor Status Among Primary, Metastatic, and Second Primary Breast Cancers: Biological Difference or Misclassification?","year":2014,"lang":"en","type":"review","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Saskatchewan","funders":"National Center for Advancing Translational Sciences; Fogarty International Center; American Cancer Society","keywords":"Medicine; Breast cancer; Estrogen receptor; Oncology; Internal medicine; Hormone receptor; Progesterone receptor; Receptor; Primary tumor; Epidemiology; Cancer; Gynecology; Hormone; Metastasis","score_opus":0.050056378111768426,"score_gpt":0.32662751271552665,"score_spread":0.2765711346037582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108248587","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80334145,0.081570774,0.10082125,0.005449894,0.0011811646,0.00046055368,0.004071242,0.0002503772,0.002853293],"genre_scores_gemma":[0.98573744,0.0026044406,0.008884476,0.00082505454,0.00027430413,0.00014272776,0.0012525218,0.000040610976,0.0002384819],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9125948,0.05084276,0.010993437,0.013712818,0.010770538,0.0010857211],"domain_scores_gemma":[0.70896053,0.19280028,0.064635865,0.023332031,0.009431587,0.0008396938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13575257,0.0009601017,0.0023481627,0.0028279312,0.000555128,0.0021812548,0.0026160406,0.0014204064,0.0011174153],"category_scores_gemma":[0.249093,0.0006442496,0.0035768596,0.0042289523,0.0021282143,0.0016619009,0.0018301404,0.0014701406,0.00020095108],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010155458,0.00005219031,0.92724323,0.0035129944,0.011088744,0.0003545761,0.0017252864,0.002336624,0.0006179755,0.0025195947,0.001520664,0.04801265],"study_design_scores_gemma":[0.00023372027,0.00044127714,0.9415395,0.0032753083,0.009284086,0.0024280522,0.0005979776,0.010580209,0.0037987754,0.01879698,0.008822631,0.0002013333],"about_ca_topic_score_codex":0.00369793,"about_ca_topic_score_gemma":0.002834075,"teacher_disagreement_score":0.13575257,"about_ca_system_score_codex":0.0015463517,"about_ca_system_score_gemma":0.0012173263,"threshold_uncertainty_score":0.7179368},"labels":[],"label_agreement":null},{"id":"W2108261465","doi":"10.1634/theoncologist.2010-0093","title":"Understanding Micrometastatic Disease and <i>Anoikis</i> Resistance in Ewing Family of Tumors and Osteosarcoma","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Institutes of Health Research; University College London Hospitals NHS Foundation Trust; National Institutes of Health; Michael Smith Health Research BC","keywords":"Anoikis; Osteosarcoma; Medicine; Cancer research; Metastasis; Primary tumor; Disease; Pathology; Oncology; Cancer; Internal medicine","score_opus":0.17445346071956425,"score_gpt":0.3616517035293135,"score_spread":0.18719824280974923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108261465","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001044323,0.998099,0.00008984453,0.00044486282,0.00027140765,0.0000047402636,0.000013456408,0.0000057892175,0.0009663822],"genre_scores_gemma":[0.0004318271,0.99852765,0.000117094925,0.00023759587,0.00014986556,0.000004908137,0.000016581133,7.995611e-7,0.0005136404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990475,0.000012723153,0.000013522458,0.000016831347,0.000042613672,0.000009487056],"domain_scores_gemma":[0.99979407,0.00008956148,0.000034776414,0.0000038665344,0.00005913248,0.000018639592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030520486,0.0005211989,0.0007436182,0.0017494913,0.00020963169,0.00071795995,0.00046878474,0.0008953942,0.0026057],"category_scores_gemma":[0.00044880688,0.00020077394,0.000320352,0.0018397097,0.00034651562,0.0013151749,0.00044255375,0.0014236058,0.0013062491],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054619606,0.000072312876,0.00018944553,0.025134854,0.000053310305,0.0002523936,0.000092865106,0.00043078084,0.002116757,0.004015344,0.04329813,0.9242892],"study_design_scores_gemma":[0.00001075584,0.000104364415,0.0008826036,0.0055135693,0.000062903586,0.0015863957,0.000092437236,0.00010118443,0.00043217314,0.0023044166,0.9888926,0.000016557917],"about_ca_topic_score_codex":0.0012475377,"about_ca_topic_score_gemma":0.002110979,"teacher_disagreement_score":0.0026057,"about_ca_system_score_codex":0.0005688046,"about_ca_system_score_gemma":0.00095676916,"threshold_uncertainty_score":0.008716941},"labels":[],"label_agreement":null},{"id":"W2108757112","doi":"10.1634/theoncologist.2014-0438","title":"Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Nausea and vomiting management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Antiemetic; Medicine; Nausea; Chemotherapy-induced nausea and vomiting; Vomiting; Intensive care medicine; Chemotherapy; Quality of life (healthcare); Anesthesia; Internal medicine; Nursing","score_opus":0.09718358085502046,"score_gpt":0.3713657553445975,"score_spread":0.27418217448957705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108757112","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032589252,0.1637607,0.000716673,0.80872154,0.014314704,0.000027436594,0.000081484504,0.00008666159,0.009031848],"genre_scores_gemma":[0.07128437,0.3757006,0.006727331,0.4844774,0.050862387,0.00013750735,0.0002553855,0.00020021861,0.010354819],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973003,0.001221012,0.00039464078,0.00022205425,0.00066178566,0.00020028757],"domain_scores_gemma":[0.9839489,0.008024757,0.0015760454,0.0005049768,0.0035712912,0.0023741084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048396946,0.00041843753,0.0018608024,0.0006406402,0.0011940906,0.0035535304,0.0011011043,0.004399994,0.01556258],"category_scores_gemma":[0.025686055,0.00027248278,0.00088569394,0.00079095806,0.0024969545,0.008209584,0.0016070551,0.009845202,0.0033593758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005934718,0.000269378,0.004510426,0.005016355,0.00018514485,0.0011636481,0.0010547229,0.00012805178,0.0010918824,0.008801752,0.41877028,0.5584148],"study_design_scores_gemma":[0.00042331556,0.00054723356,0.017072089,0.017051503,0.00024753553,0.004648893,0.005771769,0.00014876989,0.0005483044,0.023040228,0.9303322,0.00016820466],"about_ca_topic_score_codex":0.0031760053,"about_ca_topic_score_gemma":0.013374383,"teacher_disagreement_score":0.01556258,"about_ca_system_score_codex":0.0017082171,"about_ca_system_score_gemma":0.0057146433,"threshold_uncertainty_score":0.052062035},"labels":[],"label_agreement":null},{"id":"W2108979762","doi":"10.1634/theoncologist.12-3-331","title":"Optimal Adjuvant Therapy for Non-Small Cell Lung Cancer—How to Handle Stage I Disease","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Adjuvant; Adjuvant therapy; Oncology; Disease; Chemotherapy; Adjuvant chemotherapy; Internal medicine; Cancer; Intensive care medicine; Breast cancer","score_opus":0.0861324768492604,"score_gpt":0.4181407240567727,"score_spread":0.3320082472075123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108979762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000103901286,0.998548,0.0000931732,0.0006507714,0.00012987264,0.0000062329054,0.000012157158,0.0000042464612,0.00045163077],"genre_scores_gemma":[0.0014489258,0.99723697,0.00034250133,0.0005099931,0.00014243035,0.000013716668,0.000024721105,0.0000018448599,0.00027884677],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999699,0.00012930144,0.00004560172,0.00003181522,0.00007612281,0.000018081768],"domain_scores_gemma":[0.9996574,0.00019914011,0.00006942574,0.000010167032,0.000046837667,0.000017006354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078747986,0.0006168302,0.0023956012,0.0012357208,0.00016790502,0.0007152069,0.00087126106,0.0011598825,0.0034774307],"category_scores_gemma":[0.0015442822,0.00024916837,0.0008043775,0.0014190078,0.00035044146,0.0012930311,0.0004099079,0.0014685295,0.001294627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018048336,0.00005082903,0.00020660652,0.030711042,0.00036215648,0.0000972179,0.000041854863,0.0003994004,0.0005153628,0.0021947306,0.037184175,0.9280562],"study_design_scores_gemma":[0.00062404183,0.00025602954,0.0043008076,0.05499031,0.0011838947,0.0018261793,0.00019010613,0.00042643465,0.0004651852,0.01097039,0.92473096,0.00003576863],"about_ca_topic_score_codex":0.0014202312,"about_ca_topic_score_gemma":0.0033686596,"teacher_disagreement_score":0.0034774307,"about_ca_system_score_codex":0.0005944063,"about_ca_system_score_gemma":0.00095758354,"threshold_uncertainty_score":0.011633158},"labels":[],"label_agreement":null},{"id":"W2109116356","doi":"10.1634/theoncologist.5-4-302","title":"SPIKES—A Six-Step Protocol for Delivering Bad News: Application to the Patient with Cancer","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":3045,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Protocol (science); Medicine; Cancer; Medical information; Medical emergency; Medical physics; Medical education; Family medicine; Alternative medicine; Pathology; Internal medicine","score_opus":0.1853504159787481,"score_gpt":0.4751298314215793,"score_spread":0.28977941544283115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109116356","genre_codex":"protocol","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07188472,0.0010286844,0.4256767,0.022383522,0.0035198757,0.43089098,0.002347234,0.0043621757,0.037906118],"genre_scores_gemma":[0.06501464,0.0012417552,0.5345516,0.004632107,0.0006893043,0.38380155,0.00071940414,0.00022007406,0.00912961],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96737504,0.025751755,0.003278036,0.0006980393,0.0019769473,0.0009202049],"domain_scores_gemma":[0.95027786,0.035241153,0.0022815256,0.0057849903,0.003580267,0.0028342833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.043147147,0.0010158506,0.0006679498,0.00097441184,0.0032701013,0.001437283,0.0023533942,0.003767362,0.020333046],"category_scores_gemma":[0.077587605,0.00094783306,0.0011268482,0.0007564483,0.0016210404,0.0017693192,0.0047925985,0.004640639,0.0074983705],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007963607,0.011279108,0.0028996486,0.0058264467,0.00015043357,0.0029098121,0.02033106,0.0040822513,0.01014362,0.019063342,0.15194193,0.7634088],"study_design_scores_gemma":[0.02005244,0.03881735,0.013133813,0.0044753593,0.0003498903,0.0053494964,0.022233088,0.018319413,0.018990086,0.054779883,0.8022666,0.0012325839],"about_ca_topic_score_codex":0.0007457916,"about_ca_topic_score_gemma":0.0015772284,"teacher_disagreement_score":0.043147147,"about_ca_system_score_codex":0.0012895972,"about_ca_system_score_gemma":0.00647183,"threshold_uncertainty_score":0.22818667},"labels":[],"label_agreement":null},{"id":"W2110202780","doi":"10.1634/theoncologist.2015-0058","title":"Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Body mass index; Lean body mass; Toxicity; Body surface area; Afatinib; Lung cancer; Body surface; Internal medicine; Cancer; Oncology; Gastroenterology; Body weight; Gefitinib","score_opus":0.013567195967992085,"score_gpt":0.29274849743977227,"score_spread":0.27918130147178016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110202780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99926525,0.00044272293,0.000040584076,0.000027081556,0.0000038631774,0.000005728954,0.00008240875,0.0000015789144,0.00013087977],"genre_scores_gemma":[0.9997528,0.00005891148,0.000033523338,0.000015001346,0.0000040727227,0.000004113902,0.00008398697,4.469051e-7,0.00004721128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997824,0.00006288324,0.00004262553,0.00003780542,0.0000441068,0.000030165465],"domain_scores_gemma":[0.99923825,0.00011549907,0.000426992,0.000023589791,0.000060725684,0.0001349192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028428368,0.00020339323,0.00038172855,0.00032853446,0.00027878082,0.00031459058,0.00012441906,0.00023373278,0.00094645633],"category_scores_gemma":[0.0010749989,0.00012377439,0.0003825854,0.000519052,0.00016722135,0.00021788465,0.0002117658,0.00037676143,0.0000898209],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010075541,0.000057068388,0.9952668,0.000019857816,0.00009900146,0.00006457673,0.00001338715,0.000075175616,0.00082520064,0.000004995438,0.00005449036,0.0025119397],"study_design_scores_gemma":[0.000024518127,0.0003952735,0.99870265,0.0000034817604,0.000051374143,0.00025890418,0.000027438715,0.00031172938,0.00012034215,0.000014947051,0.000086665066,0.0000027750414],"about_ca_topic_score_codex":0.00075656804,"about_ca_topic_score_gemma":0.0012614777,"teacher_disagreement_score":0.00094645633,"about_ca_system_score_codex":0.00021154965,"about_ca_system_score_gemma":0.00016599463,"threshold_uncertainty_score":0.0031662583},"labels":[],"label_agreement":null},{"id":"W2110525437","doi":"10.1634/theoncologist.2014-0130","title":"The Opioid Rotation Ratio of Hydrocodone to Strong Opioids in Cancer Patients","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; National Cancer Institute; U.S. Food and Drug Administration","keywords":"Hydrocodone; Medicine; Opioid; Anesthesia; Morphine; Oxycodone; Internal medicine","score_opus":0.02047041567370187,"score_gpt":0.3158234698289761,"score_spread":0.2953530541552742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110525437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693334,0.0022635206,0.00015113586,0.00007700925,0.000007870038,0.000020922957,0.0001404115,0.0000071618974,0.00039868426],"genre_scores_gemma":[0.9991799,0.00041043636,0.00020810399,0.000037471775,0.000008132035,0.0000070234423,0.00009814333,0.0000017139811,0.00004911425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992305,0.000264634,0.00011171016,0.00010017378,0.00022409944,0.00006887844],"domain_scores_gemma":[0.9954868,0.0008878736,0.0030942378,0.00009725059,0.00021287841,0.00022098182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009229449,0.00015380669,0.0002540951,0.0004508748,0.00020678336,0.00039327348,0.00020690683,0.00017844426,0.0013716357],"category_scores_gemma":[0.0063558808,0.000104781015,0.00025512048,0.000522554,0.00023665265,0.00029090844,0.00024597216,0.0003148507,0.00022048753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064053293,0.00003521149,0.9808219,0.00006607376,0.000059544105,0.00012165824,0.00007009442,0.00010042459,0.00084422436,0.000016888052,0.0001833729,0.017040104],"study_design_scores_gemma":[0.00003449374,0.0008232146,0.9956682,0.000033581382,0.000060193328,0.0015762028,0.00014113571,0.0003704003,0.00075263873,0.00002731723,0.0005055807,0.0000069882535],"about_ca_topic_score_codex":0.0008881633,"about_ca_topic_score_gemma":0.0013579354,"teacher_disagreement_score":0.0013716357,"about_ca_system_score_codex":0.0004840767,"about_ca_system_score_gemma":0.0003367553,"threshold_uncertainty_score":0.004881084},"labels":[],"label_agreement":null},{"id":"W2110859080","doi":"10.1634/theoncologist.2012-0228","title":"The Case for Chemotherapy Alone for Limited-Stage Hodgkin's Lymphoma","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Hodgkin lymphoma; Lymphoma; Chemotherapy; Stage (stratigraphy); Oncology; Disease; Radiation therapy; Internal medicine","score_opus":0.052371290433459845,"score_gpt":0.3465056750231264,"score_spread":0.29413438458966656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110859080","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011849286,0.074084915,0.006155985,0.82241374,0.021514544,0.00011292443,0.0001835113,0.00013788408,0.06354722],"genre_scores_gemma":[0.243795,0.052794706,0.014555488,0.49407694,0.1646356,0.00024741766,0.00023472979,0.00033533378,0.02932493],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995989,0.0016616405,0.0004827989,0.0006070139,0.0007535974,0.00050592836],"domain_scores_gemma":[0.9766926,0.016052278,0.0017117627,0.0019850994,0.0018216138,0.0017366568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008088674,0.00039117734,0.0014875904,0.0008677102,0.0026385314,0.0028722207,0.0016118054,0.010629594,0.018523585],"category_scores_gemma":[0.032096997,0.00046481125,0.0023772337,0.00091759756,0.004325819,0.006749377,0.0016669641,0.0139186075,0.003382177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027518112,0.0002778017,0.030972429,0.0032959217,0.0008289286,0.08688929,0.0012002756,0.00073682255,0.0032974656,0.16674964,0.37329498,0.3297046],"study_design_scores_gemma":[0.00036830496,0.00054601335,0.009190075,0.0041530784,0.0005441879,0.12188415,0.0015377686,0.0008052887,0.0012491375,0.113817886,0.7457509,0.00015321087],"about_ca_topic_score_codex":0.0016665141,"about_ca_topic_score_gemma":0.004197581,"teacher_disagreement_score":0.018523585,"about_ca_system_score_codex":0.0015773447,"about_ca_system_score_gemma":0.003745755,"threshold_uncertainty_score":0.06196755},"labels":[],"label_agreement":null},{"id":"W2111879300","doi":"10.1634/theoncologist.2010-0081","title":"A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Toronto; University Health Network; Sunnybrook Health Science Centre","funders":"National Cancer Institute; American Society of Clinical Oncology; BC Cancer Agency; AstraZeneca","keywords":"Pazopanib; Medicine; Metastatic breast cancer; Clinical endpoint; Internal medicine; Oncology; Neutropenia; Progressive disease; Breast cancer; Progression-free survival; Chemotherapy; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Sunitinib","score_opus":0.020701137887031117,"score_gpt":0.30937759705815965,"score_spread":0.28867645917112855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111879300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816457,0.006152869,0.00085090275,0.0016078178,0.00016139836,0.0046229395,0.0011451842,0.00012904445,0.003684318],"genre_scores_gemma":[0.97164536,0.0053234175,0.0033716888,0.0027870482,0.00033294197,0.006998121,0.004245727,0.000042855318,0.0052528116],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958056,0.00023981385,0.00001391896,0.000054089363,0.000044840202,0.00006677731],"domain_scores_gemma":[0.99930155,0.000096615564,0.00016067931,0.000041292238,0.0000487955,0.00035096478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016739953,0.0013861583,0.0015502445,0.00030545954,0.00033725364,0.0006886599,0.00096561096,0.0014268475,0.0033976503],"category_scores_gemma":[0.00094717543,0.00041221967,0.0009603968,0.0003861683,0.0006769674,0.0004931681,0.00031464818,0.0026201024,0.0007070178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6798207,0.048494622,0.011437982,0.0018956558,0.0021729262,0.00064830127,0.00043685656,0.003621086,0.041963946,0.0006532071,0.019319635,0.18953505],"study_design_scores_gemma":[0.8409788,0.13635921,0.014009401,0.00004500902,0.00033469626,0.0005464363,0.00003360581,0.0011776417,0.0018593918,0.00019982434,0.004430917,0.000025047804],"about_ca_topic_score_codex":0.00082028576,"about_ca_topic_score_gemma":0.002146996,"teacher_disagreement_score":0.0033976503,"about_ca_system_score_codex":0.0007891621,"about_ca_system_score_gemma":0.0011541613,"threshold_uncertainty_score":0.011366248},"labels":[],"label_agreement":null},{"id":"W2112098903","doi":"10.1634/theoncologist.2015-0023","title":"Geriatric Assessment of Older Adults With Cancer During Unplanned Hospitalizations: An Opportunity in Disguise","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital","funders":"National Cancer Institute","keywords":"Medicine; Psychosocial; Activities of daily living; Population; Depression (economics); Geriatric oncology; Patient-Reported Outcomes Measurement Information System; Cancer; Physical therapy; Gerontology; Psychiatry; Internal medicine","score_opus":0.038526120285594385,"score_gpt":0.35430732410554067,"score_spread":0.3157812038199463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112098903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88659304,0.009956759,0.0026833266,0.087579004,0.00084658887,0.00038488925,0.00032899668,0.00011069197,0.011516886],"genre_scores_gemma":[0.98700935,0.003367311,0.00383695,0.004292175,0.0008872301,0.00014904175,0.000111167006,0.000011146919,0.00033556405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974093,0.001474838,0.000303711,0.00010140323,0.00042452448,0.00028631883],"domain_scores_gemma":[0.9914569,0.002425368,0.0022746013,0.00038690702,0.0011577919,0.002298411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007461763,0.00029059662,0.00028046034,0.0007373239,0.00079073507,0.0015744983,0.0006310639,0.0008050619,0.0012160757],"category_scores_gemma":[0.01268792,0.00025339157,0.00027096362,0.0005386896,0.00070592307,0.002353252,0.001899907,0.0012904358,0.00018996776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023693187,0.00025231278,0.8681926,0.00029321425,0.000043634147,0.0020233693,0.004611881,0.00012723517,0.000504518,0.00038207482,0.016514938,0.10681721],"study_design_scores_gemma":[0.000073988595,0.0012081764,0.9455385,0.0013938779,0.00006074909,0.0069830287,0.023966638,0.0010274199,0.00025526615,0.0012728082,0.018162446,0.000057107256],"about_ca_topic_score_codex":0.0026605166,"about_ca_topic_score_gemma":0.013387041,"teacher_disagreement_score":0.007461763,"about_ca_system_score_codex":0.0006734905,"about_ca_system_score_gemma":0.0025693732,"threshold_uncertainty_score":0.03946203},"labels":[],"label_agreement":null},{"id":"W2112422374","doi":"10.1634/theoncologist.2009-0237","title":"Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Dacarbazine; Temozolomide; Chemotherapy; Internal medicine; Oncology; Melanoma; Multivariate analysis; Survival analysis; Cancer; Univariate analysis; Surgery; Cancer research","score_opus":0.021188396224277452,"score_gpt":0.27461178080380977,"score_spread":0.25342338457953234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112422374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989485,0.00057499844,0.000025339012,0.00007862925,0.0000039936444,0.0000037878374,0.00010133556,0.0000017371398,0.00026163127],"genre_scores_gemma":[0.9994821,0.0001913801,0.000026952639,0.00003246582,0.000011673136,0.000005543262,0.000200738,4.7271695e-7,0.000048685823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998524,0.000032018757,0.000014064928,0.000023099623,0.000028132767,0.000050289727],"domain_scores_gemma":[0.9991999,0.00013864684,0.00035800843,0.00001766527,0.00005685618,0.00022895478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026379584,0.00009692723,0.00026068452,0.00032123987,0.00037585796,0.00032456176,0.00015961472,0.00030739093,0.0008852193],"category_scores_gemma":[0.0013095371,0.000075762946,0.00022597541,0.00041916454,0.00016584195,0.00024176309,0.00021830428,0.00034531165,0.00010546064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045846618,0.000041639032,0.9942555,0.000015677157,0.000025919959,0.0003925774,0.000049431877,0.000103510894,0.00026629024,0.000011937954,0.00019070349,0.004188337],"study_design_scores_gemma":[0.000041394836,0.00043530753,0.9968316,0.00001960251,0.000047070098,0.0017308826,0.00011500967,0.00025013325,0.0001133246,0.000037504517,0.00037416007,0.0000039236584],"about_ca_topic_score_codex":0.0027017095,"about_ca_topic_score_gemma":0.0055393446,"teacher_disagreement_score":0.0027017095,"about_ca_system_score_codex":0.00044820708,"about_ca_system_score_gemma":0.00034159143,"threshold_uncertainty_score":0.005371928},"labels":[],"label_agreement":null},{"id":"W2112983735","doi":"10.1634/theoncologist.6-2-147","title":"Early Lung Cancer Action Project: A Summary of the Findings on Baseline Screening","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Eastman Kodak","keywords":"Medicine; Baseline (sea); Lung cancer; Action (physics); Oncology; Internal medicine; Intensive care medicine","score_opus":0.12643529530993078,"score_gpt":0.4413769561260123,"score_spread":0.31494166081608155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112983735","genre_codex":"dataset","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.099026814,0.057610877,0.0106283,0.07081564,0.005711929,0.02552864,0.62949145,0.0021509845,0.09903542],"genre_scores_gemma":[0.19528851,0.036958743,0.04559002,0.013978865,0.0018678335,0.031987354,0.6339537,0.0005926022,0.03978236],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.99172485,0.003229547,0.0010684093,0.0005762181,0.002223349,0.0011776444],"domain_scores_gemma":[0.9773356,0.0029617818,0.0014968027,0.0005981848,0.014014739,0.0035929582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02480482,0.0014324541,0.0009045394,0.004852496,0.0011282063,0.0025378775,0.002767072,0.0015970613,0.0049744467],"category_scores_gemma":[0.01109467,0.000684363,0.0010293934,0.006302414,0.00035018128,0.0011325668,0.002443316,0.0020361808,0.0022119526],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015759753,0.0015061816,0.24250452,0.0076807714,0.00042006595,0.00048581895,0.0010782555,0.0010982566,0.0010726842,0.00095019554,0.46881217,0.27281505],"study_design_scores_gemma":[0.00035932328,0.0012101231,0.65344787,0.0037035027,0.00040369644,0.00031749322,0.001962983,0.00042424072,0.0016577303,0.00022659988,0.3362053,0.00008123204],"about_ca_topic_score_codex":0.11864951,"about_ca_topic_score_gemma":0.08200863,"teacher_disagreement_score":0.11864951,"about_ca_system_score_codex":0.0063789086,"about_ca_system_score_gemma":0.026422538,"threshold_uncertainty_score":0.2359178},"labels":[],"label_agreement":null},{"id":"W2113167936","doi":"10.1634/theoncologist.2011-0379","title":"Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ministry of Health; Canadian Centre for Applied Research in Cancer Control; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Genentech; Canadian Cancer Society","keywords":"Medicine; Trastuzumab; Breast cancer; Regimen; Cost effectiveness; Oncology; Adjuvant; Quality of life (healthcare); Internal medicine; Quality-adjusted life year; Cancer","score_opus":0.1251169310672112,"score_gpt":0.4951463378981687,"score_spread":0.37002940683095753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113167936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715641,0.016059276,0.006524399,0.0016988014,0.00007331504,0.0005013864,0.0018364368,0.000031945474,0.001710313],"genre_scores_gemma":[0.99577737,0.0018902883,0.0015294465,0.00010545001,0.000018325813,0.00013770297,0.00046457004,0.0000048284683,0.00007202975],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9912277,0.007324899,0.00045616904,0.0003029418,0.00042577332,0.0002626007],"domain_scores_gemma":[0.95677805,0.0374368,0.0040556206,0.00053861196,0.00082593935,0.00036497417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015332401,0.00093811733,0.0012029754,0.0015574041,0.00020097043,0.0015950591,0.0009994559,0.0013865683,0.0013384427],"category_scores_gemma":[0.0618186,0.0007366419,0.0029452383,0.0014520059,0.00055173907,0.0015252422,0.00090564927,0.001088034,0.00009335089],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013075756,0.0013487621,0.11274723,0.0042421585,0.014800975,0.0002922718,0.00014186566,0.7995326,0.00051523646,0.0029633092,0.0011430165,0.04919682],"study_design_scores_gemma":[0.00412565,0.010716057,0.1036947,0.002481035,0.015280274,0.0006953843,0.00045558007,0.8455587,0.0015917581,0.0125447735,0.002632704,0.00022334489],"about_ca_topic_score_codex":0.012969973,"about_ca_topic_score_gemma":0.008580839,"teacher_disagreement_score":0.015332401,"about_ca_system_score_codex":0.005598222,"about_ca_system_score_gemma":0.0031354318,"threshold_uncertainty_score":0.08108646},"labels":[],"label_agreement":null},{"id":"W2113825200","doi":"10.1634/theoncologist.2014-0268","title":"The Value of Personalizing Medicine: Medical Oncologists’ Views on Gene Expression Profiling in Breast Cancer Treatment","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research; Canadian Centre for Applied Research in Cancer Control; Cancer Care Ontario","keywords":"Medicine; Breast cancer; Test (biology); Family medicine; MEDLINE; Clinical Practice; Precision medicine; Personalized medicine; Oncology; Internal medicine; Cancer; Bioinformatics; Pathology","score_opus":0.0673460606571507,"score_gpt":0.38438444260291743,"score_spread":0.3170383819457667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113825200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.622447,0.018197387,0.003735399,0.33094507,0.0011957365,0.00010618342,0.00007371993,0.000030888114,0.023268446],"genre_scores_gemma":[0.9743547,0.002325929,0.0011255343,0.021322357,0.00024945138,0.000042266285,0.00001107552,0.000013226316,0.0005554795],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9251812,0.067053206,0.001096023,0.0011451212,0.0033579078,0.002166475],"domain_scores_gemma":[0.8879802,0.0925787,0.007905914,0.0011453242,0.004803262,0.0055865454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.040999375,0.00029229713,0.00039841852,0.0010120836,0.0080021275,0.007604466,0.0010680015,0.004580597,0.0016551787],"category_scores_gemma":[0.06124718,0.00048286284,0.00047737014,0.00094965904,0.014170254,0.0047278753,0.0061654146,0.00676978,0.00019742658],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014278345,0.0000727582,0.016597832,0.0007187057,0.000050722203,0.001088681,0.93456453,0.00019499812,0.0010361775,0.005714068,0.007736813,0.032081824],"study_design_scores_gemma":[0.000046894198,0.00020593836,0.008376482,0.0013092824,0.000066983484,0.0015760994,0.9101931,0.0002585589,0.000685956,0.003916762,0.073294364,0.000069538044],"about_ca_topic_score_codex":0.0031220035,"about_ca_topic_score_gemma":0.004485984,"teacher_disagreement_score":0.040999375,"about_ca_system_score_codex":0.0055828365,"about_ca_system_score_gemma":0.0076881205,"threshold_uncertainty_score":0.21682799},"labels":[],"label_agreement":null},{"id":"W2114029286","doi":"10.1634/theoncologist.2007-0234","title":"Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?","year":2008,"lang":"en","type":"review","venue":"The Oncologist","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Genitourinary system; Tamoxifen; Population; Cancer; Estrogen; Gynecology; Intensive care medicine; Menopause; Oncology; Internal medicine","score_opus":0.034860762930713475,"score_gpt":0.32379934626937695,"score_spread":0.28893858333866346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114029286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003107028,0.9726068,0.00048664937,0.01407111,0.002416893,0.000065531654,0.00014435462,0.000026817714,0.0070747873],"genre_scores_gemma":[0.013645517,0.97265077,0.0009828089,0.006777638,0.0025866542,0.000065642394,0.00018291178,0.0000072736425,0.0031008648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979883,0.000065247405,0.000031341293,0.000015221218,0.000067212786,0.000022120019],"domain_scores_gemma":[0.9994692,0.00027734687,0.0000933549,0.00000713456,0.00011359671,0.00003932182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053379865,0.00014914648,0.00055274204,0.0005411387,0.000184681,0.00056213286,0.00034616023,0.0010350365,0.006097394],"category_scores_gemma":[0.0020110128,0.00009615576,0.00050492544,0.00039062917,0.00018266402,0.00071568723,0.00025560718,0.0010956837,0.0011904332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025569103,0.000100739024,0.0017768688,0.016847404,0.00008344807,0.0012557439,0.00020167537,0.00013756004,0.0009705701,0.0014147928,0.094580665,0.8823748],"study_design_scores_gemma":[0.00013624327,0.00061943755,0.009557012,0.02263998,0.0002424016,0.009381337,0.0006612963,0.0001643594,0.00092552026,0.0024506545,0.9531791,0.000042642867],"about_ca_topic_score_codex":0.0010269138,"about_ca_topic_score_gemma":0.0027565146,"teacher_disagreement_score":0.006097394,"about_ca_system_score_codex":0.00030422903,"about_ca_system_score_gemma":0.0006637372,"threshold_uncertainty_score":0.020397842},"labels":[],"label_agreement":null},{"id":"W2115861091","doi":"10.1634/theoncologist.2010-0387","title":"Targeting Angiogenesis in Esophagogastric Adenocarcinoma","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"AstraZeneca; Chugai Pharmaceutical; Pfizer; Amgen","keywords":"Medicine; Sorafenib; Bevacizumab; Sunitinib; Angiogenesis; Internal medicine; Receptor tyrosine kinase; Oncology; Cancer research; Cancer; Vascular endothelial growth factor; Chemotherapy; Receptor; Hepatocellular carcinoma","score_opus":0.11466906553746307,"score_gpt":0.36169405916973296,"score_spread":0.24702499363226987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115861091","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24041344,0.4499826,0.01635414,0.06356221,0.026768275,0.00095955224,0.000713791,0.0012600956,0.19998595],"genre_scores_gemma":[0.48887125,0.31164247,0.011477582,0.021107743,0.01619362,0.0005067456,0.00096964964,0.00014649003,0.14908445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999666,0.000006914365,0.0000024487651,0.0000033264698,0.000010904152,0.0000097989],"domain_scores_gemma":[0.99994135,0.000010494149,0.0000068469126,0.0000015686294,0.000015738178,0.0000240617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020399394,0.000294696,0.00019916319,0.0002518359,0.00009674522,0.0003533084,0.00019241252,0.00038435802,0.0062628975],"category_scores_gemma":[0.00022343107,0.00005853324,0.00015246186,0.00010504152,0.000072289076,0.00025211653,0.00026269452,0.0006641422,0.0013697109],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013865097,0.0008327119,0.0020330695,0.0015537728,0.000028941302,0.0025163426,0.00007106906,0.000730206,0.069913745,0.0034590638,0.14818998,0.76928455],"study_design_scores_gemma":[0.0010792565,0.007917354,0.014770532,0.001370296,0.00011404457,0.012416229,0.0001538022,0.0038964022,0.059520237,0.004736005,0.89398605,0.00003987939],"about_ca_topic_score_codex":0.00024187144,"about_ca_topic_score_gemma":0.0005500962,"teacher_disagreement_score":0.0062628975,"about_ca_system_score_codex":0.00033288723,"about_ca_system_score_gemma":0.00020885102,"threshold_uncertainty_score":0.02095151},"labels":[],"label_agreement":null},{"id":"W2116280772","doi":"10.1634/theoncologist.2008-0070","title":"Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Sanofi; AstraZeneca; Pfizer","keywords":"Anthracycline; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Stage (stratigraphy); Topoisomerase; Cancer; Chemotherapy; Trastuzumab","score_opus":0.11737981977320233,"score_gpt":0.4823295088974135,"score_spread":0.36494968912421116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116280772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058446592,0.99930537,0.000030438163,0.00024819354,0.000058623555,0.000001134893,0.000004097604,0.0000020739722,0.00029156654],"genre_scores_gemma":[0.0003990279,0.99904567,0.00006466539,0.00014744842,0.00007379127,0.0000014299492,0.000006413968,4.3083998e-7,0.0002611247],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998467,0.00004211862,0.000022856164,0.000020334666,0.000057385638,0.000010618952],"domain_scores_gemma":[0.9996313,0.000182254,0.000056725792,0.000011908064,0.00009100841,0.000026792351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054415694,0.00054486725,0.0015635273,0.0012191486,0.00022758367,0.0006567007,0.0006709321,0.00089863944,0.0029549988],"category_scores_gemma":[0.0007697406,0.00020497406,0.00032368698,0.001968893,0.00043208292,0.0012864311,0.00035938734,0.0013825432,0.0017984016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010370297,0.00006522506,0.0001816723,0.019291345,0.00008171091,0.00025263432,0.00006750186,0.00022012243,0.0010183693,0.0021930546,0.034580823,0.9419438],"study_design_scores_gemma":[0.00005471241,0.0001719011,0.0016611734,0.007377788,0.00019116842,0.0026304005,0.00012466691,0.00010130209,0.00046862185,0.0026210153,0.9845785,0.000018759027],"about_ca_topic_score_codex":0.0014643484,"about_ca_topic_score_gemma":0.0037178404,"teacher_disagreement_score":0.0029549988,"about_ca_system_score_codex":0.0005725048,"about_ca_system_score_gemma":0.00097368145,"threshold_uncertainty_score":0.00988543},"labels":[],"label_agreement":null},{"id":"W2116338644","doi":"10.1634/theoncologist.2013-0469","title":"Measuring the Population Impact of Introducing Stereotactic Ablative Radiotherapy for Stage I Non-Small Cell Lung Cancer in Canada","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"SABR volatility model; Medicine; Pneumonectomy; Lung cancer; Radiation therapy; Population; Quality-adjusted life year; Cancer registry; Surgery; Cost effectiveness; Oncology; Environmental health; Economics","score_opus":0.023859573479758457,"score_gpt":0.32158829061413097,"score_spread":0.2977287171343725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116338644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95870835,0.0019988322,0.003976129,0.0024505064,0.00004331745,0.00032632047,0.019694664,0.00010286123,0.012699046],"genre_scores_gemma":[0.9928826,0.0005533625,0.0021428014,0.00016148642,0.0000065277063,0.000059474936,0.0035438763,0.000013582701,0.0006363107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983411,0.00031572004,0.00006985027,0.00019777955,0.00058758626,0.00048802845],"domain_scores_gemma":[0.9963405,0.0007829622,0.0006443488,0.0000835068,0.0017501442,0.00039864064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020634965,0.0005249417,0.00034978424,0.001334976,0.0007533065,0.0011660724,0.0014430563,0.0004416182,0.0017264937],"category_scores_gemma":[0.010114081,0.0002389592,0.0010739634,0.0024145953,0.00049453345,0.0004562041,0.0009779782,0.00072830234,0.0001379958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041441107,0.00018063423,0.7317415,0.00034892285,0.0007491095,0.00020418689,0.00029481444,0.22248507,0.00024260605,0.004105619,0.007950218,0.031282913],"study_design_scores_gemma":[0.00017063586,0.00054248655,0.6747567,0.00028756534,0.00092631957,0.00018846338,0.0014506418,0.3078442,0.0009779828,0.0019913684,0.010744523,0.00011914336],"about_ca_topic_score_codex":0.9896359,"about_ca_topic_score_gemma":0.98627496,"teacher_disagreement_score":0.07823135,"about_ca_system_score_codex":0.07823135,"about_ca_system_score_gemma":0.058643714,"threshold_uncertainty_score":0.56761086},"labels":[],"label_agreement":null},{"id":"W2116456578","doi":"10.1634/theoncologist.11-90001-13","title":"The Role of Bisphosphonates in Early Breast Cancer","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.03476832903059714,"score_gpt":0.3826331772062494,"score_spread":0.3478648481756523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116456578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054277545,0.99956125,0.000015072259,0.000066897184,0.000033629294,0.0000026067537,0.0000038944813,0.0000015351316,0.00026084573],"genre_scores_gemma":[0.00064129004,0.9990632,0.000046079094,0.00008805129,0.000023763025,0.000003337287,0.0000071883637,4.341116e-7,0.00012673353],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99963903,0.00011682203,0.00005228996,0.00004557659,0.00012337008,0.000022905004],"domain_scores_gemma":[0.9993887,0.00041600008,0.00009448765,0.000011160925,0.00006677946,0.000022800163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008798552,0.000751927,0.0021486834,0.002225312,0.00025467257,0.0007366704,0.0007663468,0.0011968663,0.0037837673],"category_scores_gemma":[0.0012716807,0.00027488338,0.0008613187,0.0025803815,0.00048744943,0.0007846009,0.0004332933,0.0012704524,0.0011179295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024763076,0.000071949566,0.00019855685,0.049479663,0.00029986736,0.00012671949,0.000043182565,0.0002578243,0.0006737609,0.0015660779,0.013332626,0.9337022],"study_design_scores_gemma":[0.00032723634,0.00054309017,0.0042000273,0.03795505,0.0012053322,0.002843317,0.00016193627,0.00016627809,0.0008741083,0.0034639603,0.9482296,0.000029993362],"about_ca_topic_score_codex":0.0024653126,"about_ca_topic_score_gemma":0.0053174812,"teacher_disagreement_score":0.0037837673,"about_ca_system_score_codex":0.0006510076,"about_ca_system_score_gemma":0.001089933,"threshold_uncertainty_score":0.01265794},"labels":[],"label_agreement":null},{"id":"W2116488544","doi":"10.1634/theoncologist.2011-0151","title":"Preliminary Report: Vitamin D Deficiency in Advanced Cancer Patients with Symptoms of Fatigue or Anorexia","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Medicine; Vitamin D and neurology; Internal medicine; vitamin D deficiency; Cancer; Anorexia; Cachexia; Gastroenterology; Appetite; Vitamin; Endocrinology","score_opus":0.05281606135876366,"score_gpt":0.3459507428955177,"score_spread":0.29313468153675404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116488544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96518576,0.015342386,0.0007618935,0.0021656223,0.00048503545,0.00019766187,0.0037409696,0.00005326684,0.012067426],"genre_scores_gemma":[0.9933954,0.0028072826,0.00029100382,0.0005239287,0.00023488126,0.000055550696,0.0013741158,0.0000054428087,0.0013124308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977356,0.000047604928,0.000056202563,0.00003626873,0.00006006995,0.000026237012],"domain_scores_gemma":[0.9984297,0.00059131836,0.0004153903,0.000043045697,0.00037130967,0.00014920974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004119995,0.00012944987,0.00018409273,0.00041115453,0.00030712783,0.0003541467,0.00017736606,0.00032581674,0.0051207645],"category_scores_gemma":[0.0025732436,0.00007643157,0.00018837614,0.00057065964,0.00018313035,0.00020452874,0.00016078925,0.00027647667,0.00086555746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025690152,0.00006651198,0.9740539,0.0003028024,0.0000402943,0.0029047194,0.00015960111,0.0000357236,0.0007757957,0.000019928111,0.00401912,0.017364675],"study_design_scores_gemma":[0.00006404982,0.0009329975,0.9576783,0.00015793901,0.00008234597,0.026652025,0.0003980901,0.000079677,0.0006339305,0.00004193189,0.013269545,0.000009204224],"about_ca_topic_score_codex":0.001635912,"about_ca_topic_score_gemma":0.0017185002,"teacher_disagreement_score":0.0051207645,"about_ca_system_score_codex":0.00016653158,"about_ca_system_score_gemma":0.00029205394,"threshold_uncertainty_score":0.017130613},"labels":[],"label_agreement":null},{"id":"W2117590220","doi":"10.1634/theoncologist.11-6-590","title":"Cancer in 15- to 29-Year-Olds by Primary Site","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Medicine; Ethnic group; Race (biology); Cancer survival; Demography; Quarter (Canadian coin); Incidence (geometry); Cancer; Cancer incidence; Gerontology; Internal medicine","score_opus":0.0429315510139662,"score_gpt":0.3956065011842133,"score_spread":0.3526749501702471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117590220","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9106679,0.01066613,0.00047160478,0.0008773183,0.00047342898,0.0002756264,0.04856946,0.00015150715,0.027847026],"genre_scores_gemma":[0.9693573,0.006888941,0.00026135004,0.00044447518,0.00019683517,0.00017226391,0.014850405,0.000014967454,0.007813443],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.999775,0.00001818029,0.00002060529,0.00004881769,0.000059027512,0.00007842407],"domain_scores_gemma":[0.9996809,0.000010752551,0.000085505344,0.000010331658,0.00007832938,0.00013432905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015429789,0.0002517423,0.00031884073,0.001097113,0.00038542706,0.00040505393,0.00025324785,0.00031287252,0.007570048],"category_scores_gemma":[0.00042900784,0.00010733974,0.0004321964,0.001279787,0.00016225949,0.00038916714,0.00052052323,0.00043241505,0.0016513632],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043724955,0.000037842598,0.986177,0.00009157364,0.000054130975,0.00022781343,0.00011890369,0.00006105154,0.00026299956,0.00008313245,0.0059205075,0.0069213216],"study_design_scores_gemma":[0.0000036835602,0.00005078775,0.9961111,0.000059413826,0.000019345642,0.000546936,0.00016082972,0.00004833554,0.00004530176,0.00003584806,0.002915166,0.0000033434765],"about_ca_topic_score_codex":0.014027849,"about_ca_topic_score_gemma":0.012659786,"teacher_disagreement_score":0.014027849,"about_ca_system_score_codex":0.00028129504,"about_ca_system_score_gemma":0.00039476805,"threshold_uncertainty_score":0.027892351},"labels":[],"label_agreement":null},{"id":"W2119824367","doi":"10.1634/theoncologist.6-suppl_4-12","title":"Answering Patients' Needs: Oral Alternatives to Intravenous Therapy","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Capecitabine; Quality of life (healthcare); Medical prescription; Patient education; Tegafur; Intensive care medicine; Bolus (digestion); Oncology; Internal medicine; Colorectal cancer; Chemotherapy; Cancer; Pharmacology; Nursing","score_opus":0.10779214304453844,"score_gpt":0.4047876122001642,"score_spread":0.29699546915562575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119824367","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25229493,0.14554988,0.018001549,0.27412033,0.0044189547,0.00068286806,0.00031846768,0.00025239412,0.30436057],"genre_scores_gemma":[0.83825153,0.06764622,0.02966048,0.045882247,0.0037476767,0.00057896215,0.00026366953,0.00009654298,0.01387257],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99687636,0.002313935,0.0001518387,0.00007287211,0.00040710904,0.00017779782],"domain_scores_gemma":[0.99613273,0.0025804345,0.00042211683,0.00010028927,0.00026684292,0.00049757963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003640917,0.00021008991,0.00039980872,0.00022934374,0.0007643776,0.0024070332,0.000535658,0.0015660728,0.012811506],"category_scores_gemma":[0.012756785,0.00009089925,0.00053036644,0.00034019913,0.00083322596,0.0018304791,0.0021071506,0.0018365931,0.001011325],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013097249,0.0006432414,0.0055081192,0.0015552916,0.00006490476,0.0006782731,0.0038368816,0.0003471308,0.0008651401,0.0131458845,0.044483118,0.9275623],"study_design_scores_gemma":[0.0021969082,0.007333567,0.021552043,0.0065195435,0.00038627125,0.009772975,0.04001477,0.0019204564,0.0018408289,0.055100534,0.85319006,0.00017207334],"about_ca_topic_score_codex":0.00039543153,"about_ca_topic_score_gemma":0.0009676956,"teacher_disagreement_score":0.012811506,"about_ca_system_score_codex":0.00059442496,"about_ca_system_score_gemma":0.0010738898,"threshold_uncertainty_score":0.04285878},"labels":[],"label_agreement":null},{"id":"W2120603700","doi":"10.1634/theoncologist.2014-0437","title":"A Time-Trend Economic Analysis of Cancer Drug Trials","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Interior Health; Cancer Care Ontario; University of Toronto; University of British Columbia; St. Michael's Hospital; Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"Reimbursement; Medicine; Clinical trial; Cost effectiveness; Health care; Cost–benefit analysis; Colorectal cancer; Cancer drugs; Drug; Intensive care medicine; Oncology; Cancer; Internal medicine; Pharmacology; Risk analysis (engineering)","score_opus":0.6119905934439245,"score_gpt":0.5361387412957954,"score_spread":0.07585185214812906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120603700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63372725,0.12453555,0.14825471,0.01171022,0.0014781345,0.009974648,0.036393996,0.0006763728,0.033249166],"genre_scores_gemma":[0.95732695,0.010367971,0.017833283,0.00068231387,0.00032770014,0.0029915406,0.007929278,0.00009015717,0.0024509025],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9416798,0.04853587,0.0024398593,0.002350066,0.0038497716,0.001144614],"domain_scores_gemma":[0.7963464,0.17760421,0.014065057,0.0043865615,0.006471243,0.0011266293],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06704875,0.0013946526,0.0033957926,0.009738261,0.0005104902,0.0028782263,0.0018618078,0.001915444,0.0070690513],"category_scores_gemma":[0.19661756,0.0007875668,0.007966188,0.009305453,0.0009152496,0.003737092,0.0015390202,0.0032781106,0.0006233767],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01932284,0.0009473013,0.14652604,0.009889691,0.032357994,0.00077251106,0.00035029315,0.5443883,0.0005379748,0.049100738,0.020408865,0.1753975],"study_design_scores_gemma":[0.002186449,0.0055173305,0.0906433,0.0021348044,0.012776368,0.00073921593,0.0005501785,0.81714547,0.00055980834,0.045576468,0.021927336,0.00024323298],"about_ca_topic_score_codex":0.0109168375,"about_ca_topic_score_gemma":0.0050733853,"teacher_disagreement_score":0.9329513,"about_ca_system_score_codex":0.005653546,"about_ca_system_score_gemma":0.003298891,"threshold_uncertainty_score":0.3545919},"labels":[],"label_agreement":null},{"id":"W2121508408","doi":"10.1634/theoncologist.2015-0026","title":"Financial Distress and Its Associations With Physical and Emotional Symptoms and Quality of Life Among Advanced Cancer Patients","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":237,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health","keywords":"Interquartile range; Medicine; Psychosocial; Distress; Quality of life (healthcare); Confidence interval; Hospital Anxiety and Depression Scale; Anxiety; Internal medicine; Psychiatry; Clinical psychology","score_opus":0.05155118971980753,"score_gpt":0.28822914647198816,"score_spread":0.23667795675218062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121508408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99929345,0.0003292456,0.000015907488,0.000083579,0.0000037764362,0.0000040681734,0.00011210012,7.316977e-7,0.00015698078],"genre_scores_gemma":[0.99976,0.00008197928,0.00002352902,0.000020114923,0.0000090436215,0.0000035572598,0.00007663845,1.963347e-7,0.000025008801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994448,0.00025221173,0.00006777805,0.000050964234,0.00010370204,0.000080560756],"domain_scores_gemma":[0.9971455,0.000641919,0.0015178833,0.000053722637,0.00022194357,0.00041916096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009120704,0.00018178605,0.00021933996,0.0006968716,0.00033784332,0.00046705638,0.00020035724,0.00031762535,0.0013245291],"category_scores_gemma":[0.005078574,0.0001235752,0.00023277894,0.0008734563,0.0003004983,0.000394576,0.00046079123,0.0004158982,0.00009619346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030372385,0.000018856952,0.99891615,0.000006718346,0.00001988332,0.000021567954,0.000051288924,0.000019645788,0.000025495674,0.0000039899023,0.00005869379,0.0008272665],"study_design_scores_gemma":[0.0000048734078,0.00007117049,0.9994118,0.000007810026,0.000010156056,0.00015218569,0.00016440562,0.00008380457,0.000012136351,0.000007823914,0.00007180049,0.0000019557995],"about_ca_topic_score_codex":0.002808872,"about_ca_topic_score_gemma":0.0036739137,"teacher_disagreement_score":0.002808872,"about_ca_system_score_codex":0.00022627444,"about_ca_system_score_gemma":0.00017522585,"threshold_uncertainty_score":0.005585015},"labels":[],"label_agreement":null},{"id":"W2121803170","doi":"10.1634/theoncologist.2012-0432","title":"Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Intrahepatic Cholangiocarcinoma; Adjuvant; Adjuvant therapy; Internal medicine; Oncology; Cancer","score_opus":0.06203818774280435,"score_gpt":0.3306661924151549,"score_spread":0.26862800467235054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121803170","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0071120514,0.8181161,0.0014982675,0.16087614,0.0057466566,0.000016717688,0.000052540094,0.00004317743,0.0065383585],"genre_scores_gemma":[0.062955275,0.7746821,0.0024862946,0.0731586,0.083040155,0.000053500866,0.00018158271,0.00006601966,0.003376525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987192,0.0005341602,0.00027245574,0.0001301078,0.00025117848,0.00009298747],"domain_scores_gemma":[0.9860474,0.010478576,0.0011053715,0.00045495437,0.0013306256,0.0005830515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005702502,0.00031803106,0.0012192247,0.00064643275,0.00047950217,0.0017863868,0.0008172765,0.004335944,0.00331614],"category_scores_gemma":[0.011437602,0.00020736028,0.0006213638,0.00082434074,0.0016769496,0.0032212099,0.0007036773,0.0050203833,0.0019608317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042250747,0.00013483663,0.005974453,0.0027054755,0.00020832803,0.0026174209,0.0003032385,0.00042065862,0.0010817903,0.008235641,0.07464236,0.90325326],"study_design_scores_gemma":[0.00032184066,0.00089830323,0.010626822,0.013755446,0.00053117407,0.020864725,0.0013357735,0.00076277927,0.00074428925,0.017955543,0.9321135,0.00008976082],"about_ca_topic_score_codex":0.0004633527,"about_ca_topic_score_gemma":0.0013875504,"teacher_disagreement_score":0.005702502,"about_ca_system_score_codex":0.0007585681,"about_ca_system_score_gemma":0.0008345235,"threshold_uncertainty_score":0.030158043},"labels":[],"label_agreement":null},{"id":"W2123632377","doi":"10.1634/theoncologist.2011-0324","title":"Retinopathy Associated with Adjuvant High-Dose Interferon-α2b in a Patient with Resected Melanoma: A Case Report and Review of the Literature","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"3M (Canada); Queen's University","funders":"","keywords":"Medicine; Discontinuation; Asymptomatic; Melanoma; Cotton wool spots; Interferon; Adjuvant; Dermatology; Retinal; Retinopathy; Alpha interferon; Surgery; Oncology; Ophthalmology; Immunology; Cancer research; Endocrinology","score_opus":0.013974257052632538,"score_gpt":0.27720175270548164,"score_spread":0.2632274956528491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123632377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7453914,0.21230221,0.009547112,0.005078381,0.002243139,0.00043329954,0.00037637676,0.00051362097,0.02411441],"genre_scores_gemma":[0.94634134,0.043219164,0.0022930086,0.0022193955,0.002874347,0.0000568627,0.00016051967,0.00004575853,0.0027896108],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99940205,0.00009815308,0.00013402534,0.00014055356,0.000088360735,0.00013685957],"domain_scores_gemma":[0.9988506,0.00042950825,0.00035953315,0.00009471384,0.000077044264,0.00018863169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004974111,0.0013992378,0.0012692327,0.0021505428,0.0013170557,0.0015021082,0.0013538367,0.0044636796,0.0020615729],"category_scores_gemma":[0.0019439212,0.0006709235,0.0010369043,0.0020923913,0.001301121,0.0016408445,0.00067044667,0.0016762847,0.0013061796],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024492741,0.000052821895,0.003545035,0.000142879,0.000017183695,0.99284124,0.000084361025,0.00005031339,0.0004240687,0.00004761623,0.00040044266,0.002369493],"study_design_scores_gemma":[0.000007090895,0.000060004597,0.0034113263,0.00005034087,0.00003375983,0.9951007,0.00009493893,0.00009920569,0.0001756238,0.0000575021,0.00089896197,0.000010437274],"about_ca_topic_score_codex":0.0010618834,"about_ca_topic_score_gemma":0.0015967648,"teacher_disagreement_score":0.0044636796,"about_ca_system_score_codex":0.00071130216,"about_ca_system_score_gemma":0.000489129,"threshold_uncertainty_score":0.0068966746},"labels":[],"label_agreement":null},{"id":"W2123662332","doi":"10.1634/theoncologist.2014-0180","title":"How to Implement a Geriatric Assessment in Your Clinical Practice","year":2014,"lang":"en","type":"review","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Psychosocial; Geriatric oncology; Medicine; Psychological intervention; Clinical Practice; Population; Disease; Health care; Family medicine; Cancer; Gerontology; Intensive care medicine; Nursing; Psychiatry; Pathology; Internal medicine","score_opus":0.22050453729119543,"score_gpt":0.5553935414049408,"score_spread":0.33488900411374534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123662332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027758179,0.8110517,0.025781043,0.11439671,0.010807753,0.002700708,0.0006059394,0.0010963365,0.030784033],"genre_scores_gemma":[0.013943096,0.8516046,0.09399183,0.029078744,0.004190916,0.0018105992,0.0005815504,0.00013074538,0.0046679764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934906,0.0026294678,0.0014459494,0.00034893924,0.0018873004,0.00019773334],"domain_scores_gemma":[0.9840486,0.0077565,0.0016493719,0.00046253737,0.0048729284,0.0012100748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075639747,0.001234525,0.0023960047,0.003263352,0.0009475428,0.0031495178,0.0018919358,0.0052394504,0.007224701],"category_scores_gemma":[0.04246567,0.0007468114,0.0019538214,0.002227921,0.00087200524,0.0062828874,0.001985662,0.00423803,0.006669304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041896707,0.00023351132,0.0013662883,0.02020677,0.00013361721,0.00061892165,0.0009346735,0.00020698296,0.0003882615,0.001265031,0.12682268,0.8477813],"study_design_scores_gemma":[0.00018736131,0.0002083734,0.008188392,0.1427093,0.00043438934,0.0052309665,0.0030099014,0.00034750352,0.00059386843,0.007612412,0.8313095,0.00016794911],"about_ca_topic_score_codex":0.0037771661,"about_ca_topic_score_gemma":0.006506849,"teacher_disagreement_score":0.0075639747,"about_ca_system_score_codex":0.0009143549,"about_ca_system_score_gemma":0.0067442264,"threshold_uncertainty_score":0.040002644},"labels":[],"label_agreement":null},{"id":"W2123863371","doi":"10.1634/theoncologist.2013-0022","title":"Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Medicine; Neoadjuvant therapy; Colorectal cancer; Radiation therapy; Magnetic resonance imaging; Stage (stratigraphy); Disease; Oncology; Risk stratification; Internal medicine; Cancer; Radiology","score_opus":0.08088204818895696,"score_gpt":0.4086585103131368,"score_spread":0.3277764621241799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123863371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003662542,0.9982614,0.00009760138,0.00039123726,0.00010958601,0.0000071397194,0.00001592717,0.00000289948,0.0007479879],"genre_scores_gemma":[0.0017693733,0.99742633,0.00023006847,0.00019322007,0.00010389688,0.00000889477,0.000041215142,9.538178e-7,0.0002260038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998555,0.0000417084,0.000031506643,0.000019681635,0.000042250867,0.000009429224],"domain_scores_gemma":[0.99974936,0.00014401646,0.0000493318,0.0000041632265,0.000039357234,0.000013826444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036997529,0.00043623042,0.00096430734,0.0010040882,0.00018011332,0.0005708925,0.00049630174,0.0005628628,0.0024400628],"category_scores_gemma":[0.0010579051,0.00011332522,0.00041076806,0.00094132667,0.00022226523,0.0005602551,0.00032940102,0.00073523336,0.00072022964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051866933,0.000045150617,0.0010364883,0.017530944,0.000095278054,0.00025200384,0.000053211388,0.00018252149,0.0005147015,0.0007235116,0.017076952,0.9624374],"study_design_scores_gemma":[0.000088122404,0.00023897017,0.012026729,0.042972036,0.0007630844,0.008686829,0.0005079768,0.00026367616,0.00075976586,0.0030492882,0.9305914,0.000052087755],"about_ca_topic_score_codex":0.0007825355,"about_ca_topic_score_gemma":0.00220781,"teacher_disagreement_score":0.0024400628,"about_ca_system_score_codex":0.00024313592,"about_ca_system_score_gemma":0.00063018966,"threshold_uncertainty_score":0.008162856},"labels":[],"label_agreement":null},{"id":"W2124443610","doi":"10.1634/theoncologist.10-10-780","title":"Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epirubicin; Medicine; Trastuzumab; Breast cancer; Oncology; Cardiotoxicity; Adjuvant; Anthracycline; Internal medicine; Chemotherapy; Doxorubicin; Cancer","score_opus":0.0729664907286145,"score_gpt":0.3820396497003825,"score_spread":0.309073158971768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124443610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017978653,0.9965964,0.00021384517,0.00060334394,0.00025812117,0.000007782635,0.0000148655545,0.000009708597,0.0021161265],"genre_scores_gemma":[0.00096609094,0.997001,0.00027880952,0.00035333383,0.00022026198,0.00000967185,0.000023763465,0.0000018857979,0.0011451762],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988174,0.000027490267,0.000016603473,0.000015505022,0.0000502551,0.000008410854],"domain_scores_gemma":[0.99979347,0.00008962362,0.00004047605,0.000006285273,0.000054083812,0.00001596094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045142294,0.000564548,0.0010639512,0.0012450941,0.00015096692,0.0005805201,0.00059199915,0.00079276686,0.0034728998],"category_scores_gemma":[0.00064278446,0.00017287854,0.00027936164,0.0012744671,0.0002524634,0.0008110973,0.00027224468,0.001257204,0.002817993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080382284,0.000059964383,0.00016148441,0.0062051923,0.000030932406,0.00033581952,0.000025256459,0.0002543631,0.0010412147,0.001417105,0.03724286,0.9531454],"study_design_scores_gemma":[0.00004793675,0.00012805879,0.0013298753,0.0035417257,0.00005785045,0.0028616565,0.000046914265,0.0001115836,0.00075815973,0.001318977,0.98978454,0.000012714955],"about_ca_topic_score_codex":0.000654202,"about_ca_topic_score_gemma":0.0014750916,"teacher_disagreement_score":0.0034728998,"about_ca_system_score_codex":0.00044454247,"about_ca_system_score_gemma":0.00055985874,"threshold_uncertainty_score":0.011618018},"labels":[],"label_agreement":null},{"id":"W2124531563","doi":"10.1634/theoncologist.2008-0061","title":"Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency","keywords":"Medicine; Bevacizumab; Colorectal cancer; Irinotecan; Internal medicine; Chemotherapy; Oxaliplatin; Oncology; Cetuximab; Geriatric oncology; Clinical trial; Medical record; Cancer","score_opus":0.08099379445058258,"score_gpt":0.3781104254251143,"score_spread":0.2971166309745317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124531563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979011,0.00055380014,0.000045564266,0.00031960703,0.000006704814,0.000015173589,0.00030904877,0.0000018389754,0.0008471701],"genre_scores_gemma":[0.9995467,0.00015881784,0.000036604855,0.000088449575,0.0000075029784,0.0000074652785,0.0001122612,5.4223517e-7,0.000041736217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999089,0.0003124865,0.0001507174,0.00014953139,0.0001723834,0.00012602209],"domain_scores_gemma":[0.9957989,0.0010408453,0.0023047281,0.000076589444,0.000267405,0.000511424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008772279,0.000060387832,0.00019225225,0.000764567,0.00034082602,0.00037592655,0.0002689709,0.0002324334,0.0017051307],"category_scores_gemma":[0.00550205,0.00009495962,0.00017965795,0.0011871753,0.0001779398,0.0004005691,0.00041698435,0.0002767248,0.00009275399],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035309236,0.00004058584,0.99657345,0.0000205826,0.000025058353,0.000042693104,0.00017306628,0.000031374067,0.000051725703,0.000046933805,0.0003098125,0.002649354],"study_design_scores_gemma":[0.0000058546025,0.00006161797,0.99880123,0.000022885153,0.000009723843,0.00010173629,0.00053786015,0.00014702651,0.000026987733,0.0000272239,0.00025529784,0.0000026532473],"about_ca_topic_score_codex":0.012678236,"about_ca_topic_score_gemma":0.02451991,"teacher_disagreement_score":0.012678236,"about_ca_system_score_codex":0.00061976456,"about_ca_system_score_gemma":0.0006180021,"threshold_uncertainty_score":0.02520889},"labels":[],"label_agreement":null},{"id":"W2124870334","doi":"10.1634/theoncologist.2014-0295","title":"Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Clinical trial; Breast cancer; Randomized controlled trial; Radiation therapy; Nuclear medicine; Cancer; Medical physics; Radiology; Internal medicine","score_opus":0.35488795266247003,"score_gpt":0.5036175293651448,"score_spread":0.14872957670267478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124870334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83373237,0.06624934,0.07046653,0.0033309874,0.00020046064,0.0056574075,0.0034958953,0.00021931337,0.016647657],"genre_scores_gemma":[0.97565514,0.0028252872,0.016721155,0.0005378329,0.00013870027,0.0028011291,0.00073920126,0.000040392228,0.0005410057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.80572814,0.16012722,0.01646857,0.005219604,0.011628371,0.0008281714],"domain_scores_gemma":[0.6290565,0.28205466,0.06706661,0.013467397,0.0072070207,0.0011477856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13045025,0.000513016,0.001016923,0.0018470435,0.00048768646,0.0019270547,0.0007913781,0.0014749476,0.0018705139],"category_scores_gemma":[0.19957423,0.00037331576,0.0023614068,0.0026509066,0.001337254,0.0009752872,0.0012962068,0.0013012692,0.00027796577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011855187,0.00032970667,0.8628975,0.0029536935,0.0060672937,0.00044738463,0.0012519697,0.006938721,0.0016258458,0.004698544,0.0012419141,0.09969225],"study_design_scores_gemma":[0.0016270374,0.009651096,0.91927373,0.0024557167,0.009072874,0.0038828354,0.00067391957,0.012376043,0.0065083234,0.012767877,0.021551631,0.00015885229],"about_ca_topic_score_codex":0.0004181353,"about_ca_topic_score_gemma":0.00042717514,"teacher_disagreement_score":0.13045025,"about_ca_system_score_codex":0.0012169025,"about_ca_system_score_gemma":0.0013002717,"threshold_uncertainty_score":0.6898951},"labels":[],"label_agreement":null},{"id":"W2124957996","doi":"10.1634/theoncologist.2011-0164","title":"Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Antiandrogen; Ovarian cancer; Oncology; Prostate cancer; Cancer; Internal medicine","score_opus":0.08430796692686533,"score_gpt":0.388245100507742,"score_spread":0.3039371335808767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124957996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007239385,0.99787843,0.000073589035,0.00057638035,0.0002779945,0.000004051811,0.000010778235,0.0000044643857,0.0011019375],"genre_scores_gemma":[0.0005406704,0.9979851,0.00012242304,0.0004127772,0.00031806855,0.000005344475,0.000017634322,0.0000013383672,0.00059663143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997756,0.00005825796,0.000035336285,0.00002788958,0.000085755906,0.00001718455],"domain_scores_gemma":[0.9995154,0.00027749356,0.000055103956,0.00001252138,0.00011589958,0.000023573795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007502257,0.00056723785,0.0011958554,0.0022019374,0.00025382583,0.0009621727,0.00074351724,0.0010488604,0.003950747],"category_scores_gemma":[0.000815319,0.00024458423,0.00045129878,0.001898459,0.0004581144,0.0013582918,0.00047563115,0.002186841,0.0022321767],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069629,0.000065271,0.0001565307,0.013651341,0.000060024122,0.00033520078,0.0000596706,0.00040885553,0.00091051735,0.005654561,0.046835046,0.9317934],"study_design_scores_gemma":[0.000023864837,0.000070970156,0.00059836236,0.003788197,0.000041034833,0.00138032,0.00005861192,0.00009732514,0.0002463081,0.002097674,0.9915863,0.000010936982],"about_ca_topic_score_codex":0.0013751829,"about_ca_topic_score_gemma":0.0034046876,"teacher_disagreement_score":0.003950747,"about_ca_system_score_codex":0.00072277925,"about_ca_system_score_gemma":0.001056498,"threshold_uncertainty_score":0.013216555},"labels":[],"label_agreement":null},{"id":"W2125128981","doi":"10.1634/theoncologist.7-suppl_1-14","title":"Molecular Targets of Arsenic Trioxide in Malignant Cells","year":2002,"lang":"en","type":"review","venue":"The Oncologist","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; Medicine; Cancer research; Apoptosis; Signal transduction; Intracellular; Leukemia; Cell biology; Immunology; Chemistry; Biology; Biochemistry; Cell culture; Retinoic acid; Genetics","score_opus":0.030062198932065857,"score_gpt":0.30761009359995994,"score_spread":0.2775478946678941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125128981","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4456527,0.18740614,0.034747936,0.027513687,0.0059365435,0.0008198213,0.0039882665,0.0028065443,0.2911284],"genre_scores_gemma":[0.777519,0.06488276,0.0067492705,0.0025080682,0.00095563376,0.00022698962,0.00197592,0.0001331247,0.14504927],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999144,0.000012613,0.000003833293,0.000011449164,0.000041381998,0.000016404347],"domain_scores_gemma":[0.99994135,0.000008420714,0.000009171719,0.0000047293483,0.000020350191,0.000015984067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012470044,0.00032830337,0.0001766609,0.0003629939,0.00025378543,0.000554965,0.00026451133,0.00053750305,0.012956523],"category_scores_gemma":[0.00014185609,0.00012092561,0.00022402387,0.00022078944,0.00011997505,0.0002725623,0.00027165143,0.0005032039,0.003337305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032473332,0.00014642756,0.0007757302,0.00066269666,0.00003790387,0.000958046,0.00008455024,0.0005448118,0.896459,0.0096486965,0.02235757,0.0679997],"study_design_scores_gemma":[0.000058063284,0.0006456695,0.0056771124,0.000097670425,0.00004784361,0.0018519112,0.00016591704,0.0013517704,0.7556966,0.005394303,0.22899818,0.0000149098205],"about_ca_topic_score_codex":0.00026351353,"about_ca_topic_score_gemma":0.00034020888,"teacher_disagreement_score":0.012956523,"about_ca_system_score_codex":0.0004911757,"about_ca_system_score_gemma":0.00023206823,"threshold_uncertainty_score":0.0433439},"labels":[],"label_agreement":null},{"id":"W2125385675","doi":"10.1634/theoncologist.2013-0292","title":"Advancing Cervical Cancer Prevention in India: Implementation Science Priorities","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"World Bank Group","keywords":"Cervical cancer; Medicine; Cancer prevention; Scale (ratio); Health care; Quarter (Canadian coin); Cancer; Family medicine; Economic growth","score_opus":0.13150389422321318,"score_gpt":0.5411910074762077,"score_spread":0.40968711325299456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125385675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015020084,0.9860611,0.00027474377,0.011155396,0.0006434783,0.00008085136,0.000026742622,0.00001828629,0.0015891384],"genre_scores_gemma":[0.0026089172,0.99301094,0.001362827,0.0023658164,0.0003174012,0.00009116682,0.00003356857,0.0000026549822,0.00020676314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952055,0.0022218372,0.00068018434,0.00024468664,0.0012076361,0.0004402066],"domain_scores_gemma":[0.9747492,0.018424097,0.0014329433,0.0005914856,0.0038616853,0.0009405362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013444235,0.001121779,0.002472422,0.0036618672,0.00087259745,0.004880973,0.0027463627,0.0037775985,0.004447227],"category_scores_gemma":[0.027143357,0.0006607579,0.0022517156,0.004598543,0.0015960261,0.0045005456,0.0021317739,0.006105103,0.0006674001],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007949176,0.00023611869,0.0006517139,0.1387169,0.0003079072,0.00018524792,0.0005027015,0.00065657176,0.0002568667,0.014057631,0.032083556,0.8122653],"study_design_scores_gemma":[0.00015902969,0.0003654907,0.004122016,0.22317457,0.0013018849,0.0009457654,0.0016602515,0.00043944945,0.0005874853,0.012778943,0.75438285,0.000082274164],"about_ca_topic_score_codex":0.011322911,"about_ca_topic_score_gemma":0.013691332,"teacher_disagreement_score":0.013444235,"about_ca_system_score_codex":0.004524513,"about_ca_system_score_gemma":0.03966046,"threshold_uncertainty_score":0.07110071},"labels":[],"label_agreement":null},{"id":"W2125598437","doi":"10.1634/theoncologist.10-1-63","title":"Prior Red Blood Cell Transfusions in Cancer Patients Increase the Risk of Subsequent Transfusions With or Without Recombinant Human Erythropoietin Management","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Alberta Cancer Foundation; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Epoetin alfa; Erythropoietin; Relative risk; Placebo; Blood transfusion; Confidence interval; Internal medicine; Anemia; Cancer; Surgery","score_opus":0.043849160933739466,"score_gpt":0.3523709464523417,"score_spread":0.3085217855186022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125598437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28643674,0.7048977,0.0027135252,0.0021154059,0.00051070354,0.00013192047,0.00083203224,0.000061462146,0.002300575],"genre_scores_gemma":[0.93211675,0.06379721,0.0013340175,0.0010905951,0.00047116412,0.000067490015,0.00059958064,0.000017111977,0.0005061201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943568,0.0033141633,0.0007923806,0.0006937906,0.00068137725,0.00016148623],"domain_scores_gemma":[0.97144026,0.021861108,0.0045434665,0.0011356949,0.0007247526,0.0002947162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008033035,0.00063474587,0.002661824,0.0010706318,0.00038176437,0.0015727056,0.00046009052,0.0016000643,0.0015473607],"category_scores_gemma":[0.019023517,0.00056140864,0.013184843,0.0017405072,0.00051953853,0.0006581044,0.0004978485,0.002502338,0.00014148769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037729383,0.00048294754,0.45443538,0.021744208,0.33019918,0.00071400346,0.00019435622,0.004102387,0.0018415094,0.00082233705,0.002866685,0.14486761],"study_design_scores_gemma":[0.004438932,0.005150445,0.5044612,0.0039743213,0.4600647,0.0018498258,0.00015196958,0.0055170297,0.0016888375,0.0035378071,0.009041278,0.00012355793],"about_ca_topic_score_codex":0.0018700269,"about_ca_topic_score_gemma":0.0023536729,"teacher_disagreement_score":0.008033035,"about_ca_system_score_codex":0.00050799915,"about_ca_system_score_gemma":0.00069792103,"threshold_uncertainty_score":0.04248327},"labels":[],"label_agreement":null},{"id":"W2125976746","doi":"10.1634/theoncologist.7-6-481","title":"The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy","year":2002,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Zoledronic acid; Medicine; Bisphosphonate; Malignancy; Bone resorption; Clinical trial; Internal medicine; Osteoporosis; Urology; Oncology; Gastroenterology","score_opus":0.24410217519784713,"score_gpt":0.39480416255587153,"score_spread":0.1507019873580244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125976746","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013801488,0.96155834,0.003465127,0.0047067334,0.0014651535,0.00010664388,0.000109115834,0.00013215185,0.014655343],"genre_scores_gemma":[0.14868537,0.8263351,0.0067394148,0.0042239847,0.0024199397,0.000104308405,0.00031359363,0.000025767074,0.011152512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986327,0.00002172772,0.000015828899,0.000014731014,0.000071452356,0.0000130061135],"domain_scores_gemma":[0.99986994,0.000040676543,0.000041270087,0.0000051265365,0.00002715206,0.00001580983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031229827,0.00023301072,0.0002701212,0.00087389426,0.00016824238,0.00041726188,0.00029087628,0.0004087065,0.0024065294],"category_scores_gemma":[0.00054698845,0.000085756365,0.00050809863,0.0003702632,0.0001914282,0.00032453146,0.00024244287,0.00063726655,0.0008666446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006300967,0.00019425261,0.001690174,0.0023992178,0.00009563587,0.00093900604,0.00004283709,0.00028951943,0.01962633,0.0022841766,0.028618876,0.94319],"study_design_scores_gemma":[0.0009956207,0.003403385,0.020157445,0.0016328803,0.000412009,0.02619513,0.00007901554,0.0010889611,0.025318105,0.0033752979,0.9172926,0.000049469116],"about_ca_topic_score_codex":0.0004778714,"about_ca_topic_score_gemma":0.001345212,"teacher_disagreement_score":0.0024065294,"about_ca_system_score_codex":0.0004459775,"about_ca_system_score_gemma":0.0006072211,"threshold_uncertainty_score":0.00805068},"labels":[],"label_agreement":null},{"id":"W2125984241","doi":"10.1634/theoncologist.6-2-114","title":"George Wesley Santos","year":2001,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cuban History and Society","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"George (robot); Medicine; Environmental ethics; Classics; Art history; History; Philosophy","score_opus":0.05802392085245066,"score_gpt":0.359659550879684,"score_spread":0.3016356300272333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125984241","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034594333,0.076514795,0.004898429,0.25574118,0.07424334,0.00013004505,0.00079852645,0.0009871362,0.5832272],"genre_scores_gemma":[0.014292086,0.033928283,0.0021746438,0.037317224,0.0042934897,0.00007312186,0.0003750352,0.0004496096,0.9070965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982364,0.0002768505,0.00006371207,0.00038684343,0.00081349636,0.00022269764],"domain_scores_gemma":[0.9970149,0.0004947591,0.00014433532,0.00014922267,0.0009368878,0.0012599402],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013253966,0.000889262,0.00063216366,0.001361431,0.0032100542,0.005214612,0.0011943921,0.0024162612,0.14539315],"category_scores_gemma":[0.0065650363,0.00037258386,0.0004152867,0.0006249451,0.0013297139,0.0026279758,0.0029555906,0.0051400303,0.07402185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013858132,0.000018892208,0.00021555558,0.00006467734,0.0000028658944,0.00020501442,0.00019765727,0.000046197343,0.00010127814,0.009287988,0.9420584,0.047787614],"study_design_scores_gemma":[0.000001610773,0.000006771926,0.00012777529,0.00010245358,0.0000013498462,0.00035867057,0.00013753175,0.000020637173,0.000071640316,0.0011629242,0.9980034,0.000005259626],"about_ca_topic_score_codex":0.005556569,"about_ca_topic_score_gemma":0.009084505,"teacher_disagreement_score":0.85460687,"about_ca_system_score_codex":0.002073196,"about_ca_system_score_gemma":0.005508101,"threshold_uncertainty_score":0.48638856},"labels":[],"label_agreement":null},{"id":"W2126451936","doi":"10.1634/theoncologist.2011-0458","title":"Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors","year":2012,"lang":"en","type":"review","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Somatostatin; Neuroendocrine tumors; Cancer research; Somatostatin receptor; Pharmacology; Internal medicine; Oncology","score_opus":0.06464550285194756,"score_gpt":0.4085036108327406,"score_spread":0.3438581079807931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126451936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031346097,0.99632144,0.000039342653,0.00007373316,0.0000326949,0.000028279379,0.00006442199,0.0000016913101,0.0003038056],"genre_scores_gemma":[0.08020854,0.9184831,0.00042093723,0.00037260514,0.00017433315,0.00008647253,0.0001324602,0.0000028887607,0.00011866933],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768984,0.0009529246,0.00073954544,0.00017433152,0.0004116683,0.000031807467],"domain_scores_gemma":[0.9820608,0.013965819,0.0033454956,0.00009628362,0.00044651167,0.000085065345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003973691,0.00047899166,0.0026240167,0.0020167162,0.0001589651,0.0009857641,0.00036555654,0.0007626001,0.0019648504],"category_scores_gemma":[0.009532381,0.00025435688,0.0025480664,0.0025491235,0.0004327006,0.0005706354,0.0002586845,0.0005470239,0.00012328697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041319258,0.00010349052,0.0073148035,0.68356186,0.016387532,0.00046160026,0.00014191864,0.00071611285,0.0022840684,0.0005710329,0.0015468878,0.28277883],"study_design_scores_gemma":[0.008905194,0.012769589,0.060858607,0.6258842,0.1912914,0.0081364745,0.0006549873,0.00086755,0.006792683,0.0028353701,0.08088307,0.000120861565],"about_ca_topic_score_codex":0.0007460624,"about_ca_topic_score_gemma":0.0015978676,"teacher_disagreement_score":0.003973691,"about_ca_system_score_codex":0.00066992355,"about_ca_system_score_gemma":0.00093995506,"threshold_uncertainty_score":0.021015167},"labels":[],"label_agreement":null},{"id":"W2126653682","doi":"10.1634/theoncologist.11-3-261","title":"Oxaliplatin-Related Acute Myelogenous Leukemia","year":2006,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Medicine; FOLFOX; Oxaliplatin; Pancytopenia; Colorectal cancer; Internal medicine; Leukemia; Bone marrow; Oncology; Chemotherapy regimen; Gastroenterology; Bevacizumab; Chemotherapy; Surgery; Cancer","score_opus":0.01542555954039006,"score_gpt":0.2863170583020318,"score_spread":0.27089149876164176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126653682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97678065,0.0042982097,0.00076899084,0.0022891427,0.00016442234,0.00022614324,0.0003768459,0.000046305413,0.015049312],"genre_scores_gemma":[0.99254274,0.0015953041,0.0003818199,0.001018033,0.00013313301,0.00002165002,0.00027953487,0.0000049450437,0.004022779],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9999324,0.0000094063,0.000009243316,0.000014125066,0.000007795605,0.00002698266],"domain_scores_gemma":[0.9998332,0.0000419765,0.00004022798,0.000012879037,0.000013024639,0.000058647303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001135146,0.00030059344,0.00037923595,0.00022938508,0.0006209997,0.00028136585,0.00015799976,0.00043172945,0.00221498],"category_scores_gemma":[0.0005339437,0.0001261199,0.00015363988,0.00025783305,0.0002151315,0.00022052371,0.0002414187,0.00053625414,0.0005312911],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035127122,0.0006217521,0.12751946,0.00034315346,0.000060135488,0.80452853,0.0004775776,0.0005066172,0.020467907,0.0016463688,0.0025819114,0.0377339],"study_design_scores_gemma":[0.0010174471,0.0033507412,0.2389382,0.00012602248,0.00014330287,0.71037567,0.0003902852,0.0015094206,0.0077173696,0.0015810357,0.03481412,0.00003641561],"about_ca_topic_score_codex":0.00081812026,"about_ca_topic_score_gemma":0.0013865663,"teacher_disagreement_score":0.00221498,"about_ca_system_score_codex":0.00043362656,"about_ca_system_score_gemma":0.00025394687,"threshold_uncertainty_score":0.007409811},"labels":[],"label_agreement":null},{"id":"W2127779058","doi":"10.1634/theoncologist.2014-0381","title":"Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review","year":2015,"lang":"en","type":"review","venue":"The Oncologist","topic":"Vitamin C and Antioxidants Research","field":"Nursing","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Complementary and Integrative Health; National Center for Complementary and Alternative Medicine; National Institutes of Health","keywords":"Medicine; Observational study; Randomized controlled trial; Placebo; Internal medicine; Toxicity; Chemotherapy; Meta-analysis; Vitamin; Cancer; Oncology; Pathology; Alternative medicine","score_opus":0.10093488176845763,"score_gpt":0.4190439661201262,"score_spread":0.3181090843516685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127779058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030677047,0.9992061,0.000034447727,0.00020182706,0.000055827484,0.000056384593,0.000037604572,0.0000022449033,0.00009881207],"genre_scores_gemma":[0.0067180474,0.99244094,0.00021822964,0.00036808927,0.000051691273,0.00011831517,0.00003748114,0.0000013217791,0.000045932615],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9959787,0.0018260739,0.0011921887,0.000249636,0.00063078426,0.00012259348],"domain_scores_gemma":[0.98582053,0.010310064,0.0024746524,0.00015680683,0.0010301616,0.00020780404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006253841,0.0010451494,0.007124643,0.005234527,0.0005375965,0.002208023,0.0016407782,0.0023003237,0.0040700063],"category_scores_gemma":[0.025758272,0.0008100044,0.005817673,0.005571053,0.0007987961,0.0020436689,0.0009495581,0.0011399438,0.00024741137],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026003286,0.000018095443,0.00044329214,0.937336,0.0068722502,0.000058094032,0.00010052952,0.00006124038,0.00009373018,0.00017282402,0.0014506013,0.053133205],"study_design_scores_gemma":[0.00053483376,0.00033238775,0.0030395861,0.8850891,0.09057299,0.00031652028,0.0002722488,0.00010428349,0.00015203345,0.00032920172,0.019225113,0.00003176487],"about_ca_topic_score_codex":0.007826568,"about_ca_topic_score_gemma":0.021902412,"teacher_disagreement_score":0.007826568,"about_ca_system_score_codex":0.0030867164,"about_ca_system_score_gemma":0.008354731,"threshold_uncertainty_score":0.033073843},"labels":[],"label_agreement":null},{"id":"W2128422065","doi":"10.1634/theoncologist.2012-0461","title":"Bladder Preservation Therapy for Muscle-Invading Bladder Cancers on Radiation Therapy Oncology Group Trials 8802, 8903, 9506, and 9706: Vascular Endothelial Growth Factor B Overexpression Predicts for Increased Distant Metastasis and Shorter Survival","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Ohio State University; Pennsylvania Department of Health","keywords":"Medicine; Bladder cancer; Vascular endothelial growth factor; Cystectomy; Radiation therapy; Urology; Metastasis; Internal medicine; Oncology; Pathology; Cancer; VEGF receptors","score_opus":0.08997251775910423,"score_gpt":0.3525537434276973,"score_spread":0.2625812256685931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128422065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99483925,0.0025543468,0.00009815193,0.00028054958,0.000053768614,0.00054781494,0.0007407021,0.000011176527,0.00087430235],"genre_scores_gemma":[0.99431074,0.0016088472,0.0003235875,0.0005310641,0.00009965509,0.0004443199,0.0020986286,0.0000059256777,0.0005772412],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99883205,0.0007994477,0.000094328796,0.00008100567,0.00008561471,0.000107571854],"domain_scores_gemma":[0.9987674,0.00023965647,0.00045326652,0.00010346654,0.000099787125,0.00033653644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033993397,0.00048097732,0.0012780543,0.00029102247,0.00031051843,0.000847752,0.00066552503,0.000604146,0.0013655091],"category_scores_gemma":[0.0012281524,0.00022625632,0.00115965,0.00046332425,0.00041398016,0.00034365788,0.00035493917,0.0012820417,0.00040382845],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5603849,0.011704715,0.29002672,0.0012962157,0.0062918756,0.00027398093,0.00032066795,0.0021524103,0.014761341,0.00041605264,0.0074431724,0.104927845],"study_design_scores_gemma":[0.22155975,0.29255283,0.4575776,0.00039246716,0.006309074,0.00078139146,0.0002604637,0.0020152112,0.0072475933,0.0003657439,0.0108710835,0.000066767054],"about_ca_topic_score_codex":0.0008146139,"about_ca_topic_score_gemma":0.0019208422,"teacher_disagreement_score":0.0033993397,"about_ca_system_score_codex":0.000491571,"about_ca_system_score_gemma":0.0009554146,"threshold_uncertainty_score":0.017977655},"labels":[],"label_agreement":null},{"id":"W2128730708","doi":"10.1634/theoncologist.2011-0127","title":"Molecular Alterations Between the Primary Breast Cancer and the Subsequent Locoregional/Metastatic Tumor","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Oncology; Primary tumor; Cancer; Internal medicine; Cancer research; Pathology; Metastasis","score_opus":0.0218103041826829,"score_gpt":0.2918508419238959,"score_spread":0.27004053774121295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128730708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634892,0.0048089875,0.0030723412,0.001883222,0.000279577,0.00016029744,0.0032595736,0.0002090611,0.022837782],"genre_scores_gemma":[0.9884322,0.0013189887,0.0012841423,0.00020953962,0.00011006962,0.000051602026,0.00083197345,0.000024971107,0.0077364673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997303,0.000030418018,0.000022170496,0.00007207216,0.0001031701,0.000041777857],"domain_scores_gemma":[0.9993625,0.00017080721,0.00019121035,0.000030257854,0.00013473256,0.00011050608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047143156,0.00020039448,0.00017201464,0.0006263965,0.00022156084,0.0004511218,0.00025438113,0.00028523145,0.022297192],"category_scores_gemma":[0.0022274961,0.000088597706,0.00018676475,0.00043429277,0.00030519467,0.00021769777,0.0003702371,0.00035843867,0.0016680642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007046804,0.00013348662,0.8796011,0.00020629494,0.00008510957,0.0017716389,0.00013265944,0.00030567157,0.0074099326,0.0003358021,0.011179183,0.09813452],"study_design_scores_gemma":[0.000018690125,0.00017353501,0.983677,0.00008371118,0.00006841938,0.006865325,0.0001880472,0.00048440925,0.002017711,0.00017303179,0.006243169,0.0000066953453],"about_ca_topic_score_codex":0.0026964264,"about_ca_topic_score_gemma":0.0034650678,"teacher_disagreement_score":0.022297192,"about_ca_system_score_codex":0.0007034306,"about_ca_system_score_gemma":0.00048709763,"threshold_uncertainty_score":0.07459158},"labels":[],"label_agreement":null},{"id":"W2130164418","doi":"10.1634/theoncologist.2015-0220","title":"Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; London Health Sciences Centre; Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Temsirolimus; Oncology; Castration; Internal medicine; Cancer; Discovery and development of mTOR inhibitors; Apoptosis; PI3K/AKT/mTOR pathway; Hormone","score_opus":0.09766706703691744,"score_gpt":0.3809797610678705,"score_spread":0.28331269403095305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130164418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862096,0.012000686,0.0004881844,0.0004808411,0.000053294734,0.0001128102,0.000054384655,0.000035348025,0.0005648811],"genre_scores_gemma":[0.9952898,0.003181619,0.00066744443,0.0002843155,0.0000891715,0.00009415271,0.00010698162,0.0000047600533,0.0002816951],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997929,0.000091792775,0.000017914546,0.000027538072,0.00003000983,0.00003991529],"domain_scores_gemma":[0.99976546,0.00006732113,0.000068863024,0.00002397602,0.000016098596,0.00005821855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007488892,0.00019261298,0.00070562237,0.00014989871,0.00011215771,0.0003581301,0.0003516846,0.00029559474,0.00043899176],"category_scores_gemma":[0.00053701014,0.000071630384,0.0003368335,0.00021714965,0.00031109416,0.00026225307,0.00012098801,0.000996676,0.00008325506],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059566904,0.008484567,0.025353892,0.001268597,0.0006905123,0.00067999697,0.0003488424,0.0044490257,0.09081649,0.0005732932,0.0038949205,0.8038729],"study_design_scores_gemma":[0.065346055,0.6061954,0.23933223,0.0004203113,0.0012397704,0.00430651,0.00024005848,0.010150225,0.046022344,0.0011524423,0.025491465,0.000103209175],"about_ca_topic_score_codex":0.00044051764,"about_ca_topic_score_gemma":0.0013480328,"teacher_disagreement_score":0.0007488892,"about_ca_system_score_codex":0.0003667437,"about_ca_system_score_gemma":0.00054076203,"threshold_uncertainty_score":0.00396055},"labels":[],"label_agreement":null},{"id":"W2130207808","doi":"10.1634/theoncologist.11-90001-42","title":"The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Cancer; Colorectal cancer","score_opus":0.050020701675656275,"score_gpt":0.3936264737207917,"score_spread":0.3436057720451354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130207808","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012386184,0.9989963,0.000046180798,0.00013226435,0.000069434165,0.0000029630821,0.0000057264456,0.0000041569815,0.00061906694],"genre_scores_gemma":[0.0010808274,0.99827313,0.00009596855,0.000101882455,0.000087089014,0.000004215904,0.000012605394,9.476774e-7,0.00034334228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981445,0.000043878885,0.000022446391,0.000029884643,0.00007771746,0.000011743287],"domain_scores_gemma":[0.9998017,0.00009571503,0.000044697645,0.0000065402673,0.00003528824,0.00001604108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005482391,0.00069303386,0.0017018961,0.0017326543,0.00021954041,0.000654488,0.00068263983,0.0007432388,0.0030087365],"category_scores_gemma":[0.0006371323,0.0002098831,0.00048492834,0.0016282969,0.00033062077,0.00070348824,0.00038095965,0.0014268468,0.0014983553],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116930554,0.00006191377,0.00015570644,0.009276188,0.000085913925,0.00030637192,0.00003887912,0.00020837077,0.0012320684,0.0010143106,0.018453054,0.9690503],"study_design_scores_gemma":[0.00015922908,0.00034816496,0.0026423666,0.0051462287,0.0002306316,0.005008942,0.000043909393,0.00018056978,0.0010793806,0.0013868375,0.9837515,0.000022333581],"about_ca_topic_score_codex":0.0012668563,"about_ca_topic_score_gemma":0.002779282,"teacher_disagreement_score":0.0030087365,"about_ca_system_score_codex":0.00052639755,"about_ca_system_score_gemma":0.00062657474,"threshold_uncertainty_score":0.010065198},"labels":[],"label_agreement":null},{"id":"W2130730771","doi":"10.1634/theoncologist.2007-0245","title":"Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"Novartis Pharmaceuticals Corporation; Amgen","keywords":"Medicine; Denosumab; Zoledronic acid; Breast cancer; Clinical trial; Osteonecrosis of the jaw; Internal medicine; Multiple myeloma; Oncology; Adverse effect; Cancer; Surgery; Osteoporosis; Bisphosphonate","score_opus":0.0494458585787789,"score_gpt":0.3779195865178927,"score_spread":0.3284737279391138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130730771","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15540582,0.80448073,0.0024221635,0.017174939,0.0008227074,0.00083006226,0.000683128,0.0000734104,0.01810697],"genre_scores_gemma":[0.8190455,0.16100155,0.00738176,0.0078074224,0.0013661096,0.00071381027,0.000663572,0.000024175793,0.001996129],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970872,0.0017360748,0.00045245004,0.00012412711,0.00048753238,0.000112578615],"domain_scores_gemma":[0.9957177,0.0025092664,0.000990015,0.00009544195,0.00043531696,0.00025226382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004479617,0.00030722332,0.001452483,0.00061392755,0.00028390772,0.0008839942,0.00025176606,0.00079253194,0.0036253664],"category_scores_gemma":[0.012276946,0.000119580334,0.0017301027,0.00075390656,0.00020153153,0.0007209369,0.00048283962,0.0012538484,0.00045688718],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022697862,0.001109008,0.024898332,0.016412405,0.0040009995,0.0003153841,0.00026954678,0.0013307043,0.0030941735,0.0030487806,0.011204943,0.9116178],"study_design_scores_gemma":[0.055975255,0.06291068,0.39703774,0.03514456,0.03522504,0.006309385,0.0016259445,0.005367961,0.011028901,0.036454663,0.3525671,0.0003528354],"about_ca_topic_score_codex":0.0008330795,"about_ca_topic_score_gemma":0.0020734111,"teacher_disagreement_score":0.004479617,"about_ca_system_score_codex":0.0006955085,"about_ca_system_score_gemma":0.0011390407,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2130760214","doi":"10.1634/theoncologist.2009-0122","title":"The Assessment and Management of Delirium in Cancer Patients","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institute of Nursing Research; National Cancer Institute; U.S. Food and Drug Administration; National Institutes of Health","keywords":"Delirium; Cancer; Medicine; Intensive care medicine; Psychology; Internal medicine","score_opus":0.06672662386925798,"score_gpt":0.43852848822329704,"score_spread":0.37180186435403906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130760214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004224218,0.99740785,0.00015107315,0.000514053,0.00029556185,0.00002057319,0.000011767805,0.000006735305,0.0011700176],"genre_scores_gemma":[0.0031862983,0.9953885,0.00046455275,0.00025654552,0.00024997393,0.000033415818,0.000025064699,0.0000010229512,0.00039444867],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996469,0.00012628309,0.00006698305,0.000024682091,0.000114121656,0.00002102437],"domain_scores_gemma":[0.99944085,0.00022627848,0.00012258546,0.0000071113836,0.00016765422,0.0000354625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067349215,0.00064634683,0.0012682907,0.001239146,0.00025843948,0.00047408044,0.00078575313,0.0008718308,0.0019949537],"category_scores_gemma":[0.0024453541,0.0001766678,0.00047958014,0.0010639126,0.00021515858,0.00061212445,0.00038004466,0.00088910694,0.00088644616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071067116,0.00008176265,0.0007477372,0.016291022,0.00007653105,0.00041892807,0.00007897373,0.00020905264,0.00030398997,0.00039572446,0.023542088,0.9577831],"study_design_scores_gemma":[0.00028559027,0.0014372239,0.043245222,0.09559232,0.00073948514,0.030356167,0.0012113285,0.0011414654,0.0019937917,0.004322496,0.81954825,0.00012665294],"about_ca_topic_score_codex":0.0017482741,"about_ca_topic_score_gemma":0.0028074807,"teacher_disagreement_score":0.0019949537,"about_ca_system_score_codex":0.00050670234,"about_ca_system_score_gemma":0.0011021626,"threshold_uncertainty_score":0.006673813},"labels":[],"label_agreement":null},{"id":"W2131178461","doi":"10.1634/theoncologist.2010-0137","title":"Treatment Beyond Progression: Is It Moving from Belief to Evidence?","year":2010,"lang":"en","type":"letter","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; MEDLINE; Internal medicine; Family medicine; Cancer","score_opus":0.17719670831203707,"score_gpt":0.4723174421791335,"score_spread":0.2951207338670965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131178461","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005763855,0.0006052558,0.00003240969,0.98447984,0.014298545,0.0000027225628,0.000012175119,0.0000055641376,0.00050601264],"genre_scores_gemma":[0.0011925375,0.0010439961,0.0001434354,0.9474936,0.04845286,0.000011319001,0.000009214489,0.0000110856,0.0016419902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98777884,0.005475547,0.0015332969,0.0010585515,0.0031656686,0.0009881522],"domain_scores_gemma":[0.94567966,0.03864334,0.0030615919,0.0008991167,0.0076665273,0.004049672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013415368,0.0009588502,0.0022023146,0.0009788162,0.004538044,0.0057072625,0.0031568261,0.05537018,0.0074257012],"category_scores_gemma":[0.0847985,0.0009684275,0.0020099566,0.0009679976,0.0047490587,0.008268301,0.0022506842,0.06909161,0.0047142194],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046450525,0.00001872914,0.00020155667,0.00006759923,0.00001880447,0.00043927124,0.000112747344,0.000025910751,0.0000367701,0.0017918353,0.9921475,0.005092852],"study_design_scores_gemma":[0.00041595387,0.00017436079,0.00097505096,0.0013394821,0.00011069082,0.0029088398,0.0008394189,0.00050181313,0.00030567258,0.020582443,0.9717106,0.00013559431],"about_ca_topic_score_codex":0.0052137114,"about_ca_topic_score_gemma":0.0117930155,"teacher_disagreement_score":0.05537018,"about_ca_system_score_codex":0.005863059,"about_ca_system_score_gemma":0.007422855,"threshold_uncertainty_score":0.070948064},"labels":[],"label_agreement":null},{"id":"W2132177175","doi":"10.1634/theoncologist.2008-0166","title":"Cancer and Immune Response: Old and New Evidence for Future Challenges","year":2008,"lang":"en","type":"review","venue":"The Oncologist","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, New York University; York University; Pfizer Pharmaceuticals; Pfizer","keywords":"Immune system; Medicine; Tumor microenvironment; Antigen; Cancer research; Cancer; Cytotoxic T cell; Immunology; Immunotherapy; Monoclonal antibody; T cell; Tumor antigen; Antigen presentation; Antibody; Biology; Internal medicine","score_opus":0.17279561935091028,"score_gpt":0.3999065979431267,"score_spread":0.22711097859221643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132177175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000032756085,0.99648714,0.000083227125,0.002020766,0.0008169961,0.0000015707348,0.0000050502167,0.000005213829,0.0005472839],"genre_scores_gemma":[0.00037487084,0.99648476,0.0001332076,0.0009011515,0.0013719641,0.0000042923652,0.000008369546,0.0000018455053,0.00071949535],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995202,0.00012916753,0.000053957865,0.00006557488,0.00019418284,0.000036939135],"domain_scores_gemma":[0.9986261,0.0007938468,0.00010034039,0.000044427754,0.00030364707,0.00013153683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001440547,0.0011658331,0.0020573097,0.002080144,0.0005044499,0.0021558632,0.0013502822,0.002556851,0.006449184],"category_scores_gemma":[0.0018127951,0.00030650158,0.00055225124,0.002473798,0.0017811642,0.0047534085,0.0011215664,0.0038384518,0.0037882314],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102159815,0.000078509926,0.0003236326,0.010278683,0.000073819116,0.00046898893,0.00011123555,0.00033545154,0.0008478042,0.010480537,0.14231038,0.8345887],"study_design_scores_gemma":[0.000018355018,0.00006726876,0.00087483553,0.0049102996,0.000035625526,0.0018433098,0.00022915096,0.00011065968,0.00012996687,0.01111648,0.98064214,0.000021835718],"about_ca_topic_score_codex":0.00080817175,"about_ca_topic_score_gemma":0.0014820267,"teacher_disagreement_score":0.006449184,"about_ca_system_score_codex":0.0012769337,"about_ca_system_score_gemma":0.0015011294,"threshold_uncertainty_score":0.021574676},"labels":[],"label_agreement":null},{"id":"W2132357234","doi":"10.1634/theoncologist.2013-0314","title":"An mHealth Model to Increase Clinic Attendance for Breast Symptoms in Rural Bangladesh: Can Bridging the Digital Divide Help Close the Cancer Divide?","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Women's College Hospital; University of Toronto","funders":"Grand Challenges Canada; International Breast Cancer Research Foundation","keywords":"Medicine; mHealth; Attendance; Family medicine; Phone; Breast cancer; Health promotion; Randomized controlled trial; Health care; Nursing; Public health; Cancer; Surgery; Psychological intervention","score_opus":0.05753068777894978,"score_gpt":0.4429766403923279,"score_spread":0.38544595261337816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132357234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97499156,0.0041059805,0.0015205191,0.0036497884,0.00042811217,0.009000946,0.0005503821,0.000108205524,0.005644483],"genre_scores_gemma":[0.9828572,0.0037424152,0.004540552,0.0007820641,0.00013987852,0.006217247,0.00013164981,0.000004874549,0.0015840814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99889934,0.000696761,0.000085272186,0.00009322759,0.00012229459,0.00010312329],"domain_scores_gemma":[0.9991111,0.00036634452,0.00018469791,0.0000451546,0.000064295185,0.0002283566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019375456,0.0005126878,0.00056630926,0.00039678262,0.0003959,0.00079668366,0.0007735187,0.0009393159,0.009690179],"category_scores_gemma":[0.0030034662,0.00023453888,0.0008174992,0.00031752422,0.0005085439,0.0009953651,0.0008697916,0.00093691685,0.00039656556],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2339055,0.099649996,0.009618667,0.016770395,0.0018195839,0.00029399578,0.0021089395,0.0024242834,0.010155781,0.0017050916,0.0030581632,0.6184896],"study_design_scores_gemma":[0.34076053,0.59272623,0.03274364,0.0034861555,0.0030164667,0.00013610687,0.00254809,0.0043780054,0.0052634533,0.0011602136,0.013676862,0.00010425142],"about_ca_topic_score_codex":0.0036575748,"about_ca_topic_score_gemma":0.0050039985,"teacher_disagreement_score":0.009690179,"about_ca_system_score_codex":0.00074686017,"about_ca_system_score_gemma":0.001617198,"threshold_uncertainty_score":0.03241682},"labels":[],"label_agreement":null},{"id":"W2132590238","doi":"10.1634/theoncologist.2010-0107","title":"The Invisible Effects of Therapeutic Failure","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics and Legal Issues in Pediatric Healthcare","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.015616589142856945,"score_gpt":0.35310643369741407,"score_spread":0.3374898445545571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132590238","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41835693,0.020664552,0.01029844,0.182164,0.0029097619,0.00008077455,0.00012677733,0.00012086661,0.36527783],"genre_scores_gemma":[0.9914691,0.0021288053,0.00063058693,0.0031964288,0.00037925094,0.000027758912,0.000007240633,0.000031574706,0.0021290653],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9859007,0.010975573,0.00019565952,0.00032374036,0.0017778751,0.0008264201],"domain_scores_gemma":[0.9446511,0.046439916,0.0031220133,0.0021489363,0.0013346868,0.0023032755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010551873,0.00026512865,0.0004456067,0.0007146921,0.00444004,0.0032427714,0.0008037963,0.0023673163,0.007596535],"category_scores_gemma":[0.04211971,0.00016677534,0.00061513967,0.0004171197,0.017195363,0.0035243374,0.0053703287,0.004458828,0.0004146852],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010489344,0.00055633736,0.022206713,0.00090058474,0.00020467026,0.009945168,0.11881254,0.0016501426,0.0026924263,0.5721445,0.027128272,0.24270967],"study_design_scores_gemma":[0.00042316993,0.0013550165,0.07328168,0.0029396068,0.00041108672,0.020676292,0.1990256,0.0027455247,0.003919638,0.42647985,0.26850536,0.00023709064],"about_ca_topic_score_codex":0.001570167,"about_ca_topic_score_gemma":0.0016153705,"teacher_disagreement_score":0.010551873,"about_ca_system_score_codex":0.0026376848,"about_ca_system_score_gemma":0.0024642833,"threshold_uncertainty_score":0.055804312},"labels":[],"label_agreement":null},{"id":"W2133017309","doi":"10.1634/theoncologist.6-3-257","title":"Review of Recent Advances in Fluorescence Bronchoscopy in Early Localization of Central Airway Lung Cancer","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Field cancerization; Lung cancer; Bronchoscopy; Malignancy; Radiology; Autofluorescence; Sputum; Occult; Lung; Cancer; Airway obstruction; Pathology; Airway; Surgery; Internal medicine; Tuberculosis","score_opus":0.0421778709408694,"score_gpt":0.4129237320005013,"score_spread":0.3707458610596319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133017309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008917213,0.99874073,0.000096739415,0.00018337373,0.00028539193,0.0000059017725,0.000016724263,0.0000070713427,0.0005748421],"genre_scores_gemma":[0.00037237926,0.9985765,0.00021949381,0.00018144274,0.00029407028,0.0000071966842,0.000032129457,0.0000012882165,0.000315569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996631,0.00007047399,0.000078710116,0.00005764159,0.00010964009,0.00002051319],"domain_scores_gemma":[0.9987925,0.00066747295,0.00015292113,0.000026853817,0.0002786504,0.000081647275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092841755,0.0010940129,0.0019851178,0.0052233655,0.00030348828,0.0009487401,0.001417105,0.0009890496,0.005565735],"category_scores_gemma":[0.0018223034,0.0004120578,0.0007496304,0.0056594633,0.00041676493,0.0018766811,0.0005473181,0.0011406689,0.003161496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001029447,0.00006436397,0.00029786187,0.029339692,0.00011812317,0.00044224836,0.000060451956,0.00031583197,0.0008468763,0.00072967017,0.04272844,0.9249535],"study_design_scores_gemma":[0.000047189293,0.00015962486,0.0027396688,0.010023279,0.00033663824,0.004161043,0.000105149906,0.00013449084,0.00037127876,0.00095818687,0.98092425,0.000039341143],"about_ca_topic_score_codex":0.0016570811,"about_ca_topic_score_gemma":0.00345824,"teacher_disagreement_score":0.005565735,"about_ca_system_score_codex":0.00067178183,"about_ca_system_score_gemma":0.0009941335,"threshold_uncertainty_score":0.01861924},"labels":[],"label_agreement":null},{"id":"W2133116306","doi":"10.1634/theoncologist.9-5-561","title":"Management of Bleeding in Patients with Advanced Cancer","year":2004,"lang":"en","type":"review","venue":"The Oncologist","topic":"Spinal Hematomas and Complications","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cancer; Intensive care medicine; MEDLINE; General surgery; Internal medicine","score_opus":0.052212947890718744,"score_gpt":0.40066858651916787,"score_spread":0.34845563862844914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133116306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003879546,0.99803096,0.00007364901,0.00025550075,0.00009069208,0.0000059719873,0.000008140039,0.000003845673,0.0011432412],"genre_scores_gemma":[0.0034514733,0.995663,0.00016733186,0.00015129347,0.00009882,0.000006977941,0.0000149352045,6.2444514e-7,0.00044550968],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999793,0.000055610028,0.00003117275,0.00002460353,0.00008151391,0.000014040734],"domain_scores_gemma":[0.99966073,0.00016211568,0.00007927318,0.0000046289424,0.00007689468,0.000016425243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033868404,0.0004769951,0.0007289519,0.0017871726,0.00025103547,0.00052729866,0.00044459538,0.00063229835,0.0019812295],"category_scores_gemma":[0.0011567252,0.0001256551,0.0002782866,0.0021614365,0.00028512158,0.00058730226,0.00023790028,0.00057076814,0.00060392835],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007164327,0.000063252526,0.0014129856,0.016214961,0.00006673004,0.00094891596,0.00012913301,0.00018082127,0.00043154534,0.00070980034,0.019378694,0.9603915],"study_design_scores_gemma":[0.00009655634,0.0005795314,0.026680512,0.037533768,0.00043543582,0.05271652,0.0012424528,0.00036139545,0.0014259627,0.0026688604,0.87619346,0.0000656281],"about_ca_topic_score_codex":0.0022244565,"about_ca_topic_score_gemma":0.003850826,"teacher_disagreement_score":0.0022244565,"about_ca_system_score_codex":0.0004994167,"about_ca_system_score_gemma":0.0007966464,"threshold_uncertainty_score":0.0066278577},"labels":[],"label_agreement":null},{"id":"W2133193675","doi":"10.1634/theoncologist.12-7-785","title":"First-Line Treatment Options for Patients with HER-2–Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Society for Medical Oncology; Pfizer","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Adjuvant; Oncology; Adjuvant therapy; Clinical trial; Quality of life (healthcare); Chemotherapy; Cancer; Randomized controlled trial; Internal medicine; Intensive care medicine","score_opus":0.1131886795486073,"score_gpt":0.466774363464914,"score_spread":0.35358568391630674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133193675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013357104,0.9988129,0.00008763479,0.0002508315,0.00008200204,0.0000031432437,0.0000069094176,0.0000036705721,0.0006194348],"genre_scores_gemma":[0.0006068835,0.99877435,0.00014945837,0.00013396428,0.00006465098,0.0000037175407,0.00001009912,5.924751e-7,0.00025636592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981767,0.00004772672,0.000023601036,0.000024480676,0.000074648284,0.00001189014],"domain_scores_gemma":[0.9997156,0.00016146371,0.00004937381,0.0000075318358,0.000050272396,0.000015760665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004551009,0.0006058609,0.0015258938,0.0014273014,0.00020855115,0.0005919518,0.0006168625,0.00072714,0.0027864554],"category_scores_gemma":[0.000672555,0.00016739029,0.0005444888,0.0013563669,0.0002514439,0.0007849838,0.00029692482,0.0012798547,0.001218744],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056649144,0.0000673493,0.00015008361,0.014419992,0.00009586919,0.00017200607,0.00003167242,0.00032740907,0.000782591,0.0013169387,0.016705357,0.965874],"study_design_scores_gemma":[0.00009174877,0.00023225982,0.002831311,0.011403634,0.0003456924,0.0043433122,0.000104074104,0.0002530449,0.0007466571,0.0026187946,0.97700274,0.000026686466],"about_ca_topic_score_codex":0.00093335693,"about_ca_topic_score_gemma":0.0024662062,"teacher_disagreement_score":0.0027864554,"about_ca_system_score_codex":0.0005241253,"about_ca_system_score_gemma":0.00070836063,"threshold_uncertainty_score":0.00932163},"labels":[],"label_agreement":null},{"id":"W2135108459","doi":"10.1634/theoncologist.5-6-471","title":"The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":218,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Alberta","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Bladder cancer; Urology; Cystoscopy; Radiation therapy; Concomitant; Cisplatin; Cystectomy; Surgery; Urinary bladder; Chemotherapy; Urinary system; Cancer; Internal medicine","score_opus":0.09270750294284641,"score_gpt":0.3860997258673921,"score_spread":0.2933922229245457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135108459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955462,0.0018497546,0.00028670154,0.00015890007,0.00003620141,0.0009799548,0.00037903912,0.000050871186,0.00071225833],"genre_scores_gemma":[0.9909546,0.0015893185,0.0020844836,0.00058864185,0.00009897888,0.0015915921,0.001655946,0.000018966159,0.0014176199],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99949336,0.00026193503,0.00003634432,0.00007566042,0.0000415218,0.0000912122],"domain_scores_gemma":[0.99945635,0.0000833678,0.00010655402,0.00005072277,0.000018416582,0.00028455572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013513936,0.0014218303,0.0019520974,0.00031019858,0.00033375507,0.0007234842,0.0011978295,0.0009246441,0.0027673591],"category_scores_gemma":[0.00070690765,0.0004681692,0.0012077844,0.00037905594,0.0009058504,0.0004037988,0.00037425954,0.0024934665,0.0006402157],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78097224,0.03535047,0.011799578,0.0012991399,0.0014344843,0.00032829598,0.00037097975,0.003394626,0.046840858,0.00021965134,0.0020982525,0.1158914],"study_design_scores_gemma":[0.44022775,0.5294389,0.016743759,0.000078116616,0.0007160431,0.0005778271,0.00006992846,0.0009231763,0.008559876,0.00010591103,0.002532653,0.0000261611],"about_ca_topic_score_codex":0.0008760222,"about_ca_topic_score_gemma":0.0026434439,"teacher_disagreement_score":0.0027673591,"about_ca_system_score_codex":0.0007433628,"about_ca_system_score_gemma":0.0013897544,"threshold_uncertainty_score":0.009257734},"labels":[],"label_agreement":null},{"id":"W2135678986","doi":"10.1634/theoncologist.10-6-412","title":"AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lymphoma; Sarcoma; Disease; Immunology; Cancer; Malignancy; Population; Oncology; Internal medicine; Pathology","score_opus":0.08541992104712179,"score_gpt":0.36949023867191405,"score_spread":0.2840703176247923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135678986","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050827772,0.39359128,0.0026000896,0.53600174,0.018599113,0.00007228487,0.000263177,0.00031505988,0.04347442],"genre_scores_gemma":[0.047169115,0.71503145,0.008817022,0.15007764,0.05541656,0.00015342179,0.0005165147,0.0001362216,0.022682024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99924916,0.00024120387,0.00007474228,0.0000632568,0.00022795903,0.00014363628],"domain_scores_gemma":[0.99590176,0.0015945637,0.00030123856,0.000055238394,0.00064054166,0.0015067991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020311368,0.00044272083,0.0006510125,0.0008078006,0.001192413,0.0034582336,0.000736822,0.0030809622,0.017523581],"category_scores_gemma":[0.0062178764,0.00026528188,0.0004569257,0.0006799874,0.0007407276,0.0042844145,0.0018812875,0.006987495,0.0033644054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007094483,0.00014671971,0.0040190835,0.0013030863,0.000021205748,0.00206734,0.00054475415,0.00027408643,0.00034284746,0.008289,0.46290928,0.52001166],"study_design_scores_gemma":[0.000031060365,0.00017487252,0.0047888234,0.004098702,0.000037489222,0.00843831,0.0022645728,0.0004884362,0.0001267406,0.020169964,0.95933163,0.000049300463],"about_ca_topic_score_codex":0.0011530108,"about_ca_topic_score_gemma":0.0033567555,"teacher_disagreement_score":0.017523581,"about_ca_system_score_codex":0.0011720792,"about_ca_system_score_gemma":0.0026674974,"threshold_uncertainty_score":0.05862224},"labels":[],"label_agreement":null},{"id":"W2135743613","doi":"10.1634/theoncologist.12-9-1035","title":"Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity","year":2007,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Waterloo","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Zoledronic acid; Breast cancer; Internal medicine; Bisphosphonate; N-terminal telopeptide; Oncology; Post-hoc analysis; Creatinine; Multiple myeloma; Bone metastasis; Metastatic breast cancer; Hazard ratio; Cancer; Osteoporosis; Urology; Surgery; Confidence interval; Alkaline phosphatase; Osteocalcin","score_opus":0.015697575009305784,"score_gpt":0.30163218920294516,"score_spread":0.28593461419363936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135743613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705195,0.0024777292,0.00006077935,0.000056780827,0.000007310391,0.0000143199195,0.00014734795,0.0000045997144,0.00017906653],"genre_scores_gemma":[0.9994018,0.00024493856,0.00005928005,0.00003129352,0.000008708738,0.000010142993,0.00015872062,5.162599e-7,0.00008455071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997286,0.000105218816,0.00003019916,0.00004117667,0.00005593301,0.000038914743],"domain_scores_gemma":[0.9990042,0.00031890388,0.00046721502,0.00003045715,0.000053322605,0.00012592225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064689555,0.00016662975,0.0005297945,0.00019930814,0.00013355163,0.000285944,0.00013479918,0.00027710025,0.0008258164],"category_scores_gemma":[0.0017788775,0.00012339882,0.00064184197,0.00024846476,0.00012572679,0.00014383106,0.00015435631,0.00024555763,0.000076459786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052154854,0.0003590852,0.92023015,0.00021907598,0.0013092414,0.00013660535,0.000059679307,0.001037632,0.0022483584,0.00004037484,0.00034519966,0.021859746],"study_design_scores_gemma":[0.0037196428,0.011273332,0.9802067,0.00004500733,0.0011984811,0.00056074344,0.000055423094,0.001339687,0.0007866861,0.00008290045,0.0007200851,0.000011336179],"about_ca_topic_score_codex":0.00085255574,"about_ca_topic_score_gemma":0.0016691802,"teacher_disagreement_score":0.00085255574,"about_ca_system_score_codex":0.00020176262,"about_ca_system_score_gemma":0.000279384,"threshold_uncertainty_score":0.0034211278},"labels":[],"label_agreement":null},{"id":"W2136121072","doi":"10.1634/theoncologist.2013-0343","title":"Effect of Place of Residence and Treatment on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma in British Columbia","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Residence; Rural area; Confidence interval; Hazard ratio; Diffuse large B-cell lymphoma; Cancer registry; Demography; Cancer; Lymphoma; Internal medicine; Pathology","score_opus":0.006921278772214086,"score_gpt":0.24701985129497664,"score_spread":0.24009857252276257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136121072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979919,0.00054060575,0.000028945411,0.00020918276,0.0000092558075,0.0000055991154,0.00055107113,0.0000037406187,0.00065972726],"genre_scores_gemma":[0.9993175,0.00014997696,0.000023991597,0.00004467638,0.0000047560184,0.0000031447566,0.00030658272,0.0000015195931,0.00014778646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999539,0.00008612948,0.000030108664,0.000068506066,0.000095692805,0.0001805478],"domain_scores_gemma":[0.99839693,0.00018102472,0.00046683592,0.000056074885,0.00035311034,0.00054606795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035970338,0.0002115801,0.0002870631,0.000679161,0.0009873271,0.00083978474,0.0006800043,0.00034715084,0.0018293295],"category_scores_gemma":[0.0015941353,0.00015365951,0.00033960745,0.0016153473,0.00050572644,0.00020411554,0.0006240684,0.00066722865,0.00017134447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007692856,0.000015173696,0.9980775,0.000009948269,0.000024548834,0.00006692261,0.00006347948,0.000054400174,0.00004136065,0.000008991335,0.0002453518,0.0013152243],"study_design_scores_gemma":[0.000007756333,0.00002384048,0.99908054,0.0000159835,0.000019196379,0.000095889845,0.00034828307,0.00013658778,0.0000126153,0.000011994504,0.0002436002,0.0000037836767],"about_ca_topic_score_codex":0.7972598,"about_ca_topic_score_gemma":0.882361,"teacher_disagreement_score":0.20274019,"about_ca_system_score_codex":0.004498224,"about_ca_system_score_gemma":0.004386768,"threshold_uncertainty_score":0.40786833},"labels":[],"label_agreement":null},{"id":"W2139768542","doi":"10.1634/theoncologist.2013-0173","title":"Lost in Transition? Thoughts on Retirement—“Will You Still Need Me, Will You Still Feed Me, When I'm Sixty-Four?”","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Ottawa Hospital; Credit Valley Hospital; University of Ottawa","funders":"","keywords":"Transition (genetics); Plan (archaeology); Psychology; Gerontology; Business; Medicine; History","score_opus":0.02565525011998069,"score_gpt":0.3326521737490066,"score_spread":0.30699692362902586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139768542","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04264726,0.026421512,0.0028717855,0.8556596,0.017278904,0.000055512017,0.00017457466,0.00013554667,0.05475531],"genre_scores_gemma":[0.6422381,0.053061627,0.0031723154,0.22153537,0.0074829203,0.00012149355,0.00029921476,0.00010722587,0.071981795],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991027,0.0005034409,0.00004547527,0.000041444815,0.00016460511,0.00014232079],"domain_scores_gemma":[0.99821764,0.00041881844,0.00023627479,0.000050288443,0.0002945452,0.00078239467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019608485,0.00029232778,0.00023669619,0.00044790405,0.004898767,0.0022986608,0.00051162887,0.0016654601,0.008973272],"category_scores_gemma":[0.007056935,0.00014307843,0.00053001824,0.00032270557,0.0026487543,0.004107272,0.0028730251,0.004815316,0.0019785094],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055817145,0.00007560043,0.009754158,0.00022549769,0.000029738414,0.002183082,0.047672693,0.00009217079,0.00036237718,0.026919035,0.77241814,0.14021164],"study_design_scores_gemma":[0.000018564882,0.00016062085,0.013032003,0.0013132798,0.000026809514,0.0063503007,0.23830101,0.00012065392,0.00028360472,0.025060251,0.71523964,0.00009330679],"about_ca_topic_score_codex":0.004129389,"about_ca_topic_score_gemma":0.011415756,"teacher_disagreement_score":0.008973272,"about_ca_system_score_codex":0.0013757789,"about_ca_system_score_gemma":0.0028478696,"threshold_uncertainty_score":0.030018568},"labels":[],"label_agreement":null},{"id":"W2139939379","doi":"10.1634/theoncologist.2008-0232","title":"The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":692,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Docetaxel; Gemcitabine; Oncology; Internal medicine; Histology; Hazard ratio; Lung cancer; Proportional hazards model; Chemotherapy; Cisplatin; Confidence interval","score_opus":0.13005089114996987,"score_gpt":0.5312090846097777,"score_spread":0.4011581934598078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139939379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019793808,0.9966633,0.00024131636,0.0003593941,0.00011257648,0.00012824431,0.00013194817,0.000010496059,0.0003734266],"genre_scores_gemma":[0.024706703,0.97148186,0.0010860672,0.0016399102,0.00019474703,0.00034792023,0.00032852392,0.00002650898,0.00018784162],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99567884,0.0013713391,0.0017673501,0.00040615958,0.0006686414,0.00010771594],"domain_scores_gemma":[0.96857667,0.01967671,0.007475128,0.00071898464,0.003069422,0.00048305988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016304933,0.00081889244,0.0050538806,0.0024445017,0.0003372575,0.0023108358,0.0018425215,0.0010978485,0.0013822042],"category_scores_gemma":[0.024629524,0.0005813939,0.0044568367,0.0042983755,0.0007909087,0.0013478628,0.00079083146,0.0016001376,0.00022050164],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006292912,0.0002533458,0.0036392198,0.2782051,0.011885584,0.00018825232,0.0003951087,0.0004132254,0.003741581,0.0007897239,0.006536813,0.687659],"study_design_scores_gemma":[0.0074165165,0.015620733,0.044156108,0.40864813,0.16974247,0.002718678,0.0008606572,0.000705537,0.00763487,0.0021051697,0.34014937,0.00024174692],"about_ca_topic_score_codex":0.0010419446,"about_ca_topic_score_gemma":0.0028619163,"teacher_disagreement_score":0.016304933,"about_ca_system_score_codex":0.0017984075,"about_ca_system_score_gemma":0.0029292349,"threshold_uncertainty_score":0.08622974},"labels":[],"label_agreement":null},{"id":"W2140300450","doi":"10.1634/theoncologist.2007-0185","title":"The Ethical Justification for Minor Sibling Bone Marrow Donation: A Case Study","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Sibling; Minor (academic); Donation; Medicine; Sister; Duty; Bone marrow; Surgery; Family medicine; Immunology; Developmental psychology; Psychology; Law","score_opus":0.3481356631908239,"score_gpt":0.4929653174632175,"score_spread":0.14482965427239358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140300450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531308,0.0054305545,0.0069328933,0.014508385,0.00049001095,0.00030335668,0.000043375523,0.000027517415,0.019133098],"genre_scores_gemma":[0.9886829,0.0034193941,0.0034828396,0.0016265474,0.00033496917,0.00009509447,0.000018893972,0.000011183936,0.0023281402],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99668866,0.0020525896,0.00022765459,0.00016480764,0.00040903623,0.00045725447],"domain_scores_gemma":[0.993046,0.0045641987,0.0010738394,0.00022449042,0.00026659557,0.000824851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027101173,0.00093319645,0.00060195924,0.0016103021,0.006921056,0.0022515943,0.0013478845,0.005484279,0.0023790798],"category_scores_gemma":[0.017496468,0.0005337658,0.0008342683,0.0012303847,0.0036272132,0.0020569782,0.0027022029,0.0044116317,0.0003044986],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005230692,0.00023921912,0.01307382,0.000149972,0.000020481632,0.951884,0.014505902,0.00033963047,0.00038048488,0.010276091,0.0016884326,0.0073896535],"study_design_scores_gemma":[0.000010353146,0.00007238619,0.0013909477,0.00014342624,0.000013764198,0.97912747,0.011469806,0.00044156847,0.00035383453,0.0016421826,0.005309728,0.000024624353],"about_ca_topic_score_codex":0.0027389028,"about_ca_topic_score_gemma":0.00524666,"teacher_disagreement_score":0.006921056,"about_ca_system_score_codex":0.0021862742,"about_ca_system_score_gemma":0.0015616688,"threshold_uncertainty_score":0.015862584},"labels":[],"label_agreement":null},{"id":"W2142170680","doi":"10.1634/theoncologist.2011-0237","title":"Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Angiosarcoma; Medicine; Sorafenib; Sarcoma; Soft tissue sarcoma; Clinical endpoint; Internal medicine; Surgery; Toxicity; Oncology; Chemotherapy; Clinical trial; Pathology; Hepatocellular carcinoma","score_opus":0.022873127416478768,"score_gpt":0.29801002391551856,"score_spread":0.2751368964990398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142170680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98893225,0.0058744727,0.000409113,0.00070844794,0.00008455082,0.0017894774,0.0005777777,0.00005224024,0.0015717051],"genre_scores_gemma":[0.98777944,0.0036758021,0.0018293099,0.0011329958,0.00022542368,0.0018684637,0.0019552791,0.000011894676,0.0015215353],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996667,0.00019573285,0.000015635804,0.000037839385,0.00003250931,0.00005156876],"domain_scores_gemma":[0.9996952,0.000047531197,0.00007087642,0.00001601302,0.000026832779,0.00014360176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016699241,0.0008376841,0.0009187891,0.00025164246,0.00020589882,0.0004149806,0.00026818045,0.00042725026,0.0020373526],"category_scores_gemma":[0.0005785043,0.00018156381,0.00092809525,0.00021856088,0.0003413772,0.00025461358,0.00021043436,0.00069122756,0.00028429154],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64176536,0.025447046,0.018239854,0.0020300085,0.0026760052,0.00041534047,0.0003728034,0.003335686,0.0353878,0.0006022083,0.009858915,0.25986904],"study_design_scores_gemma":[0.7752931,0.18268967,0.031815954,0.00009691394,0.0006525864,0.00043614744,0.000047475674,0.0009958354,0.0012577642,0.00024085454,0.0064460407,0.000027628212],"about_ca_topic_score_codex":0.0010345973,"about_ca_topic_score_gemma":0.003749152,"teacher_disagreement_score":0.0020373526,"about_ca_system_score_codex":0.0005343041,"about_ca_system_score_gemma":0.0013295505,"threshold_uncertainty_score":0.008831561},"labels":[],"label_agreement":null},{"id":"W2143006986","doi":"10.1634/theoncologist.2010-0263","title":"Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"Genentech; GlaxoSmithKline; Pfizer","keywords":"Sunitinib; Medicine; Dosing; Renal cell carcinoma; Intensive care medicine; Tyrosine-kinase inhibitor; Toxicity; Oncology; Internal medicine; Cancer","score_opus":0.20589735659080372,"score_gpt":0.37857232910030164,"score_spread":0.17267497250949793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143006986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023355921,0.98838264,0.0008879161,0.005813879,0.0011305915,0.00009288199,0.0001318324,0.00004142831,0.0032853633],"genre_scores_gemma":[0.0010111508,0.99090576,0.003565779,0.0017610657,0.00040803678,0.000076400705,0.00017981009,0.000004882411,0.0020870604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936086,0.00018041821,0.00016723474,0.000048789,0.00021600853,0.00002673205],"domain_scores_gemma":[0.99919814,0.0002325785,0.00018783282,0.000020571531,0.00031322928,0.000047581474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013165246,0.0009607071,0.0016856494,0.0029351136,0.0003504082,0.0007487732,0.0013780823,0.0015250122,0.0028907438],"category_scores_gemma":[0.0019926159,0.00034720261,0.0009148433,0.0028062328,0.00031035414,0.0014234532,0.00045008922,0.0018926256,0.0023397529],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073879695,0.00010609292,0.0002752117,0.022350268,0.00013278006,0.0004996817,0.00010108583,0.0005466423,0.0012445614,0.0016274721,0.15518886,0.8178534],"study_design_scores_gemma":[0.00006382968,0.0000654598,0.0016347871,0.017544469,0.0002661409,0.0018428065,0.000100798505,0.00020389217,0.00030314873,0.0016714948,0.976278,0.000025206044],"about_ca_topic_score_codex":0.0023268613,"about_ca_topic_score_gemma":0.005730999,"teacher_disagreement_score":0.0029351136,"about_ca_system_score_codex":0.0010327967,"about_ca_system_score_gemma":0.0022720646,"threshold_uncertainty_score":0.009670496},"labels":[],"label_agreement":null},{"id":"W2143008582","doi":"10.1634/theoncologist.2013-0390","title":"Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"Terry Fox Research Institute; Canada Research Chairs; Genome British Columbia; Genome Canada","keywords":"Transcriptome; Medicine; DNA sequencing; Genome; Precision medicine; Cancer; Personalized medicine; SMARCB1; Computational biology; Oncology; Bioinformatics; Genetics; Pathology; Internal medicine; Gene; Biology","score_opus":0.05352112794267109,"score_gpt":0.2999288822729578,"score_spread":0.2464077543302867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143008582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778871,0.001384709,0.015152326,0.0020505935,0.00009091139,0.00004398712,0.00016288893,0.00017878406,0.003048704],"genre_scores_gemma":[0.98532015,0.0005323176,0.013359105,0.00033355283,0.00003306413,0.0000052655014,0.00006582577,0.000014179915,0.00033665885],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99986553,0.000030412182,0.000016500335,0.000026345491,0.00003118423,0.00002997111],"domain_scores_gemma":[0.9997774,0.00009919495,0.000027857812,0.000021688322,0.000022661872,0.00005127526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004169438,0.00018946812,0.00019484229,0.00067320623,0.0005054626,0.0005701942,0.00018804829,0.0007717225,0.0007503083],"category_scores_gemma":[0.0008083243,0.00015847068,0.00020629459,0.0002270241,0.000492791,0.00032982367,0.0003093887,0.0005770507,0.00019052756],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010658306,0.0000883447,0.12465886,0.0001575912,0.00005591931,0.31346878,0.0008732845,0.0022179598,0.49554437,0.0033145412,0.0014680512,0.05708643],"study_design_scores_gemma":[0.000087093664,0.00061633135,0.112789206,0.00019250308,0.00022570117,0.5576681,0.0024898844,0.039242808,0.254319,0.009345133,0.02293654,0.00008770981],"about_ca_topic_score_codex":0.001207984,"about_ca_topic_score_gemma":0.0032843438,"teacher_disagreement_score":0.001207984,"about_ca_system_score_codex":0.00045176345,"about_ca_system_score_gemma":0.00032483603,"threshold_uncertainty_score":0.0032777786},"labels":[],"label_agreement":null},{"id":"W2143013795","doi":"10.1634/theoncologist.2015-0008","title":"Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Oncology; Cancer; Pharmacology; Intensive care medicine; Internal medicine; Medical physics","score_opus":0.9526026533308177,"score_gpt":0.7811456566783852,"score_spread":0.17145699665243253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143013795","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42914984,0.4076444,0.045798767,0.017987834,0.0017279249,0.02381443,0.0065564397,0.00058222073,0.06673817],"genre_scores_gemma":[0.83669966,0.07285699,0.060910635,0.012872649,0.0007723103,0.007389473,0.004077172,0.0001222638,0.004298802],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99661666,0.0018706896,0.00048245303,0.00035784804,0.0005236381,0.00014866971],"domain_scores_gemma":[0.99481404,0.0029306498,0.0010927148,0.00014738277,0.0005214789,0.00049379404],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012387511,0.00041386136,0.0010673479,0.0011132461,0.0003047112,0.0017744167,0.0006810727,0.0013409371,0.0064618117],"category_scores_gemma":[0.00772764,0.00025484018,0.0011990388,0.00081581675,0.0004003635,0.00097070227,0.00042719225,0.0015026197,0.001482474],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04319597,0.0017339278,0.028893491,0.018715382,0.0019789513,0.00094185927,0.00039424477,0.004450049,0.060707398,0.006047442,0.014915451,0.8180258],"study_design_scores_gemma":[0.065938406,0.110529594,0.08395933,0.027567169,0.008126922,0.005140982,0.00074316445,0.007719795,0.057971522,0.022285698,0.6096318,0.0003855626],"about_ca_topic_score_codex":0.000093406365,"about_ca_topic_score_gemma":0.00045002316,"teacher_disagreement_score":0.9876125,"about_ca_system_score_codex":0.0008279778,"about_ca_system_score_gemma":0.0010726178,"threshold_uncertainty_score":0.06551224},"labels":[],"label_agreement":null},{"id":"W2143483266","doi":"10.1634/theoncologist.11-5-488","title":"Primary Mediastinal Large B-Cell Lymphoma","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Cancer research; Oncology; Internal medicine","score_opus":0.051360434164611356,"score_gpt":0.350298974765783,"score_spread":0.29893854060117164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143483266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024757473,0.9956728,0.00012112384,0.00038889516,0.00042399683,0.000009149287,0.000019518757,0.000017578772,0.0030993244],"genre_scores_gemma":[0.002180068,0.9940415,0.00017895713,0.0004009652,0.0005599479,0.000008828173,0.00006440564,0.0000022465565,0.0025630759],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998958,0.000013936927,0.000013331356,0.000018784705,0.000046434852,0.00001167789],"domain_scores_gemma":[0.99983215,0.000051192907,0.000032497577,0.0000051846237,0.00005284273,0.000026043646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025853657,0.00082721596,0.0014982568,0.0019232973,0.00024464927,0.0005190119,0.0005751451,0.00060799945,0.008223426],"category_scores_gemma":[0.00053957914,0.00022049995,0.00030800284,0.0021718722,0.00022593662,0.00095482083,0.00030421859,0.00068892085,0.006382521],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067571105,0.000060358616,0.0003308715,0.0070013283,0.00004888432,0.0016901925,0.000026124078,0.0001254085,0.0009958198,0.00034769214,0.071544476,0.91776127],"study_design_scores_gemma":[0.0000693765,0.00017297226,0.0040191067,0.004800111,0.00016232234,0.022764385,0.00009867257,0.0001016862,0.00075404835,0.0012603876,0.9657768,0.00002014129],"about_ca_topic_score_codex":0.0012218922,"about_ca_topic_score_gemma":0.0020175923,"teacher_disagreement_score":0.008223426,"about_ca_system_score_codex":0.00036948867,"about_ca_system_score_gemma":0.0007140457,"threshold_uncertainty_score":0.027510047},"labels":[],"label_agreement":null},{"id":"W2144226378","doi":"10.1634/theoncologist.2011-0011","title":"<i>KRAS</i> and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; U.S. Food and Drug Administration; National Comprehensive Cancer Network","keywords":"Panitumumab; KRAS; Medicine; Cetuximab; Colorectal cancer; Timeline; Clinical trial; Vetting; Oncology; Internal medicine; Cancer","score_opus":0.24113086418533014,"score_gpt":0.5272951237733174,"score_spread":0.2861642595879873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144226378","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011421861,0.0049788966,0.0036605606,0.9783132,0.008766402,0.000141424,0.000014639198,0.0000342423,0.0029484178],"genre_scores_gemma":[0.0404101,0.0034361384,0.015408451,0.90687037,0.030566413,0.00084106147,0.000016058983,0.000094826064,0.0023566654],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.2950803,0.61412126,0.038921818,0.007856782,0.039433736,0.0045860712],"domain_scores_gemma":[0.14164217,0.7774955,0.024092644,0.019570721,0.028133852,0.0090651],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.5901016,0.00091723184,0.0028506522,0.002326631,0.0058110356,0.022332449,0.0073528322,0.051127378,0.0019578172],"category_scores_gemma":[0.6908421,0.0014329146,0.0023527707,0.0023550258,0.040741306,0.017973488,0.0080512,0.04824681,0.0010811996],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093379687,0.00018924578,0.0036594037,0.0037180749,0.0005251806,0.0022847294,0.016661664,0.001978471,0.0012199687,0.33800888,0.49286902,0.13795151],"study_design_scores_gemma":[0.00083961646,0.00065641565,0.0041385093,0.008517218,0.00030874042,0.0018010703,0.010013918,0.0042577498,0.0011404047,0.36963904,0.59819543,0.00049192243],"about_ca_topic_score_codex":0.0033337227,"about_ca_topic_score_gemma":0.008480855,"teacher_disagreement_score":0.5901016,"about_ca_system_score_codex":0.011313802,"about_ca_system_score_gemma":0.033689696,"threshold_uncertainty_score":0.5054778},"labels":[],"label_agreement":null},{"id":"W2144498495","doi":"10.1634/theoncologist.2012-0342","title":"Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; World Bank Group; GlaxoSmithKline","keywords":"Medicine; Trastuzumab; Institutional review board; Lapatinib; Clinical trial; Breast cancer; Interquartile range; Randomized controlled trial; Informed consent; Internal medicine; Cancer; Surgery; Alternative medicine","score_opus":0.1228155068648815,"score_gpt":0.4756288442860815,"score_spread":0.35281333742119997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144498495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98338217,0.0027548298,0.0062166713,0.0006897673,0.000040224277,0.00020410903,0.0010334819,0.000046557892,0.0056321924],"genre_scores_gemma":[0.9972115,0.0003286189,0.0013054558,0.00014954875,0.000029637054,0.00015913673,0.00048300048,0.000032188083,0.00030091213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98600096,0.01054674,0.00094230816,0.0010679797,0.0008426255,0.0005993818],"domain_scores_gemma":[0.9041724,0.057228804,0.025427386,0.004121606,0.005378734,0.0036710678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021738913,0.00031905176,0.0006037787,0.0008009696,0.0003878579,0.0013786126,0.00045477564,0.00039061613,0.0035811514],"category_scores_gemma":[0.062326994,0.00020404355,0.0010468658,0.0011518048,0.0004660493,0.0010324809,0.0012228388,0.0009949958,0.00043709288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019887615,0.00053262926,0.83292735,0.00048264593,0.0016475603,0.00035794778,0.0013246083,0.01268646,0.003242684,0.0014492122,0.0042946152,0.121166654],"study_design_scores_gemma":[0.0008302239,0.009819494,0.96560997,0.00014926204,0.0010209123,0.0007023886,0.0019832554,0.008705564,0.003345705,0.00085285946,0.006905247,0.000075192154],"about_ca_topic_score_codex":0.0016313493,"about_ca_topic_score_gemma":0.0027518077,"teacher_disagreement_score":0.021738913,"about_ca_system_score_codex":0.0010984762,"about_ca_system_score_gemma":0.0013052355,"threshold_uncertainty_score":0.11496776},"labels":[],"label_agreement":null},{"id":"W2144648936","doi":"10.1634/theoncologist.12-5-610","title":"Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency; Vrije Universiteit Amsterdam; Institut Claudius Regaud; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cetuximab; Colorectal cancer; Toxicity; Grading (engineering); Quality of life (healthcare); Gefitinib; Cancer; Oncology; Internal medicine","score_opus":0.2509656558099983,"score_gpt":0.5050140510855577,"score_spread":0.25404839527555945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144648936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016369409,0.995544,0.00032578126,0.0028249354,0.000323734,0.0000052247697,0.0000038423805,0.000009082852,0.00079964945],"genre_scores_gemma":[0.0015414051,0.9953295,0.0009462024,0.0011680613,0.00064081006,0.0000111336185,0.00001150336,0.0000024227468,0.00034892245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890804,0.00039556244,0.00016315798,0.00011210455,0.00036942906,0.000051778836],"domain_scores_gemma":[0.99853873,0.0007312145,0.00018470903,0.000040776282,0.00041354637,0.00009106861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029501994,0.0009483678,0.002447513,0.0026640606,0.00046203862,0.002170652,0.0016844406,0.0021843226,0.0013718826],"category_scores_gemma":[0.0027278052,0.00032691448,0.0006213221,0.0030680087,0.0016181845,0.0032721502,0.0008790428,0.0037740043,0.0009932261],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060007096,0.00007309213,0.00030604596,0.008363609,0.00006379673,0.0004498687,0.0001739414,0.00046052955,0.00062793144,0.008172874,0.03238411,0.9488642],"study_design_scores_gemma":[0.000074956304,0.00020519109,0.0018607866,0.010870665,0.000108499036,0.0055517317,0.00063200673,0.00045768014,0.00030100936,0.010792134,0.9690934,0.000051879437],"about_ca_topic_score_codex":0.0014206682,"about_ca_topic_score_gemma":0.0029705158,"teacher_disagreement_score":0.0029501994,"about_ca_system_score_codex":0.0019565346,"about_ca_system_score_gemma":0.0022535631,"threshold_uncertainty_score":0.01560235},"labels":[],"label_agreement":null},{"id":"W2145295241","doi":"10.1634/theoncologist.2009-0265","title":"Changes in Functional Performance Measures in Adults Undergoing Chemoradiation for Primary Malignant Glioma: A Feasibility Study","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health","keywords":"Medicine; Cohort; Quality of life (healthcare); Glioma; Cardiorespiratory fitness; Prospective cohort study; Internal medicine; Physical therapy; Cohort study; Magnetic resonance imaging; Radiology","score_opus":0.0867454477016953,"score_gpt":0.35122269367165077,"score_spread":0.2644772459699555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145295241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994772,0.00011947272,0.00008877316,0.000022429278,0.000003040021,0.000069529364,0.000083132305,0.0000036576157,0.00013275538],"genre_scores_gemma":[0.999358,0.00005219456,0.00021833101,0.00003922105,0.000010593658,0.00009207806,0.00016166554,8.491321e-7,0.000067025656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994386,0.00024059112,0.000048030466,0.00009424505,0.00010044022,0.00007808325],"domain_scores_gemma":[0.99854773,0.00021048806,0.0005341393,0.00008273467,0.00025813282,0.00036667573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014277732,0.00035652154,0.00041902988,0.00036135004,0.00029298099,0.00030246718,0.0002444977,0.00045409423,0.0005953591],"category_scores_gemma":[0.0025123786,0.00019713727,0.00032605912,0.00030434594,0.00031074142,0.0003529825,0.0003184021,0.0004075692,0.00033261348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034869083,0.0006650237,0.9883415,0.00003128245,0.00006229474,0.00012130053,0.00015820331,0.000038925544,0.0011266618,0.0000067368205,0.000100049525,0.005861037],"study_design_scores_gemma":[0.00021071285,0.009193773,0.9895459,0.0000059161803,0.0000433901,0.000311666,0.00010117647,0.00012465537,0.00023954854,0.000006906268,0.00021117114,0.0000051149564],"about_ca_topic_score_codex":0.0012353573,"about_ca_topic_score_gemma":0.0022058433,"teacher_disagreement_score":0.0014277732,"about_ca_system_score_codex":0.00033186373,"about_ca_system_score_gemma":0.00049777876,"threshold_uncertainty_score":0.0075508356},"labels":[],"label_agreement":null},{"id":"W2145362773","doi":"10.1634/theoncologist.6-4-353","title":"Hormone Replacement in Women with a History of Breast Cancer","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Hormone replacement therapy (female-to-male); Estrogen; Menopause; Endometrial cancer; Internal medicine; Osteoporosis; Cancer; Oncology; Hypoestrogenism; Gynecology; Testosterone (patch)","score_opus":0.0196726031997262,"score_gpt":0.2962291045613742,"score_spread":0.276556501361648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145362773","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6175203,0.34776142,0.00026248448,0.009081812,0.001841912,0.00023639976,0.0012278425,0.00005363113,0.022014128],"genre_scores_gemma":[0.9165605,0.072392635,0.00035086795,0.0041594324,0.0011815306,0.0001275001,0.0005978622,0.0000046548903,0.00462494],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997552,0.00007741173,0.000027067226,0.000026151398,0.00007637047,0.000037843492],"domain_scores_gemma":[0.99966097,0.00009729434,0.0001058318,0.000016278414,0.000026313388,0.00009333853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036145444,0.000100187746,0.000558588,0.00034262563,0.00030797874,0.00024723922,0.00014003261,0.0005383465,0.002736583],"category_scores_gemma":[0.0013081321,0.000100337376,0.00049803505,0.0006561033,0.00011530616,0.00016442391,0.00013376588,0.00045263354,0.00046119266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012666715,0.0011975284,0.50996923,0.0029146478,0.0007655912,0.0031316713,0.000418338,0.00014000092,0.0030726916,0.00028745012,0.01827884,0.4471574],"study_design_scores_gemma":[0.0024179674,0.010129177,0.92693985,0.0011598758,0.0010137246,0.007867514,0.0004233327,0.00024494686,0.00065276684,0.00043857476,0.04867998,0.000032379467],"about_ca_topic_score_codex":0.00178638,"about_ca_topic_score_gemma":0.0032169092,"teacher_disagreement_score":0.002736583,"about_ca_system_score_codex":0.00022399567,"about_ca_system_score_gemma":0.00043541033,"threshold_uncertainty_score":0.009154737},"labels":[],"label_agreement":null},{"id":"W2146383436","doi":"10.1634/theoncologist.9-90005-70","title":"Epoetin Alfa: Future Directions and Future Research","year":2004,"lang":"en","type":"article","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Epoetin alfa; Intensive care medicine; Erythropoietin; MEDLINE; Internal medicine","score_opus":0.05167018119413207,"score_gpt":0.38307059997183895,"score_spread":0.3314004187777069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146383436","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022112408,0.9549492,0.0008293248,0.03508646,0.0015411428,0.000035830264,0.000098381264,0.000045977802,0.005202327],"genre_scores_gemma":[0.021113753,0.9548443,0.0049708663,0.010000541,0.0057170466,0.00014924505,0.00029010625,0.000024219307,0.0028899522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982389,0.00075380696,0.00022279422,0.00020673436,0.00031757832,0.00026017491],"domain_scores_gemma":[0.99154073,0.0045244633,0.0007013405,0.00024863318,0.0018336733,0.0011512908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012196178,0.00090165896,0.0028721648,0.0009842226,0.0007907121,0.0056109037,0.0018952263,0.0046424735,0.01730307],"category_scores_gemma":[0.006811124,0.00035015808,0.0012823518,0.0018060044,0.002326165,0.0068337996,0.0010009235,0.004466115,0.003424886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028124228,0.0007198202,0.002962465,0.0054304115,0.000253901,0.00047116829,0.00020683388,0.00043444426,0.0011499403,0.013779349,0.04044413,0.9313351],"study_design_scores_gemma":[0.0022451293,0.0040321266,0.0098021105,0.017883498,0.0013070133,0.0029561091,0.0026516137,0.0018205132,0.0018179157,0.05825808,0.8970226,0.00020319936],"about_ca_topic_score_codex":0.0020517393,"about_ca_topic_score_gemma":0.0038838952,"teacher_disagreement_score":0.01730307,"about_ca_system_score_codex":0.0022999593,"about_ca_system_score_gemma":0.00565586,"threshold_uncertainty_score":0.06450033},"labels":[],"label_agreement":null},{"id":"W2147758491","doi":"10.1634/theoncologist.2009-s503","title":"Pathophysiology and Animal Models of Cancer-Related Painful Peripheral Neuropathy","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; Louise and Alan Edwards Foundation; Canada Research Chairs","keywords":"Medicine; Pathophysiology; Peripheral neuropathy; Neuropathic pain; Cancer; Chemotherapy; Bioinformatics; Inflammation; Neuroscience; Pathology; Anesthesia; Surgery; Internal medicine; Diabetes mellitus","score_opus":0.05423585709037299,"score_gpt":0.3663754116518573,"score_spread":0.3121395545614843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147758491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034222606,0.997186,0.00035219608,0.00022726457,0.00014339373,0.000013136236,0.00001817722,0.000010600757,0.0017069237],"genre_scores_gemma":[0.0016411424,0.9969733,0.00035139802,0.00018330688,0.00007360275,0.000016244434,0.000028926157,0.0000013499468,0.00073065807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998323,0.000036936082,0.000019941413,0.000026260584,0.00006962986,0.000014976335],"domain_scores_gemma":[0.9998466,0.00006382993,0.000030490712,0.0000071626873,0.00003665196,0.000015176054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047538208,0.0010472778,0.0013422264,0.001866592,0.0003055041,0.0007361854,0.00091049314,0.0013118671,0.0020584106],"category_scores_gemma":[0.00032703165,0.00025256764,0.00047097882,0.0013489774,0.00068528036,0.0011485849,0.00047020544,0.0016438087,0.001739274],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021270664,0.00042089456,0.00038810063,0.028179556,0.00013761035,0.0013019254,0.0001378965,0.00082861393,0.03264592,0.010269541,0.03626036,0.8892169],"study_design_scores_gemma":[0.000046516525,0.00034308017,0.0015096298,0.0031918397,0.00012945643,0.0054830513,0.00009511876,0.00018490003,0.005218731,0.0053868387,0.9783709,0.000039844803],"about_ca_topic_score_codex":0.0008593628,"about_ca_topic_score_gemma":0.0013957708,"teacher_disagreement_score":0.0020584106,"about_ca_system_score_codex":0.00065852073,"about_ca_system_score_gemma":0.0005250033,"threshold_uncertainty_score":0.006886065},"labels":[],"label_agreement":null},{"id":"W2148381189","doi":"10.1634/theoncologist.2008-0018","title":"Homage to Judah Folkman","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Jewish and Middle Eastern Studies","field":"Social Sciences","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.09070523643718799,"score_gpt":0.34614805340371024,"score_spread":0.25544281696652227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148381189","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003755639,0.0176883,0.0004018885,0.8627104,0.102976225,0.000010123277,0.00006515284,0.00007241397,0.015699852],"genre_scores_gemma":[0.007887814,0.0078082024,0.0004297006,0.8587984,0.033609193,0.00003614784,0.000044082277,0.00012657353,0.091259934],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968881,0.00094726245,0.00012007803,0.0006623239,0.0009726409,0.00040958048],"domain_scores_gemma":[0.9935402,0.0019196663,0.00027157587,0.00025527013,0.0018684522,0.0021448177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003213434,0.00082982046,0.000921611,0.0007036894,0.0046379743,0.004435734,0.0014171981,0.00655922,0.022094779],"category_scores_gemma":[0.019000359,0.00034802398,0.0006602234,0.0003981203,0.0032382603,0.0051349467,0.0025797936,0.01981869,0.01143935],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007742301,0.00000850486,0.000049898725,0.000014243014,0.0000017765868,0.00006364336,0.0001542357,0.000005490103,0.000024538922,0.0023873262,0.9925782,0.004704386],"study_design_scores_gemma":[0.0000035776357,0.000010266303,0.00012223524,0.00009413557,0.0000018409047,0.00038705257,0.00046150282,0.000019731906,0.00004528142,0.0021642202,0.9966804,0.000009786501],"about_ca_topic_score_codex":0.007452336,"about_ca_topic_score_gemma":0.009814519,"teacher_disagreement_score":0.022094779,"about_ca_system_score_codex":0.002697727,"about_ca_system_score_gemma":0.0041173566,"threshold_uncertainty_score":0.07391441},"labels":[],"label_agreement":null},{"id":"W2150013126","doi":"10.1634/theoncologist.2009-0116","title":"Do We Have Enough Evidence to Implement Particle Therapy as Standard Treatment in Lung Cancer? A Systematic Literature Review","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lung cancer; Systematic review; Intensive care medicine; Treatment of lung cancer; MEDLINE; Medical physics; Oncology","score_opus":0.10961618221409285,"score_gpt":0.48448823342484315,"score_spread":0.3748720512107503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150013126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023267437,0.9942781,0.00048437575,0.0011247648,0.00025361075,0.00067221787,0.00046142517,0.000015987242,0.0003828506],"genre_scores_gemma":[0.06560522,0.92587805,0.0036108328,0.0021792606,0.00018276922,0.0018857185,0.0005385998,0.000016767937,0.000102817794],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.95781225,0.019876169,0.015094834,0.0020353359,0.0046454873,0.00053588406],"domain_scores_gemma":[0.8508173,0.113454945,0.023770237,0.0020643037,0.008960729,0.00093245244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03647832,0.0014659314,0.012665898,0.013362162,0.00074128085,0.0041681933,0.0031148396,0.0033659856,0.0043954924],"category_scores_gemma":[0.17064689,0.0018981881,0.009098161,0.01260342,0.002000242,0.0061215186,0.0019301387,0.0016639853,0.00037546654],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026581384,0.000014059994,0.0013346242,0.9525623,0.01921167,0.00009037946,0.00017269937,0.00012801899,0.000081904655,0.00035880302,0.000990293,0.024789603],"study_design_scores_gemma":[0.0004948539,0.00025014888,0.003552862,0.9076191,0.07902893,0.00024296557,0.00041097504,0.00020053981,0.00015451992,0.00059828034,0.007405016,0.000041909378],"about_ca_topic_score_codex":0.006716096,"about_ca_topic_score_gemma":0.017277403,"teacher_disagreement_score":0.03647832,"about_ca_system_score_codex":0.007940563,"about_ca_system_score_gemma":0.016052306,"threshold_uncertainty_score":0.19291812},"labels":[],"label_agreement":null},{"id":"W2150141450","doi":"10.1634/theoncologist.2010-0421","title":"Nuclear Medicine Imaging of Infection in Cancer Patients (With Emphasis on FDG-PET)","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hematological disorders and diagnostics","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Positron emission tomography; Scintigraphy; Neutropenia; Cancer; Malignancy; Febrile neutropenia; Nuclear medicine imaging; Gold standard (test); Radiology; Nuclear medicine; Internal medicine; Chemotherapy","score_opus":0.04325586301881398,"score_gpt":0.3175688953059096,"score_spread":0.27431303228709564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150141450","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027545338,0.8779722,0.021804214,0.016066825,0.004308216,0.00017406722,0.00031328367,0.00080818887,0.051007695],"genre_scores_gemma":[0.1240974,0.7983737,0.0404853,0.0090816375,0.011543398,0.00020685495,0.000630304,0.00019104556,0.015390508],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998072,0.000068052934,0.000024351213,0.000023285824,0.00004400978,0.000033188502],"domain_scores_gemma":[0.9997838,0.00007037919,0.000039626524,0.000015399615,0.000058336438,0.000032586628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000520783,0.0007408172,0.0006203188,0.0019075939,0.00026334022,0.0009288162,0.0005380597,0.0018661862,0.0045708213],"category_scores_gemma":[0.00077793025,0.00039471613,0.00060345884,0.0009952608,0.00046874653,0.000870705,0.0005018502,0.001671047,0.0029415775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006056051,0.00019827818,0.019957105,0.0039708577,0.00030331424,0.041854326,0.0002166098,0.0012214137,0.04181129,0.0035362502,0.1446711,0.74165386],"study_design_scores_gemma":[0.0001393524,0.00097266276,0.04997158,0.0038937058,0.0004373867,0.39017472,0.00039422247,0.0024496221,0.014278841,0.005546269,0.5316009,0.00014069056],"about_ca_topic_score_codex":0.0008612075,"about_ca_topic_score_gemma":0.0012625686,"teacher_disagreement_score":0.0045708213,"about_ca_system_score_codex":0.00045688957,"about_ca_system_score_gemma":0.00026742162,"threshold_uncertainty_score":0.015290916},"labels":[],"label_agreement":null},{"id":"W2150866539","doi":"10.1634/theoncologist.2014-0028","title":"An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; FOLFOX; Bevacizumab; Oncology; Colorectal cancer; Neutropenia; Progression-free survival; Oxaliplatin; Regimen; Phases of clinical research; Adverse effect; Chemotherapy; Cancer","score_opus":0.07877267716082854,"score_gpt":0.4312235175892444,"score_spread":0.35245084042841585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150866539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928213,0.0019359553,0.0006939699,0.0002645216,0.00020561257,0.0024466396,0.000564828,0.000131552,0.00093576027],"genre_scores_gemma":[0.9894868,0.0013096615,0.0024107439,0.00057446316,0.00034504873,0.0029267948,0.001120793,0.00003504642,0.0017907337],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992342,0.00037955775,0.00003182315,0.00015219043,0.000078823236,0.00012334963],"domain_scores_gemma":[0.9986332,0.00024405189,0.0002555481,0.00012933035,0.00009835247,0.000639443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002242899,0.0019198952,0.0035985282,0.0006022069,0.0005595866,0.0011548381,0.0015071695,0.0018052282,0.0043851896],"category_scores_gemma":[0.0016913555,0.00086182856,0.0014473516,0.0004393139,0.0016206554,0.0012924339,0.00038783994,0.00409431,0.0011858168],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80892205,0.11673595,0.0019724115,0.00075373607,0.0012352755,0.00018503872,0.0001959983,0.0013530566,0.018334808,0.00013287431,0.0015502488,0.04862859],"study_design_scores_gemma":[0.49758363,0.49637502,0.002761963,0.000019074861,0.00022493758,0.00012791128,0.000022682763,0.0009234039,0.001188328,0.00006113184,0.00069287367,0.000019022978],"about_ca_topic_score_codex":0.00089049904,"about_ca_topic_score_gemma":0.0019380251,"teacher_disagreement_score":0.0043851896,"about_ca_system_score_codex":0.0012611708,"about_ca_system_score_gemma":0.001793681,"threshold_uncertainty_score":0.014669955},"labels":[],"label_agreement":null},{"id":"W2151287258","doi":"10.1634/theoncologist.2013-0217","title":"HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital; St. Michael's Hospital; University of Toronto; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Disease; Breast cancer; Clinical trial; Cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2","score_opus":0.25965523279335295,"score_gpt":0.48847452959125165,"score_spread":0.2288192967978987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151287258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009084487,0.98112434,0.00014914898,0.007570753,0.006639483,0.000009784158,0.000032961783,0.000013542179,0.0043690517],"genre_scores_gemma":[0.0006029675,0.98135996,0.00021782574,0.0062068813,0.0032245375,0.000009616211,0.000040986015,0.00000638092,0.008330805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997377,0.000060065795,0.000022424256,0.00003322771,0.00012620691,0.000020366528],"domain_scores_gemma":[0.9996977,0.00015205235,0.000026657797,0.000007967527,0.0000760825,0.000039589264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006356939,0.00076079054,0.0008404856,0.0010297303,0.00045319757,0.0012804632,0.0008205762,0.0018407353,0.009525711],"category_scores_gemma":[0.0013740531,0.00018832856,0.00051403465,0.0013858012,0.0005207902,0.0025526674,0.0007612018,0.0037138208,0.007895495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004922211,0.00004881648,0.000120535035,0.0058110496,0.000034184173,0.0002733012,0.00011649024,0.00011983335,0.00060933986,0.003942664,0.46189287,0.5269816],"study_design_scores_gemma":[0.0000059971585,0.00002228848,0.00015417863,0.0015460209,0.000012258378,0.00087429275,0.000046624944,0.00001615098,0.00008265276,0.0011311972,0.99610186,0.000006520105],"about_ca_topic_score_codex":0.001006366,"about_ca_topic_score_gemma":0.0023309006,"teacher_disagreement_score":0.009525711,"about_ca_system_score_codex":0.0005373908,"about_ca_system_score_gemma":0.00079537055,"threshold_uncertainty_score":0.03186667},"labels":[],"label_agreement":null},{"id":"W2151507583","doi":"10.1634/theoncologist.12-4-426","title":"Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Medicine; Clinical trial; Pharmacokinetics; Refractory (planetary science); Pharmacology; Oncology; Drug; Toxicity; Safety profile; Phases of clinical research; Internal medicine; Medical physics; Adverse effect; Hepatocellular carcinoma","score_opus":0.07306418962376841,"score_gpt":0.4061245175451803,"score_spread":0.3330603279214119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151507583","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010373872,0.9981744,0.00017410342,0.00019897956,0.0000398906,0.000029198674,0.000069125024,0.000009042171,0.00026787503],"genre_scores_gemma":[0.0075883204,0.9911885,0.00045344414,0.0003870451,0.00005733298,0.000050658222,0.00012781504,0.0000070095634,0.00013985597],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9989202,0.0003125216,0.00036993297,0.00013422071,0.0002302259,0.00003291683],"domain_scores_gemma":[0.9960336,0.0022419165,0.0010265055,0.00007221165,0.00050943345,0.000116451214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033290773,0.00069807365,0.002896372,0.00193218,0.00025410793,0.0010625968,0.0011550158,0.0006359826,0.0010873388],"category_scores_gemma":[0.0045810994,0.00035454906,0.0021934635,0.0030315307,0.00049213733,0.0010811177,0.00040789865,0.0008342118,0.00029752613],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012524985,0.00009750547,0.001475196,0.1760388,0.002715233,0.00026871567,0.00023341502,0.00053426024,0.0043726815,0.00049665157,0.010438369,0.8020767],"study_design_scores_gemma":[0.0022726925,0.0071587716,0.031882904,0.16761757,0.044318452,0.0067443606,0.00082032377,0.0009174586,0.0068785218,0.0020648648,0.7291472,0.00017680085],"about_ca_topic_score_codex":0.0006792542,"about_ca_topic_score_gemma":0.0017828065,"teacher_disagreement_score":0.0033290773,"about_ca_system_score_codex":0.0007506566,"about_ca_system_score_gemma":0.0015667262,"threshold_uncertainty_score":0.01760608},"labels":[],"label_agreement":null},{"id":"W2151595350","doi":"10.1634/theoncologist.10-6-438","title":"Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve","year":2005,"lang":"en","type":"article","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Area under the curve; Receiver operating characteristic; Quartile; Anemia; Epoetin alfa; Internal medicine; Clinical trial; Clinical significance; Logistic regression; Confidence interval","score_opus":0.3144654092705074,"score_gpt":0.4611387039297435,"score_spread":0.14667329465923606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151595350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8170675,0.025235118,0.13862434,0.0011601965,0.0002489156,0.00037814153,0.006451714,0.001032119,0.009801971],"genre_scores_gemma":[0.98254836,0.001483199,0.01404543,0.00018609816,0.00010761274,0.00009865066,0.001164069,0.000038418322,0.0003280365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953654,0.0024911223,0.00039294764,0.00049837393,0.0011709442,0.000081209364],"domain_scores_gemma":[0.97088087,0.01598166,0.008416138,0.0014698409,0.0026785012,0.00057299697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00952693,0.00070298597,0.00091641105,0.002870521,0.00013455263,0.001499026,0.0004896288,0.0006070565,0.0011774577],"category_scores_gemma":[0.023642339,0.00012718387,0.0006431598,0.002486887,0.0007858456,0.000879825,0.00056110934,0.0007002909,0.00029182265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023422162,0.0002858817,0.7339076,0.0006911736,0.0018247602,0.00013299996,0.00032180393,0.019008914,0.00617946,0.0020116246,0.003991643,0.22930194],"study_design_scores_gemma":[0.00017380467,0.0054359073,0.8763762,0.00045456924,0.0009953592,0.001559617,0.00034140472,0.08261127,0.012377343,0.008063725,0.011424432,0.00018635072],"about_ca_topic_score_codex":0.0010348231,"about_ca_topic_score_gemma":0.0005668687,"teacher_disagreement_score":0.00952693,"about_ca_system_score_codex":0.000507085,"about_ca_system_score_gemma":0.0005404596,"threshold_uncertainty_score":0.050383806},"labels":[],"label_agreement":null},{"id":"W2151979638","doi":"10.1634/theoncologist.10-5-345","title":"HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Rash; Medicine; Dermatology; Acne; EGFR inhibitors; Adverse effect; Etiology; Epidermal growth factor receptor; Pathology; Internal medicine; Cancer","score_opus":0.06765387642643766,"score_gpt":0.36904424410560627,"score_spread":0.3013903676791686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151979638","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013500205,0.15553026,0.007363035,0.7403177,0.02911646,0.00081763725,0.0034285535,0.0010350576,0.04889118],"genre_scores_gemma":[0.15767944,0.37844616,0.05650752,0.23823951,0.09181954,0.003446581,0.018254932,0.0007566652,0.05484966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963187,0.0014722662,0.00039681018,0.00017684227,0.0010598601,0.00057543034],"domain_scores_gemma":[0.9625424,0.008081742,0.0029436955,0.00076986675,0.014622969,0.011039391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011811773,0.00068152725,0.0011734404,0.0018952993,0.0014605701,0.004251596,0.001445638,0.0031040024,0.03582477],"category_scores_gemma":[0.03664202,0.00026819628,0.002166991,0.0013411843,0.00064881274,0.005587744,0.0032310653,0.0051742024,0.0064671375],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035600417,0.00042247944,0.0132695045,0.0015970375,0.000045185076,0.0002774334,0.00017475194,0.00024818917,0.00011054798,0.0021347017,0.4993369,0.4820273],"study_design_scores_gemma":[0.0007392232,0.0014992036,0.056033645,0.022474913,0.00048832677,0.0022318903,0.003382989,0.0021713101,0.00041721007,0.023600286,0.88673097,0.00022988905],"about_ca_topic_score_codex":0.0031025226,"about_ca_topic_score_gemma":0.0061636968,"teacher_disagreement_score":0.03582477,"about_ca_system_score_codex":0.0025556048,"about_ca_system_score_gemma":0.007034408,"threshold_uncertainty_score":0.11984581},"labels":[],"label_agreement":null},{"id":"W2152078521","doi":"10.1634/theoncologist.2010-0279","title":"Early Breast Cancer in the Older Woman","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Tamoxifen; Contraindication; Trastuzumab; Cancer; Oncology; Internal medicine; Adjuvant; Systemic therapy; Disease; Gynecology; Alternative medicine; Pathology","score_opus":0.04541263312813848,"score_gpt":0.35289623139835535,"score_spread":0.3074835982702169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152078521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001061409,0.9993789,0.00001782582,0.00013276943,0.00006662233,0.000001489003,0.0000074257355,0.0000016329811,0.0002871651],"genre_scores_gemma":[0.0010852887,0.99849486,0.000040048584,0.00012627512,0.000088310924,0.0000026389298,0.000011167982,3.3262418e-7,0.00015104293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979156,0.00005939157,0.0000421114,0.0000285521,0.00006322417,0.00001523008],"domain_scores_gemma":[0.99951684,0.00025788386,0.00011191782,0.000009182718,0.00008173236,0.000022417466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005339429,0.0005258321,0.0011954807,0.0016854351,0.00017664574,0.0005973701,0.00040392278,0.0006266106,0.0017077139],"category_scores_gemma":[0.0012319848,0.00015367841,0.00035472788,0.0019505315,0.00025323554,0.0007052234,0.0003314486,0.0005593501,0.0006959739],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009536366,0.000032749955,0.0012896042,0.03293624,0.00014674544,0.00049335754,0.000065811,0.00011826892,0.0005075066,0.00078244705,0.029748341,0.93378377],"study_design_scores_gemma":[0.000054876127,0.00019760805,0.011076565,0.036885317,0.00080683886,0.014623554,0.0003104065,0.00009484467,0.0006910531,0.0017053263,0.93352175,0.000031841293],"about_ca_topic_score_codex":0.001316134,"about_ca_topic_score_gemma":0.0024173742,"teacher_disagreement_score":0.0017077139,"about_ca_system_score_codex":0.00034681524,"about_ca_system_score_gemma":0.00081022555,"threshold_uncertainty_score":0.005712807},"labels":[],"label_agreement":null},{"id":"W2152531047","doi":"10.1634/theoncologist.2008-0193","title":"Current Treatment Approaches for Infants with Malignant Central Nervous System Tumors","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Neurocognitive; Medulloblastoma; Ependymoma; Choroid plexus; Oncology; Chemotherapy; Brain tumor; Central nervous system; Glioma; Radiation therapy; Internal medicine; Pathology; Cognition; Cancer research; Psychiatry","score_opus":0.09317912667532544,"score_gpt":0.3399365523694173,"score_spread":0.24675742569409184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152531047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020849466,0.99827754,0.00020319558,0.00023264141,0.00011727299,0.000005575659,0.000009948193,0.000009440127,0.00093594444],"genre_scores_gemma":[0.0010556456,0.9976889,0.00037341216,0.00019921441,0.000119750504,0.000011307962,0.000028947083,0.0000016454424,0.0005212458],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988043,0.000022191658,0.000019772882,0.00002107968,0.000044363325,0.000012149199],"domain_scores_gemma":[0.9998776,0.00006500979,0.000020903115,0.0000037652333,0.000023648685,0.000009127768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037228424,0.0007050336,0.0010130275,0.0013074471,0.00026050713,0.00045467055,0.0008989654,0.0007616269,0.0020764177],"category_scores_gemma":[0.0004462088,0.00018965374,0.00048780855,0.0008191992,0.00030305487,0.0006300858,0.00041334252,0.0012957483,0.001377042],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004845168,0.000059535003,0.00019385274,0.0066203275,0.00005500918,0.00043023046,0.000050335042,0.00030039024,0.0014692356,0.0012668761,0.013187103,0.9763188],"study_design_scores_gemma":[0.00004647411,0.0001856886,0.002404892,0.005211028,0.0001842963,0.008232338,0.00012917099,0.00017368517,0.0012145218,0.002548938,0.97963834,0.000030602165],"about_ca_topic_score_codex":0.0009248661,"about_ca_topic_score_gemma":0.0020774424,"teacher_disagreement_score":0.0020764177,"about_ca_system_score_codex":0.00044800862,"about_ca_system_score_gemma":0.0005372948,"threshold_uncertainty_score":0.0069463253},"labels":[],"label_agreement":null},{"id":"W2154006657","doi":"10.1634/theoncologist.10-9-760","title":"Nimotuzumab: Evidence of Clinical Benefit Without Rash","year":2005,"lang":"en","type":"letter","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rash; Nimotuzumab; Dermatology; Pharmacology; Oncology; Intensive care medicine; Internal medicine; Cancer; Epidermal growth factor receptor","score_opus":0.23652912594375666,"score_gpt":0.4906644354273119,"score_spread":0.2541353094835552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154006657","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21989448,0.44624072,0.0036731197,0.06595781,0.008063592,0.0012459793,0.004308559,0.0006384502,0.24997729],"genre_scores_gemma":[0.7810729,0.117607236,0.0030125447,0.05249056,0.007437662,0.00040914433,0.0035137986,0.0001271965,0.03432909],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99929786,0.00037435925,0.0000493393,0.00006959091,0.00016572833,0.00004310552],"domain_scores_gemma":[0.9983265,0.00092172384,0.00023656728,0.000088186884,0.0001527437,0.00027430462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016893543,0.00038906327,0.0015100547,0.00024227002,0.00023000069,0.000655662,0.0004276861,0.0010101286,0.016181907],"category_scores_gemma":[0.003886994,0.00011073213,0.0004961317,0.0003822077,0.00042257656,0.0005227298,0.0002376414,0.0016467269,0.002944124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05861572,0.000914393,0.004417874,0.005449785,0.0011197097,0.0020920068,0.00007751133,0.00045578904,0.012555376,0.004354825,0.10435469,0.8055924],"study_design_scores_gemma":[0.080873065,0.051257264,0.04680753,0.0028135963,0.002578766,0.012321099,0.00013751443,0.001396072,0.012984119,0.008563293,0.7801874,0.00008025631],"about_ca_topic_score_codex":0.00018044491,"about_ca_topic_score_gemma":0.00068517524,"teacher_disagreement_score":0.016181907,"about_ca_system_score_codex":0.00066960853,"about_ca_system_score_gemma":0.00051790325,"threshold_uncertainty_score":0.054133892},"labels":[],"label_agreement":null},{"id":"W2154336771","doi":"10.1634/theoncologist.2011-0337","title":"Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer","year":2011,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine","score_opus":0.13268345324556344,"score_gpt":0.4542650043348345,"score_spread":0.3215815510892711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154336771","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059418217,0.011979207,0.00007426355,0.96424794,0.010830659,0.00001398391,0.00026198398,0.000019002271,0.0066311737],"genre_scores_gemma":[0.06310677,0.018630203,0.00029193296,0.85215276,0.058583625,0.0000750214,0.00024044517,0.000018332366,0.00690091],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9975793,0.001179466,0.00031195657,0.00016716824,0.0005770193,0.00018518878],"domain_scores_gemma":[0.99043614,0.006467314,0.0006512464,0.00023692958,0.0016091454,0.00059916667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027242906,0.00029783093,0.00100848,0.000518138,0.0011710586,0.0009845068,0.00069769163,0.008327356,0.0022645204],"category_scores_gemma":[0.018831767,0.00020011266,0.0007132079,0.0009247728,0.0008248432,0.00095257466,0.00055853795,0.006725766,0.0015527761],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010308933,0.00018332225,0.043115817,0.00036652441,0.00015081937,0.0054049366,0.00026446383,0.00023600298,0.0004314379,0.0017034438,0.84158856,0.10552384],"study_design_scores_gemma":[0.001531107,0.001346669,0.13225605,0.002785459,0.0006518761,0.019177867,0.0015700791,0.0014909337,0.0013195676,0.013273709,0.8243749,0.00022180773],"about_ca_topic_score_codex":0.007882694,"about_ca_topic_score_gemma":0.015631223,"teacher_disagreement_score":0.008327356,"about_ca_system_score_codex":0.0021047886,"about_ca_system_score_gemma":0.0019396343,"threshold_uncertainty_score":0.015673578},"labels":[],"label_agreement":null},{"id":"W2155750728","doi":"10.1634/theoncologist.2011-0384","title":"A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316)","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Celgene; Eisai; Sanofi; Breast Cancer Research Foundation; Pfizer; GlaxoSmithKline","keywords":"Breast cancer; Medicine; Clinical trial; Oncology; Clinical decision making; Medical decision making; Cancer; Family medicine; Internal medicine; Gerontology","score_opus":0.35969123631201794,"score_gpt":0.6029037017443813,"score_spread":0.2432124654323634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155750728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989994,0.00017760899,0.0000346609,0.000116390765,0.0000059857175,0.000022985507,0.00025456844,0.0000014972888,0.0003868645],"genre_scores_gemma":[0.9994204,0.00007615081,0.00007073952,0.00010010389,0.000010506141,0.000030362457,0.00018772327,0.0000020087668,0.00010210825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967242,0.0019164504,0.00041550215,0.00026340442,0.0003513504,0.00032910955],"domain_scores_gemma":[0.95654815,0.014795453,0.020804053,0.0012333796,0.0014944631,0.005124439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059064724,0.0002026868,0.00033115168,0.00071557704,0.00057800306,0.0009933094,0.00039532184,0.0006296827,0.003218982],"category_scores_gemma":[0.022018008,0.00033437327,0.0006708605,0.0015935252,0.00037073545,0.0007861729,0.0006767326,0.0010882382,0.00044511806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006336875,0.00018370783,0.99714065,0.000016795499,0.00004499825,0.00002994578,0.00020356917,0.000026684442,0.000028721232,0.000013990523,0.0002980741,0.0013791767],"study_design_scores_gemma":[0.00008411414,0.00074233476,0.9977749,0.000025263447,0.00004830356,0.00008855201,0.0005634903,0.00024630222,0.00003396286,0.000024686624,0.00036011162,0.000007987287],"about_ca_topic_score_codex":0.0036524225,"about_ca_topic_score_gemma":0.005226597,"teacher_disagreement_score":0.0059064724,"about_ca_system_score_codex":0.00051373855,"about_ca_system_score_gemma":0.0009308986,"threshold_uncertainty_score":0.031236827},"labels":[],"label_agreement":null},{"id":"W2155848488","doi":"10.1634/theoncologist.2012-0260","title":"Compliance in Early-Phase Cancer Clinical Trials Research","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Compliance (psychology); Clinical trial; Protocol (science); Informed consent; Intensive care medicine; Action (physics); Alternative medicine; Medical emergency; Pathology; Psychology; Social psychology","score_opus":0.9924332197048782,"score_gpt":0.8700124277728657,"score_spread":0.1224207919320125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155848488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014616859,0.93739873,0.012135173,0.029896483,0.0029771307,0.0020437601,0.00015923227,0.00007122883,0.013856681],"genre_scores_gemma":[0.07315576,0.8435466,0.03682551,0.028936852,0.004751857,0.008431685,0.0004636197,0.00011811467,0.003769964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.51380044,0.37767875,0.05283385,0.005581134,0.048200186,0.0019055603],"domain_scores_gemma":[0.31503507,0.5764,0.06182117,0.023514647,0.020636793,0.002592348],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.28399676,0.0008426917,0.003455845,0.0032744857,0.0018189022,0.006281214,0.003853011,0.008736865,0.0032946826],"category_scores_gemma":[0.41921827,0.0010747085,0.001685436,0.0066125644,0.010189615,0.006232972,0.0042636264,0.007391243,0.0011309668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035696203,0.00017805923,0.0028088489,0.08747163,0.00043266514,0.0005971448,0.0034543057,0.00069943554,0.0004811512,0.09301794,0.04422847,0.7662734],"study_design_scores_gemma":[0.00042744476,0.0005595237,0.0061761085,0.16542648,0.00057817367,0.0036787863,0.0015009467,0.0007025842,0.0015333525,0.101616986,0.7176697,0.00012988465],"about_ca_topic_score_codex":0.0009817657,"about_ca_topic_score_gemma":0.0012200681,"teacher_disagreement_score":0.99126315,"about_ca_system_score_codex":0.0045341514,"about_ca_system_score_gemma":0.032079592,"threshold_uncertainty_score":0.8829595},"labels":[],"label_agreement":null},{"id":"W2155895485","doi":"10.1634/theoncologist.2013-0159","title":"Screening for Lung Cancer With Low-Dose Computed Tomography","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; National Lung Screening Trial; Lung cancer screening; Lung cancer; Computed tomography; Radiology; Cancer; Lung; Oncology; Internal medicine","score_opus":0.022751318131551155,"score_gpt":0.3275069069583498,"score_spread":0.3047555888267986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155895485","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.104156315,0.7668296,0.006737303,0.06758055,0.0016834954,0.0004205176,0.00054209185,0.00013757696,0.051912587],"genre_scores_gemma":[0.5993536,0.3552569,0.006724506,0.026244812,0.004836598,0.00029121246,0.00091559516,0.000026823105,0.0063498802],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99806494,0.0011517394,0.00012260751,0.00010963353,0.00046100953,0.00008993636],"domain_scores_gemma":[0.9977042,0.0015120037,0.00031995747,0.00008854286,0.0002258026,0.00014944837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022881213,0.0002077848,0.0007544664,0.00061993144,0.00024799068,0.00080082647,0.0003864948,0.0008348775,0.0024971531],"category_scores_gemma":[0.0063221366,0.000096707314,0.000708553,0.0006395135,0.00059160433,0.0005271944,0.00038836812,0.001291767,0.0005162221],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004866193,0.0006944377,0.060609106,0.007970208,0.0006828228,0.0009472337,0.0001254088,0.00063904014,0.008487608,0.0051126257,0.022690143,0.88717514],"study_design_scores_gemma":[0.0060719843,0.020529076,0.4139995,0.020298636,0.0030297057,0.022869457,0.00056906376,0.0021071269,0.016625239,0.015947988,0.47768813,0.00026401746],"about_ca_topic_score_codex":0.0014709661,"about_ca_topic_score_gemma":0.0031729466,"teacher_disagreement_score":0.0024971531,"about_ca_system_score_codex":0.0007624134,"about_ca_system_score_gemma":0.00070276356,"threshold_uncertainty_score":0.012100875},"labels":[],"label_agreement":null},{"id":"W2156070031","doi":"10.1634/theoncologist.11-3-227","title":"Too Much, Too Little, Too Late to Start Again? Assessing the Efficacy of Bisphosphonates in Patients with Bone Metastases from Breast Cancer","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Natural history; Bone metastasis; Oncology; Cancer; Internal medicine","score_opus":0.044214047789870946,"score_gpt":0.37743343132559865,"score_spread":0.3332193835357277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156070031","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014207551,0.9992355,0.000031582647,0.00018413822,0.00005794171,0.000003768863,0.0000063380417,0.0000021321125,0.00033644272],"genre_scores_gemma":[0.0010733347,0.99830663,0.00014383675,0.00021219434,0.00005561809,0.0000060695193,0.000009165217,8.4139214e-7,0.00019229193],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.999493,0.0001687958,0.000097145785,0.000043183813,0.00018272598,0.000015156371],"domain_scores_gemma":[0.9993655,0.00042301446,0.00010166677,0.0000083108625,0.00008516688,0.000016382228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012546147,0.0005303538,0.0024831635,0.001621986,0.00017596707,0.00070172356,0.0007124901,0.0010652188,0.0017253876],"category_scores_gemma":[0.0019524549,0.00025492886,0.00060178863,0.001813861,0.00036536335,0.0010250332,0.0002539689,0.0008819258,0.0009508486],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019005325,0.000057372916,0.0003573743,0.035148628,0.00032136534,0.00016022139,0.000076148535,0.00011058708,0.000682609,0.00094227627,0.010915778,0.9510376],"study_design_scores_gemma":[0.00040873443,0.0007947332,0.0086852005,0.04430367,0.0017271786,0.005757251,0.0005786681,0.00026164742,0.001673548,0.003210752,0.9325298,0.000068886045],"about_ca_topic_score_codex":0.001354461,"about_ca_topic_score_gemma":0.0036866704,"teacher_disagreement_score":0.0024831635,"about_ca_system_score_codex":0.0004786934,"about_ca_system_score_gemma":0.0007430196,"threshold_uncertainty_score":0.0066351295},"labels":[],"label_agreement":null},{"id":"W2156097169","doi":"10.1634/theoncologist.6-suppl_4-1","title":"Thymidine Phosphorylase (TP) Activation: Convenience Through Innovation","year":2001,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Thymidine phosphorylase; Medicine; Tolerability; Colorectal cancer; Fluorouracil; Oncology; Internal medicine; Bolus (digestion); Regimen; Pharmacology; Cancer; Adverse effect","score_opus":0.0672375730742489,"score_gpt":0.3522997622602957,"score_spread":0.2850621891860468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156097169","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22213864,0.14915036,0.13240373,0.05761687,0.00590967,0.00042203345,0.00052664126,0.0014077794,0.4304243],"genre_scores_gemma":[0.88099545,0.042408023,0.022147639,0.0034350401,0.0022489526,0.00018422698,0.00014158593,0.00020658787,0.048232444],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848735,0.00044711868,0.000088947476,0.00026119465,0.0004974888,0.00021785848],"domain_scores_gemma":[0.9972453,0.0016047744,0.00030976065,0.00035606854,0.00017802212,0.00030609523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003945186,0.0004026201,0.00042541753,0.00088725274,0.00051397464,0.0040378952,0.0006012116,0.00091350975,0.017246615],"category_scores_gemma":[0.004863624,0.00023064303,0.00048881833,0.000589595,0.0017119504,0.0040425216,0.0021136065,0.0018410385,0.0030264852],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010137276,0.00031509853,0.0034960215,0.000964132,0.00012455758,0.0003131573,0.00080467947,0.00095387327,0.051494684,0.17989947,0.017172955,0.7434476],"study_design_scores_gemma":[0.0006726239,0.0026090017,0.0099236835,0.001065855,0.00030952875,0.0020677405,0.0015186347,0.004878384,0.14005862,0.25649405,0.5802384,0.00016354804],"about_ca_topic_score_codex":0.00024996145,"about_ca_topic_score_gemma":0.00057142705,"teacher_disagreement_score":0.017246615,"about_ca_system_score_codex":0.0009459218,"about_ca_system_score_gemma":0.0009056652,"threshold_uncertainty_score":0.057695627},"labels":[],"label_agreement":null},{"id":"W2156648140","doi":"10.1634/theoncologist.2015-0012","title":"Frequency, Predictors, and Medical Record Documentation of Chemical Coping Among Advanced Cancer Patients","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Multinational Association of Supportive Care in Cancer","keywords":"Medicine; Coping (psychology); Medical record; Confidence interval; Odds ratio; Concordance; Palliative care; Psychiatry; Internal medicine; Family medicine; Nursing","score_opus":0.02101207527441902,"score_gpt":0.3204544320849842,"score_spread":0.2994423568105652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156648140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99947685,0.00016925053,0.000035698053,0.000031053478,0.0000022728825,0.0000068931663,0.00013779328,0.0000022282447,0.0001380129],"genre_scores_gemma":[0.9996407,0.00006892683,0.00006920663,0.000012789004,0.000006985157,0.0000064591236,0.00016866818,7.0764753e-7,0.000025448602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930096,0.0002465973,0.00009776015,0.000095994,0.00017218648,0.00008645935],"domain_scores_gemma":[0.995321,0.0012283687,0.0026423298,0.00017075098,0.00028177915,0.00035568915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055902585,0.00017494956,0.00026662045,0.0008009784,0.0003229241,0.00048350374,0.0002627897,0.00034314327,0.0017643613],"category_scores_gemma":[0.0049261483,0.00020563611,0.00026783932,0.0008602168,0.00020677844,0.0003469571,0.00042250307,0.00052487495,0.00018772634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001954625,0.000012239013,0.99948585,0.0000034444536,0.0000056709073,0.000022398308,0.00001951323,0.000008621707,0.000034393415,0.000001405884,0.000018405712,0.00036855703],"study_design_scores_gemma":[0.000004663349,0.00008624322,0.99903846,0.0000067049386,0.00000937483,0.00048345546,0.00012459166,0.00014474364,0.000040171934,0.0000043410355,0.00005536726,0.000001947235],"about_ca_topic_score_codex":0.0019368624,"about_ca_topic_score_gemma":0.0020810824,"teacher_disagreement_score":0.0019368624,"about_ca_system_score_codex":0.00018690761,"about_ca_system_score_gemma":0.00028686065,"threshold_uncertainty_score":0.00590235},"labels":[],"label_agreement":null},{"id":"W2157027442","doi":"10.1634/theoncologist.12-9-1114","title":"Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Temozolomide; Medicine; Dacarbazine; Oncology; Internal medicine; Clinical trial; Melanoma; Thalidomide; Meta-analysis; Randomized controlled trial; Phases of clinical research; Adverse effect; Chemotherapy; Cancer research; Multiple myeloma","score_opus":0.15281898241311778,"score_gpt":0.42483401823406086,"score_spread":0.2720150358209431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157027442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009195745,0.99823123,0.00006636481,0.00018203331,0.00007166569,0.0002087482,0.00015350654,0.000005069856,0.0001619206],"genre_scores_gemma":[0.014779094,0.98348135,0.00049005845,0.00044226547,0.00008359322,0.00045756428,0.00013862416,0.0000032023231,0.00012418916],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99566686,0.0020981487,0.0011141951,0.00027748264,0.0006973664,0.00014601],"domain_scores_gemma":[0.9882108,0.0077661765,0.0025747074,0.00013786365,0.0011114926,0.00019893642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057473197,0.0012968879,0.007788551,0.006360122,0.00048822368,0.0015601937,0.0015597021,0.0015681335,0.004175073],"category_scores_gemma":[0.022627495,0.0007553203,0.00557309,0.0072366716,0.00071579055,0.0015724428,0.00087587285,0.0009382527,0.00025299905],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002989491,0.000015313557,0.00045707313,0.9627203,0.008947321,0.00009571468,0.00009627495,0.000096248135,0.00012211753,0.00011229584,0.0014453422,0.025593095],"study_design_scores_gemma":[0.0008583138,0.0005106167,0.0049241837,0.8695026,0.10403335,0.00046460665,0.000242895,0.00017883022,0.0002134508,0.00026422107,0.018765302,0.00004166654],"about_ca_topic_score_codex":0.008194685,"about_ca_topic_score_gemma":0.026106164,"teacher_disagreement_score":0.008194685,"about_ca_system_score_codex":0.0029977316,"about_ca_system_score_gemma":0.008425354,"threshold_uncertainty_score":0.03039509},"labels":[],"label_agreement":null},{"id":"W2157270051","doi":"10.1634/theoncologist.11-2-165","title":"Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Glioma; Multidisciplinary approach; MEDLINE; Intensive care medicine; Oncology; Cancer research","score_opus":0.08917163167619094,"score_gpt":0.38126598461418376,"score_spread":0.2920943529379928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157270051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018492849,0.9911981,0.00034330972,0.0032539268,0.0019955921,0.00001328308,0.000010655823,0.000016918242,0.002983395],"genre_scores_gemma":[0.0011528846,0.9926075,0.00068657385,0.002724604,0.0014424223,0.000021617472,0.00003163723,0.0000027095966,0.0013300382],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994948,0.0001881145,0.00006647816,0.000049357543,0.00016363416,0.00003765266],"domain_scores_gemma":[0.9994435,0.00024491627,0.00008129191,0.000011575885,0.00013513843,0.000083687744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010649976,0.0009228003,0.0011486257,0.0018570307,0.00047203482,0.0012940426,0.0011880656,0.0019853,0.004501926],"category_scores_gemma":[0.0013941939,0.00026031447,0.0004718672,0.002400406,0.00058988534,0.002625416,0.00096251187,0.002093919,0.0021223004],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004306509,0.00007079867,0.000225005,0.006819891,0.000055385437,0.0006010029,0.00016939687,0.00031896337,0.00026328338,0.0027639386,0.09745728,0.89121205],"study_design_scores_gemma":[0.00003581838,0.00008115794,0.0010378017,0.0068057,0.00004567085,0.003438091,0.00028249345,0.00011586344,0.00006153092,0.0022196523,0.98585576,0.00002038592],"about_ca_topic_score_codex":0.001586524,"about_ca_topic_score_gemma":0.006135864,"teacher_disagreement_score":0.004501926,"about_ca_system_score_codex":0.001294236,"about_ca_system_score_gemma":0.0016696269,"threshold_uncertainty_score":0.015060484},"labels":[],"label_agreement":null},{"id":"W2158430615","doi":"10.1634/theoncologist.9-1-1","title":"The Means, the Mission, and the Pledge of <i>The Oncologist</i>","year":2004,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in medical practice","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pledge; Radiation oncologist; Internal medicine; Radiation therapy","score_opus":0.08498701638529445,"score_gpt":0.47568134161404774,"score_spread":0.3906943252287533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158430615","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019856902,0.02149976,0.0011070226,0.637646,0.31871194,0.00002788885,0.000062613435,0.00015175629,0.020594424],"genre_scores_gemma":[0.007408586,0.02568353,0.0025990047,0.5235889,0.29135364,0.00009662368,0.00015317765,0.00043151734,0.1486851],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948742,0.001545277,0.0003110614,0.00062051025,0.002067608,0.00058133295],"domain_scores_gemma":[0.977239,0.0034966627,0.0012285636,0.0010605486,0.009476955,0.0074982867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006905843,0.0009517827,0.00096807425,0.0009969543,0.0029284926,0.009250581,0.0011606341,0.00497544,0.022702195],"category_scores_gemma":[0.023292923,0.00045403928,0.0007128552,0.0005709877,0.00355576,0.007809087,0.0033121612,0.016471567,0.022393445],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018873241,0.000005740603,0.00013627822,0.00007119637,0.0000038588983,0.000048800663,0.00008376399,0.00001159867,0.0001152257,0.0034765464,0.98085207,0.015176006],"study_design_scores_gemma":[0.000003176622,0.000009346438,0.00010731652,0.00008279146,0.0000028393515,0.0002204015,0.00017657597,0.000012763459,0.000039010403,0.0012355536,0.9981027,0.000007526356],"about_ca_topic_score_codex":0.0019247843,"about_ca_topic_score_gemma":0.0035105273,"teacher_disagreement_score":0.022702195,"about_ca_system_score_codex":0.0023629486,"about_ca_system_score_gemma":0.005405664,"threshold_uncertainty_score":0.07594639},"labels":[],"label_agreement":null},{"id":"W2158925468","doi":"10.1634/theoncologist.2009-0219","title":"Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?","year":2009,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Stage (stratigraphy); Cancer; Oncology; Adjuvant; Adjuvant chemotherapy; Internal medicine","score_opus":0.04782780240256192,"score_gpt":0.3933731187100704,"score_spread":0.3455453163075085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158925468","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023428258,0.0008283122,0.000040135146,0.98333156,0.014051017,0.000009510213,0.00004308247,0.000014819715,0.0014473492],"genre_scores_gemma":[0.0016297345,0.00068312825,0.00012887042,0.97547036,0.018385584,0.000019080162,0.000019246652,0.00001243333,0.0036514904],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625444,0.0013106404,0.00039237383,0.0004660941,0.0011739343,0.0004024204],"domain_scores_gemma":[0.9906557,0.0056543127,0.0006192858,0.00016313502,0.0018848033,0.0010228103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003454349,0.00089696026,0.0018133991,0.0006512285,0.004613985,0.002701066,0.0028615422,0.073099814,0.0066272984],"category_scores_gemma":[0.02128607,0.00086353254,0.0014245632,0.00094788265,0.0022727696,0.004005782,0.0012057555,0.04941558,0.007253277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000742172,0.00002550589,0.00024665403,0.000046063924,0.000009983003,0.0009768059,0.000077544915,0.000047803664,0.000109990324,0.0009719205,0.99385625,0.0035571281],"study_design_scores_gemma":[0.00028988003,0.00015975417,0.0014648715,0.0005129218,0.00005755913,0.0031394674,0.00048750534,0.00064937974,0.00036181102,0.007780519,0.9850087,0.000087623346],"about_ca_topic_score_codex":0.011049116,"about_ca_topic_score_gemma":0.019019691,"teacher_disagreement_score":0.073099814,"about_ca_system_score_codex":0.005220752,"about_ca_system_score_gemma":0.006383392,"threshold_uncertainty_score":0.037879407},"labels":[],"label_agreement":null},{"id":"W2160175915","doi":"10.1634/theoncologist.11-5-503","title":"Ewing's Sarcoma Family of Tumors: Current Management","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":518,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; CD99; Sarcoma; Ewing's sarcoma; Rhabdomyosarcoma; Radiology; Pathology","score_opus":0.12088628657714595,"score_gpt":0.40478320808142126,"score_spread":0.2838969215042753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160175915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021949468,0.9052925,0.0050279466,0.04299916,0.0022561904,0.0000734284,0.00031554926,0.0002513526,0.0218345],"genre_scores_gemma":[0.13383964,0.82437855,0.006518989,0.012023817,0.010967806,0.00015429613,0.0011661559,0.00005784047,0.010892957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975723,0.000031331085,0.000043179,0.000043899392,0.00006772479,0.000056717843],"domain_scores_gemma":[0.99944335,0.00017184451,0.00011866293,0.000013898641,0.00010526577,0.00014692558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050355034,0.0005410616,0.000642062,0.001443861,0.0005220357,0.0006945017,0.0007211397,0.0013777018,0.004165758],"category_scores_gemma":[0.0012790121,0.0001604693,0.00028146783,0.0010099419,0.0005269575,0.0019564899,0.0006522655,0.0016797883,0.001650909],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010027081,0.00014889613,0.012997131,0.0011456546,0.000031777246,0.012733576,0.0002075681,0.001005642,0.00070941215,0.0039523523,0.10309669,0.8638711],"study_design_scores_gemma":[0.00010315398,0.0003799935,0.028931422,0.008485231,0.00018179782,0.3245951,0.0019312868,0.0030615602,0.0006505142,0.028470553,0.60308105,0.00012836899],"about_ca_topic_score_codex":0.000878941,"about_ca_topic_score_gemma":0.0010714383,"teacher_disagreement_score":0.004165758,"about_ca_system_score_codex":0.0006218028,"about_ca_system_score_gemma":0.0006167558,"threshold_uncertainty_score":0.013935864},"labels":[],"label_agreement":null},{"id":"W2160326987","doi":"10.1634/theoncologist.9-2-232","title":"Highlights from the Tenth World Conference on Lung Cancer","year":2004,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Vinorelbine; Lung cancer; Gemcitabine; Oncology; Internal medicine; Taxane; Gefitinib; Chemotherapy; Cancer; Breast cancer; Cisplatin; Epidermal growth factor receptor","score_opus":0.06200918382975023,"score_gpt":0.35023634560874084,"score_spread":0.2882271617789906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160326987","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037848088,0.08954293,0.00033066465,0.43393686,0.45059672,0.00020546459,0.0010922638,0.000113700255,0.023802975],"genre_scores_gemma":[0.005162337,0.091697775,0.0008081,0.29561734,0.5327986,0.0004804664,0.002636612,0.0001994304,0.07059932],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953876,0.0008432873,0.00044788612,0.0006306651,0.0019062236,0.0007841987],"domain_scores_gemma":[0.98818856,0.0014695332,0.00080955395,0.0002877456,0.004446882,0.0047977204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007280157,0.0019734465,0.0017068613,0.0014946808,0.0020526904,0.0073400396,0.0028925969,0.012345033,0.026925344],"category_scores_gemma":[0.013257697,0.00049976935,0.0021582074,0.0014532676,0.0013426833,0.003908169,0.002642598,0.016585724,0.01761296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006897154,0.00002116266,0.00009326012,0.00026220808,0.000009572156,0.00005540592,0.000011021867,0.000023266319,0.000059938488,0.00042651503,0.9753076,0.023661032],"study_design_scores_gemma":[0.00004831299,0.00003219327,0.00072178623,0.00054660445,0.000021231994,0.000093760405,0.000043239106,0.00002349576,0.000057964367,0.00067010475,0.99772614,0.000015051346],"about_ca_topic_score_codex":0.004461538,"about_ca_topic_score_gemma":0.009968504,"teacher_disagreement_score":0.026925344,"about_ca_system_score_codex":0.0050680656,"about_ca_system_score_gemma":0.0072001964,"threshold_uncertainty_score":0.0900743},"labels":[],"label_agreement":null},{"id":"W2162200636","doi":"10.1634/theoncologist.2013-0160","title":"Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Bevacizumab; Breast cancer; Newspaper; Headline; Food and drug administration; Family medicine; Clinical trial; Metastatic breast cancer; Cancer; Oncology; Internal medicine; Advertising; Pharmacology; Chemotherapy","score_opus":0.024574839051825687,"score_gpt":0.35788425867525075,"score_spread":0.3333094196234251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162200636","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90195507,0.052045252,0.0024413997,0.016026933,0.0010772141,0.00040688136,0.003794087,0.00015477726,0.0220983],"genre_scores_gemma":[0.9619662,0.02339649,0.0034002245,0.0043555507,0.002028538,0.00027698345,0.0018220366,0.00008091116,0.0026730737],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904947,0.0037129913,0.0018651424,0.0005059803,0.003110037,0.00031112487],"domain_scores_gemma":[0.84493315,0.087837435,0.05383379,0.0022824388,0.009270593,0.0018425866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010894053,0.00031802442,0.0003695488,0.010545203,0.0010404577,0.0043358845,0.0003517359,0.0005319785,0.0021555403],"category_scores_gemma":[0.04905777,0.00032942646,0.000398808,0.0100311,0.0017623889,0.0035896094,0.0015983118,0.0005717556,0.00052459206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093986065,0.00012282573,0.520532,0.009190016,0.00044717154,0.0020602373,0.08555444,0.000083105515,0.0047280733,0.003698321,0.034960955,0.337683],"study_design_scores_gemma":[0.000035271747,0.0003060378,0.7596288,0.005754208,0.00041843354,0.0040718936,0.09865356,0.00031127653,0.0016265438,0.0015251584,0.12756509,0.000103728366],"about_ca_topic_score_codex":0.0012583997,"about_ca_topic_score_gemma":0.003296736,"teacher_disagreement_score":0.010894053,"about_ca_system_score_codex":0.0011935658,"about_ca_system_score_gemma":0.0010668458,"threshold_uncertainty_score":0.05761391},"labels":[],"label_agreement":null},{"id":"W2162278616","doi":"10.1634/theoncologist.2013-0442","title":"Effect of M1a and M1b Category in Metastatic Colorectal Cancer","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Metastasis; Hazard ratio; Internal medicine; Oncology; Colorectal cancer; Cancer; Proportional hazards model; Univariate analysis; Primary tumor; Surgical oncology; Survival analysis; Multivariate analysis; Confidence interval","score_opus":0.01799191052558404,"score_gpt":0.34086446671635745,"score_spread":0.32287255619077343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162278616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972264,0.0018271265,0.00009183558,0.00011980988,0.000017779537,0.000008399389,0.00018010705,0.000004481071,0.0005238803],"genre_scores_gemma":[0.99944025,0.00017520541,0.00006536479,0.000020756816,0.000018610248,0.0000034547086,0.00015694306,0.000002141341,0.0001172867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995003,0.0001970323,0.000030177265,0.000084902145,0.000110751644,0.00007686914],"domain_scores_gemma":[0.9969926,0.0011295395,0.0009990897,0.00011232023,0.00018211338,0.0005844107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012165623,0.00027796047,0.00032179223,0.0005162499,0.0002552455,0.0004497142,0.00023884211,0.0003426335,0.0019052757],"category_scores_gemma":[0.004313369,0.00011606644,0.0005871027,0.0003700448,0.00029686818,0.0003339763,0.00046207447,0.00049971294,0.00024075051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007789271,0.000024617531,0.99537426,0.000017843844,0.000052427524,0.00006597587,0.000015377207,0.00012114238,0.00022478017,0.000012495513,0.00012538183,0.0031866706],"study_design_scores_gemma":[0.000020199072,0.0004191856,0.99817514,0.000016685504,0.00007113179,0.00038402856,0.000049230457,0.00045016938,0.00009464411,0.000055244236,0.0002591507,0.000005182245],"about_ca_topic_score_codex":0.0028280618,"about_ca_topic_score_gemma":0.0051370277,"teacher_disagreement_score":0.0028280618,"about_ca_system_score_codex":0.00033037786,"about_ca_system_score_gemma":0.00038160663,"threshold_uncertainty_score":0.0064338446},"labels":[],"label_agreement":null},{"id":"W2162313743","doi":"10.1634/theoncologist.2010-0214","title":"Factors Associated with Response to Methylphenidate in Advanced Cancer Patients","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Methylphenidate; Medicine; Cancer-related fatigue; Breast cancer; Cancer; Clinical trial; Internal medicine; Physical therapy; Attention deficit hyperactivity disorder; Psychiatry","score_opus":0.0882969024258374,"score_gpt":0.3333576239215738,"score_spread":0.2450607214957364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162313743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985628,0.012478315,0.00010752016,0.000159682,0.000022112752,0.00005404195,0.0008525994,0.000004133442,0.0006936167],"genre_scores_gemma":[0.9970693,0.0020454002,0.0001470512,0.000100913014,0.000029336932,0.000040208466,0.00044969315,0.0000012649905,0.000116845986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99948716,0.0001487105,0.00012515804,0.00007349807,0.00012874352,0.000036695645],"domain_scores_gemma":[0.9966294,0.0013512005,0.001614019,0.00004726295,0.00022000085,0.00013802218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007208899,0.000090580485,0.0004815765,0.00052754954,0.00023552266,0.0002313809,0.00018006301,0.0003224479,0.0012034086],"category_scores_gemma":[0.00346041,0.00009570952,0.00047317817,0.0011069687,0.0001017657,0.0002184488,0.00013401048,0.0002794149,0.00009415972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039990887,0.000033327324,0.9930044,0.00018859604,0.00010226824,0.00013954197,0.000034364926,0.000026905333,0.00028324284,0.000006090742,0.0002004065,0.0055809976],"study_design_scores_gemma":[0.00002308112,0.00022990556,0.99856013,0.00004288744,0.000077636534,0.00047273358,0.00006021418,0.000054890035,0.00009481932,0.000005857969,0.0003750597,0.000002732324],"about_ca_topic_score_codex":0.0013209136,"about_ca_topic_score_gemma":0.0025762538,"teacher_disagreement_score":0.0013209136,"about_ca_system_score_codex":0.00020525452,"about_ca_system_score_gemma":0.00026457186,"threshold_uncertainty_score":0.004025817},"labels":[],"label_agreement":null},{"id":"W2163214112","doi":"10.1634/theoncologist.2009-0331","title":"Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine–Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Tolerability; Carboplatin; Regimen; Medicine; Gemcitabine; Internal medicine; Oncology; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.05658101786179498,"score_gpt":0.3669097908403569,"score_spread":0.31032877297856193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163214112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049950094,0.99395156,0.00013490976,0.0001398977,0.00006386751,0.00025394658,0.00023769887,0.0000075049174,0.00021564522],"genre_scores_gemma":[0.080221534,0.9174167,0.00086073694,0.00048988714,0.00013060287,0.00047640284,0.00027614526,0.000008636823,0.000119424396],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99391645,0.0024219123,0.0022406888,0.00046481454,0.0008540589,0.00010218739],"domain_scores_gemma":[0.97765756,0.013819747,0.006259663,0.0002355935,0.0017015779,0.00032588202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075164693,0.0010881205,0.009382684,0.0048167165,0.00039874602,0.0018385121,0.0016106287,0.0013316307,0.0023353435],"category_scores_gemma":[0.026093384,0.00077021937,0.006729029,0.0049668546,0.00079976424,0.0014498277,0.0007803585,0.00076304685,0.00018039021],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015924121,0.000034117165,0.0016965023,0.912525,0.045612734,0.00017092912,0.00015920316,0.00019224493,0.0005197477,0.00007998111,0.00060572714,0.036811464],"study_design_scores_gemma":[0.0027635475,0.0026506511,0.013115098,0.54721695,0.41744128,0.001072404,0.00040615318,0.00035605786,0.0007749537,0.00026768862,0.013857433,0.00007791982],"about_ca_topic_score_codex":0.0033715584,"about_ca_topic_score_gemma":0.010449129,"teacher_disagreement_score":0.009382684,"about_ca_system_score_codex":0.0023652462,"about_ca_system_score_gemma":0.004368691,"threshold_uncertainty_score":0.03975141},"labels":[],"label_agreement":null},{"id":"W2163216057","doi":"10.1634/theoncologist.2014-0006","title":"How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer","year":2014,"lang":"en","type":"review","venue":"The Oncologist","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Ramucirumab; Crizotinib; Biomarker; Disease; Cancer; Oncology; Internal medicine; Predictive marker; Trastuzumab; MEDLINE; Bioinformatics; Breast cancer; Lung cancer","score_opus":0.08941645987040653,"score_gpt":0.35814495783542843,"score_spread":0.2687284979650219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163216057","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039595962,0.9892363,0.0003868582,0.0085138045,0.0006199228,0.000006035691,0.000033349024,0.0000124688,0.0007952803],"genre_scores_gemma":[0.008027669,0.98602015,0.0013434811,0.0030426127,0.0011778346,0.000016402397,0.00005490692,0.0000072981,0.00030954456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976076,0.001108265,0.00040275764,0.00020774461,0.00059848424,0.000075171265],"domain_scores_gemma":[0.9933776,0.004156777,0.00093256496,0.00015333774,0.0012439181,0.00013584802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044422685,0.0005347232,0.0014141116,0.0022616673,0.00025245905,0.0024635063,0.00065838115,0.0013164707,0.0014939009],"category_scores_gemma":[0.012814698,0.00020622711,0.00084772526,0.0020868706,0.0010384385,0.0036326782,0.0006225962,0.0020418104,0.000707193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023004958,0.00003497787,0.00245657,0.0424342,0.0006269985,0.0004379721,0.00045145332,0.00054238556,0.0010158708,0.011805923,0.04098157,0.89898205],"study_design_scores_gemma":[0.00008692443,0.0002457009,0.0071654287,0.07941041,0.0015207451,0.003128155,0.00090436346,0.0005692142,0.0010016584,0.028776005,0.8770669,0.00012448654],"about_ca_topic_score_codex":0.0013639566,"about_ca_topic_score_gemma":0.0019850943,"teacher_disagreement_score":0.0044422685,"about_ca_system_score_codex":0.0012614111,"about_ca_system_score_gemma":0.002307233,"threshold_uncertainty_score":0.02349329},"labels":[],"label_agreement":null},{"id":"W2165229942","doi":"10.1634/theoncologist.2010-0197","title":"Effect of Exercise Training on Peak Oxygen Consumption in Patients with Cancer: A Meta-Analysis","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Meta-analysis; Confidence interval; VO2 max; Randomized controlled trial; Physical therapy; Adverse effect; Pooled variance; Internal medicine; Heart rate","score_opus":0.16104487862887207,"score_gpt":0.39103577701304354,"score_spread":0.22999089838417147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165229942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027388372,0.96864814,0.0016091318,0.00033335894,0.00039559315,0.0005659802,0.0005674468,0.00006308922,0.0004290435],"genre_scores_gemma":[0.52812284,0.45934543,0.0065573175,0.001461218,0.0005759446,0.002362713,0.0009906851,0.00006916283,0.0005147528],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9872972,0.007563425,0.0024614749,0.0013679336,0.0009149641,0.00039500938],"domain_scores_gemma":[0.98477995,0.011528338,0.0020662295,0.00062539993,0.0007959341,0.0002040184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017598782,0.003382637,0.01843642,0.0051916116,0.00069020985,0.0034600399,0.0021595357,0.0027242335,0.0027996406],"category_scores_gemma":[0.032233473,0.0017460538,0.06241258,0.0047069336,0.00067272846,0.0014099288,0.0013728046,0.0020635633,0.00028187037],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004242086,0.00004884607,0.004224589,0.059888497,0.92477244,0.00008415972,0.000032525622,0.00071248587,0.00019379501,0.000052115814,0.00017474475,0.005573738],"study_design_scores_gemma":[0.0010882183,0.00036380545,0.0033745205,0.004218326,0.99007857,0.000057914123,0.000014948332,0.00020913975,0.00008485882,0.000082737875,0.00041464603,0.000012369153],"about_ca_topic_score_codex":0.0059503834,"about_ca_topic_score_gemma":0.010292891,"teacher_disagreement_score":0.01843642,"about_ca_system_score_codex":0.002143758,"about_ca_system_score_gemma":0.002135141,"threshold_uncertainty_score":0.093072355},"labels":[],"label_agreement":null},{"id":"W2165595478","doi":"10.1634/theoncologist.2009-0150","title":"Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"American Society of Clinical Oncology; Sanofi; Eli Lilly and Company","keywords":"Docetaxel; Medicine; Oncology; Internal medicine; Hazard ratio; Metastatic breast cancer; Breast cancer; Regimen; Estrogen receptor; Odds ratio; Confidence interval; Cancer","score_opus":0.019327851943031174,"score_gpt":0.30794130428793387,"score_spread":0.2886134523449027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165595478","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32303953,0.66738015,0.002756525,0.0007551293,0.0007875572,0.0017042959,0.0020044995,0.00011435785,0.0014579721],"genre_scores_gemma":[0.90931875,0.08367676,0.002005984,0.00082370575,0.00045861016,0.0016950794,0.0014415107,0.00003921889,0.0005403818],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9841574,0.0104452185,0.002669611,0.0013423607,0.0010139535,0.00037142148],"domain_scores_gemma":[0.9824096,0.010184412,0.0053168577,0.0009223801,0.00079358154,0.00037309487],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.018633623,0.0019349692,0.010641225,0.0019073252,0.00031221492,0.002020747,0.0008008116,0.0014389458,0.0017227697],"category_scores_gemma":[0.023692442,0.00087882247,0.023503454,0.0022869937,0.0007439272,0.0009703702,0.0007505528,0.0015934122,0.00017850006],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24757113,0.00024299494,0.017505359,0.02490915,0.68646777,0.00012266141,0.00005353797,0.0018962286,0.0008270512,0.000134225,0.0006938687,0.019576048],"study_design_scores_gemma":[0.10859936,0.008992374,0.02523635,0.0018658334,0.8513903,0.00018547116,0.00005040405,0.00096977694,0.00041165846,0.0004515937,0.0017913418,0.000055557197],"about_ca_topic_score_codex":0.0011519832,"about_ca_topic_score_gemma":0.0020936332,"teacher_disagreement_score":0.9893588,"about_ca_system_score_codex":0.0012305897,"about_ca_system_score_gemma":0.0010887935,"threshold_uncertainty_score":0.09854519},"labels":[],"label_agreement":null},{"id":"W2165702053","doi":"10.1634/theoncologist.2012-0316","title":"Recursive Partitioning Analysis for the Prediction of Stereotactic Radiosurgery Brain Metastases Lesion Control","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Radiosurgery; Medicine; Recursive partitioning; Lesion; Radiology; Medical physics; Internal medicine; Pathology; Radiation therapy","score_opus":0.06091035380502197,"score_gpt":0.31731968977001895,"score_spread":0.256409335964997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165702053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9574218,0.0006431224,0.039460108,0.00020907362,0.000015156759,0.00016662558,0.0013390364,0.00021304989,0.00053211953],"genre_scores_gemma":[0.98900104,0.00007538509,0.009290922,0.000015762756,0.000015035506,0.00008418023,0.0013514332,0.00002465671,0.0001416454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804294,0.0012060337,0.000110255176,0.00026197804,0.00027459834,0.00010410844],"domain_scores_gemma":[0.99249953,0.0053706225,0.0010246044,0.00042359217,0.00047752363,0.00020416394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025649336,0.00055805984,0.00067595043,0.0022059472,0.00027865858,0.00064899947,0.00059612136,0.00030343275,0.0011215551],"category_scores_gemma":[0.012481264,0.00016343789,0.0010388492,0.0009940881,0.00022925323,0.0002796985,0.00045498554,0.0005109466,0.00034180138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010317864,0.00015178982,0.8807606,0.000078713885,0.00082001335,0.0002823219,0.0001713939,0.030383537,0.0032256031,0.00056031195,0.0011062493,0.08142768],"study_design_scores_gemma":[0.000085014784,0.0007352608,0.54876804,0.000037552567,0.00036046284,0.0010850524,0.00017531659,0.4422932,0.0022113714,0.002175206,0.002017872,0.000055688106],"about_ca_topic_score_codex":0.0051706,"about_ca_topic_score_gemma":0.0035897477,"teacher_disagreement_score":0.0051706,"about_ca_system_score_codex":0.00043297393,"about_ca_system_score_gemma":0.00078111293,"threshold_uncertainty_score":0.013564825},"labels":[],"label_agreement":null},{"id":"W2166003630","doi":"10.1634/theoncologist.11-6-624","title":"End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Disease-Free Survival as a Surrogate End Point for Overall Survival?","year":2006,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Surrogate endpoint; Clinical endpoint; Clinical trial; Adjuvant therapy; Adjuvant; End point; Endpoint Determination; Intensive care medicine; Disease; Oncology; Internal medicine; Cancer","score_opus":0.10893625307390128,"score_gpt":0.37209338186582086,"score_spread":0.26315712879191955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166003630","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012730521,0.4560532,0.18575053,0.300718,0.023453142,0.004594067,0.0013144593,0.00026804904,0.0151179675],"genre_scores_gemma":[0.1881969,0.19787855,0.3730263,0.1713822,0.027353888,0.033614557,0.0021762382,0.0006718479,0.0056995014],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.6353787,0.32188654,0.019972946,0.0033746136,0.018674558,0.0007126392],"domain_scores_gemma":[0.5021564,0.4245039,0.03143837,0.01825651,0.01984026,0.0038045736],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.41869357,0.0017030978,0.008130233,0.0024924409,0.0013471069,0.009856276,0.0036244292,0.008260157,0.0038002569],"category_scores_gemma":[0.45558468,0.0007633432,0.004017596,0.0062075397,0.005845733,0.010280962,0.0036709285,0.015900422,0.0019606908],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018038012,0.00033797696,0.011891752,0.023204682,0.002808368,0.00040259078,0.0014534883,0.0034599728,0.0014344807,0.17214967,0.030346997,0.73447204],"study_design_scores_gemma":[0.01669401,0.012956624,0.013976293,0.053735085,0.0030630673,0.0017066512,0.0013833846,0.014208947,0.0020107157,0.5607546,0.31883386,0.00067680905],"about_ca_topic_score_codex":0.0006209988,"about_ca_topic_score_gemma":0.00091179844,"teacher_disagreement_score":0.58130646,"about_ca_system_score_codex":0.003440709,"about_ca_system_score_gemma":0.00840166,"threshold_uncertainty_score":0.71685433},"labels":[],"label_agreement":null},{"id":"W2166336441","doi":"10.1634/theoncologist.8-4-381","title":"Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE Survey","year":2003,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Venous thromboembolism; Cancer; Thrombosis; Malignancy; Venous thrombosis; Intensive care medicine; MEDLINE; Low molecular weight heparin; Surgery; Internal medicine","score_opus":0.05359443108603156,"score_gpt":0.3261288330397681,"score_spread":0.2725344019537365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166336441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806933,0.0011914063,0.00015110012,0.0019170492,0.000022468581,0.00019666672,0.012460916,0.000011803491,0.00335533],"genre_scores_gemma":[0.9910364,0.0014863269,0.00035227014,0.001229587,0.000052456042,0.00024959046,0.005246425,0.0000049926066,0.00034191093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975358,0.0010299102,0.00053483085,0.00016118973,0.00041819722,0.00031994068],"domain_scores_gemma":[0.9897111,0.002220671,0.0049338406,0.00023735885,0.001917188,0.0009798452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029892044,0.0001476169,0.00036235387,0.0018004461,0.0003218054,0.00079252134,0.00030288647,0.000744169,0.0014251792],"category_scores_gemma":[0.010660937,0.00015081455,0.0003931826,0.0034323118,0.00013515828,0.00067571923,0.0008042304,0.00039919713,0.0003632869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000104873114,0.00009089715,0.98633134,0.00016499769,0.00003843421,0.000102301,0.0009059685,0.00003431088,0.00007744135,0.000027058431,0.0027112728,0.00941113],"study_design_scores_gemma":[0.000015140978,0.00019350219,0.9950027,0.0000722887,0.00002293277,0.00016300844,0.002116984,0.00010764525,0.000034665118,0.000021111593,0.0022432362,0.000006803694],"about_ca_topic_score_codex":0.00932404,"about_ca_topic_score_gemma":0.01062253,"teacher_disagreement_score":0.00932404,"about_ca_system_score_codex":0.0006389566,"about_ca_system_score_gemma":0.00073798187,"threshold_uncertainty_score":0.018539548},"labels":[],"label_agreement":null},{"id":"W2166883496","doi":"10.1634/theoncologist.2011-0171","title":"Re: Selective Application of Routine Preoperative Axillary Ultrasonography Reduces Costs for Invasive Breast Cancers","year":2011,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Ultrasonography; Ultrasound; Radiology; Surgery; Cancer; Internal medicine","score_opus":0.016734165932575065,"score_gpt":0.27324199349885264,"score_spread":0.2565078275662776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166883496","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017432334,0.00088203285,0.00013348051,0.9820065,0.0083552925,0.000011346233,0.000078367666,0.00004643591,0.0067432155],"genre_scores_gemma":[0.01505897,0.0011270196,0.00041423956,0.9342837,0.03251568,0.0000373326,0.000060952894,0.000028237047,0.016473912],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998985,0.0003180974,0.00015705508,0.00012684742,0.00027279655,0.00014018467],"domain_scores_gemma":[0.9964413,0.0019775697,0.00020746634,0.00012049122,0.00085106795,0.00040201526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012672306,0.00063657603,0.000775605,0.00035285667,0.0013626569,0.0014321444,0.001166829,0.024713878,0.0093257],"category_scores_gemma":[0.013706634,0.00033770275,0.0005644837,0.00044312933,0.0008683661,0.001394093,0.0004450544,0.01587277,0.00866245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026012174,0.00010603235,0.0018004418,0.00006382247,0.000027600481,0.0032810632,0.00008630964,0.00017259929,0.00074194465,0.0017226374,0.96645087,0.025286717],"study_design_scores_gemma":[0.0004180619,0.00035528603,0.00818449,0.00041600695,0.00007488699,0.010365088,0.00055644446,0.0020360074,0.0014629207,0.008560031,0.96744317,0.0001276007],"about_ca_topic_score_codex":0.0033506558,"about_ca_topic_score_gemma":0.0076003787,"teacher_disagreement_score":0.024713878,"about_ca_system_score_codex":0.0026010282,"about_ca_system_score_gemma":0.0017516486,"threshold_uncertainty_score":0.031197608},"labels":[],"label_agreement":null},{"id":"W2167419679","doi":"10.1634/theoncologist.2013-0091","title":"Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; William Osler Health System; University of Alberta","funders":"Genentech; Sanofi","keywords":"Medicine; Docetaxel; Trastuzumab; Tolerability; Breast cancer; Internal medicine; Regimen; Oncology; Carboplatin; Taxane; Adjuvant; Chemotherapy; Cancer; Adverse effect; Cisplatin","score_opus":0.009473063582280821,"score_gpt":0.24856754078916854,"score_spread":0.23909447720688773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167419679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99839103,0.0012060219,0.000026731768,0.000028986193,0.0000045798397,0.000022709773,0.00012858442,0.0000014415667,0.00018999397],"genre_scores_gemma":[0.9990484,0.00033717992,0.00006862947,0.000056498895,0.000010532602,0.000026543685,0.00036754156,8.373304e-7,0.00008393652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943537,0.00029872128,0.00004074527,0.000060607766,0.00010064202,0.00006384367],"domain_scores_gemma":[0.9991843,0.00021428804,0.0002947489,0.00003957131,0.00005684309,0.00021019444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015844437,0.00031284956,0.0006617996,0.0002787019,0.00016845443,0.00039820964,0.00024517937,0.00036417446,0.0006053855],"category_scores_gemma":[0.0013895155,0.00010936583,0.00078061473,0.0005340676,0.00020713265,0.00025306756,0.00030249543,0.000534485,0.00011257923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055055,0.003847273,0.89248735,0.00025069385,0.0014329704,0.00014134233,0.00018564222,0.00087875646,0.0016876501,0.000025721922,0.00047835655,0.04352926],"study_design_scores_gemma":[0.0041944077,0.020650784,0.972636,0.00003739303,0.0005358926,0.0002676245,0.000079795835,0.00047233826,0.00033549583,0.000032039457,0.00074526545,0.00001293958],"about_ca_topic_score_codex":0.0010504193,"about_ca_topic_score_gemma":0.0015842814,"teacher_disagreement_score":0.0015844437,"about_ca_system_score_codex":0.00048004228,"about_ca_system_score_gemma":0.00031608864,"threshold_uncertainty_score":0.0083794},"labels":[],"label_agreement":null},{"id":"W2167634945","doi":"10.1634/theoncologist.2011-0079","title":"Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Oncology; Stage (stratigraphy); Cancer research; Internal medicine; Pharmacology","score_opus":0.06412952942016496,"score_gpt":0.38629462010173876,"score_spread":0.3221650906815738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167634945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707043,0.002148367,0.000039096467,0.00016493935,0.00000766274,0.0000056217064,0.00012996187,0.0000027562696,0.0004311739],"genre_scores_gemma":[0.9990853,0.0005145246,0.00006042595,0.000076978344,0.000014217361,0.0000045444017,0.00015860712,0.0000010234929,0.00008440947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995877,0.00012896527,0.000046338715,0.00006276364,0.00011572086,0.000058508176],"domain_scores_gemma":[0.99812895,0.00040206563,0.0010503783,0.000054713808,0.00013322587,0.00023064697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008173441,0.00008361404,0.00016680508,0.00023770597,0.00013969134,0.00030096047,0.00015238643,0.00023460508,0.00073308963],"category_scores_gemma":[0.0027512726,0.00005704571,0.0003085533,0.00029020733,0.0001602045,0.00025138326,0.00020051756,0.00033391896,0.000078727746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006442183,0.00009308056,0.98323566,0.000029692146,0.00006596423,0.0000430841,0.00002577185,0.00013793776,0.0003410995,0.0000127509,0.0001520163,0.015218674],"study_design_scores_gemma":[0.00002478704,0.0005694023,0.9984969,0.000014659401,0.00004555579,0.00013840059,0.00003838213,0.00021183501,0.0001349727,0.00001239096,0.0003112621,0.0000015105287],"about_ca_topic_score_codex":0.0024341552,"about_ca_topic_score_gemma":0.005325854,"teacher_disagreement_score":0.0024341552,"about_ca_system_score_codex":0.0005590453,"about_ca_system_score_gemma":0.00038922852,"threshold_uncertainty_score":0.0048399568},"labels":[],"label_agreement":null},{"id":"W2167723770","doi":"10.1634/theoncologist.2009-0277","title":"Review of the Clinical Studies Using the 21-Gene Assay","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cyclophosphamide; Breast cancer; Oncology; Internal medicine; Chemotherapy; Fluorouracil; Methotrexate; Doxorubicin; Adjuvant; Cancer","score_opus":0.2377358967915531,"score_gpt":0.5080055087202885,"score_spread":0.2702696119287354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167723770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011840669,0.9987519,0.000079763166,0.00038988242,0.0001742183,0.000019335297,0.00010228245,0.0000038314442,0.00036047574],"genre_scores_gemma":[0.0013925816,0.997131,0.00030964156,0.0006851013,0.00020106898,0.000039840463,0.00012515532,0.0000032442235,0.00011232114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641454,0.0009847949,0.0014278702,0.0003328995,0.0007585893,0.00008136841],"domain_scores_gemma":[0.98025423,0.013457802,0.0027673843,0.0002988661,0.0029837242,0.0002380118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004566196,0.001061541,0.003354958,0.007811512,0.00040240597,0.0019995207,0.0018088665,0.0013282659,0.0049285125],"category_scores_gemma":[0.017831093,0.0006469538,0.002374285,0.011377221,0.0007513733,0.001701827,0.0008849435,0.0011791202,0.0010778629],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032751475,0.000045610526,0.0012967977,0.3936179,0.0016610061,0.00038308377,0.00017747941,0.00023050762,0.00073090167,0.0010506145,0.034600712,0.56587785],"study_design_scores_gemma":[0.00011562395,0.0003747356,0.009261241,0.3716512,0.0089133745,0.0031631165,0.00039275378,0.00013424797,0.00064566976,0.0011425739,0.6041309,0.00007445165],"about_ca_topic_score_codex":0.002327499,"about_ca_topic_score_gemma":0.004316866,"teacher_disagreement_score":0.007811512,"about_ca_system_score_codex":0.0014381238,"about_ca_system_score_gemma":0.0049774162,"threshold_uncertainty_score":0.024148643},"labels":[],"label_agreement":null},{"id":"W2168507982","doi":"10.1634/theoncologist.2014-0372","title":"Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University; Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Federación Española de Enfermedades Raras; Cancer Research UK; Breast Cancer Research Foundation","keywords":"Breast cancer; Expression (computer science); Cancer; Cancer research; Computational biology; Biology; Oncology; Medicine; Genetics; Computer science","score_opus":0.02440197533705295,"score_gpt":0.3159511142045415,"score_spread":0.29154913886748857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168507982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732439,0.008531631,0.012295077,0.00011872551,0.000019923848,0.00054446334,0.0022315618,0.00007483355,0.0029399549],"genre_scores_gemma":[0.98998624,0.0005376599,0.006141549,0.00014672181,0.000029805331,0.00034203313,0.0025173784,0.000025751498,0.00027289224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958288,0.0016672021,0.0006105771,0.00066934316,0.001007719,0.00021635063],"domain_scores_gemma":[0.9961117,0.0011056954,0.0015048045,0.0006636796,0.00046123815,0.00015300103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073148245,0.00046304325,0.001334017,0.00076020864,0.0002577576,0.000782045,0.0006227348,0.00034035635,0.0011124855],"category_scores_gemma":[0.0062304437,0.00022521762,0.0010814298,0.00068083947,0.0004910291,0.00050866127,0.00081321585,0.00044795676,0.00025285146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010340964,0.0002627006,0.8628936,0.001362984,0.0020129185,0.00009535696,0.00021397755,0.0020429392,0.030698817,0.0005323349,0.00069750973,0.088845916],"study_design_scores_gemma":[0.0012151421,0.004850469,0.9559438,0.00027535338,0.0025600356,0.0019314066,0.00024500996,0.0051074177,0.017680377,0.0016748293,0.008463435,0.000052762323],"about_ca_topic_score_codex":0.00054678257,"about_ca_topic_score_gemma":0.0012404167,"teacher_disagreement_score":0.0073148245,"about_ca_system_score_codex":0.0004660222,"about_ca_system_score_gemma":0.0007517199,"threshold_uncertainty_score":0.038684964},"labels":[],"label_agreement":null},{"id":"W2171469985","doi":"10.1634/theoncologist.11-1-73","title":"Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ozmosis Research (Canada); Regional Municipality of Durham; Royal Columbian Hospital; Saint John Regional Hospital; Mount Sinai Hospital; Lakeridge Health; Hôtel-Dieu de Québec; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Epoetin alfa; Erythropoietin; Anemia; Placebo; Internal medicine; Blood transfusion; Clinical trial; Hemoglobin; Randomized controlled trial; Chemotherapy","score_opus":0.048760332779745,"score_gpt":0.32552822682743127,"score_spread":0.27676789404768626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171469985","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7715873,0.19328868,0.001931582,0.002484342,0.0001724757,0.0005903483,0.024779093,0.000039948754,0.005126182],"genre_scores_gemma":[0.96511567,0.025365634,0.0020333643,0.0007900912,0.0000887191,0.000119326425,0.005932865,0.000026052738,0.0005283572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99269897,0.001947498,0.0009292238,0.0010736483,0.0025650011,0.00078569126],"domain_scores_gemma":[0.981025,0.0049646837,0.005094652,0.0010584485,0.006472001,0.0013852458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008095231,0.0010706879,0.004110421,0.0028546222,0.0015043905,0.0023474265,0.001344546,0.000861698,0.0026836568],"category_scores_gemma":[0.018862957,0.0005697724,0.008013873,0.013219457,0.0007549159,0.00054887356,0.0010312382,0.0015672692,0.00012757219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015239827,0.000131003,0.84636134,0.008971909,0.06710622,0.00042090146,0.0010734303,0.0015017383,0.0006887922,0.0010663426,0.006331705,0.0511068],"study_design_scores_gemma":[0.0021329976,0.0006277819,0.8879413,0.0022791193,0.09324673,0.00045709452,0.0009172119,0.0016972403,0.0002544376,0.00038188286,0.009869057,0.00019509227],"about_ca_topic_score_codex":0.90150106,"about_ca_topic_score_gemma":0.9385486,"teacher_disagreement_score":0.09849894,"about_ca_system_score_codex":0.017958,"about_ca_system_score_gemma":0.030852797,"threshold_uncertainty_score":0.19815797},"labels":[],"label_agreement":null},{"id":"W2171987744","doi":"10.1634/theoncologist.2009-0186","title":"Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Stage (stratigraphy); Clinical trial; Disease; Adjuvant therapy; Radiation therapy; Randomized controlled trial; Adjuvant; Chemotherapy","score_opus":0.03930313211394137,"score_gpt":0.3853508005870658,"score_spread":0.3460476684731244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171987744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042068314,0.9994261,0.00003243439,0.00023436671,0.00006802907,0.00000144132,0.00000341363,0.000002284166,0.00018993573],"genre_scores_gemma":[0.0003096024,0.9992607,0.000083729916,0.00014409304,0.00008370349,0.000002722475,0.000005987124,4.4250706e-7,0.000109008775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997924,0.000061218976,0.00003494411,0.000031823656,0.00006242896,0.000017250914],"domain_scores_gemma":[0.999335,0.0003939707,0.00009646292,0.000014763345,0.00012113674,0.000038632792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086586794,0.00076318503,0.0018677918,0.0012600056,0.0002249783,0.00092916354,0.00084152777,0.0012564391,0.0029618514],"category_scores_gemma":[0.0011957888,0.0001946039,0.000577114,0.0023899146,0.0005515085,0.0015653946,0.00049353513,0.0014288558,0.0011860331],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010198483,0.000068811205,0.00016406272,0.017485127,0.00008174635,0.00012389691,0.00003787604,0.00034020012,0.00048573385,0.0016767865,0.01779189,0.9616418],"study_design_scores_gemma":[0.0001029196,0.00027437482,0.0019492358,0.017582275,0.00039653547,0.001548525,0.00016677738,0.00026061703,0.0003353855,0.00372671,0.9736301,0.000026573374],"about_ca_topic_score_codex":0.0013700984,"about_ca_topic_score_gemma":0.003358359,"teacher_disagreement_score":0.0029618514,"about_ca_system_score_codex":0.0006092269,"about_ca_system_score_gemma":0.0013232342,"threshold_uncertainty_score":0.009908378},"labels":[],"label_agreement":null},{"id":"W2172085565","doi":"10.1634/theoncologist.2008-0017","title":"Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Darbepoetin alfa; Aerobic exercise; Cardiorespiratory fitness; Randomized controlled trial; Quality of life (healthcare); Clinical endpoint; Anemia; Epoetin alfa; Dosing; VO2 max; Physical therapy; Internal medicine; Erythropoietin; Heart rate; Blood pressure","score_opus":0.0195430276610687,"score_gpt":0.29278919327578745,"score_spread":0.27324616561471876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172085565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602198,0.020528786,0.0010497029,0.0016639999,0.0017444441,0.010520755,0.0014826778,0.00017422819,0.0026156085],"genre_scores_gemma":[0.9733935,0.007379,0.0016966092,0.0016541824,0.0008617518,0.01206511,0.0009279388,0.000018396857,0.0020034898],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985958,0.00080062187,0.00014794656,0.00023263833,0.00008503557,0.00013800016],"domain_scores_gemma":[0.99820006,0.00065131724,0.00049228704,0.00011371721,0.00011347832,0.00042902265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025488809,0.0013564348,0.0043331063,0.00052666204,0.0006352439,0.00125781,0.0009430625,0.0022476623,0.0069290185],"category_scores_gemma":[0.003128124,0.0006501386,0.0028234262,0.0006670827,0.0011452679,0.00082694757,0.0004164425,0.0023671451,0.00064536225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98872596,0.0022595862,0.0003724245,0.00096879236,0.0013060208,0.000022289512,0.000019181622,0.00012082231,0.00040498492,0.000041956253,0.00026365745,0.0054943566],"study_design_scores_gemma":[0.98392385,0.014336314,0.00067349174,0.000053497704,0.0005725339,0.00000942502,0.000008456167,0.0001303313,0.000054973214,0.000043983062,0.00018812991,0.000005012474],"about_ca_topic_score_codex":0.0012913629,"about_ca_topic_score_gemma":0.0022352396,"teacher_disagreement_score":0.0069290185,"about_ca_system_score_codex":0.0007904985,"about_ca_system_score_gemma":0.0015062769,"threshold_uncertainty_score":0.02317983},"labels":[],"label_agreement":null},{"id":"W2172287368","doi":"10.1634/theoncologist.2010-s1-24","title":"Drug Pricing and Value in Oncology","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Reimbursement; Medicine; Incentive; Pharmacy; Actuarial science; Cancer drugs; Medical prescription; Medicare Part D; Cost sharing; Prescription drug; Specialty; Leverage (statistics); Drug prices; Negotiation; Value (mathematics); Drug; Family medicine; Business; Public economics; Pharmacology; Health care; Economics; Nursing","score_opus":0.028503005344527776,"score_gpt":0.2669798053598916,"score_spread":0.2384768000153638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172287368","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.070369065,0.28485867,0.03449555,0.18756603,0.004460309,0.0001371479,0.0003122844,0.000083854895,0.41771704],"genre_scores_gemma":[0.90801424,0.055252627,0.0059958175,0.011467673,0.0062024198,0.000081314865,0.00007765575,0.00007094127,0.01283738],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99323297,0.0038231562,0.00025610471,0.00039646533,0.00195397,0.00033739058],"domain_scores_gemma":[0.9789028,0.015465309,0.0019684606,0.0007413776,0.0019755894,0.00094637345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064968048,0.00039510994,0.00076357054,0.002777481,0.0013248156,0.006862098,0.0008865893,0.0029493219,0.005975519],"category_scores_gemma":[0.036166836,0.00033133329,0.0005967973,0.0033000768,0.00905971,0.008855713,0.0024244138,0.0035373801,0.00045769537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007827613,0.00004989675,0.00494585,0.0001616089,0.000039982853,0.00014348469,0.00030961705,0.0031028243,0.00009501122,0.89488506,0.008808804,0.08737955],"study_design_scores_gemma":[0.000026006413,0.0001043226,0.004920448,0.0005378124,0.000026239995,0.00037401318,0.00056087936,0.0032556744,0.00015073629,0.9161823,0.07381983,0.00004182133],"about_ca_topic_score_codex":0.0039236415,"about_ca_topic_score_gemma":0.0036580262,"teacher_disagreement_score":0.007115362,"about_ca_system_score_codex":0.007115362,"about_ca_system_score_gemma":0.0032453972,"threshold_uncertainty_score":0.051625848},"labels":[],"label_agreement":null},{"id":"W2201187369","doi":"10.1634/theoncologist.2015-0266","title":"The Effect of Introducing the Spinal Instability Neoplastic Score in Routine Clinical Practice for Patients With Spinal Metastases","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Spine Surgery Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Medicine; Radiation therapy; Surgery; Spinal surgery; Clinical Practice; Spinal disease; Physical therapy; Lumbar","score_opus":0.05544374934467581,"score_gpt":0.3984314944545013,"score_spread":0.3429877451098255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2201187369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99795216,0.00044747884,0.000077353216,0.00047279574,0.000026899397,0.000037134556,0.00008351427,0.000011206838,0.0008915677],"genre_scores_gemma":[0.9993777,0.00012585876,0.00020732897,0.000059670034,0.000029926707,0.000020616675,0.00010156538,0.0000011160744,0.00007611481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839044,0.0005713119,0.00023140151,0.0002060494,0.00042090038,0.00017996492],"domain_scores_gemma":[0.9885511,0.0032546297,0.0050111893,0.00016175484,0.00096350274,0.0020578948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014844771,0.0002550998,0.0003608292,0.0008002921,0.0004117433,0.0006187907,0.00037524433,0.0005662795,0.0015282285],"category_scores_gemma":[0.015863098,0.0001703488,0.00058692676,0.0007649747,0.00035884333,0.00052729365,0.0008139772,0.00066246,0.00017281757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037910152,0.0002204118,0.98364013,0.00006534601,0.000055003926,0.000053857504,0.0001362697,0.0001518768,0.00015249783,0.000012441936,0.00037573578,0.014757289],"study_design_scores_gemma":[0.000021887834,0.0007309589,0.9985043,0.000019198667,0.000028019993,0.00008479756,0.00015112647,0.00024486563,0.00006033382,0.000010039308,0.00013908569,0.000005410948],"about_ca_topic_score_codex":0.005174428,"about_ca_topic_score_gemma":0.012172618,"teacher_disagreement_score":0.005174428,"about_ca_system_score_codex":0.0010231395,"about_ca_system_score_gemma":0.0017414346,"threshold_uncertainty_score":0.010288596},"labels":[],"label_agreement":null},{"id":"W2214942476","doi":"10.1634/theoncologist.2015-0295","title":"S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Imatinib; Oncology; Internal medicine; Stromal cell; Phases of clinical research; Imatinib mesylate; Chemotherapy","score_opus":0.06706704764157113,"score_gpt":0.36808130624342006,"score_spread":0.30101425860184894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214942476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97901934,0.0048503918,0.00096537115,0.0032179563,0.0008003689,0.005139215,0.001798201,0.00020943183,0.003999752],"genre_scores_gemma":[0.9760113,0.0029320528,0.0032802832,0.004725672,0.000581965,0.0047210767,0.0027489518,0.000032377873,0.004966414],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991191,0.00059668627,0.000050030725,0.0000846629,0.0000613611,0.00008813949],"domain_scores_gemma":[0.9990658,0.0002117363,0.00015148325,0.00004147579,0.000057273657,0.00047219978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029075062,0.0015469268,0.0018518586,0.00058282056,0.00036437812,0.0014599353,0.0010643151,0.0019401966,0.00616174],"category_scores_gemma":[0.0015462001,0.0005048051,0.002018863,0.0005908509,0.0013613125,0.0014438425,0.00048179092,0.0030187545,0.0010447188],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92413723,0.018002786,0.0024284718,0.0010007095,0.001459358,0.00016767698,0.0001626589,0.00092610496,0.0076656956,0.0004982843,0.004186655,0.03936438],"study_design_scores_gemma":[0.91304886,0.08275549,0.0018315539,0.00003442543,0.0002811047,0.00005841633,0.00003100912,0.0004116695,0.0003283765,0.00012996283,0.0010740286,0.000015102597],"about_ca_topic_score_codex":0.0010868489,"about_ca_topic_score_gemma":0.004968575,"teacher_disagreement_score":0.00616174,"about_ca_system_score_codex":0.00082041626,"about_ca_system_score_gemma":0.0020364784,"threshold_uncertainty_score":0.020613134},"labels":[],"label_agreement":null},{"id":"W2234005477","doi":"10.1634/theoncologist.2015-0209","title":"Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Erlotinib; Medicine; Oncology; Erlotinib Hydrochloride; Epidermal growth factor receptor; Internal medicine; Lung cancer; Chemotherapy; EGFR inhibitors; Gefitinib; Cancer","score_opus":0.04183407779112243,"score_gpt":0.362706235453725,"score_spread":0.3208721576626026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234005477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019017603,0.9741872,0.000115922914,0.0029930847,0.0008901954,0.000066918765,0.00038251263,0.000018202716,0.0023284184],"genre_scores_gemma":[0.40208358,0.5867537,0.0005586684,0.005887803,0.0024607738,0.00015133648,0.00075308,0.000011328868,0.0013396092],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940443,0.00025024297,0.00011102495,0.00007499204,0.000103379905,0.000055933597],"domain_scores_gemma":[0.9985423,0.0005619272,0.0006302259,0.000029232899,0.00014807133,0.00008829643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019335202,0.00033508136,0.0010981791,0.00027277626,0.00013488611,0.0009499504,0.0005082774,0.0007365745,0.0035807823],"category_scores_gemma":[0.0023818372,0.000114891074,0.0011775986,0.0005566916,0.00024667132,0.00054918416,0.0002604252,0.001029908,0.00040834918],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023480363,0.00046858715,0.0114957085,0.08536274,0.0058399066,0.00014017713,0.000071159404,0.0016595942,0.0018326315,0.00097322353,0.019264104,0.84941185],"study_design_scores_gemma":[0.06942248,0.032611273,0.20485485,0.1331284,0.07768147,0.0036560518,0.0007792108,0.0056703156,0.0079963235,0.006682848,0.4573266,0.00019025274],"about_ca_topic_score_codex":0.0011009533,"about_ca_topic_score_gemma":0.0027025845,"teacher_disagreement_score":0.0035807823,"about_ca_system_score_codex":0.00054075813,"about_ca_system_score_gemma":0.000815067,"threshold_uncertainty_score":0.011978924},"labels":[],"label_agreement":null},{"id":"W2239866897","doi":"10.1634/theoncologist.2015-0352","title":"Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; University of British Columbia, Okanagan Campus; University of British Columbia; BC Cancer Agency; Interior Health","funders":"National Cancer Institute; Canadian Institutes of Health Research; Michael Smith Health Research BC; Canadian Cancer Society","keywords":"Medicine; Cardiology; Internal medicine; Ejection fraction; Contractility; Anthracycline; Breast cancer; Subclinical infection; Arterial stiffness; Chemotherapy; Cancer; Heart failure; Blood pressure","score_opus":0.01337261817468551,"score_gpt":0.2811754560489555,"score_spread":0.26780283787427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2239866897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99973196,0.00009996079,0.000013549357,0.000008754557,0.0000021054943,0.000002394123,0.000029790355,8.003194e-7,0.00011056601],"genre_scores_gemma":[0.9997683,0.000060122937,0.000015538533,0.000008759017,0.00000603767,0.0000025663694,0.00007744744,3.5494324e-7,0.0000608833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998914,0.000023222228,0.00001072137,0.000019581166,0.00002289065,0.00003216606],"domain_scores_gemma":[0.9994326,0.00007867321,0.00025381008,0.000020286932,0.000045323348,0.00016934024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022474078,0.00018464279,0.00032306236,0.00044603785,0.0003545697,0.0003348987,0.0001531747,0.00034923461,0.00064228167],"category_scores_gemma":[0.0008492683,0.00011849688,0.00019083628,0.00056290487,0.00018559524,0.00017060824,0.00022635625,0.00034258695,0.000119889395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031081974,0.000051451552,0.9968079,0.0000068550657,0.000019270794,0.00037628025,0.00010186242,0.000029477636,0.0006894013,0.0000055649502,0.00002925192,0.001571825],"study_design_scores_gemma":[0.0000046916807,0.00023706774,0.9990569,0.0000017154346,0.000013762948,0.00043091757,0.0000924686,0.00004610408,0.000051301875,0.0000073226747,0.00005581989,0.0000019407562],"about_ca_topic_score_codex":0.0017775114,"about_ca_topic_score_gemma":0.0026989318,"teacher_disagreement_score":0.0017775114,"about_ca_system_score_codex":0.00020663456,"about_ca_system_score_gemma":0.00020614476,"threshold_uncertainty_score":0.0035343766},"labels":[],"label_agreement":null},{"id":"W2271999910","doi":"10.1634/theoncologist.2014-0412","title":"Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Mayo Clinic","keywords":"Medicine; Breast cancer; Pregnancy; Oncology; Obstetrics; Phenotype; Family history; Cohort; Cancer; Prospective cohort study; Young adult; Biomarker; Cohort study; Gynecology; Internal medicine; Gene; Biology","score_opus":0.0205317983764983,"score_gpt":0.31800519575887376,"score_spread":0.29747339738237544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271999910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993467,0.000193272,0.000041893305,0.0000129934315,0.0000028494535,0.0000062138092,0.00026521407,0.0000016732424,0.00012908944],"genre_scores_gemma":[0.99937063,0.00014082486,0.000048071695,0.00001760963,0.000004315343,0.000010301438,0.00032618936,0.0000014136173,0.00008060167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974996,0.000052232263,0.000029786035,0.0000747903,0.000044023083,0.000049274],"domain_scores_gemma":[0.9991411,0.00017022301,0.00037831164,0.00007022986,0.00006994872,0.00017018666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004661895,0.0001798439,0.0003029685,0.000860753,0.00031374593,0.0003678409,0.00021895362,0.00033111317,0.000922624],"category_scores_gemma":[0.0016146332,0.00023588176,0.00032835128,0.0007881288,0.00022995421,0.00033437327,0.0003449479,0.00026629426,0.00020210535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006062107,0.0000048444135,0.99922585,0.000003115624,0.000012734538,0.00007186604,0.000038955535,0.0000076339675,0.00017755458,0.000003738624,0.000023282499,0.00036991033],"study_design_scores_gemma":[0.000002039872,0.000046341193,0.99940467,0.0000024765402,0.000010173782,0.00033159627,0.000084236504,0.000028352451,0.000024295747,0.000006810262,0.000057732086,0.0000013179374],"about_ca_topic_score_codex":0.004141289,"about_ca_topic_score_gemma":0.004347886,"teacher_disagreement_score":0.004141289,"about_ca_system_score_codex":0.00019876497,"about_ca_system_score_gemma":0.00024241004,"threshold_uncertainty_score":0.008234382},"labels":[],"label_agreement":null},{"id":"W2281889317","doi":"10.1634/theoncologist.2014-0341","title":"Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Cancer; Emergency department; Presentation (obstetrics); Palliative care; Disease; Intensive care medicine; Health care; Quality of life (healthcare); Malignancy; Medical diagnosis; Medical emergency; Nursing; Internal medicine; Surgery; Pathology","score_opus":0.046443827871196046,"score_gpt":0.4155791656044463,"score_spread":0.36913533773325025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281889317","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18629923,0.40869847,0.002565829,0.3692372,0.006218578,0.00012008121,0.0035950697,0.00039680448,0.022868713],"genre_scores_gemma":[0.56867486,0.33560532,0.005456558,0.074948385,0.007418778,0.00022519295,0.004169248,0.000201956,0.0032997683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998072,0.00036803272,0.00038227523,0.00033315673,0.00051255384,0.0003318632],"domain_scores_gemma":[0.98369265,0.002869208,0.004126178,0.0002915677,0.0052332776,0.0037871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002922498,0.00029416714,0.0005996176,0.0020086295,0.0012415514,0.0031207157,0.0011723153,0.0016296632,0.005141201],"category_scores_gemma":[0.0118683055,0.00025674317,0.0006520007,0.0053152572,0.0014412468,0.0032322311,0.0024454272,0.0031856527,0.0008663739],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041334302,0.00024091479,0.2839766,0.0053167916,0.00023685132,0.0007715566,0.006082123,0.0009774866,0.00097463635,0.008044064,0.13755323,0.5554125],"study_design_scores_gemma":[0.000052420866,0.00039201797,0.6172002,0.0046088463,0.00021770367,0.0026262228,0.024083896,0.0011993061,0.00039674903,0.0034142332,0.34566548,0.00014287475],"about_ca_topic_score_codex":0.015084858,"about_ca_topic_score_gemma":0.01916173,"teacher_disagreement_score":0.015084858,"about_ca_system_score_codex":0.0032733637,"about_ca_system_score_gemma":0.0052310396,"threshold_uncertainty_score":0.02999413},"labels":[],"label_agreement":null},{"id":"W2287831934","doi":"10.1634/theoncologist.2015-0056","title":"Media Reporting of Practice-Changing Clinical Trials in Oncology: A North American Perspective","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Grand River Hospital; Foothills Medical Centre; University of Ottawa","funders":"University of Ottawa; University of Calgary; American Society of Clinical Oncology","keywords":"Social media; Medicine; Clinical trial; Newspaper; Citation; The Internet; Internal medicine; Advertising; World Wide Web; Computer science","score_opus":0.5674891192042176,"score_gpt":0.6463256784029308,"score_spread":0.07883655919871313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287831934","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15700856,0.27464148,0.008875747,0.46626836,0.004483648,0.0002914456,0.0035822894,0.00018882524,0.08465971],"genre_scores_gemma":[0.7416097,0.17568403,0.0065278015,0.050648656,0.021052035,0.0002980492,0.0011130378,0.00013695162,0.002929828],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9656632,0.020766534,0.0044010533,0.002325748,0.006222529,0.0006210372],"domain_scores_gemma":[0.45251733,0.39676654,0.09674873,0.008645751,0.041241124,0.00408053],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.050812233,0.00043701375,0.0006343431,0.010969843,0.0013661264,0.0101710595,0.0014414144,0.0022177314,0.004098522],"category_scores_gemma":[0.22248082,0.00045338878,0.0004943428,0.0105927,0.0046538175,0.010973738,0.0033846693,0.0024287582,0.00062514766],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047015576,0.0003134146,0.26838988,0.008806107,0.00040274445,0.0006235841,0.02672599,0.0006563759,0.0012293806,0.028346721,0.081299566,0.5827361],"study_design_scores_gemma":[0.00010760715,0.0006135096,0.5257886,0.03558533,0.0008293398,0.0029040512,0.04313456,0.0028562483,0.0021694188,0.030235846,0.35536647,0.00040903137],"about_ca_topic_score_codex":0.008082632,"about_ca_topic_score_gemma":0.008567892,"teacher_disagreement_score":0.94918776,"about_ca_system_score_codex":0.0037005346,"about_ca_system_score_gemma":0.0042020082,"threshold_uncertainty_score":0.26872396},"labels":[],"label_agreement":null},{"id":"W2300207219","doi":"10.1634/theoncologist.2016-0069","title":"Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?","year":2016,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Cardiotoxicity; Dexrazoxane; Trastuzumab; Anthracycline; Cardioprotection; Oncology; Doxorubicin; Regimen; Internal medicine; Pharmacology; Adverse effect; Clinical trial; Cardiology; Chemotherapy; Cancer; Myocardial infarction; Breast cancer","score_opus":0.062470239359428435,"score_gpt":0.3184028482091724,"score_spread":0.255932608849744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300207219","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022289166,0.7023406,0.005164207,0.25092688,0.010091096,0.0001469241,0.00019316288,0.0002732479,0.008574716],"genre_scores_gemma":[0.13975029,0.64633137,0.016298367,0.14705355,0.046254966,0.00019861675,0.0003850059,0.00010706092,0.0036207973],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981446,0.00077906594,0.00019361792,0.00026495263,0.0004508684,0.0001669551],"domain_scores_gemma":[0.9904531,0.006100238,0.0005484612,0.00037378445,0.0015888317,0.0009355259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005285171,0.0008775573,0.0020371373,0.0006548782,0.00062499783,0.0028370977,0.0022232293,0.0046556843,0.0041056494],"category_scores_gemma":[0.013909657,0.00029548432,0.0011007829,0.0004705884,0.0023972348,0.0062569,0.0008322389,0.007648671,0.0014777017],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009894976,0.0008721334,0.008770453,0.004211795,0.00027438079,0.006521931,0.0005995526,0.00065461895,0.0023695382,0.0054051485,0.06104508,0.9082858],"study_design_scores_gemma":[0.00087773474,0.008376837,0.041023936,0.03530891,0.0015318427,0.06209214,0.007989701,0.0065681674,0.005277182,0.059367113,0.77085835,0.00072809204],"about_ca_topic_score_codex":0.002044846,"about_ca_topic_score_gemma":0.0040133395,"teacher_disagreement_score":0.005285171,"about_ca_system_score_codex":0.0011886928,"about_ca_system_score_gemma":0.0016482186,"threshold_uncertainty_score":0.027951002},"labels":[],"label_agreement":null},{"id":"W2309664335","doi":"10.1634/theoncologist.2015-0239","title":"Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Debulking; Medicine; Ovarian cancer; Randomized controlled trial; Clinical trial; Oncology; Internal medicine; Cancer; Serous fluid; Surgery","score_opus":0.0784323802967087,"score_gpt":0.382023392231853,"score_spread":0.3035910119351443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309664335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049766567,0.9154211,0.009983607,0.01493803,0.003214662,0.0032000428,0.0014045573,0.00007928173,0.0019920764],"genre_scores_gemma":[0.8642815,0.08709811,0.01340496,0.024333462,0.0029162555,0.0050094407,0.0020969345,0.00007041435,0.0007890462],"study_design_codex":"meta_analysis","study_design_gemma":"systematic_review","domain_scores_codex":[0.9070064,0.0696593,0.01297863,0.0049780053,0.0044720857,0.0009055762],"domain_scores_gemma":[0.91982895,0.0650342,0.009315057,0.0022364026,0.0024212534,0.0011641578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08102674,0.001909148,0.011081954,0.0027966006,0.00058734475,0.00430966,0.0021231046,0.004189714,0.004249249],"category_scores_gemma":[0.08580583,0.0007425326,0.024413854,0.003127272,0.0019703216,0.0035504338,0.001953905,0.0038883274,0.00025517933],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06998396,0.00037522762,0.061977163,0.2088899,0.50220424,0.00028347987,0.0006993221,0.002182088,0.0012060736,0.0042982725,0.008049321,0.13985093],"study_design_scores_gemma":[0.0567267,0.0065056896,0.046372622,0.046350364,0.7932453,0.00037533246,0.0007867603,0.0056567113,0.00075962837,0.023307253,0.019683044,0.00023053258],"about_ca_topic_score_codex":0.0016021759,"about_ca_topic_score_gemma":0.0037537746,"teacher_disagreement_score":0.08102674,"about_ca_system_score_codex":0.0015406741,"about_ca_system_score_gemma":0.0024251,"threshold_uncertainty_score":0.4285155},"labels":[],"label_agreement":null},{"id":"W2345838610","doi":"10.1634/theoncologist.2015-0248","title":"Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Institute for Health and Care Research; Cancer Research UK","keywords":"PI3K/AKT/mTOR pathway; Medicine; Protein kinase B; Phosphatidylinositol; Kinase; RPTOR; Incidence (geometry); Sirolimus; Cancer research; Internal medicine; Signal transduction; Cell biology; Biology","score_opus":0.02312363592342188,"score_gpt":0.30505262826347057,"score_spread":0.2819289923400487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345838610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90216994,0.08972285,0.0012776551,0.0015331819,0.00016516742,0.0006896532,0.0008224394,0.000030681436,0.0035884536],"genre_scores_gemma":[0.98465884,0.011993625,0.0009348179,0.0006828983,0.00029843833,0.00037221314,0.0007952426,0.000008814592,0.000255197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973339,0.0015428008,0.00039971626,0.00021590968,0.0003342053,0.00017356359],"domain_scores_gemma":[0.9915025,0.0031079033,0.0042844913,0.00015110274,0.00039291455,0.00056109624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007383645,0.00035538862,0.0008453489,0.00055682665,0.0002776977,0.0012886929,0.00041098564,0.00059351715,0.0009703333],"category_scores_gemma":[0.007377815,0.00020311221,0.0011342014,0.0013201582,0.0003333239,0.0007175718,0.0002838736,0.0010393962,0.00011544456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1694001,0.003050014,0.5808577,0.0031181914,0.005783649,0.00041892182,0.00019236526,0.0025027515,0.0038215397,0.000724581,0.006235652,0.22389449],"study_design_scores_gemma":[0.08038224,0.12705019,0.74488336,0.002581046,0.009843944,0.0048396783,0.0004769103,0.010866889,0.0061174976,0.0021396184,0.010681516,0.00013710799],"about_ca_topic_score_codex":0.00019184517,"about_ca_topic_score_gemma":0.0005964698,"teacher_disagreement_score":0.007383645,"about_ca_system_score_codex":0.00072324567,"about_ca_system_score_gemma":0.00095563586,"threshold_uncertainty_score":0.03904891},"labels":[],"label_agreement":null},{"id":"W2345972868","doi":"10.1634/theoncologist.2015-0336","title":"The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Canadian Institutes of Health Research; National Institute for Health and Care Research; National Cancer Institute; Ovarian Cancer Research Fund; National Institutes of Health; Cancer Research UK; American Society of Clinical Oncology; National Institute for Health and Care Excellence; Royal Marsden NHS Foundation Trust; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Oncology; Prostate cancer screening; Family history; Internal medicine; Prostate-specific antigen; Logistic regression; Population; Single-nucleotide polymorphism; Prostate; Gynecology; Cancer; Genotype","score_opus":0.05336829173518951,"score_gpt":0.3218246425786746,"score_spread":0.26845635084348507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345972868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970187,0.00018019149,0.0007553826,0.00011156221,0.000011782435,0.00071929005,0.00031835443,0.000013031399,0.0008717976],"genre_scores_gemma":[0.99713135,0.00013502265,0.0013146106,0.00015801443,0.00003499055,0.0005364705,0.0003726208,0.0000048328666,0.00031211996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994018,0.00036801095,0.000025066065,0.00009951332,0.00005315938,0.000052464697],"domain_scores_gemma":[0.9987274,0.00043578618,0.00024248539,0.000127618,0.0001102946,0.0003564855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014015677,0.00067136995,0.0004131477,0.00040193732,0.0004995696,0.0003024718,0.00040725793,0.00046417984,0.002289833],"category_scores_gemma":[0.003074981,0.00036452385,0.00054707786,0.00022371096,0.00031471928,0.000508462,0.00074321084,0.0005681958,0.00043309265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057855517,0.010652194,0.8719963,0.0003134401,0.00046291336,0.0020177888,0.00050638773,0.0007154879,0.00796629,0.00021642004,0.0011753573,0.046121996],"study_design_scores_gemma":[0.014625732,0.15016125,0.81898,0.000057469693,0.00060669915,0.0060115713,0.0003897458,0.0026080497,0.0035116554,0.0005422817,0.0024418496,0.000063770654],"about_ca_topic_score_codex":0.0013101746,"about_ca_topic_score_gemma":0.0016228271,"teacher_disagreement_score":0.002289833,"about_ca_system_score_codex":0.0002449819,"about_ca_system_score_gemma":0.00081353367,"threshold_uncertainty_score":0.0076602697},"labels":[],"label_agreement":null},{"id":"W2397623993","doi":"10.1634/theoncologist.2016-0006","title":"Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Referral; Palliative care; Medicine; Family medicine; Cancer; Nursing; Internal medicine","score_opus":0.4229028458163722,"score_gpt":0.5719189273617419,"score_spread":0.14901608154536966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397623993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045019644,0.9884688,0.00055394764,0.0007563415,0.00022543219,0.0031477301,0.0015687093,0.000032002798,0.0007451373],"genre_scores_gemma":[0.06068272,0.9221377,0.0045353547,0.0019544265,0.00020122904,0.008371963,0.0017459614,0.00003688214,0.00033379984],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9728272,0.008877607,0.011731446,0.0014341571,0.004585055,0.0005445163],"domain_scores_gemma":[0.8993211,0.06966832,0.02049053,0.00096893887,0.0085850675,0.0009660168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020683222,0.0018771358,0.010435918,0.018981667,0.0013342567,0.0036393467,0.0028955168,0.0024152226,0.00553195],"category_scores_gemma":[0.10847836,0.0015281069,0.008623396,0.020827243,0.0014594656,0.0036924533,0.0024139795,0.0013509844,0.0005455462],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013311776,0.000013916226,0.0014636931,0.9735252,0.0032614446,0.00012563603,0.0004273664,0.00005133102,0.000077146025,0.0001339109,0.0016533905,0.01913393],"study_design_scores_gemma":[0.0002685578,0.00009623567,0.0046055685,0.9645483,0.021367801,0.00044318166,0.0006285377,0.000080180645,0.000094453266,0.00020314034,0.00761905,0.000045113095],"about_ca_topic_score_codex":0.012852055,"about_ca_topic_score_gemma":0.044494975,"teacher_disagreement_score":0.020683222,"about_ca_system_score_codex":0.008516488,"about_ca_system_score_gemma":0.02197244,"threshold_uncertainty_score":0.1093846},"labels":[],"label_agreement":null},{"id":"W2464278690","doi":"10.1634/theoncologist.2015-0433","title":"Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Oral Health Pathology and Treatment","field":"Dentistry","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Simon Fraser University; Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"Terry Fox Research Institute; Provincial Health Services Authority; Canadian Cancer Society; Genome British Columbia; Canadian Centre for Applied Research in Cancer Control","keywords":"Loss of heterozygosity; Medicine; Dysplasia; Internal medicine; Biology; Genetics","score_opus":0.06110671640983808,"score_gpt":0.35818234342944655,"score_spread":0.2970756270196085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464278690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9466857,0.010977127,0.0033023495,0.0057333256,0.00019802706,0.0026272493,0.0119010545,0.00016795604,0.018407263],"genre_scores_gemma":[0.9915991,0.0021836427,0.0017674457,0.00043983577,0.000016861963,0.00032493932,0.001712288,0.00001413413,0.001941835],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9970782,0.001329455,0.00012520552,0.00024753864,0.00045809173,0.0007615987],"domain_scores_gemma":[0.99431324,0.0027131091,0.00049281295,0.00011958504,0.0012031274,0.0011581237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033654254,0.0012133936,0.001591691,0.0014909869,0.0012340241,0.001880917,0.0021291077,0.0012621894,0.005410314],"category_scores_gemma":[0.012905206,0.0007285088,0.0024002232,0.0018186192,0.00092261384,0.0005384383,0.0011097695,0.0015820543,0.0002040774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03326473,0.0033333984,0.106542535,0.0047345865,0.0061332537,0.0007954938,0.00037475154,0.7080511,0.0013592931,0.010020429,0.01959224,0.10579817],"study_design_scores_gemma":[0.018313903,0.00923254,0.16779931,0.0021410654,0.006467157,0.00053632614,0.0016339509,0.7767946,0.0010359853,0.005929364,0.009687145,0.0004287253],"about_ca_topic_score_codex":0.9774296,"about_ca_topic_score_gemma":0.9747218,"teacher_disagreement_score":0.09712426,"about_ca_system_score_codex":0.09712426,"about_ca_system_score_gemma":0.088438906,"threshold_uncertainty_score":0.70468915},"labels":[],"label_agreement":null},{"id":"W2474699717","doi":"10.1634/theoncologist.2016-0097","title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Medicine; Palbociclib; Fulvestrant; Neutropenia; Placebo; Metastatic breast cancer; Internal medicine; Adverse effect; Febrile neutropenia; Oncology; Common Terminology Criteria for Adverse Events; Breast cancer; Cancer; Chemotherapy; Estrogen receptor","score_opus":0.009780463777112593,"score_gpt":0.29616004749887154,"score_spread":0.2863795837217589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474699717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98527366,0.008833434,0.00065643346,0.00031644484,0.0000588959,0.0020099694,0.0014133083,0.000068812435,0.0013690626],"genre_scores_gemma":[0.9939831,0.0025366212,0.00049269653,0.00031653576,0.00010375191,0.0008791511,0.0012531667,0.000010594619,0.0004243071],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993436,0.00038014393,0.00005056222,0.00008882802,0.000081801154,0.00005508371],"domain_scores_gemma":[0.9992187,0.00022964487,0.000288547,0.0000647947,0.000057815112,0.00014060365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022695884,0.0007260456,0.001212541,0.0005020935,0.00024372662,0.0005817977,0.0005429382,0.0006464577,0.0032895398],"category_scores_gemma":[0.001360831,0.0003102725,0.0013537214,0.0006274762,0.0005220337,0.00042321975,0.00022137922,0.001114115,0.0003854533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8344373,0.011258957,0.0145122055,0.0017324477,0.004719192,0.00018651875,0.00012089849,0.001787266,0.022269432,0.00011034314,0.0016575768,0.107207924],"study_design_scores_gemma":[0.7248825,0.22584973,0.039879132,0.00009667047,0.0030295195,0.00033843017,0.000045344335,0.00080587354,0.0024140277,0.00013294777,0.0025007094,0.000025132094],"about_ca_topic_score_codex":0.0005549605,"about_ca_topic_score_gemma":0.0017425051,"teacher_disagreement_score":0.0032895398,"about_ca_system_score_codex":0.00064689806,"about_ca_system_score_gemma":0.00097595516,"threshold_uncertainty_score":0.012002826},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2477946877","doi":"10.1634/theoncologist.2016-0176","title":"Early Palliative Care and Its Role in Oncology: A Qualitative Study","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Cancer Society; Ministry of Health, Ontario","keywords":"Medicine; Palliative care; Oncology; Family medicine; Intervention (counseling); Focus group; Qualitative research; Internal medicine; Nursing","score_opus":0.20370539117459793,"score_gpt":0.5117691189028938,"score_spread":0.3080637277282958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2477946877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886285,0.0012373863,0.0022986014,0.0024862436,0.000078299774,0.00069388124,0.00021968846,0.000013206523,0.0043441546],"genre_scores_gemma":[0.99366295,0.0013778588,0.0011108853,0.0009836699,0.00002182038,0.0009776223,0.00006565856,0.000014016947,0.0017853975],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.98861444,0.009030911,0.00027764845,0.00046891396,0.0005031257,0.001105006],"domain_scores_gemma":[0.97769356,0.017404994,0.0013641533,0.0003351488,0.0014321723,0.0017700152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016485158,0.0006305889,0.0009042188,0.0015384605,0.009108139,0.003743544,0.0015681081,0.0016986583,0.0036946815],"category_scores_gemma":[0.01760087,0.000698967,0.0003898331,0.0019620536,0.00807394,0.003986011,0.004849578,0.0029622456,0.00036551527],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043372722,0.000086274486,0.001703054,0.00019982451,0.0000029604985,0.00035197032,0.9936604,0.000024572893,0.00042178092,0.0007489573,0.0002539579,0.00250298],"study_design_scores_gemma":[0.000009294246,0.00008608419,0.0009973235,0.00023605194,0.0000030100107,0.00016073383,0.9942099,0.00004800074,0.00013764772,0.00020533247,0.0038993172,0.000007362381],"about_ca_topic_score_codex":0.006614851,"about_ca_topic_score_gemma":0.0094807325,"teacher_disagreement_score":0.016485158,"about_ca_system_score_codex":0.0055706934,"about_ca_system_score_gemma":0.005784539,"threshold_uncertainty_score":0.08718288},"labels":[],"label_agreement":null},{"id":"W2486839133","doi":"10.1634/theoncologist.2016-0186","title":"Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Agència de Gestió d'Ajuts Universitaris i de Recerca; National Cancer Institute; U.S. Food and Drug Administration; National Institutes of Health","keywords":"Hedgehog signaling pathway; Vismodegib; Basal cell carcinoma; Discontinuation; Medicine; Dysgeusia; Adverse effect; Quality of life (healthcare); Hedgehog; Smoothened; Internal medicine; Oncology; Signal transduction; Biology; Basal cell; Nursing","score_opus":0.013263329222364192,"score_gpt":0.25382602863173337,"score_spread":0.24056269940936917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486839133","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879241,0.0073781577,0.00057440816,0.00034722761,0.0000270583,0.00015409572,0.0005117484,0.000017530165,0.0030655153],"genre_scores_gemma":[0.99668354,0.0013910516,0.00067736336,0.00028996746,0.000050907835,0.00004519463,0.0006088572,0.000003287172,0.00024987175],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99950695,0.00011114282,0.00010447086,0.00006368246,0.0001513709,0.0000624287],"domain_scores_gemma":[0.99904317,0.00022521899,0.00040510393,0.000029907644,0.00016053532,0.00013599882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059274834,0.00015987884,0.00058009365,0.00054339325,0.0002684424,0.00046962584,0.00016915136,0.00030162747,0.0005393249],"category_scores_gemma":[0.001865157,0.00009306044,0.00037599306,0.00072744704,0.00013710406,0.00033284345,0.00020343026,0.00055780326,0.00013021435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006972308,0.00013379887,0.95927924,0.00012707837,0.00010207636,0.0018004649,0.00016839548,0.00019852891,0.0020226527,0.00007800988,0.0005146394,0.034877975],"study_design_scores_gemma":[0.000047753972,0.0007622466,0.9893355,0.00005707091,0.00008883089,0.006270491,0.00026532705,0.00047639757,0.0005385719,0.0001324867,0.002012571,0.0000126964305],"about_ca_topic_score_codex":0.00068275986,"about_ca_topic_score_gemma":0.00095584436,"teacher_disagreement_score":0.00068275986,"about_ca_system_score_codex":0.00033025315,"about_ca_system_score_gemma":0.00034531625,"threshold_uncertainty_score":0.003134787},"labels":[],"label_agreement":null},{"id":"W2518422528","doi":"10.1634/theoncologist.2016-0164","title":"Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Adverse effect; Tolerability; Lung cancer; Oncology; Chemotherapy; Immune system; Immunotherapy; Monoclonal antibody; Internal medicine; Intensive care medicine; Immunology; Antibody","score_opus":0.03120782614683579,"score_gpt":0.34147288587707575,"score_spread":0.31026505973023993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518422528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016801532,0.9987644,0.00010314663,0.00028030222,0.00008947913,0.0000057991574,0.000011950455,0.0000046160326,0.0005722523],"genre_scores_gemma":[0.001387336,0.9976972,0.00026069718,0.00020491453,0.00010631028,0.000008813629,0.000024201714,0.0000011231249,0.00030943297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997327,0.000065885855,0.00005351754,0.000026408447,0.000106200656,0.000015347456],"domain_scores_gemma":[0.99961275,0.00017096438,0.000086824904,0.000007762715,0.000102247286,0.000019442012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006536128,0.0004627915,0.001006531,0.0014861921,0.00017774513,0.0006458616,0.0005017051,0.000692711,0.0018072098],"category_scores_gemma":[0.001005094,0.0001466125,0.0005977255,0.0010119776,0.00021082898,0.0007304122,0.00041496297,0.0010826157,0.00077950495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053275417,0.00004946474,0.00032955225,0.017289951,0.00012925059,0.00020230703,0.00005072302,0.00022783985,0.000803404,0.0009479856,0.016284883,0.9636314],"study_design_scores_gemma":[0.00005541884,0.0002495512,0.0029637641,0.016385669,0.00044359284,0.004973788,0.00011426704,0.00025016646,0.001101352,0.0018806026,0.9715493,0.00003246229],"about_ca_topic_score_codex":0.00064970873,"about_ca_topic_score_gemma":0.0016259807,"teacher_disagreement_score":0.0018072098,"about_ca_system_score_codex":0.0003421171,"about_ca_system_score_gemma":0.0007444832,"threshold_uncertainty_score":0.0060457587},"labels":[],"label_agreement":null},{"id":"W2519439632","doi":"10.1634/theoncologist.2016-0161","title":"Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Abiraterone; Cancer research; Abiraterone acetate; Population; Cancer; Medicine; Mechanism (biology); splice; Bioinformatics; Computational biology; Biology; Gene; Internal medicine; Genetics; Androgen deprivation therapy","score_opus":0.04893143347236359,"score_gpt":0.3605005743744425,"score_spread":0.3115691409020789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519439632","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038722105,0.906395,0.021862155,0.012674088,0.0025271766,0.00011157376,0.00021698371,0.00030313712,0.017187763],"genre_scores_gemma":[0.18027645,0.7692666,0.017315382,0.007934339,0.0021571538,0.00010617963,0.00031560563,0.000054631884,0.022573654],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999256,0.0000101631485,0.0000042267147,0.000011320545,0.000036347592,0.000012412335],"domain_scores_gemma":[0.9999634,0.00000655382,0.000009511402,0.0000024211424,0.000007225178,0.00001080432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002587388,0.00032543397,0.0002881734,0.00030159843,0.0001735003,0.00071218365,0.00032196284,0.000497497,0.001742029],"category_scores_gemma":[0.00010638868,0.0001007434,0.00034026094,0.00023565965,0.00040287196,0.00067925744,0.00043660484,0.0013430127,0.0008698807],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038956004,0.0002703883,0.001246345,0.0025174376,0.00007805957,0.0008300488,0.00014220417,0.00094964745,0.2747424,0.01889735,0.024993133,0.67494345],"study_design_scores_gemma":[0.00021619174,0.0014244061,0.00402616,0.00056523713,0.0001574904,0.0076710763,0.00010486121,0.0027786253,0.06738506,0.0062678824,0.909335,0.00006811844],"about_ca_topic_score_codex":0.00048800782,"about_ca_topic_score_gemma":0.0013376647,"teacher_disagreement_score":0.001742029,"about_ca_system_score_codex":0.000491622,"about_ca_system_score_gemma":0.00045288814,"threshold_uncertainty_score":0.0058276653},"labels":[],"label_agreement":null},{"id":"W2529995173","doi":"10.1634/theoncologist.2016-0222","title":"Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Cancer Research UK; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Medicine; Carcinoembryonic antigen; Interquartile range; Asymptomatic; Colorectal cancer; Positron emission tomography; Confidence interval; Radiology; Occult; Cancer; Internal medicine; Nuclear medicine; Pathology","score_opus":0.01338134069089638,"score_gpt":0.28322510132026457,"score_spread":0.2698437606293682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529995173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995647,0.0002187424,0.00002087618,0.00003367027,0.0000060162397,0.00000298962,0.000044615892,0.000001163313,0.000107224114],"genre_scores_gemma":[0.999762,0.00005918452,0.000011829715,0.000014104206,0.000009609037,0.0000022812105,0.00011446398,3.5505272e-7,0.000026099926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997898,0.000047704547,0.000017689374,0.000047159203,0.000037180696,0.000060534676],"domain_scores_gemma":[0.9989507,0.00022243954,0.0003721227,0.000046038025,0.00009572464,0.00031289287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043347012,0.00023420593,0.00036591725,0.00040509156,0.00038991298,0.00045919776,0.0002586061,0.00051095197,0.00060845714],"category_scores_gemma":[0.0022551494,0.00014335511,0.0003310614,0.00038839754,0.0003169272,0.000396199,0.00028379433,0.00046731756,0.00013062138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024512602,0.00003305262,0.9977374,0.0000064780975,0.000020495787,0.00042422456,0.000034759,0.000045057568,0.00020132196,0.0000072163984,0.000059116905,0.0011857415],"study_design_scores_gemma":[0.000021797365,0.00043783957,0.9974354,0.0000072328075,0.000049936792,0.0015361267,0.00009625799,0.00021264295,0.00007331656,0.000030639847,0.00009257834,0.0000062043623],"about_ca_topic_score_codex":0.0018549865,"about_ca_topic_score_gemma":0.0024942078,"teacher_disagreement_score":0.0018549865,"about_ca_system_score_codex":0.0003426859,"about_ca_system_score_gemma":0.00028078753,"threshold_uncertainty_score":0.0036884546},"labels":[],"label_agreement":null},{"id":"W2534012350","doi":"10.1634/theoncologist.2016-0188","title":"The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Genome Alberta; Genome Canada","keywords":"Biomarker; Medicine; Interim; Precision medicine; ERCC1; Companion diagnostic; Personalized medicine; Translational research; Biomarker discovery; Bioinformatics; Nucleotide excision repair; Cancer; Internal medicine; Pathology; DNA repair; Proteomics","score_opus":0.0905969875901333,"score_gpt":0.36914266392083955,"score_spread":0.27854567633070626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534012350","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007613693,0.06380918,0.09637698,0.8053168,0.005452159,0.00039909297,0.00061482645,0.0002482029,0.020169204],"genre_scores_gemma":[0.28199494,0.03495019,0.34252423,0.3176518,0.016106194,0.0021171747,0.00058919063,0.0005797126,0.0034865984],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.5234174,0.36612186,0.02391005,0.02752713,0.054449104,0.0045744157],"domain_scores_gemma":[0.20735723,0.6660379,0.0218914,0.05668235,0.043512564,0.004518573],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.5554972,0.0026673921,0.006481323,0.0066973357,0.0071952012,0.019618591,0.0075062714,0.022120716,0.0054000164],"category_scores_gemma":[0.5733071,0.0021904933,0.004387639,0.007157568,0.055357512,0.043599326,0.013141002,0.03132146,0.002438307],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001216208,0.0003462079,0.03185201,0.0042118994,0.0011975054,0.0023362173,0.010093922,0.006073963,0.0013370202,0.51729995,0.08281846,0.34121674],"study_design_scores_gemma":[0.00026384337,0.0005074283,0.005409245,0.0057299794,0.0003710501,0.001903024,0.0037579774,0.005253881,0.0018153371,0.8416423,0.133041,0.0003047995],"about_ca_topic_score_codex":0.010076703,"about_ca_topic_score_gemma":0.00659093,"teacher_disagreement_score":0.5554972,"about_ca_system_score_codex":0.012554581,"about_ca_system_score_gemma":0.026175642,"threshold_uncertainty_score":0.54815114},"labels":[],"label_agreement":null},{"id":"W2547499110","doi":"10.1634/theoncologist.2015-0084","title":"Targeting the KRAS Pathway in Non-Small Cell Lung Cancer","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Lung cancer; Medicine; Targeted therapy; Cancer research; Adenocarcinoma; Cancer; Oncogene; Oncology; Internal medicine; Colorectal cancer; Cell cycle","score_opus":0.024955253064500485,"score_gpt":0.3139234364054693,"score_spread":0.28896818334096885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547499110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019122627,0.997623,0.00018390594,0.00029226454,0.0001950254,0.0000053546046,0.000018015213,0.000013637934,0.0014775905],"genre_scores_gemma":[0.0008907971,0.9978669,0.00016407807,0.00014663201,0.00009575812,0.0000057200537,0.000028347999,0.0000016824258,0.0008000306],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998832,0.000014497568,0.000014271796,0.000021000862,0.0000543317,0.000012678233],"domain_scores_gemma":[0.9999062,0.000031748637,0.000014991618,0.000003757535,0.000030208643,0.00001318524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025521073,0.00057729555,0.0007657234,0.0015075376,0.00024217974,0.0005653199,0.0005184705,0.00072845747,0.0026299811],"category_scores_gemma":[0.00029233142,0.00016168357,0.00041686665,0.0011623402,0.00029519456,0.0009149354,0.00048370656,0.0015171682,0.0021607145],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065547785,0.00007549455,0.00017742855,0.0133124795,0.000055646186,0.00022671868,0.000045364148,0.0002936152,0.004955731,0.0030660953,0.0267684,0.9509575],"study_design_scores_gemma":[0.000012180793,0.000110077315,0.00066448015,0.0015986575,0.00006480258,0.001762188,0.000031020616,0.000080914826,0.0010793181,0.0013308564,0.9932527,0.000012736348],"about_ca_topic_score_codex":0.0006219984,"about_ca_topic_score_gemma":0.0012159727,"teacher_disagreement_score":0.0026299811,"about_ca_system_score_codex":0.00043488145,"about_ca_system_score_gemma":0.00066668994,"threshold_uncertainty_score":0.008798182},"labels":[],"label_agreement":null},{"id":"W2549108333","doi":"10.1634/theoncologist.2016-0153","title":"Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Alliance for Clinical Trials in Oncology Foundation; Mayo Clinic","keywords":"Medicine; Metformin; Internal medicine; Hazard ratio; Folinic acid; Cetuximab; Oxaliplatin; FOLFOX; Proportional hazards model; Colorectal cancer; Oncology; Cancer; Confidence interval; Insulin","score_opus":0.039866502888569584,"score_gpt":0.28391484069314665,"score_spread":0.24404833780457708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549108333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988373,0.0003034114,0.000022168128,0.00003970342,0.0000073395627,0.000016185668,0.0005387459,0.0000022479535,0.0002328671],"genre_scores_gemma":[0.997184,0.00015761232,0.00007181157,0.00008507479,0.00002022049,0.000035276094,0.0021088538,0.0000028865613,0.00033429917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99964285,0.000139067,0.00003134627,0.00006104565,0.000079861886,0.000045893856],"domain_scores_gemma":[0.9985812,0.0002588507,0.0005828697,0.00009922426,0.0002031072,0.00027483236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096945773,0.00022428611,0.00037034563,0.00059219444,0.0002851496,0.0003410594,0.00032948298,0.00036350553,0.001075299],"category_scores_gemma":[0.0012905359,0.0001938753,0.00045966264,0.0006466453,0.0001643203,0.00016247887,0.00039220398,0.00034872608,0.0002162016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040226267,0.00018408138,0.99177086,0.000040525643,0.00015555778,0.00006188163,0.00006095112,0.00007348687,0.00043025945,0.000006728301,0.0005137303,0.0026793776],"study_design_scores_gemma":[0.00031349057,0.0007261905,0.9982461,0.000013210371,0.00008145907,0.000090046495,0.00005368488,0.00012042223,0.000062020394,0.000006117791,0.00028332858,0.0000039533115],"about_ca_topic_score_codex":0.007843152,"about_ca_topic_score_gemma":0.017455189,"teacher_disagreement_score":0.007843152,"about_ca_system_score_codex":0.0004372104,"about_ca_system_score_gemma":0.00061041256,"threshold_uncertainty_score":0.015594959},"labels":[],"label_agreement":null},{"id":"W2554177440","doi":"10.1634/theoncologist.2016-0185","title":"Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2– Advanced Breast Cancer","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary; Nova Scotia Cancer Centre; BC Cancer Agency; Dalhousie University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Exemestane; Letrozole; Everolimus; Oncology; Breast cancer; Internal medicine; Sunitinib; Adverse effect; Combination therapy; Cancer; Metastatic breast cancer; Tamoxifen","score_opus":0.0302134003723064,"score_gpt":0.3549598303514997,"score_spread":0.3247464299791933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554177440","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26978016,0.6609833,0.02210294,0.006807298,0.0011846359,0.0012624569,0.0011307788,0.00059755676,0.036150865],"genre_scores_gemma":[0.7282347,0.22932285,0.025399905,0.004812157,0.0009808363,0.0008467866,0.0014806614,0.000082084014,0.008840029],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997898,0.00006584721,0.00001856132,0.000026607571,0.000079102836,0.000020027584],"domain_scores_gemma":[0.9998173,0.00006168754,0.000053662417,0.0000138801515,0.000032410713,0.000021078833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053320854,0.0002771116,0.00047054084,0.0006359063,0.00011692258,0.00048854796,0.0003327949,0.00027006277,0.003699594],"category_scores_gemma":[0.0006818209,0.00009165214,0.00053492043,0.00037334496,0.00013552647,0.00041211557,0.00033059085,0.000726267,0.0008185289],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026287965,0.0006662683,0.0021367713,0.0018312342,0.00027046763,0.00025174994,0.00005890587,0.0010207972,0.027309794,0.00078167603,0.0060145212,0.957029],"study_design_scores_gemma":[0.009023867,0.04852943,0.04980974,0.0031197995,0.0028409255,0.007877087,0.0003567773,0.0063914824,0.06282327,0.006863641,0.8022329,0.00013102754],"about_ca_topic_score_codex":0.0002733808,"about_ca_topic_score_gemma":0.0012184823,"teacher_disagreement_score":0.003699594,"about_ca_system_score_codex":0.0002516672,"about_ca_system_score_gemma":0.00023613965,"threshold_uncertainty_score":0.012376368},"labels":[],"label_agreement":null},{"id":"W2587511691","doi":"10.1634/theoncologist.2016-0371","title":"Predatory Invitations from Journals: More Than Just a Nuisance?","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Academic integrity and plagiarism","field":"Social Sciences","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Institute of Cancer Research; University of Alberta; Ottawa Public Health; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Family medicine","score_opus":0.14680079515793984,"score_gpt":0.44178195580643137,"score_spread":0.29498116064849156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587511691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818178,0.0019036861,0.0020964157,0.0053558387,0.00015985851,0.00013619663,0.00025976368,0.00009228338,0.008178221],"genre_scores_gemma":[0.99523807,0.0006455747,0.0010246002,0.0014252678,0.0004422134,0.00005828325,0.00010183807,0.000034939534,0.0010293258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9806849,0.0103323795,0.0023496985,0.0010810638,0.004833583,0.00071831985],"domain_scores_gemma":[0.70857507,0.1354579,0.12298972,0.009463744,0.01846397,0.0050495327],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015177619,0.00023958908,0.0005515871,0.0040884637,0.0017003259,0.0032317073,0.00062708376,0.0009663997,0.0042977533],"category_scores_gemma":[0.1593714,0.0002784934,0.00024338668,0.0033665518,0.0019180167,0.0027471492,0.0015206387,0.0009630398,0.0011450105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067864114,0.00027070788,0.88704723,0.0007807082,0.00014065143,0.0010701228,0.0337892,0.00009309996,0.0020758903,0.0018119202,0.0076617077,0.064580075],"study_design_scores_gemma":[0.00002448005,0.0004595246,0.938182,0.0007091808,0.00010040123,0.004833989,0.028397257,0.00078695314,0.0016469836,0.002544024,0.022243444,0.00007169743],"about_ca_topic_score_codex":0.0009958883,"about_ca_topic_score_gemma":0.0012173193,"teacher_disagreement_score":0.99903363,"about_ca_system_score_codex":0.0013054475,"about_ca_system_score_gemma":0.0011044225,"threshold_uncertainty_score":0.080267906},"labels":[],"label_agreement":null},{"id":"W2591046956","doi":"10.1634/theoncologist.2016-0265","title":"Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"U.S. Food and Drug Administration; Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Capecitabine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Clinical endpoint; Phases of clinical research; Cancer; Randomized controlled trial; Confidence interval; Oncology; Chemotherapy; Colorectal cancer","score_opus":0.051736645608612145,"score_gpt":0.408330866346466,"score_spread":0.35659422073785385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591046956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822442,0.0036948936,0.0009343976,0.0008627067,0.0006312564,0.007321375,0.0014628172,0.00017906264,0.0026692383],"genre_scores_gemma":[0.9803689,0.0025298996,0.0025182755,0.0017672194,0.0005418607,0.006334945,0.002237085,0.00005168023,0.0036501586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991935,0.00048567462,0.000039623224,0.00012691286,0.00005642939,0.00009781258],"domain_scores_gemma":[0.998871,0.00023502686,0.0002538335,0.00009745602,0.0000750495,0.00046757885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022649027,0.0016968045,0.0033217224,0.00041758595,0.00037965464,0.0011796756,0.0011025288,0.0014881747,0.0066407453],"category_scores_gemma":[0.0018403935,0.0010085616,0.0012872258,0.0004410555,0.0011495218,0.0010822822,0.00039161314,0.0033217066,0.0013787872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9460851,0.024013475,0.0012868177,0.00052006816,0.0010735361,0.00008634418,0.000080423,0.00058443955,0.006224033,0.00011746269,0.0017385606,0.01818976],"study_design_scores_gemma":[0.91709745,0.07968563,0.0013831751,0.000013161861,0.00022253596,0.000047315392,0.000013497881,0.0004101587,0.00033508087,0.00006310587,0.0007191555,0.000009633427],"about_ca_topic_score_codex":0.0010749559,"about_ca_topic_score_gemma":0.0027439543,"teacher_disagreement_score":0.0066407453,"about_ca_system_score_codex":0.001105277,"about_ca_system_score_gemma":0.0020105776,"threshold_uncertainty_score":0.022215486},"labels":[],"label_agreement":null},{"id":"W2591210005","doi":"10.1634/theoncologist.2016-0078","title":"Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"National Cancer Institute; CRIS Cancer Foundation; Sociedad Española de Oncología Médica","keywords":"Medicine; Hazard ratio; Proportional hazards model; Concordance; Renal cell carcinoma; Oncology; Internal medicine; Clinical endpoint; Gene signature; Overall survival; Confidence interval; Gene; Gene expression; Clinical trial; Biology","score_opus":0.041624701129055905,"score_gpt":0.3126501555619361,"score_spread":0.2710254544328802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591210005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874889,0.0007184274,0.00499258,0.00059590937,0.00005970232,0.000057821948,0.0037124464,0.00011097098,0.002263213],"genre_scores_gemma":[0.99602497,0.00007985093,0.0015043686,0.000035084202,0.000021342283,0.000017771707,0.0020130388,0.000010762208,0.00029278034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887604,0.00043581528,0.00009346559,0.00025520253,0.00021867927,0.00012086767],"domain_scores_gemma":[0.996926,0.0013073304,0.00053944724,0.00038624683,0.00047045367,0.00037053414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026398369,0.00049712963,0.0006211051,0.0012626384,0.0003055962,0.0011168837,0.00060596335,0.00032427383,0.0026547178],"category_scores_gemma":[0.008465288,0.00010847779,0.00081081333,0.0012167409,0.00017045684,0.00047308597,0.00091092446,0.00047959475,0.00047435483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048713334,0.000050199273,0.97817695,0.000028452452,0.00027529488,0.000041377312,0.000026682965,0.0047743823,0.00024279447,0.0001416236,0.0017303132,0.014024637],"study_design_scores_gemma":[0.00012011806,0.00034571026,0.7835592,0.00007796413,0.00076925894,0.0004170002,0.00019757901,0.20828818,0.001153934,0.0016538993,0.0033693274,0.000047881014],"about_ca_topic_score_codex":0.011716336,"about_ca_topic_score_gemma":0.011790065,"teacher_disagreement_score":0.011716336,"about_ca_system_score_codex":0.0007913128,"about_ca_system_score_gemma":0.0010950122,"threshold_uncertainty_score":0.023296297},"labels":[],"label_agreement":null},{"id":"W2611234918","doi":"10.1634/theoncologist.2016-0500","title":"Implementation of the Edmonton Symptom Assessment System for Symptom Distress Screening at a Community Cancer Center: A Pilot Program","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Medicine; Psychosocial; Referral; Distress; Triage; Family medicine; Palliative care; Cancer; Emergency medicine; Psychiatry; Nursing; Internal medicine; Clinical psychology","score_opus":0.08253998639699035,"score_gpt":0.441523884883796,"score_spread":0.3589838984868057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611234918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99229676,0.00003635748,0.0004401335,0.0005045866,0.00002955383,0.0057522603,0.00011843525,0.00010113266,0.00072075333],"genre_scores_gemma":[0.98154527,0.00013213651,0.007927646,0.00082874007,0.00007213672,0.007950227,0.00054446724,0.0000135005375,0.0009858431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99671125,0.0012741316,0.0001807177,0.00028829294,0.00041562176,0.0011299618],"domain_scores_gemma":[0.98881197,0.0016158482,0.001171197,0.0006865966,0.0012106196,0.0065037753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073567973,0.00086956826,0.0003654442,0.0011825445,0.0020093762,0.0010752205,0.0019767147,0.0010547146,0.0029453954],"category_scores_gemma":[0.007968966,0.000803789,0.0008517068,0.00068759953,0.0013646829,0.0013525493,0.0032696615,0.0017174106,0.00030890034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010472991,0.27425548,0.34494293,0.0006725607,0.00023253386,0.0022575203,0.009526604,0.0033924414,0.013636505,0.0003050892,0.007908589,0.33239672],"study_design_scores_gemma":[0.007223699,0.14372292,0.83281124,0.00018969909,0.00012645811,0.0004190931,0.004923267,0.0038878857,0.002758394,0.00015752755,0.0036720426,0.00010775587],"about_ca_topic_score_codex":0.032051075,"about_ca_topic_score_gemma":0.060020614,"teacher_disagreement_score":0.032051075,"about_ca_system_score_codex":0.0049049305,"about_ca_system_score_gemma":0.018954037,"threshold_uncertainty_score":0.06372905},"labels":[],"label_agreement":null},{"id":"W2611921030","doi":"10.1634/theoncologist.2016-0356","title":"Prospective Evaluation of the Relationship Between Mechanical Stability and Response to Palliative Radiotherapy for Symptomatic Spinal Metastases","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre; Vancouver Spine Surgery Institute; Vancouver Coastal Health; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Radiation therapy; Lumbosacral joint; Odds ratio; Prospective cohort study; Palliative care; Confidence interval; Lumbar; Spinal disease; Thoracic vertebrae; Surgery; Internal medicine; Lumbar vertebrae","score_opus":0.23570749795307425,"score_gpt":0.4604883266165991,"score_spread":0.22478082866352486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611921030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997148,0.00009085108,0.0000437593,0.0000101133155,0.0000010502077,0.0000048417296,0.00005438864,0.0000011749794,0.00007893324],"genre_scores_gemma":[0.9998441,0.000019136625,0.000026192662,0.0000041186277,0.0000031240425,0.000004547697,0.00008018968,3.8507545e-7,0.000018188657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995301,0.00021060815,0.000050040377,0.00006487252,0.00008785962,0.000056541878],"domain_scores_gemma":[0.997122,0.00096251006,0.0013293461,0.000119240874,0.00021435478,0.00025257212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009855166,0.00017791554,0.00023728369,0.00043132366,0.00019305866,0.00031432556,0.00017787212,0.00024657327,0.0013641021],"category_scores_gemma":[0.0038062439,0.0001331897,0.00030734754,0.00045759065,0.00022851366,0.000199322,0.00027953138,0.00030504106,0.00015741886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014303568,0.000015602305,0.99901307,0.000004391751,0.000023182321,0.000016995393,0.0000138424,0.000025215943,0.00010766905,0.0000023575917,0.000013889265,0.00062063936],"study_design_scores_gemma":[0.000008493465,0.00030717996,0.9992611,0.0000018360316,0.00001629961,0.00016216203,0.000036595025,0.00011146434,0.000055682416,0.0000036412657,0.000034240944,0.0000012909154],"about_ca_topic_score_codex":0.00068570505,"about_ca_topic_score_gemma":0.00091932237,"teacher_disagreement_score":0.0013641021,"about_ca_system_score_codex":0.00014938475,"about_ca_system_score_gemma":0.00016735295,"threshold_uncertainty_score":0.005212009},"labels":[],"label_agreement":null},{"id":"W2613439971","doi":"10.1634/theoncologist.2016-0415","title":"Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study","year":2017,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Retrospective cohort study; Oncology; Germline mutation; Cancer; Family history; Gastroenterology; Mutation; Gene; Genetics","score_opus":0.2001530791259961,"score_gpt":0.4553380343336708,"score_spread":0.2551849552076747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613439971","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991955,0.00019171336,0.00004673898,0.000010764728,0.0000022045815,0.000007958447,0.0003637915,0.0000022485517,0.00017886101],"genre_scores_gemma":[0.9994485,0.000069739006,0.00003847745,0.000010159016,0.000007201341,0.000008799142,0.00038706092,0.0000014113699,0.000028709868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993436,0.00013823422,0.00011127502,0.00022809758,0.00008216682,0.00009663141],"domain_scores_gemma":[0.99825174,0.00023991498,0.00077900843,0.00015479783,0.0002236051,0.0003509716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007809544,0.0002902336,0.00042949108,0.0015865858,0.00054730684,0.00059975276,0.00037844465,0.0004305015,0.0011723869],"category_scores_gemma":[0.001665675,0.00035703447,0.00046260114,0.0017781518,0.00037361143,0.00058247236,0.000534947,0.00031552985,0.0002651178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049905684,0.0000097830825,0.99943644,0.0000029107546,0.000021347743,0.00009309251,0.000023719027,0.000011581898,0.000084213156,0.0000031162092,0.00002684805,0.00023703661],"study_design_scores_gemma":[0.0000069000776,0.00007492132,0.99854773,0.0000046296573,0.000036517355,0.0008305548,0.00017595004,0.0001081501,0.000055724235,0.000009095065,0.00014593326,0.0000038924027],"about_ca_topic_score_codex":0.0026977912,"about_ca_topic_score_gemma":0.0024325936,"teacher_disagreement_score":0.0026977912,"about_ca_system_score_codex":0.0003640854,"about_ca_system_score_gemma":0.00029485364,"threshold_uncertainty_score":0.00536412},"labels":[],"label_agreement":null},{"id":"W2621574813","doi":"10.1634/theoncologist.2016-0455","title":"Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Society for Medical Oncology; Clalit Health Services; Burroughs Wellcome Fund","keywords":"Medicine; Bevacizumab; Colorectal cancer; Incremental cost-effectiveness ratio; Quality-adjusted life year; Cost effectiveness; Cost-effectiveness analysis; Willingness to pay; Cost–benefit analysis; Adverse effect; Oncology; Demography; Internal medicine; Chemotherapy; Cancer","score_opus":0.0896050830222645,"score_gpt":0.4412394298392327,"score_spread":0.3516343468169682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621574813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.623951,0.24678282,0.05458478,0.015500322,0.00077556283,0.002477364,0.024429772,0.00037064857,0.031127738],"genre_scores_gemma":[0.9566902,0.024474097,0.010200733,0.0011920696,0.00019529898,0.0006056304,0.0057195043,0.000060275972,0.00086236047],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9967968,0.0023615686,0.0001135959,0.00020213536,0.00034779048,0.00017808635],"domain_scores_gemma":[0.99556476,0.0035694775,0.0003833625,0.00009868876,0.00026788318,0.00011586656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007765788,0.0016907203,0.0023275998,0.0037622382,0.0001775038,0.0015018077,0.00079551875,0.0010240664,0.0037124483],"category_scores_gemma":[0.014484569,0.00052308745,0.0072092074,0.0038401918,0.00044038793,0.0013370711,0.0009847705,0.0014385326,0.00018508593],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057203113,0.00046206533,0.02990947,0.007830705,0.028352266,0.0007386283,0.00013226556,0.7772335,0.00065326237,0.010435568,0.011928761,0.12660322],"study_design_scores_gemma":[0.004959425,0.0066153957,0.080073476,0.0072528766,0.062242247,0.0025727833,0.0007622996,0.75530463,0.0012292812,0.04370765,0.034902584,0.00037734912],"about_ca_topic_score_codex":0.012613149,"about_ca_topic_score_gemma":0.009541109,"teacher_disagreement_score":0.012613149,"about_ca_system_score_codex":0.0046388595,"about_ca_system_score_gemma":0.0023045617,"threshold_uncertainty_score":0.041069865},"labels":[],"label_agreement":null},{"id":"W2624530626","doi":"10.1634/theoncologist.2017-0047","title":"Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"UCLH Biomedical Research Centre; Medical Research Council; National Health and Medical Research Council; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK; American Society of Clinical Oncology","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Proportional hazards model; Quality of life (healthcare); Carboplatin; Cancer; Logistic regression; Cisplatin","score_opus":0.031498484669945155,"score_gpt":0.3183567643721904,"score_spread":0.28685827970224526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624530626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825543,0.0005379209,0.000040414398,0.0003457808,0.000010060919,0.000020548774,0.000325534,0.0000029388743,0.00046135683],"genre_scores_gemma":[0.9992073,0.0001290745,0.000097210774,0.00008946837,0.000019454083,0.000013008444,0.00033799227,0.0000016241902,0.0001048573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996413,0.0001757811,0.000029741414,0.000042900072,0.00006403733,0.00004622159],"domain_scores_gemma":[0.99635196,0.0014103135,0.0014619543,0.00013558306,0.0001386491,0.00050150166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015089142,0.00023138289,0.0002814611,0.00031209408,0.00029643744,0.0005891358,0.00031302142,0.00063227274,0.0012698766],"category_scores_gemma":[0.0072101974,0.00012116152,0.00052944315,0.00045294577,0.00022344619,0.000379503,0.00041672363,0.0009886821,0.00011199815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011034143,0.0001587007,0.99252254,0.000031918076,0.00019156236,0.00004567891,0.00007453291,0.00011771239,0.00007756259,0.000023287446,0.00035750997,0.0052955276],"study_design_scores_gemma":[0.00010807649,0.00042743533,0.99804986,0.000017389213,0.00016945919,0.00009898428,0.00009929117,0.00041194353,0.00003410131,0.000090028625,0.00048783282,0.00000558756],"about_ca_topic_score_codex":0.0025470378,"about_ca_topic_score_gemma":0.0028619736,"teacher_disagreement_score":0.0025470378,"about_ca_system_score_codex":0.00033609557,"about_ca_system_score_gemma":0.00050169503,"threshold_uncertainty_score":0.007980049},"labels":[],"label_agreement":null},{"id":"W2637410905","doi":"10.1634/theoncologist.2017-0235","title":"Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pregabalin; Neuropathic pain; Oxaliplatin; Anesthesia; Allodynia; Placebo; Analgesic; Chronic pain; Duloxetine; Peripheral neuropathy; Randomized controlled trial; Nociception; Internal medicine; Colorectal cancer; Hyperalgesia; Cancer; Physical therapy","score_opus":0.2068603240696497,"score_gpt":0.45655941135312983,"score_spread":0.24969908728348014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2637410905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94837135,0.023009147,0.001558148,0.0016703117,0.0026946,0.016607212,0.0017166388,0.00034423496,0.004028514],"genre_scores_gemma":[0.9565313,0.012683446,0.0031111024,0.0026046888,0.001823327,0.016254997,0.00095443026,0.00003444353,0.0060022934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992748,0.0003653166,0.00006799686,0.00012810741,0.000059749018,0.00010392318],"domain_scores_gemma":[0.99929166,0.00020665537,0.0001660966,0.00006607572,0.00006963084,0.0001998767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015575412,0.0016211362,0.0039028467,0.000533731,0.00047215942,0.0009612042,0.0011400426,0.0025638847,0.008147897],"category_scores_gemma":[0.0015155395,0.00069159793,0.0020113804,0.0005119892,0.0011329412,0.0009962298,0.00040523717,0.0025624488,0.0010230327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9820747,0.005114284,0.00013678409,0.0010386157,0.00059678726,0.000018592958,0.000015739466,0.00008811121,0.0009863946,0.000057135385,0.00033781052,0.009534942],"study_design_scores_gemma":[0.9823231,0.016765025,0.00031560403,0.00003097003,0.00019398645,0.000007487296,0.00000431206,0.00007472392,0.00008725037,0.000038741346,0.00015441114,0.000004287636],"about_ca_topic_score_codex":0.0010480888,"about_ca_topic_score_gemma":0.0020566413,"teacher_disagreement_score":0.008147897,"about_ca_system_score_codex":0.000617823,"about_ca_system_score_gemma":0.0013180005,"threshold_uncertainty_score":0.027257442},"labels":[],"label_agreement":null},{"id":"W2719623628","doi":"10.1634/theoncologist.2017-0072","title":"Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cancer Research UK; AstraZeneca; American Society of Clinical Oncology; Pfizer","keywords":"Palbociclib; Fulvestrant; Medicine; Goserelin; Anastrozole; Internal medicine; Oncology; Breast cancer; Adverse effect; Neutropenia; Placebo; Letrozole; Gynecology; Cancer; Metastatic breast cancer; Chemotherapy; Tamoxifen","score_opus":0.022065930195343083,"score_gpt":0.3371386426214998,"score_spread":0.3150727124261567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2719623628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98548734,0.009367217,0.00029001787,0.00069945643,0.00006210779,0.0006255565,0.0009611484,0.000049024875,0.0024581614],"genre_scores_gemma":[0.994689,0.002234647,0.00038171504,0.0004485396,0.000085254054,0.00030898786,0.0010696803,0.000010800204,0.00077149045],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963033,0.00018261417,0.000023858285,0.000053286156,0.000057816593,0.000052153846],"domain_scores_gemma":[0.999385,0.00018040932,0.0001448466,0.00005051592,0.00006566394,0.00017356132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015008786,0.0005833021,0.00091432745,0.00035911147,0.00018348657,0.00070907484,0.00048691517,0.0005282721,0.0036383937],"category_scores_gemma":[0.0011812955,0.00018011883,0.0014131301,0.00040428122,0.0003789963,0.00038497115,0.0003093902,0.0014389333,0.00054447656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61276275,0.01629139,0.051509373,0.0016898795,0.003912049,0.00053641805,0.0002330746,0.0013245402,0.022138275,0.00021428411,0.0029795563,0.28640842],"study_design_scores_gemma":[0.29294726,0.4783129,0.1876821,0.00031939216,0.0063554165,0.0022019173,0.00020264853,0.0021471572,0.01319115,0.0004350055,0.016135328,0.000069657115],"about_ca_topic_score_codex":0.0012491215,"about_ca_topic_score_gemma":0.0034465936,"teacher_disagreement_score":0.0036383937,"about_ca_system_score_codex":0.00078107836,"about_ca_system_score_gemma":0.0010938867,"threshold_uncertainty_score":0.012171626},"labels":[],"label_agreement":null},{"id":"W2759254671","doi":"10.1634/theoncologist.2017-0205","title":"Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK)","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi","keywords":"Medicine; Pulmonary embolism; Lung cancer; Internal medicine; Thrombosis; Deep vein; Cancer; Prospective cohort study; Venous thrombosis; Proportional hazards model; Population; Cohort study; Surgery","score_opus":0.031006028234536936,"score_gpt":0.355612829883407,"score_spread":0.32460680164887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759254671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983588,0.00020302091,0.000041313637,0.00003801511,0.0000046308082,0.000013094441,0.0011599694,0.0000024244512,0.00017863984],"genre_scores_gemma":[0.9975878,0.00010190693,0.00006226375,0.000027172886,0.000011408371,0.000021636342,0.002062263,0.0000020412967,0.0001234493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99953187,0.00016346226,0.000039918574,0.00011572985,0.00006882527,0.000080233316],"domain_scores_gemma":[0.9989134,0.00016233239,0.000293786,0.00009607764,0.00017893112,0.00035548004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093790906,0.0005422227,0.0002923919,0.000983389,0.00043662108,0.00069147896,0.00036328813,0.00040117823,0.0011822478],"category_scores_gemma":[0.0011455979,0.0002724446,0.0006252573,0.0012320816,0.00040141254,0.00043899723,0.00082584476,0.00047972708,0.00019909863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018299636,0.0000228022,0.99903774,0.000009402267,0.000065734275,0.00002855251,0.0000427476,0.0000291226,0.000069917674,0.000005050817,0.0001130776,0.00039289836],"study_design_scores_gemma":[0.00003473223,0.00010567946,0.99938977,0.000004726244,0.000049470116,0.000070880575,0.00011678354,0.00008283492,0.000027442566,0.000007683011,0.000106484855,0.0000034625027],"about_ca_topic_score_codex":0.010785381,"about_ca_topic_score_gemma":0.012841393,"teacher_disagreement_score":0.010785381,"about_ca_system_score_codex":0.000399188,"about_ca_system_score_gemma":0.00049113116,"threshold_uncertainty_score":0.021445215},"labels":[],"label_agreement":null},{"id":"W2761496515","doi":"10.1634/theoncologist.2017-0248","title":"Outcomes of a Specialized Interdisciplinary Approach for Patients with Cancer with Aberrant Opioid-Related Behavior","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Opioid; Psychological intervention; Cancer pain; Anxiety; Internal medicine; Intervention (counseling); Cancer; Medical record; Morphine; Chronic pain; Outpatient clinic; Physical therapy; Psychiatry","score_opus":0.0300207352605767,"score_gpt":0.3519193241832878,"score_spread":0.3218985889227111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761496515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985892,0.0004669508,0.000081732236,0.00012093015,0.000016752103,0.000056110184,0.00005053176,0.000011264304,0.00060652714],"genre_scores_gemma":[0.9992442,0.00020461256,0.00017057147,0.000074890675,0.000024608422,0.00004470609,0.00013418359,0.0000010521006,0.00010117413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994974,0.00018811949,0.000038770773,0.000064373315,0.00009079564,0.00012057111],"domain_scores_gemma":[0.9980604,0.00020357902,0.00073723885,0.00006131508,0.0001658717,0.0007716057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042121075,0.0001935124,0.0002979633,0.00039325343,0.0005180444,0.00033330228,0.000310012,0.00027510698,0.0014388298],"category_scores_gemma":[0.002156722,0.00007869532,0.00037344673,0.0003609522,0.00023308185,0.00026253678,0.0008461274,0.0004968634,0.000103374616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030961705,0.010288909,0.81219614,0.0004628651,0.0005474912,0.00058601884,0.0007852493,0.0007853084,0.0019729654,0.00006263601,0.0023663417,0.16684999],"study_design_scores_gemma":[0.00039289412,0.010358674,0.9852188,0.00011257946,0.00018492238,0.00061345816,0.00096745876,0.00079104956,0.00049938663,0.000063288106,0.00078351644,0.000014061104],"about_ca_topic_score_codex":0.0025198667,"about_ca_topic_score_gemma":0.0074114525,"teacher_disagreement_score":0.0025198667,"about_ca_system_score_codex":0.0006555223,"about_ca_system_score_gemma":0.0007963489,"threshold_uncertainty_score":0.0050103664},"labels":[],"label_agreement":null},{"id":"W2763843183","doi":"10.1634/theoncologist.2017-0141","title":"Effectiveness of Oncologist-Referred Exercise and Healthy Eating Programming as a Part of Supportive Adjuvant Care for Early Breast Cancer","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency; Canadian Institutes of Health Research","keywords":"Medicine; Physical therapy; Breast cancer; Quality of life (healthcare); Referral; Adverse effect; Randomized controlled trial; Aerobic exercise; Clinical trial; Cancer; Adjuvant therapy; Internal medicine; Family medicine; Nursing","score_opus":0.036725446287990134,"score_gpt":0.3759492769604419,"score_spread":0.33922383067245176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763843183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936342,0.003523261,0.00021500867,0.00037620193,0.00005213034,0.0006489261,0.000076461445,0.000032056505,0.0014416963],"genre_scores_gemma":[0.994762,0.002122362,0.0014859668,0.00027012205,0.00009469498,0.00074657815,0.00015526397,0.0000033949077,0.00035955186],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99903584,0.0006031487,0.00007690248,0.00007818245,0.00014230963,0.00006359796],"domain_scores_gemma":[0.99874616,0.0005961416,0.0003074902,0.00005559468,0.000065529035,0.00022902242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012828081,0.00026106584,0.00039145807,0.00037658997,0.00022705528,0.0003015392,0.00041280524,0.0004961847,0.002124389],"category_scores_gemma":[0.0038259225,0.00011475268,0.00062033656,0.00021413303,0.0001678218,0.00021161379,0.00031046395,0.0007047007,0.00013041901],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091932,0.09435857,0.027740112,0.0050092293,0.00265707,0.00009770242,0.00038263647,0.0023519793,0.0032596546,0.00015473216,0.0011318531,0.77092445],"study_design_scores_gemma":[0.13472909,0.5005395,0.34097824,0.0035050835,0.004659102,0.00039212042,0.0003576718,0.004354742,0.005203536,0.00032370014,0.0049108565,0.000046393445],"about_ca_topic_score_codex":0.0011338055,"about_ca_topic_score_gemma":0.0032132235,"teacher_disagreement_score":0.002124389,"about_ca_system_score_codex":0.00048235062,"about_ca_system_score_gemma":0.00087218266,"threshold_uncertainty_score":0.0071068406},"labels":[],"label_agreement":null},{"id":"W2763983027","doi":"10.1634/theoncologist.2017-0277","title":"Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; University of Toronto; University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canadian Liver Foundation","keywords":"Medicine; Nivolumab; Head and neck; Oncology; Head and neck squamous-cell carcinoma; Basal cell; Head and neck cancer; Internal medicine; Radiology; Surgery; Immunotherapy; Radiation therapy; Cancer","score_opus":0.11201356065839797,"score_gpt":0.3941711687163503,"score_spread":0.2821576080579523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763983027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978307,0.0023672925,0.007475558,0.0009851794,0.00005603603,0.00031570822,0.0017111584,0.000093219285,0.008688828],"genre_scores_gemma":[0.99794775,0.00023106631,0.0010897359,0.00004457742,0.0000039345227,0.000028519073,0.00029178977,0.0000069122607,0.00035565713],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9993474,0.0002968378,0.000032106705,0.00006594896,0.00013007148,0.00012760567],"domain_scores_gemma":[0.9982469,0.0011566979,0.0001583944,0.000037022768,0.00023667977,0.00016434622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020393159,0.0005056103,0.0006659825,0.0009149745,0.00036608943,0.0013450384,0.0011417163,0.0006629694,0.0032847887],"category_scores_gemma":[0.007232928,0.00034692354,0.0011547765,0.00078436726,0.0004316237,0.0007794336,0.0005493158,0.00073779374,0.00011900974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002152365,0.0002501097,0.019382192,0.00030445354,0.00046589816,0.00030234482,0.00006428508,0.9425311,0.00064098637,0.002761835,0.001082438,0.03006204],"study_design_scores_gemma":[0.0005577353,0.00091916695,0.017510016,0.00019444061,0.0009115,0.00022498019,0.0001606028,0.973046,0.001107406,0.00329827,0.0020196086,0.000050318395],"about_ca_topic_score_codex":0.19979437,"about_ca_topic_score_gemma":0.16707857,"teacher_disagreement_score":0.19979437,"about_ca_system_score_codex":0.015432136,"about_ca_system_score_gemma":0.007520657,"threshold_uncertainty_score":0.3972628},"labels":[],"label_agreement":null},{"id":"W2767785601","doi":"10.1634/theoncologist.2017-0297","title":"A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve","year":2017,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Quality of life (healthcare); Randomized controlled trial; MEDLINE; Systematic review; Disease; Internal medicine; Physical therapy; Intensive care medicine","score_opus":0.6354246175069749,"score_gpt":0.6413765227387773,"score_spread":0.005951905231802446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767785601","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002023879,0.9901238,0.0012838643,0.0018920283,0.00063555496,0.0026257418,0.0009265468,0.000043111322,0.00044543645],"genre_scores_gemma":[0.068192326,0.8968976,0.013115383,0.0051628663,0.0007068514,0.014263318,0.0013225295,0.00008487339,0.00025414577],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.71444,0.14496692,0.108028166,0.007144239,0.023950178,0.0014705197],"domain_scores_gemma":[0.44300574,0.40432334,0.10220675,0.011468141,0.03697979,0.0020162093],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.17395687,0.0023472111,0.019414505,0.014620203,0.0014251276,0.007422637,0.004062587,0.0036545382,0.0037643262],"category_scores_gemma":[0.44840667,0.0022173012,0.013472262,0.017026735,0.003866275,0.0074420515,0.003600933,0.0030681766,0.00043725377],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027784146,0.00001023066,0.0008559629,0.96355283,0.013021584,0.00004184622,0.0003059998,0.000088789406,0.000116763345,0.00034827448,0.0015504187,0.01982952],"study_design_scores_gemma":[0.00063692546,0.00017902863,0.0030473918,0.9346049,0.049948823,0.00011962899,0.0002797971,0.0001648715,0.00017616988,0.00068080786,0.010109059,0.000052638137],"about_ca_topic_score_codex":0.006948153,"about_ca_topic_score_gemma":0.019083055,"teacher_disagreement_score":0.8260431,"about_ca_system_score_codex":0.011097255,"about_ca_system_score_gemma":0.03114624,"threshold_uncertainty_score":0.91998285},"labels":[],"label_agreement":null},{"id":"W2772890129","doi":"10.1634/theoncologist.2017-0103","title":"Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pomalidomide; Daratumumab; Medicine; Internal medicine; Multiple myeloma; Hazard ratio; Population; Confidence interval; Propensity score matching; Oncology; Dexamethasone; Surgery; Lenalidomide; Environmental health","score_opus":0.13851089506331335,"score_gpt":0.4163297299963975,"score_spread":0.2778188349330841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772890129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93292576,0.049046963,0.0076428754,0.0004248918,0.0007727777,0.0019020531,0.0024625713,0.00008200706,0.0047401665],"genre_scores_gemma":[0.9941677,0.0016832124,0.0021870248,0.00022934568,0.00012555644,0.0005494382,0.0005865292,0.000008913882,0.00046236103],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.97995365,0.016364146,0.0011528656,0.001016494,0.0011490722,0.0003637859],"domain_scores_gemma":[0.98857725,0.007858613,0.0018637398,0.00090154045,0.00046330385,0.0003356085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012222625,0.0014897763,0.0033685267,0.0011208481,0.00024324814,0.0013741159,0.0011917442,0.0011179966,0.004513373],"category_scores_gemma":[0.017189272,0.00042736737,0.00812324,0.0009610219,0.00063642865,0.0006629315,0.0010947328,0.0015144612,0.00023022207],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7298852,0.00080323085,0.020333145,0.0076309917,0.18701,0.00012266166,0.0002075584,0.003935805,0.002943456,0.0016478077,0.0007330056,0.044747185],"study_design_scores_gemma":[0.34235314,0.15794027,0.107514404,0.0018139456,0.34220508,0.0004784528,0.00039265893,0.021264436,0.0085942475,0.0073902793,0.009748422,0.00030458326],"about_ca_topic_score_codex":0.0011298378,"about_ca_topic_score_gemma":0.0012457536,"teacher_disagreement_score":0.012222625,"about_ca_system_score_codex":0.0009658226,"about_ca_system_score_gemma":0.0008185979,"threshold_uncertainty_score":0.064640224},"labels":[],"label_agreement":null},{"id":"W2781449980","doi":"10.1634/theoncologist.2017-0237","title":"Racial and Ethnic Composition of Cancer Clinical Drug Trials: How Diverse Are We?","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Microsoft","keywords":"Medicine; Clinical trial; Ethnic group; Drug; Cancer; Clinical research; Pharmacology; Internal medicine","score_opus":0.8741845997911862,"score_gpt":0.7193066874101237,"score_spread":0.15487791238106252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781449980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5685125,0.08370219,0.056745034,0.22174193,0.003902236,0.0022359442,0.0019601337,0.0002450147,0.06095509],"genre_scores_gemma":[0.93060756,0.013583987,0.015359344,0.034008883,0.0025862104,0.0013509515,0.0008153918,0.00018660036,0.001501098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.69969124,0.22485429,0.029948603,0.009718975,0.032419577,0.0033673195],"domain_scores_gemma":[0.7021152,0.15393482,0.06838395,0.019544719,0.043691732,0.012329668],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.18044804,0.00040418524,0.0014785187,0.0057828915,0.0038139573,0.007010498,0.001514082,0.0015098109,0.0027306473],"category_scores_gemma":[0.42244768,0.0006416212,0.0008172472,0.005275568,0.0051315106,0.0075227153,0.004327878,0.0023934918,0.00083761936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001228791,0.00030193554,0.53807795,0.0015589063,0.0014608253,0.00031013536,0.022327213,0.0007088685,0.0011856513,0.02610048,0.02096739,0.38577187],"study_design_scores_gemma":[0.00058262853,0.0012799151,0.6371798,0.0080304155,0.0013468739,0.0028413006,0.040698767,0.0044167303,0.0030740998,0.121571794,0.17858908,0.00038863765],"about_ca_topic_score_codex":0.0035975813,"about_ca_topic_score_gemma":0.0081713805,"teacher_disagreement_score":0.81955194,"about_ca_system_score_codex":0.0032432661,"about_ca_system_score_gemma":0.008484646,"threshold_uncertainty_score":0.95431185},"labels":[],"label_agreement":null},{"id":"W2784883128","doi":"10.1634/theoncologist.2017-0346","title":"Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Genomic Health","keywords":"Medicine; Breast cancer; Internal medicine; Chemotherapy; Oncology; Confidence interval; Prospective cohort study; Adjuvant; Stage (stratigraphy); Cancer; Lymph node","score_opus":0.02940338891775906,"score_gpt":0.32099860819347475,"score_spread":0.2915952192757157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784883128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720013,0.00016509536,0.00006257767,0.0002403991,0.000007070407,0.00013187427,0.001022928,0.0000037002023,0.001166253],"genre_scores_gemma":[0.9986694,0.000097203396,0.00018578726,0.00009622846,0.0000062332592,0.0000472497,0.00048020997,0.0000017204729,0.00041610107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979709,0.00052714115,0.000121141784,0.00021552917,0.00074340584,0.00042190618],"domain_scores_gemma":[0.9926071,0.0011883037,0.002114463,0.00018763254,0.002710375,0.0011920187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019886447,0.00027493262,0.00028434358,0.00039276094,0.0014271743,0.00051636307,0.0006805926,0.00031857518,0.0011077467],"category_scores_gemma":[0.0074942796,0.00028486646,0.00042645578,0.0012389236,0.0005857347,0.00020365579,0.00050472235,0.00040213583,0.00015172036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039877795,0.0000846419,0.9952656,0.000023719838,0.000022070979,0.000059360453,0.00042329467,0.00013047604,0.00014978724,0.000014355041,0.0005364244,0.002891497],"study_design_scores_gemma":[0.000036395635,0.0002057355,0.998403,0.000008352168,0.000017582533,0.000030442017,0.00037944442,0.00034149867,0.00005682936,0.000004737002,0.00050858577,0.000007375509],"about_ca_topic_score_codex":0.96265996,"about_ca_topic_score_gemma":0.9775149,"teacher_disagreement_score":0.97813153,"about_ca_system_score_codex":0.021868493,"about_ca_system_score_gemma":0.023130655,"threshold_uncertainty_score":0.1586678},"labels":[],"label_agreement":null},{"id":"W2800380359","doi":"10.1634/theoncologist.2018-0153","title":"Can We Hang Our Hats on One Percent?","year":2018,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Hang; Breast cancer; Oncology; Chemotherapy; Residual; Neoadjuvant therapy; Internal medicine; Cancer","score_opus":0.04305294382414494,"score_gpt":0.3000418980827577,"score_spread":0.2569889542586128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800380359","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013591662,0.00086784543,0.0000363476,0.9794322,0.018517826,0.000005116107,0.00003239266,0.000015913518,0.0009563713],"genre_scores_gemma":[0.0009340498,0.0006834736,0.00008421566,0.9701229,0.02572921,0.000017533504,0.00001676467,0.000012763233,0.0023990865],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954964,0.0014456847,0.0005638036,0.00056145457,0.0014378336,0.0004948675],"domain_scores_gemma":[0.9836754,0.009253407,0.0009812405,0.00049099687,0.0033548218,0.002244082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005449652,0.00089315075,0.0014647306,0.0008545402,0.0047863163,0.003003613,0.002647417,0.04700353,0.010815693],"category_scores_gemma":[0.040926624,0.00066187687,0.0012981701,0.00089185854,0.003763195,0.0047427905,0.0017395606,0.048216753,0.008317473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003312812,0.0000283479,0.00037459435,0.00004001257,0.000007995206,0.0004937483,0.0000809123,0.000021065205,0.000076987286,0.0010296169,0.9916421,0.0061715133],"study_design_scores_gemma":[0.000087724824,0.00007716156,0.0011785177,0.00038473748,0.000026958482,0.0008982631,0.00060204905,0.00013255492,0.00018592627,0.0060905204,0.9902754,0.000060319875],"about_ca_topic_score_codex":0.0087656,"about_ca_topic_score_gemma":0.01694724,"teacher_disagreement_score":0.04700353,"about_ca_system_score_codex":0.0035208764,"about_ca_system_score_gemma":0.005398014,"threshold_uncertainty_score":0.036182046},"labels":[],"label_agreement":null},{"id":"W2804901132","doi":"10.1634/theoncologist.2017-0668","title":"Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Intervention (counseling); Multivariate analysis; Cancer; Physical therapy; Quality of life (healthcare); Internal medicine; Psychiatry; Nursing","score_opus":0.0397346557057647,"score_gpt":0.4027323460979189,"score_spread":0.36299769039215424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804901132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971886,0.00041592,0.00012461527,0.00014097443,0.00002003577,0.000038263872,0.0002768671,0.000013264601,0.0017814669],"genre_scores_gemma":[0.999461,0.000056848694,0.00014045679,0.000034715,0.000012550646,0.00001757669,0.00017176234,0.0000012996027,0.00010392034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99884355,0.00039403394,0.00012999176,0.00010201759,0.0004175181,0.0001128573],"domain_scores_gemma":[0.9957151,0.0011904363,0.001877953,0.00012647467,0.00038465133,0.0007053552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014884874,0.00034287106,0.00040958583,0.000700393,0.00027640155,0.0006568181,0.00023155368,0.0004399895,0.0018612399],"category_scores_gemma":[0.0072820005,0.00010727518,0.00059340545,0.00052360643,0.00035049923,0.0005111831,0.0005169962,0.00059553504,0.00022851257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004118883,0.00014470863,0.99055827,0.0000557089,0.00013095507,0.000055608634,0.00027413116,0.00026331327,0.00017418207,0.000024617373,0.00036604892,0.0075406753],"study_design_scores_gemma":[0.0000278061,0.00043881978,0.998546,0.000010063433,0.000024607834,0.000105186795,0.00020945283,0.0004003517,0.000055215874,0.00004403755,0.00012838613,0.000010006139],"about_ca_topic_score_codex":0.0010139878,"about_ca_topic_score_gemma":0.0017201615,"teacher_disagreement_score":0.0018612399,"about_ca_system_score_codex":0.00045870518,"about_ca_system_score_gemma":0.00021636431,"threshold_uncertainty_score":0.007871985},"labels":[],"label_agreement":null},{"id":"W2808946203","doi":"10.1634/theoncologist.2017-0136","title":"Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"European Society for Medical Oncology","keywords":"Sarcoma; Oncology; Retrospective cohort study; Medicine; Overall survival; Internal medicine; Pathology","score_opus":0.028485064380589776,"score_gpt":0.32010100933809843,"score_spread":0.29161594495750864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808946203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99753124,0.0013725972,0.00009961696,0.000041531915,0.0000036229117,0.000013185976,0.0005848469,0.0000051055977,0.00034825888],"genre_scores_gemma":[0.998609,0.00036608047,0.00005349482,0.0000355358,0.0000140995935,0.0000111487825,0.00084220595,0.0000022998456,0.0000662444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946755,0.000118010896,0.000061002942,0.00013245287,0.00011887025,0.00010208921],"domain_scores_gemma":[0.9984719,0.00029390943,0.0007310386,0.000096904674,0.00019556213,0.00021068133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008541274,0.00042975607,0.0004624409,0.0016510495,0.00042513237,0.0005230062,0.00028986472,0.0004430408,0.0011964092],"category_scores_gemma":[0.0015726777,0.00027554433,0.00058914424,0.0012810548,0.00029208264,0.00029023914,0.00035510314,0.0002492373,0.0002526558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012290264,0.000013307353,0.9974132,0.000013594038,0.00007210619,0.0002507625,0.000056065488,0.000043593656,0.00012891465,0.000007983204,0.00014979969,0.0017277072],"study_design_scores_gemma":[0.000011525263,0.00012784348,0.9976375,0.000011119184,0.00004915277,0.0014136416,0.00013787537,0.00008465562,0.000043469558,0.000009310773,0.0004679778,0.000005931289],"about_ca_topic_score_codex":0.019599652,"about_ca_topic_score_gemma":0.015396395,"teacher_disagreement_score":0.019599652,"about_ca_system_score_codex":0.0008778981,"about_ca_system_score_gemma":0.0006512251,"threshold_uncertainty_score":0.038971126},"labels":[],"label_agreement":null},{"id":"W2888017273","doi":"10.1634/theoncologist.2018-0089","title":"Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Placebo; Lung cancer; Confidence interval; Gastroenterology; Population; Oncology; Cancer; Pathology","score_opus":0.015630401558201345,"score_gpt":0.35533037232813364,"score_spread":0.3396999707699323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888017273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99917895,0.00026856764,0.00012272855,0.000022496222,0.0000085583815,0.000029605435,0.00016935007,0.0000047891926,0.00019496461],"genre_scores_gemma":[0.99946755,0.000028770359,0.00011193845,0.00004059682,0.0000062698637,0.000012631891,0.00026317392,0.0000012472935,0.00006777158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990545,0.00036093104,0.00006909814,0.00027241363,0.00017977763,0.00006325015],"domain_scores_gemma":[0.998351,0.00047435184,0.00062597066,0.00012476029,0.0001717186,0.0002521506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021928542,0.00030223368,0.00048097072,0.00027691777,0.0002503989,0.00052063016,0.00025862435,0.0005216624,0.00060284865],"category_scores_gemma":[0.0025228073,0.00020860147,0.00043551243,0.00026039092,0.00030795732,0.00034640054,0.00021828285,0.00043990245,0.000166143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05683053,0.0011840261,0.90048534,0.000081136815,0.0009015412,0.0003085206,0.00011979517,0.00075123203,0.020811403,0.000075074066,0.0004378506,0.018013509],"study_design_scores_gemma":[0.0014658625,0.031326916,0.9574363,0.00000783699,0.00032100218,0.0008253659,0.000063364794,0.0018062583,0.005892928,0.00005614827,0.00078439596,0.000013486307],"about_ca_topic_score_codex":0.00031570377,"about_ca_topic_score_gemma":0.0004131097,"teacher_disagreement_score":0.0021928542,"about_ca_system_score_codex":0.00044973858,"about_ca_system_score_gemma":0.0002682119,"threshold_uncertainty_score":0.011597037},"labels":[],"label_agreement":null},{"id":"W2888939095","doi":"10.1634/theoncologist.2018-0103","title":"The Role of Primary Care Physicians in Childhood Cancer Survivorship Care: Multiperspective Interviews","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Council NSW; National Health and Medical Research Council; Kids' Cancer Project; Medical Research Council; McGill University; Kids Cancer Alliance; Cancer Institute NSW","keywords":"Survivorship curve; Cancer survivorship; Childhood cancer; Primary care; Cancer; Medicine; Family medicine; Nursing; Psychology","score_opus":0.027361689225604904,"score_gpt":0.3321610920573526,"score_spread":0.3047994028317477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888939095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936488,0.0012335026,0.0011350389,0.0012425579,0.000035742534,0.00026915644,0.00012411113,0.000008148745,0.0023027717],"genre_scores_gemma":[0.9961746,0.0009208899,0.0012223382,0.00065381697,0.000018781648,0.00021483144,0.000058713897,0.0000037218192,0.0007322483],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9913982,0.006798989,0.00031327872,0.00036086162,0.00045674297,0.000671808],"domain_scores_gemma":[0.9852565,0.0106096305,0.0017846805,0.0001840831,0.0011395792,0.0010254869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009768836,0.0003569936,0.00026206236,0.0009214757,0.003282072,0.002112438,0.0006756519,0.0009806774,0.0014257092],"category_scores_gemma":[0.013156451,0.00052063237,0.0002141996,0.00078781083,0.001255011,0.0017670627,0.0026872724,0.0012170526,0.00016095598],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010921223,0.00016531495,0.037282396,0.00031635168,0.000018768445,0.0026735472,0.94020694,0.000069957045,0.0019114579,0.00031357835,0.0013264953,0.015605999],"study_design_scores_gemma":[0.000018179844,0.00015818627,0.019070495,0.00023331576,0.000016172295,0.0011649507,0.9719977,0.00017554569,0.000702168,0.00023646868,0.006210126,0.000016780034],"about_ca_topic_score_codex":0.0046047876,"about_ca_topic_score_gemma":0.017562965,"teacher_disagreement_score":0.009768836,"about_ca_system_score_codex":0.0022627928,"about_ca_system_score_gemma":0.0027653896,"threshold_uncertainty_score":0.0516631},"labels":[],"label_agreement":null},{"id":"W2892457888","doi":"10.1634/theoncologist.2018-0081","title":"Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Venous thromboembolism; Retrospective cohort study; Sarcoma; Intensive care medicine; Internal medicine; Oncology; Pathology; Thrombosis","score_opus":0.01287297081359609,"score_gpt":0.2784377941867393,"score_spread":0.26556482337314324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892457888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979012,0.0012330691,0.00018750639,0.0000362121,0.000006333455,0.000022553733,0.00017705205,0.000003903175,0.00043221828],"genre_scores_gemma":[0.99927527,0.0003702221,0.00008072058,0.000037123446,0.000017026787,0.000010247898,0.00017134174,0.0000011664807,0.000036922615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988986,0.00029620552,0.00023735252,0.000245855,0.00022027183,0.00010168917],"domain_scores_gemma":[0.99711156,0.00087687664,0.0011742217,0.00022491584,0.00026120743,0.00035107994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087525416,0.00019671067,0.0004963029,0.0012888985,0.0003515735,0.0006508395,0.00028391395,0.00045808076,0.0015216853],"category_scores_gemma":[0.003087293,0.0003121429,0.00030860922,0.0017568351,0.0004386728,0.0006391591,0.00039459948,0.00037102486,0.00027325755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044820456,0.000032395747,0.9983088,0.000018525838,0.000023587589,0.0003792187,0.000039863833,0.000015440422,0.00008773796,0.00001483433,0.00004839153,0.0009863153],"study_design_scores_gemma":[0.000030409063,0.00058867387,0.9815439,0.000058553444,0.00011195724,0.015529056,0.0006408806,0.0002991583,0.00019979637,0.000059498387,0.000925183,0.000013004698],"about_ca_topic_score_codex":0.0012752764,"about_ca_topic_score_gemma":0.0011092933,"teacher_disagreement_score":0.0015216853,"about_ca_system_score_codex":0.00025108334,"about_ca_system_score_gemma":0.0004172855,"threshold_uncertainty_score":0.0050905347},"labels":[],"label_agreement":null},{"id":"W2892659800","doi":"10.1634/theoncologist.2017-0583","title":"Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Cancer pain; Logistic regression; Internal medicine; Anxiety; Prospective cohort study; Odds ratio; Cancer; Anesthesia; Physical therapy; Psychiatry","score_opus":0.02215017312329074,"score_gpt":0.3137666455798363,"score_spread":0.29161647245654554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892659800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99830246,0.0012559966,0.00005352279,0.000060128583,0.0000048185716,0.000011482298,0.00009069522,0.0000020261352,0.00021879582],"genre_scores_gemma":[0.9994838,0.0002838282,0.000037697944,0.000040674102,0.000013202491,0.000006247166,0.00009926839,5.465214e-7,0.000034589953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990415,0.00047180548,0.000101314545,0.00007629412,0.00020848117,0.00010044217],"domain_scores_gemma":[0.9952785,0.0019956848,0.0020275048,0.00009480217,0.000302896,0.0003005936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010441293,0.00012312096,0.00041285477,0.0002630542,0.00011049437,0.00032136208,0.00013833611,0.00023444653,0.00093002187],"category_scores_gemma":[0.006647376,0.00007334998,0.00035275306,0.00034338085,0.00013093563,0.00021014381,0.00017076642,0.00030390202,0.00014534095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013280502,0.00013546758,0.9863187,0.000107569234,0.00011207128,0.00015688653,0.00008473762,0.000120976554,0.0005497428,0.000007980716,0.00015699353,0.010920738],"study_design_scores_gemma":[0.000094306815,0.0019096958,0.9962231,0.00003823305,0.000063750536,0.000719338,0.00015097084,0.00036368315,0.00021255125,0.000014596575,0.00020432434,0.000005483465],"about_ca_topic_score_codex":0.00049373275,"about_ca_topic_score_gemma":0.00064372394,"teacher_disagreement_score":0.0010441293,"about_ca_system_score_codex":0.00017378508,"about_ca_system_score_gemma":0.00014413502,"threshold_uncertainty_score":0.005521953},"labels":[],"label_agreement":null},{"id":"W2892927588","doi":"10.1634/theoncologist.2018-0290","title":"A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; Central China Normal University","keywords":"Bevacizumab; Glioblastoma; Medicine; Oncology; Randomized controlled trial; Internal medicine; Chemotherapy; Cancer research","score_opus":0.09663458954944744,"score_gpt":0.42544317385276065,"score_spread":0.3288085843033132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892927588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98495704,0.005185101,0.00096262957,0.0009830899,0.000520052,0.005211075,0.00082421384,0.000162029,0.0011948581],"genre_scores_gemma":[0.9795997,0.0023024674,0.0034954492,0.0013653565,0.0006800443,0.009615708,0.0012177892,0.000036803223,0.0016867556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988373,0.0007016158,0.000067104425,0.00020684092,0.0000758049,0.000111220026],"domain_scores_gemma":[0.9982268,0.00046097857,0.0005226619,0.00015809483,0.000121432684,0.0005100726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024696095,0.0017300847,0.0024168808,0.0005570209,0.00044021165,0.00094360847,0.00088553823,0.001550991,0.0042305226],"category_scores_gemma":[0.0029998445,0.0006755289,0.001803399,0.00047489366,0.0011420355,0.0009003309,0.00048608647,0.0028271219,0.00073580036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9645599,0.006313551,0.0011911399,0.0005142506,0.0010634161,0.000045133824,0.000062771316,0.00029220857,0.0034007384,0.00012097678,0.00092474447,0.021511208],"study_design_scores_gemma":[0.9529296,0.044836026,0.00097222015,0.000018292527,0.00037059525,0.000036015193,0.000007722059,0.0002230974,0.00020358844,0.000063171145,0.0003327069,0.0000070102665],"about_ca_topic_score_codex":0.0012153699,"about_ca_topic_score_gemma":0.003353168,"teacher_disagreement_score":0.0042305226,"about_ca_system_score_codex":0.0009593415,"about_ca_system_score_gemma":0.0018540279,"threshold_uncertainty_score":0.014152527},"labels":[],"label_agreement":null},{"id":"W2893040167","doi":"10.1634/theoncologist.2018-0150","title":"Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; St. Joseph’s Healthcare Hamilton","funders":"Canadian Institutes of Health Research","keywords":"Osimertinib; Medicine; Cost effectiveness; Lung cancer; Quality-adjusted life year; Oncology; Epidermal growth factor receptor; Internal medicine; Erlotinib; Cancer; Risk analysis (engineering)","score_opus":0.02511183467803173,"score_gpt":0.38573719465674927,"score_spread":0.36062535997871753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893040167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782624,0.0057840548,0.0072124694,0.0016585111,0.0000545769,0.00033876565,0.0012718617,0.00003811615,0.0053792265],"genre_scores_gemma":[0.9985312,0.00056534953,0.00044799584,0.000083935956,0.000009390315,0.000048957263,0.00017893329,0.000002159554,0.00013198043],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980696,0.001296823,0.00007832935,0.00013695346,0.0001974706,0.0002208634],"domain_scores_gemma":[0.9947667,0.0038045447,0.0008756117,0.00009219251,0.000193042,0.00026785486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003996442,0.0007329772,0.0009205171,0.001025395,0.00031381293,0.0012291471,0.0009265212,0.000863977,0.0020299784],"category_scores_gemma":[0.010102506,0.0004094041,0.0023531334,0.00080750283,0.0005985002,0.0012969682,0.0007206725,0.0009890806,0.00006901527],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049005053,0.00036433857,0.037859343,0.0004606877,0.0013600719,0.00024344919,0.000054450004,0.9270885,0.00042525725,0.0033483016,0.00075173046,0.023143394],"study_design_scores_gemma":[0.001496328,0.0038456605,0.031590864,0.00037875283,0.0025365679,0.00045239177,0.00021238916,0.9475345,0.0011299995,0.009136099,0.0016171305,0.00006928595],"about_ca_topic_score_codex":0.017036946,"about_ca_topic_score_gemma":0.013732985,"teacher_disagreement_score":0.017036946,"about_ca_system_score_codex":0.008124109,"about_ca_system_score_gemma":0.0047745924,"threshold_uncertainty_score":0.05894482},"labels":[],"label_agreement":null},{"id":"W2894135776","doi":"10.1634/theoncologist.2018-0049","title":"A Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; University of Alberta","funders":"International Business Machines Corporation","keywords":"Medicine; Breast cancer; Blood pressure; Internal medicine; Chemotherapy; Aerobic exercise; Cancer; Cardiology; Heart rate; Radiation therapy; Tachycardia; Oncology","score_opus":0.07737978190183593,"score_gpt":0.35204089321258497,"score_spread":0.27466111131074905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894135776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99937797,0.00011550728,0.00012751068,0.000023179822,0.000004648817,0.000010085582,0.00016874081,0.000002875682,0.0001694237],"genre_scores_gemma":[0.99929583,0.000040638417,0.00009518682,0.00002151693,0.000005184759,0.000020011432,0.00030424015,0.0000013595941,0.00021601835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994869,0.00021769009,0.000025198064,0.00010501076,0.00006677233,0.00009844754],"domain_scores_gemma":[0.9986914,0.00020060195,0.0004070599,0.00017758556,0.00016648955,0.00035702178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012560119,0.00018640625,0.00020189735,0.00028260527,0.0004159765,0.00039132097,0.00020717076,0.00034110312,0.00080741785],"category_scores_gemma":[0.0019297373,0.00021292327,0.0002502471,0.000443557,0.00013182899,0.00027276974,0.0002733568,0.0006016418,0.00019160095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003823749,0.00024155491,0.99728596,0.0000031036025,0.00006961234,0.000019730192,0.000061125684,0.000026468217,0.00035527916,0.000011125521,0.00007205905,0.0014716442],"study_design_scores_gemma":[0.00000806289,0.00030081015,0.9993561,0.0000015781999,0.000015819587,0.00002954823,0.000041556974,0.00010658825,0.00004290256,0.000009016747,0.000086145505,0.0000018351278],"about_ca_topic_score_codex":0.00375409,"about_ca_topic_score_gemma":0.0043584737,"teacher_disagreement_score":0.00375409,"about_ca_system_score_codex":0.00021648005,"about_ca_system_score_gemma":0.00033906492,"threshold_uncertainty_score":0.0074644685},"labels":[],"label_agreement":null},{"id":"W2898225012","doi":"10.1634/theoncologist.2018-0244","title":"Symptom Expression in Patients with Advanced Cancer Admitted to an Acute Supportive/Palliative Care Unit With and Without Delirium","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Delirium; Medicine; Palliative care; Nausea; Depression (economics); Anxiety; Cancer; Intensive care medicine; Internal medicine; Psychiatry; Nursing","score_opus":0.020069111794756858,"score_gpt":0.34724141998073726,"score_spread":0.3271723081859804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898225012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997147,0.00012664274,0.000010790523,0.000016625812,0.0000037454897,0.0000036112992,0.00003096608,5.3670465e-7,0.000092452035],"genre_scores_gemma":[0.99977213,0.00005851071,0.000024551784,0.000014485192,0.0000059900676,0.0000044579533,0.000086384374,3.051203e-7,0.000033255554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99953544,0.0001156591,0.0000730279,0.000066146255,0.00010658969,0.0001030329],"domain_scores_gemma":[0.9983821,0.00021985412,0.0008185337,0.000032343913,0.0001648542,0.00038237302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038383258,0.00023938676,0.0004666009,0.00064754207,0.00047781947,0.0006357848,0.00021904132,0.00039517396,0.00090280746],"category_scores_gemma":[0.0029638684,0.00018694256,0.00037643776,0.0006502511,0.00034443475,0.0004530371,0.0006275288,0.00052737986,0.00015421904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014050001,0.00003363274,0.9985259,0.000010882192,0.000019848407,0.00015628712,0.00017094634,0.000016366765,0.00015439621,0.000004086964,0.000028787914,0.0007384333],"study_design_scores_gemma":[0.000007743073,0.00022082114,0.9987545,0.0000063907987,0.000011233639,0.00049355783,0.00036037166,0.000060687955,0.000024922016,0.000006525534,0.000049639788,0.0000035377554],"about_ca_topic_score_codex":0.0028964393,"about_ca_topic_score_gemma":0.0037455629,"teacher_disagreement_score":0.0028964393,"about_ca_system_score_codex":0.00040078524,"about_ca_system_score_gemma":0.0003874586,"threshold_uncertainty_score":0.00575912},"labels":[],"label_agreement":null},{"id":"W2898510460","doi":"10.1634/theoncologist.2018-0434","title":"Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; AstraZeneca","keywords":"Medicine; Blockade; Rash; Immune checkpoint; Multidisciplinary approach; Immune system; Oncology; Internal medicine; Pharmacology; Immunology; Receptor","score_opus":0.029282654386571155,"score_gpt":0.28493885733428814,"score_spread":0.25565620294771696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898510460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8585458,0.013856265,0.02696623,0.0551208,0.003382816,0.0013525491,0.00047497707,0.0005207382,0.039779775],"genre_scores_gemma":[0.97302395,0.0032586465,0.005991862,0.012066835,0.0019519172,0.0001232033,0.0001592617,0.0000797109,0.0033445288],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99897814,0.0001689652,0.00010785037,0.00018899993,0.00020663132,0.0003494512],"domain_scores_gemma":[0.99851054,0.0002807052,0.00028508055,0.00006063125,0.00013362106,0.00072937954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005267426,0.001600524,0.0010817724,0.0015215215,0.0042355596,0.001611125,0.0013002849,0.005425551,0.0025949923],"category_scores_gemma":[0.003126135,0.0008241589,0.0019382383,0.0015684897,0.0012071029,0.0024372276,0.0025300353,0.0060923104,0.0006019733],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022784918,0.00008385849,0.008779934,0.00004902196,0.000027137767,0.9854334,0.0004082124,0.00024558103,0.0005253106,0.0003609883,0.0017581207,0.00230567],"study_design_scores_gemma":[0.000014409001,0.0000635501,0.0029392526,0.000051395968,0.000016629385,0.99380326,0.0003703235,0.0005548227,0.00019604007,0.00038204898,0.0015887177,0.000019529785],"about_ca_topic_score_codex":0.0040057325,"about_ca_topic_score_gemma":0.005518431,"teacher_disagreement_score":0.005425551,"about_ca_system_score_codex":0.0019923085,"about_ca_system_score_gemma":0.0012701077,"threshold_uncertainty_score":0.014455318},"labels":[],"label_agreement":null},{"id":"W2898956824","doi":"10.1634/theoncologist.2018-0285","title":"Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Takotsubo Cardiomyopathy and Associated Phenomena","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Metastatic breast cancer; Cardiomyopathy; Oncology; Breast cancer; Internal medicine; Cancer; Cardiotoxicity; Heart failure; Chemotherapy","score_opus":0.03175590898587456,"score_gpt":0.3230132588942679,"score_spread":0.29125734990839336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898956824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993453,0.002062899,0.001043261,0.00041967328,0.00008786743,0.000038711016,0.000021547221,0.000030053412,0.0028430521],"genre_scores_gemma":[0.99891055,0.00043466478,0.00012152953,0.00013985456,0.00014588355,0.0000073239207,0.000014534524,0.000003637448,0.00022192122],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99981326,0.000035705743,0.00002624679,0.00003130145,0.000025184401,0.00006833528],"domain_scores_gemma":[0.99921715,0.00023051209,0.00031565945,0.000043621178,0.000029514607,0.00016346987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021692946,0.00053576496,0.00041446148,0.00055453356,0.0012015513,0.00046942488,0.0003289742,0.001159798,0.00074928504],"category_scores_gemma":[0.0013709767,0.00031489696,0.0004919354,0.00038082965,0.0005823902,0.00048730473,0.00048505247,0.0010745022,0.0002626885],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020955576,0.00006693801,0.05426895,0.00005664687,0.000024302204,0.93669295,0.00045452625,0.00012957252,0.0041974015,0.00014899945,0.00023737038,0.0035127888],"study_design_scores_gemma":[0.000044400524,0.00042424747,0.0638191,0.000055791414,0.000072089715,0.9307847,0.00034377846,0.00057874474,0.0022425693,0.00030275653,0.0013134957,0.000018357201],"about_ca_topic_score_codex":0.00060390326,"about_ca_topic_score_gemma":0.0010755012,"teacher_disagreement_score":0.0012015513,"about_ca_system_score_codex":0.00043923373,"about_ca_system_score_gemma":0.00031252345,"threshold_uncertainty_score":0.003186822},"labels":[],"label_agreement":null},{"id":"W2902282658","doi":"10.1634/theoncologist.2018-0501","title":"Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Systemic therapy; Internal medicine; Mesothelioma; Radiation therapy; Surgery; Pneumonectomy; Oncology; Retrospective cohort study; Chemotherapy; Lung; Cancer; Pathology","score_opus":0.03152490983254817,"score_gpt":0.2983456519169877,"score_spread":0.2668207420844395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902282658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990803,0.0005360039,0.00004294577,0.000022415903,0.0000024684466,0.000003407324,0.000052540483,0.0000032277037,0.0002567004],"genre_scores_gemma":[0.99969923,0.000081401704,0.000016872864,0.0000121727535,0.0000063333982,0.000003109072,0.00011701183,7.6599304e-7,0.0000631659],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998436,0.00003663263,0.000025972487,0.000033993438,0.00003568579,0.000024169827],"domain_scores_gemma":[0.999049,0.00018906848,0.000524463,0.000038868715,0.00004715699,0.00015138033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033356645,0.00011272771,0.00020672717,0.00020617286,0.00014698568,0.00023949407,0.00013024067,0.00017496341,0.0010042575],"category_scores_gemma":[0.0010585256,0.000053016855,0.00030237,0.00020339497,0.00016995324,0.0001710803,0.00019321518,0.0002677867,0.00012762511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045760846,0.00005670533,0.9910245,0.000029135865,0.000055275814,0.00032489785,0.000048434922,0.00012700344,0.0013175511,0.0000096757385,0.000082414,0.0064667077],"study_design_scores_gemma":[0.000014041067,0.0005862288,0.99726653,0.000006656769,0.00004965729,0.0013595404,0.00004284099,0.00013277946,0.00032082765,0.000013797369,0.00020489054,0.0000023628659],"about_ca_topic_score_codex":0.00027573563,"about_ca_topic_score_gemma":0.0005908571,"teacher_disagreement_score":0.0010042575,"about_ca_system_score_codex":0.00016038807,"about_ca_system_score_gemma":0.00014465657,"threshold_uncertainty_score":0.0033595562},"labels":[],"label_agreement":null},{"id":"W2907407844","doi":"10.1634/theoncologist.2018-0838","title":"An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Weill Cornell Medical College; AstraZeneca; Genentech; Eli Lilly and Company; Agios Pharmaceuticals; Exelixis","keywords":"Medicine; Hepatocellular carcinoma; Cohort; Pharmacokinetics; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Toxicity; Gastroenterology; Phases of clinical research; Small interfering RNA; RNA","score_opus":0.06688128871368598,"score_gpt":0.3491842452595836,"score_spread":0.2823029565458976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907407844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960062,0.00023917061,0.0008944852,0.00011433562,0.00003929987,0.0018277726,0.00037247158,0.00007373478,0.0004325774],"genre_scores_gemma":[0.98875296,0.00025491137,0.0033837021,0.0003772527,0.000087858665,0.0037354946,0.0015868502,0.000037633083,0.0017834011],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992773,0.00034552955,0.000037411475,0.00012544601,0.0000749544,0.0001393614],"domain_scores_gemma":[0.99903,0.00012031859,0.00016869976,0.0001967744,0.0000921029,0.00039206925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029792248,0.0013413638,0.0017267804,0.0003441079,0.00048996194,0.0005367842,0.0007739883,0.0008200934,0.0021920353],"category_scores_gemma":[0.0008324415,0.0004619206,0.00093293464,0.0003726649,0.00097017747,0.00079039263,0.00038806925,0.002900477,0.00069335895],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42851207,0.24213263,0.022903016,0.0003932009,0.00085626304,0.00036967194,0.0005785596,0.0030963474,0.20088634,0.00036508165,0.004082307,0.09582453],"study_design_scores_gemma":[0.13046303,0.83240205,0.019163776,0.000010911262,0.00025665716,0.0003300632,0.000058682406,0.0014512419,0.013577403,0.0001625058,0.0020934776,0.000030125067],"about_ca_topic_score_codex":0.00050647033,"about_ca_topic_score_gemma":0.0010256256,"teacher_disagreement_score":0.0029792248,"about_ca_system_score_codex":0.00083173346,"about_ca_system_score_gemma":0.0013309435,"threshold_uncertainty_score":0.015755832},"labels":[],"label_agreement":null},{"id":"W2914157560","doi":"10.1634/theoncologist.2018-0332","title":"Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Terminology; MEDLINE; Clinical trial; Family medicine; Internal medicine","score_opus":0.2136689892187956,"score_gpt":0.4715527577252995,"score_spread":0.25788376850650385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914157560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7873051,0.0016109933,0.057970844,0.0024590848,0.00042663183,0.1092253,0.012680129,0.00032552582,0.027996257],"genre_scores_gemma":[0.82374644,0.0006788128,0.064838536,0.0014564988,0.00024843455,0.10000256,0.005819726,0.00015338644,0.0030556775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.85658544,0.111666396,0.013200447,0.0035109697,0.01274219,0.0022945916],"domain_scores_gemma":[0.8596851,0.0726358,0.02720705,0.012393319,0.02614595,0.0019327747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13180152,0.0007268455,0.0015552872,0.0014574087,0.0010280003,0.0018133406,0.0008339825,0.00094018615,0.005891929],"category_scores_gemma":[0.15118821,0.00044577496,0.0019617148,0.0020687308,0.0010136415,0.001484263,0.0013849675,0.0014672294,0.0016836976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05564581,0.013455022,0.6650136,0.003219915,0.0018448768,0.000274481,0.0031271572,0.0025671045,0.0079403715,0.0031743315,0.017898068,0.2258392],"study_design_scores_gemma":[0.010114842,0.07285906,0.83645934,0.0005758708,0.0011399046,0.0006165482,0.0014971223,0.008329785,0.014136906,0.0015706602,0.052499454,0.0002005861],"about_ca_topic_score_codex":0.0014092723,"about_ca_topic_score_gemma":0.0033731242,"teacher_disagreement_score":0.13180152,"about_ca_system_score_codex":0.0010854789,"about_ca_system_score_gemma":0.004228653,"threshold_uncertainty_score":0.6970414},"labels":[],"label_agreement":null},{"id":"W2917215615","doi":"10.1634/theoncologist.2018-0570","title":"Minimally Invasive Cordotomy for Refractory Cancer Pain: A Randomized Controlled Trial","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Cordotomy; Medicine; Randomized controlled trial; Palliative care; Refractory (planetary science); Cancer pain; Anesthesia; Surgery; Cancer; Internal medicine; Nursing; Spinal cord","score_opus":0.025206983129715532,"score_gpt":0.32027818486016446,"score_spread":0.29507120173044893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917215615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8857176,0.0561573,0.0026433675,0.003908859,0.0034567206,0.042153142,0.0017291822,0.0002586988,0.0039751716],"genre_scores_gemma":[0.92959905,0.016794208,0.005219436,0.0031102702,0.0020171134,0.0398683,0.0007626651,0.000021174224,0.0026077325],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965849,0.0023091938,0.0003244832,0.00035878093,0.00022628396,0.00019637667],"domain_scores_gemma":[0.9964211,0.0018431302,0.00080082804,0.00019480193,0.00020482464,0.00053532823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044822423,0.0014520627,0.0039899256,0.000629269,0.000748454,0.0013213288,0.0012355596,0.0031339256,0.00970673],"category_scores_gemma":[0.007073842,0.00062471494,0.0025518723,0.00084775925,0.0016758029,0.0013502822,0.00064656924,0.0023020306,0.0006889993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9759981,0.0060621668,0.0004489496,0.0037862086,0.0018408723,0.000047466827,0.000044322875,0.00014434662,0.00050453586,0.00018565502,0.00052369974,0.0104137175],"study_design_scores_gemma":[0.98216313,0.016451688,0.00025636563,0.00013380656,0.00057246647,0.000012290702,0.00001051846,0.0000967231,0.00004940283,0.000068624635,0.00018019007,0.0000049397536],"about_ca_topic_score_codex":0.0012002736,"about_ca_topic_score_gemma":0.0022947504,"teacher_disagreement_score":0.00970673,"about_ca_system_score_codex":0.0009769328,"about_ca_system_score_gemma":0.0026884226,"threshold_uncertainty_score":0.032472253},"labels":[],"label_agreement":null},{"id":"W2919830364","doi":"10.1634/theoncologist.2018-0341","title":"Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Biosimilar; Filgrastim; Medicine; European union; Business; Neutropenia; Internal medicine; International trade; Chemotherapy","score_opus":0.018386966891525917,"score_gpt":0.2894433573541078,"score_spread":0.2710563904625819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919830364","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15114634,0.2599213,0.0046437792,0.13174258,0.0026579932,0.0007366692,0.002390789,0.00034366577,0.44641703],"genre_scores_gemma":[0.6480564,0.23615928,0.010155395,0.05826972,0.0009707176,0.00029109058,0.0033405176,0.0003687588,0.04238805],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98868865,0.0022368443,0.00061961624,0.0008312921,0.006067432,0.0015561865],"domain_scores_gemma":[0.9717458,0.0027814864,0.0017124348,0.00044178066,0.02002604,0.0032924386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017357113,0.00034322866,0.00029702391,0.0013511723,0.0036131009,0.003953781,0.0011352072,0.001638147,0.00449917],"category_scores_gemma":[0.020399647,0.00022320451,0.000618875,0.0032503786,0.0026300363,0.0014652649,0.0015818803,0.0024936087,0.0006274075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014194037,0.0006704222,0.043991663,0.0033733635,0.00017274066,0.0027961475,0.016540866,0.0027731971,0.008291513,0.029297346,0.28031301,0.61036044],"study_design_scores_gemma":[0.00008490168,0.00045241613,0.020024065,0.0018547486,0.00012401589,0.0016914442,0.005970914,0.00032994698,0.0040697656,0.0008950816,0.964401,0.00010172085],"about_ca_topic_score_codex":0.59221053,"about_ca_topic_score_gemma":0.6924345,"teacher_disagreement_score":0.40778947,"about_ca_system_score_codex":0.02414678,"about_ca_system_score_gemma":0.067413434,"threshold_uncertainty_score":0.82038206},"labels":[],"label_agreement":null},{"id":"W2920656486","doi":"10.1634/theoncologist.2018-0808","title":"Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"European Society for Medical Oncology; National Cancer Centre of Singapore; Princess Margaret Cancer Foundation","keywords":"Phase (matter); Family medicine; Medicine; Physics","score_opus":0.03733968357720229,"score_gpt":0.3652438090691786,"score_spread":0.3279041254919763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920656486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917883,0.0015152667,0.00046554115,0.0026220314,0.00004262472,0.00015218189,0.0005781302,0.000044124048,0.0027917612],"genre_scores_gemma":[0.9984479,0.00026316408,0.00024801274,0.0004831948,0.000055889384,0.00007272435,0.00020904733,0.00000811947,0.00021187491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99472886,0.0023061717,0.0005227243,0.0008479382,0.0009106354,0.000683713],"domain_scores_gemma":[0.9505972,0.012421331,0.027430328,0.00075950817,0.0016648031,0.00712681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005177509,0.00014433693,0.0002701995,0.00081527,0.00088089536,0.0012862931,0.0007201899,0.0007594509,0.004214647],"category_scores_gemma":[0.022398336,0.00019308111,0.0004007591,0.0014511083,0.000612369,0.0009412644,0.0009018488,0.0013569031,0.00038273202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005715883,0.00023895876,0.98744196,0.000043289463,0.000027362326,0.00021369217,0.00019271282,0.00011781298,0.00033144167,0.00010386207,0.0014796351,0.009237694],"study_design_scores_gemma":[0.00007563839,0.00074324216,0.9950629,0.000070916096,0.0000479997,0.0008155141,0.0005351612,0.0005358521,0.00039074576,0.00012383613,0.0015847572,0.000013405907],"about_ca_topic_score_codex":0.0038075314,"about_ca_topic_score_gemma":0.0056541977,"teacher_disagreement_score":0.005177509,"about_ca_system_score_codex":0.0019658455,"about_ca_system_score_gemma":0.0027127166,"threshold_uncertainty_score":0.027381659},"labels":[],"label_agreement":null},{"id":"W2921192143","doi":"10.1634/theoncologist.2018-0711","title":"What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Metastatic breast cancer; Oncology; Clinical decision making; Qualitative research; Internal medicine; Intensive care medicine; Cancer; Sociology","score_opus":0.043849595869289194,"score_gpt":0.43253152101234943,"score_spread":0.3886819251430602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921192143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605248,0.0014429424,0.009673194,0.014963309,0.00025908407,0.000572293,0.00044146852,0.00003742954,0.012085372],"genre_scores_gemma":[0.99020314,0.00089561054,0.003804784,0.0021025445,0.000036985093,0.0004601037,0.00013767707,0.000039430208,0.0023197418],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9677247,0.026930459,0.0006963272,0.0008699252,0.0014023308,0.002376324],"domain_scores_gemma":[0.949396,0.042890295,0.0017409393,0.0005691841,0.002615918,0.002787586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023026932,0.0006972891,0.00088262407,0.0018538709,0.010584902,0.005933547,0.0021793148,0.0024187819,0.0028518685],"category_scores_gemma":[0.03655146,0.0006802327,0.0006433048,0.002097681,0.0118387425,0.004752709,0.0053034066,0.004161171,0.0002978071],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040837058,0.000021943508,0.0009943143,0.0001163789,0.000004713858,0.00041881084,0.9931687,0.000050183993,0.00029241273,0.0017028373,0.00057045027,0.0026184279],"study_design_scores_gemma":[0.000006361884,0.000018253902,0.000340185,0.00013822035,0.0000032257929,0.00013328038,0.99210936,0.000100751924,0.0001505621,0.00071362377,0.0062752734,0.000010963434],"about_ca_topic_score_codex":0.009775776,"about_ca_topic_score_gemma":0.012684784,"teacher_disagreement_score":0.023026932,"about_ca_system_score_codex":0.008975291,"about_ca_system_score_gemma":0.009693872,"threshold_uncertainty_score":0.1217795},"labels":[],"label_agreement":null},{"id":"W2929364833","doi":"10.1634/theoncologist.2018-0613","title":"Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Health and Medical Research Council; Medical Research Council","keywords":"Medicine; Hazard ratio; Confidence interval; Oncology; Internal medicine; Proportional hazards model; Survival analysis; Cancer","score_opus":0.027073408286832062,"score_gpt":0.32788491364721906,"score_spread":0.300811505360387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929364833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674402,0.0022641057,0.024248173,0.0014779137,0.00007247131,0.00012726658,0.00089543144,0.00006661704,0.003407949],"genre_scores_gemma":[0.9959033,0.00012128112,0.0033723773,0.0001172332,0.00002578373,0.0000329169,0.00034397654,0.000005711814,0.00007747667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9534705,0.03825916,0.0022526323,0.0027060362,0.002604377,0.0007072867],"domain_scores_gemma":[0.7025727,0.25591135,0.025319608,0.009219527,0.005647201,0.0013295795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06625282,0.0004966725,0.0005994199,0.0013267936,0.0005305113,0.0019865145,0.00069016515,0.0014510212,0.0010152154],"category_scores_gemma":[0.21750258,0.00042388597,0.0011617545,0.00076586317,0.0008669256,0.0013214194,0.001588945,0.0011347126,0.0002748781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018488037,0.0000612541,0.92004895,0.00020653376,0.0011682543,0.00013780464,0.0008512112,0.049243506,0.00024460012,0.0014953683,0.0010100881,0.023683602],"study_design_scores_gemma":[0.00052597834,0.0012976804,0.6459029,0.00092831615,0.0012068963,0.0014415723,0.0023064858,0.31369203,0.0023800523,0.023738207,0.006331067,0.0002489359],"about_ca_topic_score_codex":0.003170027,"about_ca_topic_score_gemma":0.0032656514,"teacher_disagreement_score":0.06625282,"about_ca_system_score_codex":0.0014835537,"about_ca_system_score_gemma":0.0010542887,"threshold_uncertainty_score":0.35038257},"labels":[],"label_agreement":null},{"id":"W2930221971","doi":"10.1634/theoncologist.2019-0039","title":"Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Guideline; Systemic therapy; Oncology; Internal medicine; Chemotherapy; Targeted therapy; Cancer; Pathology","score_opus":0.02766453742285076,"score_gpt":0.3211048916340345,"score_spread":0.29344035421118375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930221971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95640785,0.012786834,0.0008329602,0.011142689,0.00009785039,0.000032194723,0.009981182,0.000030089363,0.00868844],"genre_scores_gemma":[0.99245995,0.0036366412,0.0004412066,0.00085285614,0.00008251023,0.000015800486,0.0020828259,0.000008161428,0.00042015035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864894,0.00039789797,0.00024253549,0.00026795611,0.00029948965,0.0001431915],"domain_scores_gemma":[0.98992974,0.0017790969,0.006372872,0.00020019108,0.0011291467,0.0005889989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001359878,0.000078601646,0.00017901551,0.0010547165,0.00018299751,0.0011315801,0.00040839295,0.0004212397,0.0018060508],"category_scores_gemma":[0.008430985,0.00011469011,0.0003147799,0.0026348336,0.00020908275,0.00094922935,0.00046702498,0.00070394797,0.00023186672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007334622,0.00006904435,0.9804857,0.000095079864,0.00008849074,0.000060112354,0.00018369943,0.00027918754,0.0001004827,0.0005241343,0.0027868175,0.015253914],"study_design_scores_gemma":[0.000009490712,0.000057691886,0.9920081,0.00015990563,0.00002976282,0.00017676392,0.0006364391,0.001011288,0.00011881241,0.00022911193,0.0055531138,0.000009441044],"about_ca_topic_score_codex":0.01947459,"about_ca_topic_score_gemma":0.03170708,"teacher_disagreement_score":0.01947459,"about_ca_system_score_codex":0.0012203035,"about_ca_system_score_gemma":0.0010605565,"threshold_uncertainty_score":0.038722456},"labels":[],"label_agreement":null},{"id":"W2934360602","doi":"10.1634/theoncologist.2018-0544","title":"The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of British Columbia; Sunnybrook Health Science Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neurocognitive; Oncology; Brain metastasis; Internal medicine; Psychiatry; Cancer; Cognition; Metastasis","score_opus":0.059878475264912,"score_gpt":0.3970551460321346,"score_spread":0.3371766707672226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2934360602","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32197002,0.6628219,0.0014457124,0.004119064,0.00027508943,0.0005140575,0.0054822345,0.00001992784,0.0033519964],"genre_scores_gemma":[0.9447786,0.05205943,0.00096899277,0.0005526617,0.00018486471,0.00017792716,0.0011209917,0.000005492367,0.00015098395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9784596,0.014731933,0.0030287723,0.0008955989,0.002510032,0.00037399473],"domain_scores_gemma":[0.8821918,0.088547364,0.022498654,0.0016099861,0.004174933,0.0009772014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025274113,0.0008188854,0.0020799728,0.003889454,0.0002728808,0.0029111996,0.0014319979,0.0012596018,0.0026909693],"category_scores_gemma":[0.062201347,0.0004706826,0.010171343,0.0040909206,0.0008965826,0.001115589,0.0011353721,0.001557421,0.00024072823],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015142844,0.00060584344,0.5180535,0.069436744,0.28835252,0.0002596908,0.00017054816,0.0035726237,0.00025858884,0.001151887,0.0018968727,0.101098396],"study_design_scores_gemma":[0.0047403,0.0077978675,0.59538203,0.036162093,0.33733502,0.00083814067,0.00074061827,0.005922839,0.0004738614,0.0021527656,0.0082619535,0.00019260887],"about_ca_topic_score_codex":0.003826039,"about_ca_topic_score_gemma":0.006370479,"teacher_disagreement_score":0.025274113,"about_ca_system_score_codex":0.0018795825,"about_ca_system_score_gemma":0.0016180922,"threshold_uncertainty_score":0.1336639},"labels":[],"label_agreement":null},{"id":"W2935205376","doi":"10.1634/theoncologist.2018-0621","title":"Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Docetaxel; Pantoprazole; Autophagy; Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Pharmacology; Cancer research; Chemistry; Apoptosis","score_opus":0.024193007141688032,"score_gpt":0.3156571043337689,"score_spread":0.2914640971920809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935205376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963683,0.0013564711,0.00015852191,0.00022312404,0.000044133943,0.0006695317,0.00028040522,0.000058995032,0.0008405201],"genre_scores_gemma":[0.99507314,0.0012412852,0.00079979387,0.00024273488,0.000056553523,0.0006256332,0.0007261824,0.000010342656,0.0012243335],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997814,0.00009265399,0.000013813997,0.000036341484,0.000022326034,0.000053508156],"domain_scores_gemma":[0.9997409,0.000032402273,0.000058872305,0.000018767936,0.000016799322,0.00013223347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082913286,0.00087767484,0.0007680038,0.0003817469,0.00031005425,0.0007480376,0.00058602315,0.00072865636,0.0023571206],"category_scores_gemma":[0.0004365597,0.00043451763,0.00083695236,0.00040681657,0.0007700091,0.0005198836,0.00027644084,0.0014865686,0.00036892184],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60252416,0.05873339,0.012122413,0.002016957,0.0021802068,0.00043879705,0.00049338053,0.0059436285,0.07076337,0.0008114318,0.005738468,0.23823382],"study_design_scores_gemma":[0.46508712,0.49353996,0.024691997,0.000087964625,0.000826545,0.0006839561,0.00009312107,0.0023980127,0.0076060095,0.00023413783,0.0046991683,0.00005199672],"about_ca_topic_score_codex":0.0011847471,"about_ca_topic_score_gemma":0.004481348,"teacher_disagreement_score":0.0023571206,"about_ca_system_score_codex":0.0007894728,"about_ca_system_score_gemma":0.0014410465,"threshold_uncertainty_score":0.0078853965},"labels":[],"label_agreement":null},{"id":"W2935807963","doi":"10.1634/theoncologist.2018-0695","title":"Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Lung cancer; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Population; ERBB3; Cancer; Confidence interval","score_opus":0.011574831623580938,"score_gpt":0.32075461059253885,"score_spread":0.30917977896895793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935807963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874822,0.0025546197,0.00092977786,0.0007589697,0.00075573823,0.00435217,0.0011847536,0.00012769755,0.0018540653],"genre_scores_gemma":[0.9883956,0.0010958108,0.0012362321,0.00089063135,0.0005287478,0.004114683,0.0014878657,0.000022493477,0.002227801],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99913496,0.00050562125,0.000043144057,0.00014444801,0.00005545785,0.00011635739],"domain_scores_gemma":[0.99899334,0.00021736896,0.000218415,0.00009323369,0.00007938354,0.0003982332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021354163,0.0018848625,0.0031830373,0.00043076032,0.00044686132,0.0013670642,0.000972473,0.0012833636,0.004910995],"category_scores_gemma":[0.0015728635,0.00081228575,0.0017404029,0.0004264196,0.001234758,0.0011672655,0.0004532447,0.0030546307,0.0009855818],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9789321,0.007443739,0.00079212576,0.00019451273,0.0006071722,0.00003892407,0.00003091411,0.0003805541,0.0027340448,0.00007796096,0.0006116029,0.008156412],"study_design_scores_gemma":[0.92664504,0.07032034,0.0013926966,0.000009257486,0.0002474302,0.000032463893,0.000013999907,0.00051927427,0.00033114987,0.00010781629,0.000370854,0.0000095591795],"about_ca_topic_score_codex":0.0007589145,"about_ca_topic_score_gemma":0.0018814112,"teacher_disagreement_score":0.004910995,"about_ca_system_score_codex":0.001016124,"about_ca_system_score_gemma":0.0014961825,"threshold_uncertainty_score":0.016428947},"labels":[],"label_agreement":null},{"id":"W2947039620","doi":"10.1634/theoncologist.2019-0043","title":"The Development of an International Oncofertility Competency Framework: A Model to Increase Oncofertility Implementation","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Oncofertility; Medicine; Fertility preservation; Psychosocial; Delphi method; Family medicine; Referral; Survivorship curve; Service (business); Documentation; Nursing; Fertility; Cancer; Internal medicine; Population","score_opus":0.05400106707867692,"score_gpt":0.4023251791756242,"score_spread":0.3483241120969473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947039620","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28940603,0.0025784266,0.40299663,0.10161481,0.00082803745,0.015576649,0.0003662894,0.0009502042,0.18568291],"genre_scores_gemma":[0.4612266,0.00084435573,0.52816474,0.0018346214,0.00003388083,0.0037398678,0.00028628943,0.000046595964,0.0038230957],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9842259,0.011259738,0.0007307831,0.0006432711,0.001704371,0.0014358396],"domain_scores_gemma":[0.98464453,0.005737446,0.0012036458,0.00073686097,0.0037110632,0.003966533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025941858,0.0009224645,0.0003330958,0.004003591,0.0043023406,0.004694191,0.0028159663,0.0022671558,0.0026916876],"category_scores_gemma":[0.021575525,0.00033481888,0.0010575126,0.0015817214,0.0046787015,0.0065339487,0.009555635,0.0030626042,0.0005105452],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001267886,0.0022668405,0.04003654,0.0017941678,0.00006612922,0.0008412207,0.10871927,0.0070596957,0.0022537324,0.22758566,0.02114728,0.58810276],"study_design_scores_gemma":[0.00036533154,0.0024077531,0.050895378,0.012333245,0.000219138,0.002196548,0.32116723,0.07679696,0.0063675838,0.20519026,0.32164133,0.00041919478],"about_ca_topic_score_codex":0.018212046,"about_ca_topic_score_gemma":0.022991093,"teacher_disagreement_score":0.025941858,"about_ca_system_score_codex":0.012560725,"about_ca_system_score_gemma":0.068171024,"threshold_uncertainty_score":0.13719535},"labels":[],"label_agreement":null},{"id":"W2947290320","doi":"10.1634/theoncologist.2019-0027","title":"Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; University Health Network; Royal Victoria Hospital; University of Alberta; Royal Victoria Regional Health Centre; Juravinski Cancer Centre; Montreal General Hospital; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Pembrolizumab; Medicine; Atezolizumab; Oncology; Lung cancer; Internal medicine; Nivolumab; Bevacizumab; Pemetrexed; Anaplastic lymphoma kinase; Chemotherapy; Ipilimumab; Cancer; Immunotherapy; Cisplatin","score_opus":0.029609471225638256,"score_gpt":0.3227680076414282,"score_spread":0.2931585364157899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947290320","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028028332,0.9958182,0.00007256409,0.00021277835,0.00009243212,0.00014706094,0.00021129753,0.000007570204,0.0006353197],"genre_scores_gemma":[0.054813504,0.9424403,0.0006017394,0.00095586607,0.00023146454,0.00029238634,0.00039272007,0.000005938487,0.00026609085],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977744,0.0009977795,0.00065620424,0.00017813935,0.00033993414,0.000053516524],"domain_scores_gemma":[0.99238825,0.0051550693,0.0018866488,0.00007028165,0.00041074835,0.000089053516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002837176,0.0006232641,0.003131077,0.0019215086,0.00021271672,0.0013025457,0.00060799945,0.00083984755,0.005471807],"category_scores_gemma":[0.0096303765,0.00026317508,0.004696433,0.0025139027,0.000307536,0.0010183792,0.00040281418,0.00083453424,0.00027151473],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032400382,0.000099434576,0.0018818027,0.7795986,0.013637748,0.00011918719,0.000088379595,0.00026406205,0.00061069045,0.00028631507,0.0026063307,0.19756745],"study_design_scores_gemma":[0.0097391885,0.0057936357,0.019291263,0.6723531,0.21027955,0.0014271676,0.00034631853,0.00046530683,0.0014268634,0.0013902365,0.077410035,0.00007738439],"about_ca_topic_score_codex":0.001253787,"about_ca_topic_score_gemma":0.0043384274,"teacher_disagreement_score":0.005471807,"about_ca_system_score_codex":0.0009737018,"about_ca_system_score_gemma":0.0019137884,"threshold_uncertainty_score":0.018305004},"labels":[],"label_agreement":null},{"id":"W2948431030","doi":"10.1634/theoncologist.2019-0304","title":"Why “Reply All” Can Push All the Wrong Buttons","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Etiquette; Medicine; Advice (programming); Internet privacy; Law; Computer science","score_opus":0.15568255928481467,"score_gpt":0.43558072621781196,"score_spread":0.2798981669329973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948431030","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012605771,0.0032070384,0.00026239656,0.9644262,0.027503232,0.0000051542534,0.000015460997,0.000031972384,0.0044224183],"genre_scores_gemma":[0.005915732,0.004560281,0.00042732945,0.9513439,0.028250815,0.000026208225,0.000018111436,0.0001141889,0.009343442],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9653959,0.019758614,0.0024152002,0.0025340053,0.0077924374,0.0021038128],"domain_scores_gemma":[0.86200434,0.10833808,0.00343625,0.0017671849,0.021988362,0.002465805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019938843,0.0010212613,0.0011256658,0.001302003,0.0071609165,0.007192112,0.00352302,0.03647676,0.018420113],"category_scores_gemma":[0.12572257,0.00080176035,0.002186705,0.00097353396,0.017075343,0.0126376515,0.0029531673,0.041456684,0.011460971],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046854362,0.000012319282,0.00012366242,0.00027558333,0.000022737422,0.00018579463,0.0016968457,0.00004630893,0.00013524029,0.02955926,0.9587798,0.009115622],"study_design_scores_gemma":[0.0000276801,0.00002499592,0.0002712747,0.001049917,0.000023440167,0.00020739238,0.002068495,0.00009631148,0.0002601147,0.0119504165,0.98396987,0.000050102542],"about_ca_topic_score_codex":0.017850485,"about_ca_topic_score_gemma":0.022809964,"teacher_disagreement_score":0.03647676,"about_ca_system_score_codex":0.0065397364,"about_ca_system_score_gemma":0.00864741,"threshold_uncertainty_score":0.10544795},"labels":[],"label_agreement":null},{"id":"W2950856878","doi":"10.1634/theoncologist.2019-0019","title":"Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary; University of Alberta","funders":"Genentech; Pfizer","keywords":"Letrozole; Palbociclib; Medicine; Oncology; Internal medicine; Postmenopausal women; Randomized controlled trial; Breast cancer; Cancer; Gynecology; Tamoxifen; Metastatic breast cancer","score_opus":0.006386544342530553,"score_gpt":0.2729757012801935,"score_spread":0.26658915693766294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950856878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602706,0.024240488,0.0011393846,0.0018063314,0.00043090258,0.00397395,0.00263492,0.00019144997,0.0053119725],"genre_scores_gemma":[0.9853219,0.0052436125,0.0008664511,0.00140759,0.00040136478,0.003042973,0.0016998623,0.00002356011,0.0019926769],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998934,0.00075056124,0.00005428851,0.00010404261,0.000094853545,0.00006223431],"domain_scores_gemma":[0.99922514,0.0002534795,0.00025408165,0.000050947445,0.000064239146,0.00015217163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00234526,0.00088510255,0.001456029,0.00036813997,0.00023052056,0.0009441709,0.00068507466,0.0010274701,0.0044606086],"category_scores_gemma":[0.0025284428,0.00037401053,0.001563709,0.0003987063,0.0005145484,0.00066848856,0.00038442563,0.0020722128,0.00043983117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9454441,0.002981177,0.002346808,0.001385669,0.0029499978,0.00008186959,0.00004196246,0.00086723984,0.003980536,0.00023877804,0.0023611304,0.037320808],"study_design_scores_gemma":[0.93486625,0.054649323,0.0043125222,0.00010182794,0.0019306585,0.000111399255,0.000027713815,0.0007292224,0.0007452311,0.0003389392,0.0021724568,0.000014426855],"about_ca_topic_score_codex":0.00059383013,"about_ca_topic_score_gemma":0.0016328294,"teacher_disagreement_score":0.0044606086,"about_ca_system_score_codex":0.00068398914,"about_ca_system_score_gemma":0.0010896729,"threshold_uncertainty_score":0.014922202},"labels":[],"label_agreement":null},{"id":"W2954003036","doi":"10.1634/theoncologist.2019-0112","title":"Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Manitoba; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Neuroendocrine tumors; Prospective cohort study; Population; Oncology; Internal medicine; Environmental health","score_opus":0.017433329605233833,"score_gpt":0.33207714291055607,"score_spread":0.3146438133053222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954003036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998917,0.00014181962,0.00009175146,0.000032648168,0.0000029262544,0.0000064952137,0.00069707906,0.000002684345,0.00010764083],"genre_scores_gemma":[0.99913436,0.00005004752,0.00005841241,0.000010017039,0.0000030788235,0.000008551432,0.00071389443,0.0000012035273,0.000020439826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987973,0.0003942423,0.00016205954,0.0003050847,0.00019705002,0.00014420584],"domain_scores_gemma":[0.99623007,0.00066501874,0.0021801777,0.00029610496,0.0002533128,0.00037527218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019469592,0.00023033074,0.00036170712,0.0010024298,0.00032762866,0.00071876333,0.00045864898,0.00034051228,0.00062185526],"category_scores_gemma":[0.0041870186,0.0002456937,0.00071564154,0.0017453982,0.0003494659,0.0005965201,0.00084647984,0.0006219554,0.000117411386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023570134,0.000006406938,0.9996271,0.000003131952,0.000036817135,0.000010567971,0.000021214306,0.000030698855,0.00002334513,0.0000054872776,0.000025086449,0.00018639262],"study_design_scores_gemma":[0.0000027551387,0.000037309943,0.999534,0.000003300436,0.000017712326,0.00006995214,0.00009654684,0.00016497626,0.000012926425,0.000012385793,0.00004562982,0.0000025342003],"about_ca_topic_score_codex":0.0063643153,"about_ca_topic_score_gemma":0.008134872,"teacher_disagreement_score":0.0063643153,"about_ca_system_score_codex":0.00045346553,"about_ca_system_score_gemma":0.0005093344,"threshold_uncertainty_score":0.012654543},"labels":[],"label_agreement":null},{"id":"W2958239779","doi":"10.1634/theoncologist.2019-0263","title":"Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University; Impact","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Oncology; Adjuvant; Breast cancer; Internal medicine; Randomized controlled trial; Asymptomatic; Clinical trial; Intensive care medicine; Cancer; Chemotherapy","score_opus":0.020489147009520346,"score_gpt":0.2785177104400517,"score_spread":0.2580285634305313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958239779","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028299612,0.14094612,0.0016735933,0.83849674,0.012427493,0.00008422874,0.000081617996,0.000031335076,0.0034289327],"genre_scores_gemma":[0.058092497,0.19364472,0.0067490367,0.64400935,0.09257493,0.00030765214,0.00011454568,0.000068223235,0.0044390853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99272984,0.0041248337,0.00093962735,0.00050562504,0.0014106821,0.0002893697],"domain_scores_gemma":[0.97417766,0.018871574,0.0020920117,0.00047111223,0.00316207,0.0012256503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015598614,0.00058278,0.002328129,0.00066254905,0.00079144933,0.0034882296,0.0016346041,0.0075954893,0.0038338508],"category_scores_gemma":[0.051414315,0.00022762427,0.0011238889,0.0005599724,0.002844408,0.0064743473,0.001366304,0.012681906,0.0011688059],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038170728,0.0004694012,0.0027582676,0.005370583,0.0012127261,0.00051149906,0.00046632654,0.0010823666,0.0024211295,0.041737866,0.28071404,0.6594387],"study_design_scores_gemma":[0.0043040705,0.0024626425,0.0043757893,0.020774541,0.002118165,0.00091367814,0.0009736834,0.0016838836,0.0015718859,0.1272443,0.83338106,0.00019626251],"about_ca_topic_score_codex":0.0011434986,"about_ca_topic_score_gemma":0.0038551092,"teacher_disagreement_score":0.015598614,"about_ca_system_score_codex":0.0022212341,"about_ca_system_score_gemma":0.004689947,"threshold_uncertainty_score":0.08249432},"labels":[],"label_agreement":null},{"id":"W2961237381","doi":"10.1634/theoncologist.2019-0149","title":"Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Manitoba","funders":"Engineering and Physical Sciences Research Council; Medical Research Council; Versus Arthritis","keywords":"Medicine; Breast cancer; Hazard ratio; Population; Internal medicine; Osteoporosis; Aromatase inhibitor; Cohort; Cohort study; Body mass index; Cancer; Gynecology; Confidence interval; Aromatase","score_opus":0.01965315509597552,"score_gpt":0.3419158688717647,"score_spread":0.3222627137757892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961237381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964598,0.00035189427,0.0001765557,0.000065875276,0.000012251749,0.000037318056,0.0024189665,0.0000088265715,0.0004685753],"genre_scores_gemma":[0.99773175,0.00028191457,0.0002164024,0.000063514584,0.00001875655,0.000046388734,0.0014663978,0.0000042527818,0.00017072241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989988,0.00025738173,0.00013232132,0.000297507,0.00019198626,0.00012201712],"domain_scores_gemma":[0.9981723,0.00022187145,0.00076812523,0.00033891742,0.00026171733,0.00023720098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012796414,0.00038002126,0.00063095265,0.0011053403,0.0006241329,0.0008822314,0.0006806636,0.0006118151,0.001387489],"category_scores_gemma":[0.0028434112,0.00063869817,0.0009600564,0.0023034338,0.0002520413,0.00059983105,0.00060321245,0.0008829386,0.0004014177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115079034,0.000055010485,0.9987073,0.000010207934,0.00017290375,0.000046715075,0.000041462445,0.000022854518,0.00008969504,0.000011570436,0.00017603625,0.0005512248],"study_design_scores_gemma":[0.000045717767,0.00011747919,0.9986099,0.000013117822,0.00020571887,0.00026176815,0.0001700592,0.00022745087,0.000043497155,0.000020236239,0.00027788646,0.0000070948945],"about_ca_topic_score_codex":0.017383026,"about_ca_topic_score_gemma":0.020943977,"teacher_disagreement_score":0.017383026,"about_ca_system_score_codex":0.00035151347,"about_ca_system_score_gemma":0.0006333807,"threshold_uncertainty_score":0.03456372},"labels":[],"label_agreement":null},{"id":"W2963339930","doi":"10.1634/theoncologist.2019-0272","title":"Chemotherapy Toxicity in <i>BRCA</i> Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Medicine; Neutropenia; BRCA mutation; Chemotherapy; Internal medicine; Germline mutation; Oncology; Ovarian cancer; Absolute neutrophil count; Mitoxantrone; Febrile neutropenia; Toxicity; Germline; Mutation; Cancer; Gastroenterology; Genetics","score_opus":0.02314792721266745,"score_gpt":0.30981821872294474,"score_spread":0.2866702915102773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963339930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997292,0.000102789534,0.0000130048165,0.000007620642,0.0000013005628,0.0000043446503,0.000041041825,6.604346e-7,0.00010008776],"genre_scores_gemma":[0.99981314,0.00004812556,0.000018520943,0.000011352287,0.000003384721,0.0000028311972,0.000058797046,4.630896e-7,0.00004336055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99980825,0.000037172944,0.000025563068,0.000051123574,0.000033100787,0.000044815526],"domain_scores_gemma":[0.9993431,0.00011403051,0.00038335408,0.000020959955,0.000040625888,0.000097894896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000306534,0.00015593535,0.00030324387,0.0005277641,0.0003512832,0.00037908342,0.00012274199,0.00022909897,0.0009710066],"category_scores_gemma":[0.0013663736,0.00014697152,0.0003264557,0.00046894542,0.0001653452,0.00025307143,0.00022118218,0.00024569326,0.00009289384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021037525,0.000022067066,0.997806,0.0000058178716,0.000016273996,0.00028024268,0.000033718865,0.000020135605,0.00029945525,0.0000057690245,0.00003374946,0.0012664258],"study_design_scores_gemma":[0.000013433289,0.0004666423,0.99698776,0.000007763587,0.000039768354,0.0018799364,0.00013397139,0.00013479969,0.00016805364,0.000018646806,0.00014584498,0.000003432324],"about_ca_topic_score_codex":0.0024008069,"about_ca_topic_score_gemma":0.0023500982,"teacher_disagreement_score":0.0024008069,"about_ca_system_score_codex":0.00037096327,"about_ca_system_score_gemma":0.0002660963,"threshold_uncertainty_score":0.0047736764},"labels":[],"label_agreement":null},{"id":"W2965982329","doi":"10.1634/theoncologist.2019-0261","title":"Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Centers for Disease Control and Prevention; National Comprehensive Cancer Network; American Association for Cancer Research; Bristol-Myers Squibb; American Society of Clinical Oncology; American College of Radiology; U.S. Food and Drug Administration; Memorial Sloan-Kettering Cancer Center; Flatiron Health; Oncology Nursing Society; Merck; Helsinn Therapeutics; Pfizer; Cancer Research Society; American Cancer Society; Livestrong Foundation","keywords":"Medicine; Cancer; Patient care; Medical physics; Pathology; Intensive care medicine; Nursing; Internal medicine","score_opus":0.06185223611591327,"score_gpt":0.31472269836428424,"score_spread":0.25287046224837095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965982329","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002124622,0.009282994,0.0019657188,0.9758007,0.0013104422,0.00001994634,0.00006367677,0.000021564296,0.009410422],"genre_scores_gemma":[0.5523014,0.102680095,0.013207643,0.29443106,0.025008498,0.000296671,0.00044900193,0.00014516439,0.011480394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9850199,0.010348408,0.00047357526,0.00052266056,0.0020617682,0.0015736638],"domain_scores_gemma":[0.905158,0.06368786,0.0077511207,0.0014729248,0.0063129906,0.015617146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023669468,0.000306534,0.0004993594,0.001263122,0.0028257926,0.010455209,0.0015522232,0.006924059,0.028253116],"category_scores_gemma":[0.08650926,0.00042113167,0.000585456,0.0017428551,0.0039118626,0.008563702,0.008283944,0.008925372,0.0012691161],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001570812,0.00018908293,0.020777628,0.0019364179,0.00009046094,0.00060640555,0.0019322523,0.0030220554,0.0003406948,0.1892666,0.52864134,0.25304005],"study_design_scores_gemma":[0.00012665155,0.00027246104,0.0323536,0.005614814,0.00008557136,0.0015536989,0.013980268,0.0041901614,0.0005620359,0.25796255,0.6831239,0.0001742896],"about_ca_topic_score_codex":0.011983304,"about_ca_topic_score_gemma":0.020363336,"teacher_disagreement_score":0.028253116,"about_ca_system_score_codex":0.01066215,"about_ca_system_score_gemma":0.023295851,"threshold_uncertainty_score":0.12517762},"labels":[],"label_agreement":null},{"id":"W2967092667","doi":"10.1634/theoncologist.2018-0830","title":"Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre; Public Health Ontario; University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"University of Toronto","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Family medicine; Feeling; Adverse effect; Logistic regression; Cancer; Patient-reported outcome; Odds ratio; Internal medicine; Quality of life (healthcare); Nursing","score_opus":0.11625246028930719,"score_gpt":0.4370898867345482,"score_spread":0.320837426445241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967092667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987143,0.00017714512,0.000081485545,0.00020367045,0.0000038106903,0.00003886203,0.0000869177,0.0000048066313,0.0006890615],"genre_scores_gemma":[0.9992669,0.00014683242,0.00014293713,0.00014213826,0.000008529653,0.0000406312,0.00008305357,0.0000026138562,0.0001662952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960114,0.0022574037,0.00047476968,0.00026897943,0.0007146409,0.00027280545],"domain_scores_gemma":[0.98547494,0.0047728424,0.006126826,0.0003740335,0.0016602045,0.001591181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035718053,0.00019017002,0.00034347875,0.0005052699,0.00049594656,0.0010492961,0.0003498654,0.00037251392,0.0018204916],"category_scores_gemma":[0.014601222,0.00019912749,0.00027848966,0.0006512468,0.00045366914,0.00058540044,0.0010537117,0.00050429534,0.00025300292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003781543,0.00017871922,0.9791559,0.00013998138,0.00004293599,0.00041147563,0.004561398,0.000095954245,0.00088939356,0.0000251682,0.0009873332,0.01313359],"study_design_scores_gemma":[0.000026412024,0.0015513478,0.98902637,0.000047651352,0.000023126788,0.0011427435,0.0059440774,0.00031569254,0.00034500164,0.000016082187,0.0015384811,0.000023039218],"about_ca_topic_score_codex":0.0035102589,"about_ca_topic_score_gemma":0.0046094256,"teacher_disagreement_score":0.0035718053,"about_ca_system_score_codex":0.00069680245,"about_ca_system_score_gemma":0.0006343654,"threshold_uncertainty_score":0.018889725},"labels":[],"label_agreement":null},{"id":"W2968495081","doi":"10.1634/theoncologist.2019-0297","title":"Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with<i>RAS/RAF</i>Alterations","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; National Center for Advancing Translational Sciences; Array BioPharma","keywords":"KRAS; Medicine; Neuroblastoma RAS viral oncogene homolog; MEK inhibitor; Internal medicine; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Toxicity; Phases of clinical research; Pharmacology; Colorectal cancer; MAPK/ERK pathway; Kinase","score_opus":0.009872657720289805,"score_gpt":0.3163407426654571,"score_spread":0.3064680849451673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968495081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933382,0.0015532591,0.00059733924,0.00028927738,0.00007773946,0.0019075401,0.0006846186,0.00007512145,0.0014770109],"genre_scores_gemma":[0.9914894,0.0010546637,0.0016272662,0.00048166988,0.00013359809,0.002044421,0.0020043098,0.000029245348,0.0011355306],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994148,0.00025064824,0.0000405614,0.00010005361,0.00006741861,0.00012661924],"domain_scores_gemma":[0.9990569,0.0001094775,0.00021489753,0.00008301441,0.00006138584,0.00047441295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015906495,0.001611224,0.0023665088,0.0005057633,0.00046798287,0.0011517106,0.0010980739,0.00083700905,0.0034412143],"category_scores_gemma":[0.00072667655,0.00072886224,0.0012535021,0.0005357849,0.0008820889,0.0009679574,0.00047712948,0.0032468121,0.0010779569],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7276503,0.11654051,0.0107208565,0.0007494814,0.0018978865,0.00033377233,0.00031996172,0.0030787208,0.062308185,0.00024161804,0.002945838,0.073212825],"study_design_scores_gemma":[0.45212123,0.53055876,0.008417297,0.00003184923,0.00047545528,0.0004219356,0.000050853403,0.0012583865,0.004613877,0.00011884285,0.0019053257,0.000026173191],"about_ca_topic_score_codex":0.000701395,"about_ca_topic_score_gemma":0.0015130515,"teacher_disagreement_score":0.0034412143,"about_ca_system_score_codex":0.001047907,"about_ca_system_score_gemma":0.0019096751,"threshold_uncertainty_score":0.0115119815},"labels":[],"label_agreement":null},{"id":"W2969017474","doi":"10.1634/theoncologist.2019-0321","title":"A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Chemotherapy; Gastroenterology; Clinical trial; Nivolumab; Immunotherapy","score_opus":0.05384371908796651,"score_gpt":0.4257430872117402,"score_spread":0.37189936812377367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969017474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930012,0.0013261326,0.00021876284,0.00032866918,0.00009312079,0.0018930334,0.00069934106,0.00007715643,0.0023625172],"genre_scores_gemma":[0.9927255,0.0009440473,0.0008011548,0.00048733692,0.00012481312,0.0010920385,0.0016541248,0.000014729815,0.0021561845],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997125,0.00013072373,0.000013704348,0.000039212,0.000029543156,0.00007419488],"domain_scores_gemma":[0.9997254,0.00003217906,0.000035153716,0.00001902772,0.0000152092325,0.00017291865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008162417,0.0008008121,0.001364538,0.0002594752,0.0003059466,0.0005612214,0.00072026014,0.00060577545,0.002754938],"category_scores_gemma":[0.00039064055,0.00030094013,0.00046909117,0.00028551603,0.00048096429,0.0003045445,0.00025286232,0.0015493975,0.00057638285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7198088,0.057478484,0.008352256,0.00073393213,0.00082188466,0.0005907738,0.00019426124,0.002560682,0.054408886,0.0004236566,0.0093792025,0.14524716],"study_design_scores_gemma":[0.63400954,0.3416829,0.0129252,0.000040004707,0.00029719603,0.00041247162,0.00003777202,0.0017519199,0.0046107885,0.0001666297,0.0040401085,0.000025503532],"about_ca_topic_score_codex":0.0020373943,"about_ca_topic_score_gemma":0.0063188476,"teacher_disagreement_score":0.002754938,"about_ca_system_score_codex":0.00088261854,"about_ca_system_score_gemma":0.0012960302,"threshold_uncertainty_score":0.00921613},"labels":[],"label_agreement":null},{"id":"W2972627853","doi":"10.1634/theoncologist.2019-0314","title":"Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Public health; Family medicine; Business; Cancer; Internal medicine","score_opus":0.1516429570092212,"score_gpt":0.40838842309651435,"score_spread":0.25674546608729315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972627853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8960742,0.013668555,0.0028685608,0.027313225,0.00023995052,0.00036199,0.02134369,0.00009554955,0.03803433],"genre_scores_gemma":[0.9927044,0.0016079508,0.0005594139,0.0010051155,0.000026850485,0.00005116469,0.0020587079,0.000023478578,0.0019628704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9863901,0.0021359276,0.0007284675,0.0006921121,0.005382803,0.0046705985],"domain_scores_gemma":[0.9715657,0.004736945,0.007920255,0.000649928,0.010108476,0.005018661],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007140432,0.00034134777,0.00055114273,0.0026641479,0.0036952994,0.004358513,0.002043453,0.0008730353,0.0044256104],"category_scores_gemma":[0.030559978,0.00026697555,0.0016309873,0.006038614,0.0021415276,0.0015082288,0.0028186617,0.0023179231,0.0002498478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000895928,0.00013395355,0.8918707,0.00041885508,0.00073443877,0.00067270896,0.0027699752,0.009606964,0.00022465545,0.00951041,0.016105196,0.06705623],"study_design_scores_gemma":[0.00008830114,0.00018856322,0.9484233,0.000761492,0.00041449483,0.0005575293,0.0049339156,0.0094091995,0.00036921742,0.002503854,0.032191638,0.00015857778],"about_ca_topic_score_codex":0.9786381,"about_ca_topic_score_gemma":0.98199224,"teacher_disagreement_score":0.99285954,"about_ca_system_score_codex":0.12715504,"about_ca_system_score_gemma":0.09527474,"threshold_uncertainty_score":0.9225787},"labels":[],"label_agreement":null},{"id":"W2979515484","doi":"10.1634/theoncologist.2019-0446","title":"De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Hazard ratio; Internal medicine; Breast cancer; Pertuzumab; Clinical endpoint; Oncology; Proportional hazards model; Metastasis; Trastuzumab; Confidence interval; Cancer; Chemotherapy; Cancer registry; Progression-free survival; Clinical trial","score_opus":0.05891216506106133,"score_gpt":0.37614151386067546,"score_spread":0.3172293487996141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979515484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892117,0.00038696633,0.00012700904,0.000110069566,0.000004537922,0.000030549512,0.0095565235,0.0000075094035,0.0008557492],"genre_scores_gemma":[0.9822,0.00032370753,0.00021951976,0.000107094624,0.00002308315,0.00010628765,0.016741883,0.000007563648,0.00027084464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991198,0.00020424575,0.00016392836,0.00024029244,0.00019100885,0.00008073019],"domain_scores_gemma":[0.996768,0.00063988025,0.0019790719,0.00019817273,0.00022637345,0.00018862655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013258713,0.00012934265,0.00033104976,0.0007798608,0.00023785833,0.00040398573,0.00033516987,0.0002389255,0.002147414],"category_scores_gemma":[0.0028667415,0.00013872724,0.00032910376,0.0014173142,0.00018082402,0.00047659993,0.0004749317,0.00032489334,0.000335167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043851617,0.00004113399,0.9960748,0.000031392057,0.00007211155,0.000055267014,0.000051297982,0.00007580194,0.00015079817,0.00004630724,0.0011083699,0.001854338],"study_design_scores_gemma":[0.000096683354,0.0001983006,0.99707067,0.00002534329,0.00010089468,0.00046764922,0.00012186981,0.0002718561,0.00014648371,0.000043235348,0.0014493108,0.0000076971655],"about_ca_topic_score_codex":0.0023752,"about_ca_topic_score_gemma":0.0047841296,"teacher_disagreement_score":0.0023752,"about_ca_system_score_codex":0.00036450164,"about_ca_system_score_gemma":0.00053783844,"threshold_uncertainty_score":0.00718379},"labels":[],"label_agreement":null},{"id":"W2980349677","doi":"10.1634/theoncologist.2019-0512","title":"Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Anxiety; Breast cancer; Psychosocial; Cancer; Mastectomy; Psychological intervention; Internal medicine; Prospective cohort study; Oncology; Physical therapy; Psychiatry","score_opus":0.007887843030105068,"score_gpt":0.24207633286700117,"score_spread":0.2341884898368961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980349677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99910444,0.00020602517,0.000022287522,0.000092775364,0.000007224557,0.0000048433812,0.00008939409,0.0000015589342,0.00047133397],"genre_scores_gemma":[0.999747,0.000055698227,0.0000213232,0.000023151437,0.000007579674,0.000003241865,0.00011248207,4.2648128e-7,0.000029130577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945515,0.00021930471,0.000061008468,0.00006182966,0.00010796157,0.000094781935],"domain_scores_gemma":[0.9967765,0.0010700118,0.0013295535,0.000063938336,0.00014043936,0.0006196103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006083142,0.00011590784,0.00016178814,0.00032219928,0.0002455366,0.00057897787,0.00015067167,0.00022620261,0.0010908486],"category_scores_gemma":[0.0053754156,0.00009519507,0.0004787424,0.00036541492,0.00019179653,0.00024883292,0.0003151868,0.00051975995,0.00006847306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030700117,0.00004540527,0.9972205,0.0000065512068,0.000059492933,0.000031300562,0.000042521657,0.000041123414,0.000052381696,0.000010019643,0.00008894118,0.0020946676],"study_design_scores_gemma":[0.0000071231807,0.00013954274,0.99944466,0.0000067701776,0.00002866336,0.00006270531,0.00010348567,0.00013310944,0.000014060721,0.000011799711,0.000045352044,0.0000026410141],"about_ca_topic_score_codex":0.0033443242,"about_ca_topic_score_gemma":0.007462723,"teacher_disagreement_score":0.0033443242,"about_ca_system_score_codex":0.00047344368,"about_ca_system_score_gemma":0.00034464514,"threshold_uncertainty_score":0.0066497326},"labels":[],"label_agreement":null},{"id":"W2982225675","doi":"10.1634/theoncologist.2019-0553","title":"Medical Oncologists’ Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"National Center for Advancing Translational Sciences","keywords":"FOLFOX; Medicine; Oxaliplatin; Confidence interval; Colorectal cancer; Odds ratio; Adjuvant; Internal medicine; Oncology; Family medicine; Stage (stratigraphy); Cancer","score_opus":0.03702173781733555,"score_gpt":0.3772266499945785,"score_spread":0.34020491217724297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982225675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95650935,0.0022860062,0.0004208809,0.033455778,0.00017722374,0.00007722164,0.00020203699,0.000014540574,0.0068570245],"genre_scores_gemma":[0.9917555,0.0012608934,0.0010098852,0.0052932873,0.00016852637,0.000061040046,0.00008621994,0.000008139169,0.00035660723],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.95840394,0.034055885,0.0018808,0.00080500566,0.0027616827,0.0020926427],"domain_scores_gemma":[0.91551113,0.045245726,0.021149127,0.0012315547,0.0065673674,0.010295094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0402657,0.00020960173,0.00029697208,0.00067657785,0.0015869733,0.002393066,0.00045249783,0.0015991133,0.0019901148],"category_scores_gemma":[0.07695027,0.00023147951,0.0007663012,0.00075863925,0.0011799948,0.0016298642,0.0034194153,0.0014234174,0.0002637468],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002122047,0.00045687502,0.7854657,0.0010039194,0.00027831917,0.001047636,0.074117936,0.0009359093,0.0019206451,0.000844666,0.017240219,0.11456617],"study_design_scores_gemma":[0.0007948675,0.00554479,0.7050799,0.0024215772,0.00057868555,0.002205622,0.20365973,0.0015810278,0.0026718662,0.0021917159,0.07296961,0.0003005791],"about_ca_topic_score_codex":0.0028165076,"about_ca_topic_score_gemma":0.006441696,"teacher_disagreement_score":0.0402657,"about_ca_system_score_codex":0.0027498272,"about_ca_system_score_gemma":0.005650705,"threshold_uncertainty_score":0.2129479},"labels":[],"label_agreement":null},{"id":"W2990253155","doi":"10.1634/theoncologist.2019-0501","title":"Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Research, Innovation and Science","keywords":"Lenvatinib; Sorafenib; Medicine; Hepatocellular carcinoma; Oncology; Internal medicine; Clinical trial","score_opus":0.1282177910948125,"score_gpt":0.3195378907818478,"score_spread":0.1913200996870353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990253155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94575197,0.0062558055,0.029490158,0.0024908106,0.0001164611,0.001352404,0.0031004995,0.000109723034,0.011332242],"genre_scores_gemma":[0.99401516,0.00084735896,0.0033757046,0.000158803,0.000024137824,0.0002303659,0.00053066306,0.000011073287,0.00080677203],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973109,0.0020642194,0.00007005497,0.00014985204,0.00018857565,0.00021644113],"domain_scores_gemma":[0.98628575,0.01231542,0.00059360097,0.00014467529,0.00034926113,0.00031120994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006481194,0.0015620467,0.002211738,0.0022561345,0.00036904746,0.0016151092,0.0013581404,0.0015538578,0.0061031766],"category_scores_gemma":[0.017190576,0.00085010665,0.0037913222,0.0016305192,0.0005761363,0.0015779517,0.000959538,0.001796298,0.0001863375],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032210867,0.00039087393,0.0040867445,0.00041050604,0.0011811017,0.00020897867,0.000032688044,0.97738826,0.0002432657,0.004440174,0.0007355256,0.0076607545],"study_design_scores_gemma":[0.0008607789,0.0014133335,0.0033519468,0.00011795815,0.0015553854,0.00011900297,0.00008745781,0.9872858,0.00021335682,0.0044221357,0.0005311978,0.000041690077],"about_ca_topic_score_codex":0.014446304,"about_ca_topic_score_gemma":0.0068032388,"teacher_disagreement_score":0.014446304,"about_ca_system_score_codex":0.0058841086,"about_ca_system_score_gemma":0.0030405107,"threshold_uncertainty_score":0.042692423},"labels":[],"label_agreement":null},{"id":"W2990484449","doi":"10.1634/theoncologist.2019-0628","title":"Supervised, Multimodal Exercise: The Chemotherapy Supportive Therapy That Almost Does It All","year":2019,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Susan G. Komen","keywords":"Medicine; Context (archaeology); Chemotherapy; Physical therapy; Psychological intervention; Randomized controlled trial; Intensive care medicine; Exercise therapy; Clinical trial; Oncology; Internal medicine; Nursing","score_opus":0.0479219492012831,"score_gpt":0.3185474806793348,"score_spread":0.2706255314780517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990484449","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018415289,0.0007906001,0.000036490328,0.9907142,0.007256937,0.000004524472,0.000027171021,0.0000081910875,0.0009777452],"genre_scores_gemma":[0.0014090058,0.0006924108,0.00010223881,0.9757205,0.020071749,0.000019877025,0.000016890599,0.000010546264,0.0019566428],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995799,0.0018899834,0.00047491275,0.00045226366,0.00095570117,0.00042801988],"domain_scores_gemma":[0.9872377,0.00881366,0.00067684415,0.00026955348,0.0017300725,0.0012721547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045609237,0.00080406637,0.0012807156,0.00061081524,0.0047605466,0.0031206459,0.0019440629,0.04148998,0.0072341505],"category_scores_gemma":[0.022932753,0.00054619164,0.0012884352,0.00072572945,0.0026290144,0.0039410824,0.0013831062,0.0375722,0.005390976],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094599294,0.000042156793,0.00045917946,0.000071351744,0.00001660688,0.0005512711,0.00014180613,0.000043288128,0.00014710588,0.002023227,0.9840629,0.012346474],"study_design_scores_gemma":[0.0004584582,0.00019773122,0.002116871,0.00088752096,0.00006996098,0.001273155,0.0008063349,0.00040735657,0.00029172492,0.0101726595,0.98322207,0.0000961858],"about_ca_topic_score_codex":0.015450992,"about_ca_topic_score_gemma":0.029049143,"teacher_disagreement_score":0.04148998,"about_ca_system_score_codex":0.0043884157,"about_ca_system_score_gemma":0.006146997,"threshold_uncertainty_score":0.031840384},"labels":[],"label_agreement":null},{"id":"W2996147814","doi":"10.1634/theoncologist.2019-0437","title":"Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network; Canadian Cancer Society Research Institute; NRG Oncology; ECOG-ACRIN Cancer Research Group; Sanofi","keywords":"Medicine; Bevacizumab; Oxaliplatin; Fluorouracil; Colorectal cancer; Clinical endpoint; Surgery; Neutropenia; Internal medicine; Leukopenia; Chemotherapy; Randomized controlled trial; Cancer","score_opus":0.06494311937460169,"score_gpt":0.39106730842488907,"score_spread":0.3261241890502874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996147814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96930176,0.0044276277,0.0015064058,0.001926883,0.0012761933,0.012209978,0.0040556137,0.00022053534,0.005074933],"genre_scores_gemma":[0.9607985,0.0028309906,0.0034613754,0.004231865,0.00059233786,0.01663353,0.003992169,0.000054421896,0.0074047633],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99907863,0.0005879441,0.000039824517,0.0001212337,0.000053586933,0.00011876825],"domain_scores_gemma":[0.9988732,0.00022909566,0.00032294606,0.00009083435,0.00007773543,0.0004062315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002863468,0.0019325119,0.0018862796,0.00043806375,0.0004137174,0.0011802174,0.0010973043,0.0018701073,0.007611367],"category_scores_gemma":[0.0020692113,0.00068557594,0.0016963377,0.0004756119,0.0009436453,0.00085134245,0.0005119704,0.0031753911,0.0011895219],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.975007,0.007981308,0.00072861614,0.00031328906,0.00065502664,0.000028840062,0.000046458114,0.00038186004,0.0020816626,0.00016212197,0.0020168007,0.010597047],"study_design_scores_gemma":[0.9641003,0.033219494,0.0010959425,0.000022404403,0.00019860099,0.000019708714,0.000014692172,0.0002877574,0.00019375245,0.000093792696,0.00074540783,0.000008145365],"about_ca_topic_score_codex":0.0014423213,"about_ca_topic_score_gemma":0.0040765693,"teacher_disagreement_score":0.007611367,"about_ca_system_score_codex":0.0010448875,"about_ca_system_score_gemma":0.0017659351,"threshold_uncertainty_score":0.025462568},"labels":[],"label_agreement":null},{"id":"W2996280469","doi":"10.1634/theoncologist.2019-0562","title":"Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Oncology; Marital status; Proportional hazards model; Hazard ratio; Multivariate analysis; Pancreatic cancer; Survival analysis; Univariate analysis; Population; Cancer registry; Cancer","score_opus":0.025035103920083644,"score_gpt":0.3365644235079453,"score_spread":0.3115293195878617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996280469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992957,0.00008617654,0.000035876994,0.00002079681,0.0000033173055,0.000013291551,0.00044042428,0.0000018653261,0.00010253695],"genre_scores_gemma":[0.998005,0.00008173833,0.00009505933,0.000021673422,0.00001323781,0.000021506192,0.0016858961,0.0000022330328,0.00007368179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992224,0.00034439794,0.00007816365,0.00009314877,0.00017201128,0.000089844834],"domain_scores_gemma":[0.99821705,0.00041196478,0.00068430894,0.00024988892,0.00017651303,0.0002602675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016089926,0.00032451755,0.00047627543,0.0009061909,0.000363731,0.00044730178,0.00042421944,0.0002733227,0.00097388326],"category_scores_gemma":[0.0026428,0.00017210914,0.00053509336,0.0011208443,0.00023021306,0.00035513242,0.0007218024,0.00048156895,0.00023600055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017414363,0.00014979005,0.99466187,0.000015046547,0.00011312905,0.00008993263,0.00007696375,0.000087465225,0.00027174715,0.000007987862,0.00026092524,0.0025236874],"study_design_scores_gemma":[0.00013721299,0.00090890843,0.9976521,0.0000047764274,0.000111156514,0.00026743833,0.00011092429,0.00031629688,0.00019851919,0.000012677722,0.00027477206,0.0000051512047],"about_ca_topic_score_codex":0.0027481997,"about_ca_topic_score_gemma":0.0033360207,"teacher_disagreement_score":0.0027481997,"about_ca_system_score_codex":0.00039459573,"about_ca_system_score_gemma":0.0004142565,"threshold_uncertainty_score":0.008509278},"labels":[],"label_agreement":null},{"id":"W3000094994","doi":"10.1634/theoncologist.2019-0777","title":"Exercise Intolerance in Anthracycline-Treated Breast Cancer Survivors: The Role of Skeletal Muscle Bioenergetics, Oxygenation, and Composition","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Innovates; Susan G. Komen for the Cure","keywords":"Bioenergetics; Anthracycline; Skeletal muscle; Breast cancer; Exercise intolerance; Medicine; Internal medicine; Composition (language); Cancer; Oxygenation; Endocrinology; Biology; Heart failure; Biochemistry","score_opus":0.013371865050071291,"score_gpt":0.2708306323130751,"score_spread":0.25745876726300376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000094994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9997888,0.00009782291,0.000012962117,0.000007720086,0.0000011975754,0.0000011664047,0.000018633878,7.156589e-7,0.00007101337],"genre_scores_gemma":[0.99980384,0.000055554712,0.000013534549,0.000008090825,0.000003437751,0.0000020358775,0.00004860684,4.2405424e-7,0.00006448166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999398,0.000018323226,0.0000055115597,0.000012978622,0.000010398892,0.000013075176],"domain_scores_gemma":[0.99979,0.000037161066,0.00008621168,0.000009127334,0.000016819931,0.0000607211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001374782,0.0002116241,0.00023336604,0.00039856212,0.00017012237,0.00024779688,0.00009587769,0.00023743212,0.0008551547],"category_scores_gemma":[0.00046703007,0.00009587605,0.00012279174,0.00028024812,0.00015223249,0.00010791766,0.00016711328,0.00016472898,0.00009909394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006846069,0.00006896852,0.9905551,0.000016185084,0.000047794376,0.00015178118,0.00010125146,0.000038632308,0.0044985972,0.000007252893,0.00003808215,0.0037917336],"study_design_scores_gemma":[0.0000041803005,0.00014557515,0.99942774,0.0000018546044,0.0000133182675,0.00014256408,0.000063828564,0.00005809413,0.00011087887,0.0000052902496,0.00002584459,7.5168487e-7],"about_ca_topic_score_codex":0.0015623121,"about_ca_topic_score_gemma":0.001953574,"teacher_disagreement_score":0.0015623121,"about_ca_system_score_codex":0.000120747245,"about_ca_system_score_gemma":0.000071518785,"threshold_uncertainty_score":0.0031064153},"labels":[],"label_agreement":null},{"id":"W3001231147","doi":"10.1634/theoncologist.2019-0605","title":"Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Manitoba; University of Calgary","funders":"","keywords":"Sunitinib; Renal cell carcinoma; Medicine; Oncology; Internal medicine","score_opus":0.07169468822399246,"score_gpt":0.3543708603305172,"score_spread":0.28267617210652474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001231147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591297,0.00030572506,0.00008578879,0.00004923313,0.0000035507805,0.000015367288,0.0032266176,0.000004066935,0.0003965421],"genre_scores_gemma":[0.99704224,0.000077493474,0.00010491577,0.000020026504,0.000006062139,0.000013445314,0.0026957581,0.0000012177024,0.000038915732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988488,0.00025120753,0.00025965224,0.00027081103,0.00025005735,0.00011944476],"domain_scores_gemma":[0.9936314,0.0006206824,0.00464648,0.00022533079,0.00047184696,0.00040422287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010876429,0.00014918773,0.0004092523,0.00089943054,0.00029380724,0.0008992091,0.00033686575,0.00032991267,0.00071300974],"category_scores_gemma":[0.0037543362,0.00011142781,0.0004416965,0.0014330326,0.00017654587,0.0005903018,0.00044175715,0.0003632341,0.00015878634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008251199,0.000009167562,0.999006,0.0000075075563,0.000030820574,0.000018180863,0.000017360351,0.00003959743,0.000027906115,0.0000074966315,0.000096965014,0.000656514],"study_design_scores_gemma":[0.000008410275,0.000053837488,0.99888843,0.0000068595805,0.00003066272,0.00026803595,0.000083720675,0.0002970798,0.00007156339,0.00001519389,0.00027259623,0.0000037121727],"about_ca_topic_score_codex":0.0059886607,"about_ca_topic_score_gemma":0.009080334,"teacher_disagreement_score":0.0059886607,"about_ca_system_score_codex":0.00082759245,"about_ca_system_score_gemma":0.00046389695,"threshold_uncertainty_score":0.0119075775},"labels":[],"label_agreement":null},{"id":"W3003473057","doi":"10.1634/theoncologist.2019-0581","title":"A Randomized Trial of Real-Time Geriatric Assessment Reporting in Nonelectively Hospitalized Older Adults with Cancer","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital","funders":"National Cancer Institute; John A. Hartford Foundation","keywords":"Medicine; Polypharmacy; Psychological intervention; Randomized controlled trial; Anxiety; Population; Referral; Cancer; Geriatrics; Intervention (counseling); Physical therapy; Internal medicine; Family medicine; Psychiatry","score_opus":0.02714126691220669,"score_gpt":0.345100156033863,"score_spread":0.3179588891216563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003473057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97498965,0.0028549754,0.001198939,0.0014447953,0.0018384906,0.015029642,0.0007347583,0.00015957735,0.0017492598],"genre_scores_gemma":[0.96644765,0.0012490483,0.004039222,0.0015308419,0.00085972005,0.023745999,0.00053789694,0.00001671263,0.0015729911],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99584347,0.0028200306,0.0003728553,0.0004890018,0.00019996849,0.00027464668],"domain_scores_gemma":[0.9930501,0.0031999936,0.0019288879,0.0004207357,0.00032088434,0.0010793614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040025567,0.0017791444,0.0023899851,0.00060122245,0.0006033752,0.0013136137,0.0012562757,0.0031796878,0.0083010765],"category_scores_gemma":[0.009563898,0.0007549346,0.002477093,0.00043609968,0.0014629477,0.0013959337,0.00085541594,0.0030908217,0.0008357808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98044354,0.0104001025,0.00048206418,0.0005112699,0.0006653577,0.000020480342,0.00004181035,0.00023057422,0.00027538784,0.000080856844,0.00031325693,0.006535413],"study_design_scores_gemma":[0.9555377,0.042921387,0.00051610766,0.000040151153,0.00028272005,0.0000092886785,0.000015182112,0.0003151237,0.00009598383,0.000080148406,0.00017983603,0.000006387907],"about_ca_topic_score_codex":0.0013628405,"about_ca_topic_score_gemma":0.0016519097,"teacher_disagreement_score":0.0083010765,"about_ca_system_score_codex":0.0011034617,"about_ca_system_score_gemma":0.00221417,"threshold_uncertainty_score":0.027769864},"labels":[],"label_agreement":null},{"id":"W3005570342","doi":"10.1634/theoncologist.2019-0674","title":"Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Medicine; Nivolumab; Adverse effect; Pembrolizumab; Pneumonitis; Hazard ratio; Ipilimumab; Internal medicine; Melanoma; Cancer; Immunotherapy; Confidence interval; Lung","score_opus":0.03187919730524732,"score_gpt":0.31172232012643114,"score_spread":0.27984312282118384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005570342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699724,0.0017091879,0.00007885926,0.000089837326,0.000004161137,0.000009603707,0.00037068853,0.0000061718706,0.00073422136],"genre_scores_gemma":[0.99932706,0.00024975062,0.000044375447,0.000019624613,0.000007746758,0.0000028624245,0.00022323668,7.5906104e-7,0.0001246173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977356,0.00005274669,0.00001565244,0.000039391383,0.00007734496,0.000041362204],"domain_scores_gemma":[0.99830866,0.00019216198,0.0011400916,0.00003421431,0.00014927743,0.0001755856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005946474,0.00014405505,0.00016755877,0.00040457633,0.00019110304,0.0003741862,0.00021254804,0.00017691105,0.0015851823],"category_scores_gemma":[0.0014893989,0.00007583711,0.00022875363,0.0004936504,0.00020481151,0.00017683886,0.00021586727,0.00031538968,0.00010929671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003763362,0.000035324607,0.992415,0.00004722616,0.000059023638,0.00005730372,0.000025107447,0.0002485256,0.00019580152,0.000015537647,0.00015008415,0.0063747815],"study_design_scores_gemma":[0.000011242734,0.00009207483,0.99923813,0.00001022134,0.000023048582,0.0001654637,0.000018938394,0.00017193494,0.000058243855,0.00002030106,0.00018892024,0.0000015061963],"about_ca_topic_score_codex":0.009988662,"about_ca_topic_score_gemma":0.019592049,"teacher_disagreement_score":0.009988662,"about_ca_system_score_codex":0.00077033025,"about_ca_system_score_gemma":0.00063608296,"threshold_uncertainty_score":0.019861042},"labels":[],"label_agreement":null},{"id":"W3008706206","doi":"10.1634/theoncologist.2019-0709","title":"Gaps in the Management of Depression Symptoms Following Cancer Diagnosis: A Population-Based Analysis of Prospective Patient-Reported Outcomes","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Manitoba; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Depression (economics); Medicine; Prospective cohort study; Management of depression; Cancer; Population; Psychiatry; Family medicine; Internal medicine; Environmental health; Primary care","score_opus":0.025126573153505534,"score_gpt":0.33180545258232175,"score_spread":0.3066788794288162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008706206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776554,0.0005319657,0.00013550144,0.00013145129,0.000010228844,0.0000313847,0.0011933952,0.0000038668377,0.0001965572],"genre_scores_gemma":[0.9987613,0.0001339435,0.00007988953,0.000054941895,0.000008619877,0.000037181893,0.0008868006,0.000002006244,0.000035402114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602425,0.0016620916,0.0005972478,0.00076856057,0.0005305129,0.00041733106],"domain_scores_gemma":[0.9907295,0.0022121924,0.005134643,0.0006988383,0.00057664694,0.00064802606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004784225,0.00031690305,0.000624118,0.0013090433,0.0005030142,0.0010270806,0.00075831474,0.000828261,0.0010927093],"category_scores_gemma":[0.010064395,0.00044997293,0.0014430089,0.002583584,0.00046027717,0.0010061375,0.0014185687,0.0011101041,0.00020345257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006079071,0.000032646876,0.99916506,0.000016023376,0.00011521196,0.000012566114,0.000057254118,0.000026713384,0.00001461262,0.000009607514,0.00006744755,0.00042210417],"study_design_scores_gemma":[0.000011062142,0.000098747776,0.9992686,0.000015511407,0.0000490223,0.000055440203,0.00021514365,0.00015782106,0.000011529089,0.000014454333,0.00009890036,0.000003836956],"about_ca_topic_score_codex":0.007967338,"about_ca_topic_score_gemma":0.007926493,"teacher_disagreement_score":0.007967338,"about_ca_system_score_codex":0.0006455508,"about_ca_system_score_gemma":0.00074049854,"threshold_uncertainty_score":0.025301695},"labels":[],"label_agreement":null},{"id":"W3014203766","doi":"10.1634/theoncologist.2019-0950","title":"Identifying Geriatric Oncology Competencies for Medical Oncology Trainees: A Modified Delphi Consensus Study","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Advancing Translational Sciences; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Internal medicine; Oncology; Medicine; Geriatric oncology; Delphi method; Psychosocial; Oncology nursing; Delphi; Curriculum; Family medicine; Cancer; Nursing; Psychology; Nurse education; Psychiatry","score_opus":0.15512981236419615,"score_gpt":0.40303296866355676,"score_spread":0.2479031562993606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014203766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9439568,0.00068460964,0.01934768,0.0014212809,0.00013445686,0.028027441,0.00038779472,0.000030521183,0.006009465],"genre_scores_gemma":[0.8796874,0.0014576988,0.054171007,0.0011867576,0.0000563988,0.061471928,0.00054120936,0.000030000978,0.0013975842],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9201856,0.058663923,0.0076610562,0.0024417217,0.006547667,0.0045000236],"domain_scores_gemma":[0.9194671,0.050167408,0.004053516,0.002012102,0.022403762,0.001896114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10920088,0.0010911033,0.0016362376,0.0041767466,0.003463308,0.0018590213,0.0019393712,0.0021227915,0.002490875],"category_scores_gemma":[0.1024672,0.001311799,0.0021740443,0.0030775063,0.0033540924,0.0025290656,0.007984561,0.0023111228,0.0006260844],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017946755,0.0014979859,0.060446527,0.010873005,0.00046658787,0.0019275193,0.7570051,0.0030523438,0.007827205,0.00537961,0.00739816,0.14233133],"study_design_scores_gemma":[0.0007888293,0.003858789,0.06632326,0.0069266236,0.00037130763,0.001119109,0.8707967,0.011674391,0.004246282,0.006005571,0.027493242,0.00039600913],"about_ca_topic_score_codex":0.0035240361,"about_ca_topic_score_gemma":0.0057661757,"teacher_disagreement_score":0.10920088,"about_ca_system_score_codex":0.0054617114,"about_ca_system_score_gemma":0.014994522,"threshold_uncertainty_score":0.5775163},"labels":[],"label_agreement":null},{"id":"W3014319236","doi":"10.1634/theoncologist.2020-0213","title":"A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":719,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Juravinski Cancer Centre; University of Toronto; McMaster University; Windsor Regional Hospital; Impact","funders":"F. Hoffmann-La Roche","keywords":"Pandemic; Medicine; Outbreak; Disease; Public health; Cancer; Population; Intensive care medicine; Transmission (telecommunications); Coronavirus; Pneumonia; Infectious disease (medical specialty); Coronavirus disease 2019 (COVID-19); Environmental health; Virology; Internal medicine; Pathology","score_opus":0.3677715450091028,"score_gpt":0.5553454666213564,"score_spread":0.1875739216122536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014319236","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001568989,0.8942505,0.009570814,0.0688669,0.01053264,0.00040917742,0.00016700679,0.00022479157,0.014409194],"genre_scores_gemma":[0.009862916,0.931451,0.019071825,0.027498454,0.005144387,0.0005622502,0.00035981022,0.000039142924,0.0060101775],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986338,0.000630095,0.00021239712,0.00011490717,0.00028786564,0.00012095931],"domain_scores_gemma":[0.99808073,0.0005809434,0.00020068148,0.00004820514,0.0008128639,0.00027652344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027731233,0.00073956593,0.0008318325,0.0012184195,0.00078830984,0.0017254527,0.0012455301,0.0024492377,0.0049436935],"category_scores_gemma":[0.0059503447,0.00024190787,0.0013213841,0.00065688504,0.0006626722,0.0024069748,0.0017640197,0.0042513986,0.0016739515],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103489816,0.00017141167,0.00097308506,0.011815754,0.00011398025,0.0011092005,0.0010964322,0.00060152967,0.0011118853,0.0067636385,0.20795527,0.76818424],"study_design_scores_gemma":[0.00004883612,0.00019316791,0.0013160501,0.009448783,0.00013058745,0.0015834883,0.0010969251,0.00026987478,0.00038022402,0.004486265,0.980992,0.00005374315],"about_ca_topic_score_codex":0.0026812227,"about_ca_topic_score_gemma":0.0058686957,"teacher_disagreement_score":0.0049436935,"about_ca_system_score_codex":0.00094193994,"about_ca_system_score_gemma":0.004601235,"threshold_uncertainty_score":0.016538322},"labels":[],"label_agreement":null},{"id":"W3016237720","doi":"10.1634/theoncologist.2020-0040","title":"Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Retrospective cohort study; Cohort; Blockade; Immune checkpoint; Internal medicine; Progression-free survival; Oncology; Chemotherapy","score_opus":0.03091760045063636,"score_gpt":0.33629506853513286,"score_spread":0.3053774680844965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016237720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983369,0.001101498,0.00013131025,0.0000449105,0.000005417186,0.00000783935,0.000051031642,0.0000028713664,0.00031812544],"genre_scores_gemma":[0.99966097,0.00012944074,0.00005214878,0.00002692147,0.00000936602,0.000004621234,0.00006671342,0.0000011157904,0.000048798018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990362,0.00046117615,0.000075649754,0.00012987654,0.00014603068,0.00015113519],"domain_scores_gemma":[0.9976648,0.000840755,0.0009296871,0.00017371078,0.00010040616,0.00029069255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017571043,0.00010233087,0.00037676663,0.00026961483,0.0003062145,0.00071133405,0.00017287988,0.00019998143,0.0004195855],"category_scores_gemma":[0.0030614107,0.00009478673,0.00034404587,0.00029899142,0.00031064457,0.00041193253,0.00038208952,0.0005745153,0.00005361594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009709547,0.00035589605,0.89706546,0.0000903266,0.00032357904,0.00050101994,0.000204641,0.0010420306,0.004350353,0.00019624189,0.00024375995,0.08591719],"study_design_scores_gemma":[0.00028389983,0.009415518,0.9820342,0.000047417103,0.00033989156,0.0017651403,0.00020500281,0.0012279161,0.0025551876,0.00026126704,0.0018508517,0.000013777756],"about_ca_topic_score_codex":0.0005976902,"about_ca_topic_score_gemma":0.0011711669,"teacher_disagreement_score":0.0017571043,"about_ca_system_score_codex":0.0005208647,"about_ca_system_score_gemma":0.00045175912,"threshold_uncertainty_score":0.009292543},"labels":[],"label_agreement":null},{"id":"W3019309608","doi":"10.1634/theoncologist.2019-0887","title":"Oncology in 2050 – A Retrospective?","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Retrospective cohort study; Oncology; MEDLINE; Internal medicine","score_opus":0.02291055533458568,"score_gpt":0.28886977021186433,"score_spread":0.26595921487727864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019309608","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17372064,0.10270331,0.0032084403,0.53749514,0.033723652,0.00009435365,0.0053452533,0.00016763857,0.14354159],"genre_scores_gemma":[0.77422875,0.06762691,0.0017109099,0.12382219,0.01026551,0.00012880677,0.0025307888,0.0001783672,0.019507749],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990734,0.00031298265,0.00007565243,0.00009042493,0.00019064818,0.00025682914],"domain_scores_gemma":[0.9951497,0.0021621394,0.0007070452,0.000212462,0.00091057026,0.00085803936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003465509,0.0002834247,0.0002390499,0.001661791,0.004181664,0.0054347343,0.0005362498,0.002356569,0.0047464343],"category_scores_gemma":[0.013853066,0.00024241881,0.00025744937,0.0017633227,0.0026757913,0.0050314423,0.002619376,0.0058663837,0.0008931409],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062857,0.0001463654,0.033912394,0.0010118745,0.0001034688,0.011160799,0.07988271,0.0005823204,0.0006301149,0.24882838,0.49112055,0.13199244],"study_design_scores_gemma":[0.0000075191197,0.00007752341,0.0061400207,0.0014032748,0.00004040896,0.0055457507,0.027777018,0.00005854933,0.00024333328,0.0076166275,0.9510341,0.000055756223],"about_ca_topic_score_codex":0.0108843865,"about_ca_topic_score_gemma":0.020120416,"teacher_disagreement_score":0.0108843865,"about_ca_system_score_codex":0.002489539,"about_ca_system_score_gemma":0.003751218,"threshold_uncertainty_score":0.02164203},"labels":[],"label_agreement":null},{"id":"W3019602056","doi":"10.1634/theoncologist.2020-0194","title":"Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Blockade; Tocilizumab; Melanoma; Immunotherapy; Oncology; Immune checkpoint; Immune system; Adverse effect; Cytokine; Chimeric antigen receptor; Internal medicine; Immunology; Cancer research; Receptor; Disease","score_opus":0.038032293583396076,"score_gpt":0.3468623536365209,"score_spread":0.30883006005312486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019602056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015348342,0.9962083,0.0003897615,0.000447063,0.00029868764,0.000008453366,0.00001886907,0.000012356383,0.0010816351],"genre_scores_gemma":[0.012091812,0.98553663,0.0004978613,0.0006769053,0.0006045834,0.000010089381,0.000047769,0.000005423537,0.00052885426],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9998246,0.000026398233,0.000048112983,0.000041120697,0.000041207688,0.000018527691],"domain_scores_gemma":[0.99971145,0.00016166181,0.00005677418,0.000010091555,0.000032543336,0.00002748797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023326925,0.00066467945,0.001326801,0.0021238998,0.00033091687,0.00062886614,0.0007884571,0.0010807228,0.0012796457],"category_scores_gemma":[0.0005994473,0.00021928665,0.0006493249,0.0017929844,0.00054621376,0.0010365912,0.0003258245,0.0013051082,0.0007228884],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013954764,0.00017477758,0.0026615337,0.027629605,0.00041993125,0.10171306,0.00031684974,0.000672333,0.00563491,0.0020452216,0.034981396,0.82361084],"study_design_scores_gemma":[0.000052733398,0.00022618502,0.005913771,0.0071988157,0.0006652101,0.60749,0.00045647463,0.00042103097,0.002479852,0.0018149136,0.3731724,0.0001086512],"about_ca_topic_score_codex":0.0006025712,"about_ca_topic_score_gemma":0.0011715076,"teacher_disagreement_score":0.0021238998,"about_ca_system_score_codex":0.00040659864,"about_ca_system_score_gemma":0.0005743653,"threshold_uncertainty_score":0.004280865},"labels":[],"label_agreement":null},{"id":"W3022563976","doi":"10.1634/theoncologist.2019-0676","title":"Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Thrombosis; Internal medicine; Oncology; Medical physics; Family medicine","score_opus":0.37416401922442544,"score_gpt":0.46257101003916545,"score_spread":0.08840699081474002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022563976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890027,0.00020858659,0.00014356755,0.0009319194,0.00003630123,0.00029385142,0.0075061894,0.000016083199,0.0018608664],"genre_scores_gemma":[0.9875485,0.00037063184,0.00040352225,0.0017371288,0.000057885907,0.00055939297,0.007586056,0.000010371505,0.001726607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840254,0.0004179487,0.00021913226,0.00018867695,0.00035719876,0.00041457597],"domain_scores_gemma":[0.99297357,0.00076798204,0.0025615932,0.0002583572,0.0014929023,0.0019456174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030273555,0.00023509591,0.00035782365,0.0012932479,0.0004577946,0.0007913649,0.0003065843,0.0009535204,0.002312899],"category_scores_gemma":[0.0056796535,0.000294505,0.0005438438,0.0016257021,0.00019697718,0.000993875,0.0009281836,0.00086653116,0.0012226682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005383444,0.0002420514,0.9928838,0.00003028046,0.00001824388,0.00006354418,0.00042605842,0.000025711806,0.00014548155,0.000017743017,0.0025473488,0.0035458666],"study_design_scores_gemma":[0.000010869767,0.00020962906,0.996953,0.00001701053,0.000009416729,0.00008491504,0.00085609645,0.00008426331,0.000056487876,0.000008069071,0.0017046316,0.0000056333124],"about_ca_topic_score_codex":0.008360526,"about_ca_topic_score_gemma":0.007166828,"teacher_disagreement_score":0.008360526,"about_ca_system_score_codex":0.0009293128,"about_ca_system_score_gemma":0.0009896664,"threshold_uncertainty_score":0.016623735},"labels":[],"label_agreement":null},{"id":"W3023770233","doi":"10.1634/theoncologist.2020-0329","title":"In Reply","year":2020,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Impact; Western University; Juravinski Cancer Centre; McMaster University; University of Toronto","funders":"Roche","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Medicine; Intensive care medicine; Philosophy; Internal medicine; Infectious disease (medical specialty)","score_opus":0.05260909331288252,"score_gpt":0.3349026653436883,"score_spread":0.28229357203080574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023770233","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014696777,0.0013644701,0.000053898588,0.9301304,0.066198304,0.000015368307,0.00006459786,0.000040613264,0.0019854459],"genre_scores_gemma":[0.0008391227,0.00067758636,0.00006669302,0.9611366,0.03221897,0.000022504271,0.000023202252,0.00001913267,0.004996216],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964844,0.000989932,0.00041049565,0.00047832727,0.001053534,0.00058327726],"domain_scores_gemma":[0.98989177,0.004345914,0.0007283847,0.00027107814,0.0029348028,0.0018280898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004290497,0.00113586,0.0016472106,0.0009902942,0.00394685,0.004691376,0.002872737,0.040757306,0.01454606],"category_scores_gemma":[0.03440644,0.00094894896,0.0014411631,0.00069647253,0.0024113904,0.00447547,0.0023831192,0.03751572,0.013717661],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019027719,0.0000081882,0.00014398884,0.000026459278,0.0000048201964,0.00030069554,0.000055541186,0.000010662453,0.000027914575,0.00030017868,0.9972572,0.0018454861],"study_design_scores_gemma":[0.00006415974,0.000037044843,0.0006137291,0.00024259006,0.000018901572,0.0009660924,0.00043935806,0.00009618347,0.0001205208,0.0018919528,0.995453,0.000056386747],"about_ca_topic_score_codex":0.0069965995,"about_ca_topic_score_gemma":0.011377193,"teacher_disagreement_score":0.040757306,"about_ca_system_score_codex":0.0034043416,"about_ca_system_score_gemma":0.005696244,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W3027051509","doi":"10.1634/theoncologist.2019-0384","title":"Frequency, Timing, and Predictors of Palliative Care Consultation in Patients with Advanced Cancer at a Tertiary Cancer Center: Secondary Analysis of Routinely Collected Health Data","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Covenant Health; Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine; Cancer; Odds ratio; Palliative care; Cancer registry; Family medicine; Tertiary care; Residence; Logistic regression; Confidence interval; Health care; Emergency medicine; Gerontology; Internal medicine; Demography; Nursing","score_opus":0.11321776236724916,"score_gpt":0.4174774897412399,"score_spread":0.3042597273739907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027051509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970872,0.0001447366,0.00009045256,0.000060668048,0.000004373047,0.00003389494,0.0022423894,0.000006051229,0.00033031948],"genre_scores_gemma":[0.9974637,0.000053928616,0.00013960857,0.000041680512,0.000009931404,0.000034704095,0.0021289827,0.000002216245,0.0001250861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986552,0.00033798048,0.00015107034,0.00028321127,0.00032372688,0.0002487733],"domain_scores_gemma":[0.9954209,0.0009283204,0.0021643047,0.00029705474,0.00062956125,0.00055995595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015125191,0.00025722093,0.00035273813,0.0016783783,0.00052992505,0.0006442285,0.0006647342,0.00033999878,0.001517974],"category_scores_gemma":[0.0040427,0.00026060277,0.0005886671,0.002869031,0.00032866382,0.00024307174,0.00088137813,0.00057690335,0.00015836855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007187342,0.00002485794,0.999037,0.000014860293,0.000040525883,0.000023739662,0.0000546706,0.000041831026,0.000047641133,0.000007251686,0.00018687797,0.00044881328],"study_design_scores_gemma":[0.000010640931,0.00004389625,0.9992157,0.00001390844,0.000024122535,0.00006091224,0.0001772425,0.00026642036,0.000030724143,0.0000066520506,0.00014655279,0.0000032452201],"about_ca_topic_score_codex":0.1390918,"about_ca_topic_score_gemma":0.18386535,"teacher_disagreement_score":0.1390918,"about_ca_system_score_codex":0.0018554009,"about_ca_system_score_gemma":0.002374128,"threshold_uncertainty_score":0.27656436},"labels":[],"label_agreement":null},{"id":"W3033163494","doi":"10.1634/theoncologist.2020-0416","title":"Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Stereotactic radiotherapy; Pandemic; Radiation therapy; Medical physics; Radiology; Internal medicine; Virology; Radiosurgery","score_opus":0.11875690017119633,"score_gpt":0.32598310306311906,"score_spread":0.20722620289192273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033163494","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054643257,0.0057072258,0.000094145245,0.9449824,0.04797619,0.0000033782683,0.000011577231,0.000011414516,0.0006673024],"genre_scores_gemma":[0.011546518,0.020862056,0.00047278975,0.5433812,0.42164582,0.00001345971,0.000026644231,0.00003117145,0.002020361],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760014,0.00091510307,0.00040090462,0.00022614669,0.00059811777,0.0002596088],"domain_scores_gemma":[0.98421246,0.00798338,0.0013614206,0.00039862652,0.0038787369,0.002165328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048137256,0.0005945658,0.0014203158,0.00073407043,0.0020614336,0.0033700732,0.001749717,0.018447002,0.0031818922],"category_scores_gemma":[0.029772364,0.00040558793,0.00095523166,0.00067896553,0.0028361806,0.0057646176,0.0011354209,0.018523157,0.001457664],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012884222,0.00005111191,0.0029486346,0.0002796065,0.00003796189,0.0038963389,0.00029023612,0.00015364042,0.00021671629,0.0038997775,0.9594039,0.028693283],"study_design_scores_gemma":[0.00017094822,0.0002496112,0.0057584704,0.0016829037,0.00011995428,0.017429635,0.0030815112,0.0008117655,0.00050811394,0.01765246,0.95232004,0.00021463193],"about_ca_topic_score_codex":0.003854569,"about_ca_topic_score_gemma":0.009388816,"teacher_disagreement_score":0.018447002,"about_ca_system_score_codex":0.0026329535,"about_ca_system_score_gemma":0.0040315185,"threshold_uncertainty_score":0.02545774},"labels":[],"label_agreement":null},{"id":"W3033319492","doi":"10.1634/theoncologist.2019-0875","title":"Neurological and Dexterity Assessments in a Woman with Radiation-Induced Brachial Plexopathy After Breast Cancer","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Peripheral Nerve Disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Brachial Plexopathy; Medicine; Breast cancer; Complication; Cancer; Physical therapy; Physical medicine and rehabilitation; Surgery; Brachial plexus; Internal medicine","score_opus":0.02715071571202974,"score_gpt":0.32369098163615684,"score_spread":0.2965402659241271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033319492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676013,0.004082815,0.0016784507,0.008245319,0.00040995295,0.0001122893,0.00025698324,0.00013004412,0.01748277],"genre_scores_gemma":[0.9931906,0.0015454981,0.0008728464,0.0017088656,0.00049081346,0.000017618006,0.0000858554,0.00001854847,0.002069498],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99953055,0.00008005155,0.0000622745,0.00008773691,0.00008868127,0.00015073427],"domain_scores_gemma":[0.998998,0.00032607422,0.00020230525,0.00004963541,0.000109210254,0.0003147408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040626703,0.0008837235,0.0006389612,0.0022801699,0.0013835382,0.0009958668,0.00080205034,0.0031478023,0.001933697],"category_scores_gemma":[0.0031266268,0.00056892337,0.000581981,0.00090208603,0.00091294246,0.001130738,0.00095860596,0.0026174693,0.0007447234],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037428286,0.00006146325,0.012068101,0.000017787941,0.000005235993,0.98478764,0.00031147842,0.00009807236,0.00063645176,0.00007542552,0.00032624853,0.0015747],"study_design_scores_gemma":[0.0000068807694,0.00018147033,0.012428022,0.000039283757,0.000013520789,0.985335,0.00028489076,0.00040051475,0.00047159079,0.00012487068,0.0006992523,0.000014756086],"about_ca_topic_score_codex":0.004123657,"about_ca_topic_score_gemma":0.0064314594,"teacher_disagreement_score":0.004123657,"about_ca_system_score_codex":0.0013083109,"about_ca_system_score_gemma":0.0008545048,"threshold_uncertainty_score":0.009492457},"labels":[],"label_agreement":null},{"id":"W3035631034","doi":"10.1634/theoncologist.2020-0451","title":"Evolution of Cancer Care in Response to the COVID-19 Pandemic","year":2020,"lang":"en","type":"letter","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Impact; Western University; Juravinski Cancer Centre; McMaster University; University of Toronto","funders":"Genentech; Pfizer","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Betacoronavirus; Medicine; Virology; Internal medicine; Outbreak; Infectious disease (medical specialty); Disease","score_opus":0.15634369681455573,"score_gpt":0.4652982179968371,"score_spread":0.3089545211822814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035631034","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041988422,0.00045320953,0.00004109142,0.98911566,0.007298652,0.000004229793,0.000015914158,0.000007701692,0.0026435857],"genre_scores_gemma":[0.003592683,0.00056312454,0.00011302873,0.9799564,0.012327885,0.000010013087,0.000014693939,0.000015462248,0.0034068292],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99415565,0.002057784,0.0005048326,0.00046370403,0.0013409304,0.001477011],"domain_scores_gemma":[0.98608726,0.005849012,0.0009819941,0.00036374762,0.0024129779,0.0043049445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059210807,0.00037123024,0.00066075154,0.0005927879,0.0077179708,0.0070873457,0.001878876,0.05079014,0.011182201],"category_scores_gemma":[0.031127188,0.000495561,0.0010904984,0.00076445664,0.0039048623,0.004826274,0.0034919211,0.032437723,0.0038398963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027687523,0.00003339323,0.0015777644,0.00005149518,0.000010828474,0.0019376053,0.0005027309,0.000109709275,0.00016334138,0.0068276688,0.9800947,0.008663073],"study_design_scores_gemma":[0.000036639285,0.000048140904,0.0019866338,0.0002653989,0.0000126364785,0.0016110989,0.0017861963,0.0003601795,0.00016147645,0.008291254,0.98537976,0.000060665512],"about_ca_topic_score_codex":0.025340894,"about_ca_topic_score_gemma":0.06750783,"teacher_disagreement_score":0.05079014,"about_ca_system_score_codex":0.009249266,"about_ca_system_score_gemma":0.016252093,"threshold_uncertainty_score":0.06710845},"labels":[],"label_agreement":null},{"id":"W3044963562","doi":"10.1634/theoncologist.2020-0502","title":"Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an <i>HLA-DRB1-MET</i> Gene Fusion","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"EMD Serono","keywords":"Crizotinib; Cabozantinib; Fusion gene; ROS1; Medicine; Lung cancer; Cancer research; KRAS; Erlotinib; Clinical trial; Oncology; Tyrosine kinase; Gene; Cancer; Internal medicine; Bioinformatics; Biology; Genetics; Receptor; Colorectal cancer; Epidermal growth factor receptor; Adenocarcinoma","score_opus":0.023497750649620886,"score_gpt":0.3182121643940267,"score_spread":0.2947144137444058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044963562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668103,0.0014675114,0.00014510253,0.00045534584,0.000027412878,0.000017448465,0.000067552086,0.000015451764,0.0011230436],"genre_scores_gemma":[0.998694,0.0005543457,0.0001095758,0.00016529349,0.000029945131,0.000004027934,0.00007799584,0.0000028470683,0.00036194964],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9999261,0.000011959873,0.000011731837,0.000017373122,0.000012644026,0.000020299234],"domain_scores_gemma":[0.9998598,0.000043394473,0.000020838257,0.000007634696,0.000007737343,0.000060500824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010091925,0.0003076228,0.00056813605,0.00020441256,0.0004264255,0.00034250482,0.00018947679,0.0006649145,0.0005904031],"category_scores_gemma":[0.00043072214,0.00013248718,0.00032500457,0.00016276883,0.00017552418,0.00024918048,0.00016976813,0.0008251199,0.0002174314],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015535524,0.0037062399,0.09279823,0.0005022887,0.00037063865,0.59760636,0.00113744,0.0038724702,0.16298929,0.0004655745,0.002556897,0.11845898],"study_design_scores_gemma":[0.0017193748,0.04345651,0.18975681,0.00006436428,0.0005536924,0.70164245,0.00042260124,0.008038475,0.04345184,0.00040655,0.0103546595,0.00013263516],"about_ca_topic_score_codex":0.0005053523,"about_ca_topic_score_gemma":0.0012982875,"teacher_disagreement_score":0.0006649145,"about_ca_system_score_codex":0.00031186568,"about_ca_system_score_gemma":0.0001886285,"threshold_uncertainty_score":0.0022627711},"labels":[],"label_agreement":null},{"id":"W3045831398","doi":"10.1634/theoncologist.2020-0054","title":"Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Randomized controlled trial; Medicine; Confidence interval; Guideline; Subspecialty; Brier score; Sample size determination; Medical physics; Family medicine; Statistics; Surgery; Internal medicine; Mathematics","score_opus":0.6602040357516019,"score_gpt":0.6079458512679481,"score_spread":0.052258184483653825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045831398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6912334,0.04405809,0.19299436,0.042289093,0.0013840179,0.0039872695,0.003445673,0.00063977996,0.019968335],"genre_scores_gemma":[0.9591431,0.0018708749,0.033197757,0.0036159446,0.00068590173,0.00084903947,0.0004755359,0.000031723303,0.00013014607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.65038127,0.29720804,0.019637577,0.013785703,0.017285872,0.0017015546],"domain_scores_gemma":[0.08865814,0.82193065,0.057435032,0.020240802,0.009641598,0.002093756],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3679161,0.001244436,0.0027815,0.004472126,0.00064658094,0.003894617,0.0020735504,0.0037657088,0.0024058907],"category_scores_gemma":[0.75097656,0.00087081874,0.0028679264,0.0027089666,0.0035319906,0.0059861327,0.0019307415,0.0030068692,0.0008215655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073419935,0.00053671084,0.721112,0.0037507515,0.010659514,0.00022134393,0.0026709477,0.030855445,0.0005156079,0.0042611444,0.009094035,0.20898044],"study_design_scores_gemma":[0.00481815,0.0061814515,0.6005092,0.0069478257,0.006662446,0.0015155011,0.0017127033,0.20337763,0.0028598502,0.14737947,0.017486634,0.000549043],"about_ca_topic_score_codex":0.0013520754,"about_ca_topic_score_gemma":0.0020639983,"teacher_disagreement_score":0.6320839,"about_ca_system_score_codex":0.0015475611,"about_ca_system_score_gemma":0.0029237377,"threshold_uncertainty_score":0.779472},"labels":[],"label_agreement":null},{"id":"W3046214598","doi":"10.1634/theoncologist.2020-0167","title":"Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"American Cancer Society","keywords":"Medicine; Blockade; Lymphoma; Hodgkin lymphoma; Oncology; Intensive care medicine; Internal medicine","score_opus":0.08913903546279209,"score_gpt":0.3272881326373819,"score_spread":0.2381490971745898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046214598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941041,0.0029282148,0.00036479652,0.0001195478,0.000011147836,0.00006088866,0.00009035386,0.000018744362,0.0023022727],"genre_scores_gemma":[0.9989102,0.0005772766,0.00014657828,0.000093045535,0.000027117307,0.000018141329,0.0000996727,0.0000028219958,0.0001250939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99942636,0.00016812973,0.00010116739,0.00007445501,0.00011762458,0.00011230529],"domain_scores_gemma":[0.9976907,0.00079871167,0.0011060096,0.00012085176,0.00012524395,0.00015852293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001387896,0.00013638729,0.00028182604,0.00037326326,0.00016821799,0.00044823956,0.00015926307,0.00018235357,0.0018420473],"category_scores_gemma":[0.0030989232,0.00006198018,0.00031648818,0.00032990324,0.00022819077,0.00027346006,0.0002929184,0.00035194724,0.00017553523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013919813,0.00021683011,0.92730606,0.0002274552,0.00015955666,0.0005559316,0.00015742563,0.00030363057,0.0046305554,0.00013652068,0.00029918388,0.06461493],"study_design_scores_gemma":[0.00021977597,0.0029579832,0.97951734,0.00014220826,0.00029793824,0.005842829,0.00015824616,0.00056458235,0.004698607,0.00025809743,0.005334224,0.000008242412],"about_ca_topic_score_codex":0.00032646194,"about_ca_topic_score_gemma":0.00068967865,"teacher_disagreement_score":0.0018420473,"about_ca_system_score_codex":0.00048332152,"about_ca_system_score_gemma":0.00029232667,"threshold_uncertainty_score":0.0073399544},"labels":[],"label_agreement":null},{"id":"W3046580696","doi":"10.1634/theoncologist.2020-0420","title":"Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Ottawa; University of Manitoba; BC Cancer Agency; Ottawa Hospital; University of British Columbia; CancerCare Manitoba","funders":"","keywords":"Outbreak; Pandemic; Coronavirus disease 2019 (COVID-19); Coronavirus; Virology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Germ cell tumors; Disease; Medicine; Infectious disease (medical specialty); Pathology; Internal medicine","score_opus":0.21996722950197187,"score_gpt":0.41524940432469926,"score_spread":0.1952821748227274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046580696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763405,0.00032800902,0.00005884317,0.0005089444,0.0000097455195,0.00002726625,0.00016231013,0.0000038753947,0.0012669577],"genre_scores_gemma":[0.99860495,0.0005153731,0.00011784879,0.000323722,0.000015700873,0.000018820861,0.00017338601,0.0000023610735,0.00022786291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991924,0.00027997716,0.0000898483,0.000093554234,0.00014146828,0.00020268107],"domain_scores_gemma":[0.9960096,0.00060082553,0.0018814882,0.00009629122,0.00052788475,0.00088391756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017127523,0.0001437507,0.00013626873,0.000701955,0.0004750917,0.00051853596,0.0002961482,0.00051102525,0.0014472365],"category_scores_gemma":[0.004477355,0.00012978804,0.00019671235,0.00087126193,0.0004147275,0.0005113278,0.0006604059,0.00037335456,0.00018446612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045516266,0.000053670457,0.9868997,0.00005493719,0.000010910025,0.00019080636,0.0050488478,0.000054671524,0.00026993058,0.00003758852,0.0011720576,0.0061614225],"study_design_scores_gemma":[0.0000064294754,0.0001937384,0.9780552,0.000068188274,0.000009603307,0.0004341726,0.017859451,0.00013382763,0.00009252094,0.0000125422375,0.0031253512,0.000008985281],"about_ca_topic_score_codex":0.012291989,"about_ca_topic_score_gemma":0.011483067,"teacher_disagreement_score":0.012291989,"about_ca_system_score_codex":0.0008427117,"about_ca_system_score_gemma":0.0010696169,"threshold_uncertainty_score":0.024440885},"labels":[],"label_agreement":null},{"id":"W3080782372","doi":"10.1634/theoncologist.2020-0572","title":"Cancer and Risk of COVID-19 Through a General Community Survey","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Engineering and Physical Sciences Research Council; Medical Research Council; Stand Up To Cancer; Stiftelsen för Strategisk Forskning; National Institute for Health and Care Research; Medical Research Council Canada; Massachusetts Consortium on Pathogen Readiness; Wellcome Trust; Alzheimer's Society; King's College London; Seerave Foundation; Crohn's and Colitis Foundation; British Heart Foundation","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cancer; Pandemic; Medicine; Geography; Virology; Pathology; Disease; Internal medicine; Outbreak; Infectious disease (medical specialty)","score_opus":0.35047692151969706,"score_gpt":0.49412428660631635,"score_spread":0.1436473650866193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080782372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880463,0.0012200881,0.00018107572,0.0005682473,0.00003407095,0.00008032972,0.0070840456,0.0000163072,0.0027694495],"genre_scores_gemma":[0.9965229,0.0005553537,0.00011426464,0.00029521118,0.000021766502,0.000040703595,0.0019646625,0.0000039221068,0.00048120195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940693,0.00014519817,0.00006279886,0.00014997536,0.00012052732,0.00011455283],"domain_scores_gemma":[0.9985934,0.00012062899,0.0006981853,0.00007964593,0.0002055227,0.00030268912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005220205,0.0001568021,0.00022188936,0.00081373716,0.00042982693,0.000555558,0.0002934338,0.0004412014,0.0021996452],"category_scores_gemma":[0.0026153093,0.0002563425,0.00045513368,0.0015565731,0.00018327741,0.00052833883,0.00059673644,0.00058719923,0.00033350763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000417318,0.000031059324,0.9978333,0.000024199988,0.000057963076,0.000019560253,0.000060828897,0.00001726878,0.000050081075,0.000014507472,0.0005765385,0.0012729521],"study_design_scores_gemma":[0.000004016688,0.000036302517,0.9992219,0.000020166275,0.000017243867,0.00004936619,0.00013909051,0.000059325248,0.000010996822,0.000016136757,0.00042231748,0.0000031191316],"about_ca_topic_score_codex":0.0504388,"about_ca_topic_score_gemma":0.056952026,"teacher_disagreement_score":0.0504388,"about_ca_system_score_codex":0.00051330583,"about_ca_system_score_gemma":0.00047838525,"threshold_uncertainty_score":0.10029042},"labels":[],"label_agreement":null},{"id":"W3080952862","doi":"10.1634/theoncologist.2020-0379","title":"Therapeutic Potential of Afatinib in<i>NRG1</i>Fusion-Driven Solid Tumors: A Case Series","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; University of Toronto","funders":"National Cancer Institute","keywords":"Afatinib; Series (stratigraphy); Fusion; Computer science; Computational biology; Cancer research; Medicine; Biology; Internal medicine; Cancer","score_opus":0.08401261259245403,"score_gpt":0.391276329499115,"score_spread":0.307263716906661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080952862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97208834,0.007123539,0.005068329,0.002285829,0.0003395794,0.00019572479,0.00029043283,0.00026554248,0.012342843],"genre_scores_gemma":[0.99497116,0.0015745746,0.0014165232,0.00043109225,0.0003891566,0.000025212552,0.00010285862,0.00003035364,0.001059088],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9993268,0.00007409867,0.00010040457,0.00013179945,0.00012862397,0.00023819525],"domain_scores_gemma":[0.99848855,0.0003885397,0.00034184597,0.00018584859,0.00008194845,0.0005133353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036020952,0.0016354113,0.0010040168,0.0015341495,0.0020234885,0.0016076495,0.0010550839,0.0047837123,0.0017002124],"category_scores_gemma":[0.0019296306,0.00064287236,0.0016496732,0.0010866642,0.0014248997,0.001416251,0.001023663,0.002337232,0.0013262755],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033001466,0.0000494644,0.0037024028,0.000040138144,0.000017302906,0.99222916,0.00012118658,0.00015830011,0.0010745414,0.00013024543,0.00023479643,0.0022094673],"study_design_scores_gemma":[0.000008761923,0.00005858166,0.001462119,0.000007805832,0.000012354961,0.99693847,0.000042689764,0.00024987658,0.000568986,0.000060217608,0.00058378465,0.000006323363],"about_ca_topic_score_codex":0.0010583557,"about_ca_topic_score_gemma":0.0014780014,"teacher_disagreement_score":0.0047837123,"about_ca_system_score_codex":0.00115046,"about_ca_system_score_gemma":0.00060141593,"threshold_uncertainty_score":0.008347213},"labels":[],"label_agreement":null},{"id":"W3081953801","doi":"10.1634/theoncologist.2020-0193","title":"Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McMaster University; Trillium Health Centre; Juravinski Cancer Centre; Hôpital du Sacré-Cœur de Montréal; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Université de Montréal; William Osler Health System; University of Toronto; University of British Columbia","funders":"Pfizer Canada; Merck Canada; AstraZeneca Canada","keywords":"Medicine; Oncology; Tremelimumab; Lung cancer; Chemotherapy; Internal medicine; Durvalumab; Ipilimumab; Clinical trial; Immunotherapy; Radiation therapy; Maintenance therapy; Cancer; Stage (stratigraphy); Intensive care medicine; Nivolumab","score_opus":0.08041116675697593,"score_gpt":0.41151793173614376,"score_spread":0.3311067649791678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081953801","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009557234,0.9968094,0.00006620194,0.00131813,0.00013636777,0.000015817845,0.00004655414,0.000003911724,0.00064779294],"genre_scores_gemma":[0.0141899735,0.98321366,0.00032718913,0.0012682333,0.0005394182,0.000036164467,0.00009163412,0.0000025558127,0.0003311779],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99953306,0.00017321347,0.00010785853,0.000056218898,0.0001013096,0.000028408414],"domain_scores_gemma":[0.9978941,0.0011905001,0.0005662659,0.000031111675,0.0002417015,0.00007638913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021706396,0.0003749148,0.0012832645,0.0013659637,0.0001642279,0.0009753109,0.0005861477,0.00083119946,0.0039927256],"category_scores_gemma":[0.0030726108,0.000115730145,0.0011087317,0.001755927,0.00030461795,0.0012977466,0.00048490916,0.0012051178,0.00046583096],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010338464,0.00007275468,0.00072918093,0.06742095,0.0005008293,0.00016162726,0.00006508615,0.00042865152,0.0011836734,0.0014340669,0.0091791125,0.91779023],"study_design_scores_gemma":[0.0022929402,0.004926622,0.02046155,0.18720074,0.007619913,0.0033490998,0.000519172,0.0011835744,0.0022334892,0.010359396,0.75973517,0.00011835365],"about_ca_topic_score_codex":0.00073450635,"about_ca_topic_score_gemma":0.002763142,"teacher_disagreement_score":0.0039927256,"about_ca_system_score_codex":0.0006447251,"about_ca_system_score_gemma":0.0013488143,"threshold_uncertainty_score":0.013357043},"labels":[],"label_agreement":null},{"id":"W3087595029","doi":"10.1002/onco.13534","title":"Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Sex and Gender in Healthcare","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical trial; Cancer; Odds ratio; Population; Incidence (geometry); Confidence interval; Hazard ratio; Colorectal cancer; Lung cancer","score_opus":0.4713897760368523,"score_gpt":0.5288085882184081,"score_spread":0.05741881218155587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087595029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8457279,0.081900425,0.01354334,0.019146506,0.00079799176,0.0011332344,0.008665643,0.00010556525,0.02897926],"genre_scores_gemma":[0.982277,0.008730371,0.0020608224,0.003127037,0.0007825231,0.00060606503,0.0016419634,0.000045525718,0.00072867004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.90721905,0.060850035,0.012785409,0.0069247535,0.010431789,0.0017890268],"domain_scores_gemma":[0.7462166,0.14553572,0.089617334,0.009377601,0.0065302467,0.002722448],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06196573,0.00025854545,0.0008831548,0.0042119147,0.00058290054,0.0019756153,0.00074662926,0.0007312629,0.0047216844],"category_scores_gemma":[0.165619,0.0002780246,0.0012487902,0.0046925424,0.0012603728,0.0017792654,0.0019511182,0.000909341,0.0005796161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028372584,0.00008082419,0.87848383,0.002155576,0.0014433053,0.00025318854,0.0017258483,0.00030407205,0.0008007473,0.0031912657,0.0042472268,0.104476824],"study_design_scores_gemma":[0.00057807146,0.0013278308,0.9364188,0.0028714687,0.0016510685,0.0037701605,0.0019893001,0.0010497031,0.0019969586,0.008047564,0.0402222,0.000076798104],"about_ca_topic_score_codex":0.00081846846,"about_ca_topic_score_gemma":0.001352266,"teacher_disagreement_score":0.9380343,"about_ca_system_score_codex":0.0008567178,"about_ca_system_score_gemma":0.0015528514,"threshold_uncertainty_score":0.32771003},"labels":[],"label_agreement":null},{"id":"W3088260985","doi":"10.1002/onco.13540","title":"D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; National Institutes of Health","keywords":"Medicine; Apixaban; Placebo; Ambulatory; Internal medicine; Number needed to treat; Hazard ratio; Cohort; Randomization; Randomized controlled trial; Surgery; Warfarin; Confidence interval; Relative risk; Rivaroxaban; Pathology; Atrial fibrillation","score_opus":0.016637845471905083,"score_gpt":0.26783478285282286,"score_spread":0.25119693738091775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088260985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99345475,0.0046498096,0.0001429144,0.00031388877,0.000049351052,0.00008471283,0.00010694958,0.000016675314,0.001180809],"genre_scores_gemma":[0.9978097,0.0013822024,0.0002751716,0.00015916099,0.0000883936,0.000039358045,0.0001185932,0.0000016381975,0.0001258917],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99962115,0.00019412766,0.00003950455,0.0000431765,0.000059156147,0.0000428653],"domain_scores_gemma":[0.99893385,0.00042725189,0.00034007008,0.000033006745,0.000046184385,0.00021956649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085758034,0.00014384257,0.0007022159,0.00014025954,0.00013381548,0.00032981831,0.00012439047,0.00025092086,0.0018339718],"category_scores_gemma":[0.002411994,0.000082737686,0.00046974534,0.00020576888,0.00013108828,0.0001579136,0.00021119152,0.0005138977,0.00015878498],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23565876,0.014802834,0.21755582,0.0019215975,0.0024928153,0.000336275,0.0002750815,0.0023488218,0.0111687,0.00038291427,0.00541649,0.5076399],"study_design_scores_gemma":[0.06835175,0.20403896,0.7121463,0.00024801196,0.0019713503,0.0010486635,0.00010242696,0.00412055,0.0030323674,0.00068677013,0.0042200424,0.00003292357],"about_ca_topic_score_codex":0.0002561754,"about_ca_topic_score_gemma":0.00050106394,"teacher_disagreement_score":0.0018339718,"about_ca_system_score_codex":0.00020120703,"about_ca_system_score_gemma":0.00032859397,"threshold_uncertainty_score":0.006135285},"labels":[],"label_agreement":null},{"id":"W3097964344","doi":"10.1002/onco.13586","title":"Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Medical Research Council Canada; AstraZeneca; University College London; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Pulmonologists; Multidisciplinary approach; Medicine; Best practice; Health care; Intensive care medicine; Medical physics","score_opus":0.07099644965333216,"score_gpt":0.4012783948059526,"score_spread":0.33028194515262044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097964344","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014368487,0.084740564,0.0005898467,0.88294566,0.029490124,0.000036155026,0.000103525104,0.00002752366,0.0019229911],"genre_scores_gemma":[0.008509643,0.13199101,0.0017866585,0.7930016,0.06241593,0.00020980817,0.00016461925,0.00005532427,0.0018654509],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.974912,0.016089853,0.0029788704,0.0015388143,0.0034194111,0.0010610636],"domain_scores_gemma":[0.84324425,0.11536783,0.0052137435,0.0011778846,0.030018656,0.0049776793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01940106,0.0010617104,0.0022033616,0.001456434,0.002998815,0.0041701416,0.005421783,0.023458343,0.007831779],"category_scores_gemma":[0.15298206,0.00064143835,0.0037424683,0.0018652882,0.0040779635,0.008369841,0.0036869857,0.026059233,0.003310907],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000530203,0.000015805383,0.00021326343,0.00486233,0.00009262782,0.0006234632,0.0009134862,0.0002671086,0.000050856688,0.003534963,0.9486832,0.040689886],"study_design_scores_gemma":[0.00019363996,0.00007540071,0.0006427386,0.05087087,0.00032838646,0.0020939878,0.0024020467,0.0004350269,0.000112632624,0.015427765,0.9272652,0.00015224594],"about_ca_topic_score_codex":0.016152123,"about_ca_topic_score_gemma":0.02759218,"teacher_disagreement_score":0.023458343,"about_ca_system_score_codex":0.007885245,"about_ca_system_score_gemma":0.01885915,"threshold_uncertainty_score":0.10260385},"labels":[],"label_agreement":null},{"id":"W3107319220","doi":"10.1002/onco.13619","title":"Edmonton Symptom Assessment Scale Time Duration of Self-Completion Versus Assisted Completion in Patients with Advanced Cancer: A Randomized Comparison","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health; American Society of Clinical Oncology","keywords":"Medicine; Interquartile range; Randomized controlled trial; Quality of life (healthcare); Physical therapy; Stopwatch; Health literacy; Cancer; Health care; Internal medicine; Nursing","score_opus":0.0220338104379046,"score_gpt":0.31391132910199093,"score_spread":0.29187751866408634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107319220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981385,0.004886461,0.0007539454,0.0007427685,0.0012901111,0.008059471,0.0008164059,0.000054259996,0.0020115124],"genre_scores_gemma":[0.9767091,0.0026007139,0.0018645386,0.00083839055,0.0010027295,0.014315758,0.00050867297,0.000015466194,0.0021445996],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951632,0.0031756628,0.00039878808,0.0005613517,0.00033013322,0.00037079206],"domain_scores_gemma":[0.9944149,0.0029632768,0.001245853,0.00026396613,0.00028233303,0.00082960294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051136906,0.0015535754,0.004509538,0.0009232246,0.0005554389,0.0015781191,0.0015780823,0.003502307,0.010973087],"category_scores_gemma":[0.0072549917,0.0010665231,0.0034408823,0.0007742982,0.0014023246,0.002142245,0.0008948552,0.0030562284,0.001099075],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98970044,0.004345722,0.00056088786,0.00030753764,0.00055514264,0.0000124335675,0.00003094932,0.0000855692,0.00017840428,0.000055898177,0.00011955907,0.004047438],"study_design_scores_gemma":[0.89938635,0.09768902,0.0015214133,0.00005566672,0.00053970714,0.000012921829,0.00003938623,0.00027680016,0.00010372415,0.00012757146,0.00023437547,0.000013099045],"about_ca_topic_score_codex":0.0010158714,"about_ca_topic_score_gemma":0.0016726474,"teacher_disagreement_score":0.010973087,"about_ca_system_score_codex":0.0015478956,"about_ca_system_score_gemma":0.0018859942,"threshold_uncertainty_score":0.036708653},"labels":[],"label_agreement":null},{"id":"W3107519578","doi":"10.1002/onco.13570","title":"Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Intensive care medicine; Cancer; Venous thromboembolism; Malignancy; Thrombosis; Population; MEDLINE; Best practice; Surgery; Internal medicine; Environmental health","score_opus":0.1017201912939881,"score_gpt":0.35207370136422816,"score_spread":0.2503535100702401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107519578","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022412243,0.3769629,0.0055825156,0.5972542,0.0072540087,0.000106579435,0.00015709204,0.00008959086,0.010351912],"genre_scores_gemma":[0.047131293,0.7322762,0.026493944,0.17070258,0.020059764,0.00031414753,0.00040156257,0.00007591763,0.002544645],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900765,0.0048581525,0.0018239759,0.0009241305,0.0017618226,0.0005554738],"domain_scores_gemma":[0.9372761,0.041822743,0.0042607174,0.0009583099,0.010880993,0.0048011346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014720138,0.00076602487,0.0016174613,0.0038074576,0.0029845056,0.007233935,0.0027315996,0.00568065,0.007196111],"category_scores_gemma":[0.06676,0.0005493399,0.0011722981,0.0022903113,0.0033538805,0.011267423,0.005012997,0.011889093,0.0023435282],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058930844,0.00019006732,0.0061687212,0.018521944,0.00018364635,0.0046346444,0.007739077,0.00075083744,0.000253543,0.022173764,0.24845898,0.69086576],"study_design_scores_gemma":[0.000044694116,0.00010390226,0.0035539467,0.119454764,0.00026539635,0.01978842,0.034545615,0.0009409611,0.00022802291,0.11766648,0.7032224,0.00018545505],"about_ca_topic_score_codex":0.006815241,"about_ca_topic_score_gemma":0.015647976,"teacher_disagreement_score":0.014720138,"about_ca_system_score_codex":0.0046627936,"about_ca_system_score_gemma":0.017830148,"threshold_uncertainty_score":0.077848494},"labels":[],"label_agreement":null},{"id":"W3109542415","doi":"10.1002/onco.13596","title":"Update on Guidelines for the Management of Cancer-Associated Thrombosis","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Clinical Practice; Disease management; Intensive care medicine; MEDLINE; Disease; Cancer; Best practice; Evidence-based practice; Alternative medicine; Family medicine; Pathology; Health management system; Political science; Internal medicine","score_opus":0.2789887118213781,"score_gpt":0.49205105712313496,"score_spread":0.21306234530175688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109542415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026776965,0.9660204,0.001420591,0.014493683,0.005460912,0.00031735838,0.0019844675,0.00015746095,0.009877387],"genre_scores_gemma":[0.0017019311,0.9738192,0.007274527,0.0076597785,0.0014997798,0.0003793256,0.0031597628,0.000037944912,0.004467773],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996965,0.00095698074,0.0007165008,0.0001325775,0.0010929814,0.00013585422],"domain_scores_gemma":[0.993149,0.002265997,0.0011618201,0.00012241713,0.003051506,0.0002493882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030345598,0.00091720594,0.0021206795,0.005603255,0.00051061064,0.0017316197,0.0021316174,0.0032731425,0.01376189],"category_scores_gemma":[0.013446233,0.00049103284,0.0035200685,0.0038406078,0.00045276427,0.0016779917,0.001183923,0.003406089,0.0062892847],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010879028,0.000083643565,0.00035847508,0.05266354,0.0003825983,0.00027039667,0.00018990568,0.00028356953,0.0003947425,0.0040014936,0.42644376,0.514819],"study_design_scores_gemma":[0.00005813391,0.000039261988,0.0008519118,0.042743195,0.0006485975,0.00055647996,0.00004140739,0.000067123525,0.00006718846,0.0012486981,0.9536595,0.000018517525],"about_ca_topic_score_codex":0.008106301,"about_ca_topic_score_gemma":0.015305241,"teacher_disagreement_score":0.01376189,"about_ca_system_score_codex":0.0019896291,"about_ca_system_score_gemma":0.008804997,"threshold_uncertainty_score":0.04603809},"labels":[],"label_agreement":null},{"id":"W3109953138","doi":"10.1002/onco.13626","title":"Implementing <i>DPYD*2A</i> Genotyping in Clinical Practice: The Quebec, Canada, Experience","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux des Laurentides; Centre Hospitalier Universitaire de Sherbrooke; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Développement Economique Longueuil; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"DPYD; Medicine; Mucositis; Internal medicine; Chemotherapy; Capecitabine; Genotyping; Dihydropyrimidine dehydrogenase; Oncology; Fluorouracil; Gastroenterology; Rash; Cancer; Pharmacogenetics; Genotype; Colorectal cancer; Genetics","score_opus":0.07498892060660377,"score_gpt":0.40888616775684533,"score_spread":0.33389724715024155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109953138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95212513,0.008693595,0.0022450218,0.012095362,0.00023245196,0.00076749065,0.0017288676,0.00017463742,0.021937326],"genre_scores_gemma":[0.98451567,0.0035044374,0.0034282985,0.0032309755,0.00007894193,0.0000964921,0.00090607774,0.00005710962,0.004181965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967908,0.00066960335,0.00015451718,0.00045708747,0.0012086533,0.00071928854],"domain_scores_gemma":[0.98485005,0.00092592975,0.0011361012,0.00031070714,0.0076147737,0.005162418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028527323,0.00049664226,0.0002499207,0.0004986048,0.0022850132,0.0016780627,0.0013573302,0.00071245246,0.001954998],"category_scores_gemma":[0.006294449,0.00030009606,0.00021909564,0.0017350973,0.0011892086,0.0005354114,0.0009281509,0.00092030666,0.000302217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006448442,0.0008878552,0.761946,0.00039457387,0.00010309638,0.0017841518,0.0061883735,0.0017975485,0.005085628,0.000651001,0.01972307,0.20079383],"study_design_scores_gemma":[0.00023759516,0.0016292863,0.95524716,0.00032914933,0.000073875766,0.0011616623,0.00468833,0.002177915,0.0010653415,0.00010753485,0.033200454,0.000081706916],"about_ca_topic_score_codex":0.9857799,"about_ca_topic_score_gemma":0.989842,"teacher_disagreement_score":0.041177765,"about_ca_system_score_codex":0.041177765,"about_ca_system_score_gemma":0.07937709,"threshold_uncertainty_score":0.29876697},"labels":[],"label_agreement":null},{"id":"W3111161573","doi":"10.1002/onco.13628","title":"A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Astellas Pharma","keywords":"Axitinib; Medicine; Renal cell carcinoma; Clinical endpoint; Internal medicine; Adverse effect; Population; Oncology; Phases of clinical research; Nausea; Gastroenterology; Urology; Pharmacology; Randomized controlled trial; Clinical trial; Sunitinib","score_opus":0.0631375381713145,"score_gpt":0.31530819442871005,"score_spread":0.25217065625739554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111161573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98631525,0.002516196,0.00066455704,0.0009803774,0.0004663928,0.0060904264,0.0009209285,0.00009591399,0.0019499708],"genre_scores_gemma":[0.9842874,0.0016321938,0.0016751267,0.0016676041,0.0005402164,0.005791783,0.0011527953,0.000025825635,0.0032270702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99910885,0.00050247944,0.000048801357,0.00013013049,0.00007534033,0.000134239],"domain_scores_gemma":[0.9984641,0.0002875531,0.00033765938,0.00014135223,0.000098923985,0.0006704693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032989508,0.0013812397,0.0024336954,0.00044234536,0.0005274769,0.0010860866,0.00096857233,0.0019130899,0.0052520935],"category_scores_gemma":[0.0020372886,0.0007093225,0.0018071515,0.0004705121,0.0015365727,0.001121044,0.00037591724,0.0038810794,0.0008667756],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9358647,0.028125005,0.0022542044,0.00039154256,0.001072994,0.00012541871,0.00010025807,0.00081787683,0.0073452084,0.00017310638,0.0015958627,0.022133758],"study_design_scores_gemma":[0.8797808,0.11606075,0.002252886,0.0000122758465,0.00019616683,0.000064021464,0.0000151889935,0.00038960733,0.0004107256,0.00011585538,0.0006904621,0.000011366184],"about_ca_topic_score_codex":0.00116192,"about_ca_topic_score_gemma":0.003373565,"teacher_disagreement_score":0.0052520935,"about_ca_system_score_codex":0.0012405431,"about_ca_system_score_gemma":0.0023067968,"threshold_uncertainty_score":0.017570019},"labels":[],"label_agreement":null},{"id":"W3113051965","doi":"10.1002/onco.13625","title":"Timing of Palliative Care Referral Before and After Evidence from Trials Supporting Early Palliative Care","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Kelowna General Hospital; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of Toronto","keywords":"Palliative care; Referral; Medicine; Nursing; Intensive care medicine; Family medicine","score_opus":0.40214878206941823,"score_gpt":0.4974772671245456,"score_spread":0.09532848505512737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113051965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64720666,0.29624075,0.007121391,0.027885674,0.0018746081,0.002468569,0.0074920426,0.00014942365,0.009560934],"genre_scores_gemma":[0.9725193,0.01439614,0.005648357,0.0037258465,0.0007168954,0.0012015749,0.0013789295,0.000035188765,0.0003777602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9100167,0.054002702,0.021031074,0.004939155,0.008065168,0.0019452502],"domain_scores_gemma":[0.49317947,0.31107962,0.16491969,0.0069774785,0.015356746,0.008486971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.067679375,0.00036756764,0.0023531287,0.0023552533,0.0007789755,0.004509035,0.0012412416,0.001881131,0.0039115595],"category_scores_gemma":[0.28717408,0.00048564278,0.0035178645,0.0037633516,0.00078289397,0.0028375094,0.0017574263,0.002640241,0.0003782333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048100915,0.0009542792,0.7447718,0.026444877,0.008520624,0.0004833879,0.0011523819,0.0011415313,0.0008862843,0.0017679892,0.006678949,0.15909702],"study_design_scores_gemma":[0.0069686696,0.009589894,0.9295319,0.022000453,0.008957358,0.0015224589,0.001061228,0.0012397816,0.0011759239,0.003244426,0.01455296,0.00015505121],"about_ca_topic_score_codex":0.001861466,"about_ca_topic_score_gemma":0.0052807406,"teacher_disagreement_score":0.067679375,"about_ca_system_score_codex":0.0027472093,"about_ca_system_score_gemma":0.00552257,"threshold_uncertainty_score":0.35792702},"labels":[],"label_agreement":null},{"id":"W3114428517","doi":"10.1002/onco.13651","title":"In Reply","year":2020,"lang":"en","type":"letter","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Medicine; Intensive care medicine; Epistemology; Psychology; Philosophy; Internal medicine","score_opus":0.14115873482929422,"score_gpt":0.427964403193791,"score_spread":0.2868056683644967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114428517","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025788034,0.000924648,0.000064359876,0.95563185,0.039569754,0.000015023439,0.000068425776,0.00003988592,0.0034281511],"genre_scores_gemma":[0.0015324391,0.0004967238,0.00010366322,0.9715487,0.01922513,0.000021757089,0.00002504782,0.000019354626,0.0070272],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973188,0.0007583326,0.00032239433,0.00036361365,0.00082314346,0.00041367166],"domain_scores_gemma":[0.9927291,0.0031190643,0.00046795694,0.0002007545,0.0023053284,0.0011777424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033553662,0.0007650017,0.001256427,0.00079046044,0.0037124185,0.0036333601,0.0021922428,0.036194228,0.0139411185],"category_scores_gemma":[0.026262216,0.0007244539,0.0009882221,0.0006127213,0.0020620604,0.0035853686,0.0016524728,0.029564574,0.012478471],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021028774,0.000009151394,0.00025685225,0.000021893717,0.0000048090305,0.0006240566,0.00007080763,0.000014640449,0.000041653737,0.00046246388,0.9962935,0.0021791325],"study_design_scores_gemma":[0.000049961138,0.0000305406,0.000802609,0.00019434876,0.000016251886,0.001806481,0.0004683524,0.00012888151,0.00014854515,0.002358473,0.99394196,0.000053460848],"about_ca_topic_score_codex":0.006922308,"about_ca_topic_score_gemma":0.010713799,"teacher_disagreement_score":0.036194228,"about_ca_system_score_codex":0.003109737,"about_ca_system_score_gemma":0.005022205,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W3123647779","doi":"10.1002/onco.13684","title":"Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Internal medicine; Neutropenia; Breast cancer; Oncology; Adverse effect; Hazard ratio; Tolerability; Cumulative incidence; Febrile neutropenia; Cancer; Gastroenterology; Gynecology; Metastatic breast cancer; Chemotherapy; Confidence interval; Cohort","score_opus":0.01612740092076149,"score_gpt":0.3158817434457096,"score_spread":0.2997543425249481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123647779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8244634,0.14075923,0.0052841133,0.0004516004,0.00040253563,0.00070369523,0.025033189,0.00028840773,0.002613771],"genre_scores_gemma":[0.97934854,0.006227596,0.0010896248,0.0004166013,0.00025359204,0.00038476224,0.011535776,0.00005378016,0.00068969995],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9912751,0.0035206194,0.0013925985,0.0018609426,0.0015539768,0.00039682543],"domain_scores_gemma":[0.981445,0.0064085885,0.0071221553,0.0022597883,0.0023859073,0.00037852812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020620666,0.001403165,0.004507411,0.001999518,0.00031265276,0.0021885077,0.0011339923,0.0009064082,0.0021673434],"category_scores_gemma":[0.017237242,0.000811008,0.016922567,0.0029254965,0.00035825095,0.001212025,0.0010564196,0.0013102107,0.0003392638],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12247567,0.0003391666,0.22539164,0.008855204,0.5913545,0.00035015226,0.00010561101,0.0050264522,0.0030132637,0.00016319085,0.0039880085,0.038937125],"study_design_scores_gemma":[0.013503525,0.009500249,0.44688326,0.00065965304,0.51575327,0.0008081948,0.00010773038,0.0032326684,0.0018163976,0.00037271605,0.0072423564,0.000119969285],"about_ca_topic_score_codex":0.002340579,"about_ca_topic_score_gemma":0.003410608,"teacher_disagreement_score":0.020620666,"about_ca_system_score_codex":0.0012511958,"about_ca_system_score_gemma":0.0012541644,"threshold_uncertainty_score":0.10905379},"labels":[],"label_agreement":null},{"id":"W3125242144","doi":"10.1002/onco.13692","title":"Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neurofibromatosis and Schwannoma Cases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Malignant peripheral nerve sheath tumor; Peripheral; Peripheral nerve; Nuclear export signal; Cancer research; Surgery; Pathology; Internal medicine; Anatomy; Cell nucleus","score_opus":0.033631520149199984,"score_gpt":0.29399889639403337,"score_spread":0.2603673762448334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125242144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778437,0.009098642,0.004344401,0.00092264067,0.00010104551,0.00013412372,0.00013049175,0.00013145353,0.0072934707],"genre_scores_gemma":[0.9931179,0.003135269,0.0012925088,0.00024364487,0.00005981198,0.00002479257,0.00010417794,0.000015336907,0.0020066292],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.999908,0.000011497826,0.000016696213,0.000017696764,0.000021054004,0.000025015173],"domain_scores_gemma":[0.9998221,0.00005970095,0.000042661704,0.000015320546,0.000010419604,0.00004988991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011683197,0.00036126844,0.00029434668,0.00039579318,0.00050268084,0.00021924693,0.00024110978,0.0004648283,0.00083465234],"category_scores_gemma":[0.00038487447,0.0001260235,0.00042148872,0.00015611523,0.00045481618,0.0002261362,0.00027195254,0.00060176366,0.0002937823],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014384361,0.0010263,0.06531297,0.0005778115,0.00027861394,0.597781,0.0011828535,0.0023476721,0.110391565,0.0010437326,0.0029355418,0.21568346],"study_design_scores_gemma":[0.00029024907,0.0043909973,0.04619776,0.000043450604,0.00019658948,0.87476164,0.00023858076,0.0014944767,0.048100244,0.0003990274,0.023846844,0.000040212384],"about_ca_topic_score_codex":0.00039697727,"about_ca_topic_score_gemma":0.0013171593,"teacher_disagreement_score":0.00083465234,"about_ca_system_score_codex":0.0003129686,"about_ca_system_score_gemma":0.00019959378,"threshold_uncertainty_score":0.0027921796},"labels":[],"label_agreement":null},{"id":"W3144358433","doi":"10.1002/onco.13783","title":"Patients’ and Oncologists’ Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative Review","year":2021,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; MEDLINE; Genomic sequencing; Exome sequencing; Inclusion (mineral); Test (biology); Medical education; Family medicine; Psychology; Genome; Genetics; Biology","score_opus":0.11855698234563061,"score_gpt":0.3682822482625384,"score_spread":0.2497252659169078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3144358433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012053712,0.9965648,0.000083422994,0.0011510194,0.000121290985,0.000032784326,0.00014701241,0.000002463829,0.00069192774],"genre_scores_gemma":[0.016263673,0.98154324,0.00025020112,0.0014303394,0.0001708006,0.000104542225,0.00012125248,0.0000026446219,0.00011329558],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9960264,0.001535922,0.0014807729,0.00029284332,0.0005461582,0.00011790679],"domain_scores_gemma":[0.96015763,0.034048624,0.0039107013,0.00017749469,0.0014854675,0.00022004187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005246155,0.00061277824,0.0018335154,0.0051578665,0.00052836654,0.0023877237,0.00092349906,0.0020515537,0.0028832927],"category_scores_gemma":[0.031123016,0.00048031303,0.0018123164,0.0059162998,0.0008133205,0.0025114156,0.00096933346,0.001119606,0.00036303228],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025653502,0.00004581654,0.0028728272,0.7849063,0.0020446798,0.001237288,0.0031533167,0.0001753683,0.0002999198,0.0022912826,0.012255181,0.19046152],"study_design_scores_gemma":[0.000072501,0.0001559403,0.0056217276,0.8573379,0.00720586,0.0041334974,0.0037086508,0.00007607509,0.00022953832,0.0011493736,0.12024584,0.000063196705],"about_ca_topic_score_codex":0.0017897809,"about_ca_topic_score_gemma":0.003912762,"teacher_disagreement_score":0.005246155,"about_ca_system_score_codex":0.0016441552,"about_ca_system_score_gemma":0.004955067,"threshold_uncertainty_score":0.027744591},"labels":[],"label_agreement":null},{"id":"W314684632","doi":"10.1634/theoncologist.2019-0628","title":"Doctoral Recital: 2007-04-18 - Alfredo Arjona, piano","year":2007,"lang":"en","type":"article","venue":"The Oncologist","topic":"Music Technology and Sound Studies","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Piano; Art; Humanities; Art history; Visual arts","score_opus":0.05259014567133634,"score_gpt":0.30740841247236217,"score_spread":0.2548182668010258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W314684632","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002007865,0.010751709,0.00016180676,0.75434315,0.21336003,0.000040280418,0.00034625235,0.00008352173,0.020712543],"genre_scores_gemma":[0.004090913,0.011776381,0.00035433914,0.6439465,0.120577,0.00016436348,0.00028344183,0.00020105207,0.21860592],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984763,0.00039858796,0.00012520496,0.0002846136,0.0005251135,0.00019007725],"domain_scores_gemma":[0.9928845,0.0037826211,0.00040969666,0.0001704929,0.001922456,0.0008303177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032000244,0.00060473476,0.0011146012,0.0006866018,0.0017730454,0.0023435047,0.001371978,0.008373668,0.06827742],"category_scores_gemma":[0.01837064,0.00034443804,0.00056108047,0.0005682362,0.0009318157,0.0016328216,0.0010753825,0.010788505,0.03793336],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025611978,0.000005006671,0.000033351127,0.00003841115,0.0000018845551,0.0000360775,0.00001969207,0.0000060598054,0.000021550219,0.00039813746,0.996745,0.0026691516],"study_design_scores_gemma":[0.000027635446,0.000018314458,0.00034152978,0.00017836517,0.0000055888495,0.000091511436,0.00007743889,0.000023600594,0.0000643654,0.00042585217,0.9987373,0.000008531265],"about_ca_topic_score_codex":0.0054454436,"about_ca_topic_score_gemma":0.014701396,"teacher_disagreement_score":0.06827742,"about_ca_system_score_codex":0.002155413,"about_ca_system_score_gemma":0.0023815017,"threshold_uncertainty_score":0.22841072},"labels":[],"label_agreement":null},{"id":"W3148647097","doi":"10.1634/theoncologist.9-90005-55","title":"rHuEPO and Treatment Outcomes: the Clinical Experience","year":2004,"lang":"en","type":"review","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Medicine; Intensive care medicine; Oncology","score_opus":0.2774252065710417,"score_gpt":0.5205807751593616,"score_spread":0.24315556858831994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148647097","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.761261,0.109648176,0.002903879,0.031843565,0.0009469614,0.000382561,0.00211328,0.00010285684,0.09079778],"genre_scores_gemma":[0.95469075,0.03238782,0.0021434997,0.003984007,0.00110621,0.00015208744,0.0008735067,0.000049545466,0.0046125134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885106,0.00060137967,0.000102485945,0.00009287513,0.0002481943,0.00010400877],"domain_scores_gemma":[0.9965274,0.0015679839,0.00044493008,0.00015145326,0.00046168332,0.0008467044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034567104,0.00029181986,0.0003704913,0.00048148283,0.0004101719,0.0013542881,0.0004078026,0.0007578301,0.0034854342],"category_scores_gemma":[0.0086232815,0.00011116229,0.00023302253,0.0009459403,0.00050674943,0.0010076147,0.0008408958,0.0014949974,0.0006596778],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001702568,0.002179341,0.28741652,0.00035871548,0.00015756147,0.002166984,0.0023952506,0.00086184987,0.00046444434,0.0021485984,0.03895614,0.661192],"study_design_scores_gemma":[0.0010038806,0.009541718,0.73854166,0.0027186999,0.00030323185,0.018439993,0.0061170748,0.002692297,0.0016178073,0.0046984083,0.21410361,0.00022162998],"about_ca_topic_score_codex":0.0012683481,"about_ca_topic_score_gemma":0.0011131396,"teacher_disagreement_score":0.0034854342,"about_ca_system_score_codex":0.0008957505,"about_ca_system_score_gemma":0.0007545419,"threshold_uncertainty_score":0.018281043},"labels":[],"label_agreement":null},{"id":"W3157026044","doi":"10.1002/onco.13803","title":"Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute for Health and Care Research; Sanofi","keywords":"Medicine; Taxane; Prostate cancer; Post-hoc analysis; Internal medicine; Chemotherapy; Quality of life (healthcare); Oncology; Clinical trial; Cancer; Prostate-specific antigen; Physical therapy; Breast cancer","score_opus":0.05615861530145853,"score_gpt":0.3824828340930081,"score_spread":0.32632421879154955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157026044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931838,0.002838771,0.00043633473,0.000096332085,0.00005614576,0.0004895997,0.0018635455,0.0000160158,0.0010195686],"genre_scores_gemma":[0.9947497,0.0002975829,0.0006011283,0.00012814724,0.000056922883,0.0010223323,0.0026362627,0.000010207793,0.0004976969],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9949816,0.0034032564,0.00029430012,0.0006054773,0.00042474142,0.00029070835],"domain_scores_gemma":[0.9938261,0.0033134196,0.0013835651,0.0006212935,0.0004376518,0.00041797085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073184334,0.00071578234,0.0015482184,0.00071496057,0.0003732485,0.00094059604,0.000649927,0.00046849035,0.0029231315],"category_scores_gemma":[0.004416346,0.0002701431,0.0039361925,0.00077448634,0.0005296786,0.000714125,0.0007672883,0.001410638,0.00018344281],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64468306,0.0030887746,0.2846372,0.0018900135,0.028396752,0.00017959595,0.00043846175,0.0016737239,0.004621159,0.0002644975,0.0025795312,0.027547214],"study_design_scores_gemma":[0.037179023,0.079616435,0.8623173,0.0001506562,0.01223705,0.00031930103,0.00037560763,0.0016292111,0.001954837,0.0002900372,0.0038584266,0.00007214762],"about_ca_topic_score_codex":0.0005238261,"about_ca_topic_score_gemma":0.001688703,"teacher_disagreement_score":0.0073184334,"about_ca_system_score_codex":0.00041478104,"about_ca_system_score_gemma":0.0007010885,"threshold_uncertainty_score":0.038704038},"labels":[],"label_agreement":null},{"id":"W3157276232","doi":"10.1002/onco.13804","title":"Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, <i>PIK3CA</i>-Mutated Breast Cancer","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Aromatase inhibitor; Breast cancer; Cohort; Letrozole; Metastatic breast cancer; Palbociclib; Cancer; Clinical trial; Estrogen receptor; Aromatase","score_opus":0.01295471819976937,"score_gpt":0.2979926871360865,"score_spread":0.28503796893631717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157276232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998075,0.0010054429,0.00008711883,0.000072965995,0.000015687154,0.000079501246,0.0001854323,0.000008827534,0.00047002707],"genre_scores_gemma":[0.99886024,0.00029095955,0.00015328414,0.000059938546,0.000021821323,0.000064148604,0.000399484,0.0000017493112,0.00014849413],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99927837,0.00043986444,0.00004047588,0.00012208828,0.00006151216,0.000057769616],"domain_scores_gemma":[0.9992167,0.00024294129,0.00026497353,0.00006625261,0.00003292402,0.00017615828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013676565,0.0003077061,0.0007155109,0.00028296112,0.00012755614,0.0005018196,0.000381605,0.0003263695,0.001585858],"category_scores_gemma":[0.0014827711,0.00010300435,0.00076483405,0.00021659382,0.00031221402,0.0004027612,0.00030213833,0.00053821714,0.00013611886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8090714,0.008105197,0.056988936,0.00048136926,0.0023809166,0.000073848816,0.00017325245,0.0027714444,0.0077227564,0.00023115742,0.0012175118,0.11078218],"study_design_scores_gemma":[0.23215148,0.52667356,0.21717294,0.00014365459,0.003137516,0.0006668277,0.00023489085,0.0064845732,0.0069122193,0.00048553155,0.005863928,0.00007292289],"about_ca_topic_score_codex":0.0004924897,"about_ca_topic_score_gemma":0.001120666,"teacher_disagreement_score":0.001585858,"about_ca_system_score_codex":0.0007150123,"about_ca_system_score_gemma":0.00042398318,"threshold_uncertainty_score":0.007232964},"labels":[],"label_agreement":null},{"id":"W3158544382","doi":"10.1002/onco.13808","title":"Lost in Transition? Thoughts on Retirement, Part 2. “Should I Stay or Should I Go Now?”","year":2021,"lang":"en","type":"letter","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Calgary; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Face (sociological concept); Plan (archaeology); Pandemic; Retirement planning; Transition (genetics); Burnout; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Psychology; Medicine; Business; Actuarial science; Sociology; History; Clinical psychology","score_opus":0.3115314209543923,"score_gpt":0.45137995837862516,"score_spread":0.13984853742423287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158544382","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011271962,0.0016164414,0.000045532597,0.98432815,0.0070641884,0.000018471424,0.00003872052,0.000012934052,0.0057483967],"genre_scores_gemma":[0.006609244,0.0010137499,0.00006488608,0.9763714,0.0047848173,0.000041563777,0.000019006795,0.000011333424,0.011084013],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980946,0.0006739814,0.00018034072,0.00018589721,0.00040202614,0.00046304817],"domain_scores_gemma":[0.99677724,0.0012502678,0.0002154472,0.000078204874,0.0005205215,0.0011582521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030936275,0.0006714176,0.0005337379,0.00049806514,0.010385981,0.00285934,0.0015379112,0.03415042,0.008398868],"category_scores_gemma":[0.012946186,0.00065819954,0.00084344967,0.00040199,0.0027530643,0.004269017,0.0023481036,0.02845772,0.0033260423],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020137733,0.00004833238,0.0013250911,0.00003482838,0.0000055361556,0.0026600624,0.0012536807,0.000042446507,0.000119590826,0.0021890297,0.98593277,0.0063684676],"study_design_scores_gemma":[0.00008443808,0.00014750593,0.0072978023,0.0013836987,0.00002592287,0.006181444,0.00948467,0.00056957046,0.00021999457,0.0061826967,0.96833134,0.00009080906],"about_ca_topic_score_codex":0.0336962,"about_ca_topic_score_gemma":0.06553196,"teacher_disagreement_score":0.03415042,"about_ca_system_score_codex":0.005275425,"about_ca_system_score_gemma":0.008669054,"threshold_uncertainty_score":0.06700015},"labels":[],"label_agreement":null},{"id":"W3159055654","doi":"10.1002/onco.13814","title":"Opportunities for Improvement in the Administration of Neoadjuvant Chemotherapy for <scp>T4</scp> Breast Cancer: A Comparison of the U.S. and Nigeria","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Internal medicine; Chemotherapy; Cancer; Socioeconomic status; Psychological intervention; Retrospective cohort study; Surgery; Oncology; Population; Nursing","score_opus":0.04553570216089419,"score_gpt":0.3343260649030116,"score_spread":0.2887903627421174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159055654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949403,0.0020818047,0.00007906856,0.0011316921,0.000026387637,0.000013317763,0.00013399738,0.0000013627714,0.0015921949],"genre_scores_gemma":[0.9983463,0.0012012405,0.00012943914,0.00013878824,0.000007329829,0.000007903682,0.000057101675,7.0526283e-7,0.00011115518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998229,0.00005284103,0.00001987904,0.00002249763,0.000023614873,0.000058322923],"domain_scores_gemma":[0.99954504,0.0000805269,0.0002501584,0.000007230645,0.000038046306,0.00007903688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041970072,0.00008443387,0.000117597825,0.0002774542,0.0003448415,0.00053335924,0.000119502016,0.0002063178,0.0012587754],"category_scores_gemma":[0.0011694563,0.0000912825,0.00015735072,0.00047828787,0.0002096235,0.00044907865,0.00043135305,0.0002586241,0.00008328174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020926066,0.00006996017,0.97379047,0.00012646086,0.000020510255,0.00016101549,0.0005569505,0.00006482945,0.00055870734,0.0003742851,0.00034333428,0.023724165],"study_design_scores_gemma":[0.000018990257,0.0002510634,0.98872817,0.00033159213,0.000036586425,0.00049965695,0.006487719,0.00018753993,0.00025051425,0.0002263126,0.002975741,0.000006203097],"about_ca_topic_score_codex":0.0070648924,"about_ca_topic_score_gemma":0.023246922,"teacher_disagreement_score":0.0070648924,"about_ca_system_score_codex":0.0006094821,"about_ca_system_score_gemma":0.0013621502,"threshold_uncertainty_score":0.0140475035},"labels":[],"label_agreement":null},{"id":"W3160001767","doi":"10.1002/onco.13818","title":"Moral Distress and Resilience Associated with Cancer Care Priority Setting in a Resource-Limited Context","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in medical practice","field":"Health Professions","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fogarty International Center; University of California, San Francisco; National Cancer Institute; Greenwall Foundation","keywords":"Psychological intervention; Burnout; Workforce; Medicine; Distress; Nursing; Resource (disambiguation); Psychological resilience; Context (archaeology); Equity (law); Psychology; Social psychology; Political science; Clinical psychology","score_opus":0.08449678725474075,"score_gpt":0.46677580070948727,"score_spread":0.3822790134547465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160001767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868487,0.00079273764,0.00040889028,0.0075343195,0.000071656104,0.000040512736,0.0000444827,0.000006014546,0.0042525833],"genre_scores_gemma":[0.99939346,0.00018216601,0.00009050939,0.00021853877,0.000009911209,0.000014398146,0.000010734647,0.0000014699981,0.00007875841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503565,0.0031632294,0.00014942238,0.00025563117,0.00030761107,0.0010885425],"domain_scores_gemma":[0.9900288,0.0028667147,0.0026651595,0.0003089327,0.00060601794,0.0035243507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037893418,0.00023600414,0.0003062539,0.0007829525,0.005553761,0.0032126796,0.00080634904,0.0006916344,0.0029152953],"category_scores_gemma":[0.013140544,0.0002468433,0.0003371506,0.0007064874,0.006028897,0.0018167885,0.0073543712,0.0026408252,0.000104685045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019744036,0.00043407085,0.65659404,0.00062594394,0.00018699055,0.0034917963,0.28424427,0.0006786395,0.00077898835,0.009209806,0.0068502687,0.036707703],"study_design_scores_gemma":[0.000022407168,0.00024193812,0.42564684,0.0008633557,0.00005938144,0.0017617856,0.5522306,0.00077596714,0.00023522755,0.0077128187,0.010365819,0.00008383698],"about_ca_topic_score_codex":0.012315121,"about_ca_topic_score_gemma":0.019581692,"teacher_disagreement_score":0.012315121,"about_ca_system_score_codex":0.005746788,"about_ca_system_score_gemma":0.007517419,"threshold_uncertainty_score":0.041696012},"labels":[],"label_agreement":null},{"id":"W3165169142","doi":"10.1002/onco.13830","title":"Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Puma Biotechnology","keywords":"Capecitabine; Medicine; Lapatinib; Neratinib; Internal medicine; Hazard ratio; Cumulative incidence; Gastroenterology; Oncology; Confidence interval; Cancer; Breast cancer; Trastuzumab; Colorectal cancer; Cohort","score_opus":0.02765587175429207,"score_gpt":0.2690248680371248,"score_spread":0.2413689962828327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165169142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818048,0.012151901,0.00022160553,0.0012124876,0.00017494499,0.00041394532,0.0010636882,0.00002737127,0.002929167],"genre_scores_gemma":[0.994548,0.0018095729,0.0002491892,0.0004900939,0.00014095366,0.0003077393,0.0017601416,0.000006240895,0.0006879505],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99947375,0.0002608485,0.000058081405,0.000096776355,0.00004817731,0.00006251731],"domain_scores_gemma":[0.9991936,0.00019764739,0.00024540818,0.00005226322,0.000060436938,0.0002507778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014797336,0.0004890299,0.0015331287,0.0001721945,0.00026121273,0.0007888513,0.0003867978,0.00048717938,0.0020445317],"category_scores_gemma":[0.001551813,0.00010604785,0.0015785227,0.00022705203,0.0002371663,0.00037618756,0.0003076354,0.0010921827,0.00027736378],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77911747,0.001912015,0.05556043,0.002221946,0.008112552,0.0006269196,0.00020215262,0.0019827902,0.010781678,0.00040564366,0.008989699,0.1300868],"study_design_scores_gemma":[0.6254627,0.072340496,0.25849107,0.0005421767,0.010870356,0.002241277,0.00025171397,0.004320518,0.003296843,0.0020832128,0.019991549,0.000108095286],"about_ca_topic_score_codex":0.0005308927,"about_ca_topic_score_gemma":0.0030872063,"teacher_disagreement_score":0.0020445317,"about_ca_system_score_codex":0.00063158467,"about_ca_system_score_gemma":0.00081306865,"threshold_uncertainty_score":0.007825673},"labels":[],"label_agreement":null},{"id":"W3165681703","doi":"10.1002/onco.13827","title":"The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; University of Alberta; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; University of Toronto","funders":"","keywords":"Metastatic Urothelial Carcinoma; Medicine; Oncology; Gemcitabine; Internal medicine; Targeted therapy; Context (archaeology); Chemotherapy; Hazard ratio; Cancer; Clinical trial; Bladder cancer; Confidence interval; Urothelial carcinoma","score_opus":0.07377794113633378,"score_gpt":0.38916663484967917,"score_spread":0.3153886937133454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165681703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042717907,0.9988355,0.00009044695,0.00022029699,0.00005485174,0.000064798514,0.00019099929,0.000003715277,0.00011231985],"genre_scores_gemma":[0.008058129,0.9905291,0.00037498088,0.00053617475,0.00007382688,0.00019039633,0.00017652799,0.0000037135924,0.0000572262],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99404657,0.0024496487,0.0019291763,0.00042917175,0.0009893521,0.00015604756],"domain_scores_gemma":[0.9705033,0.02225651,0.004602652,0.00032386312,0.0020925924,0.00022124419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008293947,0.0011265723,0.007438671,0.006763934,0.00037008058,0.0020427755,0.0013714319,0.0013897226,0.003318218],"category_scores_gemma":[0.028945258,0.00072610757,0.006243066,0.0088845715,0.0005704056,0.0018398962,0.00091213296,0.0009138324,0.00026116715],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013890433,0.000009347923,0.0008094167,0.94895613,0.011733384,0.00007052808,0.00009375318,0.00012613126,0.00012649193,0.00022325075,0.001988212,0.035724483],"study_design_scores_gemma":[0.00023493778,0.00023479243,0.0058663967,0.8511774,0.11033066,0.00042285814,0.00022181819,0.00019081427,0.0001621526,0.00055724574,0.030556507,0.000044307824],"about_ca_topic_score_codex":0.0061754826,"about_ca_topic_score_gemma":0.021519274,"teacher_disagreement_score":0.008293947,"about_ca_system_score_codex":0.002282068,"about_ca_system_score_gemma":0.0082741175,"threshold_uncertainty_score":0.043863058},"labels":[],"label_agreement":null},{"id":"W3173598219","doi":"10.1002/onco.13890","title":"Province-Wide Analysis of Patient-Reported Outcomes for Stage IV Non-Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; University of Manitoba; Manitoba Health; Research Institute in Oncology and Hematology; Health Sciences Centre; CancerCare Manitoba; Toronto General Hospital; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Comorbidity; Lung cancer; Anxiety; Nausea; Poisson regression; Stage (stratigraphy); Population; Cancer; Internal medicine; Physical therapy; Psychiatry","score_opus":0.027779213723623433,"score_gpt":0.33433370545531704,"score_spread":0.30655449173169363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173598219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800965,0.0010968955,0.00026146072,0.00044484856,0.000026326812,0.000046681922,0.016897362,0.000021301728,0.0011085338],"genre_scores_gemma":[0.99587774,0.00016073884,0.000096702686,0.000039524442,0.000007854802,0.000020717218,0.0036306593,0.0000041976214,0.0001618133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784315,0.0003764466,0.00017913463,0.0004681191,0.00060196914,0.0005311108],"domain_scores_gemma":[0.9918886,0.0008377799,0.0030072948,0.00060285017,0.0023640406,0.0012994921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024436368,0.00030621127,0.00055133505,0.001333932,0.001187051,0.0008972876,0.0012449215,0.00037199934,0.001500455],"category_scores_gemma":[0.007660769,0.00030069833,0.0012413427,0.0040757083,0.0005973687,0.00036525851,0.0011080296,0.00072103384,0.00019428946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062191066,0.000006969471,0.9984018,0.000028435998,0.00010136977,0.000013216831,0.00007677126,0.00011426281,0.00003293635,0.000019219575,0.00059210655,0.0005507089],"study_design_scores_gemma":[0.000007783812,0.000013880739,0.99919707,0.000013897348,0.000034690147,0.0000188414,0.00016378492,0.00023939536,0.000013922274,0.000009676078,0.0002832509,0.0000038621806],"about_ca_topic_score_codex":0.9034287,"about_ca_topic_score_gemma":0.9201356,"teacher_disagreement_score":0.096571326,"about_ca_system_score_codex":0.010104214,"about_ca_system_score_gemma":0.0107757505,"threshold_uncertainty_score":0.19428009},"labels":[],"label_agreement":null},{"id":"W3174787666","doi":"10.1002/onco.13894","title":"A 10-Item Frailty Index Based on a Comprehensive Geriatric Assessment (FI-CGA-10) in Older Adults with Cancer: Development and Construct Validation","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Fukuoka Foundation for Sound Health; Research Promotion Foundation","keywords":"Medicine; Comorbidity; Geriatric oncology; Gerontology; Mood; Construct validity; Activities of daily living; Cognition; Geriatrics; Cancer; Internal medicine; Physical therapy; Psychometrics; Clinical psychology; Psychiatry","score_opus":0.029225187821864753,"score_gpt":0.317493136519281,"score_spread":0.2882679486974163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174787666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644345,0.00068371807,0.0010099785,0.00009951062,0.00002492503,0.00032585236,0.0006781891,0.000018549861,0.00071582553],"genre_scores_gemma":[0.99293727,0.00035702108,0.004207551,0.00008222777,0.000022527034,0.0005032275,0.0016927994,0.0000035810885,0.00019382044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949276,0.00013971099,0.00009734386,0.00005893436,0.00016735683,0.000043800726],"domain_scores_gemma":[0.9979315,0.00040971563,0.0006668257,0.000075015305,0.0006914825,0.00022548065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002733694,0.0004700607,0.00047294394,0.0012620012,0.00028793284,0.00044131288,0.00044206905,0.00044198395,0.0005973311],"category_scores_gemma":[0.0060527036,0.00016362626,0.00062941626,0.0006075314,0.00027332528,0.0005985706,0.0007511474,0.0007008577,0.0001617158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001697522,0.00014296027,0.9779337,0.000061778745,0.00013784932,0.000030509722,0.0001607462,0.00022057016,0.00024662763,0.00003323097,0.0005949996,0.02026722],"study_design_scores_gemma":[0.000046859826,0.0004838145,0.9972512,0.00004262349,0.000057983092,0.0001386631,0.000119137425,0.0011699684,0.00009788422,0.00006350748,0.0005187068,0.000009763423],"about_ca_topic_score_codex":0.0043283403,"about_ca_topic_score_gemma":0.008793581,"teacher_disagreement_score":0.0043283403,"about_ca_system_score_codex":0.00052619184,"about_ca_system_score_gemma":0.0010356352,"threshold_uncertainty_score":0.014457345},"labels":[],"label_agreement":null},{"id":"W3187302100","doi":"10.1002/onco.13927","title":"Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"PTEN; Medicine; Microsatellite instability; Endometrial cancer; Metastasis; Pathology; Brain metastasis; KRAS; Immunohistochemistry; Cancer; Lesion; Oncology; Internal medicine; Colorectal cancer; Biology; Microsatellite; Gene","score_opus":0.137793161153583,"score_gpt":0.3627381149925187,"score_spread":0.22494495383893567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187302100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747815,0.0060733617,0.004678524,0.0055661523,0.000301676,0.00009727198,0.00034675025,0.00010310639,0.008051535],"genre_scores_gemma":[0.9911628,0.0018375679,0.0050959843,0.0009478503,0.00012216542,0.00001513309,0.00019548621,0.000018175091,0.00060486107],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99966586,0.00007170363,0.00005251275,0.000041055002,0.00007832866,0.000090572314],"domain_scores_gemma":[0.9993261,0.00019290931,0.00010455103,0.000041421994,0.0001770119,0.0001579125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066041976,0.00039551806,0.00029265907,0.0011958105,0.0004934361,0.00061761047,0.0003282361,0.00093391206,0.0010252334],"category_scores_gemma":[0.0029986552,0.0001532029,0.00032911473,0.00042311673,0.00041658978,0.000353553,0.00041233381,0.0006831064,0.00042442314],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089293544,0.00009097233,0.4453636,0.0002269506,0.000097638345,0.3776861,0.0007966886,0.0011800667,0.05352492,0.0019416251,0.0063220947,0.11187637],"study_design_scores_gemma":[0.000096475094,0.0005249862,0.21513376,0.0006658375,0.00031872737,0.6916182,0.0027613756,0.016940493,0.037644643,0.0073230923,0.026903283,0.00006910814],"about_ca_topic_score_codex":0.003634168,"about_ca_topic_score_gemma":0.0077986647,"teacher_disagreement_score":0.003634168,"about_ca_system_score_codex":0.0004932015,"about_ca_system_score_gemma":0.0005182948,"threshold_uncertainty_score":0.0072259903},"labels":[],"label_agreement":null},{"id":"W3188534843","doi":"10.1002/onco.13922","title":"Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Winship Cancer Institute; National Institutes of Health; Society for Immunotherapy of Cancer; National Cancer Institute; Emory University","keywords":"Medicine; Hazard ratio; Proportional hazards model; Internal medicine; Oncology; Biomarker; Body mass index; Retrospective cohort study; Odds ratio; Confidence interval","score_opus":0.012922607270704961,"score_gpt":0.2742608242748707,"score_spread":0.2613382170041657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188534843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999223,0.0002968728,0.00008357207,0.000032324886,0.0000056055246,0.0000055726905,0.00014395753,0.000003305308,0.00020585948],"genre_scores_gemma":[0.99962485,0.000051895317,0.00007958986,0.000009956501,0.0000065563204,0.0000038052046,0.0001653258,0.0000010121131,0.00005712384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977356,0.00006010915,0.0000265704,0.00004259102,0.000051070587,0.00004601328],"domain_scores_gemma":[0.9990426,0.00018059155,0.0004249428,0.00005196817,0.00011691679,0.00018299844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006558013,0.00024290214,0.00032732333,0.00067452504,0.0003583654,0.0005863779,0.00030506114,0.0003228167,0.000952503],"category_scores_gemma":[0.0015951396,0.0001470876,0.0003829182,0.00072519196,0.0002337027,0.00030223888,0.00043812412,0.00052110327,0.0001884994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015904034,0.000011416067,0.99889404,0.0000024814628,0.000017885657,0.00001902287,0.00000777878,0.00004654596,0.00011283233,0.0000030654542,0.000026059142,0.00069987297],"study_design_scores_gemma":[0.000007812859,0.000104044855,0.9987565,0.000005154444,0.000043582735,0.00015003665,0.000050842948,0.00064473855,0.00010055841,0.000013247994,0.0001213482,0.000002133612],"about_ca_topic_score_codex":0.0021489759,"about_ca_topic_score_gemma":0.0031787404,"teacher_disagreement_score":0.0021489759,"about_ca_system_score_codex":0.00029121924,"about_ca_system_score_gemma":0.00035944593,"threshold_uncertainty_score":0.004272938},"labels":[],"label_agreement":null},{"id":"W3190487880","doi":"10.1002/onco.13923","title":"Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Temozolomide; Discontinuation; Internal medicine; Regimen; Hazard ratio; Capecitabine; Clinical endpoint; Gastroenterology; Retrospective cohort study; Neuroendocrine tumors; Adverse effect; Surgery; Radiation therapy; Confidence interval; Clinical trial; Cancer","score_opus":0.028540580612285794,"score_gpt":0.35064206726557834,"score_spread":0.3221014866532925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190487880","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19288594,0.8033116,0.00023205868,0.00020472937,0.000048756345,0.00017305338,0.0021898802,0.000009983067,0.0009440598],"genre_scores_gemma":[0.5682969,0.42721468,0.0007196983,0.0005372614,0.00016127813,0.00027443824,0.0025626959,0.000013710315,0.00021920963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779797,0.0005060551,0.0009596739,0.00033180753,0.00034052623,0.000064004285],"domain_scores_gemma":[0.99099076,0.002560005,0.0051551745,0.0002581272,0.00088705984,0.00014889022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027285824,0.00024866572,0.0010339598,0.0033713086,0.0002501703,0.00085150066,0.0006705767,0.00039188055,0.0009559027],"category_scores_gemma":[0.0056456253,0.0002628699,0.0009476858,0.0071065724,0.00034362744,0.00063627097,0.00041237316,0.00020346501,0.00020867148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016883754,0.00013440782,0.780592,0.07328791,0.0057278574,0.004592317,0.0008149339,0.00020601798,0.0020923656,0.00037287184,0.0048731356,0.12561773],"study_design_scores_gemma":[0.00028792245,0.0012236009,0.8772837,0.030303773,0.017861694,0.022534873,0.0016551901,0.00024128486,0.0014484369,0.0001324737,0.046963662,0.0000633613],"about_ca_topic_score_codex":0.0015410094,"about_ca_topic_score_gemma":0.0029456292,"teacher_disagreement_score":0.0033713086,"about_ca_system_score_codex":0.0006382421,"about_ca_system_score_gemma":0.0012500136,"threshold_uncertainty_score":0.0144302845},"labels":[],"label_agreement":null},{"id":"W3197137235","doi":"10.1002/onco.13971","title":"A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Princess Margaret Cancer Centre; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Bevacizumab; Term (time); Extension (predicate logic); Solid tumor; Medicine; Oncology; Internal medicine; Computer science; Cancer; Chemotherapy; Programming language; Physics","score_opus":0.026222197415164527,"score_gpt":0.3225476534188693,"score_spread":0.2963254560037048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197137235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963415,0.0014221022,0.0002529969,0.00014943624,0.000050229937,0.00076128106,0.00042340768,0.000012839728,0.00058611727],"genre_scores_gemma":[0.9947423,0.0007009198,0.00052883255,0.0004447682,0.00019099456,0.0011266343,0.0016575059,0.0000048214433,0.00060317415],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986547,0.0007692415,0.00011860921,0.00016533349,0.00014779565,0.00014438147],"domain_scores_gemma":[0.99498653,0.00080245093,0.0014648489,0.00041198012,0.0006103281,0.0017238719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005512157,0.0006360099,0.0010390205,0.00026687834,0.00043737734,0.0006365181,0.0003519932,0.00063192274,0.0017585777],"category_scores_gemma":[0.0032012614,0.00025039984,0.001122931,0.00036348955,0.00036684563,0.00059887365,0.0005334477,0.0014592619,0.00048437284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6734971,0.0428131,0.19346552,0.0007112094,0.0029059935,0.000424392,0.00041598515,0.0007390737,0.01134837,0.00012525517,0.0026253613,0.07092873],"study_design_scores_gemma":[0.155336,0.57941777,0.25485292,0.00009053125,0.0018312921,0.0005094491,0.00011486494,0.00086155365,0.0013363787,0.00014307135,0.005464695,0.000041498533],"about_ca_topic_score_codex":0.0005411699,"about_ca_topic_score_gemma":0.0010798594,"teacher_disagreement_score":0.005512157,"about_ca_system_score_codex":0.0005516859,"about_ca_system_score_gemma":0.0014478719,"threshold_uncertainty_score":0.02915144},"labels":[],"label_agreement":null},{"id":"W3197976653","doi":"10.1002/onco.13965","title":"Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A <scp>Single-Center</scp> Retrospective Study","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Interquartile range; Cancer; Internal medicine; Oncology; Retrospective cohort study; Asymptomatic; Brain metastasis; Radiosurgery; Radiation therapy; Population; Metastasis","score_opus":0.019842861684766355,"score_gpt":0.2967036262230774,"score_spread":0.27686076453831104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197976653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984193,0.0003271237,0.00005961423,0.000035313256,0.000003075781,0.000021458196,0.00075957895,0.0000028134118,0.00037173397],"genre_scores_gemma":[0.99896276,0.00015531162,0.000057189267,0.00003714491,0.000008554,0.000020726848,0.00070063845,0.0000028910515,0.000054793414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994795,0.00008750364,0.000092730836,0.00015877324,0.00010208634,0.00007951903],"domain_scores_gemma":[0.9986998,0.00016928258,0.0007031311,0.0000817851,0.00017227075,0.00017373965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045642618,0.000195371,0.00041815505,0.0009403461,0.0005509896,0.0005286464,0.00042275325,0.0003597373,0.00093584356],"category_scores_gemma":[0.0016059612,0.000301046,0.0004168973,0.0018717491,0.00031882006,0.0004439464,0.00043315516,0.00040102433,0.00024047912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006087345,0.000015581914,0.9988423,0.000010850287,0.000031717245,0.00011364223,0.00006228173,0.000017412132,0.00006880088,0.0000061319442,0.000093540366,0.000676938],"study_design_scores_gemma":[0.000013603265,0.00015255704,0.9975973,0.000014614926,0.00004966386,0.0012139424,0.0004409903,0.000102022444,0.000057114852,0.000014654479,0.00033795828,0.0000056406366],"about_ca_topic_score_codex":0.014115053,"about_ca_topic_score_gemma":0.016893812,"teacher_disagreement_score":0.014115053,"about_ca_system_score_codex":0.00087179424,"about_ca_system_score_gemma":0.00078157464,"threshold_uncertainty_score":0.0280658},"labels":[],"label_agreement":null},{"id":"W3198339003","doi":"10.1002/onco.13963","title":"The Looming Threat: Cancer in Sub-Saharan Africa","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Medical Research Council Canada","keywords":"Looming; Medicine; Epidemiology; Cancer; Low and middle income countries; Action (physics); Environmental health; Development economics; Economic growth; Developing country; Pathology","score_opus":0.11860425454860637,"score_gpt":0.3839400994920913,"score_spread":0.26533584494348494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198339003","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038946446,0.58811384,0.00052327453,0.35065633,0.005176265,0.000029496645,0.00036941606,0.000046557667,0.016138362],"genre_scores_gemma":[0.21049672,0.740067,0.0011422228,0.036170784,0.007761998,0.000045455312,0.00022991133,0.00002827654,0.0040575317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993975,0.0002615966,0.000045089604,0.00004093406,0.00010514506,0.00014972086],"domain_scores_gemma":[0.9991386,0.00023536957,0.00016001429,0.000014657369,0.00013757635,0.00031381845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009678371,0.00030936068,0.00039282462,0.001532045,0.0016324834,0.0024802927,0.00029358355,0.0014244411,0.004877512],"category_scores_gemma":[0.002433282,0.00014586508,0.0003074457,0.002473289,0.001223211,0.0027454174,0.0022049104,0.0022856242,0.00047716883],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022440265,0.00011011839,0.1037982,0.0060176784,0.00016407059,0.006244367,0.014199951,0.000446109,0.002732607,0.025053581,0.22289567,0.61811316],"study_design_scores_gemma":[0.000033043205,0.00017928166,0.10058181,0.0060205543,0.00014749767,0.008266169,0.036275327,0.00016317118,0.0004184828,0.017810352,0.8300474,0.00005682834],"about_ca_topic_score_codex":0.009251582,"about_ca_topic_score_gemma":0.019093765,"teacher_disagreement_score":0.009251582,"about_ca_system_score_codex":0.0016503,"about_ca_system_score_gemma":0.003912896,"threshold_uncertainty_score":0.018395483},"labels":[],"label_agreement":null},{"id":"W3199756208","doi":"10.1002/onco.13974","title":"Changes in Cancer Patients' and Caregivers' Disease Perceptions While Receiving Early Palliative Care: A Qualitative and Quantitative Analysis","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Associazione Italiana Contro le Leucemie - Linfomi e Mieloma; Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Sadness; Palliative care; Psychosocial; Optimism; Anxiety; Medicine; Intervention (counseling); Psychology; Thematic analysis; Learned helplessness; Disease; Cognition; Clinical psychology; Qualitative research; Psychotherapist; Nursing; Internal medicine; Psychiatry; Anger","score_opus":0.05342108897153759,"score_gpt":0.3834297063083616,"score_spread":0.330008617336824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199756208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961004,0.00015884108,0.0013449527,0.00026194612,0.000011772898,0.00042946642,0.0004472611,0.000007290179,0.0012380476],"genre_scores_gemma":[0.9946683,0.0002725605,0.0020106295,0.0001636612,0.000007621554,0.001513263,0.00029258686,0.000008888244,0.0010625127],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99423885,0.0039619105,0.00031045685,0.00028549286,0.00064642105,0.00055687677],"domain_scores_gemma":[0.9815621,0.013783333,0.0013597864,0.00030630737,0.002328754,0.00065971765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01133412,0.00040670604,0.00057779235,0.002607723,0.0026169093,0.0016472255,0.0007869975,0.00060644496,0.0021316775],"category_scores_gemma":[0.017578688,0.00031165197,0.00045605478,0.0022980256,0.0026339141,0.0010774934,0.0019439,0.00092864677,0.00021680974],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020460632,0.0002524133,0.03349476,0.00059238466,0.000022274959,0.0005695533,0.94007826,0.00013438094,0.0025446943,0.00059297134,0.00060191023,0.020911735],"study_design_scores_gemma":[0.000023579012,0.00027461452,0.044254705,0.0002832917,0.000018647055,0.00025545628,0.94868696,0.0002336447,0.0014245,0.0003639474,0.004147997,0.000032661035],"about_ca_topic_score_codex":0.0038513371,"about_ca_topic_score_gemma":0.005522978,"teacher_disagreement_score":0.01133412,"about_ca_system_score_codex":0.0037144911,"about_ca_system_score_gemma":0.002693457,"threshold_uncertainty_score":0.05994129},"labels":[],"label_agreement":null},{"id":"W32162815","doi":"10.1634/theoncologist.2019-0501","title":"Perfil cromatográfico de oligossacarídeos na urina, atividade da alfa manosidade leucocitária e estudo histológico de caprinos intoxicados com Sida carpinifolia","year":2004,"lang":"en","type":"article","venue":"The Oncologist","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Research, Innovation and Science","keywords":"Sida; Geography; Biology; Human immunodeficiency virus (HIV); Viral disease; Virology","score_opus":0.024613506689255854,"score_gpt":0.2607880077771022,"score_spread":0.23617450108784635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W32162815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926555,0.002363903,0.0012927278,0.0001095651,0.000012657042,0.00004179153,0.00083126454,0.000020189338,0.002672469],"genre_scores_gemma":[0.9958033,0.00070291484,0.0014172916,0.000049720948,0.0000067624833,0.000020827432,0.00050893927,0.000009421903,0.0014808527],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996228,0.00010215611,0.000020204518,0.000049724946,0.00014759917,0.000057419922],"domain_scores_gemma":[0.9988483,0.00047938214,0.0003157546,0.000058086756,0.0002149904,0.00008336175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007542353,0.00022631155,0.00031183474,0.00067686965,0.00023140626,0.0007479207,0.00015588927,0.00023098038,0.0024458822],"category_scores_gemma":[0.0017185933,0.0000946991,0.00050476566,0.0005402412,0.00023128075,0.00036455342,0.00015899027,0.00027231788,0.00020441899],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011613288,0.0006185521,0.6459831,0.0009120548,0.0005563368,0.0012683354,0.00037494156,0.0045254347,0.22450443,0.0012123905,0.0006800963,0.107750945],"study_design_scores_gemma":[0.000094057556,0.003724438,0.7759199,0.00013348363,0.0006991734,0.0035229917,0.000824037,0.013821255,0.1914064,0.0016420755,0.008154588,0.000057606823],"about_ca_topic_score_codex":0.010441815,"about_ca_topic_score_gemma":0.010696573,"teacher_disagreement_score":0.010441815,"about_ca_system_score_codex":0.00096532487,"about_ca_system_score_gemma":0.00044535592,"threshold_uncertainty_score":0.020762086},"labels":[],"label_agreement":null},{"id":"W4205259021","doi":"10.1093/oncolo/oyab070","title":"Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"Entertainment Industry Foundation; National Cancer Institute; National Institutes of Health; George W. Stone Family Foundation; National Center for Advancing Translational Sciences; Alliance for Clinical Trials in Oncology Foundation; American Association for Cancer Research","keywords":"Colorectal cancer; Cancer; Stage (stratigraphy); Oncology; Alliance; Medicine; Marital status; Internal medicine; Biology; Environmental health","score_opus":0.019941578214275703,"score_gpt":0.2837501192533572,"score_spread":0.26380854103908147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205259021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99771583,0.00115333,0.000039036913,0.00014279327,0.0000100994,0.000017112878,0.00056763913,0.0000014973671,0.0003526656],"genre_scores_gemma":[0.99843925,0.00034612065,0.00005361437,0.00011674438,0.000018712475,0.000014007889,0.00092076266,9.742606e-7,0.00008980352],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958116,0.00019226423,0.00004115556,0.00004733914,0.0000936417,0.00004443955],"domain_scores_gemma":[0.99857104,0.00029688454,0.00063071185,0.00008389025,0.00016683918,0.00025055514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012452975,0.00015954411,0.00031927542,0.000439262,0.00026566966,0.00040930146,0.0002542262,0.0002066123,0.0009772293],"category_scores_gemma":[0.0021707325,0.000082915634,0.0004728078,0.0005991234,0.00017900886,0.00014937934,0.000499989,0.0003668168,0.000094043884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030964573,0.00010302352,0.98906285,0.000052857064,0.00036085353,0.00003332026,0.00006987221,0.00006436659,0.00020797794,0.000012100227,0.0005356846,0.0064006173],"study_design_scores_gemma":[0.0001929168,0.0003279839,0.99869895,0.000014881951,0.00019332254,0.000052091935,0.000053838776,0.00009651035,0.000032125183,0.000009041799,0.00032568735,0.0000026070247],"about_ca_topic_score_codex":0.012347097,"about_ca_topic_score_gemma":0.020797769,"teacher_disagreement_score":0.012347097,"about_ca_system_score_codex":0.0003762247,"about_ca_system_score_gemma":0.00047895656,"threshold_uncertainty_score":0.024550498},"labels":[],"label_agreement":null},{"id":"W4205530749","doi":"10.1093/oncolo/oyab010","title":"Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Demographics; Disease; Oncology; Internal medicine; Stage (stratigraphy); Demography","score_opus":0.04709897848308272,"score_gpt":0.32167594623167345,"score_spread":0.27457696774859075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205530749","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013990438,0.02577643,0.001646693,0.906176,0.06362154,0.000016750357,0.00010612167,0.00003764114,0.0012198413],"genre_scores_gemma":[0.035166737,0.05029945,0.0052806498,0.5919493,0.3144518,0.00007645823,0.00016488729,0.00016725388,0.0024434517],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.97916746,0.011417218,0.002966606,0.0013711458,0.0043941294,0.00068337924],"domain_scores_gemma":[0.8730311,0.09096497,0.005346369,0.0020185695,0.025816951,0.002822047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035429165,0.0007691522,0.0023714553,0.0024352982,0.0023948597,0.006474222,0.0033410517,0.009565302,0.0022442054],"category_scores_gemma":[0.13190868,0.0006008158,0.0013712288,0.0016227576,0.0068735364,0.007554234,0.0017791409,0.014731499,0.0017256694],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025252477,0.00004262973,0.0055170134,0.0012708234,0.0001780192,0.00047904058,0.0010831233,0.00023601597,0.00027740875,0.00683622,0.85628,0.12754709],"study_design_scores_gemma":[0.00019758107,0.00037441432,0.010986765,0.012533545,0.0005149211,0.0032345913,0.008052998,0.0020031345,0.0013107794,0.06762088,0.89275753,0.00041290445],"about_ca_topic_score_codex":0.0044277455,"about_ca_topic_score_gemma":0.011432396,"teacher_disagreement_score":0.035429165,"about_ca_system_score_codex":0.002913509,"about_ca_system_score_gemma":0.0051144497,"threshold_uncertainty_score":0.18736959},"labels":[],"label_agreement":null},{"id":"W4205830947","doi":"10.1093/oncolo/oyab081","title":"Methadone as First-line Opioid for the Management of Cancer Pain","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Methadone; Adverse effect; Opioid; Delirium; Anesthesia; Cancer pain; Internal medicine; Cancer; Psychiatry","score_opus":0.04345380845407366,"score_gpt":0.35047243248719895,"score_spread":0.3070186240331253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205830947","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9342794,0.06262435,0.00035890998,0.00052394345,0.00015471634,0.00014117207,0.00015684149,0.000025594927,0.0017351417],"genre_scores_gemma":[0.98176104,0.015317663,0.0011402618,0.00039536145,0.00013526094,0.00006353249,0.0002317959,0.000003406997,0.0009516855],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9997763,0.000065433494,0.000023601187,0.0000252516,0.00008192739,0.000027512886],"domain_scores_gemma":[0.99954456,0.00007089642,0.00019378022,0.000021580574,0.000053380656,0.00011575593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003363162,0.00016308078,0.00041016092,0.00018512952,0.00033111,0.00025948387,0.0002464029,0.0002725623,0.0011662452],"category_scores_gemma":[0.0008076555,0.00006556829,0.00028558628,0.0001461286,0.000080372156,0.00014924876,0.00017146245,0.00048767577,0.0002774156],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012404428,0.0045027924,0.34876528,0.002730454,0.0007073204,0.0017316457,0.00044293382,0.0005144474,0.04270613,0.00019295615,0.00312294,0.5821787],"study_design_scores_gemma":[0.0021549389,0.07000822,0.8662019,0.0017361363,0.0007540631,0.012111144,0.00056298176,0.001556273,0.014858943,0.00018046118,0.029827146,0.00004782197],"about_ca_topic_score_codex":0.00058657076,"about_ca_topic_score_gemma":0.002573682,"teacher_disagreement_score":0.0011662452,"about_ca_system_score_codex":0.00035697574,"about_ca_system_score_gemma":0.0005207406,"threshold_uncertainty_score":0.0039014816},"labels":[],"label_agreement":null},{"id":"W4206217038","doi":"10.1093/oncolo/oyac020","title":"Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; University of Calgary; Fraser Health; McMaster University; Juravinski Hospital; Queen's University","funders":"","keywords":"Medicine; Clinical trial; Cancer; Internal medicine; Oncology; Alternative medicine; Intensive care medicine; Pathology","score_opus":0.3861064120404313,"score_gpt":0.5403940469958496,"score_spread":0.1542876349554183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206217038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934639,0.053831935,0.0011999639,0.0011361359,0.00012692735,0.001646818,0.0039964817,0.000029547411,0.0033933069],"genre_scores_gemma":[0.9891272,0.0046704146,0.001137668,0.0009283056,0.00016290444,0.0013491717,0.002366739,0.000011188087,0.00024630115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98402417,0.009526639,0.0030845827,0.001275638,0.0016571629,0.00043192116],"domain_scores_gemma":[0.95256627,0.018297339,0.02497633,0.0017468559,0.0015632947,0.0008498651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020200424,0.00029261195,0.0014470683,0.00067330536,0.00045190385,0.0015645564,0.00051174936,0.00086008443,0.002176544],"category_scores_gemma":[0.036330175,0.0002527235,0.001708871,0.0023559064,0.00048180515,0.0010039222,0.0005803071,0.00081585214,0.0003147886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04423205,0.00076812156,0.8968989,0.0037751973,0.0062727933,0.0002490428,0.00030246467,0.00040148207,0.0015149695,0.00028468962,0.0024438188,0.042856432],"study_design_scores_gemma":[0.017672656,0.023580188,0.92769206,0.0021291217,0.009589385,0.0018869828,0.00026058085,0.001268184,0.002215098,0.000827998,0.012806367,0.00007138221],"about_ca_topic_score_codex":0.0002791577,"about_ca_topic_score_gemma":0.0005243606,"teacher_disagreement_score":0.020200424,"about_ca_system_score_codex":0.00058449723,"about_ca_system_score_gemma":0.0009960172,"threshold_uncertainty_score":0.10683131},"labels":[],"label_agreement":null},{"id":"W4206607110","doi":"10.1093/oncolo/oyab027","title":"Perceptions of Hope Among Bereaved Caregivers of Cancer Patients Who Received Early Palliative Care: A Content and Lexicographic Analysis","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Optimism, Hope, and Well-being","field":"Psychology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Palliative care; Perception; Cancer; Family medicine; Content analysis; Nursing; Internal medicine","score_opus":0.02837899443450177,"score_gpt":0.31420438686824603,"score_spread":0.2858253924337443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206607110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988986,0.000117158095,0.00023713308,0.00013770779,0.0000035322275,0.00002314792,0.000081453734,0.0000020823375,0.00049921137],"genre_scores_gemma":[0.99923074,0.0001426653,0.0003786885,0.000026221367,0.0000021552567,0.000025939173,0.00009410224,0.0000018323883,0.00009768507],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9992042,0.00049486576,0.000095289266,0.000043854026,0.000092411625,0.00006934683],"domain_scores_gemma":[0.99260396,0.005098391,0.0012831503,0.0001511019,0.00065209286,0.0002113217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020298548,0.00018915026,0.00024315868,0.0020796114,0.0011119562,0.0015280851,0.00021504966,0.00026009788,0.0010087447],"category_scores_gemma":[0.010775826,0.00014634879,0.00021488343,0.0014504368,0.0016991759,0.0010971434,0.0013522536,0.0005090757,0.00008759416],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002410095,0.00009213995,0.29387593,0.00041473555,0.000026488693,0.001146563,0.67939234,0.0001458342,0.0025192774,0.0013027473,0.000531349,0.020311598],"study_design_scores_gemma":[0.000009676342,0.00008619085,0.1555981,0.00016477611,0.000026465344,0.00077496713,0.83794385,0.00044213058,0.0009670641,0.00067249837,0.0032891203,0.0000251409],"about_ca_topic_score_codex":0.0028660547,"about_ca_topic_score_gemma":0.0039682984,"teacher_disagreement_score":0.0028660547,"about_ca_system_score_codex":0.0011169268,"about_ca_system_score_gemma":0.001008987,"threshold_uncertainty_score":0.010735035},"labels":[],"label_agreement":null},{"id":"W4206714415","doi":"10.1093/oncolo/oyab009","title":"Exercise-based Multimodal Programming: A Treatment Gap for Older Adults with Advanced Cancer","year":2022,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Cancer; Gerontology; Cancer treatment; Physical therapy; Internal medicine","score_opus":0.03177243009764622,"score_gpt":0.32071782337206495,"score_spread":0.2889453932744187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206714415","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012328674,0.00069555984,0.000032603155,0.9911823,0.0073787314,0.0000060673096,0.000030965875,0.000008793097,0.0005417028],"genre_scores_gemma":[0.0008465694,0.0009117629,0.00009919875,0.97813886,0.018758126,0.000030929594,0.000020328858,0.000012447242,0.0011816864],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921467,0.003302026,0.0011758391,0.0007250013,0.0019808253,0.00066954945],"domain_scores_gemma":[0.96127385,0.026165383,0.0016687682,0.00064667815,0.0062337723,0.0040115956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0097665675,0.0008785404,0.0019144188,0.0008411711,0.0052043023,0.0033370529,0.002874915,0.053633805,0.009584357],"category_scores_gemma":[0.05597316,0.00076240103,0.002119131,0.0011063052,0.0030535809,0.0072371033,0.0025072275,0.047323696,0.006094979],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000588373,0.000032902597,0.0004348054,0.00013488006,0.000013333046,0.0004642024,0.0002169694,0.000046609566,0.00008052159,0.0013770399,0.9860042,0.011135691],"study_design_scores_gemma":[0.0002963372,0.00018962902,0.0013906097,0.0014091436,0.000054860957,0.0013857721,0.0010559846,0.00030189042,0.00019146639,0.008494257,0.98513836,0.000091675254],"about_ca_topic_score_codex":0.016271284,"about_ca_topic_score_gemma":0.030816339,"teacher_disagreement_score":0.053633805,"about_ca_system_score_codex":0.0049366825,"about_ca_system_score_gemma":0.0121531105,"threshold_uncertainty_score":0.05165112},"labels":[],"label_agreement":null},{"id":"W4206943819","doi":"10.1093/oncolo/oyac031","title":"Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Monoclonal antibody; Confidence interval; Internal medicine; Optimism; Randomized controlled trial; Clinical endpoint; Oncology; Antibody; Immunology","score_opus":0.45022287493741125,"score_gpt":0.5122209442929506,"score_spread":0.061998069355539365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206943819","genre_codex":"methods","genre_gemma":"review","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044428375,0.3458993,0.44931963,0.046910636,0.018204771,0.065579414,0.0056173652,0.0016413614,0.022399114],"genre_scores_gemma":[0.51254445,0.021534123,0.31314316,0.033538435,0.005231012,0.109411485,0.0022218404,0.00045155725,0.0019239845],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.122403845,0.7213327,0.111336716,0.01769585,0.02570329,0.0015275293],"domain_scores_gemma":[0.07965395,0.81962043,0.054011505,0.032573,0.013248207,0.00089292927],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.73090184,0.0030341519,0.010333857,0.00831248,0.0017786685,0.009562989,0.005150746,0.0067585194,0.0051250174],"category_scores_gemma":[0.7954553,0.0031885172,0.013073978,0.0076843165,0.0072623687,0.008580839,0.004466859,0.005732404,0.001404413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039472878,0.0004779612,0.044789117,0.37117776,0.09886666,0.0011693127,0.009126936,0.007660187,0.0026554565,0.066773966,0.028906943,0.3289228],"study_design_scores_gemma":[0.052463092,0.009927565,0.044106875,0.22601047,0.118826546,0.002375124,0.0023800125,0.029966354,0.008173725,0.33196506,0.17237858,0.0014266593],"about_ca_topic_score_codex":0.00080620346,"about_ca_topic_score_gemma":0.0014223814,"teacher_disagreement_score":0.26909816,"about_ca_system_score_codex":0.0061187926,"about_ca_system_score_gemma":0.00847849,"threshold_uncertainty_score":0.331846},"labels":[],"label_agreement":null},{"id":"W4210388853","doi":"10.1093/oncolo/oyac030","title":"Comparing Barriers and Facilitators to Adolescent and Young Adult Clinical Trial Enrollment Across High- and Low-Enrolling Community-Based Clinics","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Facilitator; Medicine; Gatekeeping; Family medicine; Psychological intervention; Clinical trial; Intervention (counseling); Nursing; Psychology; Internal medicine","score_opus":0.10724082538982815,"score_gpt":0.4202037926898851,"score_spread":0.31296296730005696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210388853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718577,0.00017163025,0.00027371824,0.0009961328,0.000008309194,0.00021124234,0.000069423964,0.000006940605,0.0010767484],"genre_scores_gemma":[0.99878293,0.000101197955,0.0005139371,0.00023360243,0.0000050473664,0.0002009106,0.000039981056,0.0000030467122,0.00011947983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9851033,0.009615397,0.0011051497,0.0007754202,0.0014640046,0.0019366352],"domain_scores_gemma":[0.9426718,0.034517404,0.011409874,0.00076401234,0.003128441,0.0075084837],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016996516,0.00018847584,0.00032526182,0.00089499634,0.0023394122,0.002170113,0.001175664,0.0005901705,0.002552687],"category_scores_gemma":[0.042951964,0.00036414145,0.00041294473,0.0007578452,0.0014869403,0.0012953805,0.0029788595,0.001176747,0.00010036474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038184194,0.0009413367,0.7493806,0.0007842142,0.00010400833,0.00042061435,0.20987858,0.00015397786,0.0015607501,0.0012249526,0.0015399101,0.03362926],"study_design_scores_gemma":[0.00010686242,0.0008303113,0.64977866,0.0010216112,0.00009453221,0.00029249027,0.33980197,0.0010484374,0.0009381726,0.0006253789,0.005412085,0.00004942189],"about_ca_topic_score_codex":0.017649505,"about_ca_topic_score_gemma":0.03500578,"teacher_disagreement_score":0.9830035,"about_ca_system_score_codex":0.0037011448,"about_ca_system_score_gemma":0.013318867,"threshold_uncertainty_score":0.08988726},"labels":[],"label_agreement":null},{"id":"W4210930134","doi":"10.1093/oncolo/oyac039","title":"“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Mount Sinai Hospital; University of British Columbia; McGill University; St. Michael's Hospital; Jewish General Hospital; Memorial University of Newfoundland; Dalhousie University; University of Toronto; University Health Network; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Genetic testing; Thematic analysis; Health professionals; Test (biology); Health care; Cancer; Cancer screening; Family medicine; Qualitative research; Nursing; Internal medicine","score_opus":0.16324068950015908,"score_gpt":0.42232402391385887,"score_spread":0.2590833344136998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210930134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95092225,0.0011102376,0.005992751,0.02830761,0.00032117104,0.0001861309,0.00007441527,0.00004434162,0.013041164],"genre_scores_gemma":[0.9957283,0.00026101005,0.0012358113,0.002064788,0.000030497838,0.00005607844,0.000019362973,0.0000106303605,0.00059351645],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9701525,0.02502539,0.0005782581,0.00064307766,0.0016791241,0.0019216136],"domain_scores_gemma":[0.95775104,0.029674275,0.003768819,0.000611332,0.003480919,0.0047136736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019974224,0.00050609483,0.0002820053,0.0009701923,0.005633603,0.004551114,0.0015409059,0.002433002,0.0012845877],"category_scores_gemma":[0.039374918,0.00040414176,0.00047542542,0.0004603397,0.011198525,0.002654276,0.005397367,0.0033079737,0.00016797901],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008415047,0.000047945297,0.010670547,0.00019212792,0.000013372923,0.0008633319,0.9760641,0.000105018495,0.0007309475,0.0022058026,0.0015977812,0.007424943],"study_design_scores_gemma":[0.000018459943,0.00015229455,0.003954689,0.00022973542,0.000015928194,0.0007206482,0.98007,0.00048126356,0.0003849091,0.0013633635,0.01257322,0.000035410234],"about_ca_topic_score_codex":0.01579942,"about_ca_topic_score_gemma":0.014619111,"teacher_disagreement_score":0.019974224,"about_ca_system_score_codex":0.007918109,"about_ca_system_score_gemma":0.008219639,"threshold_uncertainty_score":0.10563505},"labels":[],"label_agreement":null},{"id":"W4212817368","doi":"10.1093/oncolo/oyac047","title":"Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Advanced Proteomics Techniques and Applications","field":"Chemistry","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Microvesicles; Disease; Cancer; Circulating tumor cell; Biomarker discovery; Cancer biomarkers; Disease monitoring; Biomarker; Bioinformatics; Internal medicine; microRNA; Proteomics; Metastasis; Biology","score_opus":0.21134661708314767,"score_gpt":0.4558295552984037,"score_spread":0.24448293821525602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212817368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000188705,0.9960781,0.00070265937,0.00042188517,0.0004254549,0.000011174096,0.000027851964,0.00001584285,0.0021284292],"genre_scores_gemma":[0.0015599892,0.99516594,0.00085824984,0.00032033268,0.00031205718,0.000023331217,0.00005374208,0.000003996536,0.0017023192],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99966085,0.000072863826,0.000033091237,0.000053474207,0.00015094354,0.000028722598],"domain_scores_gemma":[0.99964964,0.00016109485,0.00004490313,0.000013395905,0.00010801492,0.000023003207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008563555,0.00096024026,0.0010691371,0.002308078,0.00025698636,0.0011907336,0.00072578725,0.0013502982,0.003725671],"category_scores_gemma":[0.0009780974,0.00031214528,0.0005741097,0.0014144348,0.0004320996,0.0012841516,0.0007740676,0.0023972646,0.0037665856],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008039298,0.000105838764,0.00021451442,0.010876776,0.00008534901,0.00026247886,0.00006457367,0.0004720548,0.0079890955,0.010059488,0.035346586,0.9344428],"study_design_scores_gemma":[0.000010749223,0.000100646525,0.0003988753,0.0015939825,0.00004951079,0.0009706962,0.000030469802,0.00015501653,0.002090592,0.002086507,0.9924959,0.000017059683],"about_ca_topic_score_codex":0.0005603101,"about_ca_topic_score_gemma":0.0008092418,"teacher_disagreement_score":0.003725671,"about_ca_system_score_codex":0.00058098696,"about_ca_system_score_gemma":0.00077315426,"threshold_uncertainty_score":0.012463629},"labels":[],"label_agreement":null},{"id":"W4220717070","doi":"10.1093/oncolo/oyac065","title":"Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eisai","keywords":"Lenvatinib; Medicine; Oncology; Thyroid cancer; Adverse effect; Internal medicine; Refractory (planetary science); Cancer","score_opus":0.23130467568283522,"score_gpt":0.45538061299538324,"score_spread":0.22407593731254802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220717070","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034196046,0.98841476,0.0004940659,0.003772886,0.00029565734,0.000026735554,0.00008157956,0.000023140585,0.003471497],"genre_scores_gemma":[0.040804237,0.94945836,0.0021920863,0.0037870856,0.0011392927,0.00007241209,0.00030127022,0.000017387454,0.0022278493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997657,0.00007571626,0.000033508968,0.000026498854,0.000071060094,0.000027562886],"domain_scores_gemma":[0.99970824,0.00012718487,0.0000789002,0.0000063557577,0.000056138786,0.000023217355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006784807,0.00036768874,0.0007003573,0.00047755492,0.00012175777,0.0007749423,0.000301891,0.00043047091,0.0029508797],"category_scores_gemma":[0.0008182318,0.000099675635,0.000724601,0.00044253774,0.00016332681,0.00055123965,0.0002622881,0.0011380949,0.0006124154],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008125688,0.00009140265,0.00079579366,0.010795512,0.00044608614,0.0002725393,0.000050644758,0.0010248281,0.0054873643,0.00349048,0.041098244,0.9356345],"study_design_scores_gemma":[0.0012357981,0.0013763796,0.0056806314,0.010829636,0.0012039035,0.0031560643,0.000102657774,0.0011628873,0.003359099,0.006337816,0.96550715,0.000047959158],"about_ca_topic_score_codex":0.00031164396,"about_ca_topic_score_gemma":0.0013869274,"teacher_disagreement_score":0.0029508797,"about_ca_system_score_codex":0.0006352972,"about_ca_system_score_gemma":0.00077916257,"threshold_uncertainty_score":0.009871662},"labels":[],"label_agreement":null},{"id":"W4220913590","doi":"10.1093/oncolo/oyac067","title":"Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Daratumumab; Medicine; Internal medicine; Multiple myeloma; Hazard ratio; Oncology; Cohort; Bortezomib; Autologous stem-cell transplantation; Progression-free survival; Proportional hazards model; Surgery; Confidence interval; Chemotherapy","score_opus":0.026222690483483503,"score_gpt":0.32028486441752685,"score_spread":0.2940621739340433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220913590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525669,0.04588353,0.00026357782,0.00020178438,0.000053760257,0.000056234465,0.0003737195,0.000026708325,0.00057388423],"genre_scores_gemma":[0.9971649,0.0022988229,0.00012827755,0.00009587308,0.000025231251,0.00001382035,0.0001948232,0.0000021692001,0.000076038465],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988262,0.00061837945,0.0001675532,0.00019938653,0.000116763455,0.00007171053],"domain_scores_gemma":[0.99775785,0.00095702417,0.00095416175,0.00013935001,0.00008004129,0.000111582005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040262644,0.0004917844,0.0020207048,0.0004904629,0.00019193246,0.0007983594,0.00031302468,0.00043749643,0.0009948276],"category_scores_gemma":[0.0035900786,0.00025326043,0.0028994444,0.0004596828,0.00023520041,0.00035650047,0.0003590483,0.00076771405,0.0000774625],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29945332,0.0016164456,0.35104772,0.006463032,0.118815385,0.00026364127,0.00025002626,0.0063230777,0.009046507,0.00023519265,0.0016764567,0.20480923],"study_design_scores_gemma":[0.05821422,0.059597556,0.7385859,0.00087511836,0.124696255,0.0012948664,0.0001631302,0.0058364486,0.0051486366,0.0008478654,0.0046652174,0.0000748301],"about_ca_topic_score_codex":0.00059453177,"about_ca_topic_score_gemma":0.0015105543,"teacher_disagreement_score":0.0040262644,"about_ca_system_score_codex":0.00055955973,"about_ca_system_score_gemma":0.00032227393,"threshold_uncertainty_score":0.021293163},"labels":[],"label_agreement":null},{"id":"W4225723737","doi":"10.1093/oncolo/oyac092","title":"Longitudinal Changes in Skeletal Muscle Metabolism, Oxygen Uptake, and Myosteatosis During Cardiotoxic Treatment for Early-Stage Breast Cancer","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto","funders":"Canadian Institutes of Health Research; University Hospital Foundation; Heart and Stroke Foundation of Canada","keywords":"Medicine; Breast cancer; Skeletal muscle; Chemotherapy; Internal medicine; VO2 max; Cancer; Cardiology; Blood pressure; Heart rate","score_opus":0.03960038994207725,"score_gpt":0.30457004243541846,"score_spread":0.2649696524933412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225723737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99969435,0.00011214092,0.00004790418,0.00000846281,6.6027434e-7,0.000005194683,0.00005079541,0.0000016701746,0.000078790836],"genre_scores_gemma":[0.99949265,0.00006088004,0.000061922976,0.000013725528,0.0000018059899,0.000009983249,0.00020957226,7.348565e-7,0.00014873828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999151,0.00002044829,0.0000064971296,0.00001740723,0.000018487111,0.000021933438],"domain_scores_gemma":[0.99952555,0.000065325374,0.00022099055,0.000024389667,0.00006030712,0.0001033735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032202085,0.000139633,0.00025016456,0.00017779547,0.00017077604,0.00021684488,0.00012008024,0.00022975302,0.0005612361],"category_scores_gemma":[0.0005799513,0.00009465485,0.00015578141,0.00019001178,0.000095975665,0.00014172994,0.00017375642,0.00032396635,0.00013722935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030962517,0.000332873,0.9673874,0.000025311701,0.000058678466,0.00019602045,0.000140126,0.00026822044,0.01796486,0.00000785345,0.00008815017,0.010434289],"study_design_scores_gemma":[0.0000149509715,0.0011764477,0.99680626,0.0000028286381,0.000025422542,0.0002195362,0.000042123058,0.00014646078,0.0014298693,0.000007527046,0.0001256922,0.0000029615785],"about_ca_topic_score_codex":0.00084430404,"about_ca_topic_score_gemma":0.0016711688,"teacher_disagreement_score":0.00084430404,"about_ca_system_score_codex":0.00021889081,"about_ca_system_score_gemma":0.00012919978,"threshold_uncertainty_score":0.0018775463},"labels":[],"label_agreement":null},{"id":"W4226080629","doi":"10.1093/oncolo/oyac085","title":"Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Cancer; Hazard ratio; Internal medicine; Population; Retrospective cohort study; Proportional hazards model; Cohort; Health care; Bladder cancer; Lung cancer; Emergency medicine; Oncology; Environmental health; Confidence interval","score_opus":0.07398580857859918,"score_gpt":0.3731836956369571,"score_spread":0.2991978870583579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226080629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913924,0.0005416267,0.00017918473,0.00028065516,0.0000104941155,0.000050494404,0.0069816946,0.000008197165,0.00055532326],"genre_scores_gemma":[0.9969164,0.00022207061,0.0001557438,0.00009862541,0.000010204129,0.00003185755,0.002477397,0.0000032423627,0.000084356776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972554,0.0005892973,0.00034538942,0.0005663378,0.00074754,0.0004960625],"domain_scores_gemma":[0.99304765,0.0007438855,0.0037512174,0.0006245598,0.0011151985,0.0007174915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023748642,0.0003150489,0.00048754405,0.0015778494,0.0011563953,0.0014012613,0.0012364379,0.0005077609,0.0009512419],"category_scores_gemma":[0.0065619736,0.0005516499,0.0010390917,0.0056092516,0.0007491876,0.0006516094,0.0010379322,0.00088512147,0.00017987049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023767374,0.000013950055,0.999225,0.000014534884,0.000067992296,0.000011413655,0.00008806304,0.000032785218,0.000024414257,0.000015803234,0.00019322416,0.00028912508],"study_design_scores_gemma":[0.00000871254,0.00002406006,0.99904686,0.000021304184,0.00003886296,0.00004445987,0.00022992463,0.00023842372,0.000017666287,0.000013578645,0.00031006706,0.000005889557],"about_ca_topic_score_codex":0.706823,"about_ca_topic_score_gemma":0.7221635,"teacher_disagreement_score":0.706823,"about_ca_system_score_codex":0.0059886635,"about_ca_system_score_gemma":0.007468857,"threshold_uncertainty_score":0.58980715},"labels":[],"label_agreement":null},{"id":"W4234840939","doi":"10.1634/theoncologist.2017-0283","title":"In Reply","year":2017,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine","score_opus":0.07220726066017526,"score_gpt":0.3398013643898503,"score_spread":0.26759410372967507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234840939","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002143923,0.0009339352,0.000060791535,0.9727163,0.023082973,0.000011115469,0.00008520783,0.00004548124,0.0028498047],"genre_scores_gemma":[0.001553215,0.0005893307,0.00008963383,0.97885203,0.010606096,0.00002562509,0.000043126427,0.000026094787,0.008214857],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701,0.0008167768,0.0002964654,0.00039468263,0.0009314834,0.0005505961],"domain_scores_gemma":[0.9928651,0.0028042404,0.0004427776,0.0002013296,0.0024315058,0.0012550126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037116306,0.0007448189,0.0012164917,0.00074390986,0.004366721,0.0035825588,0.002225421,0.031938873,0.01740804],"category_scores_gemma":[0.02854201,0.000706476,0.0010423458,0.00062389474,0.0023164602,0.0038468721,0.0021631073,0.031206958,0.015629206],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015789732,0.0000071607788,0.00022321701,0.000016753556,0.0000031653783,0.00030002117,0.000067185334,0.000009280258,0.00002847534,0.0005154756,0.9965239,0.0022894922],"study_design_scores_gemma":[0.000049723756,0.00002951668,0.0005922932,0.00017361586,0.000013522694,0.0014488804,0.0006232083,0.000095986376,0.00013859168,0.0027294743,0.99405766,0.000047592344],"about_ca_topic_score_codex":0.0071779652,"about_ca_topic_score_gemma":0.011502232,"teacher_disagreement_score":0.031938873,"about_ca_system_score_codex":0.003094841,"about_ca_system_score_gemma":0.006139066,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4235646239","doi":"10.1634/theoncologist.2014-0036","title":"Overdiagnosing Overdiagnosis","year":2014,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Overdiagnosis; Medicine; Mammography; Confounding; Breast cancer; Mammography screening; Medical physics; Family medicine; Cancer; Pathology; Internal medicine","score_opus":0.15198976949068316,"score_gpt":0.3821809338026931,"score_spread":0.23019116431200992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235646239","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019403432,0.003095362,0.00022703197,0.98236495,0.0049684504,0.000009142611,0.000020120122,0.000019086756,0.007355499],"genre_scores_gemma":[0.019898405,0.0027746083,0.00028246452,0.95702505,0.018038683,0.0000102100075,0.000023378318,0.000012444629,0.0019346626],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926093,0.0032627732,0.000807106,0.00069506787,0.0018853656,0.0007403751],"domain_scores_gemma":[0.9776829,0.01360325,0.0021024335,0.00083240285,0.0039072935,0.0018717076],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007520508,0.00046627902,0.0007773494,0.0013008106,0.00283762,0.0024509274,0.0014341644,0.024927404,0.004565917],"category_scores_gemma":[0.05014321,0.0004520258,0.0009811714,0.00090904813,0.0060287314,0.0036509756,0.0019336904,0.019579202,0.0024798398],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064667984,0.000059231064,0.012655583,0.00024771714,0.000037822872,0.010565744,0.0013389821,0.00014784337,0.000610063,0.01673072,0.897905,0.05963667],"study_design_scores_gemma":[0.00012422354,0.00022382257,0.014043651,0.0045185345,0.00009053691,0.0677625,0.0054569645,0.0010505556,0.00087492215,0.053931165,0.85179746,0.00012561692],"about_ca_topic_score_codex":0.006345743,"about_ca_topic_score_gemma":0.010373682,"teacher_disagreement_score":0.9924795,"about_ca_system_score_codex":0.005224684,"about_ca_system_score_gemma":0.0035781446,"threshold_uncertainty_score":0.03977275},"labels":[],"label_agreement":null},{"id":"W4236681238","doi":"10.1634/theoncologist.2014-0232","title":"In Reply","year":2014,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Anthracycline; Radiation therapy; Lymphoma; Oncology; Chemotherapy; Internal medicine; Diffuse large B-cell lymphoma; Intensive care medicine; Cancer; Breast cancer","score_opus":0.041495251654115176,"score_gpt":0.3193977156798092,"score_spread":0.277902464025694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236681238","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035495378,0.0011914138,0.00007981982,0.9686354,0.027909487,0.00001586283,0.000071933995,0.000050769093,0.0016903797],"genre_scores_gemma":[0.0024472482,0.0006749225,0.0001234734,0.97404826,0.018238137,0.00003459281,0.000030551142,0.000019123796,0.004383641],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99791855,0.000660614,0.0002441544,0.00029134247,0.0005958294,0.0002895357],"domain_scores_gemma":[0.99225074,0.003397397,0.0005857788,0.00024428166,0.0024554164,0.0010663844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002697314,0.00078475085,0.0013885928,0.0008258837,0.002736903,0.0030138288,0.0023631249,0.031116772,0.0094099175],"category_scores_gemma":[0.025628235,0.0007343258,0.0009101758,0.00066628185,0.0020782305,0.0035834017,0.0015613448,0.031960316,0.0101449005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032088134,0.000016763339,0.0005198048,0.000033514803,0.000010192245,0.001184199,0.00008954198,0.000023047902,0.000064257874,0.00050951564,0.99372536,0.0037917467],"study_design_scores_gemma":[0.000092394024,0.00005302333,0.0015825428,0.0002322626,0.000033622393,0.004787281,0.0006945476,0.00025784507,0.00026087151,0.003415915,0.9885019,0.0000877723],"about_ca_topic_score_codex":0.0042599393,"about_ca_topic_score_gemma":0.0054877596,"teacher_disagreement_score":0.031116772,"about_ca_system_score_codex":0.002945083,"about_ca_system_score_gemma":0.0028718794,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4241446446","doi":"10.1634/theoncologist.2016-0469","title":"In Reply","year":2017,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Palbociclib; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Gynecology; Cancer","score_opus":0.049334204669764445,"score_gpt":0.36627834033573087,"score_spread":0.3169441356659664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241446446","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005260484,0.0011504877,0.000113444614,0.96297026,0.031489372,0.00002294335,0.00012316245,0.00008413147,0.0035201684],"genre_scores_gemma":[0.002372713,0.0008032351,0.00014198264,0.97068506,0.019891294,0.000037449652,0.000047193666,0.000029261157,0.0059918338],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978242,0.00062140595,0.00026556314,0.00028139347,0.00068769726,0.0003197705],"domain_scores_gemma":[0.99410135,0.0024153988,0.00045695345,0.00021036614,0.0019744146,0.0008415395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025766422,0.0007784972,0.0012086764,0.0007352848,0.0029184073,0.0030458649,0.0021237805,0.028644005,0.010219583],"category_scores_gemma":[0.020633927,0.0006387551,0.00090723933,0.00064974034,0.0020767308,0.003335978,0.0015719,0.030086251,0.013810535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003750067,0.000018797791,0.0004991671,0.000034109176,0.000008434807,0.0009919581,0.00008893724,0.000025102892,0.000076797565,0.0006146521,0.99290705,0.0046975645],"study_design_scores_gemma":[0.000088546534,0.00007047087,0.0009030842,0.00019178729,0.000028845578,0.0031589395,0.0005620272,0.00018168605,0.00028285268,0.0034619696,0.9909956,0.00007438007],"about_ca_topic_score_codex":0.004069297,"about_ca_topic_score_gemma":0.0055655846,"teacher_disagreement_score":0.028644005,"about_ca_system_score_codex":0.002756419,"about_ca_system_score_gemma":0.0038271025,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4245164110","doi":"10.1634/theoncologist.2015-0465","title":"In Reply","year":2016,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sarcopenia; Medicine; Cachexia; Cancer cachexia; Skeletal muscle; Computed tomography; Cancer; Muscle mass; Mechanism (biology); Bioinformatics; Intensive care medicine; Internal medicine; Surgery","score_opus":0.08351319906884719,"score_gpt":0.3955907078188597,"score_spread":0.3120775087500125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245164110","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025018136,0.00149811,0.00007347964,0.956927,0.039313655,0.000016674947,0.00009203553,0.00006172683,0.0017671554],"genre_scores_gemma":[0.0012638684,0.00073446723,0.00010193324,0.9692973,0.022963002,0.00003378902,0.000031145362,0.000017808024,0.005556698],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974802,0.0007014495,0.00032350793,0.00035400398,0.0008225378,0.00031831692],"domain_scores_gemma":[0.9925424,0.0030805345,0.0006283501,0.00026446293,0.0022218507,0.0012624464],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036686135,0.00095370156,0.0014899501,0.0007790349,0.0032667303,0.0035990926,0.0025595934,0.037489302,0.012474599],"category_scores_gemma":[0.024954304,0.0008435843,0.0012110751,0.00056711456,0.0026277432,0.0047572716,0.0021126794,0.038691692,0.014912744],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032868305,0.000017218665,0.00031342602,0.000037055055,0.000007486951,0.00053358974,0.00006694521,0.000017876426,0.00005967658,0.0004724524,0.99446714,0.003974195],"study_design_scores_gemma":[0.00008510686,0.000056878223,0.0009630963,0.00021242056,0.000024496405,0.0018211623,0.00041239205,0.00015452495,0.00019206785,0.0028265028,0.99318475,0.00006670623],"about_ca_topic_score_codex":0.003960278,"about_ca_topic_score_gemma":0.0059405654,"teacher_disagreement_score":0.9875254,"about_ca_system_score_codex":0.0028361443,"about_ca_system_score_gemma":0.003693448,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4248773577","doi":"10.1634/theoncologist.7-2004-14","title":"Molecular Targets of Arsenic Trioxide in Malignant Cells","year":2002,"lang":"en","type":"article","venue":"The Oncologist","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; Medicine; Cancer research; Multiple myeloma; Leukemia; Apoptosis; Immunology; Chemistry; Biology; Cell culture; Biochemistry; Retinoic acid","score_opus":0.013206392662649053,"score_gpt":0.23846106538802242,"score_spread":0.22525467272537336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248773577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46691054,0.30384064,0.033780888,0.018728966,0.00366304,0.0006811227,0.0020304648,0.0018153522,0.168549],"genre_scores_gemma":[0.83974993,0.08785268,0.005751255,0.001670997,0.00052154803,0.00018399004,0.0010959689,0.000082753606,0.06309092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998963,0.000019945162,0.000005250089,0.000012909141,0.000047643432,0.000017878798],"domain_scores_gemma":[0.9999486,0.000008721335,0.000009772761,0.000005597918,0.000015989395,0.000011252799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014949376,0.00031160828,0.00018665561,0.0004278853,0.00025926056,0.0004922656,0.00026033382,0.00053130277,0.00500864],"category_scores_gemma":[0.00012319529,0.00013788663,0.00025791247,0.00023003994,0.00014431986,0.00027426815,0.00024204075,0.00048149042,0.0021289354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016844632,0.000112090514,0.00053212326,0.00048879255,0.00004022487,0.00081737916,0.00010486456,0.0003949976,0.9369481,0.007656173,0.007834506,0.04490234],"study_design_scores_gemma":[0.000049725288,0.0005819885,0.0055905036,0.000076421136,0.00006101459,0.002442386,0.0001905142,0.001377448,0.80820733,0.004879171,0.17652781,0.00001572339],"about_ca_topic_score_codex":0.00024998956,"about_ca_topic_score_gemma":0.0004389426,"teacher_disagreement_score":0.00500864,"about_ca_system_score_codex":0.0005038809,"about_ca_system_score_gemma":0.00023953264,"threshold_uncertainty_score":0.01675558},"labels":[],"label_agreement":null},{"id":"W4255053766","doi":"10.1634/theoncologist.5-6-510","title":"The Cell Cycle","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"","field":"","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine","score_opus":0.012790185639053554,"score_gpt":0.27035796731703216,"score_spread":0.2575677816779786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255053766","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02287283,0.4094266,0.010768223,0.05787629,0.020385645,0.0001691872,0.0017191069,0.0010498473,0.47573227],"genre_scores_gemma":[0.293184,0.21564879,0.0052452683,0.02014299,0.007212419,0.0002882414,0.0024362167,0.00038850054,0.45545354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995297,0.000070573326,0.000018810322,0.00011452069,0.00019457603,0.000071854374],"domain_scores_gemma":[0.99937916,0.00008270531,0.000057365425,0.000101310136,0.0001507819,0.00022855731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005547672,0.00066000887,0.0006018213,0.0012927393,0.0012599534,0.004056098,0.0008085631,0.0016954335,0.018871453],"category_scores_gemma":[0.0012897673,0.00039314487,0.0004922417,0.00076214975,0.001739496,0.0031746828,0.0019314518,0.003571863,0.009955995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046433494,0.00011455671,0.0011543896,0.00090842944,0.000061740095,0.00031279336,0.00068246364,0.00056238833,0.04991025,0.28929713,0.2833045,0.37322697],"study_design_scores_gemma":[0.000019947178,0.0000584985,0.00074604654,0.0001188786,0.000009594339,0.00012344513,0.000116691845,0.000111784786,0.0041683004,0.016976314,0.9775407,0.000009863199],"about_ca_topic_score_codex":0.0012537332,"about_ca_topic_score_gemma":0.0016454277,"teacher_disagreement_score":0.018871453,"about_ca_system_score_codex":0.0020810605,"about_ca_system_score_gemma":0.0020687554,"threshold_uncertainty_score":0.06313133},"labels":[],"label_agreement":null},{"id":"W4282973464","doi":"10.1093/oncolo/oyac101","title":"Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Oncology; Quality of life (healthcare); Gynecology; Adverse effect; Internal medicine; Randomized controlled trial; Cancer","score_opus":0.018625086547519615,"score_gpt":0.3034899729161072,"score_spread":0.2848648863685876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282973464","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016785652,0.36925876,0.0032018076,0.58881,0.032205928,0.00034333876,0.00029790957,0.000058213212,0.00414553],"genre_scores_gemma":[0.043831985,0.55352116,0.024623388,0.32094008,0.051129647,0.0010660462,0.001145917,0.000121414974,0.0036203924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97759026,0.010050804,0.0055634403,0.0014240125,0.0041400422,0.0012315583],"domain_scores_gemma":[0.9256969,0.03441053,0.0059077246,0.0013680748,0.027182423,0.0054344377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.055842675,0.0013547126,0.0034653281,0.0021478678,0.0020156663,0.0050348016,0.004684134,0.012796391,0.0014062466],"category_scores_gemma":[0.04557951,0.00076385075,0.0036598325,0.0022701705,0.0032944917,0.0040087164,0.004692536,0.017949989,0.0009450143],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037683386,0.0001807736,0.002848543,0.014411879,0.0004778897,0.0007128431,0.0016710192,0.0009717121,0.002039306,0.007532575,0.45633253,0.512444],"study_design_scores_gemma":[0.0001854901,0.00023037817,0.004345392,0.029176727,0.0007960059,0.0012720998,0.0016433601,0.00079785654,0.00079664,0.012145312,0.9484243,0.00018652057],"about_ca_topic_score_codex":0.003730492,"about_ca_topic_score_gemma":0.0047495635,"teacher_disagreement_score":0.055842675,"about_ca_system_score_codex":0.003934508,"about_ca_system_score_gemma":0.015766177,"threshold_uncertainty_score":0.29532784},"labels":[],"label_agreement":null},{"id":"W4283022221","doi":"10.1093/oncolo/oyac106","title":"The Value of In Vivo Reflectance Confocal Microscopy as an Assessment Tool in Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; RWTH Aachen University; Bundesministerium für Bildung und Forschung; Medical Research Foundation; Melville Charitable Trust","keywords":"Medicine; Peripheral neuropathy; Chemotherapy-induced peripheral neuropathy; In vivo; Confocal microscopy; Chemotherapy; Confocal; Pathology; Peripheral; Radiology; Internal medicine; Optics","score_opus":0.04574533894228266,"score_gpt":0.4373136524696243,"score_spread":0.3915683135273416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283022221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998823,0.00016557219,0.00048399673,0.000012341692,0.000005428287,0.00025470246,0.000030832038,0.000006155285,0.00021790969],"genre_scores_gemma":[0.99828845,0.00013983705,0.0010794785,0.00003624011,0.000018480498,0.00019131404,0.00007241337,0.0000028806946,0.00017100024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988611,0.0006978878,0.00006094023,0.00015637625,0.00012002733,0.00010368201],"domain_scores_gemma":[0.9966222,0.0014557054,0.0005296269,0.00044328775,0.00060029415,0.00034880053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003348292,0.00074495375,0.00043844996,0.00042126395,0.00036967438,0.00032740788,0.0003392219,0.00048890593,0.0016625315],"category_scores_gemma":[0.003065596,0.00020983467,0.0003988949,0.00022727078,0.00072464236,0.0005369451,0.00042167434,0.0004929364,0.00033010994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097271696,0.06859405,0.45890087,0.00080626085,0.00047595348,0.0029784453,0.0020966085,0.0010686896,0.27808988,0.00018428208,0.00045410777,0.08907909],"study_design_scores_gemma":[0.003157807,0.5595851,0.40439484,0.00004411947,0.00042797046,0.0030700562,0.00065165624,0.0024692027,0.025145402,0.0000941879,0.00090930535,0.00005042991],"about_ca_topic_score_codex":0.0009885111,"about_ca_topic_score_gemma":0.0008791793,"teacher_disagreement_score":0.003348292,"about_ca_system_score_codex":0.00036181646,"about_ca_system_score_gemma":0.00044471453,"threshold_uncertainty_score":0.017707646},"labels":[],"label_agreement":null},{"id":"W4283693701","doi":"10.1093/oncolo/oyac114","title":"Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer Canada; McGill University; Pfizer","keywords":"Randomized controlled trial; Medicine; Psychological intervention; Clinical trial; Intervention (counseling); Intensive care medicine; Alternative medicine; Real world data; Medical physics; Oncology; Internal medicine; Data science; Pathology; Nursing; Computer science","score_opus":0.3162898071314984,"score_gpt":0.4826416858563563,"score_spread":0.1663518787248579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283693701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020868103,0.9574456,0.0015491399,0.03569609,0.0022509939,0.00058846676,0.00027945466,0.00001840121,0.0019631002],"genre_scores_gemma":[0.0138463,0.9246277,0.015134599,0.040183183,0.0026035686,0.002496743,0.00027735456,0.000046265755,0.0007843408],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.8776057,0.06172102,0.03213106,0.005119885,0.021881193,0.0015411926],"domain_scores_gemma":[0.59924245,0.31901944,0.025714673,0.00740591,0.045788363,0.0028292171],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.19251993,0.0025169596,0.008312322,0.01842935,0.0019859532,0.012333364,0.0059441538,0.009636833,0.005672611],"category_scores_gemma":[0.3801731,0.0021899284,0.0056652618,0.016679283,0.006931135,0.011469894,0.0047862916,0.009038687,0.0014122885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044481675,0.00006013924,0.0017654138,0.6796607,0.0065941433,0.00048638464,0.001504939,0.0006633957,0.0005747204,0.048216082,0.03341837,0.22661085],"study_design_scores_gemma":[0.0003123209,0.00011096527,0.0016607125,0.7835594,0.008096222,0.0004500145,0.00062536803,0.00039246207,0.00020696511,0.02275439,0.18173571,0.00009547539],"about_ca_topic_score_codex":0.020715266,"about_ca_topic_score_gemma":0.046433393,"teacher_disagreement_score":0.97928476,"about_ca_system_score_codex":0.015070646,"about_ca_system_score_gemma":0.05205506,"threshold_uncertainty_score":0.9957667},"labels":[],"label_agreement":null},{"id":"W4285084462","doi":"10.1093/oncolo/oyac123","title":"Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University Health Centre; Université Laval; Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"Exact Sciences Corporation","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Chemotherapy; Clinical endpoint; Prospective cohort study; Observational study; Cancer; Lymph node; Estrogen receptor; Progesterone receptor; Clinical trial; Gynecology","score_opus":0.018000210044577625,"score_gpt":0.3062927976328524,"score_spread":0.28829258758827475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285084462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970912,0.00051383,0.000089751324,0.0003446737,0.000013956595,0.00009998524,0.0012093029,0.000005111358,0.00063228304],"genre_scores_gemma":[0.9982247,0.00016849802,0.00014403963,0.00024478682,0.000012492481,0.000054393357,0.00080993056,0.0000032030853,0.00033789536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799526,0.0007755427,0.00009851516,0.00034242295,0.00040329547,0.0003849741],"domain_scores_gemma":[0.99323326,0.0013049758,0.0019117,0.00027767112,0.0016893111,0.0015829441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023940494,0.00054039626,0.00062275556,0.00037180772,0.0013511209,0.0010059442,0.0012871382,0.00092333416,0.0018839514],"category_scores_gemma":[0.0057368143,0.00027641133,0.0009686277,0.0014581708,0.0007890257,0.00042429913,0.00050850393,0.0010030116,0.00019715194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020301621,0.0006068793,0.99051356,0.000042102518,0.00031387407,0.00005643463,0.00023818808,0.00043101565,0.0002527549,0.000042701955,0.0012393674,0.004232934],"study_design_scores_gemma":[0.00038702445,0.00068449817,0.99664706,0.000021635657,0.00011475209,0.000029634066,0.0002841542,0.0012845933,0.00005370408,0.000012737446,0.0004622514,0.000017894286],"about_ca_topic_score_codex":0.946912,"about_ca_topic_score_gemma":0.95235723,"teacher_disagreement_score":0.05308801,"about_ca_system_score_codex":0.024035407,"about_ca_system_score_gemma":0.013922234,"threshold_uncertainty_score":0.1743899},"labels":[],"label_agreement":null},{"id":"W4288034414","doi":"10.1093/oncolo/oyac142","title":"Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Merck Sharp and Dohme; Eisai; Merck","keywords":"Lenvatinib; Medicine; Everolimus; Renal cell carcinoma; Quality of life (healthcare); Internal medicine; Oncology; Adverse effect; Clinical trial; Sorafenib; Hepatocellular carcinoma","score_opus":0.06752936432084708,"score_gpt":0.32773573030721215,"score_spread":0.26020636598636504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288034414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886644,0.000500663,0.000081904516,0.000035814483,0.000009570053,0.00008352599,0.00019644931,0.000006780084,0.00021883071],"genre_scores_gemma":[0.998716,0.00016285956,0.00029493799,0.00004671655,0.000022287973,0.00019328806,0.00044666292,0.0000032845462,0.00011406159],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99902403,0.00043729882,0.00008734482,0.00015192019,0.00020629544,0.00009319352],"domain_scores_gemma":[0.99843854,0.0003957564,0.00066004106,0.00009233023,0.00011387103,0.00029951677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017748718,0.0005513503,0.0014438418,0.00035924878,0.00028818767,0.0005412813,0.0004619503,0.0004385457,0.0016523855],"category_scores_gemma":[0.0020801092,0.00020729998,0.0015092826,0.0004057596,0.00030762397,0.00036629295,0.000285408,0.0013218612,0.00024849956],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6173586,0.025041142,0.20865138,0.00046449364,0.004990028,0.00017868156,0.00028050752,0.004509712,0.0220394,0.0000656189,0.0010233694,0.11539709],"study_design_scores_gemma":[0.06652014,0.35024762,0.5657918,0.000060452,0.0023470789,0.00039771895,0.00008670819,0.0034808235,0.01001788,0.00016674785,0.0008247323,0.000058272173],"about_ca_topic_score_codex":0.00052848546,"about_ca_topic_score_gemma":0.0011249337,"teacher_disagreement_score":0.0017748718,"about_ca_system_score_codex":0.00082422607,"about_ca_system_score_gemma":0.0007307606,"threshold_uncertainty_score":0.009386539},"labels":[],"label_agreement":null},{"id":"W4291209167","doi":"10.1093/oncolo/oyac165","title":"Supporting Patients with Cancer after <i>Dobbs v. Jackson Women’s Health Organization</i>","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Supreme court; Context (archaeology); Medicine; Law; Psychology; Gerontology; Political science; History","score_opus":0.009224615127688128,"score_gpt":0.3014394524339645,"score_spread":0.2922148373062764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291209167","genre_codex":"editorial","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071659475,0.013943858,0.00021355592,0.4194054,0.55747586,0.000034728862,0.00005720402,0.00003107036,0.008121821],"genre_scores_gemma":[0.00847302,0.014334915,0.00037107285,0.30324844,0.6640984,0.0000439092,0.000030041725,0.000056321256,0.009343885],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9923247,0.002219305,0.00089392887,0.00064294017,0.0029677327,0.00095128105],"domain_scores_gemma":[0.95545614,0.036338344,0.001685877,0.0003525375,0.0037629718,0.0024041058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010011103,0.0009484771,0.001431233,0.0009801595,0.005116435,0.0074873813,0.0032259505,0.022290487,0.003816062],"category_scores_gemma":[0.051237706,0.0006078155,0.0016675988,0.0008316039,0.0037830076,0.0026993002,0.0012158267,0.032332648,0.001366291],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005007975,0.00001847347,0.00024912445,0.0002971039,0.000024824727,0.0005588841,0.00040003384,0.000047383273,0.00010360085,0.004881974,0.98310685,0.010261641],"study_design_scores_gemma":[0.000064130625,0.000080938604,0.0006745708,0.0014826269,0.000104439016,0.000524572,0.0005916921,0.00015323122,0.00027855794,0.0042053675,0.99179614,0.00004356893],"about_ca_topic_score_codex":0.005178165,"about_ca_topic_score_gemma":0.014593319,"teacher_disagreement_score":0.022290487,"about_ca_system_score_codex":0.0035898925,"about_ca_system_score_gemma":0.007878603,"threshold_uncertainty_score":0.05294442},"labels":[],"label_agreement":null},{"id":"W4292616279","doi":"10.1093/oncolo/oyac130","title":"The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Biomarker; Oncology; Breast cancer; Cancer; Colorectal cancer; Lung cancer; Internal medicine; Timeline; Randomized controlled trial","score_opus":0.857347171000808,"score_gpt":0.6903379268061591,"score_spread":0.1670092441946489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292616279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8069566,0.021981003,0.15430437,0.004042595,0.0006530129,0.0009324271,0.0038569253,0.0010508654,0.00622234],"genre_scores_gemma":[0.9682542,0.0013123091,0.027861353,0.00026285532,0.00021094106,0.00058680156,0.0008910744,0.00019375674,0.00042658878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9151331,0.059587225,0.009178696,0.0083733415,0.0065816944,0.0011459433],"domain_scores_gemma":[0.26583076,0.6441424,0.06217503,0.019038368,0.006544721,0.0022687803],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.11830094,0.00075056753,0.00109043,0.0033738615,0.0006518902,0.0034904063,0.00106202,0.0010350883,0.004113897],"category_scores_gemma":[0.40264827,0.0007426572,0.0024816792,0.0042144093,0.0014320599,0.004437619,0.0019651046,0.0019267898,0.00046345365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012257342,0.0003318822,0.68468255,0.0028709495,0.0044931932,0.0001813945,0.0014310543,0.020366803,0.004966625,0.0054158787,0.00337558,0.2596267],"study_design_scores_gemma":[0.0009824085,0.00682304,0.85258824,0.000935436,0.005416354,0.001133857,0.0007538126,0.073950864,0.012148475,0.018860081,0.026111908,0.0002955036],"about_ca_topic_score_codex":0.00097540335,"about_ca_topic_score_gemma":0.0011756484,"teacher_disagreement_score":0.8816991,"about_ca_system_score_codex":0.0015841676,"about_ca_system_score_gemma":0.0019728604,"threshold_uncertainty_score":0.62564266},"labels":[],"label_agreement":null},{"id":"W4295898265","doi":"10.1093/oncolo/oyac184","title":"Open-Label Placebo for the Treatment of Cancer-Related Fatigue in Patients with Advanced Cancer: A Randomized Controlled Trial","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Placebo; Adverse effect; Cancer-related fatigue; Randomized controlled trial; Depression (economics); Physical therapy; Cancer; Internal medicine; Clinical trial; Chronic fatigue; Chronic fatigue syndrome","score_opus":0.040953403721906,"score_gpt":0.3632849129028943,"score_spread":0.3223315091809883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295898265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8492465,0.093296826,0.004158511,0.0043443195,0.007494369,0.03220051,0.0028302744,0.00057980575,0.005848904],"genre_scores_gemma":[0.92964065,0.02239284,0.0054618386,0.003436775,0.003088698,0.030819312,0.0012409955,0.000040822284,0.003878006],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981231,0.0011901432,0.00018210526,0.00023488539,0.0001359931,0.0001338468],"domain_scores_gemma":[0.998085,0.0008525454,0.000425598,0.00011560046,0.00014281942,0.0003784928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003476742,0.001452517,0.0047331895,0.00085809693,0.00066296465,0.0011910332,0.0012192276,0.0036840301,0.011365973],"category_scores_gemma":[0.0036998615,0.00065518386,0.0027181543,0.00073519093,0.0015723514,0.0013810286,0.00048239567,0.0029536814,0.0010801475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.976733,0.0044933353,0.00017041477,0.0023899807,0.0009515793,0.000034701756,0.000030292766,0.000121060526,0.00059371104,0.00012489292,0.00045081993,0.0139060505],"study_design_scores_gemma":[0.98601204,0.013169022,0.00018304233,0.000069195135,0.0001808969,0.000007638053,0.0000064003434,0.00007825246,0.000042767522,0.0000461092,0.00020089028,0.0000037313291],"about_ca_topic_score_codex":0.000719194,"about_ca_topic_score_gemma":0.0012524567,"teacher_disagreement_score":0.011365973,"about_ca_system_score_codex":0.0005951605,"about_ca_system_score_gemma":0.0013208424,"threshold_uncertainty_score":0.038022995},"labels":[],"label_agreement":null},{"id":"W4296797608","doi":"10.1093/oncolo/oyac192","title":"Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Everolimus; Medicine; Clinical endpoint; Renal cell carcinoma; Internal medicine; Adverse effect; Oncology; Randomized controlled trial; Urology; Tolerability; Phases of clinical research; Clinical trial","score_opus":0.01675006100570516,"score_gpt":0.2691139331315795,"score_spread":0.25236387212587436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296797608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845712,0.0026930196,0.00077460083,0.0009771223,0.001065507,0.0066766907,0.0011587465,0.00012244213,0.001960687],"genre_scores_gemma":[0.98272103,0.001579008,0.0015012732,0.001587586,0.0007628985,0.006926181,0.0015907444,0.000026795367,0.0033043923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991404,0.0004533199,0.000053948632,0.00014791677,0.000058378457,0.00014601095],"domain_scores_gemma":[0.9985056,0.00033140066,0.00030136987,0.00013207752,0.0000794642,0.00065010646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002570669,0.0021058745,0.004083948,0.0005389636,0.00054502673,0.001629436,0.0011600803,0.0018809501,0.00704782],"category_scores_gemma":[0.0018235841,0.0010145304,0.0020394586,0.0005123392,0.0015026231,0.0013831003,0.00053468347,0.0041826293,0.0013572088],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9834984,0.0072936914,0.0003821034,0.00015644253,0.00038865203,0.000025779353,0.000026322674,0.00034001804,0.0017818315,0.00007059404,0.0003755679,0.0056605753],"study_design_scores_gemma":[0.92328864,0.07496997,0.0005455185,0.00000890126,0.000167995,0.000021013406,0.000011633614,0.000314273,0.0002544016,0.00009813575,0.00031212275,0.0000074931886],"about_ca_topic_score_codex":0.0008127019,"about_ca_topic_score_gemma":0.0019313608,"teacher_disagreement_score":0.00704782,"about_ca_system_score_codex":0.0011096906,"about_ca_system_score_gemma":0.002276113,"threshold_uncertainty_score":0.023577332},"labels":[],"label_agreement":null},{"id":"W4297232106","doi":"10.1093/oncolo/oyac197","title":"TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Medicine; Germ cell tumors; Oncology; Germ cell; Internal medicine; Cancer research; Chemotherapy","score_opus":0.01275773032340499,"score_gpt":0.23259321674310549,"score_spread":0.2198354864197005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297232106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996326,0.00016676889,0.000037816593,0.000012852283,0.0000012622191,0.0000011323041,0.000045228393,0.0000020464602,0.00010021896],"genre_scores_gemma":[0.99984634,0.00003455916,0.00002579692,0.0000037984257,0.0000025043744,7.191724e-7,0.000057615718,4.137259e-7,0.000028207334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9999188,0.000015391344,0.000007739999,0.000018167442,0.000022118918,0.000017702645],"domain_scores_gemma":[0.9995671,0.00010689826,0.00019867824,0.000019002839,0.00003436185,0.00007399063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000146494,0.000116412506,0.00016003747,0.00035336346,0.00018485067,0.00018573881,0.00009127718,0.00014072668,0.0012725834],"category_scores_gemma":[0.00083672715,0.000062827035,0.000095650954,0.00037336646,0.00019181371,0.00011739593,0.00014372508,0.00016123035,0.000099363424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012285322,0.000008986047,0.99590033,0.0000078875955,0.0000147224855,0.0002233905,0.000023073006,0.000048104783,0.0015675563,0.000007778148,0.000046766905,0.0020285337],"study_design_scores_gemma":[0.0000037756508,0.00007677141,0.9976299,0.0000023904242,0.000019272142,0.0014881248,0.00004442764,0.00016434804,0.0004057417,0.00003297611,0.00013113118,0.0000010717865],"about_ca_topic_score_codex":0.00041886338,"about_ca_topic_score_gemma":0.0010477063,"teacher_disagreement_score":0.0012725834,"about_ca_system_score_codex":0.00011641382,"about_ca_system_score_gemma":0.0001205604,"threshold_uncertainty_score":0.0042572618},"labels":[],"label_agreement":null},{"id":"W4307971007","doi":"10.1093/oncolo/oyac227","title":"Perceptions of Death Among Patients with Advanced Cancer Receiving Early Palliative Care and Their Caregivers: Results from a Mixed-Method Analysis","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Associazione Italiana per la Lotta al Neuroblastoma","keywords":"Medicine; Palliative care; Psychological intervention; Cancer; End-of-life care; Cause of death; Family medicine; Internal medicine; Oncology; Disease; Nursing","score_opus":0.054616540138306,"score_gpt":0.386246523418409,"score_spread":0.33162998328010296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307971007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737716,0.0002667216,0.0009892733,0.00012887792,0.000011680078,0.00047378722,0.00024147655,0.0000037633001,0.0005072789],"genre_scores_gemma":[0.9935882,0.0004694302,0.002271724,0.00023676667,0.000017366276,0.0024777597,0.00034049267,0.000012259717,0.0005860009],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.98141724,0.013808156,0.0012967134,0.0007882422,0.0016319447,0.001057596],"domain_scores_gemma":[0.95988786,0.030755054,0.0032730373,0.0009828088,0.004401781,0.00069938117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026088573,0.00056170166,0.0010862284,0.0034563097,0.0025314027,0.0031633389,0.00109625,0.00090873643,0.0024261002],"category_scores_gemma":[0.040076725,0.00065007264,0.0012530783,0.0030641055,0.0020342555,0.0019403193,0.00349148,0.0011279301,0.00032084383],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000623814,0.00083517196,0.23552917,0.0010860156,0.00020596565,0.00050133234,0.7340453,0.00010638158,0.001232264,0.00052238285,0.0005540766,0.024758078],"study_design_scores_gemma":[0.00006992368,0.0008975797,0.1471513,0.0004913265,0.000119457094,0.00032193738,0.8473946,0.0004740208,0.0006383614,0.00035085424,0.0020344635,0.000056222772],"about_ca_topic_score_codex":0.0035373939,"about_ca_topic_score_gemma":0.006665893,"teacher_disagreement_score":0.026088573,"about_ca_system_score_codex":0.0027596164,"about_ca_system_score_gemma":0.0026725344,"threshold_uncertainty_score":0.13797122},"labels":[],"label_agreement":null},{"id":"W4309098807","doi":"10.1093/oncolo/oyac235","title":"Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal Cancer","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University Health Network; University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; Public Health Ontario","funders":"University Health Network","keywords":"Medicine; Internal medicine; Cancer; Proportional hazards model; Esophageal cancer; Oncology; Clinical trial; Survival analysis","score_opus":0.05138439056493653,"score_gpt":0.3854788857640811,"score_spread":0.3340944951991446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309098807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863344,0.0005239915,0.000250912,0.000068762805,0.000011766387,0.00001189982,0.00017077783,0.000005528644,0.00032280514],"genre_scores_gemma":[0.99931943,0.00007835552,0.00022689122,0.000011445822,0.000014087842,0.000010004334,0.0002916808,0.0000011178137,0.000047043788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931705,0.00026479526,0.00007853773,0.000074507094,0.00016060169,0.000104596445],"domain_scores_gemma":[0.99630725,0.001577134,0.001212908,0.000097926335,0.00033867703,0.0004660886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020036623,0.00045173563,0.0005454001,0.0009919499,0.00023132993,0.00060766516,0.0002651514,0.0004265147,0.0007934527],"category_scores_gemma":[0.006740429,0.000097639306,0.00061484776,0.00091726234,0.00026878354,0.00042290217,0.0005116891,0.00051289255,0.00016921299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013436893,0.000027197397,0.992481,0.000016097734,0.000098391894,0.000041572886,0.000022099268,0.00040166063,0.00010700689,0.000023016319,0.00012666089,0.005311526],"study_design_scores_gemma":[0.00013756714,0.0011687066,0.9931392,0.000016445854,0.00017503476,0.00048294783,0.000101561294,0.003955601,0.00021275487,0.00020490761,0.0003923497,0.000012961704],"about_ca_topic_score_codex":0.0007004618,"about_ca_topic_score_gemma":0.0008421763,"teacher_disagreement_score":0.0020036623,"about_ca_system_score_codex":0.0004512141,"about_ca_system_score_gemma":0.0003657556,"threshold_uncertainty_score":0.010596454},"labels":[],"label_agreement":null},{"id":"W4310051818","doi":"10.1093/oncolo/oyac226","title":"Management of Lung Cancer in the Patient with Interstitial Lung Disease","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Interstitial lung disease; Lung cancer; Radiation therapy; Hypersensitivity pneumonitis; Exacerbation; Idiopathic pulmonary fibrosis; Population; Pulmonary fibrosis; Pneumonitis; Lung biopsy; Lung; Treatment of lung cancer; Internal medicine; Intensive care medicine; Oncology","score_opus":0.03174755358443252,"score_gpt":0.3569824644853244,"score_spread":0.32523491090089185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310051818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013585041,0.99850696,0.000075666816,0.0003687353,0.0001454671,0.0000037690186,0.00000880342,0.0000032816672,0.0007513825],"genre_scores_gemma":[0.0014283159,0.99755764,0.00020090883,0.00035826172,0.00020287058,0.0000058077158,0.000023038605,8.2429386e-7,0.00022228976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980396,0.000059353297,0.00004017194,0.000024903844,0.00005662154,0.000015035901],"domain_scores_gemma":[0.99970406,0.0001777802,0.00004790419,0.000005575363,0.00004836954,0.000016229944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034575682,0.0004620122,0.00092411827,0.0012151026,0.00023756482,0.0006326185,0.0005146357,0.00087016384,0.0017380392],"category_scores_gemma":[0.0010049198,0.00011717661,0.0005260086,0.000816607,0.00026048254,0.0006791665,0.00036292188,0.0011717695,0.0006548735],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066632056,0.00004965094,0.0005768364,0.029453374,0.00014670221,0.0008671181,0.0000919354,0.00027321564,0.0008720238,0.0012648395,0.028831955,0.9375056],"study_design_scores_gemma":[0.00004307731,0.00016040048,0.0039564436,0.030832792,0.00040624093,0.016103104,0.00019444864,0.00018715535,0.00047733265,0.0023614112,0.9452464,0.000031044056],"about_ca_topic_score_codex":0.00081021705,"about_ca_topic_score_gemma":0.0021606681,"teacher_disagreement_score":0.0017380392,"about_ca_system_score_codex":0.00033039012,"about_ca_system_score_gemma":0.0007115981,"threshold_uncertainty_score":0.005814314},"labels":[],"label_agreement":null},{"id":"W4327759154","doi":"10.1093/oncolo/oyad054","title":"Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Profiling (computer programming); Oncology; Computational biology; Internal medicine; Bioinformatics","score_opus":0.0974705394661203,"score_gpt":0.3897565459270083,"score_spread":0.292286006460888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327759154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679386,0.004457541,0.018094135,0.0013612303,0.00008620557,0.00024686806,0.0013374236,0.00027576814,0.0062021534],"genre_scores_gemma":[0.9890577,0.00092689315,0.008560036,0.0001634847,0.000055061733,0.000052440355,0.00084717217,0.00001439915,0.0003228214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990747,0.000353373,0.000050830633,0.00020613383,0.00021844218,0.000096478914],"domain_scores_gemma":[0.997156,0.0013745541,0.00054330466,0.0001663351,0.0005041917,0.00025552983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022212393,0.00024013655,0.00024106517,0.00066083943,0.00020042926,0.0009641447,0.00034264932,0.0003939243,0.0017881971],"category_scores_gemma":[0.0043186476,0.00015628235,0.00018586122,0.0003771603,0.000284763,0.0004519084,0.0004500463,0.00032366227,0.0006337321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013726017,0.00017343709,0.79717153,0.00024709743,0.00004284836,0.001511059,0.0001667397,0.0023527963,0.02539861,0.0004540595,0.0020032164,0.169106],"study_design_scores_gemma":[0.00017686833,0.0029108229,0.89828235,0.00029059165,0.00019477944,0.0143184615,0.0008409759,0.024684547,0.037328564,0.0013922768,0.019529117,0.000050666524],"about_ca_topic_score_codex":0.0013197993,"about_ca_topic_score_gemma":0.0029288253,"teacher_disagreement_score":0.0022212393,"about_ca_system_score_codex":0.0006670124,"about_ca_system_score_gemma":0.0007870822,"threshold_uncertainty_score":0.011747181},"labels":[],"label_agreement":null},{"id":"W4327910154","doi":"10.1093/oncolo/oyad022","title":"Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Gemcitabine; Oncology; Internal medicine; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Cancer; Adverse effect; Adenocarcinoma; Phases of clinical research; Chemotherapy; Urology; Immunotherapy; Pembrolizumab","score_opus":0.07993181896745435,"score_gpt":0.4131683534045474,"score_spread":0.333236534437093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327910154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642999,0.014110945,0.0012090006,0.00251735,0.0010703289,0.0092584435,0.002250838,0.00018333971,0.005099776],"genre_scores_gemma":[0.9723794,0.004713763,0.0031774826,0.002551238,0.0011084493,0.008998567,0.0018260335,0.000045607627,0.005199574],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998181,0.001356394,0.000081672646,0.00015759187,0.000092877024,0.00013048462],"domain_scores_gemma":[0.99870455,0.0003292751,0.00040696512,0.00011490282,0.000060059883,0.0003843409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045408257,0.0017477975,0.0024234934,0.0005620029,0.0002743563,0.0012385077,0.0008431299,0.0013889942,0.006443317],"category_scores_gemma":[0.0029737358,0.0005740145,0.0022589422,0.00047016243,0.0010194631,0.0010283397,0.00085107883,0.0021361795,0.00069124834],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98186064,0.003024878,0.0006839877,0.0005761138,0.0009131728,0.000024378749,0.000019700421,0.00029600033,0.0011751426,0.00015213792,0.0008259909,0.0104478095],"study_design_scores_gemma":[0.958796,0.0370408,0.0014732807,0.000057653495,0.0006390156,0.00003379546,0.000015092444,0.0005494199,0.00025952177,0.00018899959,0.0009361692,0.000010073264],"about_ca_topic_score_codex":0.0005931805,"about_ca_topic_score_gemma":0.0014905155,"teacher_disagreement_score":0.006443317,"about_ca_system_score_codex":0.0010167413,"about_ca_system_score_gemma":0.0010083383,"threshold_uncertainty_score":0.024014473},"labels":[],"label_agreement":null},{"id":"W4361245262","doi":"10.1093/oncolo/oyad008","title":"Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"Janssen Biotech; Janssen Research and Development; Amgen; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; UroGen Pharma; Dendreon Pharmaceuticals; Progenics Pharmaceuticals; Sanofi; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Androgen receptor; Abiraterone; Androgen deprivation therapy; Internal medicine; Oncology; Cancer research; PARP1; Testosterone (patch); Pharmacology; Cancer; Poly ADP ribose polymerase; Polymerase; Gene; Biology; Genetics","score_opus":0.08989458193043044,"score_gpt":0.41774564722702856,"score_spread":0.32785106529659813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361245262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679869,0.011699233,0.0022606836,0.0017026333,0.00031400088,0.004715495,0.0036294828,0.00024151054,0.007450135],"genre_scores_gemma":[0.96180516,0.010691177,0.0045342767,0.003421222,0.00033958914,0.0040800064,0.008622802,0.00006660849,0.006439039],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996555,0.00015016797,0.000021642043,0.000048204914,0.00006659737,0.000057856378],"domain_scores_gemma":[0.99958533,0.000054377968,0.00005574597,0.000029447141,0.00004336349,0.00023172618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012684019,0.00087462814,0.001149961,0.000285911,0.0002942241,0.0010671954,0.00056003296,0.00077831105,0.0020505015],"category_scores_gemma":[0.0006895123,0.00028606752,0.0009991989,0.0003039113,0.00048009082,0.000527447,0.00029573173,0.0021342777,0.00058990164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29688838,0.12202071,0.013614558,0.002356813,0.003185472,0.0009157005,0.0006023044,0.009672489,0.09573486,0.0015729569,0.023926895,0.429509],"study_design_scores_gemma":[0.41970697,0.5005544,0.020162804,0.00020465515,0.0010936912,0.0018003508,0.00013781695,0.0038202053,0.015358609,0.0009911187,0.036085572,0.00008381259],"about_ca_topic_score_codex":0.00072644046,"about_ca_topic_score_gemma":0.0020052858,"teacher_disagreement_score":0.0020505015,"about_ca_system_score_codex":0.00059080444,"about_ca_system_score_gemma":0.0017169269,"threshold_uncertainty_score":0.006859541},"labels":[],"label_agreement":null},{"id":"W4362523523","doi":"10.1093/oncolo/oyad073","title":"Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Lactate dehydrogenase; Proportional hazards model; Oncology; Melanoma; Cohort; Retrospective cohort study; White blood cell; Cancer research","score_opus":0.020070594544156505,"score_gpt":0.2679739571272112,"score_spread":0.24790336258305473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362523523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9292577,0.00032157387,0.06744876,0.0007517026,0.00004351564,0.00011587472,0.0011556555,0.00027892686,0.0006261667],"genre_scores_gemma":[0.98812836,0.000060409173,0.010409586,0.000047552825,0.000022153672,0.00006985354,0.0011005393,0.000013437908,0.00014803359],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9992812,0.00038437085,0.000051757743,0.00012492646,0.00008940045,0.00006841697],"domain_scores_gemma":[0.99649173,0.0024130854,0.0005079139,0.00015197434,0.00028779492,0.00014738263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039935354,0.000765483,0.00060119294,0.00086714816,0.00031424887,0.0009394219,0.00054940325,0.00038223725,0.00072819856],"category_scores_gemma":[0.0064317915,0.00022033624,0.00111471,0.00034698984,0.00020851198,0.00024737505,0.00051928806,0.0008845389,0.00023719478],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010723894,0.0004073426,0.7733851,0.000070769056,0.0005785559,0.0002673397,0.0001450455,0.17684157,0.001538254,0.0004203223,0.002180197,0.043093108],"study_design_scores_gemma":[0.00007303142,0.0003049838,0.057387594,0.00003335071,0.00017804076,0.0002030075,0.00004871706,0.93957907,0.0007413917,0.000802839,0.0006308633,0.000017193051],"about_ca_topic_score_codex":0.0031674406,"about_ca_topic_score_gemma":0.002503949,"teacher_disagreement_score":0.0039935354,"about_ca_system_score_codex":0.0007206959,"about_ca_system_score_gemma":0.0013177952,"threshold_uncertainty_score":0.021120131},"labels":[],"label_agreement":null},{"id":"W4366813769","doi":"10.1093/oncolo/oyad086","title":"Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Population Health Research Institute; McMaster University","funders":"","keywords":"Cardiotoxicity; Medicine; Trastuzumab; Discontinuation; Ejection fraction; Heart failure; Internal medicine; Cardiology; Chemotherapy; Cancer; Breast cancer","score_opus":0.030480802115471148,"score_gpt":0.31234817447836216,"score_spread":0.281867372362891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366813769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999451,0.0001656619,0.000032785716,0.000017501514,0.0000030966573,0.0000054054894,0.00011197407,0.0000015901646,0.00021100804],"genre_scores_gemma":[0.9996007,0.00005009104,0.0000128277015,0.000013508358,0.000007895543,0.000004012627,0.00025372164,6.317611e-7,0.000056626766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996476,0.00005337532,0.000037601716,0.00007012535,0.00006244083,0.00012876211],"domain_scores_gemma":[0.9979373,0.00028320667,0.000959926,0.000096329386,0.00016319961,0.00056004646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062330335,0.0002040019,0.0003431346,0.00047783632,0.00047860443,0.00072235713,0.00029508423,0.00041913576,0.0011382147],"category_scores_gemma":[0.0020422204,0.00012675746,0.0005537318,0.000539174,0.0002754734,0.00044164874,0.0005728555,0.0006186385,0.00016680334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003462607,0.00003727698,0.99764854,0.0000044964636,0.00003205393,0.0003253572,0.00004797536,0.00005495888,0.00014469244,0.0000099267,0.000049004706,0.0012994141],"study_design_scores_gemma":[0.000017225668,0.0006544072,0.99786097,0.000007633441,0.00004680453,0.0009159916,0.000100818,0.00011993575,0.000105706145,0.00003055174,0.0001337346,0.000006204583],"about_ca_topic_score_codex":0.0017085692,"about_ca_topic_score_gemma":0.001562356,"teacher_disagreement_score":0.0017085692,"about_ca_system_score_codex":0.0005014808,"about_ca_system_score_gemma":0.0003533072,"threshold_uncertainty_score":0.003807664},"labels":[],"label_agreement":null},{"id":"W4376273227","doi":"10.1093/oncolo/oyad116","title":"Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute; Ottawa Hospital; University of Ottawa","funders":"National Heart, Lung, and Blood Institute; Swedish Orphan Biovitrum; LEO Pharma; Servier; Chinese Academy of Medical Sciences; KU Leuven; Ministry of Education, Culture, Sports, Science and Technology; Bayer HealthCare; Insmed; ARCA Biopharma; Kowa Company; Prothena; Five Prime Therapeutics; Agios Pharmaceuticals; Ionis Pharmaceuticals; Regeneron Pharmaceuticals; Esperion Therapeutics; Alnylam Pharmaceuticals; Cook Medical; Janssen Scientific Affairs; Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science; GlaxoSmithKline; University of Ottawa; Yale University; Alexion Pharmaceuticals; Daiichi-Sankyo; McMaster University; Brigham and Women's Hospital; Moderna; Pfizer; Heart and Stroke Foundation of Canada; CSL Behring; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Janssen Pharmaceuticals; Audentes Therapeutics; Amgen; Sanofi; American Heart Association","keywords":"Thrombosis; Intensive care medicine; Cancer; Medicine; Internal medicine","score_opus":0.03496671495848225,"score_gpt":0.3464161656841737,"score_spread":0.31144945072569147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376273227","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047970098,0.94812083,0.0004951526,0.047593437,0.0019148847,0.000009041022,0.000039686718,0.000032821496,0.0013144591],"genre_scores_gemma":[0.0053818272,0.9746115,0.0015408228,0.01086607,0.0066655115,0.00003016707,0.00012338726,0.00001358334,0.00076702045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779105,0.0007439378,0.00040111408,0.00024944567,0.0005927316,0.00022173616],"domain_scores_gemma":[0.98675215,0.006390842,0.0012310749,0.00026441095,0.00366078,0.0017006892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007722183,0.00080327987,0.0017217736,0.0014179237,0.0006593384,0.0033013914,0.0013806853,0.0045981547,0.010793702],"category_scores_gemma":[0.009229589,0.0003236447,0.0010232438,0.0019498559,0.0019283813,0.0066777216,0.0013529744,0.0056740846,0.0021725595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003669049,0.00025882947,0.0010530093,0.009303438,0.00013547998,0.0002956571,0.00016118208,0.000752999,0.0005460442,0.009481093,0.08669946,0.89094585],"study_design_scores_gemma":[0.000261922,0.0009791601,0.004038215,0.019598952,0.00039646437,0.0020468668,0.0015346241,0.0019127779,0.00042316195,0.024377156,0.94432235,0.00010841243],"about_ca_topic_score_codex":0.001759901,"about_ca_topic_score_gemma":0.005214669,"teacher_disagreement_score":0.010793702,"about_ca_system_score_codex":0.001680033,"about_ca_system_score_gemma":0.0048403195,"threshold_uncertainty_score":0.040839314},"labels":[],"label_agreement":null},{"id":"W4378171934","doi":"10.1093/oncolo/oyad128","title":"Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Safe Handling of Antineoplastic Drugs","field":"Health Professions","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"Canadian Cancer Society Research Institute; Eli Lilly Canada; American Society of Clinical Oncology; Eli Lilly and Company; Incyte; Amgen","keywords":"Cancer; Oncology; Psychology; Gerontology; Medicine; Demography; Internal medicine; Sociology","score_opus":0.16951509525966083,"score_gpt":0.46845598161689,"score_spread":0.29894088635722915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378171934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654754,0.019501148,0.0008550582,0.0027288282,0.00063619105,0.003146773,0.00252067,0.0000834015,0.0050525907],"genre_scores_gemma":[0.989985,0.0015266802,0.00080846297,0.0011237041,0.00030782356,0.0040584123,0.0011920463,0.000021355148,0.0009765847],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98180825,0.015115971,0.0009029279,0.00075373414,0.0008162207,0.0006028648],"domain_scores_gemma":[0.979565,0.010186961,0.0067159124,0.0009704168,0.0007680843,0.0017935822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0107424725,0.00070142,0.0026093295,0.00039314115,0.0006854835,0.0014163123,0.0006544371,0.0017956159,0.00447819],"category_scores_gemma":[0.024815658,0.0003360411,0.002776286,0.0009597574,0.0009947972,0.0014206013,0.00078624446,0.0038658984,0.000413428],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93937695,0.0018480271,0.011216737,0.0032346868,0.0042757294,0.00006705054,0.00021276168,0.0007708301,0.0004938571,0.0004083799,0.003390899,0.034704074],"study_design_scores_gemma":[0.8229756,0.11198778,0.046414822,0.0013814379,0.00583879,0.00020309676,0.00024235166,0.0019052472,0.00071064197,0.0015050131,0.0067482535,0.000086886976],"about_ca_topic_score_codex":0.0014638089,"about_ca_topic_score_gemma":0.004135802,"teacher_disagreement_score":0.0107424725,"about_ca_system_score_codex":0.0014585409,"about_ca_system_score_gemma":0.0026015071,"threshold_uncertainty_score":0.056812286},"labels":[],"label_agreement":null},{"id":"W4380272263","doi":"10.1093/oncolo/oyad161","title":"Drivers of Emergency Department Use Among Oncology Patients in the Era of Novel Cancer Therapeutics: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"The Oncologist","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Associated Medical Services","keywords":"Medicine; Emergency department; Cancer; Internal medicine; Medical diagnosis; Breast cancer; Chemotherapy; Oncology; Intensive care medicine; Pathology; Psychiatry","score_opus":0.19586903755817942,"score_gpt":0.4476317864169423,"score_spread":0.2517627488587629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380272263","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049194284,0.99181867,0.00013897398,0.0004228263,0.00008743632,0.0001391574,0.002139171,0.000008141063,0.0003262345],"genre_scores_gemma":[0.04688858,0.9498317,0.0005728851,0.0008712533,0.000104685736,0.00043116594,0.0011588727,0.000009597963,0.00013122697],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9933036,0.0018858162,0.0028603948,0.0006818244,0.0010377284,0.00023062553],"domain_scores_gemma":[0.96071786,0.028175382,0.007887913,0.0004803245,0.002445212,0.00029331056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050242622,0.0008223425,0.0045306184,0.007729907,0.0004613417,0.0020216925,0.0011588616,0.0012884954,0.0033063265],"category_scores_gemma":[0.038433664,0.0008060886,0.007631658,0.010431704,0.00054192974,0.0019067663,0.0013005418,0.0010266335,0.00022430984],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022996942,0.000020098643,0.010291963,0.93820286,0.01633939,0.00015197122,0.0003883794,0.00012468986,0.00008693812,0.00022473968,0.0031728062,0.030766232],"study_design_scores_gemma":[0.00021509087,0.00017499377,0.043791022,0.8439984,0.08736651,0.0008059292,0.00076650863,0.00016846151,0.00014496139,0.00039654228,0.02209974,0.00007186498],"about_ca_topic_score_codex":0.009490786,"about_ca_topic_score_gemma":0.025813082,"teacher_disagreement_score":0.009490786,"about_ca_system_score_codex":0.002062837,"about_ca_system_score_gemma":0.006467248,"threshold_uncertainty_score":0.026571214},"labels":[],"label_agreement":null},{"id":"W4382046230","doi":"10.1093/oncolo/oyad182","title":"Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Université Laval","keywords":"Medicine; Pembrolizumab; Lung cancer; Regimen; Internal medicine; Adverse effect; Dosing; Cancer; Surgery; Immunotherapy","score_opus":0.029539634537534293,"score_gpt":0.3284088507184091,"score_spread":0.2988692161808748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382046230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987118,0.0009804448,0.00003316438,0.000026199205,0.000006125936,0.00003981274,0.00004162777,0.0000012693772,0.00015961878],"genre_scores_gemma":[0.999156,0.0004388716,0.00007073788,0.000050200048,0.00001407873,0.000042098312,0.000117489864,5.132218e-7,0.000110050416],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996573,0.00012485647,0.000043744312,0.00005723798,0.00006593041,0.00005103675],"domain_scores_gemma":[0.9993888,0.00014533171,0.00026023004,0.00001968949,0.000046264107,0.00013969245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012594945,0.00017968827,0.00048673627,0.00023887285,0.00026252127,0.00029321678,0.00020137882,0.00027238668,0.0004944475],"category_scores_gemma":[0.0010327041,0.000117276875,0.00042947306,0.00032811408,0.00023333644,0.00033239694,0.0002241356,0.00040351675,0.00010745157],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.102006726,0.0032194746,0.7938249,0.0004988936,0.0007035779,0.0005196962,0.0002756587,0.0012378271,0.009154638,0.0000699481,0.0006387985,0.08784998],"study_design_scores_gemma":[0.004225263,0.06525301,0.92474216,0.000049620947,0.0003417611,0.0006656076,0.00012135152,0.0014384303,0.0014314171,0.000066589266,0.0016515348,0.000013105765],"about_ca_topic_score_codex":0.0022393835,"about_ca_topic_score_gemma":0.0043760478,"teacher_disagreement_score":0.0022393835,"about_ca_system_score_codex":0.0007795042,"about_ca_system_score_gemma":0.0006632709,"threshold_uncertainty_score":0.0066608787},"labels":[],"label_agreement":null},{"id":"W4383872161","doi":"10.1093/oncolo/oyad204","title":"Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma","year":2023,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Lymphoma; Diffuse large B-cell lymphoma; Oncology; Internal medicine; Dermatology","score_opus":0.04636142410425152,"score_gpt":0.3169775137070694,"score_spread":0.27061608960281786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872161","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034337305,0.0023528202,0.000039961124,0.9856963,0.009474806,0.000009082412,0.00013070424,0.00001413814,0.001938753],"genre_scores_gemma":[0.0026884526,0.00095277204,0.00007721499,0.964721,0.029755857,0.0000271032,0.00003523393,0.000013214993,0.0017292328],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98864615,0.0052860198,0.001256522,0.0010509213,0.0027143722,0.0010459787],"domain_scores_gemma":[0.9567975,0.031735435,0.0022138678,0.0006988822,0.005043131,0.0035112426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01085922,0.0006941966,0.002003685,0.0006857981,0.004561086,0.0035305342,0.0038163788,0.047988504,0.005980789],"category_scores_gemma":[0.042493217,0.00057408947,0.0021938037,0.0012799095,0.003086596,0.0029242602,0.0013639001,0.0321065,0.0037418888],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022254461,0.000034016673,0.0006946423,0.000087609296,0.000029241599,0.0003872259,0.00008941932,0.000073948555,0.000095682575,0.0019089397,0.9854624,0.010914327],"study_design_scores_gemma":[0.0010807004,0.00036559958,0.0038806433,0.0009026366,0.00019950839,0.000974644,0.00048615734,0.00055164157,0.00036814736,0.010055591,0.98100257,0.00013217381],"about_ca_topic_score_codex":0.038079172,"about_ca_topic_score_gemma":0.0950868,"teacher_disagreement_score":0.047988504,"about_ca_system_score_codex":0.008905002,"about_ca_system_score_gemma":0.012829673,"threshold_uncertainty_score":0.075715065},"labels":[],"label_agreement":null},{"id":"W4385410847","doi":"10.1093/oncolo/oyad207","title":"Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Genentech; Plexxikon; Eisai; Seagen; MacroGenics; Les Laboratories Pierre Fabre; Genomic Health; F. Hoffmann-La Roche; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; Bayer; AstraZeneca; Eli Lilly and Company; Breast Cancer Alliance","keywords":"Medicine; Quality of life (healthcare); Breast cancer; Anxiety; Physical therapy; Diarrhea; Cancer; Internal medicine; Psychiatry","score_opus":0.022455856401611768,"score_gpt":0.3213516366995914,"score_spread":0.2988957802979796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385410847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99882895,0.000223015,0.00002921974,0.00017582027,0.0000053484023,0.000025046369,0.00033392996,0.0000025261463,0.00037613438],"genre_scores_gemma":[0.9991498,0.00017035962,0.00010560583,0.00013333528,0.000007062476,0.000032487576,0.0003035234,0.0000012266623,0.00009663627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870634,0.0005659362,0.0002070593,0.000105820516,0.00024497314,0.00016982797],"domain_scores_gemma":[0.9961941,0.0007904942,0.001936012,0.00012621685,0.00037755206,0.00057565805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020559104,0.00014874342,0.00031118462,0.0006995301,0.00036154318,0.0005003452,0.00031263547,0.00042751958,0.0008477386],"category_scores_gemma":[0.0048667984,0.00019896976,0.0004960548,0.00076731323,0.00026260462,0.00048730473,0.0008115624,0.00057637383,0.00014037553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030727868,0.00006595631,0.99628025,0.00003459126,0.000035584697,0.000045264882,0.0005547012,0.00003357778,0.00007146487,0.0000060194175,0.00027471312,0.002567089],"study_design_scores_gemma":[0.000003882253,0.00010009437,0.9985232,0.000012315757,0.000008688859,0.00011186031,0.0008847693,0.00008244719,0.00002259221,0.0000043838913,0.00024239674,0.0000034990583],"about_ca_topic_score_codex":0.005330653,"about_ca_topic_score_gemma":0.008811221,"teacher_disagreement_score":0.005330653,"about_ca_system_score_codex":0.00059913826,"about_ca_system_score_gemma":0.00042887556,"threshold_uncertainty_score":0.010872841},"labels":[],"label_agreement":null},{"id":"W4385476617","doi":"10.1093/oncolo/oyad215","title":"A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; Conquer Cancer Foundation; National Cancer Institute; Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology; Eli Lilly and Company","keywords":"Nausea; Medicine; Vomiting; Adverse effect; Dosing; Gastroenterology; Clinical endpoint; Pharmacokinetics; Internal medicine; Neutropenia; Anemia; Pharmacology; Peripheral edema; Toxicity; Clinical trial","score_opus":0.033547687745609484,"score_gpt":0.36931083232137035,"score_spread":0.33576314457576084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385476617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778914,0.00056334474,0.00039457824,0.00008884027,0.000028495944,0.00053697673,0.00016550274,0.000032286163,0.00040067345],"genre_scores_gemma":[0.99693334,0.00039430615,0.0010434487,0.00015498103,0.000039227067,0.00044159754,0.00053128606,0.000008648236,0.00045330703],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997199,0.00011317283,0.000015706955,0.0000519746,0.000042269196,0.000056870467],"domain_scores_gemma":[0.9995708,0.00006756663,0.00010696107,0.000045158708,0.000025540035,0.00018398844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079878053,0.00076662836,0.0010520087,0.00029292091,0.00021693959,0.00045107797,0.00046359416,0.00044767547,0.0014095219],"category_scores_gemma":[0.00055729045,0.00031671068,0.0005159815,0.00032185172,0.00053738215,0.0003862572,0.00024232801,0.0017660571,0.00037901764],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32703406,0.11377743,0.019391028,0.0009927654,0.0011904871,0.0004237997,0.00056158635,0.007588228,0.3229556,0.0004728835,0.0036895333,0.20192258],"study_design_scores_gemma":[0.19504848,0.76076543,0.024182605,0.000019210593,0.00030114112,0.00038845956,0.000046478843,0.0023038888,0.014061247,0.0001259897,0.002732658,0.000024535926],"about_ca_topic_score_codex":0.00047490565,"about_ca_topic_score_gemma":0.001030192,"teacher_disagreement_score":0.0014095219,"about_ca_system_score_codex":0.0005881657,"about_ca_system_score_gemma":0.00081836665,"threshold_uncertainty_score":0.0047153234},"labels":[],"label_agreement":null},{"id":"W4385516321","doi":"10.1093/oncolo/oyad211","title":"Symptom Clusters in Patients With Advanced Cancer: A Prospective Longitudinal Cohort Study to Examine Their Stability and Prognostic Significance","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Bruyère; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Prospective cohort study; Proportional hazards model; Cancer; Cohort; Varimax rotation; Confidence interval; Psychometrics","score_opus":0.021964747149155698,"score_gpt":0.29145081044566484,"score_spread":0.26948606329650915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385516321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99963665,0.00006046483,0.000044739052,0.000015708989,0.0000026259038,0.000010759698,0.00015331405,0.0000011699835,0.000074559786],"genre_scores_gemma":[0.99943155,0.000043660883,0.00009410338,0.000017491278,0.0000051809357,0.000016312311,0.0003153895,9.747788e-7,0.00007536467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996088,0.000106940955,0.00003370841,0.00009499053,0.00006488382,0.000090684436],"domain_scores_gemma":[0.9989586,0.00015675137,0.0003738091,0.00010143452,0.0001295666,0.0002798572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008578357,0.0002465782,0.0003542141,0.0007159905,0.0007354883,0.00064383744,0.000256465,0.00041337957,0.00088984345],"category_scores_gemma":[0.0015614511,0.000260147,0.00047441496,0.0010605105,0.00020500456,0.0006747314,0.0005006887,0.0007827425,0.0001801245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120245044,0.0000460947,0.9991652,0.0000019048194,0.000019369698,0.000031024323,0.00009001395,0.000012357016,0.000112399684,0.000004614491,0.000030316689,0.00036642147],"study_design_scores_gemma":[0.0000117870695,0.00029994507,0.9989749,0.0000024935778,0.000017799675,0.00014441428,0.0002699553,0.00013669871,0.000028074588,0.000011843939,0.00009860838,0.0000034411007],"about_ca_topic_score_codex":0.006449462,"about_ca_topic_score_gemma":0.008182076,"teacher_disagreement_score":0.006449462,"about_ca_system_score_codex":0.0002913931,"about_ca_system_score_gemma":0.00041249426,"threshold_uncertainty_score":0.01282382},"labels":[],"label_agreement":null},{"id":"W4385897815","doi":"10.1093/oncolo/oyad197","title":"Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Legend Biotech; EMD Serono; Genentech; Revolution Medicines; Flatiron Health; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; National Center for Advancing Translational Sciences; LUNGevity Foundation","keywords":"Medicine; Immunotherapy; Internal medicine; Oncology; Pembrolizumab; Lung cancer; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Cancer; Progressive disease","score_opus":0.022751087646396148,"score_gpt":0.31742688171044264,"score_spread":0.2946757940640465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385897815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991085,0.0005592016,0.000042854434,0.000038858798,0.0000061128653,0.000018688874,0.000094399016,0.0000032090045,0.00012821869],"genre_scores_gemma":[0.99948347,0.00012114919,0.00004342557,0.00003620596,0.000010370244,0.000019244451,0.00021800908,9.1246005e-7,0.00006717294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995264,0.00014053674,0.000050490507,0.00013051678,0.00008005251,0.00007192866],"domain_scores_gemma":[0.99876994,0.0002643781,0.0005140371,0.000052903713,0.000056903733,0.00034179736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007846693,0.0002662303,0.00068756635,0.00027820305,0.00026483458,0.0004739512,0.00032966302,0.00050379446,0.0007922333],"category_scores_gemma":[0.00157188,0.00019101214,0.0007957572,0.0003087764,0.00025922744,0.00029564858,0.000384984,0.00059379335,0.00013013303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060381282,0.0022190486,0.8755058,0.00025319488,0.0014749311,0.00040263848,0.00016961002,0.0026694324,0.0036700359,0.000059745762,0.00080369844,0.052390505],"study_design_scores_gemma":[0.0039572595,0.037669707,0.94917154,0.00006023245,0.0011054893,0.0011000776,0.00010664078,0.003911861,0.0018623038,0.00013745137,0.00089264027,0.000024883613],"about_ca_topic_score_codex":0.0009614583,"about_ca_topic_score_gemma":0.0020623116,"teacher_disagreement_score":0.0012836343,"about_ca_system_score_codex":0.0012836343,"about_ca_system_score_gemma":0.000611266,"threshold_uncertainty_score":0.009313464},"labels":[],"label_agreement":null},{"id":"W4386002127","doi":"10.1093/oncolo/oyad210","title":"Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type <i>RAS</i> Metastatic Colorectal Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Array BioPharma; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Panitumumab; Medicine; Rash; Colorectal cancer; Internal medicine; Adverse effect; Tolerability; Phases of clinical research; MEK inhibitor; Oncology; Epidermal growth factor receptor; EGFR inhibitors; KRAS; MAPK/ERK pathway; Gastroenterology; Cancer; Clinical trial; Kinase","score_opus":0.08035892614467251,"score_gpt":0.3976185822566396,"score_spread":0.3172596561119671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386002127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930374,0.0011054047,0.0006234572,0.0003059902,0.00009438901,0.0025491172,0.0007940317,0.000085529835,0.0014046544],"genre_scores_gemma":[0.9908161,0.0010427758,0.0014821199,0.0005619897,0.000113566515,0.002327088,0.0018192594,0.000029022816,0.00180811],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961096,0.0001664272,0.000023281433,0.00007460851,0.00003732837,0.00008746759],"domain_scores_gemma":[0.9992235,0.000094614115,0.00016208943,0.00006671043,0.000049673232,0.00040339748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015376878,0.0019699587,0.001766701,0.0004826843,0.00039474678,0.00097519153,0.0009375817,0.0012170954,0.0031720344],"category_scores_gemma":[0.000845086,0.0008474132,0.0009238538,0.0004342561,0.0009963518,0.0010046321,0.00033687634,0.003591943,0.000877935],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74961436,0.11020171,0.0051493584,0.000566798,0.0010659243,0.00021172059,0.00028816453,0.0032133271,0.064070776,0.0002707866,0.0027505772,0.0625966],"study_design_scores_gemma":[0.5545768,0.42717943,0.007958307,0.000027566191,0.00031084366,0.00025170352,0.000046308873,0.0013362163,0.0064136153,0.0001594599,0.0017108821,0.00002886797],"about_ca_topic_score_codex":0.0013258139,"about_ca_topic_score_gemma":0.0025157735,"teacher_disagreement_score":0.0031720344,"about_ca_system_score_codex":0.0012633879,"about_ca_system_score_gemma":0.0018088821,"threshold_uncertainty_score":0.010611534},"labels":[],"label_agreement":null},{"id":"W4386268787","doi":"10.1093/oncolo/oyad223","title":"Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"OPKO Health; Clovis Oncology; Novavax; Karyopharm Therapeutics; INOVIO Pharmaceuticals; Sanofi; Abeona Therapeutics; Acorda Therapeutics; Pfizer","keywords":"Medicine; Melanoma; Adjuvant; Internal medicine; Adjuvant therapy; Systemic therapy; Oncology; Adverse effect; Immunotherapy; Clinical trial; Single Center; Progression-free survival; Retrospective cohort study; Stage (stratigraphy); Surgery; Cancer; Overall survival","score_opus":0.08479655175958822,"score_gpt":0.3904699091171679,"score_spread":0.30567335735757967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386268787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998548,0.00073829497,0.000114630784,0.000018326971,0.0000035546352,0.000063197884,0.00025392763,0.0000018901655,0.00025814073],"genre_scores_gemma":[0.9988403,0.00028061395,0.00014863766,0.00004396562,0.00001559104,0.00005396762,0.0005242292,0.0000019738895,0.00009077229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907684,0.00029167897,0.00015177774,0.00025390857,0.00012892493,0.000096961165],"domain_scores_gemma":[0.99792695,0.00042561276,0.0009923535,0.00018297916,0.00018136122,0.0002906517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012099175,0.0003332073,0.0004982235,0.00085598096,0.0005689058,0.0006787559,0.00030610355,0.00043827196,0.0019740711],"category_scores_gemma":[0.0015624915,0.00035797528,0.0005199515,0.001207961,0.00037603322,0.0005149433,0.0004961149,0.00041046218,0.0003489524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075371686,0.00016075766,0.9966253,0.000048236634,0.0001283831,0.0003889751,0.00009144874,0.000033945667,0.0002963267,0.000016941163,0.0001034972,0.0013524074],"study_design_scores_gemma":[0.00024714196,0.0016091675,0.9930767,0.000043909724,0.00025479187,0.0028375366,0.00051247113,0.0002460036,0.00020493908,0.000033100798,0.00091911195,0.000015174608],"about_ca_topic_score_codex":0.001581384,"about_ca_topic_score_gemma":0.002660814,"teacher_disagreement_score":0.0019740711,"about_ca_system_score_codex":0.00056626846,"about_ca_system_score_gemma":0.0006474458,"threshold_uncertainty_score":0.006603956},"labels":[],"label_agreement":null},{"id":"W4386438681","doi":"10.1093/oncolo/oyad253","title":"Coping Strategies and Associated Symptom Burden Among Patients With Advanced Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health","keywords":"Coping (psychology); Denial; Clinical psychology; Breast cancer; Medicine; Emotional distress; Distress; Maladaptive coping; Anxiety; Psychology; Psychiatry; Cancer; Internal medicine; Psychotherapist","score_opus":0.01748900832477097,"score_gpt":0.2973600153115371,"score_spread":0.27987100698676615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386438681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99865806,0.000749801,0.000028496945,0.000115759314,0.000004758604,0.0000100668385,0.0000949506,0.0000020067541,0.00033609322],"genre_scores_gemma":[0.99935955,0.00035929633,0.00006051498,0.000038271286,0.000009862439,0.000010430837,0.00011472888,5.336706e-7,0.0000468401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977535,0.00008103092,0.000030735726,0.000024986917,0.000052071697,0.000035865232],"domain_scores_gemma":[0.99868125,0.00026966087,0.0006974022,0.00002422993,0.00008338071,0.0002441367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003709076,0.00019701963,0.00027221846,0.0005736838,0.00024572018,0.0003826819,0.00014459893,0.00023780686,0.0018367979],"category_scores_gemma":[0.0024663869,0.00007617719,0.00023566549,0.00063656666,0.00020781513,0.0002479616,0.00037983948,0.0003466473,0.00011359755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005480431,0.00007467032,0.9946995,0.000044111992,0.000041825097,0.00010508734,0.00025869597,0.00004093516,0.00015272046,0.0000141287865,0.00011307249,0.0044004135],"study_design_scores_gemma":[0.0000108939075,0.00018741957,0.99840325,0.000030497788,0.000020376541,0.00047718533,0.00048373523,0.0001025395,0.000024120029,0.00003430656,0.000222447,0.0000033778597],"about_ca_topic_score_codex":0.0006508884,"about_ca_topic_score_gemma":0.00097407954,"teacher_disagreement_score":0.0018367979,"about_ca_system_score_codex":0.00014582739,"about_ca_system_score_gemma":0.00018775016,"threshold_uncertainty_score":0.0061447024},"labels":[],"label_agreement":null},{"id":"W4386632442","doi":"10.1093/oncolo/oyad250","title":"Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Placebo; Clinical endpoint; Melatonin; Interim analysis; Breast cancer; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Randomization; Radiation therapy; Cancer","score_opus":0.04681610985196225,"score_gpt":0.36119356241132783,"score_spread":0.31437745255936556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386632442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95040125,0.021334115,0.0013250806,0.0014763041,0.0021826373,0.01919001,0.0015828217,0.0002467453,0.0022610396],"genre_scores_gemma":[0.95438325,0.00985182,0.0031548573,0.0021810895,0.0014945102,0.024272814,0.00073583523,0.000034105895,0.003891737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992156,0.00038680047,0.000092522816,0.00015321835,0.000058701527,0.00009305224],"domain_scores_gemma":[0.99891317,0.00034124218,0.000256713,0.0000955461,0.00011614101,0.0002772724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002194948,0.0015536546,0.0044935117,0.00050911936,0.00086205074,0.0009642292,0.0009577702,0.0026877387,0.0070018754],"category_scores_gemma":[0.0021543896,0.0007472347,0.0024193802,0.0004879683,0.0011399643,0.0008414071,0.0004016941,0.0022201056,0.0008799529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98017347,0.0071733035,0.0002040627,0.001283002,0.0007390415,0.000022909593,0.000034618097,0.0000782784,0.0016080881,0.000029022345,0.0003557298,0.008298497],"study_design_scores_gemma":[0.9609631,0.03776192,0.00053406355,0.000037983173,0.00026100985,0.0000080470945,0.000006955226,0.00007280619,0.00010500701,0.00002701877,0.00021670444,0.000005499702],"about_ca_topic_score_codex":0.00086327136,"about_ca_topic_score_gemma":0.0020485364,"teacher_disagreement_score":0.0070018754,"about_ca_system_score_codex":0.0006080855,"about_ca_system_score_gemma":0.0016090844,"threshold_uncertainty_score":0.023423612},"labels":[],"label_agreement":null},{"id":"W4386979571","doi":"10.1093/oncolo/oyad259","title":"Breast Cancer-Related Financial Toxicity in Sri Lanka: Insights From a Lower Middle-Income Country With Free Universal Public Healthcare","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Breast cancer; Health care; Public health care; Business; Medicine; Public health; Scale (ratio); Cancer; Sri lanka; Family medicine; Finance; Economic growth; Socioeconomics; Nursing; Economics; Internal medicine; Geography; Health policy","score_opus":0.035511579826387946,"score_gpt":0.23938320681566724,"score_spread":0.2038716269892793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386979571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983688,0.00028685734,0.00001219892,0.0003057844,0.0000031570441,0.000010518303,0.00009216034,5.8910035e-7,0.00091987976],"genre_scores_gemma":[0.998912,0.00063415605,0.000031134943,0.00022654775,0.0000065131576,0.000009660723,0.00008212256,7.796317e-7,0.00009709635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993942,0.00023498833,0.000043037133,0.000030417157,0.000050176925,0.00024728163],"domain_scores_gemma":[0.9993274,0.00012987625,0.0002634675,0.000015266449,0.00008764132,0.00017627998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048088064,0.00023105991,0.0003107361,0.0010461819,0.0013992091,0.0014706475,0.0003566031,0.00037025756,0.0016948857],"category_scores_gemma":[0.0013962594,0.00024053252,0.0004172408,0.0021832555,0.0007929958,0.0008516025,0.001548239,0.00069095753,0.00017310982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005630421,0.00014645443,0.9694063,0.0001713459,0.000041638086,0.0024032386,0.021127108,0.00005283372,0.00028092726,0.00017408836,0.00048181435,0.005658048],"study_design_scores_gemma":[0.000006117238,0.0002493135,0.9076533,0.0001245025,0.000029399083,0.0014720593,0.089097746,0.000059734844,0.00003644497,0.000053091077,0.001202762,0.000015546637],"about_ca_topic_score_codex":0.057686575,"about_ca_topic_score_gemma":0.09064852,"teacher_disagreement_score":0.057686575,"about_ca_system_score_codex":0.0012823133,"about_ca_system_score_gemma":0.0014731109,"threshold_uncertainty_score":0.11470157},"labels":[],"label_agreement":null},{"id":"W4387449548","doi":"10.1093/oncolo/oyad254","title":"Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute on Minority Health and Health Disparities; Astellas Pharma; Foundation Medicine; Bayer HealthCare; Pfizer; American Association for Cancer Research; Invitae; Eli Lilly and Company; Lantheus Medical Imaging","keywords":"Docetaxel; Medicine; Placebo; Internal medicine; Clinical endpoint; Androgen deprivation therapy; Prostate cancer; Population; Adverse effect; Enzalutamide; Oncology; Randomized controlled trial; Chemotherapy; Cancer; Androgen receptor","score_opus":0.04382962024491794,"score_gpt":0.32801834829904825,"score_spread":0.2841887280541303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387449548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886022,0.006908881,0.00023617601,0.0011697366,0.00026551832,0.00063886313,0.00068146375,0.000022784146,0.0014744005],"genre_scores_gemma":[0.99140465,0.0029739754,0.0007539802,0.0012063584,0.00041412772,0.001016504,0.0010989195,0.000013074807,0.0011184136],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987563,0.00092745386,0.00005198901,0.00010742449,0.00007302221,0.000083782914],"domain_scores_gemma":[0.99894017,0.00021223404,0.00037925268,0.000063889,0.00008373515,0.00032066106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002318414,0.001095666,0.0020667198,0.00029099835,0.0003960997,0.00071017747,0.00047507207,0.0009468483,0.0038457538],"category_scores_gemma":[0.002279479,0.00037743492,0.0021766154,0.00029644847,0.00064700656,0.00045151784,0.00054639444,0.0013578273,0.00038688685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96872365,0.0017853467,0.005489637,0.00047265197,0.002523739,0.000067057365,0.00006321604,0.00034615112,0.0026389589,0.00015331034,0.0012506372,0.016485717],"study_design_scores_gemma":[0.92142236,0.05179602,0.018188365,0.00016302432,0.003922761,0.00015241197,0.00006408353,0.0007471186,0.0006374278,0.0004526592,0.002420706,0.000032987125],"about_ca_topic_score_codex":0.0007117816,"about_ca_topic_score_gemma":0.0018203683,"teacher_disagreement_score":0.0038457538,"about_ca_system_score_codex":0.00061198743,"about_ca_system_score_gemma":0.00090539304,"threshold_uncertainty_score":0.012865305},"labels":[],"label_agreement":null},{"id":"W4388000610","doi":"10.1093/oncolo/oyad291","title":"Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Referral; Cancer; Colorectal cancer; Cervical cancer; Family medicine; Health care; Internal medicine; Finance","score_opus":0.037722052113737234,"score_gpt":0.28238746535319026,"score_spread":0.244665413239453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388000610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462295,0.0009862982,0.00006138976,0.002506688,0.000026054444,0.000034271576,0.00030097255,0.000001905832,0.0014595009],"genre_scores_gemma":[0.9987086,0.0007522506,0.00012396926,0.00014627002,0.000035129986,0.000023871957,0.000102079815,8.723799e-7,0.000106856474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980684,0.0012468091,0.00016838008,0.00005541255,0.00019203936,0.00026905752],"domain_scores_gemma":[0.9956077,0.00094046,0.0026304272,0.000069812784,0.00034170377,0.00040995868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00216359,0.00020612647,0.00020631406,0.0011395307,0.0007418331,0.0014667705,0.00038736736,0.00036333507,0.0017731738],"category_scores_gemma":[0.00781766,0.00018269624,0.00030570605,0.0015951981,0.0006493949,0.001191856,0.0015407505,0.00067741144,0.00013183641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058438865,0.00005283758,0.9832839,0.00010008697,0.000026154303,0.00023939651,0.002845752,0.00007608465,0.00008051,0.00015439893,0.001628126,0.011454199],"study_design_scores_gemma":[0.000009727967,0.00018488603,0.9816248,0.00022367372,0.00002375799,0.0005784848,0.014727671,0.00027246765,0.000060312846,0.00014297721,0.0021388705,0.00001236747],"about_ca_topic_score_codex":0.007201949,"about_ca_topic_score_gemma":0.01179918,"teacher_disagreement_score":0.007201949,"about_ca_system_score_codex":0.001638839,"about_ca_system_score_gemma":0.0017412945,"threshold_uncertainty_score":0.014320016},"labels":[],"label_agreement":null},{"id":"W4388722167","doi":"10.1093/oncolo/oyad305","title":"The Use of Wearable Devices in Oncology Patients: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"CINAHL; Medicine; Wearable computer; Rehabilitation; MEDLINE; Web of science; Wearable technology; Scopus; Systematic review; Psychological intervention; Physical therapy; Meta-analysis; Medical physics; Internal medicine; Computer science; Nursing","score_opus":0.21418983090040722,"score_gpt":0.4243515335456701,"score_spread":0.2101617026452629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388722167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000847056,0.99820983,0.000087310764,0.00019362576,0.000073801784,0.00019091515,0.00019625186,0.0000047794856,0.00019654086],"genre_scores_gemma":[0.013206239,0.98499763,0.00047098828,0.00048850535,0.000091309594,0.000507197,0.00015052655,0.000004397397,0.00008328102],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9900665,0.0039988244,0.003390913,0.00066782173,0.0016247946,0.00025105535],"domain_scores_gemma":[0.9674636,0.02444683,0.0059336196,0.00038664447,0.0015257242,0.00024359168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075814375,0.0014086765,0.007031155,0.008714626,0.000600721,0.0029609024,0.0017989469,0.002061877,0.0043448214],"category_scores_gemma":[0.03852359,0.0010733303,0.0056803264,0.010245192,0.00094792247,0.002822009,0.0013111121,0.0012210243,0.000322629],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010934143,0.000010474802,0.0005311156,0.9719505,0.0043100696,0.000056893867,0.00015575002,0.000041847095,0.00006940091,0.000102175705,0.00088178675,0.021780694],"study_design_scores_gemma":[0.00012966292,0.0001462079,0.0026913544,0.95992917,0.026867608,0.0002858059,0.00024116068,0.000042649757,0.00009885009,0.00014383535,0.009402928,0.000020711372],"about_ca_topic_score_codex":0.004708938,"about_ca_topic_score_gemma":0.014525385,"teacher_disagreement_score":0.008714626,"about_ca_system_score_codex":0.0027811602,"about_ca_system_score_gemma":0.0076359236,"threshold_uncertainty_score":0.04009497},"labels":[],"label_agreement":null},{"id":"W4389005089","doi":"10.1093/oncolo/oyad312","title":"Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Alberta; Health Sciences Centre; Alberta Health Services","funders":"","keywords":"Medicine; Neuroendocrine tumors; Radionuclide therapy; Internal medicine; Oncology","score_opus":0.0848700145888727,"score_gpt":0.41599001128486035,"score_spread":0.3311199966959877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389005089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762659,0.00017609219,0.018830778,0.00034330273,0.00003904476,0.0019191682,0.00034559824,0.000017320723,0.0020627996],"genre_scores_gemma":[0.9637051,0.000146819,0.0315852,0.00023696864,0.000026315465,0.0036938465,0.00023583777,0.000003957846,0.00036601094],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9641245,0.031783354,0.0009676989,0.0010692675,0.001388339,0.00066679623],"domain_scores_gemma":[0.8046117,0.18229371,0.008458578,0.0015866953,0.0015914644,0.0014578465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.044822827,0.0012574723,0.0010617792,0.0008353262,0.0005341605,0.0020454717,0.00091788213,0.001457381,0.0035000676],"category_scores_gemma":[0.080751255,0.00046029076,0.0015822765,0.00065227173,0.0012881628,0.001378715,0.0009832489,0.0022355234,0.00020589764],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11281706,0.039059304,0.14436838,0.0047037015,0.004640614,0.0007898592,0.0074561536,0.45667255,0.018410493,0.043104336,0.0028928602,0.16508466],"study_design_scores_gemma":[0.017917272,0.047506183,0.0455315,0.00040220266,0.0010057148,0.0002490989,0.0024404933,0.7962539,0.011241964,0.073086984,0.00401176,0.0003529867],"about_ca_topic_score_codex":0.00058534014,"about_ca_topic_score_gemma":0.00073188933,"teacher_disagreement_score":0.044822827,"about_ca_system_score_codex":0.0021262364,"about_ca_system_score_gemma":0.0016874068,"threshold_uncertainty_score":0.23704863},"labels":[],"label_agreement":null},{"id":"W4390590466","doi":"10.1093/oncolo/oyad337","title":"CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Ipsen; Clovis Oncology; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Instituto de Salud Carlos III; Amgen; Pfizer; PharmaMar; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Hazard ratio; Internal medicine; Chemotherapy; Breast cancer; Oncology; Confidence interval; Progression-free survival; Randomized controlled trial; Gastroenterology; Cancer","score_opus":0.05329712438884447,"score_gpt":0.4183184199007502,"score_spread":0.3650212955119057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390590466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809914,0.01275419,0.00058938,0.0008894095,0.00029746944,0.0013587807,0.001296769,0.00004093192,0.00178156],"genre_scores_gemma":[0.98789495,0.004298772,0.0011582535,0.00079847994,0.00044851107,0.0018021459,0.0017278488,0.000024738714,0.0018463891],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99765503,0.0018730022,0.00008268586,0.00016640977,0.00009589504,0.00012700444],"domain_scores_gemma":[0.9971161,0.0013408789,0.00079729303,0.00024042561,0.00010334957,0.00040196688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050212573,0.0013616132,0.002371191,0.00033813252,0.00025075919,0.0010288414,0.0006742516,0.0010078729,0.002672264],"category_scores_gemma":[0.004178536,0.00039423705,0.0021781072,0.0004392913,0.00087619585,0.0007968256,0.00044397768,0.0018509491,0.00037847733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98447776,0.0015184892,0.0018560172,0.00038554939,0.0013207264,0.000016806003,0.000028048888,0.00034427867,0.0009555329,0.000084418454,0.00033587878,0.0086765],"study_design_scores_gemma":[0.90921575,0.07553292,0.008566652,0.00009995802,0.0036394629,0.000059835213,0.00003599913,0.0007333318,0.00058726297,0.00032225085,0.0011847386,0.000021952797],"about_ca_topic_score_codex":0.00063855393,"about_ca_topic_score_gemma":0.0017503776,"teacher_disagreement_score":0.0050212573,"about_ca_system_score_codex":0.0008169124,"about_ca_system_score_gemma":0.0010059865,"threshold_uncertainty_score":0.0265553},"labels":[],"label_agreement":null},{"id":"W4391282760","doi":"10.1093/oncolo/oyad324","title":"Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck","keywords":"Chemoimmunotherapy; Chronic lymphocytic leukemia; Medicine; Internal medicine; Lymphoma; Health care; Rituximab; Leukemia; Oncology","score_opus":0.04775565335878256,"score_gpt":0.3283996721921445,"score_spread":0.28064401883336193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391282760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544466,0.00061320746,0.000052177234,0.00037908612,0.000005037626,0.000011511265,0.0030158698,0.000004500745,0.0004740188],"genre_scores_gemma":[0.9975103,0.0003178275,0.00008872191,0.00009431977,0.000008166662,0.000018241664,0.001899036,0.0000016154278,0.0000617187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992016,0.00021247187,0.00017050856,0.000117592186,0.00014944345,0.00014846373],"domain_scores_gemma":[0.9984573,0.0001762495,0.0010487483,0.00003011322,0.00011073583,0.00017686626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048767647,0.00016245904,0.00022252474,0.001010906,0.0002708766,0.0005934487,0.00032234276,0.0003008945,0.0013093264],"category_scores_gemma":[0.0020478775,0.00014538145,0.00042643643,0.0023317512,0.00021052785,0.0004720897,0.00048576918,0.0003698256,0.00012065401],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048468362,0.000024311232,0.9975452,0.000014536197,0.00003877336,0.000030626918,0.000026991143,0.00017799636,0.000028117063,0.000037040165,0.0004706282,0.0015573238],"study_design_scores_gemma":[0.000012305868,0.000060358943,0.99764246,0.00003483693,0.000032517328,0.00026833272,0.00033566338,0.0008556989,0.000045383822,0.00006617163,0.00064177415,0.0000045873817],"about_ca_topic_score_codex":0.031206453,"about_ca_topic_score_gemma":0.037288073,"teacher_disagreement_score":0.031206453,"about_ca_system_score_codex":0.0014633866,"about_ca_system_score_gemma":0.00091557234,"threshold_uncertainty_score":0.062049627},"labels":[],"label_agreement":null},{"id":"W4391727506","doi":"10.1093/oncolo/oyae016","title":"Consuming Patients’ Days: Time Spent on Ambulatory Appointments by People With Cancer","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Healthcare Operations and Scheduling Optimization","field":"Health Professions","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health; Pancreatic Cancer Action Network","keywords":"Ambulatory; Medicine; Ambulatory care; Cancer; Emergency medicine; Surgery; Health care; Internal medicine","score_opus":0.043064319239712746,"score_gpt":0.40458772768682616,"score_spread":0.3615234084471134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391727506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337363,0.00090348494,0.00032110765,0.0014144896,0.00004054606,0.00004617347,0.0012109362,0.000014068246,0.0026757072],"genre_scores_gemma":[0.9987117,0.00030975175,0.00024354324,0.00024105897,0.000015661783,0.000059599737,0.00024170653,0.0000057368434,0.00017119857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99655825,0.0020512997,0.00037297956,0.00026073505,0.00038659584,0.0003700703],"domain_scores_gemma":[0.9879908,0.004692483,0.0045360164,0.00033232363,0.001011998,0.001436516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029378263,0.0001855871,0.00027744417,0.0009342974,0.0014298931,0.0016907814,0.0007978821,0.00048011253,0.0036574649],"category_scores_gemma":[0.0140018165,0.00025833648,0.00057656004,0.0014092274,0.0010401723,0.0018744691,0.002530004,0.0008418936,0.00024462806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023722091,0.000075573174,0.85023534,0.000719685,0.00017409079,0.00023047827,0.11029751,0.00014601702,0.0002666859,0.00040827424,0.0057520354,0.031457156],"study_design_scores_gemma":[0.000010891482,0.00018145805,0.76482546,0.0004828468,0.00006934733,0.00041232107,0.22563438,0.00021215445,0.00013394789,0.00028582977,0.00769623,0.000055228433],"about_ca_topic_score_codex":0.021034272,"about_ca_topic_score_gemma":0.029119436,"teacher_disagreement_score":0.021034272,"about_ca_system_score_codex":0.0022351493,"about_ca_system_score_gemma":0.0017925253,"threshold_uncertainty_score":0.041823685},"labels":[],"label_agreement":null},{"id":"W4392125982","doi":"10.1093/oncolo/oyae019","title":"Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Bayer HealthCare; Bayer","keywords":"Tolerability; Medicine; Adverse effect; Placebo; Prostate cancer; Internal medicine; Androgen deprivation therapy; Oncology; Cancer","score_opus":0.02509620189157084,"score_gpt":0.3702472411746977,"score_spread":0.34515103928312685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392125982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589455,0.002531022,0.0008306757,0.000047430764,0.0000151751,0.00014894162,0.00013354247,0.000025769024,0.00037294003],"genre_scores_gemma":[0.9988593,0.0003731631,0.00038414155,0.000035921737,0.00002637921,0.00006229039,0.00012677487,0.0000034014672,0.00012854981],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9990484,0.0005699893,0.00008409982,0.000074922726,0.00017261314,0.00004999566],"domain_scores_gemma":[0.99762744,0.001024187,0.0008777328,0.00015078655,0.00011842191,0.00020144515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024174545,0.00036084952,0.00086465356,0.00017298656,0.00012304232,0.00031223724,0.00029050518,0.0003946157,0.0015535791],"category_scores_gemma":[0.0028924458,0.00017631323,0.0009705229,0.00017526028,0.00026533526,0.0003887018,0.00016208105,0.0009197048,0.0001672464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45507407,0.011710169,0.044312753,0.001766592,0.0026507184,0.0005175812,0.00039419366,0.004064881,0.1779719,0.0003386375,0.00071561994,0.3004829],"study_design_scores_gemma":[0.08574959,0.59110755,0.2772606,0.00013637004,0.0016666298,0.0025113681,0.00009521798,0.006685626,0.030817661,0.000512948,0.0033785515,0.00007788716],"about_ca_topic_score_codex":0.00013822468,"about_ca_topic_score_gemma":0.0003242791,"teacher_disagreement_score":0.0024174545,"about_ca_system_score_codex":0.00024672635,"about_ca_system_score_gemma":0.0002953353,"threshold_uncertainty_score":0.012784898},"labels":[],"label_agreement":null},{"id":"W4392343556","doi":"10.1093/oncolo/oyae010","title":"Integrating Patient-Reported Outcomes Into Prognostication in Gastroesophageal Cancer: Results of a Population-Based Retrospective Cohort Analysis","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Performance status; Internal medicine; Concordance; Cohort; Retrospective cohort study; Population; Cancer","score_opus":0.015566806387348388,"score_gpt":0.33139852472861997,"score_spread":0.3158317183412716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392343556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99913824,0.00013273352,0.00025417106,0.000016686416,0.0000063487664,0.00002024849,0.0003442504,0.0000032066312,0.00008426289],"genre_scores_gemma":[0.9991259,0.000076764474,0.00015960548,0.000012782248,0.000009133396,0.000025478785,0.00054059894,0.0000030406918,0.00004664022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978934,0.00086704706,0.00020607279,0.00046258254,0.00034673564,0.0002242495],"domain_scores_gemma":[0.9961928,0.0010788471,0.0012102443,0.00071839953,0.00043832057,0.00036135907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048523997,0.00051379215,0.0006098508,0.0010592126,0.00064260006,0.0010379095,0.0005881184,0.00053205807,0.00090189173],"category_scores_gemma":[0.0068351524,0.0004805136,0.0013502024,0.0016148861,0.0004356767,0.000731913,0.00091972976,0.00075653306,0.00023578036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028419762,0.000034308792,0.9987587,0.0000046709347,0.00012862551,0.00004075307,0.000049039874,0.000041458406,0.000073418596,0.000007760464,0.000040994204,0.0005361672],"study_design_scores_gemma":[0.00004296368,0.00032671346,0.99833566,0.000006780489,0.00019594707,0.00021297843,0.00017937865,0.0004582436,0.00006291909,0.000017159751,0.00015207373,0.000009268563],"about_ca_topic_score_codex":0.0039879805,"about_ca_topic_score_gemma":0.003291388,"teacher_disagreement_score":0.0048523997,"about_ca_system_score_codex":0.00048540812,"about_ca_system_score_gemma":0.00063038676,"threshold_uncertainty_score":0.025662243},"labels":[],"label_agreement":null},{"id":"W4393142464","doi":"10.1093/oncolo/oyae036","title":"Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Bruyère; University of Ottawa","funders":"Astellas Pharma","keywords":"Medicine; Prostate cancer; Zoledronic acid; Denosumab; Radiation therapy; Internal medicine; Oncology; Androgen deprivation therapy; Cancer; Osteoporosis","score_opus":0.0875235150987341,"score_gpt":0.4214431469459067,"score_spread":0.33391963184717255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393142464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912907,0.0011942886,0.00015890313,0.00027207544,0.000009553803,0.0000505669,0.006112629,0.000010848479,0.0009003103],"genre_scores_gemma":[0.997387,0.00018973956,0.00019624781,0.000046134155,0.000010587799,0.000019263942,0.0020976504,0.00000148099,0.00005191516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975069,0.0010760464,0.00023795587,0.0003861744,0.00058355427,0.00020948025],"domain_scores_gemma":[0.9889158,0.002337407,0.0061836974,0.00038995664,0.0013384463,0.0008346519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00283168,0.00021521437,0.00041915034,0.00068162894,0.00045182867,0.00084786984,0.00057721057,0.00031378245,0.0011945888],"category_scores_gemma":[0.012253961,0.00015316332,0.00064424414,0.0018600693,0.00039422858,0.00038550294,0.0005094565,0.00040508577,0.00011223111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006604829,0.00004000696,0.99485403,0.00009917751,0.00015994164,0.000015579848,0.00005857073,0.00042646588,0.000049142243,0.00003874964,0.00037988435,0.0032180406],"study_design_scores_gemma":[0.00005479731,0.00022448646,0.9973792,0.000033317905,0.000078393125,0.00005767715,0.00017048218,0.0012904619,0.000066780376,0.00003841346,0.00059727224,0.000008812349],"about_ca_topic_score_codex":0.2027016,"about_ca_topic_score_gemma":0.3048544,"teacher_disagreement_score":0.2027016,"about_ca_system_score_codex":0.004014758,"about_ca_system_score_gemma":0.0029047097,"threshold_uncertainty_score":0.4030435},"labels":[],"label_agreement":null},{"id":"W4393376515","doi":"10.1093/oncolo/oyae050","title":"Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Foundation Medicine; Eisai; Flatiron Health; Teva Pharmaceutical Industries; Broad Institute; Celldex Therapeutics; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Palliative care; Context (archaeology); Hospital Anxiety and Depression Scale; Randomized controlled trial; Quality of life (healthcare); Clinical endpoint; Anxiety; Lung cancer; Depression (economics); Clinical trial; Randomization; Physical therapy; Internal medicine; Nursing; Psychiatry","score_opus":0.08905191217252234,"score_gpt":0.4477167426748217,"score_spread":0.35866483050229936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393376515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96330166,0.012329959,0.0009391147,0.0024184184,0.0011782324,0.013499259,0.0016498693,0.00007784539,0.004605638],"genre_scores_gemma":[0.9645898,0.0062011057,0.0026614396,0.0017203878,0.00094250333,0.019161766,0.0017020288,0.000014725181,0.0030062844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992785,0.00047375992,0.000036726564,0.00010225337,0.000039782713,0.00006904005],"domain_scores_gemma":[0.9990049,0.00037844607,0.00023821005,0.000058484657,0.00006553757,0.00025448127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017656301,0.0010153048,0.0018828901,0.00030028922,0.00041761223,0.0009944263,0.0006110432,0.0014182682,0.0062368303],"category_scores_gemma":[0.0024674113,0.00034456546,0.001569572,0.0003173968,0.00067203,0.0009600203,0.0005967183,0.0020625854,0.00039053275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97670686,0.0050327117,0.0009787977,0.0012817042,0.00078911864,0.000038216225,0.000026792279,0.000272133,0.00045703535,0.00019429559,0.0007955502,0.013426952],"study_design_scores_gemma":[0.94989187,0.044775452,0.0024278655,0.00013616656,0.00090408104,0.000025669868,0.000021380461,0.00038478905,0.00010406504,0.0001795747,0.0011415094,0.000007591922],"about_ca_topic_score_codex":0.00069106487,"about_ca_topic_score_gemma":0.0012349867,"teacher_disagreement_score":0.0062368303,"about_ca_system_score_codex":0.00056529726,"about_ca_system_score_gemma":0.0017194918,"threshold_uncertainty_score":0.020864248},"labels":[],"label_agreement":null},{"id":"W4394869936","doi":"10.1093/oncolo/oyae072","title":"Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Dalhousie University; Western University; Baker Hughes (Canada); Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Confounding; Logistic regression; Proportional hazards model; Univariate analysis; Oncology; Kidney cancer; Multivariate analysis","score_opus":0.04695649256119615,"score_gpt":0.3369761675759084,"score_spread":0.29001967501471226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394869936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99913067,0.0003579367,0.00003959829,0.00004742433,0.000005521299,0.0000043697905,0.00014525844,0.0000013946909,0.00026786278],"genre_scores_gemma":[0.99965584,0.00008936609,0.00002181589,0.000015572612,0.000008913326,0.0000029844005,0.00016160627,6.3020974e-7,0.00004320341],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995993,0.00011184841,0.000047276742,0.00006451792,0.00010579136,0.00007129608],"domain_scores_gemma":[0.9980124,0.00052259344,0.0009635484,0.00007461974,0.00015770552,0.00026907885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077589066,0.000121285324,0.00026626125,0.00037889465,0.00022535746,0.0004996212,0.000234466,0.0003017451,0.00089921115],"category_scores_gemma":[0.0023987337,0.0000999408,0.0004114733,0.0005905086,0.00020014777,0.00037187221,0.00024090709,0.0003950314,0.00012144145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011649579,0.000018384964,0.9987753,0.0000039111305,0.000029617502,0.000034199173,0.000009494775,0.000027899672,0.00007444561,0.000005432315,0.000020235053,0.0008845666],"study_design_scores_gemma":[0.000006694251,0.00010771331,0.99921596,0.000004653044,0.000039760384,0.00017647208,0.000036633246,0.0002584095,0.000044714892,0.000017020988,0.000090052534,0.0000018339467],"about_ca_topic_score_codex":0.0014462658,"about_ca_topic_score_gemma":0.003111541,"teacher_disagreement_score":0.0014462658,"about_ca_system_score_codex":0.00029483144,"about_ca_system_score_gemma":0.00033735237,"threshold_uncertainty_score":0.0041033626},"labels":[],"label_agreement":null},{"id":"W4394909371","doi":"10.1093/oncolo/oyae041","title":"A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Alberta; Ottawa Hospital; University of Ottawa; University of Calgary; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"Ontario Ministry of Health and Long-Term Care; Hamilton Health Sciences","keywords":"Medicine; Proportional hazards model; Internal medicine; Multiple myeloma; Population; Retrospective cohort study; Emergency medicine; Oncology; Intensive care medicine","score_opus":0.04688907369917945,"score_gpt":0.3251112198427596,"score_spread":0.27822214614358015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394909371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626548,0.0005336447,0.031104552,0.0017474758,0.00009957411,0.000101348116,0.0023333943,0.00025616694,0.0011689836],"genre_scores_gemma":[0.9925982,0.00010924348,0.0055436455,0.000079190104,0.000039414612,0.00006665614,0.0011715216,0.000009872521,0.0003822885],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99903154,0.0006066078,0.00006902068,0.0001345562,0.00006599845,0.00009223435],"domain_scores_gemma":[0.99418515,0.004012557,0.00087031536,0.00027366265,0.00041747597,0.00024086928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056477645,0.00067470025,0.00059074844,0.0011232813,0.00033226042,0.00089452276,0.0008465148,0.000567643,0.0018476616],"category_scores_gemma":[0.011981843,0.00024999885,0.0010371458,0.00071667857,0.00020055429,0.0005121627,0.0007440733,0.0012665023,0.0003046522],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012308498,0.00043884874,0.85951805,0.00007058922,0.0006510658,0.00025186376,0.00024299682,0.09595348,0.0002797695,0.0012291196,0.0027708253,0.03736258],"study_design_scores_gemma":[0.0001524224,0.00087437895,0.08127281,0.000058598143,0.00049195124,0.0003036032,0.00020171075,0.91231114,0.00022928322,0.002604932,0.0014580425,0.000041000934],"about_ca_topic_score_codex":0.005609563,"about_ca_topic_score_gemma":0.00461045,"teacher_disagreement_score":0.0056477645,"about_ca_system_score_codex":0.000682379,"about_ca_system_score_gemma":0.0012863851,"threshold_uncertainty_score":0.029868603},"labels":[],"label_agreement":null},{"id":"W4398131449","doi":"10.1093/oncolo/oyae089","title":"Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immunotherapy; Melanoma; Medicine; Oncology; Targeted therapy; Internal medicine; Cancer research; Cancer","score_opus":0.013438049135509457,"score_gpt":0.2830156575480475,"score_spread":0.26957760841253803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398131449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8855371,0.00216214,0.10186723,0.0013511037,0.000033738364,0.0007944532,0.004855566,0.00015063533,0.003247994],"genre_scores_gemma":[0.97819155,0.0004556917,0.016962437,0.00012768684,0.000026364043,0.0005269808,0.0034797953,0.000011734686,0.000217719],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.98620254,0.010508767,0.0007433112,0.0012779012,0.0007319931,0.0005355269],"domain_scores_gemma":[0.86235905,0.12368477,0.009350423,0.0019060358,0.0014547895,0.001245012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026414787,0.0010393917,0.0010432698,0.0024902734,0.00042862172,0.0022730203,0.0010605272,0.0015337762,0.0023530112],"category_scores_gemma":[0.06909213,0.00056451245,0.0023355326,0.0015671119,0.00079714,0.0018557478,0.0015961888,0.001734223,0.00026740608],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018939932,0.00023439666,0.14949398,0.00036894483,0.0012411745,0.0004871315,0.0003102123,0.8180941,0.0004597517,0.0067754453,0.0012267191,0.019414159],"study_design_scores_gemma":[0.0003533848,0.0015634729,0.05834879,0.00031802768,0.0006432394,0.0014169005,0.0006661935,0.9002737,0.0011371806,0.03191937,0.0032194762,0.00014035832],"about_ca_topic_score_codex":0.001975035,"about_ca_topic_score_gemma":0.0012067937,"teacher_disagreement_score":0.026414787,"about_ca_system_score_codex":0.0025138885,"about_ca_system_score_gemma":0.0010725412,"threshold_uncertainty_score":0.13969636},"labels":[],"label_agreement":null},{"id":"W4399352342","doi":"10.1093/oncolo/oyae131","title":"Has the blood-brain barrier finally been busted?","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Blood–brain barrier; Faith; Neuroscience; Psychology; Medicine; Philosophy; Central nervous system; Epistemology","score_opus":0.05261219151529272,"score_gpt":0.32228744724746117,"score_spread":0.26967525573216844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399352342","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019060669,0.051569566,0.0003240085,0.89648545,0.049464248,0.0000037860887,0.000017696228,0.000020866291,0.0019237658],"genre_scores_gemma":[0.008498534,0.060757853,0.00045260633,0.8362255,0.08820314,0.00001805142,0.000022947757,0.00005921497,0.0057621766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943198,0.0018047703,0.00048383095,0.0008568322,0.0018658853,0.000668846],"domain_scores_gemma":[0.9856376,0.010264619,0.0007087722,0.00034242048,0.0021395679,0.000906965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007845449,0.0006776839,0.0020166421,0.00044447675,0.0037212383,0.0066846865,0.0036277922,0.024966061,0.004749681],"category_scores_gemma":[0.02387659,0.00037317237,0.0013864785,0.00039427576,0.0152154695,0.011317237,0.0029333853,0.047907606,0.002028497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016126971,0.000027471107,0.00017154207,0.00088616874,0.000071348266,0.0007359223,0.0008112929,0.00014881024,0.0005915868,0.0893572,0.85557705,0.051460378],"study_design_scores_gemma":[0.000028407709,0.00007363714,0.00014618636,0.0006602987,0.000027076232,0.00047179183,0.000565087,0.00006566928,0.0003061351,0.025336992,0.9722783,0.00004049125],"about_ca_topic_score_codex":0.006647996,"about_ca_topic_score_gemma":0.013317998,"teacher_disagreement_score":0.024966061,"about_ca_system_score_codex":0.005107828,"about_ca_system_score_gemma":0.0068369005,"threshold_uncertainty_score":0.04149121},"labels":[],"label_agreement":null},{"id":"W4400572999","doi":"10.1093/oncolo/oyae172","title":"It is time to rethink randomized clinical trial approaches","year":2024,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"BATES; Randomized controlled trial; Clinical trial; Psychology; Medical physics; Medicine; Engineering; Internal medicine","score_opus":0.1228221381364503,"score_gpt":0.4079856865953792,"score_spread":0.2851635484589289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400572999","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006463669,0.0018473445,0.0003960754,0.93962926,0.057409666,0.00004237276,0.00005243817,0.000038310143,0.0005198196],"genre_scores_gemma":[0.0006981182,0.00095608085,0.0014872528,0.92063296,0.07526969,0.00013347894,0.000024637491,0.00003721747,0.0007605093],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.85267305,0.08152476,0.02283682,0.009981323,0.029543133,0.0034408448],"domain_scores_gemma":[0.45807502,0.44969597,0.016190976,0.012818832,0.048647713,0.014571453],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.18169354,0.0018947871,0.006266279,0.002893399,0.0055664107,0.014935007,0.010039665,0.062293112,0.010878033],"category_scores_gemma":[0.43055668,0.001801196,0.0062015387,0.0027728372,0.012072014,0.01831998,0.0041451,0.09854201,0.009111071],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003755593,0.000072375966,0.0002673671,0.00046476664,0.00024144152,0.00022537148,0.00016213991,0.00015007565,0.00010079726,0.010476651,0.962107,0.025356462],"study_design_scores_gemma":[0.0026088494,0.00043675798,0.0009547499,0.003308167,0.00037886386,0.00039131285,0.00038784003,0.0014257112,0.00027484263,0.09874957,0.8908331,0.00025031678],"about_ca_topic_score_codex":0.0039734985,"about_ca_topic_score_gemma":0.008418314,"teacher_disagreement_score":0.81830645,"about_ca_system_score_codex":0.010185096,"about_ca_system_score_gemma":0.015938137,"threshold_uncertainty_score":0.96089876},"labels":[],"label_agreement":null},{"id":"W4400968014","doi":"10.1093/oncolo/oyae187","title":"Patients’ considerations of time toxicity when assessing cancer treatments with marginal benefit","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; University of Ottawa; Queen's University","funders":"Canadian Institutes of Health Research; Pancreatic Cancer Action Network","keywords":"Toxicity; Medicine; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.040454438839272557,"score_gpt":0.2718258838074402,"score_spread":0.23137144496816767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400968014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886085,0.0005278629,0.005636309,0.0024214496,0.000036557412,0.00023032242,0.00009074212,0.000009230996,0.0024390884],"genre_scores_gemma":[0.99458015,0.0003403149,0.0039819563,0.0005396199,0.000016366534,0.00034687133,0.000031652253,0.0000049449263,0.00015811644],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.96674335,0.029730704,0.0009973353,0.0004327367,0.0013770264,0.0007187984],"domain_scores_gemma":[0.92997503,0.05892991,0.0071545457,0.0009019013,0.0020331424,0.0010055258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03329926,0.00042532652,0.00037504456,0.00084136345,0.002186764,0.0024677352,0.0009934613,0.0010028688,0.0020222564],"category_scores_gemma":[0.07144142,0.00040206377,0.0006242305,0.00056334934,0.0033754413,0.0028416463,0.0027059384,0.0016805145,0.00017265996],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083801686,0.00019696703,0.086006895,0.0015133481,0.000120964374,0.0009796587,0.85510176,0.00041840647,0.004393376,0.0027060364,0.001240045,0.046484485],"study_design_scores_gemma":[0.00011977965,0.0008464954,0.03617756,0.0011789976,0.00012231519,0.0017706649,0.9308491,0.0015637497,0.0036810383,0.005901333,0.017663471,0.00012553026],"about_ca_topic_score_codex":0.0012332769,"about_ca_topic_score_gemma":0.0027171592,"teacher_disagreement_score":0.03329926,"about_ca_system_score_codex":0.0023080364,"about_ca_system_score_gemma":0.0024963133,"threshold_uncertainty_score":0.17610538},"labels":[],"label_agreement":null},{"id":"W4401041181","doi":"10.1093/oncolo/oyae190","title":"Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Palliative chemotherapy; Chemotherapy; Incidence (geometry); Gastric carcinoma; Internal medicine; Oncology; Carcinoma; Palliative care; Clinical trial; Cancer; Nursing","score_opus":0.0227292670198159,"score_gpt":0.32953007751447055,"score_spread":0.30680081049465463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401041181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99919254,0.00035483006,0.00002766817,0.000030804815,0.00000412022,0.000005168639,0.00013890865,0.0000010781828,0.00024492998],"genre_scores_gemma":[0.99945027,0.00019536025,0.00002531562,0.00003145389,0.000012121224,0.0000047843296,0.00023661416,4.5243175e-7,0.000043589644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983144,0.000030188676,0.000026603277,0.000029077524,0.000037885777,0.000044832726],"domain_scores_gemma":[0.99913305,0.000088811175,0.00048793494,0.000021153266,0.00005984107,0.00020928418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030510945,0.00012969945,0.00033922706,0.0004313594,0.0003101971,0.00035178722,0.0001027338,0.00018416083,0.00082705996],"category_scores_gemma":[0.0013537407,0.00008463104,0.00026882658,0.00063018664,0.00016611179,0.00026640395,0.00034755564,0.00023946917,0.00009790987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009445596,0.000018196039,0.9980556,0.000009767115,0.000020417,0.00023013372,0.00006943848,0.00003264992,0.00007873657,0.000011670024,0.00007160737,0.0013074015],"study_design_scores_gemma":[0.000011000961,0.00023042255,0.9978046,0.000016697422,0.00002621825,0.0012764997,0.00024040033,0.00010358618,0.000031557942,0.000036106216,0.00022053938,0.0000024209478],"about_ca_topic_score_codex":0.0016461664,"about_ca_topic_score_gemma":0.0027036334,"teacher_disagreement_score":0.0016461664,"about_ca_system_score_codex":0.0002425462,"about_ca_system_score_gemma":0.00020979207,"threshold_uncertainty_score":0.0032731295},"labels":[],"label_agreement":null},{"id":"W4401363772","doi":"10.1093/oncolo/oyae181.031","title":"23 Pre-surgical visceral adipose tissue may be a novel pre-surgical risk factor for acute kidney injury among clear cell renal cell cancer patients undergoing radical nephrectomy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Muscle and Compartmental Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Nephrectomy; Adipose tissue; Acute kidney injury; Kidney; Kidney cancer; Surgery; Cancer; Internal medicine","score_opus":0.018365667132579554,"score_gpt":0.3295378471971235,"score_spread":0.31117218006454395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401363772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924767,0.00026854515,0.000074073156,0.00003919122,0.000005660771,0.0000050278654,0.00017777007,0.0000019586435,0.00018007703],"genre_scores_gemma":[0.9996414,0.00004962747,0.000055880202,0.00001590426,0.0000107058795,0.0000042606002,0.00016862198,6.010894e-7,0.000052886084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974424,0.000054092547,0.000035332716,0.0000637214,0.000051892803,0.000050882652],"domain_scores_gemma":[0.9988709,0.0001460426,0.00058359123,0.00004813255,0.00012439542,0.0002268372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003396068,0.00021821106,0.00025271965,0.00059671764,0.0003832116,0.00055639824,0.0003081491,0.00034407375,0.0014499313],"category_scores_gemma":[0.0010997719,0.00015055577,0.0003761773,0.00089608977,0.00023500492,0.0003422497,0.00030607643,0.0005116413,0.00017696655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037842237,0.000008486183,0.9994885,0.0000034712896,0.000011663452,0.000039066163,0.000006251319,0.0000157285,0.000092123024,0.000003700652,0.000020180581,0.00027310874],"study_design_scores_gemma":[0.000002516324,0.000047644295,0.9993368,0.0000023912805,0.000014560638,0.00024272405,0.00005758553,0.00016058772,0.000053577987,0.000012711659,0.0000671271,0.0000019031236],"about_ca_topic_score_codex":0.0038836554,"about_ca_topic_score_gemma":0.005593194,"teacher_disagreement_score":0.0038836554,"about_ca_system_score_codex":0.00027069094,"about_ca_system_score_gemma":0.0004829303,"threshold_uncertainty_score":0.0077220798},"labels":[],"label_agreement":null},{"id":"W4401363791","doi":"10.1093/oncolo/oyae181.013","title":"20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Dalhousie University; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Renal cell carcinoma; Internal medicine; Oncology; Cohort; Proportional hazards model; Clinical trial","score_opus":0.07293113190360824,"score_gpt":0.35448449782588676,"score_spread":0.28155336592227853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401363791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902982,0.004128454,0.00081686815,0.00018936099,0.00005378645,0.0005895939,0.0026651018,0.000024267556,0.0012343107],"genre_scores_gemma":[0.9939679,0.00053299364,0.0010018925,0.00024613162,0.00017068659,0.000600259,0.0030302682,0.000011777936,0.00043807633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978836,0.0012846804,0.0001692517,0.0003004523,0.00020629197,0.00015574259],"domain_scores_gemma":[0.9933396,0.0016093418,0.0022361192,0.0010191234,0.0006474163,0.0011484218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007820694,0.0007109573,0.0014545621,0.0004517163,0.00032985667,0.0012024656,0.00074255775,0.00053141033,0.0016076366],"category_scores_gemma":[0.0060965274,0.00022179353,0.0018064455,0.00075811136,0.00031722133,0.00048634273,0.00077915704,0.0011990612,0.00049559335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31661272,0.008324692,0.59319067,0.0010466642,0.0069166394,0.00017998679,0.00016005625,0.0027577388,0.0030182863,0.00029796545,0.0041758902,0.063318856],"study_design_scores_gemma":[0.048920467,0.1592657,0.7471332,0.00038058203,0.010990957,0.00086865603,0.00026704624,0.012569729,0.005159379,0.0005799325,0.01375854,0.00010590563],"about_ca_topic_score_codex":0.0012790004,"about_ca_topic_score_gemma":0.0014589375,"teacher_disagreement_score":0.007820694,"about_ca_system_score_codex":0.0011219089,"about_ca_system_score_gemma":0.001518487,"threshold_uncertainty_score":0.04136026},"labels":[],"label_agreement":null},{"id":"W4401363835","doi":"10.1093/oncolo/oyae181.036","title":"35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Lenvatinib; Medicine; Cabozantinib; Internal medicine; Renal cell carcinoma; Oncology; Cohort; Pembrolizumab; Discontinuation; Sorafenib; Cancer; Hepatocellular carcinoma; Immunotherapy","score_opus":0.015138111206525359,"score_gpt":0.2673251085670865,"score_spread":0.25218699736056116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401363835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960912,0.0022865369,0.00007828786,0.00004611493,0.0000056384674,0.000019837396,0.00084732956,0.0000037692773,0.0006214109],"genre_scores_gemma":[0.9991346,0.00016973981,0.000043692096,0.000023732924,0.000010967125,0.000008749893,0.0005403039,8.9782714e-7,0.00006742421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990165,0.0002796493,0.00014274291,0.00022519086,0.00020249664,0.00013341659],"domain_scores_gemma":[0.99703836,0.0006556263,0.0017289976,0.00010947617,0.00019349538,0.00027401335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001174627,0.00010769283,0.00047516217,0.0004779393,0.00021334962,0.000607031,0.00023623444,0.00023834415,0.0010306657],"category_scores_gemma":[0.002160142,0.00008364323,0.0006952719,0.0007811055,0.00016662608,0.00034193127,0.00027212632,0.00038866402,0.00015225644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014985302,0.00012902156,0.98784095,0.000064043954,0.00020899749,0.00010503633,0.000023487228,0.0002489257,0.00044250718,0.00002784468,0.00018204468,0.009228607],"study_design_scores_gemma":[0.00006827623,0.0013477098,0.99631774,0.000014970846,0.00016958684,0.00049808796,0.000034843266,0.0003883907,0.00038164572,0.00003332793,0.0007396241,0.0000058363366],"about_ca_topic_score_codex":0.0011262804,"about_ca_topic_score_gemma":0.0017008268,"teacher_disagreement_score":0.001174627,"about_ca_system_score_codex":0.0005587419,"about_ca_system_score_gemma":0.00043650327,"threshold_uncertainty_score":0.0062121153},"labels":[],"label_agreement":null},{"id":"W4401364054","doi":"10.1093/oncolo/oyae181.026","title":"8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Nivolumab; Ipilimumab; Sunitinib; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","score_opus":0.07148638069975227,"score_gpt":0.3484030131394102,"score_spread":0.2769166324396579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401364054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575764,0.0020540203,0.00016074488,0.00019641565,0.00006504673,0.00031003274,0.0008415902,0.000022175273,0.0005923275],"genre_scores_gemma":[0.9963405,0.0005156905,0.00027397415,0.0002206419,0.00011708841,0.00038182776,0.0015512843,0.000009386294,0.0005895405],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984238,0.0010273057,0.00007996374,0.0002108354,0.0000990958,0.00015888424],"domain_scores_gemma":[0.997675,0.0006023791,0.0007586411,0.00023413484,0.00009920315,0.00063059345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045934254,0.0009556928,0.0020071503,0.0003995957,0.000445246,0.001260673,0.00080176955,0.0011067379,0.0023160472],"category_scores_gemma":[0.0025147016,0.00037159777,0.003774712,0.00038292693,0.0004941711,0.00084406795,0.0005564049,0.0020312318,0.00034075975],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95333755,0.003874179,0.020217247,0.00030967352,0.005677917,0.00008123318,0.000057542995,0.0010217536,0.0022748183,0.00006431328,0.0011709828,0.01191274],"study_design_scores_gemma":[0.6059021,0.20780094,0.15632676,0.00011039499,0.01777166,0.00038981452,0.0001338811,0.004936852,0.0029008007,0.0006478508,0.0029839885,0.000095030395],"about_ca_topic_score_codex":0.0007896929,"about_ca_topic_score_gemma":0.0020503553,"teacher_disagreement_score":0.0045934254,"about_ca_system_score_codex":0.0008971017,"about_ca_system_score_gemma":0.0010247456,"threshold_uncertainty_score":0.024292707},"labels":[],"label_agreement":null},{"id":"W4401364392","doi":"10.1093/oncolo/oyae181.020","title":"19 Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epithelioid sarcoma; Cancer research; CD3; Mucin; SMARCB1; CD30; Pathology; Medicine; Biology; Antigen; CD8; Sarcoma; Immunohistochemistry; Immunology; Gene expression","score_opus":0.03657062688265229,"score_gpt":0.3470010378014646,"score_spread":0.3104304109188123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401364392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98318416,0.006193252,0.0013418521,0.00057543727,0.00034111875,0.0044570323,0.0014269481,0.00019178836,0.0022884165],"genre_scores_gemma":[0.9863427,0.00237612,0.0015047841,0.00070695486,0.00012592938,0.0029876642,0.0023564815,0.000024031271,0.0035752559],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996921,0.0000934215,0.000021000113,0.000050768274,0.00003533825,0.000107422944],"domain_scores_gemma":[0.9996024,0.000039560353,0.00006841815,0.000040984876,0.000036861617,0.00021193144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011673194,0.0012674344,0.0017919632,0.00041993643,0.00039936573,0.0010430571,0.0010018665,0.0015306685,0.0028697092],"category_scores_gemma":[0.00038879577,0.00040393393,0.001322674,0.0003218548,0.00065979693,0.0006372192,0.00035841667,0.00220926,0.00069967285],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4149067,0.10274904,0.00904742,0.0028367178,0.0027808347,0.0017005469,0.00037995027,0.0076879947,0.2074584,0.0018982952,0.009705623,0.2388485],"study_design_scores_gemma":[0.3223939,0.6221906,0.0101191,0.00009986955,0.000614684,0.0011689967,0.00009524441,0.0039874874,0.024714973,0.00064312323,0.013926007,0.00004602873],"about_ca_topic_score_codex":0.001100514,"about_ca_topic_score_gemma":0.0022675402,"teacher_disagreement_score":0.0028697092,"about_ca_system_score_codex":0.0011117741,"about_ca_system_score_gemma":0.0014598464,"threshold_uncertainty_score":0.009600103},"labels":[],"label_agreement":null},{"id":"W4401380032","doi":"10.1093/oncolo/oyae181.027","title":"9 Delving into molecular underpinnings of sarcomatoid/rhabdoid dedifferentioation in renal cancers using spatial profiling","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Transcriptome; Phenotype; Biology; Clear cell renal cell carcinoma; Renal cell carcinoma; Computational biology; Exome; Pathology; Exome sequencing; Bioinformatics; Medicine; Gene; Genetics; Gene expression","score_opus":0.03754108721285215,"score_gpt":0.3317309242573873,"score_spread":0.29418983704453516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401380032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9397457,0.005325324,0.04155555,0.00045339126,0.000041342988,0.0000590679,0.008640792,0.00045858652,0.0037203212],"genre_scores_gemma":[0.97561103,0.0014953476,0.016712587,0.00016766968,0.000023742321,0.000038949976,0.005111877,0.00005908593,0.0007797138],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9996823,0.00003951367,0.000019919626,0.00013226886,0.00008293198,0.00004308996],"domain_scores_gemma":[0.9995925,0.00010101519,0.00015120275,0.00006390517,0.000063320185,0.0000281006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045837427,0.00021291536,0.0003495242,0.0007408194,0.000203742,0.0008749674,0.00026252927,0.00030300487,0.0008551564],"category_scores_gemma":[0.00048669943,0.00021664835,0.0004679425,0.0006831068,0.00031716478,0.00032577856,0.00048880785,0.0003563625,0.00039398985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026444596,0.000058949674,0.1148593,0.0005741015,0.00018582582,0.0003999585,0.00019594259,0.008245578,0.82468927,0.0026235299,0.00091281155,0.046990328],"study_design_scores_gemma":[0.00002245732,0.00026865234,0.57953537,0.00012215605,0.00026553674,0.0017275569,0.0007338655,0.052018825,0.3326415,0.006169827,0.026420156,0.00007419569],"about_ca_topic_score_codex":0.0013255198,"about_ca_topic_score_gemma":0.0026040063,"teacher_disagreement_score":0.0013255198,"about_ca_system_score_codex":0.0003561667,"about_ca_system_score_gemma":0.00035846842,"threshold_uncertainty_score":0.002860725},"labels":[],"label_agreement":null},{"id":"W4401792490","doi":"10.1093/oncolo/oyae215","title":"Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Foundation Medicine; EMD Serono; Eisai; National Cancer Institute; Aptitude Health; Natera; Seagen; Loxo Oncology; Astellas Pharma; Calithera Biosciences; Mirati Therapeutics; bluebird bio; Sanofi; Exelixis; Genentech; MEI Pharma; Regeneron Pharmaceuticals; Gilead Sciences; Merck KGaA; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Gemcitabine; Pembrolizumab; Avelumab; Carboplatin; Medicine; Chemotherapy; Cisplatin; Oncology; Nivolumab; Metastatic Urothelial Carcinoma; Regimen; Internal medicine; Urothelial carcinoma; Bladder cancer; Cancer; Immunotherapy","score_opus":0.041673547470804276,"score_gpt":0.360458438488445,"score_spread":0.31878489101764074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401792490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00077767915,0.9929946,0.00023236182,0.0043350584,0.0002452349,0.0000073003475,0.000026101769,0.0000089549085,0.0013726547],"genre_scores_gemma":[0.006009264,0.98950255,0.00069218763,0.0027964201,0.0005264178,0.000021482467,0.000074150455,0.0000066175417,0.00037092328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993436,0.00024925268,0.00014807416,0.000059668735,0.00016049434,0.000038909257],"domain_scores_gemma":[0.99901605,0.00052276935,0.00014115048,0.000018223542,0.0002480585,0.000053750013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015734709,0.00023064611,0.0008016763,0.00082737044,0.00026361932,0.0011085185,0.0006259063,0.00079947466,0.0012092182],"category_scores_gemma":[0.0030851716,0.00014010114,0.0005604399,0.0010112706,0.00046279898,0.0013040942,0.0005913847,0.001719077,0.00043683755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111059395,0.000040227267,0.0011466838,0.01159596,0.00011578059,0.0003635928,0.0002929898,0.00043689823,0.00078816846,0.003370794,0.036050104,0.9456878],"study_design_scores_gemma":[0.00006317384,0.0002152468,0.003714739,0.010703118,0.0003136165,0.0017144645,0.0003171236,0.0002365848,0.00036190485,0.0033233243,0.9790046,0.00003206744],"about_ca_topic_score_codex":0.0013656009,"about_ca_topic_score_gemma":0.004665074,"teacher_disagreement_score":0.0015734709,"about_ca_system_score_codex":0.00073474646,"about_ca_system_score_gemma":0.0015180085,"threshold_uncertainty_score":0.008321404},"labels":[],"label_agreement":null},{"id":"W4402326482","doi":"10.1093/oncolo/oyae219","title":"Evaluating early intervention in smoldering myeloma clinical trials: a systematic review","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Clinical endpoint; Clinical trial; Internal medicine; Randomized controlled trial; Oncology; Surgery","score_opus":0.6741545513710383,"score_gpt":0.6617437026961426,"score_spread":0.012410848674895725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402326482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016388322,0.995773,0.00038169543,0.00040400054,0.0001432229,0.0009759929,0.00036347483,0.000019640831,0.00030013727],"genre_scores_gemma":[0.06872254,0.9189982,0.004002425,0.0021077741,0.00034292127,0.0049446165,0.00065104134,0.000034139557,0.00019644835],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.93749124,0.036185935,0.018294998,0.002530877,0.004762335,0.0007346195],"domain_scores_gemma":[0.75557256,0.19586433,0.03331304,0.003203383,0.010532919,0.001513832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.043786764,0.0019010911,0.017530823,0.008346806,0.0008005179,0.004487526,0.0027770111,0.0030329577,0.005510408],"category_scores_gemma":[0.16145101,0.0016507927,0.011898775,0.00890677,0.0015114092,0.0042564077,0.0021571827,0.002305541,0.00040012982],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001636917,0.000036763042,0.0010711289,0.92619413,0.034762986,0.00005488449,0.00015676241,0.00014686298,0.00011128667,0.00028429186,0.0011072559,0.03443673],"study_design_scores_gemma":[0.004454279,0.00079328904,0.00507566,0.7949052,0.17982794,0.00017015141,0.00022059184,0.00025506603,0.00022200416,0.00087684946,0.013135643,0.000063264786],"about_ca_topic_score_codex":0.0036346035,"about_ca_topic_score_gemma":0.00984193,"teacher_disagreement_score":0.043786764,"about_ca_system_score_codex":0.005446428,"about_ca_system_score_gemma":0.010993893,"threshold_uncertainty_score":0.23156929},"labels":[],"label_agreement":null},{"id":"W4403220541","doi":"10.1093/oncolo/oyae261","title":"A rapid review of nutrition and exercise approaches to managing unintentional weight loss, muscle loss, and malnutrition in cancer","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"State Government of Victoria","keywords":"Malnutrition; Weight loss; Medicine; Psychological intervention; Medical nutrition therapy; Intensive care medicine; Nutritional Supplementation; Randomized controlled trial; Enteral administration; Parenteral nutrition; Physical therapy; Surgery; Internal medicine; Obesity; Nursing","score_opus":0.28439050253138654,"score_gpt":0.4193227246138907,"score_spread":0.13493222208250416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403220541","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010306585,0.9984773,0.000099722085,0.00042132335,0.0003641489,0.000045402096,0.00012429885,0.000008259508,0.00035656794],"genre_scores_gemma":[0.00073129474,0.99782157,0.00030614447,0.00055397867,0.00019137506,0.000070779744,0.00010641372,0.0000030363576,0.00021540387],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9979031,0.00063217303,0.0006246137,0.00021943514,0.0005235503,0.00009703632],"domain_scores_gemma":[0.99474394,0.0032125837,0.00090606057,0.00009227431,0.0009230138,0.00012201835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029433346,0.0014962807,0.0042303964,0.0064964695,0.0004549968,0.0021194112,0.0013205198,0.0015193434,0.007896556],"category_scores_gemma":[0.009209662,0.0005193722,0.0043392642,0.006447055,0.00045393908,0.001842569,0.0011114972,0.0017196964,0.0009788353],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019067299,0.000047540223,0.00027128527,0.621556,0.0019828319,0.00011910819,0.0001747291,0.00021893835,0.0005055457,0.0012967285,0.03269161,0.34094495],"study_design_scores_gemma":[0.00013138952,0.0002819081,0.0031472945,0.4791362,0.010655283,0.00063716614,0.00019034461,0.00012563054,0.00024160492,0.0012386338,0.50416136,0.00005314629],"about_ca_topic_score_codex":0.0036851277,"about_ca_topic_score_gemma":0.009176652,"teacher_disagreement_score":0.007896556,"about_ca_system_score_codex":0.0018404794,"about_ca_system_score_gemma":0.008097701,"threshold_uncertainty_score":0.02641654},"labels":[],"label_agreement":null},{"id":"W4403565766","doi":"10.1093/oncolo/oyae237","title":"Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Adverse effect; Population; Cancer; Androgen receptor","score_opus":0.2252177205887461,"score_gpt":0.48773709342720395,"score_spread":0.26251937283845783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403565766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021886837,0.97415835,0.0003947964,0.00040316035,0.00024623214,0.00088541553,0.000746939,0.00001640825,0.001261971],"genre_scores_gemma":[0.44259173,0.5497122,0.0026519024,0.0012981306,0.00044491552,0.0017911964,0.0010216022,0.000020767602,0.0004675022],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98707527,0.0077952743,0.0028873286,0.00076570903,0.0012828117,0.00019357275],"domain_scores_gemma":[0.9810271,0.011904024,0.005296856,0.00034500792,0.001145667,0.0002812793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014305549,0.0010485736,0.0071309595,0.0043868287,0.00032164776,0.002230018,0.0010683119,0.0016338325,0.0036847405],"category_scores_gemma":[0.031206638,0.0005690739,0.012712787,0.0028329985,0.0007272315,0.0012878978,0.0008647058,0.0013540618,0.00027023096],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043290734,0.0003770198,0.0031688372,0.58152425,0.2882102,0.00011371864,0.00019025047,0.00074102153,0.0009113457,0.00067034265,0.00082426274,0.07997806],"study_design_scores_gemma":[0.03707649,0.016214041,0.015311195,0.12888218,0.78967005,0.00035603752,0.00031700474,0.0008902496,0.0009501634,0.001417645,0.008797957,0.00011704594],"about_ca_topic_score_codex":0.0025711663,"about_ca_topic_score_gemma":0.0061380863,"teacher_disagreement_score":0.014305549,"about_ca_system_score_codex":0.00242654,"about_ca_system_score_gemma":0.0026716616,"threshold_uncertainty_score":0.07565588},"labels":[],"label_agreement":null},{"id":"W4403622778","doi":"10.1093/oncolo/oyae277","title":"Clinical impact of <i>TP53</i> functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Bevacizumab; KRAS; Colorectal cancer; Medicine; Internal medicine; Oncology; Chemotherapy; Missense mutation; Population; Cancer; Gene; Mutation; Biology","score_opus":0.03163770663684876,"score_gpt":0.36591112428132244,"score_spread":0.33427341764447366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99900204,0.00044577257,0.00003328471,0.000053195407,0.000007135912,0.000005313981,0.00007679463,0.000002106324,0.00037443102],"genre_scores_gemma":[0.9997521,0.00005936397,0.000024003359,0.000016544265,0.000012563081,0.0000023508478,0.00009856358,7.1579103e-7,0.000033818666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997147,0.00008439058,0.000030050498,0.000061045495,0.000056370918,0.000053515658],"domain_scores_gemma":[0.99895597,0.00023164345,0.00046357175,0.000028711624,0.0000672479,0.00025278007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037568365,0.00018895918,0.0004096149,0.00044941675,0.00030607145,0.00043762615,0.00021345688,0.0004103442,0.00084145006],"category_scores_gemma":[0.0021743132,0.00010728725,0.00033154528,0.00054691994,0.00026965316,0.00024100128,0.0002195628,0.0003725798,0.00011061856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076410035,0.000031126554,0.99617344,0.000008793457,0.00004655289,0.00033194406,0.00001562107,0.00007575798,0.00044103435,0.000010908197,0.00006315442,0.0020375678],"study_design_scores_gemma":[0.000021087599,0.00031618326,0.9978397,0.0000060086863,0.00006474774,0.0010831419,0.000043651286,0.00034114879,0.000095112315,0.000025375199,0.00016007839,0.0000037279974],"about_ca_topic_score_codex":0.0018783298,"about_ca_topic_score_gemma":0.0029128776,"teacher_disagreement_score":0.0018783298,"about_ca_system_score_codex":0.00038854158,"about_ca_system_score_gemma":0.0003346389,"threshold_uncertainty_score":0.0037347674},"labels":[],"label_agreement":null},{"id":"W4403972842","doi":"10.1093/oncolo/oyae283","title":"Breast cancer incidence and mortality, by age, stage and molecular subtypes, by race/ethnicity in Canada","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Government of Canada; Statistics Canada; University of Ottawa","funders":"Women and Gender Equality Canada; Public Health Agency; Public Health Agency of Canada","keywords":"Race (biology); Ethnic group; Incidence (geometry); Breast cancer; Stage (stratigraphy); Cancer; Medicine; Demography; Oncology; Internal medicine; Biology; Gender studies; Sociology; Anthropology","score_opus":0.04235140625839118,"score_gpt":0.3588488841069859,"score_spread":0.3164974778485947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403972842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9202705,0.010598138,0.00038683316,0.0029486772,0.00007784957,0.00009830985,0.054860443,0.00009429631,0.010664907],"genre_scores_gemma":[0.9836083,0.004348535,0.00040899415,0.00037063923,0.000018509389,0.000032739397,0.009275017,0.000016053134,0.001921217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992441,0.00003886296,0.000047764253,0.00010179829,0.0002868915,0.00028067204],"domain_scores_gemma":[0.99785644,0.000082852144,0.0002866634,0.00003712479,0.001301036,0.000435923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045513062,0.0003006949,0.00038299648,0.0019107951,0.0021248378,0.0009135411,0.00085450883,0.00033892563,0.0024866776],"category_scores_gemma":[0.0019508278,0.000286923,0.0006326326,0.0052902214,0.00044546273,0.00029681614,0.0006257226,0.0006117529,0.00028631036],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114359165,0.000018081639,0.98233724,0.000096887234,0.00011497022,0.000106818545,0.00026256932,0.00027754836,0.0001408912,0.00019353854,0.007719406,0.008617848],"study_design_scores_gemma":[0.000013589922,0.0000104684295,0.9964477,0.00007260705,0.00005353402,0.00011372713,0.0004998797,0.0003799559,0.00005509401,0.000055801684,0.0022878395,0.00000987233],"about_ca_topic_score_codex":0.9968413,"about_ca_topic_score_gemma":0.99794763,"teacher_disagreement_score":0.03208834,"about_ca_system_score_codex":0.03208834,"about_ca_system_score_gemma":0.040413287,"threshold_uncertainty_score":0.2328183},"labels":[],"label_agreement":null},{"id":"W4404200415","doi":"10.1093/oncolo/oyae298","title":"Evolution in the diagnosis and treatment of carcinoma of unknown primary: a multicenter Canadian analysis","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Faculty of Medicine, University of British Columbia","keywords":"Primary (astronomy); Multicenter study; Medicine; Oncology; Internal medicine","score_opus":0.033981990015166504,"score_gpt":0.31344354251601264,"score_spread":0.27946155250084614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404200415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824973,0.0024500526,0.00024894648,0.0005502694,0.000025565278,0.00015201737,0.011551721,0.000018980427,0.0025051332],"genre_scores_gemma":[0.9924654,0.0011740304,0.00031208177,0.00022763513,0.000019490384,0.00004731358,0.0053819655,0.000016719587,0.0003552997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99710697,0.00033743464,0.00019591299,0.00056226423,0.0009425444,0.00085481885],"domain_scores_gemma":[0.99246186,0.00061700883,0.0019685556,0.00037920155,0.0032921783,0.0012811852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023419566,0.0007468637,0.00094240095,0.0024642798,0.0030524097,0.0017520748,0.0017223597,0.0007649011,0.0020563675],"category_scores_gemma":[0.005421495,0.00055869826,0.0017415549,0.008688425,0.00084736786,0.00048206543,0.001426514,0.0010149891,0.00021056941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034332753,0.000038991097,0.9935726,0.000094166484,0.00022604362,0.00010447662,0.0002879758,0.00022682405,0.000101126134,0.0000897504,0.0014230171,0.0034918142],"study_design_scores_gemma":[0.00005124454,0.000078003606,0.99580413,0.00008886111,0.00024414132,0.00022881167,0.0009766915,0.00060559914,0.00006809255,0.000034191773,0.001792277,0.000027984306],"about_ca_topic_score_codex":0.9834772,"about_ca_topic_score_gemma":0.98692954,"teacher_disagreement_score":0.9560703,"about_ca_system_score_codex":0.043929692,"about_ca_system_score_gemma":0.05420919,"threshold_uncertainty_score":0.31873375},"labels":[],"label_agreement":null},{"id":"W4404709309","doi":"10.1093/oncolo/oyae310","title":"Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; AstraZeneca; Bristol-Myers Squibb Canada; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Internal medicine; Colorectal cancer; Coronavirus disease 2019 (COVID-19); Stage (stratigraphy); Pandemic; Cancer; Propensity score matching; Oncology; Disease","score_opus":0.1278640685398695,"score_gpt":0.4997583880060044,"score_spread":0.37189431946613494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404709309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985446,0.00023515047,0.000035907953,0.000064441854,0.000009406323,0.0000094182615,0.00064885186,0.0000020397304,0.00045019557],"genre_scores_gemma":[0.99881005,0.000083673236,0.00003233483,0.000040422165,0.00001354359,0.000010517624,0.000899745,0.0000011866308,0.000108447704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995859,0.00008216505,0.000036322042,0.00010387011,0.000045889275,0.00014578311],"domain_scores_gemma":[0.9987739,0.00012884712,0.0006756201,0.000055932273,0.000107518004,0.00025823954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047605622,0.00016235666,0.0002151516,0.00049117516,0.00038810313,0.00058607233,0.00025134248,0.0003504765,0.0012471142],"category_scores_gemma":[0.0021172795,0.00011488757,0.0002907579,0.0007146778,0.00022143054,0.0003678956,0.0005632583,0.00041970774,0.00018569932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016053987,0.000021611253,0.998439,0.000010791492,0.000012924991,0.00012776183,0.00005140101,0.000032048963,0.000108304805,0.000008420018,0.00012324876,0.0009038666],"study_design_scores_gemma":[0.000006917376,0.00013639398,0.99867105,0.000009962438,0.00001295117,0.00038541833,0.00031117984,0.000091645896,0.00003832247,0.000017558848,0.0003145112,0.000004048538],"about_ca_topic_score_codex":0.0059859194,"about_ca_topic_score_gemma":0.0071554505,"teacher_disagreement_score":0.0059859194,"about_ca_system_score_codex":0.0006664107,"about_ca_system_score_gemma":0.0007074842,"threshold_uncertainty_score":0.0119021535},"labels":[],"label_agreement":null},{"id":"W4404711423","doi":"10.1093/oncolo/oyae321","title":"Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; EQ-5D; Meta-analysis; Prostate cancer; Observational study; Internal medicine; Systematic review; MEDLINE; Visual analogue scale; Oncology; Pooled analysis; Cancer; Health related quality of life; Surgery","score_opus":0.13686046811730865,"score_gpt":0.4540249715358743,"score_spread":0.3171645034185656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404711423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022667956,0.9963007,0.00039167644,0.00014449214,0.00009570086,0.00021085828,0.00038689864,0.000014598409,0.0001882433],"genre_scores_gemma":[0.11400667,0.8810902,0.0020264038,0.0007175132,0.00023180073,0.00096180994,0.0007617019,0.000026078824,0.00017778049],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98136234,0.010688895,0.004395642,0.0013110335,0.0018496295,0.00039241498],"domain_scores_gemma":[0.97279245,0.021145694,0.0033166425,0.0007783533,0.0017527462,0.00021416692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023689697,0.0028434424,0.019530198,0.009001603,0.00064351043,0.0036570013,0.0020022038,0.0018293938,0.003025501],"category_scores_gemma":[0.055668447,0.0014425595,0.038617887,0.0097593805,0.00081478665,0.0017948467,0.0017566477,0.001919516,0.0002600741],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010343882,0.000020619367,0.0026947616,0.43862465,0.542186,0.00011504476,0.00007809056,0.00063242647,0.00013120669,0.00017809543,0.0006065038,0.013698178],"study_design_scores_gemma":[0.00031775478,0.0001662995,0.0037048324,0.0435808,0.94961333,0.000112230126,0.00004390876,0.00019702561,0.00008807506,0.00029755427,0.0018523819,0.000025712856],"about_ca_topic_score_codex":0.007855361,"about_ca_topic_score_gemma":0.015355302,"teacher_disagreement_score":0.023689697,"about_ca_system_score_codex":0.0033274086,"about_ca_system_score_gemma":0.0054035545,"threshold_uncertainty_score":0.12528461},"labels":[],"label_agreement":null},{"id":"W4405221538","doi":"10.1093/oncolo/oyae348","title":"<i>Divinum opus est sedare dolorem</i>: the power (and beauty) of early palliative care","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; Università Degli Studi di Modena e Reggio Emila","keywords":"Beauty; Opus; Power (physics); Palliative care; Art; Aesthetics; Nursing; Medicine; Art history; Physics","score_opus":0.10663349626890462,"score_gpt":0.42165330260910416,"score_spread":0.31501980634019955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405221538","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004347671,0.027462976,0.0007915594,0.7032925,0.052492924,0.000020971445,0.0001461849,0.000101803205,0.21134342],"genre_scores_gemma":[0.0801769,0.021651374,0.002021378,0.6105137,0.03920301,0.000060333987,0.00016043035,0.00024027898,0.24597274],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99915826,0.0003458045,0.0000533977,0.00008740264,0.0002268834,0.00012833065],"domain_scores_gemma":[0.99902487,0.0003579918,0.00013617231,0.000047095178,0.00019672385,0.00023716937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013449398,0.00021942449,0.00023422402,0.00027965053,0.0031784896,0.003460247,0.0007796439,0.0033826272,0.011451613],"category_scores_gemma":[0.002914999,0.00013211364,0.0002211868,0.00035537186,0.0037870693,0.0027694954,0.0024401636,0.007624734,0.0033205764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026634136,0.000010808455,0.0005926466,0.00019466679,0.0000055216983,0.00064038404,0.003457896,0.00003154315,0.00050391775,0.045206085,0.91112256,0.03820733],"study_design_scores_gemma":[0.00000243865,0.000009208013,0.0006637665,0.00020778431,0.000002107135,0.0013604072,0.0016105265,0.000012541686,0.0001241756,0.0036788264,0.9923199,0.000008285114],"about_ca_topic_score_codex":0.0068569356,"about_ca_topic_score_gemma":0.02872653,"teacher_disagreement_score":0.011451613,"about_ca_system_score_codex":0.0014741212,"about_ca_system_score_gemma":0.0020277288,"threshold_uncertainty_score":0.038309395},"labels":[],"label_agreement":null},{"id":"W4406529892","doi":"10.1093/oncolo/oyae309","title":"Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Mindfulness; Renal cell carcinoma; Multinational corporation; Intervention (counseling); Medicine; Oncology; Carcinoma; Psychology; Internal medicine; Clinical psychology; Nursing; Business","score_opus":0.02287640169664145,"score_gpt":0.31155423557851736,"score_spread":0.2886778338818759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406529892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876094,0.00008414243,0.00012633901,0.000104229344,0.000007724367,0.0005671046,0.00007443837,0.0000062224444,0.00026881805],"genre_scores_gemma":[0.9967188,0.00020133694,0.0009013976,0.00027648025,0.000015979878,0.0015227697,0.00014106196,0.0000049746277,0.00021719694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805427,0.001099002,0.00014652674,0.00018095,0.00033829003,0.00018097191],"domain_scores_gemma":[0.9968166,0.0012954222,0.000671789,0.00021565656,0.0004324406,0.00056819775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049713673,0.00038014227,0.00050792407,0.0002929854,0.0007238035,0.00072353764,0.00038677713,0.00062499393,0.0015030726],"category_scores_gemma":[0.0068645445,0.00026691268,0.0010051371,0.00028508354,0.00060395367,0.00061379035,0.0007357576,0.00081502576,0.00031923706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011459659,0.03627946,0.8185497,0.00078646536,0.0008912,0.000266511,0.0074271974,0.00027885957,0.0068676593,0.00007674074,0.0012722763,0.11584424],"study_design_scores_gemma":[0.0029531058,0.05231875,0.9371573,0.00016246823,0.00052474753,0.0002516722,0.0030079193,0.0008382028,0.000897332,0.000049645085,0.0017953101,0.00004363525],"about_ca_topic_score_codex":0.0026205822,"about_ca_topic_score_gemma":0.0054107173,"teacher_disagreement_score":0.0049713673,"about_ca_system_score_codex":0.0005231278,"about_ca_system_score_gemma":0.0016237745,"threshold_uncertainty_score":0.02629143},"labels":[],"label_agreement":null},{"id":"W4406759369","doi":"10.1093/oncolo/oyae371","title":"Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Institutes of Health; Astellas Pharma; Merck; MedImmune; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Taiho Pharmaceutical; Bristol-Myers Squibb Canada; Gilead Sciences; Novartis; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Perioperative; Esophageal cancer; Chemotherapy; Chemoradiotherapy; Adenocarcinoma; Esophageal adenocarcinoma; Radiation therapy; Adjuvant; Oncology; Internal medicine; General surgery; Surgery; Cancer","score_opus":0.06521482934145607,"score_gpt":0.41803361921587184,"score_spread":0.3528187898744158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406759369","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009508226,0.998798,0.000022923829,0.00066513853,0.00018695054,0.0000020395846,0.000008620663,0.0000013181201,0.00021991403],"genre_scores_gemma":[0.0008528154,0.9978248,0.00007585318,0.00089206744,0.00017523077,0.000004738387,0.000015792004,0.000001232251,0.00015743861],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996518,0.00012339871,0.00007803818,0.000047998445,0.000074765056,0.000024017918],"domain_scores_gemma":[0.9991297,0.00058395043,0.0001239642,0.000017930257,0.00011868012,0.00002580096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012387937,0.00038866827,0.001477708,0.0009702348,0.00021387693,0.0008887106,0.0008575534,0.0012764157,0.0037792658],"category_scores_gemma":[0.0026192674,0.00022621146,0.0011028281,0.0011832499,0.0005196487,0.0017414844,0.00035476763,0.0016669775,0.0007710382],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021420736,0.000027862381,0.0002128412,0.061904967,0.00031446354,0.00009901216,0.00010394342,0.00014531503,0.00041478162,0.0023038096,0.024760813,0.90949804],"study_design_scores_gemma":[0.00021398823,0.00035554048,0.0030450386,0.069768995,0.0013757977,0.0019844472,0.0004114471,0.00008149878,0.0004202848,0.0037154243,0.9185922,0.000035367622],"about_ca_topic_score_codex":0.0016921753,"about_ca_topic_score_gemma":0.0047720256,"teacher_disagreement_score":0.0037792658,"about_ca_system_score_codex":0.0005562262,"about_ca_system_score_gemma":0.0014507731,"threshold_uncertainty_score":0.01264292},"labels":[],"label_agreement":null},{"id":"W4406760478","doi":"10.1093/oncolo/oyae356","title":"Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; Amgen","keywords":"KRAS; Medicine; Oncology; Lung cancer; Cancer; Adverse effect; Internal medicine; Pooled analysis; Cancer research; Colorectal cancer; Meta-analysis","score_opus":0.00639325103339201,"score_gpt":0.32502417040903736,"score_spread":0.31863091937564536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406760478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43407854,0.417929,0.06785394,0.0040778057,0.0015871867,0.010045373,0.042425394,0.0016497136,0.020352919],"genre_scores_gemma":[0.94318265,0.027564852,0.009353376,0.0019466903,0.000771443,0.0036814513,0.011760326,0.00017397616,0.0015652309],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97406447,0.017489363,0.0032984663,0.0018903171,0.002928484,0.0003289686],"domain_scores_gemma":[0.9723901,0.012376583,0.008912075,0.0027428996,0.0032481246,0.00033012216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04298883,0.0012037989,0.003935396,0.0017600349,0.0002271644,0.002031454,0.00077358395,0.0009554074,0.0041917395],"category_scores_gemma":[0.05264467,0.0005240154,0.014013941,0.0018078302,0.0003744601,0.0009578272,0.0009836218,0.00096509175,0.0006169251],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10545416,0.00042350136,0.049019918,0.03962021,0.56314313,0.00022878464,0.00024046219,0.008875958,0.0062328307,0.0010021189,0.011004701,0.21475425],"study_design_scores_gemma":[0.03828278,0.031901997,0.18368392,0.007105479,0.66254425,0.0015160673,0.00018958608,0.011240952,0.009326926,0.0054926598,0.04842647,0.0002889266],"about_ca_topic_score_codex":0.0005938349,"about_ca_topic_score_gemma":0.0008869151,"teacher_disagreement_score":0.04298883,"about_ca_system_score_codex":0.0010072758,"about_ca_system_score_gemma":0.0016390121,"threshold_uncertainty_score":0.22734934},"labels":[],"label_agreement":null},{"id":"W4407910233","doi":"10.1093/oncolo/oyae344","title":"Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Oncology; Lung cancer; Hazard ratio; Subgroup analysis; Proportional hazards model; Cancer; Confidence interval","score_opus":0.034434646915604855,"score_gpt":0.35041465106732034,"score_spread":0.31598000415171545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407910233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0058876523,0.9923673,0.00047941244,0.00018379412,0.00009396295,0.0001578256,0.00060826365,0.00002258563,0.00019909893],"genre_scores_gemma":[0.23411483,0.75953305,0.0023612967,0.00094685046,0.00027267603,0.0010352196,0.0013386342,0.00004371896,0.00035383648],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99180365,0.0038803557,0.0022300973,0.0010440082,0.00076751516,0.00027428166],"domain_scores_gemma":[0.9764263,0.018379059,0.0029727984,0.0006856333,0.0012859952,0.0002502482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012002159,0.0025837056,0.017716473,0.005571058,0.000664752,0.0030202572,0.0020825297,0.0022067935,0.0028072256],"category_scores_gemma":[0.028515989,0.0015247521,0.0428596,0.0072777485,0.00068585895,0.001465313,0.0013395324,0.0018758096,0.00031147402],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018642016,0.00002531656,0.007837467,0.2824059,0.69708216,0.00012158381,0.0000654474,0.00071034895,0.00024227158,0.00009531653,0.0005166359,0.009033326],"study_design_scores_gemma":[0.00026629327,0.00013420238,0.0041868393,0.013313947,0.9807751,0.0000660201,0.000024039486,0.0001872907,0.000079558165,0.00010421355,0.00084583403,0.000016625103],"about_ca_topic_score_codex":0.008042867,"about_ca_topic_score_gemma":0.014776033,"teacher_disagreement_score":0.017716473,"about_ca_system_score_codex":0.0022175014,"about_ca_system_score_gemma":0.0031340194,"threshold_uncertainty_score":0.06347424},"labels":[],"label_agreement":null},{"id":"W4408140353","doi":"10.1093/oncolo/oyae347","title":"Real-world characteristics and outcomes of <i>ERBB2-</i> mutant NSCLC in Latin American patients (CLICaP)","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Latin Americans; Mutant; Oncology; Internal medicine; Medicine; Biology; Political science; Genetics; Gene","score_opus":0.019686864164362487,"score_gpt":0.3584937315319411,"score_spread":0.3388068673675786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408140353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996687,0.00035524002,0.000043657652,0.00016485705,0.0000061636156,0.000011116294,0.0018915993,0.0000049873324,0.00083540345],"genre_scores_gemma":[0.9976628,0.00021187778,0.00004417485,0.00006899642,0.000009473315,0.000017582672,0.0018866999,0.0000021439064,0.0000962421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997708,0.000053865522,0.000031767235,0.00006235901,0.00003162969,0.000049609902],"domain_scores_gemma":[0.9990435,0.000104775354,0.0005624205,0.000047408983,0.00011856785,0.00012328375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005701592,0.0001697937,0.00019345096,0.0008200145,0.00028372696,0.00067638315,0.00027663092,0.00031085344,0.0012857964],"category_scores_gemma":[0.0018204119,0.00011727979,0.00025857775,0.0011378798,0.0002732341,0.0004386864,0.00049080007,0.00026605747,0.00019891193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004103193,0.000008535374,0.9986525,0.000009387453,0.000013042637,0.00006595705,0.00005219568,0.000025063855,0.000052024185,0.000016264488,0.00017170527,0.0008924529],"study_design_scores_gemma":[0.000011371133,0.00005720762,0.9977017,0.000030651037,0.000021295207,0.0004486066,0.0006238017,0.00015826759,0.000039810006,0.00004354555,0.0008589233,0.0000047864373],"about_ca_topic_score_codex":0.010286602,"about_ca_topic_score_gemma":0.009937859,"teacher_disagreement_score":0.010286602,"about_ca_system_score_codex":0.00063550245,"about_ca_system_score_gemma":0.0004287084,"threshold_uncertainty_score":0.020453453},"labels":[],"label_agreement":null},{"id":"W4408956488","doi":"10.1093/oncolo/oyaf037","title":"Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ramucirumab; Medicine; Internal medicine; Hazard ratio; Cancer; Paclitaxel; Oncology; Progression-free survival; Chemotherapy; Confidence interval; Gastroenterology; Trastuzumab; Breast cancer","score_opus":0.021550344865278712,"score_gpt":0.30250303699927994,"score_spread":0.2809526921340012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408956488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99906665,0.0005444702,0.00002550995,0.000029321143,0.000009828014,0.00004416847,0.00007301362,0.0000027596184,0.00020419748],"genre_scores_gemma":[0.99906605,0.00029686923,0.000073088064,0.000114092654,0.000048717196,0.000039420003,0.00020157966,0.0000024700178,0.00015782144],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991844,0.00031580447,0.0000716557,0.00021234345,0.0001048701,0.000110940826],"domain_scores_gemma":[0.9984332,0.0003418984,0.0005605818,0.000117623735,0.00010040418,0.00044626356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013093563,0.0004194873,0.0012614923,0.00041585456,0.00052767707,0.0009606128,0.00045195615,0.000802976,0.0019212598],"category_scores_gemma":[0.0018851785,0.0004391556,0.0013495076,0.00059530296,0.0003104607,0.00067390304,0.00043023727,0.00084108685,0.00030570079],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034547806,0.004425764,0.9442455,0.00012624786,0.0010385991,0.0007018896,0.00030752036,0.00020990273,0.0012790395,0.000033481876,0.00037465736,0.01270964],"study_design_scores_gemma":[0.007655356,0.036369763,0.95011145,0.000048247384,0.0010586013,0.0017233087,0.00038677373,0.0009549726,0.00041451806,0.000036689904,0.001199282,0.00004100439],"about_ca_topic_score_codex":0.0023241232,"about_ca_topic_score_gemma":0.0034782423,"teacher_disagreement_score":0.0023241232,"about_ca_system_score_codex":0.0008789347,"about_ca_system_score_gemma":0.0008823079,"threshold_uncertainty_score":0.0069245696},"labels":[],"label_agreement":null},{"id":"W4409020486","doi":"10.1093/oncolo/oyaf047","title":"A pilot survey into the landscape of neuro-oncology care in the community","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Prisma Health; Sontag Foundation; Musella Foundation For Brain Tumor Research and Information","keywords":"Oncology; Internal medicine; Medicine; Radiation oncology; Neurosurgery; Radiation therapy; Psychiatry","score_opus":0.06771435790830291,"score_gpt":0.37338338053108944,"score_spread":0.3056690226227865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409020486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572206,0.00006324185,0.000115872936,0.0009682617,0.000010310842,0.00038830214,0.00044353487,0.000006323205,0.0022819596],"genre_scores_gemma":[0.9968266,0.00029376164,0.00063129835,0.0008576851,0.000014098151,0.00043790817,0.00031938107,0.0000044870085,0.00061473076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972402,0.0010548189,0.0002629626,0.0002000178,0.00047014302,0.00077186176],"domain_scores_gemma":[0.990202,0.0021611173,0.0014579371,0.00018610549,0.0033572502,0.0026356436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043501016,0.0001858249,0.00017621877,0.0009692518,0.0018972469,0.0012931796,0.0004489911,0.00070732174,0.0027258315],"category_scores_gemma":[0.009091114,0.00031021985,0.00020046557,0.0013856831,0.0009590453,0.0013846904,0.0014346363,0.0010591923,0.00040595303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013839433,0.00097089715,0.86793166,0.00031781633,0.000017809893,0.0009729554,0.0927988,0.00011504355,0.0012130394,0.00027812025,0.0073686177,0.02787677],"study_design_scores_gemma":[0.000040494975,0.0012367195,0.6656296,0.00022381211,0.0000090698295,0.0006100984,0.3213298,0.00059517636,0.00023223161,0.00012357463,0.009937648,0.000031775566],"about_ca_topic_score_codex":0.08549469,"about_ca_topic_score_gemma":0.12416216,"teacher_disagreement_score":0.08549469,"about_ca_system_score_codex":0.0036008062,"about_ca_system_score_gemma":0.0064400486,"threshold_uncertainty_score":0.16999412},"labels":[],"label_agreement":null},{"id":"W4409381469","doi":"10.1093/oncolo/oyaf039","title":"A scoping review of clinical communication in cancer care in Africa","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute on Aging","keywords":"Cancer; Medicine; Geography; Internal medicine","score_opus":0.7220950195418481,"score_gpt":0.6738918870880464,"score_spread":0.0482031324538017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409381469","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007392364,0.9959609,0.00032825337,0.0007737758,0.00034679333,0.00070495735,0.00016945385,0.000007813527,0.0009687378],"genre_scores_gemma":[0.0045908005,0.99269694,0.00088120793,0.00042200537,0.00010620951,0.0010277312,0.00014321797,0.000005021929,0.00012674693],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9810662,0.0076219994,0.007185694,0.00087125815,0.0027087107,0.00054608064],"domain_scores_gemma":[0.91229516,0.068371914,0.00981906,0.0010140758,0.007816829,0.00068296987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02244675,0.0021057804,0.0056546642,0.03222252,0.0024186852,0.0060431184,0.0025878192,0.0038364322,0.0057542035],"category_scores_gemma":[0.09993135,0.001420815,0.004618722,0.033275697,0.002035898,0.005607629,0.0034596848,0.0021207146,0.00067964045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082402155,0.000026456688,0.00043472878,0.8757724,0.00086078397,0.00021867857,0.0015916763,0.00013356886,0.0001700498,0.00105666,0.0034371093,0.11621547],"study_design_scores_gemma":[0.000014655536,0.000041452266,0.0006988332,0.9755011,0.0020522668,0.0001481083,0.0007205347,0.000034681994,0.0000613583,0.0002529094,0.020462954,0.000011108842],"about_ca_topic_score_codex":0.008626253,"about_ca_topic_score_gemma":0.020128096,"teacher_disagreement_score":0.03222252,"about_ca_system_score_codex":0.0071384045,"about_ca_system_score_gemma":0.034118243,"threshold_uncertainty_score":0.11871117},"labels":[],"label_agreement":null},{"id":"W4409773283","doi":"10.1093/oncolo/oyaf042","title":"Barriers to publishing early phase clinical trials: the oncologists’ perspective","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; BeiGene; AstraZeneca","keywords":"Publishing; Clinical trial; Thematic analysis; Medicine; Alternative medicine; Stakeholder; Family medicine; Medical education; Public relations; Qualitative research; Political science; Internal medicine; Pathology; Social science; Sociology; Law","score_opus":0.8139993364479226,"score_gpt":0.7198450436762328,"score_spread":0.09415429277168974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409773283","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14380175,0.022038877,0.011813424,0.79189295,0.0042627095,0.00051852735,0.00021349198,0.00020086265,0.025257388],"genre_scores_gemma":[0.8375991,0.019918378,0.0139427995,0.120261274,0.0037632133,0.00077325926,0.00017254353,0.0001988843,0.0033705428],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.58546203,0.3385375,0.02742069,0.006338647,0.03528953,0.0069514983],"domain_scores_gemma":[0.124407016,0.7456783,0.05583374,0.010279501,0.04545011,0.018351324],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.26902333,0.00043900099,0.0009278432,0.002430707,0.008934276,0.01900499,0.0036720831,0.009552738,0.0047174334],"category_scores_gemma":[0.5371028,0.0010794027,0.0010123994,0.004213317,0.012732936,0.014643627,0.009072961,0.012005896,0.001573946],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056295237,0.0004439037,0.04220203,0.010143755,0.00033136833,0.007297004,0.69374585,0.0006538999,0.002599922,0.030953359,0.087534875,0.12353116],"study_design_scores_gemma":[0.00030226164,0.0007603101,0.015194736,0.013083459,0.00023489422,0.006905697,0.49648526,0.0006390582,0.0019919754,0.026573874,0.4374531,0.00037541377],"about_ca_topic_score_codex":0.0024733548,"about_ca_topic_score_gemma":0.0020030178,"teacher_disagreement_score":0.7309767,"about_ca_system_score_codex":0.0074795512,"about_ca_system_score_gemma":0.032234564,"threshold_uncertainty_score":0.9014244},"labels":[],"label_agreement":null},{"id":"W4409773286","doi":"10.1093/oncolo/oyaf041","title":"Early phase trials: the perils of nonpublication","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phase (matter); Medicine; Chemistry","score_opus":0.9085590211274656,"score_gpt":0.6702365555577398,"score_spread":0.2383224655697258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409773286","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":"methods","domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0086129615,0.38903582,0.08799921,0.4477859,0.03680139,0.0044126837,0.0048201163,0.00076143263,0.019770555],"genre_scores_gemma":[0.2827058,0.14637211,0.15425874,0.320426,0.06956214,0.01422833,0.0020369436,0.0012159422,0.009194052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.27275968,0.62107575,0.044657994,0.012143367,0.047866814,0.0014964896],"domain_scores_gemma":[0.027656324,0.9028559,0.016614145,0.035502482,0.01582253,0.0015487015],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.6983583,0.0024537249,0.0134956725,0.008053047,0.0022220544,0.01652596,0.00800875,0.015070547,0.016001487],"category_scores_gemma":[0.8510756,0.0026020205,0.009368219,0.009949914,0.017466264,0.025227446,0.007884331,0.02370256,0.0030730811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02054895,0.00054283417,0.007775941,0.101764314,0.02631742,0.00036881384,0.0038781313,0.0017815914,0.000928779,0.15398526,0.16309664,0.51901126],"study_design_scores_gemma":[0.0165606,0.0028239596,0.011069212,0.11450497,0.015626274,0.001064213,0.0013631723,0.0062434333,0.0017959588,0.5285294,0.2998781,0.00054070476],"about_ca_topic_score_codex":0.0020444822,"about_ca_topic_score_gemma":0.0037454776,"teacher_disagreement_score":0.3016417,"about_ca_system_score_codex":0.0061556664,"about_ca_system_score_gemma":0.015236418,"threshold_uncertainty_score":0.37197798},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"reporting","study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch","scholarly_communication"],"domain":"reporting","study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W4409832437","doi":"10.1093/oncolo/oyaf038","title":"Medical accuracy of artificial intelligence chatbots in oncology: a scoping review","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Waterloo; University of Toronto","funders":"","keywords":"Readability; Workload; MEDLINE; Medicine; Oncology; Inclusion (mineral); Resource (disambiguation); Internal medicine; Medical education; Psychology; Computer science; Political science","score_opus":0.46755751671685275,"score_gpt":0.6145205468759336,"score_spread":0.14696303015908085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409832437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009977537,0.9959681,0.0006491901,0.0010303782,0.00019591853,0.00011934303,0.00015330613,0.000013940249,0.00087209657],"genre_scores_gemma":[0.029854247,0.96509147,0.0027016895,0.0011806646,0.0003387154,0.00041436887,0.00028230055,0.000022475013,0.00011398188],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9583088,0.018114094,0.0134513,0.0024434049,0.007201545,0.0004807935],"domain_scores_gemma":[0.4511041,0.5040052,0.021335835,0.0038438996,0.019172441,0.00053860666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.047946893,0.0011190563,0.004217464,0.022437587,0.0009928264,0.0062094377,0.0034460155,0.0035148119,0.0041431496],"category_scores_gemma":[0.31543523,0.0013990846,0.0049893404,0.014378301,0.0036368298,0.0065652756,0.0030768479,0.0022801657,0.0006063553],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029006737,0.0000606418,0.0043812636,0.62138414,0.0031495767,0.00018866397,0.0017816394,0.0007613701,0.00014535036,0.0024516499,0.003997854,0.36140773],"study_design_scores_gemma":[0.000051021863,0.00018722117,0.00561296,0.93793935,0.009769524,0.00065279374,0.0011119534,0.0006685363,0.0003907573,0.0019078364,0.041637573,0.000070411916],"about_ca_topic_score_codex":0.010094374,"about_ca_topic_score_gemma":0.010766189,"teacher_disagreement_score":0.047946893,"about_ca_system_score_codex":0.006149246,"about_ca_system_score_gemma":0.015341905,"threshold_uncertainty_score":0.25357038},"labels":[],"label_agreement":null},{"id":"W4409832439","doi":"10.1093/oncolo/oyaf078","title":"Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Microsatellite instability; Oncology; Medicine; Internal medicine; Cancer; Renal cell carcinoma; Multivariate analysis; Atezolizumab; Population; Somatic cell; Cancer research; Gene; Immunotherapy; Pembrolizumab; Biology; Genetics; Allele; Microsatellite","score_opus":0.019410682986549025,"score_gpt":0.28700022419236093,"score_spread":0.2675895412058119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409832439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99931335,0.00015257628,0.0001856907,0.000037864917,0.0000020135421,0.0000036393453,0.00017788557,0.0000033777355,0.00012348217],"genre_scores_gemma":[0.9994405,0.000043204982,0.00012596235,0.000010597382,0.0000038926073,0.0000036507104,0.0003366542,0.0000011528406,0.00003429442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99987507,0.000033449924,0.0000139688655,0.0000307157,0.000019982015,0.000026740525],"domain_scores_gemma":[0.99933654,0.00020030758,0.00023537445,0.000027508366,0.00006601419,0.00013419049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039429078,0.00019228285,0.00026898683,0.0005302585,0.00018438487,0.00041324086,0.00019730256,0.0002170774,0.00088995113],"category_scores_gemma":[0.0014428914,0.000083399114,0.00032433536,0.00050520245,0.00012387038,0.00018550943,0.00028491972,0.0004167602,0.00012684065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014667762,0.000017495087,0.9970632,0.000005331046,0.000026460237,0.000024697878,0.000007918745,0.00026528776,0.00031299613,0.0000096492,0.00007426083,0.0020459106],"study_design_scores_gemma":[0.000013924,0.00018981704,0.994294,0.000007657598,0.00007547679,0.00023091999,0.00007338121,0.004424481,0.00033368016,0.0000885425,0.00026473543,0.0000033688561],"about_ca_topic_score_codex":0.0016067383,"about_ca_topic_score_gemma":0.0022807026,"teacher_disagreement_score":0.0016067383,"about_ca_system_score_codex":0.00026474116,"about_ca_system_score_gemma":0.0003301581,"threshold_uncertainty_score":0.003194809},"labels":[],"label_agreement":null},{"id":"W4409966546","doi":"10.1093/oncolo/oyae373","title":"Examining the evolving landscape of kidney cancer mortality in the United States","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Demography; Ethnic group; Population; Medicine; Disease control; Cancer; Gerontology; Environmental health; Internal medicine","score_opus":0.07725012360541114,"score_gpt":0.35413357562602943,"score_spread":0.27688345202061826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409966546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96560794,0.005701451,0.0009159011,0.014979414,0.00010676853,0.00003087781,0.0077342866,0.00005137428,0.0048718373],"genre_scores_gemma":[0.99119157,0.0023234885,0.00073454075,0.0011835926,0.00014037741,0.00002626626,0.0041475715,0.000012379078,0.0002402416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990435,0.0003085828,0.00012388367,0.00016756791,0.00021369607,0.00014277578],"domain_scores_gemma":[0.9967494,0.0006487966,0.0013749767,0.00013172456,0.0007400768,0.00035501047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018999332,0.00014062674,0.00022590367,0.0019140308,0.00044905228,0.0012319502,0.00051652035,0.0003977667,0.0012371778],"category_scores_gemma":[0.005909141,0.00013642032,0.00041111672,0.0034125827,0.0003545521,0.001128043,0.0011412156,0.00070586486,0.00016298068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030776962,0.000025089927,0.9854511,0.000058835147,0.00006352073,0.000048490074,0.00028133186,0.0004086363,0.000108891654,0.00046758476,0.0027435904,0.010312074],"study_design_scores_gemma":[0.0000031174864,0.000033853634,0.9936047,0.0000629152,0.000028400536,0.000084600724,0.0011227913,0.0010548912,0.00007589738,0.0004188359,0.0035019054,0.000008173086],"about_ca_topic_score_codex":0.03302012,"about_ca_topic_score_gemma":0.060527597,"teacher_disagreement_score":0.03302012,"about_ca_system_score_codex":0.0012320763,"about_ca_system_score_gemma":0.0013716847,"threshold_uncertainty_score":0.06565583},"labels":[],"label_agreement":null},{"id":"W4410207760","doi":"10.1093/oncolo/oyae294","title":"Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case report","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Fibroblast growth factor receptor; Fibroblast growth factor receptor 2; Cancer research; Fibroblast growth factor receptor 3; Point mutation; Mutation; Tyrosine kinase; Receptor tyrosine kinase; Fibroblast growth factor receptor 4; Fibroblast growth factor; FGF19; Receptor Protein-Tyrosine Kinases; Receptor; Growth factor receptor; Cancer; Medicine; Biology; Internal medicine; Gene; Genetics","score_opus":0.01449751654793558,"score_gpt":0.2872989245128247,"score_spread":0.2728014079648891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410207760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98757464,0.0036857906,0.0012492209,0.0020960295,0.00010946642,0.0000792327,0.0001355091,0.000101148304,0.0049689366],"genre_scores_gemma":[0.9951139,0.0013346268,0.0007535031,0.0008326611,0.00030177916,0.000014177874,0.000094073344,0.000033397424,0.0015218061],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99945205,0.0000736672,0.000074969,0.00015930137,0.00009078494,0.00014920149],"domain_scores_gemma":[0.9989863,0.00035266794,0.00016131054,0.000100982725,0.000054561773,0.00034410844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030136044,0.0010816787,0.0012726579,0.0013289117,0.0014752053,0.001033215,0.00069111824,0.004133709,0.0014873276],"category_scores_gemma":[0.0016284597,0.00061090314,0.0015543981,0.00068225386,0.0012738773,0.0009753527,0.00073240214,0.0019549374,0.00043035828],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102972546,0.00007216598,0.0045946734,0.000020914755,0.000019111254,0.99148893,0.00013642841,0.000059372313,0.001329642,0.0000605826,0.00010161305,0.0020136086],"study_design_scores_gemma":[0.000025073796,0.00021881386,0.003683157,0.0000047014823,0.00004302459,0.9939387,0.000056175682,0.0002515853,0.0013105138,0.000044554385,0.00040939735,0.000014328876],"about_ca_topic_score_codex":0.0018578026,"about_ca_topic_score_gemma":0.0021112172,"teacher_disagreement_score":0.004133709,"about_ca_system_score_codex":0.0010672489,"about_ca_system_score_gemma":0.00047690098,"threshold_uncertainty_score":0.007743478},"labels":[],"label_agreement":null},{"id":"W4410312427","doi":"10.1093/oncolo/oyaf048","title":"Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; Astellas Pharma; Oncolytics Biotech; Eisai; Les Laboratories Pierre Fabre; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; F. Hoffmann-La Roche; Chugai Pharmaceutical; Seagen; Roche; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Internal medicine; Trastuzumab; Chemotherapy; Oncology; Hazard ratio; Adverse effect; Quality of life (healthcare); Cohort; Cancer; Breast cancer; Confidence interval","score_opus":0.016821581969634323,"score_gpt":0.3043310066982524,"score_spread":0.28750942472861807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410312427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778986,0.0014704133,0.00005791861,0.00011517909,0.000020509964,0.00004570641,0.00017606837,0.0000029189748,0.0003214531],"genre_scores_gemma":[0.9990282,0.0003426179,0.00006442605,0.00009220652,0.00004428516,0.00005858136,0.00026430373,0.0000010039917,0.00010440927],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99900466,0.0006693366,0.00004957453,0.0000889586,0.000098233795,0.000089312736],"domain_scores_gemma":[0.997934,0.0008710149,0.00072335324,0.000068186215,0.00006181556,0.00034170155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027847532,0.00038775158,0.0008575395,0.00022271219,0.00016417903,0.00054682477,0.00033454128,0.00052289874,0.0015455444],"category_scores_gemma":[0.0023037218,0.00011571095,0.0013926214,0.00031272433,0.0003563484,0.00035317437,0.00032770674,0.00089104223,0.000111325426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81696826,0.0054151122,0.114173435,0.00056439923,0.0029719465,0.000102555416,0.00012905526,0.0026831343,0.0020795367,0.00012905072,0.001039938,0.05374351],"study_design_scores_gemma":[0.18596631,0.34763363,0.4484655,0.00019282308,0.0052856077,0.0004453038,0.00019332815,0.005788445,0.002937492,0.0005327937,0.0024962276,0.00006259368],"about_ca_topic_score_codex":0.00051672105,"about_ca_topic_score_gemma":0.0008057914,"teacher_disagreement_score":0.0027847532,"about_ca_system_score_codex":0.000642065,"about_ca_system_score_gemma":0.00046033307,"threshold_uncertainty_score":0.014727414},"labels":[],"label_agreement":null},{"id":"W4410794359","doi":"10.1093/oncolo/oyaf112","title":"Concordance with SPIRIT-AI guidelines in reporting of randomized controlled trial protocols investigating artificial intelligence in oncology: a systematic review","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Concordance; Randomized controlled trial; Medicine; Medical physics; Psychology; Oncology; Internal medicine","score_opus":0.4402670868586655,"score_gpt":0.5935877669692967,"score_spread":0.1533206801106312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410794359","genre_codex":"review","genre_gemma":"review","domain_codex":"methods","domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013759853,0.4866369,0.103356905,0.027331986,0.009869995,0.32856736,0.02029846,0.0018202559,0.008358275],"genre_scores_gemma":[0.08200725,0.08046424,0.21960069,0.010398809,0.0009858322,0.59907544,0.00596333,0.0004985274,0.0010059301],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.12464029,0.4678061,0.34992737,0.015734259,0.040154286,0.0017376958],"domain_scores_gemma":[0.078516245,0.6701662,0.11528993,0.05399943,0.079736,0.0022921767],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.66650003,0.0030258477,0.018726215,0.021937057,0.0046672197,0.013688313,0.009963494,0.011000786,0.0069171633],"category_scores_gemma":[0.85522574,0.0059520025,0.025065383,0.026166588,0.01052687,0.015621827,0.009644286,0.0075548557,0.0021547743],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008970263,0.00008300473,0.0038751664,0.9013329,0.019739097,0.00012672824,0.0047887457,0.00061094743,0.00027892936,0.0040415972,0.01100626,0.053219568],"study_design_scores_gemma":[0.0022918102,0.00032549558,0.004643145,0.9388831,0.01775398,0.00017589556,0.0012084462,0.0011701828,0.0005725218,0.0052290657,0.02752944,0.0002169385],"about_ca_topic_score_codex":0.0057283184,"about_ca_topic_score_gemma":0.010314597,"teacher_disagreement_score":0.33349997,"about_ca_system_score_codex":0.018917497,"about_ca_system_score_gemma":0.0530923,"threshold_uncertainty_score":0.4112649},"labels":[],"label_agreement":null},{"id":"W4411224532","doi":"10.1093/oncolo/oyaf165","title":"The association of health care contact days with economic measures in the CCTG LY.12 trial","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Canadian Cancer Society; Queen's University","funders":"Canadian Cancer Society Research Institute; Arnold Ventures; Eli Lilly and Company; Eli Lilly Canada; Incyte; Amgen","keywords":"Association (psychology); Psychology; Gerontology; Health care; Demography; Medicine; Political science; Psychotherapist; Sociology","score_opus":0.035996157980590235,"score_gpt":0.28564672313740347,"score_spread":0.24965056515681322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411224532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.928529,0.035728417,0.002436441,0.007966954,0.0010696881,0.0019176011,0.010115708,0.00018458994,0.012051489],"genre_scores_gemma":[0.9889607,0.0017017134,0.0010088291,0.0012071904,0.00038705044,0.002039411,0.003361736,0.000039853185,0.0012935598],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.978211,0.017883984,0.0009904167,0.00092248654,0.0011085997,0.000883554],"domain_scores_gemma":[0.9617893,0.02395736,0.009033906,0.0016277486,0.0013300001,0.0022616903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01594074,0.0010117177,0.0035047207,0.00069338136,0.0005974176,0.0021012193,0.0008134899,0.0021433257,0.005920056],"category_scores_gemma":[0.04933646,0.0004226547,0.0029073586,0.0018016058,0.0010780914,0.0021591738,0.00090414827,0.005026632,0.00052542856],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8071378,0.002001769,0.08430413,0.0058650305,0.017135078,0.000179222,0.00017638486,0.003990762,0.0003679996,0.002105955,0.019234717,0.057501175],"study_design_scores_gemma":[0.4800171,0.06410759,0.38082242,0.0040219,0.022830792,0.0007652241,0.00036810743,0.020964343,0.00092905463,0.010453642,0.014388699,0.00033101861],"about_ca_topic_score_codex":0.0027776605,"about_ca_topic_score_gemma":0.004433704,"teacher_disagreement_score":0.01594074,"about_ca_system_score_codex":0.0014851424,"about_ca_system_score_gemma":0.0022013988,"threshold_uncertainty_score":0.08430368},"labels":[],"label_agreement":null},{"id":"W4411857643","doi":"10.1093/oncolo/oyaf194","title":"Mitigation and management of adverse events associated with amivantamab therapy","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Johnson and Johnson","keywords":"Medicine; Erlotinib; Adverse effect; Rash; Oncology; Internal medicine; Epidermal growth factor receptor; Hypoalbuminemia; Chemotherapy; Paronychia; Gefitinib; Targeted therapy; Cancer; Dermatology","score_opus":0.036916925977640534,"score_gpt":0.40258748234630176,"score_spread":0.36567055636866125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411857643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.300567,0.34693176,0.14707105,0.04605956,0.003823841,0.0035425255,0.0006522148,0.0023836014,0.14896846],"genre_scores_gemma":[0.79243803,0.102244,0.07326152,0.010854252,0.0029661974,0.0013259527,0.0006902271,0.00014721537,0.016072553],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986185,0.00057988084,0.00020524503,0.0000727501,0.00044109244,0.000082589635],"domain_scores_gemma":[0.9984725,0.00037122093,0.00057187397,0.000060793955,0.00038121518,0.00014232924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016159166,0.00028399978,0.00054828456,0.0003860163,0.00040462572,0.0007993977,0.0004977168,0.0006684471,0.0016613384],"category_scores_gemma":[0.0049054218,0.000092059534,0.00048760697,0.00021065054,0.00019592448,0.00054085325,0.00043802516,0.0013588099,0.0005929303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066139025,0.0006133906,0.013566066,0.0014751526,0.00019260113,0.0023234456,0.00040652594,0.0015431494,0.0121473875,0.0026396308,0.02728164,0.9371497],"study_design_scores_gemma":[0.00074001704,0.0088162385,0.08226497,0.004670032,0.00059114874,0.030341307,0.0008468396,0.0088104475,0.044314142,0.008103308,0.8103657,0.00013594501],"about_ca_topic_score_codex":0.00038409667,"about_ca_topic_score_gemma":0.00093088974,"teacher_disagreement_score":0.0016613384,"about_ca_system_score_codex":0.00042967353,"about_ca_system_score_gemma":0.0009078922,"threshold_uncertainty_score":0.008545876},"labels":[],"label_agreement":null},{"id":"W4412124266","doi":"10.1093/oncolo/oyaf145","title":"Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind?","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lagging; Immune system; Computer science; Cancer research; Medicine; Immunology; Pathology","score_opus":0.026379924789962164,"score_gpt":0.297026984113279,"score_spread":0.27064705932331684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412124266","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009425864,0.10547464,0.0013603051,0.8647818,0.023186466,0.000025447043,0.0000965562,0.000095449315,0.0040367534],"genre_scores_gemma":[0.022766793,0.16028605,0.00430473,0.7452097,0.05795634,0.00011267287,0.0001643952,0.00021236192,0.008986968],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.98626816,0.00522055,0.0010559383,0.0014449297,0.0041334205,0.0018771285],"domain_scores_gemma":[0.9425038,0.030276319,0.0038652136,0.0017381125,0.011463314,0.010153314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.036690805,0.0013872181,0.005139952,0.0016390831,0.0056599593,0.015248988,0.0032455933,0.016059237,0.022104764],"category_scores_gemma":[0.05001768,0.0008280614,0.0022201259,0.0012137452,0.0138104055,0.03477427,0.0075273803,0.048319105,0.010787005],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010153713,0.0003812468,0.0018650966,0.0019701216,0.00040733843,0.00045510172,0.00096918055,0.00039315966,0.0012559316,0.0397923,0.7165159,0.23497917],"study_design_scores_gemma":[0.0005681423,0.0010216765,0.001535732,0.005145917,0.0004178732,0.0005960091,0.003524671,0.00067785906,0.0007912722,0.112445414,0.87293965,0.0003357581],"about_ca_topic_score_codex":0.0038574336,"about_ca_topic_score_gemma":0.009757131,"teacher_disagreement_score":0.036690805,"about_ca_system_score_codex":0.0040742317,"about_ca_system_score_gemma":0.013301115,"threshold_uncertainty_score":0.19404185},"labels":[],"label_agreement":null},{"id":"W4412486974","doi":"10.1093/oncolo/oyaf205","title":"Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"Qatar National Library; Qatar University","keywords":"Breast cancer; Frameshift mutation; Germline mutation; PTEN; Missense mutation; Genetics; Middle East; Cancer; Mutation; Medicine; Biology; Oncology; Gene; PI3K/AKT/mTOR pathway; Geography","score_opus":0.05731158232819013,"score_gpt":0.3238971773419466,"score_spread":0.2665855950137565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412486974","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007960682,0.98937035,0.00007532059,0.00019922,0.00004589254,0.00008738175,0.0019356053,0.000005223904,0.00032034537],"genre_scores_gemma":[0.06993855,0.9274501,0.00042021123,0.0005409693,0.000051425486,0.00021001787,0.001292433,0.00000515726,0.000091055284],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9977131,0.00047286935,0.0010969066,0.00030352199,0.00030699236,0.00010654177],"domain_scores_gemma":[0.9911679,0.00564169,0.0022540581,0.00016279607,0.0006626477,0.00011092328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023059864,0.00064073305,0.00317755,0.008026836,0.00037789502,0.0009982483,0.0009859176,0.00081204885,0.0024801712],"category_scores_gemma":[0.011362758,0.0004486897,0.0024539218,0.009980139,0.0005069845,0.0009535295,0.0007937472,0.0003548764,0.0001796427],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038942913,0.00001822453,0.020790532,0.87419546,0.010885607,0.0007653629,0.0005737852,0.00017291281,0.0006019156,0.00029804884,0.0046886443,0.086620174],"study_design_scores_gemma":[0.00026297168,0.0002369122,0.0912236,0.7888806,0.06267073,0.004369171,0.0011955436,0.0001121777,0.0005368691,0.00034770044,0.050095983,0.000067801884],"about_ca_topic_score_codex":0.0063188868,"about_ca_topic_score_gemma":0.018528255,"teacher_disagreement_score":0.008026836,"about_ca_system_score_codex":0.0010762074,"about_ca_system_score_gemma":0.0034166963,"threshold_uncertainty_score":0.012564242},"labels":[],"label_agreement":null},{"id":"W4412821387","doi":"10.1093/oncolo/oyaf199","title":"A blueprint for creating an early-onset colorectal cancer program based on experiences from seven clinical centers across the United States and Canada","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Research in Immunology and Cancer; Fraser Health; Occupational Cancer Research Centre","funders":"National Cancer Institute","keywords":"Blueprint; Population; Guideline; Best practice; Process (computing); Medicine; Medical education; Process management; Political science; Computer science; Business; Engineering; Environmental health","score_opus":0.040927114267063865,"score_gpt":0.4009032914234042,"score_spread":0.35997617715634034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412821387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8337592,0.002632444,0.014535754,0.11154313,0.00081927376,0.0055661174,0.0002677825,0.00024917573,0.030627059],"genre_scores_gemma":[0.93089473,0.0023594347,0.045771237,0.01073897,0.00006707054,0.0022959067,0.00019388412,0.00010201436,0.0075768284],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9546499,0.030816104,0.001086519,0.0012344752,0.005164712,0.0070483657],"domain_scores_gemma":[0.9079276,0.030689374,0.004017738,0.0017524918,0.022751804,0.03286101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04123839,0.0007658537,0.00065009494,0.0019042686,0.030309988,0.0095595075,0.0047247102,0.0026043877,0.0022895662],"category_scores_gemma":[0.03540752,0.0007075962,0.0005041271,0.002416867,0.012078551,0.0031748249,0.010329834,0.006729922,0.0003144014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083039435,0.00073063176,0.016772097,0.0009399628,0.00002160659,0.0021476713,0.8833563,0.0005223268,0.0018602879,0.005633388,0.019391717,0.06854096],"study_design_scores_gemma":[0.000021954524,0.00015455566,0.0054149567,0.00064569706,0.000009865507,0.00017317255,0.9612876,0.00030177672,0.00043624724,0.0005760562,0.030922694,0.000055367644],"about_ca_topic_score_codex":0.64138454,"about_ca_topic_score_gemma":0.8657446,"teacher_disagreement_score":0.35861546,"about_ca_system_score_codex":0.09603348,"about_ca_system_score_gemma":0.3262738,"threshold_uncertainty_score":0.72145486},"labels":[],"label_agreement":null},{"id":"W4412902428","doi":"10.1093/oncolo/oyaf240","title":"Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; London Health Sciences Centre; McGill University Health Centre; University of Ottawa; Western University; University of Toronto; SAIT Polytechnic; Sunnybrook Health Science Centre; McMaster University Medical Centre; Ottawa Hospital; CancerCare Manitoba; Hôtel-Dieu de Québec; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Alberta; Queen Elizabeth II Health Sciences Centre; University of Calgary","funders":"AstraZeneca","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Clinical endpoint; Cabozantinib; Adverse effect; Gastroenterology; Oncology; Clinical trial; Urology","score_opus":0.10093807808990458,"score_gpt":0.4306932863931999,"score_spread":0.32975520830329536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412902428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440753,0.0011582054,0.00031222557,0.00012668558,0.000009187537,0.000050955765,0.0031087666,0.000016896824,0.0008094878],"genre_scores_gemma":[0.99791306,0.00010895628,0.00017437318,0.000020387039,0.000009604584,0.000024848732,0.001704927,0.0000019729264,0.00004170454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972893,0.0010829312,0.00026024043,0.00043755065,0.00073560915,0.00019427713],"domain_scores_gemma":[0.9817693,0.0043788888,0.010826273,0.0006163358,0.0017173012,0.00069186155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046139304,0.0002488984,0.00057714916,0.00083566894,0.0003059419,0.0010321169,0.0005274797,0.00042594832,0.0008618589],"category_scores_gemma":[0.013873535,0.00010303971,0.0006901977,0.0013669522,0.00043130698,0.00063661305,0.00048323467,0.0005373808,0.00016199514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013903097,0.000068722286,0.9862752,0.00009090107,0.0003089,0.000041442763,0.000073413845,0.0015567522,0.00014779798,0.000037630714,0.00039999624,0.009609056],"study_design_scores_gemma":[0.000031289965,0.00045031577,0.9966356,0.000017918861,0.000095100426,0.00014192589,0.00005584256,0.001820288,0.00019834416,0.000055241155,0.00048560274,0.000012593985],"about_ca_topic_score_codex":0.014356294,"about_ca_topic_score_gemma":0.016014699,"teacher_disagreement_score":0.014356294,"about_ca_system_score_codex":0.0029984673,"about_ca_system_score_gemma":0.0012287245,"threshold_uncertainty_score":0.02854544},"labels":[],"label_agreement":null},{"id":"W4413111649","doi":"10.1093/oncolo/oyaf206","title":"The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Merck","keywords":"Medicine; Von Hippel–Lindau disease; General surgery; Internal medicine; Disease","score_opus":0.018821159336587567,"score_gpt":0.3029010784945106,"score_spread":0.284079919157923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413111649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981566,0.00021929629,0.00002164486,0.00013557562,0.0000041677636,0.0000107301385,0.00075818185,0.0000019295035,0.00069181825],"genre_scores_gemma":[0.9991892,0.00016809751,0.000031795324,0.00008381587,0.000006856936,0.000011627568,0.00042713658,8.4460515e-7,0.00008048665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995241,0.00015208527,0.00006977708,0.0000674238,0.00007738549,0.000109283195],"domain_scores_gemma":[0.9982494,0.0002558871,0.0009893021,0.000044447515,0.00010794266,0.00035306392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007075324,0.00017269107,0.00021257153,0.0007106528,0.00040741617,0.00053018675,0.00023247705,0.00042050343,0.0012716794],"category_scores_gemma":[0.0018680779,0.00015329862,0.0003074428,0.0010487309,0.00028741857,0.00057388784,0.00048916583,0.00045781117,0.00019213404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021571987,0.000019279883,0.99923253,0.000005347982,0.0000115174535,0.000029954279,0.00007231029,0.000015917658,0.00002321463,0.0000042846286,0.0000952996,0.00046869647],"study_design_scores_gemma":[0.000002875619,0.000068421636,0.9991492,0.0000058190176,0.000008576502,0.00015357565,0.00037864607,0.000041469673,0.000011692341,0.0000046086866,0.00017265821,0.0000024154642],"about_ca_topic_score_codex":0.006259919,"about_ca_topic_score_gemma":0.008543523,"teacher_disagreement_score":0.006259919,"about_ca_system_score_codex":0.00034181587,"about_ca_system_score_gemma":0.0002975749,"threshold_uncertainty_score":0.01244694},"labels":[],"label_agreement":null},{"id":"W4413452415","doi":"10.1093/oncolo/oyaf254","title":"Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fondazione Pezcoller; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute","keywords":"Meta-analysis; Renal cell carcinoma; Biomarker; Medicine; Oncology; Carcinoma; Internal medicine; Pathology; Biology","score_opus":0.07410309311643436,"score_gpt":0.37130033521145683,"score_spread":0.29719724209502246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413452415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0073858667,0.9908619,0.00048272277,0.00018489997,0.00012229152,0.00022552154,0.00054473284,0.000021164553,0.00017091044],"genre_scores_gemma":[0.27128473,0.72192425,0.0027352718,0.00076152023,0.00033560503,0.0015789497,0.001047401,0.000027469463,0.0003048439],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98965645,0.0054717404,0.0023790267,0.0011623534,0.0010258458,0.00030465424],"domain_scores_gemma":[0.9750054,0.01860592,0.0039268974,0.0006098056,0.0015266767,0.00032532887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013192284,0.0022437763,0.0199787,0.0062920954,0.0006591857,0.0025573508,0.0024428696,0.0021368922,0.0030620887],"category_scores_gemma":[0.029688245,0.0012625139,0.032956216,0.009603387,0.000724477,0.0015912305,0.0013365059,0.0014120579,0.00027805907],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021348428,0.000030006086,0.010781074,0.31102067,0.66534615,0.00016370625,0.00007012819,0.00069336925,0.00018915787,0.00008789975,0.0005942806,0.008888806],"study_design_scores_gemma":[0.0005537353,0.00019779603,0.00546965,0.01532561,0.97698635,0.00010920147,0.000032065025,0.00023816267,0.000082518,0.0001069953,0.0008766894,0.00002129911],"about_ca_topic_score_codex":0.005769495,"about_ca_topic_score_gemma":0.013014456,"teacher_disagreement_score":0.0199787,"about_ca_system_score_codex":0.0022126818,"about_ca_system_score_gemma":0.0037304992,"threshold_uncertainty_score":0.06976831},"labels":[],"label_agreement":null},{"id":"W4413825040","doi":"10.1093/oncolo/oyaf248.043","title":"IUC24358-87 Prognostic assessment of the Meet-URO score compared with the IMDC score in metastatic renal cell carcinoma (mRCC) receiving first-line systemic therapies (Meet-URO 33 study)","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Oncology; Urology","score_opus":0.05024075417160601,"score_gpt":0.3132272801309929,"score_spread":0.2629865259593869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413825040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995924,0.00089982327,0.0002500786,0.000055083492,0.000019406178,0.000057442096,0.0021360766,0.000008703215,0.0006495707],"genre_scores_gemma":[0.99639374,0.00013673445,0.0002398348,0.000029390932,0.000035192243,0.00005484606,0.0028674072,0.000004417522,0.000238425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987287,0.0006442572,0.00013153578,0.00018994098,0.00018671858,0.00011884945],"domain_scores_gemma":[0.99743146,0.0003510238,0.0012310754,0.00017260153,0.0003074837,0.00050633063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021935876,0.00048154368,0.0009831641,0.00069846463,0.00026158508,0.00095146074,0.00048918405,0.0004341106,0.0017482835],"category_scores_gemma":[0.0027118733,0.00017282976,0.0010899081,0.0011159393,0.00024646302,0.0004640542,0.0008345438,0.0004959189,0.00044538587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009582058,0.00016502022,0.9809647,0.00010394363,0.00048100326,0.00003246851,0.000026507963,0.00034766953,0.00061796774,0.000046810826,0.0007536416,0.0068780794],"study_design_scores_gemma":[0.00068215746,0.0044580316,0.9911662,0.000033754997,0.0004238582,0.00020177156,0.00006879357,0.0014018732,0.00044337937,0.00006495962,0.0010366633,0.000018606272],"about_ca_topic_score_codex":0.0008797169,"about_ca_topic_score_gemma":0.0013143972,"teacher_disagreement_score":0.0021935876,"about_ca_system_score_codex":0.00032308887,"about_ca_system_score_gemma":0.0002992652,"threshold_uncertainty_score":0.011600912},"labels":[],"label_agreement":null},{"id":"W4414370371","doi":"10.1093/oncolo/oyaf279","title":"Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Toxicity; Prostate cancer; Clinical trial; Overall survival; Cancer; Radiation therapy","score_opus":0.5622597241237566,"score_gpt":0.6116115389324049,"score_spread":0.049351814808648364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414370371","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69276756,0.06680135,0.19196767,0.0021091523,0.00070434966,0.025963698,0.008383982,0.00068184856,0.010620458],"genre_scores_gemma":[0.9493404,0.0021574823,0.035393227,0.00041767463,0.00014438084,0.009669907,0.0023325353,0.000071705756,0.0004726737],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.78725886,0.18256938,0.015850803,0.003540479,0.009922306,0.0008580691],"domain_scores_gemma":[0.7871808,0.17312813,0.028458562,0.0050193532,0.0051004756,0.0011127541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.18417928,0.0021878153,0.004347434,0.0053626015,0.00040392333,0.0021343995,0.0009527167,0.00072870916,0.0030071752],"category_scores_gemma":[0.19425052,0.000569871,0.010363573,0.0041158237,0.0010814237,0.002150408,0.0027147364,0.0015757146,0.00021740924],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20395812,0.0017404399,0.14468026,0.023816915,0.17303945,0.00040167785,0.00068578124,0.1289128,0.007045828,0.008780185,0.0055488325,0.30138978],"study_design_scores_gemma":[0.051557086,0.1516497,0.2401913,0.0038616369,0.10668346,0.0013461288,0.00064645184,0.36286208,0.009407541,0.043509934,0.027754432,0.0005303316],"about_ca_topic_score_codex":0.00046480462,"about_ca_topic_score_gemma":0.0005926608,"teacher_disagreement_score":0.18417928,"about_ca_system_score_codex":0.0018483909,"about_ca_system_score_gemma":0.0019678946,"threshold_uncertainty_score":0.97404474},"labels":[],"label_agreement":null},{"id":"W4414379673","doi":"10.1093/oncolo/oyaf270","title":"Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec à Montréal","funders":"Genentech; Servier; European Society for Medical Oncology; Eisai; Verastem Oncology; Clovis Oncology; Astellas Pharma; Novocure; Regeneron Pharmaceuticals; Amgen; Mereo BioPharma; Pfizer; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Mersana Therapeutics; PTC Therapeutics; GlaxoSmithKline","keywords":"Clinical trial; Ovarian cancer; Immunotherapy; Bevacizumab; PARP inhibitor; Phases of clinical research; Poly ADP ribose polymerase","score_opus":0.2927783521745961,"score_gpt":0.5819201111673444,"score_spread":0.28914175899274835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414379673","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22523865,0.67627406,0.0029814881,0.0067498568,0.0024186552,0.051387582,0.01291623,0.00046281778,0.021570679],"genre_scores_gemma":[0.59715587,0.31040052,0.009748241,0.012320503,0.0010273345,0.047265794,0.012467258,0.00013039299,0.0094840545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982565,0.0009588092,0.00032409737,0.0001695515,0.00017592288,0.00011520538],"domain_scores_gemma":[0.9973883,0.0009922986,0.000984938,0.000101880425,0.00029282176,0.00023970677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005413538,0.0007934773,0.0026652187,0.00090397714,0.00040090026,0.001707739,0.0010078821,0.001532871,0.008280955],"category_scores_gemma":[0.0071111456,0.00033443066,0.0038720511,0.0012005274,0.00047684053,0.0009879369,0.00051827927,0.00186836,0.0007469556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41286048,0.0052887523,0.0040288484,0.2060285,0.031135049,0.0005661261,0.00041645882,0.001784857,0.01219782,0.0019079125,0.02043703,0.30334818],"study_design_scores_gemma":[0.7444893,0.08929599,0.0115739135,0.030349808,0.04095619,0.0011067438,0.00025206865,0.0011520069,0.0040666107,0.0024236732,0.07423354,0.0001001854],"about_ca_topic_score_codex":0.00080634025,"about_ca_topic_score_gemma":0.0034707184,"teacher_disagreement_score":0.008280955,"about_ca_system_score_codex":0.0016078133,"about_ca_system_score_gemma":0.0028765409,"threshold_uncertainty_score":0.02862984},"labels":[],"label_agreement":null},{"id":"W4414606428","doi":"10.1093/oncolo/oyaf326","title":"An asynchronous electronic consent for improving consent in research among patients with cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; BC Cancer Agency","funders":"Canadian Institutes of Health Research; BC Cancer Foundation","keywords":"Cancer; Informed consent; Comprehension; Asynchronous communication; Work (physics); MEDLINE","score_opus":0.439706837222243,"score_gpt":0.6190294803774716,"score_spread":0.1793226431552286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414606428","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37301597,0.0040723765,0.38045874,0.07301544,0.0025853147,0.059209533,0.0011766104,0.0033730646,0.10309289],"genre_scores_gemma":[0.47103065,0.0026942068,0.47713104,0.010731844,0.000992272,0.031728126,0.00046672163,0.00024107349,0.0049841073],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.8157612,0.16616702,0.009784788,0.0018074767,0.004984265,0.0014951441],"domain_scores_gemma":[0.6463535,0.271738,0.02694829,0.029679662,0.015195873,0.010084605],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.14353743,0.00060816,0.0004804133,0.001501644,0.0023912168,0.003810602,0.0018766839,0.002093467,0.01220313],"category_scores_gemma":[0.25803876,0.000500777,0.0009932432,0.0010598768,0.0026265837,0.006053338,0.0072137415,0.0032477907,0.0034673987],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024244413,0.0026424623,0.033521794,0.004318525,0.00009443529,0.001698867,0.04536001,0.0010298555,0.00700123,0.015111319,0.04415942,0.84263766],"study_design_scores_gemma":[0.005529886,0.014359165,0.11955867,0.019369913,0.00047410018,0.012402447,0.0656222,0.01379059,0.022700803,0.0870611,0.6381429,0.0009883074],"about_ca_topic_score_codex":0.00027410974,"about_ca_topic_score_gemma":0.00070594595,"teacher_disagreement_score":0.8564626,"about_ca_system_score_codex":0.0015576918,"about_ca_system_score_gemma":0.00686647,"threshold_uncertainty_score":0.7591076},"labels":[],"label_agreement":null},{"id":"W4414609202","doi":"10.1093/oncolo/oyaf323","title":"Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Eisai; Regeneron Pharmaceuticals; Exelixis; GlaxoSmithKline; Massachusetts General Hospital; AstraZeneca; Université de Montréal; Bristol-Myers Squibb; Amgen","keywords":"Melanoma; Duration (music); Metastatic melanoma; Clinical trial; Radiation therapy; Cancer","score_opus":0.048488152527462865,"score_gpt":0.4062268393784344,"score_spread":0.35773868685097154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414609202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723226,0.0019585812,0.00010295001,0.000036190133,0.0000041116746,0.000013176959,0.000054920543,0.000005578778,0.00059208256],"genre_scores_gemma":[0.9996307,0.0001787225,0.000056976674,0.000018185188,0.000007384895,0.0000049100126,0.00004979139,8.637898e-7,0.000052454445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997702,0.00007808733,0.00001955062,0.000056504516,0.00004462992,0.00003107421],"domain_scores_gemma":[0.9991358,0.00024972993,0.00035198714,0.000051733132,0.000054135468,0.00015663855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082459924,0.000119844015,0.00030463593,0.00017554578,0.00015391466,0.0002654924,0.00011769687,0.00017579351,0.001367176],"category_scores_gemma":[0.0013442975,0.000069362715,0.0002931623,0.00019764582,0.00015037587,0.00022787268,0.00017975339,0.00027338913,0.0001100051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014131455,0.00043647186,0.8463299,0.00023572537,0.00037022683,0.00049999956,0.00014070852,0.001139418,0.0232655,0.00009534772,0.00039137513,0.11296387],"study_design_scores_gemma":[0.0003759512,0.012764975,0.97783476,0.00004884943,0.00039133456,0.0018696022,0.00009159644,0.0010508341,0.0035331887,0.00009808223,0.0019308003,0.000009968558],"about_ca_topic_score_codex":0.00038427414,"about_ca_topic_score_gemma":0.0010065531,"teacher_disagreement_score":0.001367176,"about_ca_system_score_codex":0.00028766008,"about_ca_system_score_gemma":0.00022739651,"threshold_uncertainty_score":0.004573703},"labels":[],"label_agreement":null},{"id":"W4414857438","doi":"10.1093/oncolo/oyaf330","title":"Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"Daiichi Sankyo Europe; U.S. Food and Drug Administration; Celgene; MorphoSys; Gilead Sciences; Kite Pharma; Incyte; BeiGene; TG Therapeutics; Seagen; Karyopharm Therapeutics; AstraZeneca","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Standard of care; Salvage therapy; Clinical trial","score_opus":0.02572095470819502,"score_gpt":0.3219684897978651,"score_spread":0.29624753508967006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414857438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904497,0.00068035896,0.00006110823,0.00017670738,0.0000116406745,0.00013732577,0.0073511573,0.000007866767,0.0011239855],"genre_scores_gemma":[0.9885771,0.0006596424,0.00022532405,0.0003461418,0.000026918153,0.000099727535,0.009607273,0.00000837269,0.0004494275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861157,0.0001214665,0.00008801065,0.00028474987,0.00041505723,0.0004791241],"domain_scores_gemma":[0.99771774,0.00011263887,0.00080492796,0.00015715441,0.00073629786,0.00047120097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092805503,0.00078401563,0.0007973504,0.0012373339,0.0022494616,0.0010323796,0.001623631,0.0005412506,0.0014513598],"category_scores_gemma":[0.0018266218,0.0004373315,0.0011149703,0.0041345493,0.00062989636,0.00033908288,0.0010733743,0.0007565648,0.00021795799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008189631,0.00011820936,0.9924777,0.00009986175,0.000305449,0.00016146337,0.00033742786,0.00015118762,0.00031969202,0.000082209466,0.0017153872,0.0034124001],"study_design_scores_gemma":[0.00013280283,0.00017301702,0.9964142,0.00003985996,0.00015558832,0.00020726825,0.00069304585,0.00020792714,0.00008082014,0.000020133866,0.0018527501,0.000022509175],"about_ca_topic_score_codex":0.94813454,"about_ca_topic_score_gemma":0.96847814,"teacher_disagreement_score":0.05186546,"about_ca_system_score_codex":0.025847903,"about_ca_system_score_gemma":0.02577343,"threshold_uncertainty_score":0.18754053},"labels":[],"label_agreement":null},{"id":"W4414857553","doi":"10.1093/oncolo/oyaf327","title":"Pathomic immune biomarkers define recurrence risk in early-stage melanoma","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Columbia College","funders":"National Cancer Institute; National Institutes of Health","keywords":"Melanoma; Immune system; Disease; Stage (stratigraphy); Prospective cohort study; Biomarker","score_opus":0.01625427142453583,"score_gpt":0.28495570990322294,"score_spread":0.2687014384786871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414857553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961105,0.0016137958,0.0011514517,0.0000764753,0.000009989953,0.000019492543,0.00026418007,0.00002948273,0.0007245502],"genre_scores_gemma":[0.9985208,0.00022250078,0.0007779561,0.000032233977,0.000012090012,0.000013648294,0.00021820971,0.000004202049,0.00019835126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998535,0.000039481187,0.000015848154,0.0000352493,0.00003324405,0.000022701584],"domain_scores_gemma":[0.998926,0.00025954805,0.00052118464,0.000058918806,0.00014199481,0.00009238483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006194362,0.00030428063,0.00023607526,0.0009188696,0.00011877166,0.00054375204,0.00020542387,0.00043375284,0.001322443],"category_scores_gemma":[0.0018209907,0.00011037454,0.00019383022,0.000402708,0.00021589446,0.00030494717,0.00033598134,0.00040962253,0.0003799747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004528432,0.000047496043,0.98080647,0.000039619354,0.000046802244,0.000069468435,0.000034108023,0.00049321895,0.005186454,0.000043387707,0.00019029116,0.012589798],"study_design_scores_gemma":[0.000015530195,0.00037742587,0.9917345,0.000024686055,0.00008697334,0.00071040326,0.000091681766,0.002107382,0.0036892442,0.00027051775,0.000882479,0.000009310348],"about_ca_topic_score_codex":0.00042595138,"about_ca_topic_score_gemma":0.0007337889,"teacher_disagreement_score":0.001322443,"about_ca_system_score_codex":0.0002292364,"about_ca_system_score_gemma":0.00016404992,"threshold_uncertainty_score":0.0044240355},"labels":[],"label_agreement":null},{"id":"W4414870711","doi":"10.1093/oncolo/oyaf333","title":"Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Comprehensive Cancer Network","keywords":"Identification (biology); Selection (genetic algorithm); Precision medicine; MEDLINE; Data collection; Urothelial cancer","score_opus":0.0884092151270177,"score_gpt":0.38047784830099896,"score_spread":0.29206863317398124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414870711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99509275,0.0007448412,0.00017728805,0.0018185503,0.000015876129,0.00005656699,0.00052870845,0.000009090796,0.0015562801],"genre_scores_gemma":[0.99801105,0.00066699967,0.00029743373,0.0006306104,0.0000123120935,0.000025306446,0.00025264887,0.0000026792618,0.00010098001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976649,0.0012598922,0.00028769908,0.00018134419,0.00028595774,0.0003202767],"domain_scores_gemma":[0.9890015,0.0036671865,0.0043856776,0.00024871767,0.0010350682,0.0016618016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003534902,0.00016432171,0.00023344392,0.00069639424,0.00038187832,0.00075606065,0.00033820118,0.00074338645,0.0014856672],"category_scores_gemma":[0.010446995,0.0002159939,0.00032030194,0.001150444,0.0004740104,0.0008432471,0.0009312725,0.00066493195,0.00023762985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054683784,0.00010198414,0.97978485,0.00020267582,0.000034617442,0.00016989812,0.004806083,0.00014510291,0.0002432112,0.00007245903,0.0017507324,0.012633785],"study_design_scores_gemma":[0.000021044823,0.00041524653,0.9763593,0.00022633388,0.000022043494,0.00050743815,0.017079163,0.00050090684,0.00011381933,0.00006178237,0.004674218,0.000018624687],"about_ca_topic_score_codex":0.0038314369,"about_ca_topic_score_gemma":0.00401873,"teacher_disagreement_score":0.0038314369,"about_ca_system_score_codex":0.0007276439,"about_ca_system_score_gemma":0.0010422748,"threshold_uncertainty_score":0.01869458},"labels":[],"label_agreement":null},{"id":"W4414992675","doi":"10.1093/oncolo/oyaf276.067","title":"66Patient perceptions of biomarker testing in kidney cancer (KC) from the international kidney cancer coalition (IKCC) global patient survey (GPS)","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kidney Foundation of Canada; Institute of Cancer Research; Health Care Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Biomarker; Kidney cancer; Cancer; Precision medicine; Health care; Health professionals; Kidney disease; Personalized medicine","score_opus":0.07513053520888265,"score_gpt":0.31647179660133623,"score_spread":0.2413412613924536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414992675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99348176,0.0002848307,0.00013163351,0.0021889084,0.000024732612,0.000055428573,0.0013423946,0.0000084064495,0.0024819945],"genre_scores_gemma":[0.99810237,0.00024949308,0.00014802176,0.00080049573,0.000014730631,0.000057819623,0.0004555614,0.0000029924408,0.0001684221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963561,0.0019338962,0.00043328296,0.00024139759,0.0005822236,0.00045301992],"domain_scores_gemma":[0.99269813,0.0023874904,0.0026333334,0.00022371241,0.0010170433,0.0010403866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037951965,0.00013810994,0.00028115025,0.0006129155,0.000565208,0.0011292112,0.0002855152,0.00055354025,0.002244639],"category_scores_gemma":[0.01172688,0.00016120466,0.0003840244,0.0012911218,0.00074924185,0.00089250586,0.0014966298,0.0008337926,0.00027338052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006287497,0.000053162184,0.97534186,0.00020034442,0.000036460246,0.00010593486,0.012877691,0.000107088454,0.00016447162,0.00011653423,0.0035268406,0.0074067875],"study_design_scores_gemma":[0.000017253029,0.00027533702,0.95749456,0.0002004845,0.000038575305,0.00027226316,0.037073,0.00020544918,0.00009774656,0.000084705774,0.0042175422,0.000023159611],"about_ca_topic_score_codex":0.01377935,"about_ca_topic_score_gemma":0.014433152,"teacher_disagreement_score":0.01377935,"about_ca_system_score_codex":0.0009637145,"about_ca_system_score_gemma":0.0012686381,"threshold_uncertainty_score":0.027398288},"labels":[],"label_agreement":null},{"id":"W4414992798","doi":"10.1093/oncolo/oyaf276.051","title":"50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Refractory (planetary science); Renal cell carcinoma; Logistic regression; Population; Primary tumor; Carcinoma; Overall survival","score_opus":0.0949413080994492,"score_gpt":0.3741196405361676,"score_spread":0.2791783324367184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414992798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996452,0.0001975164,0.00006749934,0.000035240148,0.00000250522,0.000026752157,0.0027524475,0.0000024465476,0.00046363735],"genre_scores_gemma":[0.99720675,0.00008616222,0.00005481172,0.000028094797,0.0000071893214,0.000020021389,0.0025158098,0.0000015260947,0.00007971652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993211,0.00018712625,0.00010717713,0.00017827262,0.00012652167,0.00007979538],"domain_scores_gemma":[0.99789256,0.00039411217,0.0009558827,0.00019394541,0.0002525991,0.00031105144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091625476,0.00015062514,0.00039195563,0.00074901915,0.0003366343,0.0007270091,0.0003368195,0.0002818666,0.0016443838],"category_scores_gemma":[0.0024251612,0.00013699193,0.0003138276,0.0016892819,0.00014757142,0.00037544555,0.0003934497,0.00026693507,0.00029708224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014228346,0.000028397133,0.99880266,0.000012008334,0.000028261642,0.000046747078,0.000026367077,0.000028114837,0.000051546598,0.000008142909,0.00018017612,0.00064538256],"study_design_scores_gemma":[0.000028423505,0.00011707205,0.9984573,0.000009468572,0.00004494154,0.00034930833,0.0001399078,0.0003056354,0.00006950758,0.000009164678,0.00046601632,0.000003349358],"about_ca_topic_score_codex":0.006676599,"about_ca_topic_score_gemma":0.0073230905,"teacher_disagreement_score":0.006676599,"about_ca_system_score_codex":0.0004991845,"about_ca_system_score_gemma":0.0005370677,"threshold_uncertainty_score":0.0132754445},"labels":[],"label_agreement":null},{"id":"W4414992847","doi":"10.1093/oncolo/oyaf276.065","title":"64defining cancer initiating cells and their vulnerabilities in renal cell carcinoma","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Montreal Neurological Institute and Hospital; McGill Genome Centre","funders":"","keywords":"Transcriptome; Renal cell carcinoma; Cancer; Spheroid; Cell; Population; Clear cell renal cell carcinoma; In vivo; Cell culture","score_opus":0.03383505517727218,"score_gpt":0.30393371236642364,"score_spread":0.27009865718915144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414992847","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98625237,0.0014348442,0.010342776,0.000049757113,0.000008224629,0.000022112941,0.0006240782,0.00012764864,0.0011382382],"genre_scores_gemma":[0.9943743,0.00068899564,0.0038400756,0.000011296101,0.0000023987084,0.000015683667,0.0005908715,0.000013136626,0.0004632437],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993205,0.000006147733,0.0000037803775,0.0000201366,0.000025371264,0.000012481334],"domain_scores_gemma":[0.99991965,0.0000151986,0.000031662166,0.0000069018324,0.000012646008,0.0000139447975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098610646,0.00020699779,0.00027176,0.00029083385,0.0002146375,0.00047933857,0.00017077278,0.0001860742,0.00081241963],"category_scores_gemma":[0.00014883465,0.000119630626,0.00031955712,0.0003075935,0.00013705072,0.00026040807,0.0002162321,0.00023170808,0.00020283391],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105896484,0.00003875289,0.013064773,0.00022148144,0.000026287142,0.00019497136,0.000066011664,0.010263781,0.96777946,0.0016350943,0.00013326142,0.0064702546],"study_design_scores_gemma":[0.000013536541,0.0002870092,0.13736814,0.000034633886,0.00011639202,0.000904168,0.0003307019,0.14811678,0.7003869,0.0035544261,0.008852895,0.00003443568],"about_ca_topic_score_codex":0.0015425758,"about_ca_topic_score_gemma":0.0014400946,"teacher_disagreement_score":0.0015425758,"about_ca_system_score_codex":0.00046770528,"about_ca_system_score_gemma":0.00039098758,"threshold_uncertainty_score":0.0033934116},"labels":[],"label_agreement":null},{"id":"W4414993075","doi":"10.1093/oncolo/oyaf276.038","title":"37Integrative multi-omic characterization of the immune landscape in renal cell carcinoma","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Mass cytometry; Immune system; Tumor microenvironment; Transcriptome; Cell; Renal cell carcinoma; Tumour heterogeneity","score_opus":0.020994979300086637,"score_gpt":0.2762426854285082,"score_spread":0.25524770612842157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414993075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86907876,0.0117575005,0.061632138,0.00090351084,0.00019400357,0.00033418956,0.04838595,0.0014736012,0.0062403106],"genre_scores_gemma":[0.8492156,0.003950477,0.098330766,0.0008602089,0.00013717718,0.00042613223,0.044194378,0.000273226,0.0026119864],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994024,0.00006015036,0.00005243367,0.00016528333,0.00024081218,0.000078917976],"domain_scores_gemma":[0.9995627,0.00008116967,0.00009736664,0.00006095414,0.00015488482,0.000042934513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008607739,0.00037772575,0.000785179,0.0022818823,0.0005630377,0.0013313778,0.00040504715,0.00048029696,0.0011179774],"category_scores_gemma":[0.00064141426,0.00017054155,0.0007391164,0.0018552964,0.0003178677,0.00039348626,0.0009149697,0.0005096411,0.0005986023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002251383,0.00006930982,0.0346695,0.0008249421,0.00021840556,0.0003377284,0.00019605288,0.0019276678,0.9295242,0.0006254271,0.001473062,0.029908633],"study_design_scores_gemma":[0.00003893719,0.00036282866,0.46628934,0.00021164949,0.0005437551,0.0016407286,0.0013409633,0.037846122,0.43289486,0.003205496,0.055481464,0.00014370667],"about_ca_topic_score_codex":0.002510539,"about_ca_topic_score_gemma":0.006037876,"teacher_disagreement_score":0.002510539,"about_ca_system_score_codex":0.00059872185,"about_ca_system_score_gemma":0.00082722586,"threshold_uncertainty_score":0.004991889},"labels":[],"label_agreement":null},{"id":"W4415502772","doi":"10.1093/oncolo/oyaf287","title":"Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Discontinuation; Adverse effect; Crown (dentistry); Post-hoc analysis; Term (time)","score_opus":0.018162467902239843,"score_gpt":0.34178945367326324,"score_spread":0.3236269857710234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415502772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266547,0.0027633412,0.00044646536,0.00021818433,0.000022910868,0.00023248626,0.0018794276,0.00003137173,0.0017403045],"genre_scores_gemma":[0.9958086,0.00031532155,0.0004314255,0.00014722892,0.00003337163,0.00009170982,0.002762274,0.0000061067244,0.0004040772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99674416,0.0012497065,0.00026679976,0.00052968255,0.0009613116,0.00024835835],"domain_scores_gemma":[0.99016386,0.0021843847,0.004247507,0.0008651001,0.001967881,0.0005711404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008424819,0.00026967295,0.00066267565,0.00037699478,0.00040054505,0.00081912265,0.0004765354,0.00050652656,0.0015223505],"category_scores_gemma":[0.0119538205,0.00013393907,0.0010439428,0.00047304717,0.00023829371,0.00049168343,0.0006612291,0.0006555092,0.00020204023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044908557,0.0005614009,0.86468184,0.0005792609,0.0023249423,0.00034688742,0.00041305486,0.0016922415,0.0026054387,0.00019798991,0.0053718756,0.07631647],"study_design_scores_gemma":[0.0018935368,0.008434914,0.9794042,0.000096019045,0.0010645706,0.00050666806,0.00013696436,0.0021628921,0.0010078355,0.00012571359,0.005119219,0.000047561938],"about_ca_topic_score_codex":0.0038157592,"about_ca_topic_score_gemma":0.009145648,"teacher_disagreement_score":0.008424819,"about_ca_system_score_codex":0.0008970974,"about_ca_system_score_gemma":0.0011893411,"threshold_uncertainty_score":0.044555247},"labels":[],"label_agreement":null},{"id":"W7117146489","doi":"10.1093/oncolo/oyaf385","title":"Clinical and radiomics parameter prognostication in metastatic uveal melanoma patients treated with hepatic arterial infusion chemotherapy","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Deutschen Konsortium für Translationale Krebsforschung","keywords":"Radiomics; Melanoma; Chemotherapy; Risk stratification; Multivariate analysis; Metastatic melanoma; Overall survival; Retrospective cohort study","score_opus":0.021762291322006192,"score_gpt":0.3339066299120575,"score_spread":0.3121443385900513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117146489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989317,0.00032322874,0.0002854307,0.000051421226,0.0000045466636,0.0000044909734,0.00018102048,0.0000071019876,0.000211034],"genre_scores_gemma":[0.9996624,0.000032910484,0.00008862582,0.000006584112,0.0000034328127,0.0000024205592,0.00016228424,0.0000010443849,0.000040436174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997279,0.00009609228,0.000029596937,0.00006399489,0.00004416294,0.0000382041],"domain_scores_gemma":[0.99887615,0.00033074582,0.00050022424,0.000082426486,0.0000818366,0.00012859429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007448707,0.00022407983,0.00030846597,0.00041090063,0.00015657677,0.00055492535,0.0001922933,0.00022283367,0.00090967765],"category_scores_gemma":[0.0025675786,0.00010062146,0.00035939246,0.00046654642,0.00015231046,0.00023816332,0.0002526305,0.00039074224,0.00015359958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050750445,0.000029181618,0.9945174,0.000007590905,0.00006406375,0.00003798922,0.000011845461,0.0007028134,0.00042074302,0.000012647171,0.000080180405,0.0036080377],"study_design_scores_gemma":[0.000021841837,0.00032593924,0.9894649,0.000008556136,0.00010475467,0.0003112392,0.00004686795,0.008772205,0.0005216866,0.00009067334,0.00032448745,0.0000068760123],"about_ca_topic_score_codex":0.0016439627,"about_ca_topic_score_gemma":0.0017492382,"teacher_disagreement_score":0.0016439627,"about_ca_system_score_codex":0.00042454616,"about_ca_system_score_gemma":0.0002924443,"threshold_uncertainty_score":0.003939271},"labels":[],"label_agreement":null}]}